{
    "M1-4ADD [FAST FACTS]": {
        "sections": {
            "Overview": "M1-4ADD is marketed as a prohormone, or a hormone precursor. Usually, a segment of the prohormone is cleaved or altered to produce a biologically active hormone such as testosterone, estrogen, or a derivative (91094, 91095).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Warnings": "Prohormones which are intended to provide anabolic activity in the body meet the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469). Certain prohormones have also been prohibited by the National Collegiate Athletic Association (NCAA) (13163).",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Prohormones can be converted to active hormones in the body and cause adverse effects such as menstrual irregularities, infertility, hair loss, and acne. Prohormones have also been associated with hepatotoxicity and increased risk of cardiovascular disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing prohormones are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Prohormones can be converted to active hormones in the body and cause adverse effects such as menstrual irregularities, infertility, hair loss, and acne. Prohormones have also been associated with hepatotoxicity and increased risk of cardiovascular disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing prohormones are dangerous (91094). Avoid using.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using M1-4ADD for athletic performance, there is insufficient reliable information about the clinical effects of M1-4ADD for this purpose.\nExercise-induced muscle damage. Although there is interest in using M1-4ADD for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of M1-4ADD for this purpose.\nMuscle strength. Although there is interest in using M1-4ADD to increase muscle strength, there is insufficient reliable information about the clinical effects of M1-4ADD for this purpose.\nObesity. Although there is interest in using M1-4ADD for weight loss, there is insufficient reliable information about the clinical effects of M1-4ADD for this purpose.\nMore evidence is needed to rate M1-4ADD for these uses.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Maca": {
        "sections": {
            "Overview": "Maca is a root vegetable that grows in the Andes mountains, especially in Peru, at an elevation of 3700-4500 meters (40231, 60705, 104516). The root occurs in three colors (red, yellow, and black) and has been eaten baked, roasted, or in soup for over 3000 years (9926, 40231, 104516). Traditionally, it has been used for improving the fertility of humans and livestock (9925, 9926).",
            "Safety": "LIKELY SAFE when maca is consumed in food amounts (9926).\nPOSSIBLY SAFE when used orally and appropriately, short term. Maca appears to be safe in doses up to 3 grams daily for 4 months (9928, 10218, 18289, 90278, 108603).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, no adverse effects have been reported with the medicinal use of maca. However, a thorough evaluation of safety outcomes has not been conducted.\nGastrointestinal\nConsumption of fresh, uncooked maca may cause stomach pain (40231).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related testosterone deficiency. It is unclear if oral maca is beneficial for age-related testosterone deficiency.\nA moderate-size clinical study in eugonadal males age 65 years on average with symptoms related to late-onset hypogonadism shows that taking maca 1.66 grams three times daily for 12 weeks improves physical, sexual, and psychological symptom scores when compared with placebo. However, maca did not lead to a significant difference in testosterone levels between groups (112012). The interpretation of these findings is limited by the use of patient-reported outcomes.\nless\nAmenorrhea. Although there has been interest in using oral maca for amenorrhea, there is insufficient reliable information about the clinical effects of maca for this purpose.\nAnemia of chronic disease. Although there has been interest in using oral maca for anemia of chronic disease, there is insufficient reliable information about the clinical effects of maca for this purpose.\nAntidepressant-induced sexual dysfunction. It is unclear if oral maca is beneficial in patients with sexual dysfunction due to antidepressants.\nPreliminary clinical research shows that taking maca 1.5 grams twice daily for 12 weeks modestly increases remission rates in females experiencing antidepressant-induced sexual dysfunction (90278).\nless\nAthletic performance. It is unclear if oral maca is beneficial for athletic performance.\nA small clinical study in male elite athletes shows that taking maca 2500 mg twice daily for 8 weeks may improve some measures of physical performance, including grip strength, power, or agility, when compared to baseline (112014). However, the interpretation of this study is limited by the lack of a control group, inconsistent results among the various types of athletes included in the study, and unreported habitual activities, such as diet, that may confound results.\nless\nChronic fatigue syndrome (CFS). Although there has been interest in using oral maca for CFS, there is insufficient reliable information about the clinical effects of maca for this purpose.\nDepression. Although there has been interest in using oral maca for depression, there is insufficient reliable information about the clinical effects of maca for this purpose.\nFatigue. Although there has been interest in using oral maca for fatigue, there is insufficient reliable information about the clinical effects of maca for this purpose.\nLeukemia. Although there has been interest in using oral maca for leukemia, there is insufficient reliable information about the clinical effects of maca for this purpose.\nMale infertility. It is unclear if oral maca is beneficial for male infertility.\nClinical research shows that taking a specific maca product (Maca Gelatinizada La Molina, Laboratorios Hersil) 1.5-3 grams daily for 4 months increases semen volume, sperm count, and sperm motility in healthy males aged 22-44 years (18289). Conversely, a meta-analysis of 2 small clinical studies in males with infertility shows that taking 2-2.8 grams of maca daily for 12-16 weeks does not improve the concentration of semen when compared with placebo (112011). However, the interpretation of this finding is limited by the heterogeneity of the included studies.\nless\nMemory. Although there has been interest in using oral maca for memory, there is insufficient reliable information about the clinical effects of maca for this purpose.\nOsteoporosis. Although there has been interest in using oral maca for osteoporosis, there is insufficient reliable information about the clinical effects of maca for this purpose.\nPostmenopausal conditions. It is unclear if oral maca is beneficial for postmenopausal conditions.\nTwo small clinical trials show that taking powdered maca (Maca Power, Incan Food, Healthychoices) 3.3 or 3.5 grams daily as a single dose or in two divided doses for 6 weeks modestly reduces anxiety, depression, and sexual dysfunction when compared with placebo (90606, 99792). However, these changes are generally small and of questionable clinical significance (90606).\nless\nSexual desire. It is unclear if oral maca improves male sexual desire; it has not been evaluated for female sexual desire.\nPreliminary clinical research shows that taking a specific maca product (Maca Gelatinizada La Molina, Laboratorios Hersil), 1.5-3 grams daily in three divided doses for 12 weeks can increase subjective feelings of sexual desire in healthy males aged 21 to 57 years (9928).\nless\nTuberculosis. Although there has been interest in using oral maca for tuberculosis, there is insufficient reliable information about the clinical effects of maca for this purpose.\nMore evidence is needed to rate maca for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMaca has been used in doses of 1.5-3.5 grams daily, usually in divided doses, for 6-16 weeks. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nTwo classes of polyunsaturated fatty acids, macaenes and macamides, are used as marker compounds for maca (9926). Analysis of commercially available maca products shows that the percentage of total macaenes and macamides in preparations varies from 0.15% to 0.84% (9926).\n\nIn one clinical trial, the maca sample contained the macamides N-benzyl-palmitamide 42.2 mg/gram, N-benzyl-stearamide 10.6 mg/gram, N-benzyl-oleamide 16.4 mg/gram, N-(methoxy-benzyl)-oleamide 2.4 mg/gram, N-benzyl-linoleamide 49.8 mg/gram, N-(methoxy-benzyl)-linoleamide 7.3 mg/gram, N-benzyl-linoleniamide 53.5 mg/gram, N-(methoxy-benzyl)-linoleniamide 4.1 mg/gram, and N-(methoxy)-benzylpalmitamide 4.4 mg/gram (90278).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "HORMONE SENSITIVE CONDITIONS\nBecause maca extracts might have estrogenic effects (18290), patients with hormone sensitive conditions should avoid maca. Some of these conditions include breast, uterine, and ovarian cancers, endometriosis, and uterine fibroids.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with maca.",
            "Pharmacokinetics": "There is insufficient available evidence about the pharmacokinetics of maca.",
            "Mechanism of Action": "General\nThe applicable part of maca is the root. Dried maca root contains 55% to 60% carbohydrates; 10% to 12% protein; 8% to 9% fiber; and 2% to 3% lipids, including linolenic, palmitic, and oleic acids. It also contains sterols such as campesterol, stigmasterol, and beta-sitosterol, and significant amounts of minerals including iron, calcium, copper, and zinc, as well as amino acids and B, C, and E vitamins (9929, 40231, 90606, 104516).\n\nTwo classes of polyunsaturated fatty acids, macaenes and macamides, are used as marker compounds for maca (9926). Analysis of commercially available maca products shows that the percentage of total macaenes and macamides in preparations varies from 0.15% to 0.84% (9926).\n\nMaca also contains glucosinolates, including glucotropaeolin (9927, 9929, 60714). The major components of the steam-distilled essential oil of maca are phenyl acetonitrile (85.9%), benzaldehyde (3.1%), and 3-methoxyphenylacetonitrile (2.1%) (60707). Other constituents of maca include (5-oxo-(6E,8E)-octadecadienoic acid), lepidiline A and B, (1R,3S)-1-methyltetrahydro-beta-carboline-3-carboxylic acid, and macaridine (9927, 60704, 60708).\nAnti-inflammatory effects\nAnimal research in mice shows that pretreatment with maca extract before strenuous exercise may reduce post-exercise levels of serum lactate dehydrogenase, lactic acid, and blood urea nitrogen when compared with a control group. These effects were similar to those seen with caffeine (108602).\nAnti-stress effects\nIn animal research, maca extract improved several markers associated with stress including ulcers, elevated corticosterone levels, and adrenal weights (60730).\nAnticancer effects\nMaca contains glucosinolates, which might have cancer-protecting properties (9927, 9929).\nAntidepressant effects\nIn animal research, maca reduced times of immobility associated with forced swimming, suggesting antidepressant effects (60724).\nAntioxidant effects\nIn vitro research in muscle cell models designed to simulate exercise-induced oxidative damage shows that maca extract may attenuate oxidative effects by preventing the inhibition of dehydrogenase activity and preserving mitochondrial function in skeletal muscle. Research in mice shows that pretreatment with maca extract before strenuous exercise may reduce oxidative stress-induced muscle damage by decreasing levels of reactive oxygen species in both blood and muscle (108602).\nCentral nervous system effects\nMaca contains glucosinolates, which might have central nervous system effects (9927, 9929). The carboline, (1R,3S)-1-methyltetrahydro-beta-carboline-3-carboxylic acid, found in maca has been reported to exert many activities on the central nervous system (9927).\nCognitive effects\nIn animal research, maca reduced time required to find water, suggesting beneficial effects on memory (60724).\nExercise effects\nIn animal research, maca extracts increased swimming activity and improved recovery from muscle fatigue based on production of lactic and malonic acids (60732). Other animal research in mice shows that administration of maca extract daily for 4 weeks improves grip strength and exercise endurance more than a control group and similarly to caffeine. Maca also appears to attenuate exercise-induced muscle fatigue and stress by increasing muscle concentrations of coenzyme nicotinamide adenine dinucleotide (NAD+) and NAD(H) and reducing markers of inflammation and oxidative stress (108602).\nFertility effects\nIn female animals, maca extract increased litter size (60718). However, in other animal research it did not increase implantation of embryos (60709).\nImmunostimulant effects\nIn animal research, diets supplemented with maca resulted in increased leukocyte counts (60733). Similarly, a small study in mice with immunocompromise due to cyclophosphamide suggests that maca polysaccharides improve immune cell counts, including white blood cells, CD4+ T cells, interleukin-2, and interferon-gamma when compared with control (112013). However, in human research, maca did not affect levels of cytokines involved in immunity (90606).\nOsteoporosis effects\nIn animal research, maca extract prevented bone loss associated with estrogen deficiency (60722).\nReproductive effects\nMaca and extracts containing macaene and macamide seem to increase sexual activity and correct erectile dysfunction in animal models. The mechanism for this activity is unknown (10218, 60700, 60702, 60706). Also in animal models, maca increases spermatogenesis and epididymal sperm count (60710, 60711, 60715, 60723), as well as the weight of the testis and epididymis (60703). However, when different types of maca are compared in rats, only the black variety appears to improve spermatogenesis (60719).\n\nMaca does not appear to significantly affect serum concentrations of reproductive hormones including testosterone, estradiol, and 17-hydroxyprogesterone in healthy males (10219, 112012). In males with various combinations of oligospermia, asthenospermia, teratospermia, and azoospermia, taking yellow maca 2.8 grams daily for 16 weeks also does not appear to significantly affect serum concentrations of luteinizing hormone, follicle-stimulating hormone, prolactin, estradiol, or testosterone (108603). However, estrogenic effects of maca have been shown in laboratory research in human breast cancer cell lines (18290). Also, in animal research, maca resulted in increased progesterone, but not estrogen, levels in females (60709) and increased testosterone levels in males (60709)."
        }
    },
    "Macadamia Nut": {
        "sections": {
            "Overview": "Macadamia nuts are a type of seed native to Australia. More than 85% of the energy in the macadamia nut is from monounsaturated fat. The nuts are grown commercially in Hawaii and to a much smaller extent in California and Florida (12601, 12603, 100034). They are commonly consumed as a food.",
            "Warnings": "The Food Allergen Labeling and Consumer Protection Act (FALCPA) of 2004 recognizes tree nuts as a major food allergen in the United States and requires that tree nuts, including macadamia nut, be labeled on packaged food and supplement products (105410).",
            "Safety": "LIKELY SAFE when used in amounts commonly found in foods (12598, 12599). Macadamia nuts have been safely consumed as part of the diet in a quantity of 40-90 grams (about 17-37 nuts) per day (12598, 12599, 100024, 102333).\nPREGNANCY AND LACTATION: LIKELY SAFE when used as food (12598, 12599).",
            "Adverse Effects": "General\nOrally, macadamia nut is well tolerated.\nSerious Adverse Effects (Rare)\nAll routes of administration: Allergic reactions, including anaphylaxis and contact dermatitis.\nImmunologic\nOrally, eating macadamia nuts or macadamia nut oil can cause allergic reactions, including anaphylaxis (12600, 12601, 100019, 100031, 100032, 100033, 100035). Processing methods may affect the allergenicity of macadamia nuts (12602).\n\nTopically, occupational exposure to macadamia nut shells has resulted in allergic contact dermatitis (12603).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nHypercholesterolemia. Most research shows that consuming macadamia nuts as part of the diet can lower cholesterol levels.\nEating macadamia nuts as part of a healthy diet seems to modestly lower total and low-density lipoprotein (LDL) cholesterol levels (12598, 12599, 100024). If the macadamia nuts are added to the existing diet, increases in high-density lipoprotein (HDL) cholesterol also occur. However, if fat from other sources is removed from the diet, HDL seems to decrease (12598, 12599, 100024). In hypercholesteremic adults eating 40-90 grams of macadamia nuts (about 17-37 nuts) daily for 4 weeks in addition to their usual diet, total cholesterol is decreased by 3% and LDL cholesterol is decreased by 5% when compared to baseline (12598). When macadamia nuts are consumed as part of a diet containing otherwise lower-fat food products, such as skim milk and low-fat mayonnaise, total cholesterol and LDL cholesterol levels decrease by approximately 9% when compared with an average American diet (100024).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCoronary heart disease (CHD). It is unclear if consuming macadamia nuts as part of the diet can reduce the risk for CHD.\nIn 2017, the US Food and Drug Administration (FDA) determined that it would allow a qualified health claim stating that consuming 1.5 ounces of macadamia nuts per day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of CHD. However, the FDA has concluded that this claim is based on supporting, rather than conclusive, evidence (102333).\nless\nMore evidence is needed to rate the effectiveness of macadamia nut for this use.",
            "Dosing & Administration": "Adult\nOral:\nMacadamia nuts are typically consumed in moderation as part of the diet. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of macadamia nut.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nExpert recommendations state that patients who are allergic to peanuts should avoid eating tree nuts due to an increased likelihood of tree nut allergy. For food labelling purposes, tree nuts include macadamia nut, pine nut, coconut, hazelnut, Brazil nut, cashew, pecan, walnut, chestnut, pistachio, and almond (100031, 100032). However, one small study shows that cross-sensitivity to macadamia nut in patients who are allergic to peanut is uncommon (100031). There is also concern that individuals with a tree nut allergy may be allergic to at least one other tree nut (100031, 100032). One allergen found in macadamia nut has cross-reactivity with hazelnut (100033).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the treatment or prevention of overdose with macadamia nut.",
            "Pharmacokinetics": "Absorption\nFollowing intake of macadamia nut, plasma levels of palmitoleic acid increase (100034).",
            "Mechanism of Action": "General\nThe applicable part of the macadamia nut is the hulled seed (nut). Macadamia nuts are about 75% fat by weight with 85% of its energy from fat. Macadamia nuts contain the highest amount of monounsaturated fatty acids (MUFA) of any food. It contains oleic acid as well as a substantial amount of palmitoleic acid. Macadamia nuts also contain plant sterols, carbohydrates, fiber, vitamins, and minerals (36623, 12598, 12599, 100024, 100034).\nHypolipidemic effects\nMacadamia nuts have been shown to reduce levels of cholesterol in human research. This is likely due to the monounsaturated fatty acids and plant sterols found in the oil of macadamia nut. The oil makes up approximately 75% by weight of the nut (12598, 12599, 100024, 100034). In people with hypercholesterolemia, macadamia nut also seems to lower levels of leukotriene B4 (LTB4), a compound involved in inflammatory processes, as well as 8-isoprostane, a measurement of oxidative stress (100034)."
        }
    },
    "Mace": {
        "sections": {
            "Overview": "Nutmeg and mace are two commonly used spices originating from the same tree, Myristica fragrans. The tree is indigenous to the Banda Islands of Indonesia, and is now cultivated in other tropical regions, such as Malaysia and the Caribbean (25969). Mace is derived from the aril (seed covering) of Myristica fragrans, while nutmeg is derived from the seed of the tree.",
            "Safety": "LIKELY SAFE when used orally and appropriately in amounts commonly found in foods. Mace is commonly used as a spice. Mace and mace oil have Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts. Mace powder in doses of up to 1.5 grams twice daily has been used with apparent safety for up to 3 months (103377).\nThere is insufficient reliable information available about the safety of larger doses of mace. However, severe cardiovascular, gastrointestinal, neurologic, ocular, and psychiatric adverse events have been reported following high intake of the related herb nutmeg (19293, 19492, 25538). Theoretically, high doses of mace may have similar effects, although there have been no reported cases in humans.\nThere is insufficient reliable information available about the safety of mace when used topically.\nPREGNANCY: POSSIBLY UNSAFE when used orally in medicinal amounts. Mace might have abortifacient activity, and its safrole content might be mutagenic (12).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, mace seems to be well tolerated when consumed in appropriate amounts. No adverse effects have been reported, although a thorough evaluation of safety outcomes has not been conducted. However, severe cardiovascular, gastrointestinal, neurologic, ocular, and psychiatric adverse events have been reported following high intake of the related herb nutmeg (19293, 19492). Theoretically, high doses of mace may have similar effects, although there have been no reported cases in humans.\n\nTopically, contact and systemic contact-type dermatitis to mace has occurred in rare cases (39898).\nCardiovascular\nThere are no reports of adverse cardiovascular events due to ingestion of mace. However, mace contains myristicin, which is structurally similar to certain hallucinogenic chemicals. High intake of nutmeg, a related herb, has been associated with non-specific electrocardiographic changes, tachycardia, palpitations, weak pulse, hypotension, chest pain, and flushing (12, 19293, 19300, 25547, 25943). Theoretically, high intake of mace may have similar effects.\nless\nDermatologic\nTopically, contact and systemic contact-type dermatitis to mace has occurred in rare cases (39898).\nless\nGastrointestinal\nThere are no reports of adverse gastrointestinal events due to ingestion of mace. However, mace contains myristicin, which is structurally similar to certain hallucinogenic chemicals. High intake of nutmeg, a similar spice, has been reported to cause nausea and vomiting, epigastric pain, and gastroenteritis (2563, 19294, 19300). Theoretically, high intake of mace may have similar effects.\nless\nImmunologic\nIn a case report, inhalation of mace induced an immediate asthmatic reaction (46245).\nless\nMusculoskeletal\nThere are no reports of adverse musculoskeletal events due to ingestion of mace. However, mace contains myristicin, which is structurally similar to certain hallucinogenic chemicals. High intake of nutmeg, a similar herb, has been reported to cause involuntary eye movement (nystagmus), muscle weakness, numbness, and ataxia (2563). Theoretically, high intake of mace may have similar effects.\nless\nNeurologic/CNS\nThere are no reports of adverse neurologic or central nervous system (CNS)-related events due to ingestion of mace. However, mace contains myristicin, which is structurally similar to certain hallucinogenic chemicals. High intake of nutmeg, a similar herb, has been reported to cause headache, dizziness, drowsiness, hot and cold sensations, sensations of limb loss, convulsions, and coma (2563, 19294, 19300, 19487). Theoretically, high intake of mace may have similar effects.\nless\nOcular/Otic\nThere are no reports of adverse ocular events due to ingestion of mace. However, mace contains myristicin, which is structurally similar to certain hallucinogenic chemicals. High intake of nutmeg, a similar herb, has been reported to cause blurred vision, double and triple vision, and pupil dilation or constriction (2563, 25948). Theoretically, high intake of mace may have similar effects.\nless\nPsychiatric\nThere are no reports of adverse psychiatric events due to ingestion of mace. However, mace contains myristicin, which is structurally similar to certain hallucinogenic chemicals. High intake of nutmeg, a similar herb, has been reported to cause mild to intense visual hallucinations, auditory hallucinations, feelings of impending doom, euphoria, anxiety, disorientation, stupor, agitation, insomnia, and restlessness (12, 2563, 19300, 19489, 19492). Theoretically, high intake of mace may have similar effects.\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDysmenorrhea. In patients with dysmenorrhea, preliminary clinical research shows that taking a palm sap-sweetened herbal decoction 180 mL made with a combination of mace 3 grams and Cassia fistula 21 grams for 3 days starting just before expected menstruation and repeating for two menstrual cycles reduces pain by a large amount and the duration of pain by a small amount when compared with the same three days of the menstrual cycle at baseline. In addition, it was as effective as taking mefenamic acid 500 mg twice daily for 3 days starting on the first day of menstruation. When the average 3-day pain was compared, the decoction was slightly more effective than mefenamic acid (103376). It is unclear if these are effects are due to mace, Cassia fistula, or the combination.\nUrinary incontinence. In women with mixed urinary incontinence of at least 2 months duration, preliminary clinical research shows that taking mace powder 1.5 grams twice daily for 3 months, in addition to doing pelvic floor muscle training, has a large benefit on severity of symptoms when compared with those using pelvic floor training alone (103377).\nMore evidence is needed to rate mace for these uses.",
            "Dosing & Administration": "Adult\nOral:\nDysmenorrhea: A palm sap-sweetened herbal decoction made with a combination of mace 3 grams and Cassia fistula 21 grams has been used for 3 days starting just before expected menstruation and repeated for two menstrual cycles (103376).\n\nUrinary incontinence: Mace powder 1.5 grams twice daily for 3 months has been used in combination with pelvic floor muscle training (103377).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mace.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nSeveral volatile oils in mace, such as methyleugenol, isoeugenol, safrole, myristicin, 1,8-cineole, and geranyl acetate, seem to have sedative effects (2563, 25545). Evidence from animal research suggests that methyleugenol can induce anesthesia for a similar duration as pentobarbital (25544). Due to the sedative effects of certain mace constituents, taking medicinal amounts of mace in combination with other CNS depressants may have additive effects. However, evidence from other animal research suggests that myristicin can reduce sleeping time in rats pretreated with phenobarbital (3492, 3493). Until more is known, use medicinal amounts of mace cautiously in combination with CNS depressants. Some CNS depressants include clonazepam (Klonopin), lorazepam (Ativan), phenobarbital (Donnatal), zolpidem (Ambien), and others.\nCYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro and animal research suggests that myristicin, a constituent of mace, can induce cytochrome P450 1A1 (CYP1A1) enzyme system (3493, 26022). Theoretically, concomitant use of mace with drugs metabolized by CYP1A1 may increase the clearance of these drugs and reduce their effects. Some of these drugs include chlorzoxazone, theophylline, and bufuralol.\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research suggests that intraperitoneal injections of myristicin, a constituent of mace, can induce cytochrome P450 1A2 (CYP1A2) enzyme system (3493). Theoretically, concomitant use of mace with drugs metabolized by CYP1A2 may increase the clearance of these drugs and reduce their effects. Some substrates of CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, zileuton (Zyflo), zolmitriptan (Zomig), and others.\nCYTOCHROME P450 2B1 (CYP2B1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research suggests that intraperitoneal injections of myristicin, a constituent of mace, can induce cytochrome P450 2B1 (CYP2B1) enzyme system (3493). Theoretically, concomitant use of mace with drugs metabolized by CYP2B1 may increase the clearance of these drugs and reduce their effects.\nCYTOCHROME P450 2B2 (CYP2B2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research suggests that intraperitoneal injections of myristicin, a constituent of mace, can induce cytochrome P450 2B2 (CYP2B2) enzyme system (3493). Theoretically, concomitant use of mace with drugs metabolized by CYP2B2 may increase the clearance of these drugs and reduce their effects.\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research suggests that mace lignans can suppress immune function (25541). Theoretically, concomitant use might enhance the effects of immunosuppressant drugs. Immunosuppressant drugs include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), and other corticosteroids (glucocorticoids).\nPHENOBARBITAL (Luminal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from animal research suggests that myristicin, a constituent of mace, can reduce sleeping time in rats pretreated with phenobarbital (3492, 3493). Theoretically, concomitant use may decrease the therapeutic effects of phenobarbital (3492).",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nSeveral volatile oils in mace, such as methyleugenol, isoeugenol, safrole, myristicin, 1,8-cineole, and geranyl acetate seem to have sedative effects (2563, 25545). Theoretically, concomitant use with supplements that have sedative properties might enhance therapeutic and adverse effects or mace. Some of these include 5-HTP, calamus, California poppy, catnip, hops, Jamaican dogwood, kava, St. John's wort, skullcap, valerian, yerba mansa, and others.\nSAFROLE-CONTAINING HERBS\nAvoid concomitant use with other safrole-containing herbs due to potential for additive toxicity (12). Other herbs that contain safrole include basil, camphor, and cinnamon.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of mace.",
            "Pharmacokinetics": "Metabolism\nIn vitro research suggests that the mace constituent myristicin is metabolized to 5-allyl-1-methoxy-2,3-dihydroxybenzene by cytochrome P450 1A2 (CYP1A2) and 3A4 (CYP3A4) enzymes (26027).\nExcretion\nAnimal research suggests that following oral administration of the mace constituent myristicin, the two metabolites 5-allyl-1-methoxy-2,3-dihydroxybenzene and 1'-hydroxymyristicin are excreted in the urine (26028). Tertiary amino methoxy methylenedioxy propiophenones have also been identified in the urine of rats and guinea pigs following oral or intraperitoneal administration of myristicin (26029).",
            "Mechanism of Action": "General\nMace is the aril of the seed of the Myristica fragrans plant. Constituents of mace include diarylpropanoids, lignans (macelignan), malabaricone B, malabaricone C, dihydroguaiaretic acid (DHGA), safrole, terpinen-4-ol, alpha-pinene, beta-pinene, gamma-terpinene, beta-phellandrene, elemicin, estragole, methyl eugenol, eugenol, isoeugenol, methoxyeugenol, myristicin, camphene, limonene, myrcene, terpinene, terpinolene, 1,8-cineole, geraniol, alpha-terpinene, linalool, sabinene, caryophyllene, and para-cymene (25539, 25974, 25975, 26011, 26012, 26013, 26014, 26016, 77020)(81401).\nAnti-inflammatory effects\nMace is of interest as an anti-inflammatory agent. In an animal model of inflammation, mace extract has anti-inflammatory effects. Myristicin is considered the active constituent (6, 25542).\nAnticancer effects\nMace is of interest for cancer. Evidence from some animal research suggests that the addition of 1% mace in the diet of mice can reduce the incidence of dimethylbenz(a)anthracene-induced skin papilloma by approximately 50% (25984). Oral mace has also been observed to reduce 3-methylcholanthrene (MCA)-induced uterine cervix carcinogenesis in animal research (25540). Constituents of mace, including dihydroguaiaretic acid (DHGA) and myristicin have shown anti-proliferation and apoptotic effects on cancer cells in vitro (25973, 81401).\nAntimicrobial effects\nMace extract is of interest for gingivitis (25543). In vitro, mace and some constituents, including the resorcinols malabaricone B and malabaricone C, have shown antibacterial effects against a range of bacteria (25539, 26009, 38374).\nImmunomodulatory effects\nIn vitro, in models of hyperstimulation, the mace constituents macelignans, have immunoinhibitory effects, including the inhibition of inflammatory cytokines released from activated lymphocytes (25541)."
        }
    },
    "Madagascar Periwinkle": {
        "sections": {
            "Overview": "Madagascar periwinkle is a common ornamental plant that is sometimes used as a medicine (100667). The vinca alkaloids isolated from Madagascar periwinkle, vinblastine and vincristine, are approved by the US Food and Drug Administration (FDA) for use as chemotherapeutic agents (6).",
            "Safety": "LIKELY UNSAFE when the plant or root are used orally. Madagascar periwinkle contains toxic vinca alkaloids, which can cause death (6).\nThere is insufficient reliable information available about the safety of Madagascar periwinkle when used topically.\nPREGNANCY: LIKELY UNSAFE when used orally. Madagascar periwinkle has abortifacient and teratogenic properties (19).\nLACTATION: LIKELY UNSAFE when used orally (6); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Madagascar periwinkle is generally regarded as unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity. Madagascar periwinkle can cause hallucinations, seizures, gastrointestinal upset, hepatotoxicity, and alopecia (17). The vinca alkaloid constituents of Madagascar periwinkle have been reported to cause nausea, vomiting, alopecia, dizziness, nystagmus, vertigo, hearing impairment, leukopenia, thrombocytopenia, bleeding, hyperuricemia, neurotoxicity, and possibly death (6, 15).\n\nExposure to the airborne pollen of Madagascar periwinkle can cause respiratory allergic reactions in sensitive individuals (100665).\nDermatologic\nOrally, Madagascar periwinkle can cause alopecia (17).\nless\nGastrointestinal\nOrally, Madagascar periwinkle can cause gastrointestinal upset (17). The vinca alkaloid constituents of Madagascar periwinkle have been reported to cause nausea and vomiting (6, 15).\nless\nHematologic\nOrally, the vinca alkaloid constituents of Madagascar periwinkle have been reported to cause leukopenia, thrombocytopenia, bleeding, and hyperuricemia (6, 15).\nless\nHepatic\nOrally, Madagascar periwinkle can cause hepatotoxicity (17).\nless\nImmunologic\nExposure to the airborne pollen of Madagascar periwinkle can cause allergic respiratory reactions. In one population of adults with respiratory allergies, 29.8% tested positive to Madagascar periwinkle pollen during skin prick testing (100665).\nless\nNeurologic/CNS\nOrally, Madagascar periwinkle can cause hallucinations and seizures (17). The vinca alkaloid constituents of Madagascar periwinkle have been reported to cause dizziness, vertigo, and neurotoxicity (6, 15).\nless\nOcular/Otic\nOrally, the vinca alkaloid constituents of Madagascar periwinkle have been reported to cause nystagmus and hearing impairment (6, 15).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Madagascar periwinkle.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Madagascar periwinkle.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nAnimal research shows that Madagascar periwinkle lowers blood glucose levels in diabetic rats (104764). Theoretically, using Madagascar periwinkle in combination with antidiabetes drugs might increase the risk of hypoglycemia; monitor blood glucose closely.\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nMadagascar periwinkle is thought to have diuretic properties (6). Theoretically, due to these potential diuretic effects, Madagascar periwinkle might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nAnimal research shows that Madagascar periwinkle lowers blood glucose levels (104764). Theoretically, taking Madagascar periwinkle with other herbs and supplements with hypoglycemic potential might increase the risk of hypoglycemia. Herbs with hypoglycemic potential include devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.",
            "Interactions with Conditions": "PERIOPERATIVE\nMadagascar periwinkle might affect blood glucose levels. Theoretically, Madagascar periwinkle might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue Madagascar periwinkle at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Madagascar periwinkle.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Madagascar periwinkle.",
            "Mechanism of Action": "General\nThe applicable parts of Madagascar periwinkle are the above ground parts and the root. The leaves and flowers of the plant contain approximately 130 different terpenoid indole alkaloids (100663, 100666). These alkaloids include vincristine, vinblastine, and leurosine (100663, 100666). The precursors to these alkaloids, catharanthine and vindoline, are found in the leaf wax exudate and leaf cells, respectively (100664). The leaf also contains flavonoids and polyphenols, including chlorogenic acid, caffeic acid, quercetin, coumaric acid, and rutin (104765). The root contains flavonoid glucosides, beta-sitosterol, and 3-epibetulinic acid, as well as small quantities of catharanthine and tabersonine (100667).\nAnti-inflammatory effects\nThe flavonoid glucosides derived from the root of Madagascar periwinkle have demonstrated anti-inflammatory activity. In vitro research shows that the flavonoid glucosides inhibit the production of matrix metallopeptidase 9 (MMP-9) and tumor necrosis factor (TNF)-alpha in cells treated with lipopolysaccharide (100667).\nAnticancer effects\nThe indole alkaloid constituents of Madagascar periwinkle have demonstrated potent anticancer activity in vitro and in vivo. Two constituents, vinblastine and vincristine, are approved by the US Food and Drug Administration (FDA) for use as chemotherapeutic agents (6). The FDA-approved vinca alkaloids work primarily by binding tubulin and inhibiting cell mitosis (6, 15). Other indole alkaloid constituents, including cathachunine, catharanthine, ajmalicine, tabersonine, lochnericine, and leurosine have also been shown to induce apoptosis of cancer cells via mediation of the NF-kB and JNK pathways. When used in combination, these compounds are believed to act synergistically (100663, 100666).\nAntidiabetes effects\nMadagascar periwinkle is traditionally used for the treatment of diabetes. Animal research shows that vindoline, a constituent of Madagascar periwinkle, reduces blood glucose following an oral glucose tolerance test in diabetic rats (104764).\n\nIn vitro research shows that vindolidine, vindolicine, and vindolinine, isolated from the leaf extract, inhibit protein tyrosine phosphatase-1B (PTP-1B), a protein involved in the development of diabetes and insulin resistance (100662). Other in vitro research shows that Madagascar periwinkle leaf extract may increase beta-cell viability during exposure to high concentrations of glucose, increase insulin secretion, and inhibit alpha glucosidase activity. Vindoline, a leaf constituent, appears to be responsible for at least part of this antidiabetic activity. Although some extracts of the leaf appear to decrease alpha amylase activity, other leaf extracts appear to increase alpha amylase activity (104765).\nAntioxidant effects\nIn vitro and animal research shows that Madagascar periwinkle leaf extract and vindolicine and vindoline, constituents of the leaf extract, have antioxidant activity. Vindolicine and vindoline scavenge free radicals and alleviate peroxide-induced oxidative damage in pancreatic cells (100662, 104765, 104764).\nCardiovascular effects\nReserpine and alstonine, constituents of the above ground parts of the plant, have hypotensive activity (6). Another constituent, ajmalicine, may have activity in the enhancement of cerebral blood flow (6).\nDiuretic effects\nThe constituent catharanthine is reported to have diuretic effects (6).\nLipid effects\nAnimal research shows that vindoline, a constituent of Madagascar periwinkle, decreases serum triglyceride and low-density lipoprotein cholesterol levels and increases serum high-density lipoprotein cholesterol levels in diabetic rats (104764).\nRenoprotective effects\nAnimal research shows that vindoline, a constituent of Madagascar periwinkle, decreases serum creatinine concentrations in diabetic rats (104764)."
        }
    },
    "Madder": {
        "sections": {
            "Overview": "Madder is a plant native to southwest and central Asia. It is also found in the Mediterranean (20043).",
            "Safety": "LIKELY UNSAFE when used orally. It is potentially carcinogenic and mutagenic (2, 18, 19).\nThere is insufficient reliable information available about the safety of madder when used topically.\nPREGNANCY: UNSAFE when used orally because it may be a potential menstrual stimulant and a genotoxin (2, 19).\nLACTATION: UNSAFE when used orally because it is a potential genotoxin (2, 19). It also can cause red-colored breast milk (2).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information available about the adverse effects of madder. Orally, madder can cause red colored urine, saliva, and perspiration (2). There is some concern that madder can stain contact lenses. Advise patients to be cautious (6002).\n\nTopically, contact dermatitis has been reported while handling madder (20044).\nDermatologic\nOrally, madder can cause red-colored perspiration (2).\nless\nGastrointestinal\nOrally, madder can cause red-colored saliva (2).\nless\nGenitourinary\nOrally, madder can cause red-colored urine (2).\nless\nImmunologic\nA case of contact dermatitis has been reported in a woman who handled madder while working in the garden (20044).\nless\nOcular/Otic\nThere is some concern that madder can stain contact lenses (6002).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of madder.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Traditionally, madder bark is prepared using one teaspoon boiled in a covered container with 3 cups of water for 30 minutes. The liquid is cooled slowly in the closed container and consumed cold as 1 to 2 cups per day (5254).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of madder.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "COLORIMETRIC TESTS\nTheoretically, madder might interfere with colorimetric tests involving urine, saliva, perspiration, and breast milk due to red coloring of these body fluids (2).\nless",
            "Overdose": "In mice, the toxicity testing of madder over 14 days resulted in a maximum tolerated dose of 3500-5000 mg/kg body weight. Toxicity testing over 90 days found no toxicity at concentrations of up to 5% of the total diet (20051). In another study in mice, there was no toxicity with a different madder extract at doses up to 10 grams/kg daily for 7 days (99990).\n\nIn rats, 10% madder root in the diet for 2 weeks increased the formation of DNA adducts in the liver, kidney, and colon (3718). The madder constituent lucidin, an anthracene derivative, has genotoxic activity, and causes dose-dependent increases in benign and malignant liver and kidney tumors in experimental rats (20047, 20049, 20052, 20053).",
            "Pharmacokinetics": "Excretion\nAfter oral intake, alizarin, a constituent of madder, is excreted in the urine and feces. The mean terminal elimination half-life was approximately 12 hours, with a renal clearance rate of 29.2 mL/minute (20056).",
            "Mechanism of Action": "General\nThe applicable part of madder is the root (99990). Madder contains the anthraquinones pseudopurpurin, purpurin, alizarin, lucidin, munjistin, and nordamnacanthal, as well as the carboxylic acids malic acid, citric acid, quinic acid, and rosmarinic acid (26154).\nAntidiarrheal effects\nMadder is traditionally used for diarrhea. The anti-diarrheal effects of madder have been shown in animal models. Madder appears to slow down intestinal transit (99990).\nAntimicrobial effects\nMadder is used topically for various skin conditions and for wound healing. In vitro, madder extract had antibacterial and antifungal effects (99989, 99991).\nAntiviral effects\nAlizarin, a constituent of madder root, and alizarin derivatives have been found to be competitive inhibitors of HIV-1 protease, an important drug target for HIV (20055).\nCalcium oxalate crystallization effects\nIn vitro evidence suggests that the madder root constituent alizarin can inhibit crystallization of calcium oxalate and phosphate under physiological conditions (20056). A reduction in calcium oxalate crystallization in the kidney might inhibit kidney or bladder stones (2). In a rat model of urolithiasis, administration of ethanolic and ethylene acetate extracts of madder root decreases crystal formation and size in a dose-dependent manner and attenuates urolithiasis-induced changes in serum and urinary biochemical parameters. Effects of the ethanolic extract appear to be more pronounced than those of the ethylene acetate extract, likely due to increased antioxidant activity and greater polyphenol content (105848)."
        }
    },
    "Magnesium": {
        "sections": {
            "Overview": "Magnesium is a chemical element that is important for normal bone structure (272). It also plays an essential role in many cellular reactions in the body (945). Foods that are high in fiber are generally high in magnesium (13382). Dietary sources of magnesium include legumes, whole grains, some vegetables, seeds, and nuts (especially almonds). Other sources include dairy products, meats, chocolate, and coffee (8088, 12504, 12505). Water with a high mineral content, or \"hard\" water, is also a source of magnesium. Dietary intake of magnesium may be low, particularly in females, African Americans, and the elderly (8088, 8099, 8998, 9001, 12504, 12505, 12510, 12511).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Oral magnesium is safe when used in doses below the tolerable upper intake level (UL) of 350 mg daily (7555). ...when used parenterally and appropriately. Parenteral magnesium sulfate is an FDA-approved prescription product (96484).\nPOSSIBLY UNSAFE when used orally in excessive doses. Doses greater than the tolerable upper intake level (UL) of 350 mg daily frequently cause loose stools and diarrhea (7555).\nCHILDREN: LIKELY SAFE when used orally and appropriately. Magnesium is safe when used in doses below the tolerable upper intake level (UL) of 65 mg daily for children 1 to 3 years, 110 mg daily for children 4 to 8 years, and 350 mg daily for children older than 8 years (7555, 89396). ...when used parenterally and appropriately (96483).\nCHILDREN: LIKELY UNSAFE when used orally in excessive doses. Tell patients not to use doses above the tolerable upper intake level (UL). Higher doses can cause diarrhea and symptomatic hypermagnesemia including hypotension, nausea, vomiting, and bradycardia (7555, 8095).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally and appropriately. Magnesium is safe for those pregnant and breast-feeding when used in doses below the tolerable upper intake level (UL) of 350 mg daily (7555).\nPREGNANCY AND LACTATION: POSSIBLY SAFE when prescription magnesium sulfate is given intramuscularly and intravenously prior to delivery for up to 5 days (12592, 89397, 99354, 99355). However, due to potential adverse effects associated with intravenous and intramuscular magnesium, use during pregnancy is limited to patients with specific conditions such as severe pre-eclampsia or eclampsia. There is some evidence that intravenous magnesium can increase fetal mortality and adversely affect neurological and skeletal development (12590, 12593, 60818, 99354, 99355). However, a more recent analysis of clinical research shows that increased risk of fetal mortality seems to occur only in the studies where antenatal magnesium is used for tocolysis and not for fetal neuroprotection or pre-eclampsia/eclampsia (102457). Furthermore, antenatal magnesium does not seem to be associated with increased risk of necrotizing enterocolitis in preterm infants (104396). There is also concern that magnesium increases the risk of maternal adverse events. A meta-analysis of clinical research shows that magnesium sulfate might increase the risk of maternal adverse events, especially in Hispanic mothers compared to other racial and ethnic groups (60971, 99319).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally in excessive doses. Tell patients to avoid exceeding the tolerable upper intake level (UL) of 350 mg daily. Taking magnesium orally in higher doses can cause diarrhea (7555). ...when prescription magnesium sulfate is given intramuscularly and intravenously prior to delivery for longer than 5 days (12592, 89397, 99354, 99355). Maternal exposure to magnesium for longer than 5-7 days is associated with an increase in neonatal bone abnormalities such as osteopenia and fractures. The U.S. Food and Drug Administration (FDA) recommends that magnesium injection not be given for longer than 5-7 days (12590, 12593, 60818, 99354, 99355).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nMagnesium is generally well tolerated. Some clinical research shows no differences in adverse effects between placebo and magnesium groups.\nMost Common Adverse Effects\nOrally: Diarrhea, gastrointestinal irritation, nausea, and vomiting.\n\nIntravenously: Bradycardia, dizziness, flushing sensation, hypotension, and localized pain and irritation. In pregnancy, may cause blurry vision, dizziness, lethargy, nausea, nystagmus, and perception of warmth.\nSerious Adverse Effects (Rare)\nAll ROAs: With toxic doses, loss of reflexes and respiratory depression can occur. High doses in pregnancy can increase risk of neonatal mortality and neurological defects.\nCardiovascular\nIntravenously, magnesium can cause bradycardia, tachycardia, and hypotension (13356, 60795, 60838, 60872, 60960, 60973, 60982, 61001, 61031, 114681). Inhaled magnesium administered by nebulizer may also cause hypotension (113466). Magnesium sulfate may cause rapid heartbeat when administered antenatally (60915, 114681).\n\nIn one case report, a 99-year-old male who took oral magnesium oxide 3000 mg daily for chronic constipation was hospitalized with hypermagnesemia, hypotension, bradycardia, heart failure, cardiomegaly, second-degree sinoatrial block, and complete bundle branch block. The patient recovered after discontinuing the magnesium oxide (108966).\nless\nDermatologic\nIntravenously, magnesium may cause flushing, sweating, and problems at the injection site (including burning pain) (60960, 60982, 111696, 114681). In a case study, two patients who received intravenous magnesium sulfate for suppression of preterm labor developed a rapid and sudden onset of an urticarial eruption (a skin eruption of itching welts). The eruption cleared when magnesium sulfate was discontinued (61045). Orally, magnesium oxide may cause allergic skin rash, but this is rare. In one case report, a patient developed a rash after taking 600 mg magnesium oxide (Maglax) (98291).\nless\nGastrointestinal\nOrally, magnesium can cause gastrointestinal irritation, nausea, vomiting, and diarrhea (1194, 4891, 10661, 10663, 18111, 60951, 61016, 98290). In rare cases, taking magnesium orally might cause a bezoar, an indigestible mass of material which gets lodged in the gastrointestinal tract. In a case report, a 75-year-old female with advanced rectal cancer taking magnesium 1500 mg daily presented with nausea and anorexia from magnesium oxide bezoars in her stomach (99314). Magnesium can cause nausea, vomiting, or dry mouth when administered intravenously or by nebulization (60818, 60960, 60982, 104400, 113466, 114681). Antenatal magnesium sulfate may also cause nausea and vomiting (60915, 114681). Two case reports suggest that giving magnesium 50 grams orally for bowel preparation for colonoscopy in patients with colorectal cancer may lead to intestinal perforation and possibly death (90006).\n\nDelayed meconium passage and obstruction have been reported rarely in neonates after intravenous magnesium sulfate was given to the mother during pregnancy (60818). In a retrospective study of 200 neonates born prematurely before 32 weeks of gestation, administration of prenatal IV magnesium sulfate, as a 4-gram loading dose and then 1-2 grams hourly, was not associated with the rate of meconium bowel obstruction when compared with neonates whose mothers had not received magnesium sulfate (108728).\nless\nGenitourinary\nIntravenously, magnesium sulfate may cause renal toxicity or acute urinary retention, although these events are rare (60818, 61012). A case of slowed cervical dilation at delivery has been reported for a patient administered intravenous magnesium sulfate for eclampsia (12592). Intravenous magnesium might also cause solute diuresis. In a case report, a pregnant patient experienced polyuria and diuresis after having received intravenous magnesium sulfate in Ringer's lactate solution for preterm uterine contractions (98284).\nless\nHematologic\nIntravenously, magnesium may cause increased blood loss at delivery when administered for eclampsia or pre-eclampsia (12592). However, research on the effect of intravenous magnesium on postpartum hemorrhage is mixed. Some research shows that it does not affect risk of postpartum hemorrhage (60982), while other research shows that intrapartum magnesium administration is associated with increased odds of postpartum hemorrhage, increased odds of uterine atony (a condition that increases the risk for postpartum hemorrhage) and increased need for red blood cell transfusions (97489).\nless\nMusculoskeletal\nIntravenously, magnesium may cause decreased skeletal muscle tone, muscle weakness, or hypocalcemic tetany (60818, 60960, 60973).\n\nAlthough magnesium is important for normal bone structure and maintenance (272), there is concern that very high doses of magnesium may be detrimental. In a case series of 9 patients receiving long-term tocolysis for 11-97 days, resulting in cumulative magnesium sulfate doses of 168-3756 grams, a lower bone mass was noted in 4 cases receiving doses above 1000 grams. There was one case of pregnancy- and lactation-associated osteoporosis and one fracture (108731). The validity and clinical significance of this data is unclear.\nless\nNeurologic/CNS\nIntravenously, magnesium may cause slurred speech, dizziness, drowsiness, confusion, or headaches (60818, 60960, 114681). With toxic doses, loss of reflexes, neurological defects, drowsiness, confusion, and coma can occur (8095, 12589, 12590).\n\nA case report describes cerebral cortical and subcortical edema consistent with posterior reversible encephalopathy syndrome (PRES), eclampsia, somnolence, seizures, absent deep tendon reflexes, hard to control hypertension, acute renal failure and hypermagnesemia (serum level 11.5 mg/dL), after treatment with intravenous magnesium sulfate for preeclampsia in a 24-year-old primigravida at 39 weeks gestation with a previously uncomplicated pregnancy. The symptoms resolved after 4 days of symptomatic treatment in an intensive care unit, and emergency cesarian delivery of a healthy infant (112785).\nless\nOcular/Otic\nIntravenously, magnesium may cause blurred vision (114681). Additionally, cases of visual impairment or nystagmus have been reported following magnesium supplementation, but these events are rare (18111, 60818).\nless\nPsychiatric\nA case of delirium due to hypermagnesemia has been reported for a patient receiving intravenous magnesium sulfate for pre-eclampsia (60780).\nless\nPulmonary/Respiratory\nIntravenously, magnesium may cause respiratory depression and tachypnea when used in toxic doses (12589, 61028, 61180).\nless\nOther\nHypothermia from magnesium used as a tocolytic has been reported (60818).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nEFFECTIVE\nBowel preparation. Various magnesium salts are used for cleansing the bowel prior to procedures such as colonoscopy.\nVarious magnesium salts, including citrate, hydroxide, oxide, and sulfate, are ingredients in bowel preparation products available over-the-counter or by prescription only.\nless\nConstipation. Magnesium salts are effective when used short-term orally to treat constipation and chronic idiopathic constipation (CIC).\nMagnesium citrate, hydroxide, oxide, and sulfate salts are commonly used as laxatives. Magnesium citrate 11.3-17.45 grams has been used; magnesium hydroxide 2.4-4.8 grams, as 30-60 mL of milk of magnesia, has also been used (113483, 113484). Magnesium sulfate, also known as Epsom salt, which seems to have the most potent effect, has been used as 10-30 grams (6430, 113485). Magnesium salts should only be used for occasional treatment of constipation, and doses should be taken with a full 8-ounce glass of water.\n\nMagnesium oxide seems to be beneficial in adults with CIC when taken short-term. Clinical guidelines published by the American Gastroenterology Association and American College of Gastroenterology in 2023 give a conditional recommendation suggesting the use of magnesium oxide over managing CIC without magnesium oxide based on low-quality studies conducted over 4 weeks. The recommended starting dose is 400-500 mg daily with dose titration per symptom response and side effects (112859). A small clinical study in patients with CIC who are not taking chronic medications shows that taking magnesium oxide 1.5 grams in three divided doses daily for 28 days increases spontaneous bowel movements when compared with placebo (104397). It is unknown if magnesium is beneficial for CIC when used long-term.\nless\nDyspepsia. Magnesium salts are effective when used orally as antacids.\nMagnesium carbonate, hydroxide, oxide, or trisilicate salts are used orally as antacids to reduce symptoms of gastric hyperacidity or gastroesophageal reflux. Magnesium hydroxide has the fastest onset of action. The onset for magnesium carbonate is slower due to its crystal structure. Magnesium trisilicate has the slowest onset and longest duration of action due to poor solubility (6844). Doses used include magnesium hydroxide 400-1200 mg (5-15 mL of milk of magnesia) up to four times daily, or magnesium oxide 800 mg daily (15).\nless\nEclampsia. Magnesium sulfate is considered the drug of choice for control of seizures.\nIntravenous (IV) and/or intramuscular (IM) magnesium sulfate is considered the agent of choice for seizure prophylaxis during eclampsia by the American College of Obstetricians and Gynecologists (ACOG) (15, 12591, 12592, 61012, 61184). Typical doses include 4-6 grams of magnesium sulfate by IV infusion in 250 mL of dextrose 5% or normal saline solution, followed by 4-5 grams of magnesium sulfate IM every 4 hours, or 1-3 grams per hour by continuous IV infusion. Doses should be adjusted according to serum levels and urinary excretion, and should not exceed 30-40 grams of magnesium sulfate daily (15, 12591). Meta-analyses of clinical research show that treatment with IV or IM magnesium reduces the risk of seizure recurrence by 33% to 69% when compared with phenytoin, and by 47% to 60% when compared with diazepam (19960, 60818, 60954, 60964, 61105). One preliminary clinical study shows that lower doses of IV magnesium sulfate (9 grams loading dose and maintenance of 2.5 grams every 4 hours for 24 hours) are as effective as higher doses (14 grams loading dose and maintenance of 5 grams every 4 hours for 24 hours) for reducing the recurrence of eclamptic seizures (89383). It is generally recommended that treatment be continued for at least 24 hours after the last seizure (15). Oral magnesium has not been evaluated for eclampsia.\nless\nHypomagnesemia. Hypomagnesemia can be effectively treated with oral or parenteral magnesium.\nTaking magnesium orally or parenterally is helpful for treating and preventing hypomagnesemia associated with alcoholism, cirrhosis of the liver, congestive heart failure (CHF), severe or prolonged diarrhea or vomiting, kidney dysfunction, inflammatory bowel disease (IBD), pancreatitis, malabsorption syndromes, and other conditions (6280, 6281, 8088, 8089).\n\nThe dose and salt of magnesium for oral replacement therapy should be chosen carefully to avoid causing diarrhea. The gluconate and chloride salts cause less diarrhea, while the oxide salt is more likely to cause diarrhea and should be avoided. Magnesium chloride should also be avoided due to poor solubility which decreases absorption (6430, 8099, 10664). Orally, magnesium sulfate 3 grams every 6 hours for four doses has been used for hypomagnesemia (15). Parenteral magnesium doses must be individualized according to serum magnesium levels, but a typical starting dose for mild deficiency is 1 gram of magnesium sulfate intramuscularly (IM) every 6 hours for 4 doses (15). For more severe deficiency, 5 grams of magnesium sulfate may be given as an intravenous (IV) infusion in 1 liter of dextrose 5% or normal saline solution over 3 hours (15).\nless\nPre-eclampsia. Magnesium sulfate is considered the drug of choice for seizure prophylaxis in patients with pre-eclampsia.\nIntravenous (IV) and/or intramuscular (IM) magnesium sulfate is considered the agent of choice for seizure prophylaxis during pre-eclampsia by the American College of Obstetricians and Gynecologists (ACOG) (12591, 12592, 61012, 61184). Some meta-analyses show that IV administration of magnesium sulfate reduces the risk of eclampsia when compared with placebo, phenytoin, or diazepam in patients with pre-eclampsia (19960, 60818, 60960, 60979). A typical initial dose is 4-5 grams of magnesium sulfate by IV infusion in 250 mL of dextrose 5% or normal saline solution, followed by 4-5 grams of magnesium sulfate IM every 4 hours, or 1-3 grams of magnesium sulfate per hour by continuous IV infusion. Doses should be adjusted according to serum levels and urinary excretion, and should not exceed 30-40 grams of magnesium sulfate daily (15, 12591). The optimal duration of prophylaxis has not been determined. A meta-analysis suggests that using a shorter duration of 12 hours or less is not associated with an increase in risk of eclamptic seizures when compared with regimens of 24 hours or longer (108732). However, studies are likely underpowered due to the low incidence of eclampsia.\n\nOral magnesium has been evaluated for the prevention of pre-eclampsia in healthy adults, but taking magnesium citrate 300 mg daily, starting at 12-20 weeks' gestation and continuing until delivery, does not reduce the incidence of pre-eclampsia when compared with placebo (103724).\nless\nLIKELY EFFECTIVE\nCerebral palsy. Most evidence shows that antenatal magnesium reduces the risk of cerebral palsy in preterm infants, although there are some inconsistent results.\nMost clinical studies and meta-analyses show that antenatal magnesium sulfate reduces the risk of cerebral palsy by about 32% and the risk of motor dysfunction by about 45% in preterm infants (60915, 60927, 60931, 61001, 97485, 103734, 103754, 114675, 114681). The lowest effective dose of magnesium sulfate seems to be 4 grams intravenously, with or without a maintenance dose of 1 gram/hour until birth or for 24 hours. In obese females, a higher dose, based on body weight, may be needed (97485, 97495, 103734, 103754). However, some studies have inconsistent results (8093, 19998, 98293, 98295, 112784). Giving females at risk of imminent preterm birth (prior to 32 weeks), intravenous magnesium sulfate 4.5 grams over 20 minutes followed by 1 gram per hour until birth or for 24 hours, in addition to a standard treatment protocol, does not reduce the incidence of cerebral palsy (112784).\n\nOral magnesium has not been evaluated for this purpose.\nless\nSeizures. Intravenous magnesium sulfate is used for treating seizures of various etiologies.\nIntravenous magnesium sulfate may be useful for controlling seizures associated with epilepsy, glomerulonephritis, hypothyroidism, and acute nephritis in children (15). Oral magnesium has not been evaluated for this purpose.\nless\nTorsades de pointes. Intravenous magnesium sulfate is the first-line treatment for torsades de pointes after measures to correct precipitating factors have been unsuccessful.\nIntravenous magnesium sulfate has been used successfully to treat the life-threatening ventricular tachycardia, torsades de pointes (15, 6844). The Advanced Cardiac Life Support (ACLS) guidelines of the American Heart Association recommend a dose of 1 to 2 grams diluted in 50-100 mL Dextrose 5% solution given IV over 5-60 minutes, followed by a continuous IV infusion of 0.5-1 gram/hour.\nless\nPOSSIBLY EFFECTIVE\nArrhythmia. Magnesium sulfate is effective for the specific type of ventricular tachycardia known as torsades de pointes, and seems to be helpful for treating other types of arrhythmias. Evidence for the role of oral or intravenous magnesium in preventing postoperative arrhythmias is conflicting.\nAdministering magnesium intravenously or orally may be helpful for treating atrial and ventricular tachycardia and fibrillation, and supraventricular tachycardia (9497, 13352, 13354, 13355, 13356, 60804, 60829, 60877, 61113, 111696). Arrhythmias associated with congestive heart failure have been treated with magnesium sulfate 8 grams infused over 12 hours (9497). For rate control in atrial fibrillation, magnesium sulfate 2.5 grams IV over 20 minutes, followed by 2.5 grams IV over 2 hours has been used (13356). For paroxysmal supraventricular tachycardia, single doses of 1-4 grams of magnesium chloride have been used (13352). For atrial tachycardia, 2 grams of magnesium sulfate in 10 mL of dextrose 5% solution has been given IV over 1-10 minutes, followed by 5-10 grams of magnesium sulfate in 250-500 mL dextrose 5% solution as an IV infusion over 5 hours (13354, 13355).\n\nResearch on the effects of intravenous magnesium for preventing arrhythmias after cardiac surgery is conflicting. Some meta-analyses show that intravenous magnesium reduces the risk of atrial fibrillation, ventricular arrhythmias, or supraventricular arrhythmias following cardiac surgery by 23% to 48% when compared with placebo (60814, 60826, 60828, 60838, 61008, 61033, 61181, 97487, 97490). Doses of magnesium sulfate used include 30 mg/kg in 500 mL normal saline (97490), or 80-100 mg/kg added to the cardioplegia solution (97487). Also, one small study in adults after CABG surgery suggests that taking magnesium hydroxide 1600 mg orally reduces arrhythmia as effectively as receiving magnesium sulfate 2000 mg intravenously (99315). However, other meta-analyses that only include higher-quality trials show that magnesium supplementation does not reduce the risk of ventricular or supraventricular arrhythmias following cardiac surgery (61010, 61024, 61031, 105081).\n\nA meta-analysis of clinical trials of intravenous magnesium for prevention of new-onset atrial fibrillation after non-cardiac surgeries shows that it does not reduce the incidence significantly when compared with placebo (112778). However, there was a high risk of bias in the analysis, and variability in types of surgery, and the salt and dose of magnesium used.\nless\nAsthma. Parenteral magnesium sulfate can help to reverse severe acute asthma attacks and reduce the need for hospital admission. It is unclear if nebulized magnesium is beneficial for acute asthma attacks. However, oral magnesium does not seem to be beneficial.\nOverall, a single dose of intravenous magnesium seems to improve pulmonary function in acute asthma exacerbation and reduce the risk of hospitalization, particularly in patients with severe asthma, and those who have failed initial treatment with nebulized albuterol and intravenous corticosteroids (60888, 90023, 96483, 104398, 107365). The typical dose used for adults is 2 grams of magnesium sulfate infused over 20 minutes (15). For children, 25-75 mg/kg, to a maximum of 2 grams, infused over 20-30 minutes has been used (15, 96483, 107365). However, a post-hoc analysis of one large clinical trial (104400) designed to assess nebulized magnesium in children with acute asthma has found that adding IV magnesium to nebulized magnesium is associated with greater odds of hospitalization when compared with no IV magnesium (105919). This post-hoc analysis did not differentiate between precautionary and necessary hospitalizations.\n\nAlthough some clinical research and a meta-analysis in patients with acute asthma exacerbation show that nebulized magnesium in combination with standard treatment improves airway function, respiratory rate, and clinical asthma severity when compared with standard treatment alone, it is unclear whether these findings are clinically relevant (90016, 113466). Most evidence, including larger clinical trials and meta-analyses, has not shown benefit of adjunct nebulized magnesium for acute asthma in adults or children (60888, 90002, 96484, 104400, 105920, 113466, 114674). Oral magnesium also does not seem to be beneficial. A meta-analysis of small clinical trials in children and adults with asthma shows that taking magnesium supplements orally does not improve lung function or reduce bronchodilator use when compared with control (104404).\nless\nColorectal cancer. Increasing dietary magnesium intake seems to lower the risk of colon cancer but not rectal cancer.\nEpidemiological research shows that increased dietary magnesium intake is associated with a reduced risk of colon cancer, but the risk of rectal cancer is not affected (89387, 90017, 90027, 101355).\nless\nDiabetes. Low dietary magnesium may increase the risk of developing type 2 diabetes, but evidence on the use of supplements for treating type 2 diabetes is conflicting.\nHigher dietary magnesium intake is associated with lower fasting insulin concentrations and a reduced risk of developing type 2 diabetes in adults and obese children (13369, 15548, 96473, 97486, 98294, 103736, 105918, 106920). In people with existing type 2 diabetes, hypomagnesemia is found in 25% to 38% of patients, especially in those with poorly controlled diabetes (1172). Population research in adults with type 2 diabetes also shows that a dietary magnesium intake of less than 250 mg daily is associated with a 56% higher risk of mortality. Preliminary subgroup analyses suggest that the risk of mortality is higher in those with glycated hemoglobin (HbA1C) levels above 7% (110051).\n\nA meta-analysis of small, heterogeneous clinical studies in adults with type 2 diabetes suggests that magnesium may modestly reduce HbA1C in patients with hypomagnesemia, but not in patients with normal magnesium levels, when compared with control (105075). Individual clinical studies using magnesium supplements in patients with type 2 diabetes or insulin resistance have shown mixed results. Some research suggests magnesium supplements can decrease fasting blood glucose and improve insulin sensitivity, as well as reduce the risk of developing diabetes in high-risk patients (10664, 12582, 13376, 60854, 99313, 106920), but other research shows no effect (1171, 1172, 13379, 13380, 112780). Discrepancies in these findings might reflect differences in magnesium salts and doses used, or differences in baseline magnesium status in study subjects.\nless\nHypercholesterolemia. Magnesium may help improve lipid levels by a small amount in people with this condition.\nThere is some evidence that taking magnesium oxide 1 gram orally daily for 6 weeks can produce small decreases in low-density lipoprotein (LDL) and total cholesterol levels, and small increases in high-density lipoprotein (HDL) levels in patients with hypercholesterolemia. However, magnesium does not seem to improve lipoprotein (a) levels (1193). Magnesium may also lower triglycerides in people with hypertriglyceridemia (97494).\nless\nMetabolic syndrome. Low dietary and serum levels of magnesium seem to be associated with the development of metabolic syndrome.\nHigher magnesium intake from diet and supplements is associated with a 27% lower risk of developing metabolic syndrome in healthy females (13371) and a 31% lower risk in healthy young adults (14304). Additional epidemiological research suggests that people with low serum magnesium levels are 6-7 times more likely to have metabolic syndrome than people with normal magnesium levels (13372). In a population analysis of over 6000 individuals without metabolic syndrome at baseline, the risk of developing this condition over a 6-year follow-up period was reduced by 16% in the highest quintile of dietary magnesium intake (median intake 371 mg daily) when compared with the lowest quintile (median intake 203 mg daily). Some, but not all, research suggests that the hazard ratio for metabolic syndrome in relation to magnesium intake may be U-shaped, with higher risk at intakes below about 150 mg daily and above 600 mg daily (108963).\n\nA combination of magnesium 20 mEq daily and potassium 40 mEq daily (magnesium potassium citrate) taken orally for 16 weeks reverses metabolic side effects of chlorthalidone, such as increased fasting plasma glucose and hypokalemia, more effectively than potassium chloride 40 mEq daily alone (112932).\nless\nOsteoporosis. Increased dietary and supplemental magnesium intake seems to increase bone mineral density and decrease bone loss in postmenopausal patients.\nPreliminary clinical research shows that taking magnesium hydroxide orally, 300-1800 mg daily for 6 months, then 600 mg daily for 18 months, or magnesium citrate orally 1830 mg daily for 30 days, might reduce bone loss and bone turnover in postmenopausal patients with osteoporosis (9104, 60928). Some epidemiological research also suggests that magnesium intake is related to increased bone mineral density (12501, 12502, 12503, 12504, 90014), although not all studies have found an association (12505, 98286).\nless\nPostoperative pain. Injectable magnesium has been used with promising results for reducing pain and the need for other analgesics postoperatively. However, it is unclear if oral magnesium is beneficial for postoperative pain.\nA meta-analysis of 25 clinical trials shows that intravenous (IV) magnesium sulfate, 5-50 mg/kg bolus followed by a continuous infusion of 6 mg/kg or 500 mg hourly during surgery, seems to reduce the 24-hour postoperative use of IV morphine by 24% when compared with placebo (19968). Adding IV magnesium sulfate 3.7-5.5 grams to patient-controlled analgesia for 24 hours after surgery has also been used (19968). Additionally, meta-analyses support that adjunctive IV or intrathecal administration of magnesium reduces post-operative pain scores, improves pain relief and sensory nerve block, and decreases the need for other analgesics, when compared with control (89390, 90012, 90015, 98287, 103728, 114676, 114677, 114678). However, some data are conflicting. In a meta-analysis of 7 trials, IV magnesium was not associated with lower pain scores over the first 48 hours postoperatively. The reasons for these discrepant findings are unclear but may be explained by differences in magnesium regimens, anesthesia protocols, and surgical populations studied. Additionally, IV magnesium appears to be less effective than dexmedetomidine (105082).\n\nTwo moderate-sized clinical studies in patients undergoing total knee arthroplasty in China show that adding magnesium sulfate 2.5 mg/mL to the periarticular infiltration analgesia (PIA) cocktail or administering IV magnesium sulfate 40 mg/kg before anesthesia induction then as a 15 mg/kg infusion during surgery reduces pain scores, increases comfort levels, limits and delays the use of postoperative opioids, prolongs analgesia, and reduces markers of inflammation when compared with the usual PIA cocktail or control (111181, 113677). Administering magnesium intravenously also seems to be helpful for pain control after hysterectomy. A 3-gram IV bolus of magnesium sulfate followed by an infusion of 0.5 grams per hour for 20 hours has been used. Lower doses were not effective (6848). In males undergoing laparoscopic radical resection for gastrointestinal cancer, administering IV magnesium intraoperatively, as a loading dose of 40 mg/kg followed by 15 mg/kg/hour through the end of surgery, reduces postoperative catheter-related bladder discomfort and analgesic requirements, when compared with placebo (112783). However, IV magnesium might not alleviate postoperative pain in children. Two small clinical studies show that administering a magnesium IV infusion does not reduce pain when compared with saline in children after tonsillectomy or after elective strabismus surgery (98282, 105077).\n\nOral magnesium has also been evaluated for postoperative pain. A small, single-center, clinical study in Thailand in adults undergoing oral surgery and taking postoperative ibuprofen shows that adding magnesium (Magnesium, Life Extension) 500 mg once prior to surgery and daily for 3 days post-surgery slightly improves self-reported pain at rest after 24 hours but not at other time points when compared with placebo (116617). These results are unlikely to be clinically significant.\nless\nPremenstrual syndrome (PMS). Taking magnesium orally seems to relieve symptoms of PMS.\nThere is some evidence that magnesium supplementation can improve symptoms, including mood changes and fluid retention, in some patients with PMS (1187, 1188, 6847). Doses used include magnesium oxide 333 mg daily for 2 menstrual cycles, or magnesium pyrrolidone carboxylic acid equivalent to 360 mg elemental magnesium three times daily, from the 15th day of the menstrual cycle until onset of menstrual flow (1187, 1188). Taking magnesium orally in a dose of 360 mg (elemental magnesium) three times daily for 2 months seems to prevent premenstrual migraine (1186, 6847). A combination of magnesium 200 mg daily plus vitamin B6 50 mg daily seems to reduce anxiety-related premenstrual symptoms, including nervous tension, mood swings, irritability, and anxiety, when compared with placebo (8555).\nless\nVasospastic angina. Intravenous magnesium seems to prevent coronary spasm in patients with this condition.\nClinical research shows that administration of intravenous magnesium sulfate 65 mg/kg infused over 20 minutes dilates coronary arteries and suppresses acetylcholine-induced coronary spasms when compared with infusion of a dextrose solution in patients with vasospastic angina (8091).\nless\nPOSSIBLY INEFFECTIVE\nAltitude sickness. Taking magnesium citrate orally does not seem to reduce acute altitude sickness risk.\nClinical research shows that taking magnesium citrate 1200 mg daily orally in three divided doses, beginning 3 days prior to mountain ascent and continuing until mountain descent, does not reduce the risk of acute altitude sickness when compared with placebo (60801).\nless\nAthletic performance. Taking magnesium orally does not seem to improve energy or endurance during athletic activity.\nMost evidence suggests that taking magnesium orally doesn't increase energy and endurance during athletic activity. Magnesium oxide, aspartate, and orotate salts do not seem to improve exercise performance when used alone or in combination with potassium, vitamin B6, or zinc (2825, 2826, 2828, 2829, 2830, 60751, 113655).\nless\nBronchiolitis. Intravenous or nebulized magnesium is not beneficial in infants with this condition.\nClinical research shows that administering a single IV dose of magnesium sulfate 100 mg/kg to infants with acute bronchiolitis does not improve, and may actually worsen, symptoms when compared with placebo (97482). A clinical study in infants with moderate to severe bronchiolitis shows that adding nebulized magnesium sulfate 40 mg/kg to nebulized epinephrine does not reduce hospital stay or the need for ventilator or oxygen support when compared with epinephrine alone (99317). Oral magnesium has not been evaluated for this use.\nless\nChemotherapy-induced peripheral neuropathy. Research on the effects of intravenous infusions of magnesium and calcium for preventing oxaliplatin neurotoxicity are inconsistent, but higher quality studies seem to show no benefit.\nPooled analyses of cohort studies and clinical trials show that calcium and magnesium infusions can decrease the incidence of severe oxaliplatin-induced neurotoxicity (90028, 90029, 90031). However, when only clinical trials are considered, the infusions do not appear to be helpful (90005, 90029, 90031, 96474, 96479).\nless\nComplex regional pain syndrome. Intravenous magnesium is not beneficial in complex regional pain syndrome type 1.\nClinical research shows that receiving magnesium sulfate 70 mg/kg intravenously at the rate of 25 mL/hour for 4 hours each day for 5 days does not improve pain or level of impairment when compared with placebo in patients with chronic complex regional pain syndrome type 1 (89395).\nless\nEmergence delirium. The majority of small clinical studies in adults and children undergoing various surgeries suggest that intravenous (IV) magnesium doesn't reduce the risk of emergence delirium. However, most clinical studies in adults suggest that IV magnesium reduces emergence agitation.\nA small clinical study in adults undergoing surgery for endovascular aortic aneurysm repair shows that administering IV magnesium 30 mg/kg as a loading dose, followed by a 10 mg/kg/hour infusion for the duration of surgery, does not improve agitation or delirium scores when compared with administering saline (111182). Similarly, a small clinical study in children ages 2-5 years undergoing elective strabismus surgery shows that administering IV magnesium during anesthesia does not seem to prevent the occurrence of emergence delirium when compared with administering saline (105077). In a meta-analysis of 8 clinical trials in children aged 2-16 years undergoing general anesthesia for oral or ophthalmic surgery, giving IV magnesium as a 30 mg/kg loading dose followed by a 10 mg/kg/hour infusion, or as a single dose of 15-30 mg/kg, does not reduce emergence delirium scores, and may actually prolong emergence times (108729).\n\nHowever, there is some conflicting evidence. In patients undergoing radical mastectomy, giving intraoperative magnesium sulfate 30mg/kg over 1 hour, followed by 10 mg/kg/hour until the end of surgery, reduces emergence agitation (odds ratio 0.26) when compared with placebo (112781).\nless\nMenopausal symptoms. Oral magnesium oxide does not seem to be beneficial for menopausal hot flashes.\nA small, low quality study in postmenopausal patients with a history of breast cancer shows that taking magnesium oxide 400-800 mg orally daily reduces hot flashes when compared with baseline (102454). However, a larger, higher quality clinical study using magnesium oxide 800-1200 mg daily did not show any benefit when compared with placebo (98290).\nless\nMuscle cramps. Oral magnesium does not seem to improve muscle cramp frequency or intensity.\nMeta-analyses of small clinical trials show that magnesium supplementation for 3-6 weeks does not decrease the frequency or intensity of skeletal muscle cramps, whether the cramps are idiopathic or due to liver cirrhosis or pregnancy, when compared with placebo (90022, 104395).\nless\nPolycystic ovary syndrome (PCOS). Oral magnesium does not seem beneficial for improving metabolic indices in patients with PCOS.\nA meta-analysis of moderate-quality clinical studies in Iran in patients with PCOS shows that taking magnesium 250 mg daily for 8-20 weeks does not improve glycemic indices, hormonal factors, lipid levels, or measures of body size (e.g., weight, waist circumference) when compared with placebo (116619) However, a clinical study, included in the above meta-analysis, shows that taking magnesium oxide orally, 250 mg daily for 10 weeks improves subjective measures of quality of life, fatigue, and emotional functioning, but not objective measures such as alopecia, abnormal uterine bleeding, or acne, when compared with placebo (108965).\n\nA clinical study using a combination of magnesium 250 mg with vitamin E 400 mg daily for 12 weeks shows a modest reduction in insulin resistance, insulin levels, and triglyceride levels, but not other lipid levels, when compared with placebo (100264). It is unclear if these beneficial effects are due to magnesium, vitamin E, or the combination.\nless\nSickle cell disease. Intravenous magnesium does not add any benefit to standard therapy for sickle cell disease in children.\nClinical research shows that giving magnesium sulfate 40-100 mg/kg (maximum of 2 grams per dose) intravenously every hour for 6-8 doses as an adjunct to standard therapy does not decrease hospital stay, pain, or opioid use, or improve quality of life, when compared with standard therapy and placebo in children with sickle cell disease (89399, 98283, 101356). Oral magnesium has not been evaluated for this purpose.\nless\nStillbirth. Magnesium administered during pregnancy does not reduce stillbirth risk.\nA meta-analysis of clinical research shows that magnesium supplementation does not significantly decrease the risk of stillbirths when administered during pregnancy (60925, 60978).\nless\nTetanus. Intravenous magnesium sulfate does not seem to improve outcomes in patients with this condition.\nA meta-analysis of clinical research shows that intravenous magnesium sulfate does not reduce mortality when compared with placebo or diazepam in patients with tetanus (61020). While some research shows that magnesium reduces the duration of hospitalization and the need for ventilation when compared with diazepam (61170), magnesium does not seem to improve these outcomes when compared with placebo (60860).\nless\nTraumatic brain injury (TBI). Magnesium does not improve clinical outcomes in patients with moderate to severe TBI. Its effect in patients with concussions is unclear.\nA meta-analysis of four clinical trials shows that treatment with magnesium does not significantly improve neurological outcomes or reduce the risk of mortality when compared with placebo in patients with moderate to severe TBI (60905). A small observational cohort study in adolescents with concussions has found that adding oral magnesium 400 mg twice daily for 5 days to standard treatment with acetaminophen and ondansetron is associated with a trend toward reduced symptom severity when compared with standard treatment alone (104401). The validity of this study is limited by its observational nature and small cohort size.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlcohol use disorder. Intravenous magnesium does not seem to help reduce symptoms of alcohol withdrawal but may reduce the duration of alcoholic delirium.\nPreliminary clinical research shows that administration of four intramuscular injections of magnesium sulfate 2 grams at 6-hour intervals does not reduce symptoms of alcohol withdrawal when compared with saline (61063). A small observational study in patients with alcoholic delirium has found that administering magnesium sulfate IV 50 mg/kg every 8 hours, in addition to usual sedation, is associated with a reduction of delirium by approximately 2 days, or 4 days when given every 12 hours in addition to dexmedetomidine, when compared with usual sedation alone (111180). However, half of patients had hypomagnesemia at baseline; it is unclear if effects would be similar for patients with normal magnesium levels. Oral magnesium has not been evaluated for this purpose.\nless\nAllergic rhinitis (hay fever). Although there has been interest in using oral magnesium for allergic rhinitis, there is insufficient reliable information about the clinical effects of magnesium for this purpose.\nAttention deficit-hyperactivity disorder (ADHD). It is unclear if oral magnesium is beneficial in children with ADHD.\nChildren with ADHD seem to have lower magnesium levels in their blood and hair (9969, 100262, 100263). A small clinical study in children aged 7-12 years with ADHD and magnesium deficiency shows that taking magnesium aspartate and lactate 6 mg/kg daily for 6 months might improve hyperactivity and magnesium levels when compared with control (1189). Another small clinical study in children with ADHD but without magnesium deficiency shows that taking magnesium 6 mg/kg daily along with vitamin D 50,000 IU weekly for 8 weeks may modestly improve emotional problems, but not inattention or hyperactivity, as measured on the strength and difficulties questionnaire (SDQ), when compared with placebo (105914).\nless\nBack pain. It is unclear if oral or intravenous magnesium is beneficial for acute or chronic back pain in adults.\nOne open-label clinical study in adults with acute low-back pain shows that taking magnesium 365 mg once daily in addition to taking etodolac 400 mg twice daily for 10 days does not further reduce pain when compared with taking etodolac alone (105913). Magnesium has also been tried for chronic back pain. A small clinical study in patients with chronic low-back pain shows that receiving magnesium sulfate 1 gram in 250 mL normal saline intravenously every 4 hours for 2 weeks, followed by magnesium gluconate 100 mg and magnesium oxide 400 mg by mouth daily for 4 weeks, reduces pain severity when compared with placebo (90035). It is unclear if oral magnesium used alone is beneficial.\nless\nBariatric surgery complications. It is unclear if oral magnesium supplementation improves metabolic parameters after bariatric surgery.\nA retrospective study of over 3000 post-bariatric surgery patients suggests that those who take oral magnesium supplements providing 100-450 mg elemental magnesium daily may have improved metabolic parameters over 4 years of follow-up. When patients taking magnesium supplements were compared with those not taking supplements, 11% and 18% had type 2 diabetes, respectively, 30% and 42% had hypertension, respectively, and 16% and 23% had elevated low-density lipoprotein (LDL) cholesterol levels, respectively. For patients with hypomagnesemia at baseline, supplementation seemed to result in greater benefits (108968).\nless\nBipolar disorder. Taking magnesium orally might improve manic symptoms in some people with bipolar disorder; however, it is unclear how it compares to current standard of care.\nOne preliminary clinical study shows that magnesium 40 mEq daily (Magnesiocard) for 32 weeks has similar effects to lithium in up to 50% of patients treated for rapid cycling bipolar affective disorder (61022). Another preliminary clinical study shows that magnesium oxide 375 mg orally daily plus verapamil 80 mg taken four times daily reduces manic symptoms more effectively than verapamil alone in patients with mania (60742).\nless\nCancer-related neuropathic pain. It is unclear if intravenous magnesium is beneficial for this condition.\nSingle 500 mg to 1 gram doses of magnesium sulfate seem to relieve neuropathic pain for up to four hours when compared to baseline (6846). The validity of this finding is limited by the lack of a comparator group.\nless\nCardiac arrest. Intravenous magnesium does not seem to be helpful in cardiac arrest; however, the risk of sudden cardiac death seems to be inversely correlated to higher plasma magnesium levels or dietary intake. It is unclear if magnesium supplementation is associated with similar risk reduction.\nAdministering magnesium intravenously doesn't seem to improve successful resuscitation in people with cardiac arrest (1190). However, higher plasma magnesium levels and higher dietary magnesium intake might reduce the risk of sudden cardiac death, possibly by protecting against fatal ventricular arrhythmias. In the Nurses' Health Study, the risk of sudden cardiac death was 77% lower in females with the highest quartile of plasma magnesium levels when compared with the lowest quartile. Also, the risk was 37% lower in females with the highest quartile of dietary magnesium intake when compared with the lowest quartile (17132).\nless\nCardiovascular disease (CVD). Evidence regarding the effect of dietary magnesium on CVD risk is conflicting.\nEpidemiological research in some populations shows that increased dietary magnesium intake is associated with decreased mortality due to strokes, coronary heart disease, ischemic heart disease, and heart failure, but other epidemiological research does not show any effect on these risks (89391, 90003, 90009, 90030, 90036, 103735). Reasons for the discrepancies may be related to serum levels of magnesium at baseline, risk of cardiovascular disease at baseline, use of concomitant medications such as diuretics, or the presence of concomitant conditions such as kidney dysfunction.\n\nA population analysis conducted in Denmark has found that magnesium intake from drinking water may be associated with cardiovascular mortality. The overall risk of cardiovascular death and death due to stroke was reduced by 4% in the lowest 3 quintiles of intake when compared with the highest quintile. However, the risk of death due to acute myocardial infarction was increased by 22% in the lowest quintile when compared with the highest (108726). The relevance of these results is unclear, given that the main dietary source of magnesium is food rather than drinking water.\nless\nChemotherapy-induced leukopenia. It is unclear if oral magnesium is beneficial in pediatric patients at risk for cisplatin-induced febrile neutropenia.\nA small clinical study in children with solid tumors aged 9 years and older shows that taking magnesium 250 mg daily while receiving cisplatin-based chemotherapy reduces febrile neutropenia by 47% and septic shock by 57% when compared with not receiving magnesium. Results from this study suggest that four pediatric patients need to take oral magnesium to avoid one case of febrile neutropenia (104394).\nless\nChemotherapy-induced nephrotoxicity. It is unclear if intravenous magnesium is beneficial for chemotherapy-induced nephrotoxicity.\nA meta-analysis of several lower quality clinical studies in adults in Japan with cancer receiving cisplatin shows that pretreatment with intravenous magnesium sulfate 5 to 20 mEq reduces the odds of chemotherapy-induced nephrotoxicity in a dose-dependent manner when compared to standard hydration therapy (115726). The validity of these findings is limited by heterogenous methods between clinical trials, including types of cancer, definitions of nephrotoxicity, and use of other nephroprotective therapies.\nless\nChronic fatigue syndrome (CFS). Limited evidence suggests that magnesium may help improve CFS symptoms, but this is controversial.\nIn people with low red blood cell magnesium, there is some evidence that intramuscular injections of 1 gram magnesium sulfate given once weekly for 6 weeks might improve CFS symptoms (7556). However, there is additional evidence that most patients with CFS have normal magnesium stores, and measurement of red cell magnesium is a poor indicator of total magnesium stores (7557, 8084, 8085, 8086, 8087).\nless\nChronic obstructive pulmonary disease (COPD). Intravenous, but not nebulized, magnesium may be helpful in acute exacerbations of COPD.\nAdministering magnesium sulfate intravenously, 1.2-2.5 grams over 20 minutes, might be helpful for treating acute exacerbations of COPD (1208, 6844, 103733). Also, giving magnesium sulfate 2 grams intravenously seems to improve exercise capacity when compared with placebo (89384). A meta-analysis of studies using intravenous magnesium sulfate for COPD exacerbations shows that it reduces hospital admission and mean length of stay and improves dyspnea scores when compared with placebo. Based on the relative risk identified in the included studies, seven patients would need to receive intravenous magnesium to prevent one hospitalization. However, intravenous magnesium sulfate does not change the need for non-invasive ventilation and the available research did not evaluate intensive care unit (ICU) admission (108967).\n\nNebulized magnesium has also been evaluated. In patients experiencing a COPD exacerbation, clinical research shows that administering nebulized magnesium sulfate with albuterol three times at 30-minute intervals does not improve pulmonary function as measured by the forced expiratory volume in 1 second (FEV1) when compared with placebo (89393). Also, a meta-analysis of a small number of low-quality studies shows that nebulized magnesium does not reduce hospital admission or the need for ventilatory support, although it might modestly improve dyspnea scores and reduce ICU admissions, when compared with placebo (108967).\nless\nCluster headache. It is unclear if a single intravenous dose of magnesium sulfate is beneficial for cluster headaches.\nAdministering magnesium sulfate intravenously, 1 gram over 5 minutes, seems to improve cluster headaches when compared with baseline(1184). The validity of this finding is limited by the lack of a comparator group.\nless\nCognitive impairment. It is unclear if oral magnesium is beneficial for cognitive impairment.\nA large observational study in adults with end-stage renal disease on hemodialysis suggests that serum magnesium levels of 20.2-22.3 mg/dL are associated with the lowest odds of mild cognitive impairment, while serum magnesium levels below and above that range of values are associated with increased odds of mild cognitive impairment (111695).\nless\nCoronary heart disease (CHD). It is unclear if magnesium supplementation is beneficial for CHD.\nClinical research shows that magnesium oxide 800-1200 mg daily for 3 months reduces platelet-dependent thrombosis by 35% when compared with placebo in patients with CHD (60759). It is unclear if this effect improves clinical outcomes.\n\nThe effect of magnesium supplementation on coronary artery calcium has also been studied. A meta-analysis of 3 clinical studies in 196 patients with chronic kidney disease (CKD) shows that taking magnesium or increasing the concentration of magnesium in dialysate does not improve coronary artery calcification (CAC) scores when compared with standard therapy. However, magnesium reduced carotid intima-media thickness (111179). Similarly, a large clinical study in patients with CKD shows that taking slow-release magnesium hydroxide (Mablet, Denmark) 360 mg twice daily for 12 months does not slow the progression of CAC scores when compared with placebo (111178). This study may not have been adequately powered to detect a difference between groups.\nless\nCoronavirus disease 2019 (COVID-19). It is unclear if oral magnesium is beneficial for COVID-19.\nA small clinical study in patients hospitalized with moderate COVID-19 shows that taking magnesium 300 mg daily for the duration of hospitalization reduces the number of patients requiring oxygen therapy but not the duration of hospital stay when compared with placebo (114680).\nless\nDepression. It is unclear if magnesium is beneficial for the treatment or prevention of depression in adults.\nSome population research shows that dietary intake of elemental magnesium between 76-360 mg daily is associated with a reduced risk of depression, but there was no association with greater amounts of magnesium, and other population research shows no association at any intake level (96480, 98289). For treatment of mild to moderate depression, one preliminary clinical study shows that taking magnesium chloride 2 grams orally daily for 6 weeks reduces depression scores by 56% and anxiety scores by about 52% when compared to baseline (96477). The validity of these findings is limited by the lack of a comparator group. However, a small clinical study in adults with recurrent depression shows that taking magnesium aspartate 120 mg daily for 8 weeks, along with fluoxetine, does not improve depression scores when compared with patients taking fluoxetine and placebo (111185). Similarly, a very small crossover clinical study in adults with mild or moderate treatment-resistant depression shows that administering a single dose of IV magnesium sulfate 4 grams does not improve depression scores when compared with an infusion of 5% dextrose (96481). However, scores were evaluated 24 hours post-infusion which may be too soon to detect improvement.\n\nGuidelines from The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce state that elemental magnesium in doses of 100-400 mg is not recommended for adjunctive or monotherapy use in patients with depression (110318).\nless\nDiabetic foot ulcers. Oral magnesium has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with grade 3 diabetic foot ulcers shows that taking magnesium oxide 250 mg plus vitamin E 400 IU daily for 12 weeks modestly reduces ulcer size when compared with placebo (101436). It is unclear if this effect is due to magnesium, vitamin E, or the combination.\nless\nExercise-induced muscle soreness. It is unclear if oral or topical magnesium reduces muscle soreness in adults.\nA very small study in healthy adults, ages 19-23, shows that taking magnesium glycinate 350 mg daily for 10 days seems to reduce muscle soreness after bench press exercise when compared with placebo (104399).\n\nAdditionally, oral magnesium has been studied in combination with other ingredients. A small clinical study in exercise-trained adults shows that taking magnesium citrate 420 mg combined with cannabidiol 70 mg, cannabigerol 50 mg, beta caryophyllene 25 mg, and branched-chain amino acids 3.8 grams twice daily for 3.5 days does not improve self-reported muscle soreness or functional aspects of recovery when compared with placebo (113050). It is unclear if this effect is due to magnesium, other ingredients, or the combination.\n\nTopical magnesium has also been evaluated for exercise-induced muscle soreness. A small clinical study in healthy adults aged 18-50 shows that applying magnesium gel 0.53mg/ml to the thigh muscle 10 minutes before and immediately after exercise did not reduce muscle soreness scores within 48 hours after a bout of downhill running when compared with placebo(117419). The validity of these results is limited by the low concentration of magnesium in the studied gel, and short study duration.\nless\nFetal and premature infant mortality. It is unclear if antenatal intravenous (IV) magnesium sulfate administration reduces the risk of fetal and premature infant mortality.\nTwo meta-analyses of up to 7 clinical studies in patients at risk of preterm birth shows that antenatal IV magnesium sulfate administration does not reduce the risk of fetal or neonatal death when compared with placebo (114675, 114681).\nless\nFetal and premature infant mortality. It is unclear if antenatal intravenous (IV) magnesium sulfate administration reduces the risk of fetal and premature infant mortality.\nTwo meta-analyses of up to 7 clinical studies in patients at risk of preterm birth shows that antenatal IV magnesium sulfate administration does not reduce the risk of fetal or neonatal death when compared with placebo (114675, 114681).\nless\nFibromyalgia. It is unclear if oral magnesium is beneficial for this condition.\nA small clinical study shows that taking magnesium chloride orally 100 mg once daily for one month reduces mild to moderate, but not severe, stress associated with fibromyalgia when compared with placebo. It also reduces pain levels, but not to a clinically significant extent, and it does not affect sleep, fatigue, or quality of life (108964). Another small clinical study shows that taking magnesium citrate 300 mg daily for 8 weeks improves some symptoms of fibromyalgia, such as number of tender points and depression, when compared to baseline (89385). The validity of this finding is limited by the lack of a comparator group.\n\nMagnesium has also been evaluated in combination therapy. A small clinical study shows that taking a combination of magnesium hydroxide and malic acid (Super Malic tablets) orally decreases fibromyalgia-related pain and tenderness in some patients when compared with placebo (3262). It is unclear if this effect is due to magnesium, malic acid, or the combination. Additionally, a single-center, crossover clinical study in adults with fibromyalgia (primarily female patients) already receiving pharmacological therapy (e.g., acetaminophen, non-steroidal anti-inflammatory drugs, antidepressants) shows that taking a combination of magnesium 600 mg, coenzyme Q10, and tryptophan daily (Trimax 10, AS & NL) for 3 months does not improve self-reported fatigue when compared to baseline (116616).\nless\nFibromyalgia. It is unclear if oral magnesium is beneficial for this condition.\nA small clinical study shows that taking magnesium chloride orally 100 mg once daily for one month reduces mild to moderate, but not severe, stress associated with fibromyalgia when compared with placebo. It also reduces pain levels, but not to a clinically significant extent, and it does not affect sleep, fatigue, or quality of life (108964). Another small clinical study shows that taking magnesium citrate 300 mg daily for 8 weeks improves some symptoms of fibromyalgia, such as number of tender points and depression, when compared to baseline (89385). The validity of this finding is limited by the lack of a comparator group.\n\nMagnesium has also been evaluated in combination therapy. A small clinical study shows that taking a combination of magnesium hydroxide and malic acid (Super Malic tablets) orally decreases fibromyalgia-related pain and tenderness in some patients when compared with placebo (3262). It is unclear if this effect is due to magnesium, malic acid, or the combination. Additionally, a single-center, crossover clinical study in adults with fibromyalgia (primarily female patients) already receiving pharmacological therapy (e.g., acetaminophen, non-steroidal anti-inflammatory drugs, antidepressants) shows that taking a combination of magnesium 600 mg, coenzyme Q10, and tryptophan daily (Trimax 10, AS & NL) for 3 months does not improve self-reported fatigue when compared to baseline (116616).\nless\nFractures. Population research suggests that higher intakes of magnesium may reduce fracture risk.\nObservational research has found that higher dietary and supplemental magnesium intake is associated with a 34% lower odds of fracture when compared with lower magnesium intake (101395).\nless\nGastric cancer. Population research suggests that higher intakes of magnesium may reduce gastric cancer risk.\nObservational research has found that higher dietary and supplemental magnesium intake is not associated with a reduced risk for gastric cancer when compared with lower intake (103730).\nless\nHearing loss. Oral magnesium may prevent and improve hearing loss due to environmental factors or loud noises.\nClinical research in healthy military recruits shows that taking magnesium aspartate 167 mg daily for 2 months prevents hearing loss from exposure to loud noises during basic military training when compared with placebo (1205). Also, in patients with acute-onset hearing loss that was not caused by environmental factors, taking magnesium aspartate 167 mg daily for 8 weeks seems to improve hearing loss when compared with placebo (60813).\nless\nHypertension. Oral magnesium supplementation may modestly reduce blood pressure, although these changes are not likely to be considered clinically significant.\nMost research shows that taking oral magnesium supplements in daily doses that are at least as high as the Recommended Dietary Allowance (RDA) for adults and up to 1000 mg daily can lower diastolic blood pressure by about 2 mmHg in adults with or without hypertension (1192, 1199, 9465, 15165, 18111, 96482). Significantly lower doses do not seem to have this effect (1180, 1195, 1197, 8098). The effect of magnesium on systolic blood pressure is conflicting. Two meta-analyses shows that taking magnesium 212-970 mg daily does not lower systolic blood pressure in patients with or without hypertension (15165, 115728). However, additional meta-analyses show that taking magnesium 120-970 mg daily can lower systolic blood pressure in a dose-dependent manner by about 2-4 mmHg in patients with or without hypertension (18111, 96482). The reasons for these discrepant findings are unclear but may be due to heterogenous methods, including dose and duration among clinical studies. In 2022, the US Food and Drug Administration (FDA) approved a qualified health claim stating that inconsistent and inconclusive evidence suggests that diets with adequate magnesium may reduce the risk of high blood pressure. Products bearing this claim must provide at least 84 mg of magnesium daily, but no more than 350 mg daily (107451).\nless\nHypokalemia. It is unclear if intravenous or oral magnesium is beneficial for hypokalemia in patients with normal magnesium levels.\nA preliminary retrospective observational study in patients with hypokalemia and unknown serum magnesium levels has found that administering oral or intravenous magnesium is not associated with improved time to normalization of serum potassium levels when compared with no magnesium treatment (110049). However, hypokalemia with concurrent hypomagnesemia can impede potassium repletion and exacerbate hypokalemia-induced rhythm disturbances. Standard of care in patients with hypokalemia and known hypomagnesemia includes prompt treatment with magnesium (110063).\nless\nImpaired glucose tolerance (prediabetes). It is unclear if oral magnesium is beneficial for prediabetes.\nPreliminary clinical research in patients with prediabetes shows that taking magnesium oxide 250 mg orally daily for 12 weeks does not improve fasting blood glucose levels, insulin resistance, or glycated hemoglobin (HbA1C) levels when compared with placebo. Taking magnesium also did not affect blood pressure, body weight, triglyceride levels, or low-density lipoprotein cholesterol levels; however, it did modestly improve high-density lipoprotein cholesterol levels (110053).\nless\nInsomnia. Oral magnesium may modestly improve sleep complaints in adults, but evidence is conflicting.\nA meta-analysis of two small clinical studies in healthy older adults with or without insomnia suggests that taking magnesium reduces the time to fall asleep by an average of 17 minutes when compared with placebo (105917). However, it does not increase the time spent asleep. Also, these findings are limited by imprecision and a high risk of bias. Studies included in the analysis used elemental magnesium 500-729 mg daily (as magnesium oxide) for up to 8 weeks (102458, 105917). Another small clinical study in patients with poor sleep quality and low magnesium status shows that taking elemental magnesium 320 mg (as magnesium citrate) in divided doses daily for 7 weeks does not improve sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), when compared with a sodium citrate placebo (102456).\n\nMagnesium has also been evaluated in combination with other ingredients. A very small crossover clinical study in patients aged 18-40 years without a sleep disorder shows that taking a combination of magnesium 300 mg, L-tryptophan 1000 mg, glycine 3000 mg, tart cherry 220 mg, and theanine 200 mg for 3 days reduces the time to fall asleep by about 24 minutes, increases total time asleep by about 22 minutes, and improves sleep efficiency, but does not improve the total time in bed or wakefulness after falling asleep when compared with cellulose placebo (111184). Another small crossover clinical study in adults with sleep disturbances shows that taking a combination of magnesium 200 mg and melatonin nightly for 4 weeks improves sleep quality, as measured by the PSQI, reduces the length of time it takes to fall asleep by about 17 minutes, and improves some other measures of sleep, such as sleep efficiency and number of awakenings, when compared with placebo. However, despite these improvements, overall sleep quality was still categorized as poor after the intervention (116160). It is unclear if these effects are due to magnesium, other ingredients, or the combination.\nless\nIntraventricular hemorrhage. It is unclear if antenatal intravenous (IV) magnesium sulfate can reduce the risk for intraventricular hemorrhage in neonates.\nA meta-analysis of clinical research in premature infants shows that if the mother received antenatal intravenous magnesium sulfate, the infant had a non-significant trend toward a reduced risk of intraventricular hemorrhage when compared with infants whose mothers received placebo (103727). This analysis may have been insufficiently powered to detect a difference between groups. Another meta-analysis of up to 6 clinical studies, some of which are included in the previously referenced meta-analysis, in patients at risk of preterm birth shows that maternal antenatal (IV) magnesium sulfate administration does not reduce the risk of intraventricular hemorrhage, but does reduce the risk of severe intraventricular hemorrhage by about 24% when compared with placebo (114681).\nless\nKidney stones (nephrolithiasis). Taking magnesium orally may prevent the recurrence of kidney stones, although evidence is conflicting.\nProphylactic treatment with magnesium hydroxide, 200 mg twice daily for one year, followed by 500 mg daily for another year, might decrease the recurrence rate of calcium stone formation (2007). However, magnesium oxide does not seem to benefit patients considered to be recurrent calcium stone formers when compared with placebo, no treatment, or chlorthalidone (8097, 38501, 61199). Magnesium oxide 300 mg in combination with vitamin B6 10 mg daily seems to decrease urinary oxalate levels in people with hyperoxaluria who have previously had kidney stones (1201), but it is unclear if this effect translates into a reduced incidence of kidney stones.\nless\nLiver cancer. Increased dietary magnesium intake is linked with a lower risk of liver cancer.\nObservational research in retired older Americans has found that higher dietary magnesium intake is associated with a 35% lower risk of liver cancer when compared with lower intake. This association was especially strong in persons who were moderate or heavy alcohol users (105080).\nless\nLung cancer. Supplemental or dietary magnesium intake does not seem to reduce the risk of lung cancer.\nA large epidemiological cancer screening trial with a mean follow-up of over 12 years suggests there is no association between dietary or supplemental magnesium intake and the risk of lung cancer. However, dietary magnesium seems to play an important yet unclear role in lung cancer prevention when taken as part of the diet with alpha-carotene, vitamin C, vitamin E, lycopene, selenium, lutein, and zeaxanthin (112096).\nless\nMigraine headache. Oral magnesium may help prevent migraine in some adults and children. Also, intravenous magnesium may help treat migraine in adults, but evidence is conflicting.\nA meta-analysis of 4 low-quality clinical studies, in adults with migraine shows that magnesium 122-600 mg daily for 4-16 weeks modestly reduces migraine frequency and severity when compared with placebo(115730). However, clinical significance is unclear, and the validity of these findings is limited by heterogeneous methods between clinical trials, including type of magnesium formulation and dose, patient population, and duration. In contrast, one small clinical study shows that taking magnesium does not reduce migraine frequency and severity by at least 50% in adults when compared with placebo (10661).\n\nLimited evidence suggests that adding oral magnesium to conventional treatment may also be beneficial. A clinical study in adults with migraine living in Iran shows that taking magnesium oxide 250 mg twice daily in addition to sodium valproate 200 mg twice daily for 12 weeks modestly reduces severity and duration of migraine, but not migraine frequency, when compared with taking sodium valproate alone (105915). It is unclear if these improvements would be considered clinically significant.\n\nFor treatment of migraine, some adults with normal magnesium levels respond to intravenous (IV) magnesium sulfate 1 gram over 5 minutes, but most patients who benefit have low magnesium levels at baseline (1185, 6844). Effects of IV magnesium in patients with unknown magnesium levels are conflicting. Some preliminary clinical research shows that magnesium 1-2 grams IV alleviates acute migraine for up to 2 hours, but other research has found no benefit (89388, 97493, 98285).\n\nIn children, treatment with magnesium oxide orally 15 mg/kg daily in 3 divided doses for up to 16 weeks reduces the frequency and severity of migraine headaches when compared with placebo (10663). However, adding magnesium sulfate 400 mg orally daily to ibuprofen or acetaminophen does not further reduce migraine severity in children (89396).\nless\nMiscarriage. Oral magnesium has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in pregnant adults with threatened miscarriage between the 6th and 13th week of gestation shows that taking a specific combination product (DAV HA, Lo.Li pharma s.r.l) containing magnesium 450 mg, alpha-lipoic acid, hyaluronic acidvitamin B6, and vitamin D daily in combination with conventional treatment of vaginal progesterone over 2 weeks of observation results in a faster resorption of the subchorionic hematoma and faster decrease of patient-reported vaginal bleeding, abdominal pain, and uterine contractions when compared with vaginal progesterone alone (113893). It is unclear if these effects are due to magnesium, other ingredients, or the combination. Additionally, the validity of these findings is limited by the lack of a placebo in the control group.\nless\nMyocardial infarction (MI). Research on the effects of intravenous or oral magnesium after myocardial infarction are conflicting.\nAdministering magnesium intravenously doesn't seem to reduce mortality after an acute MI (8999, 13357, 13358, 13359, 13360, 19990, 60872, 61082), although there is some conflicting evidence from a meta-analysis of clinical research that shows that intravenous magnesium sulfate may reduce short-term mortality by 55% when compared with placebo (60795, 60895). Clinical research with oral magnesium supplementation has found no benefit (1198, 6844).\nless\nNeonatal encephalopathy. Intravenous magnesium may improve short-term outcomes in neonates with encephalopathy.\nA meta-analysis of clinical research shows that intravenous magnesium may improve short term outcomes of neonatal encephalopathy (hypoxic ischemic encephalopathy, HIE). However, long term outcomes are not affected (90025).\nless\nNocturnal leg cramps. It is unclear if oral magnesium is helpful for nocturnal leg cramps.\nSome clinical research in adults with nocturnal leg cramps shows that taking magnesium oxide 865 mg daily at bedtime for 4 weeks does not reduce the frequency of leg cramping episodes when compared with placebo (96478). However, four weeks may be too short a time to see a benefit. In other clinical research, taking oral magnesium oxide monohydrate 226mg daily at bedtime for 60 days reduces the frequency of leg cramps when compared with placebo. This reduction was not seen after 30 days. Magnesium also reduced cramp duration and improved sleep quality, but did not affect pain scores, at 60 days when compared with placebo (106919).\nless\nNonalcoholic fatty liver disease (NAFLD). Oral magnesium hydroxide has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in adults with NAFLD shows that taking magnesium hydroxide 150 mg and L-carnitine 2000 mg daily for 16 weeks does not improve liver stiffness scores when compared with baseline or controls who took placebo for 8 weeks followed by this magnesium and L- carnitine combination for 8 weeks. Taking magnesium and L-carnitine also did not improve levels of aspartate aminotransferase (AST) or alanine transaminase (ALT) when compared to baseline (111177).\nless\nObesity. Evidence on the use of magnesium for weight loss in obese patients is conflicting; any benefit is likely small at best.\nA meta-analysis of 7 clinical studies in obese patients shows that taking magnesium reduces body mass index (BMI) by 0.3 when compared with control (103723). Another meta-analysis of 7 studies in obese patients shows that while magnesium supplementation does not reduce weight, it reduces waist circumference by 2 cm when compared with placebo (103729). Interestingly, subgroup analyses did not find that the dose of magnesium or baseline magnesium levels impacted effectiveness. One subgroup analysis found that magnesium supplementation lasting 12 weeks or less seemed to be more beneficial for obesity than supplementation lasting longer than 12 weeks (103723).\nless\nOsteoarthritis. Population research has not found a link between magnesium intake and osteoarthritis risk.\nObservational research has found that dietary and supplemental magnesium intake is not associated with the risk of developing osteoarthritis (101395).\nless\nOverall mortality. It is unclear if oral or IV magnesium reduces the risk of overall mortality.\nA meta-analysis of heterogeneous observational studies has found that increased dietary magnesium intake, but not supplemental magnesium intake, is associated with a modestly reduced risk of overall mortality (105073). A meta-analysis of 3 small, low-quality clinical studies in ICU patients shows that administering IV magnesium 24-30 mmol or as a target-directed dose for 3 days reduces overall mortality when compared with patients who did not receive magnesium (111290). However, some studies included patients with hypomagnesemia; it is unclear if effects would be similar for patients with normal levels of magnesium.\nless\nPain (acute). It is unclear if locally injected or intravenous magnesium is helpful for acute pain.\nPreliminary clinical research in patients with renal colic shows that intravenous (IV) magnesium sulfate, 50 mg/kg infused over 20 minutes, is as effective as IV morphine sulfate 0.1 mg/kg for controlling acute renal pain at 20 minutes after the dose (107367).\n\nMagnesium has also been evaluated in a dental procedure. A single-center clinical study in India in adults with irreversible pulpitis requiring a root canal shows that a local injection of 0.2 mL of 10% magnesium sulfate with lidocaine and epinephrine reduces perioperative pain when compared to lidocaine with epinephrine alone (115729).\nless\nPain (chronic). Population research suggests that higher intakes of magnesium may modestly reduce the risk for chronic pain.\nA cross-sectional observational study has found that increased magnesium intake is associated with a 7% to 8% reduced risk for chronic pain. The association was found to be stronger in females than in males (103732).\nless\nParturition. It is unclear if topical magnesium is beneficial for labor duration.\nA single-center clinical study in Iranian adults shows that applying 10 mL of a 50% magnesium sulfate solution directly to the cervix during the active phase of labor reduces the time to vaginal delivery by approximately 1.5 hours and improves the childbirth experience, as reported by patients, when compared with placebo. However, clinical significance is unclear (115727).\nless\nPerioperative anxiety. It is unclear if oral magnesium is beneficial for perioperative anxiety.\nPreliminary clinical research in adults undergoing open heart surgery shows that taking magnesium oxide 250 mg orally twice daily during hospitalization moderately improves anxiety and depression scores when compared with no magnesium therapy. Magnesium therapy was held for the 2 days immediately following surgery (110054).\nless\nPhysical performance. Oral magnesium may modestly improve physical performance in otherwise healthy, elderly females.\nClinical research in otherwise healthy elderly females shows that taking a magnesium oxide supplement (Easymag, Sanofi-Aventis) 900 mg daily for 12 weeks modestly improves walking speed and chair stand speed in elderly females when compared with no treatment (90026).\nless\nPostoperative nausea and vomiting (PONV). It is unclear if intravenous (IV) magnesium is beneficial for PONV due to mixed results from clinical research.\nA meta-analysis of 5 clinical studies in adults undergoing surgery with general anesthesia shows that administering IV magnesium sulfate intraoperatively reduces PONV (114676). However, a meta-analysis of 20 clinical studies in adults undergoing surgery with general anesthesia shows that administering IV magnesium perioperatively does not reduce the incidence of PONV (114678). A moderate-sized clinical study conducted in China in older adults undergoing total knee arthroplasty shows that administering intravenous magnesium sulfate 40 mg/kg prior to anesthesia induction then 15 mg/kg during surgery reduces the incidence of postoperative vomiting but not postoperative nausea when compared with control (113677). The reasons for these discrepant findings are unclear but may be explained by differences in magnesium regimens, anesthesia protocols, and surgical populations studied.\nless\nPostoperative recovery. It is unclear if intravenous (IV) magnesium is beneficial for postoperative recovery.\nA moderate-sized clinical study conducted in China in older adults undergoing total knee arthroplasty shows that administering IV magnesium sulfate 40 mg/kg prior to anesthesia induction then 15 mg/kg during surgery does not reduce extubation time, time spent in the post-anesthesia care unit (PACU), or duration of hospital stay when compared with control (113677). Additionally, a meta-analysis of 3 different clinical studies in adults undergoing surgery with general anesthesia shows that administering IV magnesium intraoperatively does not reduce extubation time (114676).\nless\nPostoperative sleep disturbance. It is unclear if oral magnesium is beneficial for postoperative sleep disturbances.\nPreliminary clinical research in adults undergoing open heart surgery shows that taking magnesium oxide 250 mg orally twice daily during hospitalization moderately improves sleep scores when compared with no magnesium therapy. Magnesium therapy was held for the 2 days immediately following surgery (110054).\nless\nPostoperative sore throat. It is unclear if topical magnesium sulfate is beneficial for preventing or treating sore throat pain after endotracheal intubation.\nPreliminary clinical research in patients undergoing endotracheal intubation for surgery shows that using a gargle containing magnesium sulfate 20% with lidocaine, 20 minutes before anesthesia induction, is less effective for reducing sore throat pain than a gargle containing dexmedetomidine and lidocaine (112779). The study did not include a comparison to lidocaine alone.\n\nDifferent preparations of magnesium have also been compared. A single-center clinical study in China in adults undergoing endotracheal intubation for elective surgery shows that applying a magnesium sulfate spray 15 mg/kg during intubation onto the pharyngeal area is non-inferior to a magnesium sulfate gargle 20 mg/kg used for 30 seconds 15 minutes prior to surgery in reducing the incidence of postoperative sore throat within 48 hours (116618).\nless\nPregnancy-related leg cramps. It is unclear if oral magnesium reduces leg cramps during pregnancy; evidence is conflicting.\nOne small clinical study in patients with pregnancy-related leg cramps shows that taking magnesium bisglycinate chelate 300 mg daily for 4 weeks reduces the frequency and intensity of leg cramps when compared with placebo (99318). A smaller clinical study in this population shows that taking a specific mixture of magnesium lactate and citrate (Nycoplus Magnesium) providing elemental magnesium 120 mg in the morning and 240 mg in the evening for 3 weeks reduces the frequency of cramps when compared with placebo (1194). However, not all research agrees. One small clinical study using this same supplement and dose for 2 weeks found no benefit when compared with placebo (17463). It is possible that a 2-week duration of treatment is too short to be beneficial. Finally, a meta-analysis of these studies and one other more recent clinical study shows that taking magnesium does not reduce the frequency or improve the resolution of pregnancy-related leg cramps when compared with placebo (105916). This analysis may not have been adequately powered to detect a difference between treatment groups.\nless\nPre-procedural sedation. It is unclear if intravenous magnesium is beneficial when administered in addition to other medications used for sedation during surgery.\nA moderate-sized study of adults aged 65-79 years old undergoing endoscopic retrograde cholangiopancreatography (ERCP) shows that administering a single intravenous bolus of magnesium sulfate 40 mg/kg prior to the procedure reduces intraoperative propofol requirements by about 21% and reduces some peri-procedural adverse events including the incidence of respiratory depression and involuntary movement when compared with control. However, there were no differences in recovery time, hemodynamic parameters, or the incidence of hypotension, bradycardia, perioperative nausea or vomiting, lethargy, or arrythmias (111694). Another moderate-sized study in older adults undergoing total knee arthroplasty shows that administering intravenous magnesium sulfate 40 mg/kg prior to anesthesia induction then 15 mg/kg during surgery does not reduce the need for medications used for anesthesia induction, intraoperative maintenance propofol requirements, or recovery time when compared with control. However, magnesium sulfate does seem to reduce the amount of remifentanil required for intraoperative anesthesia maintenance and increase norepinephrine requirements when compared with control (113677).\nless\nPreterm labor. The use of magnesium sulfate to inhibit uterine contractions in preterm labor (tocolysis) is controversial. However, its use for the purpose of fetal neuroprotection for up to 48 hours is supported by the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine.\nMagnesium is given intravenously (IV) during preterm labor in an effort to improve fetal neurological outcomes, such as to reduce the risk of cerebral palsy and motor dysfunction in the infant (60915, 60927, 60931, 61001, 97485, 103734, 103754, 114681). The typical dosage of magnesium sulfate is 4 grams infused IV over 10-30 minutes, followed by a maintenance infusion of 1-4 grams/hour for 48 hours or until birth. Use beyond 5-7 days has been associated with hypocalcemia and bone abnormalities in the fetus (15, 12590, 12594). Some meta-analyses of clinical research suggest that magnesium sulfate is more effective at delaying delivery by 48 hours when compared with oxytocin receptor blockers, nitrates, beta-mimetics, and/or placebo (20263, 61021). However, an additional meta-analysis of several clinical studies shows that magnesium sulfate 4 or 6 grams IV is not more effective at delaying preterm labor by 48 hours when compared with nifedipine (115639). The reason for these discrepant findings are unclear, but may be related to the heterogenous methods between clinical trials, including dose and duration.\nless\nRestless legs syndrome (RLS). It is unclear if oral magnesium is beneficial for RLS.\nSome observational research has found that hypomagnesemia is associated with RLS; however, not all research agrees (8096, 9472). Preliminary clinical research in adults with RLS who are beginning treatment with pramipexole shows that also taking magnesium oxide 250 mg orally daily for 2 months moderately improves RLS scores and sleep quality scores when compared with pramipexole and placebo (110052). Other low-quality clinical research in adults with RLS or periodic limb movement during sleep shows that taking magnesium 12.4 mmol orally in the evening for 4-6 weeks decreases movement and increases sleep when compared with baseline (9466). The validity of this finding is limited by the lack of a comparator group.\nless\nSarcopenia. It is unclear if oral magnesium is beneficial for the prevention or treatment of sarcopenia.\nPopulation research in older adults has found that lower dietary intake of magnesium is associated with sarcopenia. However, the effect of magnesium supplementation on sarcopenia prevention or treatment has not been evaluated (110055).\n\nMagnesium has been evaluated in combination with other ingredients for treatment of sarcopenia. A small clinical study in elderly individuals with sarcopenia undergoing a diet and exercise program shows that taking a combination supplement containing magnesium 300 mg, carnosine, hydroxymethylbutyrate, lactoferrin, and sodium butyrate daily for 4 months increases muscle mass, as measured by the skeletal muscle index, and improves measures of muscle function, including handgrip muscle strength, chair test, and walking speed, when compared with placebo (114682). It is unclear if these effects are due to magnesium, other ingredients, or the combination.\nless\nSepsis. It is unclear if intravenous magnesium is beneficial for sepsis.\nA very large observational study in patients with sepsis and hypomagnesaemia or normomagnesemia in the intensive care unit (ICU) suggests that administering intravenous magnesium sulfate 2 or 4 grams within 24 hours of admission reduces 28-day all-cause mortality from 25% in patients who did not use magnesium sulfate to 20% in those who were administered magnesium sulfate, regardless of baseline serum magnesium level and other baseline characteristics. Administration of intravenous magnesium sulfate in this population may also reduce ICU mortality by 4%, in-hospital mortality by 3%, and the use of renal replacement therapy by 3% but also seems to increase the length of ICU and hospital stay when compared with patients who did not use magnesium sulfate (113676). The validity of these results is limited by the observational nature of the study.\nless\nSleep deprivation. Oral magnesium has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA very small clinical study in sleep-deprived recreational athletes shows that taking a combination of magnesium 1350 mg, zinc 90 mg, and vitamin B6 31.5 mg for 3 nights at bedtime does not change sleep quality, subjective sleepiness, mood, or fatigue the next day when compared with placebo (113655).\nless\nStroke. Increased dietary magnesium may decrease stroke risk, and using a magnesium-containing salt substitute may improve neurological performance post-stroke. However, intravenous magnesium has not demonstrated benefit.\nMost population research has found that increased dietary intake of magnesium is associated with decreased stroke risk and decreased mortality from stroke (9001, 9002, 90013, 90030, 90036, 92107, 103736). In patients who have had a stroke, a preliminary clinical study shows that using a salt substitute providing the Dietary Reference Intake (DRI) of magnesium and potassium for 6 months improves neurological performance when compared with using regular salt (97491).\n\nHowever, intravenous (IV) magnesium does not seem to be beneficial in patients who have had a stroke. Large prospective clinical trials show that IV magnesium given within 12 hours of acute stroke does not reduce mortality or disability in most patients when compared with placebo. However, one subgroup analysis suggested that IV magnesium might benefit patients with lacunar (non-cortical) stroke (13361, 90021). IV magnesium also doesn't seem to reduce cardiovascular complications after acute stroke. A secondary analysis of a clinical trial in patients after ischemic and hemorrhagic stroke shows that giving IV magnesium does not reduce serious cardiac adverse events when compared with placebo (104393). Another secondary analysis of this trial shows that giving IV magnesium prior to arrival at the hospital and within 2 hours of a hemorrhagic stroke does not reduce hematoma volume on hospital arrival, hematoma expansion during hospital admission, or functional outcomes at 3 months (108733).\nless\nSubarachnoid hemorrhage. Intravenous magnesium sulfate may reduce the risk of adverse outcomes in people with subarachnoid hemorrhage, but evidence is conflicting.\nThere is mixed evidence regarding the effect of magnesium sulfate in managing aneurysmal subarachnoid hemorrhage. One meta-analysis of clinical research shows that intravenous magnesium sulfate 64-144 mmol/day for 10-18 days reduces the risk of poor outcomes following aneurysmal subarachnoid hemorrhage, including death, vegetative state, or dependency, by 46% when compared with control (60932). Also, meta-analyses of clinical research show that intravenous magnesium reduces the risk of delayed cerebral ischemia by 27% when compared with placebo (60944, 89398). However, these results were not confirmed in other meta-analyses (60973, 90034).\nless\nThrombocytopenia. It is unclear if intravenous magnesium sulfate is beneficial in patients with thrombotic thrombocytopenic purpura (TTP).\nAddition of intravenous magnesium sulfate as a 6-gram loading dose followed by 6 grams infused over 24 hours for 3 days, to standard treatment for TTP does not reduce the time to normalization of the platelet count, the incidence of TTP-related organ dysfunction, or the recurrence rate, when compared with standard treatment alone (112777). This study may have been underpowered to detect a difference.\nless\nUrinary incontinence. Although there has been interest in using oral magnesium for urinary incontinence, there is insufficient reliable information about the clinical effects of magnesium for this purpose.\nPseudoxanthoma elasticum (PXE). It is unclear if oral magnesium is beneficial for PXE.\nPreliminary clinical research in patients with PXE shows that taking magnesium oxide 800 mg (500 mg of elemental magnesium) twice daily for one year tends to reduce calcification of elastic skin fibers when compared with placebo, but the effect is not statistically significant (101393). This study was limited by small size and insufficient power to detect smaller effects.\nless\nMore evidence is needed to rate magnesium for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: For preventing deficiency, the daily Recommended Dietary Allowances (RDA) for elemental magnesium should be followed. For males: 400 mg for ages 19-30 years, 420 mg for ages 31 years and older. For females: 310 mg for ages 19-30 years, and 320 mg for ages 31 years and older. For pregnant females: 400 mg for ages 14-18 years, 350 mg for ages 19-30 years, and 360 mg for ages 31-50 years. For lactating females: 360 mg for ages 14-18 years, 310 mg for ages 19-30 years, 320 mg for ages 31-50 years (7555).\n\nTherapeutic doses of magnesium vary widely. See Effectiveness section for condition-specific information.\nIntravenous / Intramuscular:Magnesium sulfate is typically used intravenously, short-term for acute management of symptoms. Typical loading doses range from 4-14 grams IV, and can be followed by 2.5-5 grams every 4 hours IM, or a continuous IV infusion of 0.5-3 grams/hour.\nChildren\nOral:\nFor preventing deficiency, the daily Recommended Dietary Allowances (RDA) for elemental magnesium should be followed. For all children: 80 mg for ages 1-3 years, 130 mg for ages 4-8 years, 240 mg for ages 9-13 years. For males: 410 mg for ages 14-18 years. For females: 360 mg for ages 14-18 years. For pregnant females age 14-18 years, 400 mg; for lactating females age 14-18 years, 360 mg.\n\nFor infants 0-6 months of age, the adequate intake (AI) level is 30 mg. For infants 7-12 months of age, the AI is 75 mg.\n\nFor therapeutic uses, research is limited; typical dosing is unavailable.\nStandardization & Formulation\nMagnesium supplements used varied in composition, by the particular salt used in the formulation (aspartate, oxide, pidolate, and orotate) or by other confounding ingredients (multi-vitamin as magnesium source) (60751). Other salts of magnesium include citrate, chloride, lactate citrate, and gluconate.\n\nSupplement manufacturers of magnesium/calcium combination products promote a 2:1 or 3:1 ratio as being ideal for absorption of these elements. However, there is no credible research to support this claim. Products such as coral calcium that claim to have ideal combinations of magnesium and calcium to cure a variety of diseases and conditions have come under scrutiny of the FDA and FTC (12508).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nAMINOGLYCOSIDE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nConcomitant use of aminoglycoside antibiotics and magnesium can increase the risk for neuromuscular weakness.\nBoth aminoglycosides and magnesium reduce presynaptic acetylcholine release, which can lead to neuromuscular blockade and possible paralysis. This is most likely to occur with high doses of magnesium given intravenously (13362).\nless\nANTACIDS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nUse of acid reducers may reduce the laxative effect of magnesium oxide.\nA retrospective analysis shows that, in the presence of H2 receptor antagonists (H2RAs) or proton pump inhibitors (PPIs), a higher dose of magnesium oxide is needed for a laxative effect (90033). This may also occur with antacids. Under acidic conditions, magnesium oxide is converted to magnesium chloride and then to magnesium bicarbonate, which has an osmotic laxative effect. By reducing acidity, antacids may reduce the conversion of magnesium oxide to the active bicarbonate salt.\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, magnesium may have antiplatelet effects, but the evidence is conflicting.\nIn vitro evidence shows that magnesium sulfate inhibits platelet aggregation, even at low concentrations (20304, 20305). Some preliminary clinical evidence shows that infusion of magnesium sulfate increases bleeding time by 48% and reduces platelet activity (20306). However, other clinical research shows that magnesium does not affect platelet aggregation, although inhibition of platelet-dependent thrombosis can occur (60759).\nless\nBICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Biktarvy)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nMagnesium might decrease levels of bictegravir/emtricitabine/tenofovir alafenamide by reducing its absorption.\nAdvise patients that bictegravir/emtricitabine/tenofovir alafenamide should be taken at least 2 hours before or 6 hours after magnesium containing products (116930).\nless\nBISPHOSPHONATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonquantitative systematic review)\nMagnesium can decrease absorption of bisphosphonates.\nCations, including magnesium, can decrease bisphosphonate absorption. Advise patients to separate doses of magnesium and these drugs by at least 2 hours (13363).\nless\nCALCIUM CHANNEL BLOCKERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nMagnesium can have additive effects with calcium channel blockers, although evidence is conflicting.\nMagnesium inhibits calcium entry into smooth muscle cells and may therefore have additive effects with calcium channel blockers. Severe hypotension and neuromuscular blockades may occur when nifedipine is used with intravenous magnesium (3046, 20264, 20265, 20266), although some contradictory evidence suggests that concurrent use of magnesium with nifedipine does not increase the risk of neuromuscular weakness (60831). High doses of magnesium could theoretically have additive effects with other calcium channel blockers.\nless\nDIGOXIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nMagnesium salts may reduce absorption of digoxin.\nClinical evidence suggests that treatment with oral magnesium hydroxide or magnesium trisilicate reduces absorption of digoxin from the intestines (198, 20268, 20270). This may reduce the blood levels of digoxin and decrease its therapeutic effects.\nless\nGABAPENTIN (Neurontin)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Lower quality RCT)\nGabapentin absorption can be decreased by magnesium.\nClinical research shows that giving magnesium oxide orally along with gabapentin decreases the maximum plasma concentration of gabapentin by 33%, time to maximum concentration by 36%, and area under the curve by 43% (90032). Advise patients to take gabapentin at least 2 hours before, or 4 to 6 hours after, magnesium supplements.\nless\nKETAMINE (Ketalar)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nMagnesium might precipitate ketamine toxicity.\nIn one case report, a 62-year-old hospice patient with terminal cancer who had been stabilized on sublingual ketamine 150 mg four times daily experienced severe ketamine toxicity lasting for 2 hours after taking a maintenance dose of ketamine following an infusion of magnesium sulfate 2 grams (105078). Since both magnesium and ketamine block the NMDA receptor, magnesium is thought to have potentiated the effects of ketamine.\nless\nLEVODOPA/CARBIDOPA (Sinemet)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nMagnesium can reduce the bioavailability of levodopa/carbidopa.\nClinical research in healthy volunteers shows that taking magnesium oxide 1000 mg with levodopa 100 mg/carbidopa 10 mg reduces the area under the curve (AUC) of levodopa by 35% and of carbidopa by 81%. In vitro and animal research shows that magnesium produces an alkaline environment in the digestive tract, which might lead to degradation and reduced bioavailability of levodopa/carbidopa (100265).\nless\nPOTASSIUM-SPARING DIURETICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nPotassium-sparing diuretics decrease excretion of magnesium, possibly increasing magnesium levels.\nPotassium-sparing diuretics also have magnesium-sparing properties, which can counteract the magnesium losses associated with loop and thiazide diuretics (9613, 9614, 9622). Theoretically, increased magnesium levels could result from concomitant use of potassium-sparing diuretics and magnesium supplements.\nless\nQUINOLONE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nMagnesium decreases absorption of quinolones.\nMagnesium can form insoluble complexes with quinolones and decrease their absorption (3046). Advise patients to take these drugs at least 2 hours before, or 4 to 6 hours after, magnesium supplements.\nless\nSEVELAMER (Renagel, Renvela)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Clinical cohort study)\nSevelamer may increase serum magnesium levels.\nIn patients on hemodialysis, sevelamer use was associated with a 0.28 mg/dL increase in serum magnesium. The mechanism of this interaction remains unclear (96486).\nless\nSKELETAL MUSCLE RELAXANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nA (High-quality meta-analysis (quantitative systematic review))\nParenteral magnesium alters the pharmacokinetics of skeletal muscle relaxants, increasing their effects and accelerating the onset of effect.\nParenteral magnesium shortens the time to onset of skeletal muscle relaxants by about 1 minute and prolongs the duration of action by about 2 minutes. Magnesium potentiates the effects of skeletal muscle relaxants by decreasing calcium-mediated release of acetylcholine from presynaptic nerve terminals, reducing postsynaptic sensitivity to acetylcholine, and having a direct effect on the membrane potential of myocytes (3046, 97492, 107364). Magnesium also has vasodilatory actions and increases cardiac output, allowing a greater amount of muscle relaxant to reach the motor end plate (107364). A clinical study found that low-dose rocuronium (0.45 mg/kg), when given after administration of magnesium 30 mg/kg over 10 minutes, has an accelerated onset of effect, which matches the onset of effect seen with a full-dose rocuronium regimen (0.6 mg/kg) (96485). In another clinical study, onset times for rocuronium doses of 0.3, 0.6, and 1.2 mg/kg were 86, 76, and 50 seconds, respectively, when given alone, but were reduced to 66, 44, and 38 seconds, respectively, when the doses were given after a 15-minute infusion of magnesium sulfate 60 mg/kg (107364). Giving intraoperative intravenous magnesium sulfate, 50 mg/kg loading dose followed by 15 mg/kg/hour, reduces the onset time of rocuronium, enhances its clinical effects, reduces the dose of intraoperative opiates, and prolongs the spontaneous recovery time (112781, 112782). It does not affect the activity of subsequently administered neostigmine (112782).\nless\nSULFONYLUREAS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nMagnesium increases the systemic absorption of sulfonylureas, increasing their effects and side effects.\nClinical research shows that administration of magnesium hydroxide with glyburide increases glyburide absorption, increases maximal insulin response by 35-fold, and increases the risk of hypoglycemia, when compared with glyburide alone (20307). A similar interaction occurs between magnesium hydroxide and glipizide (20308). The mechanism of this effect appears to be related to the elevation of gastrointestinal pH by magnesium-based antacids, increasing solubility and enhancing absorption of sulfonylureas (22364).\nless\nTETRACYCLINE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (In vitro or animal study)\nMagnesium decreases absorption of tetracyclines.\nMagnesium can form insoluble complexes with tetracyclines in the gut and decrease their absorption and antibacterial activity (12586). Advise patients to take these drugs 1 hour before or 2 hours after magnesium supplements.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, magnesium may have antiplatelet effects, but the evidence is conflicting.\nIn vitro evidence suggests that magnesium sulfate inhibits platelet aggregation even at low concentrations (20304, 20305). Some preliminary clinical evidence suggests that infusion of magnesium sulfate increases bleeding time by 48% and reduces platelet activity (20306). However, other clinical research seems to show that magnesium does not affect platelet aggregation, although inhibition of platelet-dependent thrombosis can occur (60759). Theoretically, concomitant use of magnesium with other herbs and supplements that affect platelet aggregation might increase the risk of bleeding. See other products with antiplatelet activity here.\nless\nBORON\nBoron may reduce urinary excretion of magnesium in some people.\nBoron supplements can reduce urinary excretion of magnesium and increase serum levels in females (940, 9529, 9623). In young females, the effect appears to be greater in those that are sedentary than in those that are physically active (940). In postmenopausal adults, the effect is more marked in those with low dietary magnesium intake (9623). The clinical significance of these effects, and whether they occur in males, is unknown.\nless\nCALCIUM\nHigh doses of calcium can decrease dietary magnesium absorption.\nCalcium supplements can decrease the absorption of dietary magnesium, but only at very high, supra-therapeutic doses (2600 mg daily). In people with adequate magnesium stores, calcium doesn't have any clinically significant effect on long-term magnesium balance. Advise patients at high risk for magnesium deficiency to take calcium supplements at bedtime, instead of with meals, to avoid inhibiting dietary magnesium absorption (4623, 7555, 11159). Magnesium does not seem to affect calcium absorption (12587).\nless\nVITAMIN D\nHigh doses of some forms of vitamin D can increase magnesium absorption.\nOne intestinal route of magnesium absorption is thought to be vitamin D-dependent (9634). Various forms of vitamin D, including ergocalciferol, 25-hydroxyergocalciferol, calcifediol, and calcitriol increase magnesium absorption, especially when taken in high doses (9634, 9635, 9636, 9637). This effect has been used to treat hypomagnesemia in people with malabsorption syndromes (9516, 9635, 9636).\nless\nZINC\nHigh doses of zinc may decrease magnesium absorption.\nSupplementation with high doses of zinc, 142 mg daily, appears to decrease magnesium absorption and magnesium balance in healthy adult males (9624). Also, moderately high dietary zinc intake, 53 mg daily, seems to increase magnesium excretion without affecting copper metabolism in postmenopausal patients. This might adversely affect bone health. Zinc may compete with magnesium for ion exchange transport in the intestine (12424).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nALCOHOL USE DISORDER\nChronic alcohol use increases the risk for magnesium deficiency. Alcohol impairs the ability of the kidney to conserve magnesium (12507).\nless\nBLEEDING DISORDERS\nIn vitro evidence suggests that magnesium sulfate inhibits platelet aggregation even at low concentrations. Some preliminary clinical evidence suggests that infusions of magnesium sulfate increase bleeding time by 48% and reduce platelet activity (20304, 20305, 20306). However, other clinical research seems to show that magnesium does not affect platelet aggregation, although inhibition of platelet-dependent thrombosis can occur (60759). Theoretically, magnesium might increase the chance of bleeding in patients with existing bleeding disorders.\nless\nDIABETES\nDiabetes increases the risk for magnesium deficiency. Poorly controlled diabetes leading to glycosuria leads to reduced renal reabsorption of magnesium (12507).\nless\nHEART BLOCK\nHypermagnesemia can cause heart block. Intravenous magnesium is contraindicated in people with heart block (13358).\nless\nKIDNEY DISEASE\nKidney disease reduces magnesium excretion and increases the risk for hypermagnesemia. Use cautiously in individuals with reduced kidney function and avoid use in those with creatinine clearance <20 mL/min due to an increased risk of hypermagnesemia (12507, 112859).\nless\nMYASTHENIA GRAVIS\nIntravenous magnesium might worsen neuromuscular weakness and respiratory failure in patients with myasthenia gravis and contribute to a myasthenic crisis. Magnesium competes with calcium on the presynaptic membrane of the neuromuscular junction, inhibiting release of acetylcholine (ACh) and exacerbating the reduction in postsynaptic ACh function seen in myasthenia gravis (108969). In one case report, a 62-year-old female with myasthenia gravis and metastatic thymoma had a worsening of respiratory failure and neuromuscular weakness after receiving intravenous magnesium (98292). In a second case report, a female with a known history of myasthenia gravis developed respiratory failure requiring ventilatory support on 3 separate occasions after receiving single doses of intravenous magnesium for cardiac arrhythmias (108969).\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nALKALINE PHOSPHATASE (ALK PHOS)\nMagnesium salts can cause a false increase in serum alkaline phosphatase test results due to the activation of enzymes used in laboratory procedures (275).\nless\nCALCIUM\nMagnesium salts can cause a false increase in serum calcium test results in some procedures using edetate disodium (EDTA) (275).\nless",
            "Nutrient Depletions": "EXPAND ALL\n|\nCOLLAPSE ALL\nALDESLEUKIN (Proleukin)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nAldesleukin may cause a shift of magnesium into cells.\nAsymptomatic hypomagnesemia can occur with aldesleukin therapy, probably due to an intracellular shift of magnesium. There isn't any increase in urinary magnesium, and serum levels normalize a few days after the drug is stopped (8874).\nless\nAMIFOSTINE (Ethyol)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nAmifostine increases urinary losses of magnesium.\nAmifostine reduces serum magnesium levels by reducing renal tubular reabsorption of magnesium and increasing urinary losses (9625). This effect seems to occur acutely after a single dose, and levels may return to normal within 24 hours (9625).\nless\nAMINOGLYCOSIDE ANTIBIOTICS\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nIncreased urinary magnesium loss occurs with nephrotoxicity caused by aminoglycosides.\nNephrotoxicity caused by aminoglycosides may lead to increased urinary losses of various electrolytes, including magnesium. Monitor patients closely to detect declining renal function and electrolyte disturbances. The aminoglycoside may need to be discontinued and intravenous electrolyte replacement given (13362).\nless\nAMPHOTERICIN-B (Abelcet, others)\nDepletion Rating\nMAJOR\nA supplement is needed for most patients.\nAmphotericin-B can cause a significant decrease in magnesium levels.\nElectrolyte disturbances, including low serum magnesium levels, develop in a large proportion of patients receiving amphotericin-B. Lipid-based formulations might have a lesser effect than the conventional formulations (13364). This disturbance has been association with nephrotoxicity, and may necessitate stopping the drug and giving intravenous electrolyte replacement.\nless\nBETA-2 AGONISTS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nBeta-2 agonists cause small, generally reversible decreases in magnesium levels.\nBeta-2 agonists promote movement of magnesium from the extracellular to the intracellular space, and increase magnesium excretion in the urine (2644, 9517, 9641). Reduced serum magnesium levels occur after a single dose of albuterol or terbutaline orally, by IV infusion, SC injection, or by inhalation (2644, 6203, 6205, 6209, 6217, 8882, 9517). The reductions are generally small, about 4.5-9%, or 0.04 to 0.06 mmol/L compared with the normal serum magnesium range of 0.65 to 1.1 mmol/L (6205, 6217). However, these acute changes could contribute to ECG changes, including prolonged QT intervals (2644, 8882). With chronic use of beta-2 agonists, serum magnesium levels generally return to normal, but muscle magnesium levels may remain low (6209, 6210, 9507). For information on foods that are rich in magnesium, see our chart.\nless\nCAPECITABINE (Xeloda)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nCapecitabine may damage renal tubules and increase magnesium losses.\nA case of hypomagnesemia, characterized by weakness and dizziness, has been reported in a patient treated with capecitabine 2 months earlier. Capecitabine may cause magnesium wasting due to its effects on the renal tubules (90019). For information on foods that are rich in magnesium, see our chart.\nless\nCETUXIMAB (Erbitux)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nCetuximab causes increased loss of magnesium in the urine.\nCetuximab causes renal magnesium wasting, leading to lowered magnesium levels in 50% to 97% of patients (15541). Hypomagnesemia severe enough to require treatment occurs in 10% to 15% of cases (15542). For information on foods that are rich in magnesium, see our chart.\nless\nCHOLESTYRAMINE (Questran)\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nSmall clinical studies show that cholestyramine may slightly increase urinary magnesium excretion, possibly by binding vitamin D and leading to reduced magnesium absorption (9566, 9627). Clinically significant magnesium deficiency hasn't been reported, and supplements aren't likely to be needed. For information on foods that are rich in magnesium, see our chart.\nCORTICOSTEROIDS\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nTaking corticosteroids chronically increases excretion of magnesium in the urine.\nChronic use of corticosteroids increases the amount of magnesium excreted in the urine. This is thought to be due to catabolism of bone, releasing magnesium and increasing the amount available for excretion (9628, 9629). Generally, there is not a significant effect on serum levels (9507, 9508, 9509). For information on foods that are rich in magnesium, see our chart.\nless\nCYCLOSPORINE (Neoral, Sandimmune)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nCyclosporine can increase magnesium loss in the urine, possibly by causing damage to the renal tubules.\nCyclosporine can cause significant loss of magnesium in the urine, probably by causing renal tubular damage which reduces tubular reabsorption (9117, 9632, 9633). Hypomagnesemia may contribute to seizures and neurotoxicity associated with cyclosporine (9117, 9632).\nless\nDIGOXIN (Lanoxin)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nDigoxin increases excretion of magnesium in the urine.\nDigoxin decreases renal tubular reabsorption of magnesium, increasing excretion in the urine (4556, 9631). People taking digoxin for heart failure may also be taking loop or thiazide diuretics, increasing the potential for hypomagnesemia (9613, 9631). Low magnesium levels increase the risk of arrhythmias associated with high digoxin levels (9631, 90018). For information on foods that are rich in magnesium, see our chart.\nless\nDIURETIC DRUGS\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nSome diuretics increase the amount of magnesium excreted in the urine.\nLoop diuretics and, to a lesser extent thiazide diuretics, interfere with magnesium reabsorption in the kidneys, increasing urinary losses and reducing serum magnesium levels (4412, 9613, 9614, 9622). Potassium-sparing diuretics, such as amiloride, triamterene, or spironolactone, are also magnesium-sparing, and can therefore counteract the magnesium losses seen with loop diuretics and thiazides (9613, 9614, 9622). For information on foods that are rich in magnesium, see our chart.\nless\nESTROGENS\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nEstrogens reduce serum levels of magnesium by increasing its uptake into body tissues.\nEstrogens enhance magnesium uptake by soft tissues and bones, lowering serum levels (9621, 9639). There appears to be an inverse relationship between estrogen levels and magnesium serum levels (9638, 9639, 9640). Estrogen therapy, including the use of oral contraceptives, lowers serum magnesium levels and can cause hypomagnesemia, which may contribute to thromboembolic complications associated with estrogens (9621, 9639, 9640). For information on foods that are rich in magnesium, see our chart.\nless\nFOSCARNET (Foscavir)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nFoscarnet can increase removal of magnesium from the body, causing symptomatic hypomagnesemia.\nFoscarnet can cause various electrolyte disturbances, including symptomatic hypomagnesemia (8869, 9617). This may be due to chelation of magnesium and increased elimination (8869). For information on foods that are rich in magnesium, see our chart.\nless\nINSULIN\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nInsulin can increase magnesium excretion.\nInsulin can enhance the renal excretion of magnesium. Theoretically, it might lower magnesium stores; however, lower magnesium stores are common in patients with diabetes due to decreased intake and osmotic diuresis resulting in increased magnesium excretion (13381). For information on foods that are rich in magnesium, see our chart.\nless\nPANITUMUMAB (Vectibix)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nPanitumumab increases excretion of magnesium in the urine.\nPanitumumab causes renal magnesium wasting, leading to lowered magnesium levels in 39% of patients. Hypomagnesemia severe enough to require treatment occurs in 2% to 4% of cases (15543). For information on foods that are rich in magnesium, see our chart.\nless\nPENICILLAMINE (Cuprimine, Depen)\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nPenicillamine can reduce magnesium absorption by chelating magnesium in the gut.\nPenicillamine chelates magnesium, although with lower affinity than other metals such as copper, iron, and zinc (9630). It can potentially contribute to hypomagnesemia, especially in people with other factors which lower serum magnesium (4534). Magnesium supplements should be taken several hours apart from penicillamine to avoid forming non-absorbable chelates in the gut. For information on foods that are rich in magnesium, see our chart.\nless\nPENTAMIDINE (NebuPent)\nDepletion Rating\nMAJOR\nA supplement is needed for most patients.\nPentamidine can increase magnesium loss in the urine, probably by causing damage to the renal tubules.\nSymptomatic hypomagnesemia can occur with pentamidine, especially when given intravenously. This is likely due to renal tubular injury, leading to increased urinary losses of magnesium. Hypomagnesemia usually requires treatment with intravenous, followed by oral, magnesium supplements. Supplementation may need to be continued after pentamidine is stopped since the drug effects remain for six to eight weeks (8872, 9618, 9619).\nless\nPROTON PUMP INHIBITORS (PPIs)\nDepletion Rating\nMAJOR\nA supplement is needed for most patients.\nHypomagnesemia requiring supplementation has been reported with all PPIs.\nTaking a PPI long-term, especially over a year, has been linked to an increased risk of hypomagnesemia in observational research (17546, 17547, 17548, 17549, 17550, 17551, 17552, 17553, 17554, 17555, 17556, 89392, 90007, 100266, 101394, 107368, 110050). Higher doses are associated with a two-fold increase in the odds of hypomagnesemia when compared with lower doses (101394). Observational research in elderly hospitalized patients has also found that males, smokers, and heavy alcohol use further increase the risk of hypomagnesemia from PPI use (110050). PPIs increase intestinal pH which is thought to inhibit active transport of magnesium in the intestine, reducing its absorption (17549, 17550, 107368). The American College of Gastroenterology (ACG) does not provide a recommendation related to monitoring magnesium levels in patients taking PPIs (107368). However, other experts, including the US Food and Drug Administration (FDA), recommend that serum magnesium levels should be checked at baseline and annually thereafter in patients who are likely to take a PPI long-term. In up to 25% of patients who develop hypomagnesemia, the PPI will need to be discontinued permanently to return magnesium levels to normal and maintain them (17546, 17547, 17548, 17558). In some patients, it is possible to continue the PPI and take a magnesium supplement concurrently to maintain magnesium levels (17547, 17558). For information on foods that are rich in magnesium, see our chart.\nless\nQUINOLONE ANTIBIOTICS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nQuinolone antibiotics bind magnesium in the gut, reducing absorption of both agents.\nQuinolones form complexes with magnesium in the GI tract (3046). This could theoretically reduce absorption of both the quinolone and magnesium if taken at the same time. Significant effects on magnesium levels are unlikely when quinolones are taken at least 2 hours before, or 4 to 6 hours after, magnesium supplements.\nless\nSODIUM PHOSPHATES\nDepletion Rating\nMODERATE\nMonitor for depletion; a supplement is needed in some patients.\nHigh doses of sodium phosphates deplete magnesium.\nUse of high doses of sodium phosphates, such as those used for bowel cleansing before surgery, can cause hypomagnesemia (9615, 9616). Advise people to avoid using high doses of these products for self-treatment of constipation.\nless\nTACROLIMUS (Prograf)\nDepletion Rating\nMAJOR\nA supplement is needed for most patients.\nTacrolimus increases magnesium losses in the urine.\nTacrolimus reduces renal tubular reabsorption of magnesium, producing increased magnesium wasting (8900, 9620). This leads to hypomagnesemia in a significant proportion of people treated with tacrolimus (9620). For information on foods that are rich in magnesium, see our chart.\nless\nTETRACYCLINE ANTIBIOTICS\nDepletion Rating\nINSIGNIFICANT\nA supplement is not needed for most patients.\nTetracyclines may bind to dietary magnesium, reducing absorption of both agents.\nTetracyclines form complexes with magnesium in the GI tract, which could reduce absorption of both the tetracycline and magnesium (4412). Significant effects on magnesium levels are unlikely when tetracyclines are taken on an empty stomach, 1 hour before or 2 hours after magnesium supplements.\nless",
            "Overdose": "Presentation\nSymptoms of magnesium toxicity include thirst, hypotension, central nervous system depression, drowsiness, confusion, skeletal muscle paralysis, loss of tendon reflexes, respiratory depression, cardiac arrhythmias, and, in extreme cases, coma, cardiac arrest, and death (8095, 12589). Serum magnesium levels should be monitored. Renal insufficiency increases the likelihood of toxicity due to hypermagnesemia (61013).\n\nThere are at least two reports of fatal hypermagnesemia. One report involved a 28-month-old child treated with 800 mg of oral magnesium oxide per day for constipation, then given 2400 mg magnesium oxide for several days before hospital admission (serum magnesium 20.3 mg/dL) (1360). Another report involved a patient who gargled with Epsom salts over several weeks. Epsom salts are almost 100% magnesium sulfate. The patient used an entire box two days prior to hospital admission (serum magnesium 23.6 mg/dL) (8095).\nTreatment\nManagement of hypermagnesemia is well-established; details can be found in various medical guidelines.",
            "Pharmacokinetics": "Absorption\nMagnesium requires both parathyroid hormone and vitamin D for absorption (12585). It is absorbed throughout the gastrointestinal tract and about one third of dietary magnesium is absorbed. The efficiency of absorption depends on magnesium stores in the body. Average absorption of supplements is 38%, but varies from 65% in people with low magnesium stores to 11% in those with high magnesium stores. Magnesium plasma concentrations peak at 4 hours after a dose (9634, 12585, 13383, 61054).\n\nEnteric coating of some products may reduce the absorption of magnesium (12587, 13383). It is well absorbed from foods (12587). Fractional magnesium absorption decreases with increasing intake. The bioavailability of magnesium supplements varies. Magnesium chloride (Slo-Mag), magnesium lactate (Mag-Tab SR), and magnesium aspartate appear to be the most bioavailable. Magnesium oxide (MagOx) and magnesium sulfate are only about 4% bioavailable (13383).\nDistribution\nThe body contains about 25 grams of magnesium, which is divided in roughly equal portions between the skeleton and soft tissue (60918). About a third of skeletal magnesium is at the surface of the bone and acts as a reservoir to maintain extracellular magnesium concentrations. The remaining two-thirds is tightly bound to bone and is not readily available as a magnesium source (7555, 12499, 12507). Extracellular magnesium makes up only 1% of total body magnesium. In plasma, 55% is ionized or free, about 30% is bound to plasma proteins, and 15% is complexed to anions (12507, 60918).\n\nMagnesium is thought to undergo a filtration-reabsorption process (9628). The concentration of magnesium in the proximal tubule increases to 1.5 times that in the glomerular filtrate. Approximately 20% to 30% of filtered magnesium is reabsorbed in the proximal tubule. Reabsorption is thought to change in parallel to sodium as changes occur in the extracellular fluid volume. Approximately 65% of filtered magnesium is reabsorbed in the loop of Henle, and most of that occurs in the thick ascending limb. Reabsorption is voltage-dependent and may occur secondary to active sodium chloride reabsorption. Magnesium and calcium compete for transport on the ascending limb cell at the basolateral surface. Factors which play a role in magnesium reabsorption include parathyroid hormone, plasma magnesium and calcium level alterations, and use of loop diuretics.\nExcretion\nMagnesium excretion is primarily via the kidneys and averages only 3% to 5% of the filtered load. Excretion ranges from 10 to 5000 mg over a 24-hour period (13365, 61054). Urinary magnesium and pH are known to modulate urinary calcium excretion; however, the underlying mechanism is unknown (60896).",
            "Mechanism of Action": "General\nMagnesium (Mg) is a component of many compounds. It is the seventh most abundant element in the earth's crust by mass. It occurs in magnesite, dolomite, and in mineral waters (90051). Magnesium is well absorbed from foods (12587). Foods that are high in fiber are generally high in magnesium (13382). Dietary sources of magnesium include legumes, whole grains, vegetables (especially broccoli, squash, and green leafy vegetables), seeds, and nuts (especially almonds). Other sources include dairy products, meats, chocolate, and coffee. Water with a high mineral content, or \"hard\" water, is also a source of magnesium. Dietary intake of magnesium may be low, particularly among females (8088, 12504, 12505).\nAnalgesic effects\nMagnesium is reported to be an antagonist at N-methyl-D-aspartate (NMDA) receptors, which are involved in the potentiation of pain. This effect and magnesium's depressant effects on nerves and smooth muscle are thought to contribute to the possible effects of magnesium in relieving symptoms associated with migraine headaches, postoperative pain, neuropathic pain, erythromelalgia, Raynaud's Phenomenon, and other vascular disorders and pain syndromes (6846, 6848, 8094).\n\nMagnesium might play a role in migraine headache. Low levels of magnesium may induce cerebral arterial vasoconstriction, increase platelet aggregation and promote serotonin release, and potentiate the vasoactive properties of serotonin (6844, 12388).\nAnti-inflammatory effects\nMagnesium deficiency has been reported to be a trigger for inflammatory processes. A meta-analysis of 17 clinical trials comparing the effects of various magnesium salts, 250-500 mg daily for 4-26 weeks, on inflammatory markers shows that magnesium significantly decreases serum C-reactive protein (CRP) levels and increases nitric oxide (NO) levels when compared with placebo. However, it does not affect levels of serum interleukin (IL)-6, total antioxidant capacity, glutathione (GSH), or tumor necrosis factor (TNF)-alpha (108727).\nAntidiabetic effects\nThere is some evidence that magnesium plays a role in diabetes and metabolic syndrome (1168, 1183). In clinical research, oral magnesium has been reported to improve glycemic control in some patients with type 2 diabetes (1197, 15548, 60854, 61032, 96473). Low magnesium levels are associated with an increased risk of metabolic syndrome and obesity (13369, 13372, 105918). Poorly controlled diabetes can cause enhanced osmotic diuresis and increase urinary loss of magnesium (13381). In severe hyperglycemia, tubular reabsorption of magnesium is decreased and may result in lower magnesium levels secondary to increased excretion (13365). Autonomic neuropathy and related autoimmune gastric atrophy may reduce intestinal absorption of magnesium. Also, insulin can increase magnesium excretion (13381). However, in patients with reasonably well-controlled type 2 diabetes, dietary magnesium absorption and retention don't appear to be impaired. Lower serum levels may be related to lower dietary intake (13375). Magnesium seems to affect glucose control and insulin homeostasis. Magnesium blood levels might play a role in insulin resistance (1168, 6844, 14304, 17133). Insulin is involved with the shift of magnesium intracellularly. In turn, intracellular magnesium seems to regulate insulin activity on oxidative glucose metabolism. Low intracellular magnesium causes disorders in tyrosine kinase activity at the insulin receptor level, which results in decreased insulin sensitivity and insulin-mediated glucose uptake. Magnesium is also thought to enhance the action of enzymes involved in glucose utilization (13365, 17133).\nAntioxidant effects\nMagnesium has antioxidant effects that can be reduced by calcium (61106).\nCardiovascular effects\nMagnesium is known to be essential for all ATPase activity, including facilitating movement of calcium across and within the cell membrane of cardiac and vascular tissues (60920). In patients with congestive heart failure, there is evidence magnesium reduces coronary vascular resistance, increases coronary artery blood flow, has antiarrhythmic effects, and improves cardiac indexes (8088).\n\nThere is interest in using magnesium for preventing endothelial function decline, which is a risk factor for cardiovascular events. A meta-analysis of preliminary clinical research suggests that taking magnesium for at least 6 months improves endothelial function as measured by flow-mediated dilatation (FMD) in patients who are unhealthy, over 50 years of age, or overweight (102455). There is also interest in the effects of magnesium on arterial stiffness, which is a predictor of coronary heart disease and stroke. In overweight adults, taking magnesium 450 mg daily as the citrate, oxide, or sulfate salts for 24 weeks does not affect arterial stiffness, measured by the carotid-to-femoral pulse wave velocity, when compared with placebo (108730).\n\nThere is some evidence that magnesium is important in regulating blood pressure (1170, 1182). Magnesium deficiency has been found to increase intracellular concentrations of sodium and potassium, which can lead to increased peripheral resistance and vasospasm (8088). In cell membranes, a decreased concentration of magnesium and increased calcium to magnesium ratio has also been associated with hypertension (8092). There is also some evidence that hypertensive patients with hypomagnesemia usually require more antihypertensive medications than hypertensive patients with normal magnesium levels (8088).\n\nReduced intracellular magnesium also causes an increase in intracellular calcium. In addition to contributing to insulin resistance, higher intracellular calcium levels enhance calcium-mediated vasoconstriction, and inhibit cardiac and smooth muscle relaxation (13365). This increased vascular tone can increase blood pressure.\n\nThere is some evidence that serum magnesium deficiency might play a role in both ischemic and hemorrhagic stroke (8998).\nDeficiency\nMagnesium deficiency is not uncommon in the US. It's particularly prevalent among African Americans and the elderly. Low intake and impaired absorption of magnesium have also been associated with the development of various disease states such as osteoporosis, hypertension, atherosclerotic vascular disease, cardiomyopathy, diabetes, and stroke (8088, 8099, 8998, 9001, 12510, 12511). Hypomagnesemia is usually asymptomatic. The serum magnesium level is the most commonly used test to assess magnesium status. However, it is also known that the serum magnesium level is depressed only in cases of severe magnesium deficiency and that it poorly correlates with body magnesium (8089). The body preserves serum magnesium at the expense of magnesium in cells and bone, so serum levels may appear normal in magnesium deficiency (12510, 12511). Red cell and urine magnesium levels also have been used but they are also poor indicators of body magnesium (8085, 8089). The intravenous magnesium loading test is considered to be a more reliable test to measure magnesium status. However, the test is cumbersome and requires full participation from the patient. It is known that serum magnesium actually consists of three fractions. They are protein-bound, complexed, and free ionic magnesium. It is the free ionic magnesium that is biologically active. Whether the serum magnesium level is low or normal, free ionic magnesium levels have been shown to vary with many disorders such as cardiac disease, stroke, diabetes, and migraines. In recent years, instruments have become available that measure free ionic magnesium, allowing for a more accurate assessment of body magnesium. However, measurement of ionized magnesium may not be readily available in labs outside the research setting (8090).\n\nSymptoms of severe magnesium deficiency include convulsions; confusion; muscle weakness; abnormal muscle movements such as tremors, myoclonus, and tetany; and arrhythmias including ventricular tachycardia, fibrillation, and torsades de pointes (403, 13383). Long-term magnesium deficiency might increase the risk of arrhythmias and the rate of developing atherosclerosis (13383).\nGastrointestinal\nAs antacids, magnesium salts work by reacting with gastric acid to form magnesium chloride. Magnesium hydroxide has the fastest onset of action, magnesium carbonate is slower due to its crystal structure, and magnesium trisilicate has the slowest onset and longest duration due to its poor solubility (6844).\n\nThe laxative effects and diarrhea produced by magnesium salts are due to the osmotic effects of unabsorbed salts in the intestine and colon, and stimulation of gastric motility due to the release of gastrin and cholecystokinin (6844).\nHormonal effects\nIntracellular levels of magnesium, measured in erythrocytes and leukocytes, have been found to be lower in females with premenstrual syndrome (PMS), leading to the use of magnesium supplements for PMS (6847). Oral magnesium has been reported to benefit mood changes associated with premenstrual syndrome (PMS) (1187).\n\nSupplementation of thyroid hormone to hypothyroid animals restored magnesium levels and transport. Therefore, thyroid hormones may have an effect on magnesium homeostasis (60899).\nImmune effects\nIn clinical research, magnesium has been shown to decrease plasma cortisol levels (2826). Additional research suggests low serum magnesium is related to low-grade chronic inflammation. Hypomagnesemia is associated with elevated serum concentrations of tumor necrosis factor-alpha and C-reactive protein (CRP), which has been linked to metabolic syndrome (13366). Magnesium intake inversely correlates with CRP levels: females with high dietary magnesium intake have lower levels of CRP, which may reduce cardiovascular disease risk. The relationship is strongest in overweight or obese females (BMI >25) and current or past smokers (13369). Other epidemiological research in adults has found that consuming less that the recommended dietary allowance (RDA) for magnesium is associated with a 1.48 to 1.75 times higher risk of having an elevated CRP. In adults over age 40 with a BMI >25, consumption of less than 50% of the RDA for magnesium correlates with a 2.24 times higher risk of elevated CRP (13371, 13373). However, it is unclear if magnesium supplementation reduces CRP levels. One meta-analysis of 18 clinical trials including 927 patients with various conditions shows that supplemental magnesium does not reduce CRP levels when compared with placebo (105921). The included studies were not designed to assess CRP levels or baseline magnesium status, limiting the validity of this finding.\nMuscular effects\nExtracellular magnesium is critical to both maintaining nerve and muscle electrical potentials and transmitting impulses across neuromuscular junctions (272). The inhibitory effect of magnesium on preterm labor contractions (tocolysis) is attributed to antagonism of calcium-mediated myometrial contractions (6844). Oral magnesium has been reported to reduce the incidence of pregnancy-related leg cramps which may be associated with lower serum magnesium levels (1194). Magnesium was also found to be effective in preventing succinylcholine-induced muscle twitching, which is an adverse effect of patients undergoing general anesthesia (60834).\nNeurological effects\nExtracellular magnesium is critical to both maintaining nerve and muscle electrical potentials and transmitting impulses across neuromuscular junctions (272). Preliminary evidence shows magnesium may act as a neuroprotective agent in patients diagnosed with acute stroke. Several possible mechanisms of neuroprotection exist, including noncompetitive N-methyl-D-aspartate (NMDA) antagonism and calcium channel antagonism (9000, 9003).Magnesium levels also appear to be lower in acute attacks of paranoid schizophrenia (12584).\n\nIn animal research, magnesium has been shown to have neuroprotective effects (60986). It was shown to prevent post-hypoxic brain injury by blocking the excess release of glutamate in the calcium channel. Fetal and newborn brains appear to be more susceptible to damage from glutamate release; therefore, blocking glutamate receptors through agents such as magnesium may reduce the risk of injury in the perinatal period. However, clinical studies to date have not shown a definite fetal neuroprotective benefit from prenatal administration of magnesium to pregnant patients, although prenatal magnesium therapy may improve motor function in early childhood for infants born prematurely (114681).\n\nThe role of magnesium in the prevention or control of convulsions may involve blocking neuromuscular transmission and decreasing the release of acetylcholine at the motor nerve terminals (61006).\n\nThe mechanism of action for magnesium in pre-eclampsia and eclampsia is not clear. There is some evidence that magnesium dilates blood vessels in the central nervous system (CNS) to reduce ischemia. Contrary to this view are indications that magnesium may decrease CNS blood flow (9473). Additionally, magnesium may have anticonvulsant actions in eclampsia due to depression of neuromuscular transmission, direct depressant effect on smooth muscle, and CNS depression (6844).\n\nThere is interest in using magnesium for improving symptoms of insomnia and other sleep disturbances. In a small clinical study in elderly patients with primary insomnia, magnesium intake increased levels of melatonin and reduced levels of cortisol, which might contribute to improved sleep (102458). Additionally, low magnesium levels have been linked to poor sleep quality and also to electroencephalogram (EEG) abnormalities during slow wave sleep. Magnesium has been theorized to regulate sleep by reducing inflammation, oxidative stress and by activating N-methyl-D-aspartate and gamma-aminobutyric acid (GABA) receptors (102456).\nOtic effects\nOral magnesium treatment has been shown to reduce the incidence of temporary and permanent noise-induced hearing loss. It is hypothesized that magnesium may improve permanent hearing threshold shifts (NIPTS) (1205, 60813).\nPulmonary\nIn asthma, intravenous administration of magnesium might cause bronchodilation (2003, 60889).\nRenal effects\nThere is some evidence that magnesium metabolism is a factor in renal stone formation and prevention (2006, 2007). There is preliminary evidence that magnesium can reduce hypertension and nephrotoxicity induced by cyclosporine. Magnesium supplementation appears to reduce the thickening of the renal vascular walls that may occur with cyclosporine therapy; potassium supplementation may increase the effectiveness of magnesium for this use (9500).\nSkeletal effects\nMagnesium is important for normal bone structure (272), and plays an essential role in more than 300 cellular reactions (945). Magnesium is required for the formation of cyclic AMP (cAMP) and is involved in ion movements across cell membranes (945). It is involved in protein synthesis and carbohydrate metabolism (272).\n\nMagnesium deficiency increases the formation and activity of osteoclasts (bone resorbing cells). Magnesium deficiency causes increases in substance P and tumor necrosis factor (TNF)-alpha in bone, which increase osteoclastic bone resorption. Increased bone resorption causes release of magnesium as well as calcium from bone. Since magnesium is an essential nutrient, the body may sacrifice bone in times of deficiency as a magnesium source to maintain homeostasis (12499, 12500). Magnesium deficiency might be a risk factor for postmenopausal osteoporosis, but its exact role is unknown (7555).\n\nMagnesium, like calcium, is regulated by parathyroid hormone (PTH). In humans, severe to moderate magnesium deficiency commonly causes hypocalcemia. Normally, magnesium deficiency increases PTH activity. PTH increases renal calcium reabsorption, increases phosphate excretion, and increases renal magnesium reabsorption. Impaired parathyroid hormone (PTH) activity and impaired response to PTH seem to be the predominant reasons that magnesium-deficient people are also hypocalcemic (12499). However, clinical research shows that magnesium sulfate 350 mg taken daily by mouth for 3 weeks does not affect calcium blood levels in patients with hypoparathyroidism taking maintenance therapy of calcium and a vitamin D analog (90010).\n\nClinical research suggests that magnesium, alone or in combination with calcium, vitamin D, and zinc, reduces bone turnover (60928, 60934, 60950). In combination with calcium, vitamin D, and other minerals, magnesium increases bone density (36840). Magnesium supplementation in postmenopausal patients with osteoporosis results in decreased serum iPTH and urinary deoxypyridinoline and increased serum osteocalcin (60928, 60950)."
        }
    },
    "Magnolia": {
        "sections": {
            "Overview": "Magnolia is a genus of plants that are distributed throughout temperate and tropical regions of Asia, North America, and South America. The bark and flowers are used in Traditional Chinese Medicine to treat the \"stagnation of qi\" as well as for depression and anxiety (34246, 92459, 92464, 95035).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. A specific product containing magnolia extract and phellodendron extract (Relora, Next Pharmaceuticals, Inc.) has been used with apparent safety in clinical trials at a dose of 250 mg two to three times daily for up to 6 weeks (14349, 34246, 94904). ...when used topically in a toothpaste for up to 6 months (92464).\nPREGNANCY: UNSAFE when the magnolia flower bud is used orally due to reports of uterine stimulant activity (11953). There is insufficient reliable information available about the safety of using magnolia bark during pregnancy; avoid using.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, magnolia seems to be well tolerated.\nMost Common Adverse Effects\nTopically: Contact dermatitis.\nDermatologic\nTopically, magnolia bark has been associated with reports of allergic contact dermatitis (92463, 92468, 95030, 110709). In several cases, the use of anti-aging facial creams containing magnolia bark extract was associated with allergic contact dermatitis of the face (92463, 92468, 95030). In one case, the use of a vaginal gel containing magnolia bark extract was associated with allergic contact dermatitis of the vulva (110709). Symptoms typically resolve with the use of topical corticosteroids and discontinuation of magnolia bark extract (95030, 110709). Patch testing suggests that the magnolia bark extract constituents magnolol and honokiol are responsible for this adverse effect (110709).\nless\nEndocrine\nIn a clinical trial of an oral combination product containing extracts of magnolia and phellodendron, one patient reported thyroid dysfunction (14349). However, it's not known if this side effect is related to magnolia or some other factor.\nless\nGastrointestinal\nIn a clinical trial of an oral combination product containing extracts of magnolia and phellodendron, one patient reported heartburn (14349). However, it's not known if this side effect is related to magnolia or some other factor.\nless\nNeurologic/CNS\nIn a clinical trial of an oral combination product containing extracts of magnolia and phellodendron, one patient reported shaking hands and perilabial numbness. Another patient reported fatigue and headache (14349). However, it's not known if these side effects are related to magnolia or some other factor.\nless\nPsychiatric\nIn a clinical trial of an oral combination product containing extracts of magnolia and phellodendron, one patient reported sexual dysfunction (14349). However, it's not known if this side effect is related to magnolia or some other factor.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nGingivitis. Magnolia bark extract might modestly reduce gum bleeding and inflammation when added to gum or toothpaste.\nOne clinical study shows that chewing gum containing magnolia bark extract plus xylitol for 5 minutes three times daily for 30 days reduces gingival bleeding by 33%, compared with 24% after chewing gum containing xylitol alone (92459). Another clinical study in adults with gingivitis shows that using a fluoride toothpaste containing magnolia extract 0.3% twice daily reduces gingivitis severity by about 0.27 points on the gingival index after 3 months, compared to 0.15 points for patients using the toothpaste without magnolia extract (92464).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. Although there is interest in using topical magnolia for aging skin, there is insufficient reliable information about the clinical effects of magnolia for this purpose.\nAllergic rhinitis (hay fever). Although there is interest in using oral magnolia for hay fever, there is insufficient reliable information about the clinical effects of magnolia for this condition.\nAnxiety. Oral magnolia has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in healthy females with mild anxiety shows that taking a proprietary blend of magnolia and phellodendron bark extract (Relora, Next Pharmaceuticals), standardized to 1.5% honokiol and 0.1% berberine, 250 mg three times daily for 6 weeks reduces temporary feelings of stress-induced anxiety almost 2-fold when compared with placebo. However, taking this product does not seem to improve long-standing feelings of stress-induced anxiety (34246). It is unclear if this effect is due to magnolia, other ingredients, or the combination. Additionally, this study was funded by the supplement manufacturer.\nless\nDental plaque. It is unclear if oral magnolia is beneficial in patients with dental plaque.\nClinical research in adults with gingivitis shows that using a toothpaste containing 0.3% magnolia extract twice daily modestly reduces plaque severity by about 0.41 points on the mean plaque index after 3 months, compared to a 0.27 point reduction for patients using the toothpaste without magnolia extract (92464). While statistically significant, this improvement might not be clinically meaningful.\nless\nDiabetes. Although there is interest in using oral magnolia for diabetes, there is insufficient reliable information about the clinical effects of magnolia for this condition.\nHeadache. Although there is interest in using oral magnolia for headache, there is insufficient reliable information about the clinical effects of magnolia for this condition.\nMenopausal symptoms. Oral magnolia has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized clinical study in postmenopausal patients shows that taking a specific combination of magnolia, Vitex agnus-castus, soy isoflavones, vitamin D, and lactobacillus (Estromineral Serena Plus, Meda Pharma SpA) daily for one year decreases the frequency and intensity of hot flashes and improves sleep quality and the ability to fall asleep when compared with soy isoflavones alone (95031). Additionally, a small clinical study shows that taking this same product daily for one year improves vasomotor symptoms, mood disorders, somatic symptoms, sleep disorders, blood pressure, and glycemic control when compared to baseline (110708). However, the validity of these findings is limited by a lack of control group.\n\nOverall, it is unclear if the effects of this magnolia-containing product in postmenopausal patients are due to magnolia, other ingredients, or the combination.\nless\nObesity. Oral magnolia has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in overweight females who report stress eating shows that taking a specific product containing a combination of bark extracts of magnolia plus phellodendron (Relora, Next Pharmaceuticals, Inc.) 250 mg three times daily for 6 weeks seems to prevent weight gain, compared with a 1.5 kg weight gain in those taking placebo (14349). This finding is limited because differences between groups were not statistically compared. Furthermore, it's unclear if this product induces weight loss.\nless\nPostpartum depression. It is unclear if oral magnolia tea is beneficial for preventing postpartum depression.\nA small clinical study in healthy postpartum patients shows that drinking 1 cup of magnolia tea daily for 3 weeks may improve depressive symptoms and sleep efficiency when compared with usual care alone. Magnolia tea (plant part unspecified) was steeped in 300 mL of hot water for 12 minutes prior to consumption (105089).\nless\nStress. Oral magnolia has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small low-quality clinical trial in moderately stressed healthy adults shows that taking a proprietary blend of magnolia and phellodendron bark extract (Relora, Next Pharmaceuticals) 250 mg twice daily for 4 weeks improves overall mood and decreases stress when compared with placebo (94904). It is unclear if this effect is due to magnolia, other ingredients, or the combination. Additionally, this study was funded by the supplement manufacturer.\nless\nMore evidence is needed to rate magnolia for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nCommercial magnolia products are standardized to magnolol and honokiol constituents, which range from 40% to 90% of total polyphenols (95035).\n\nIn one clinical trial, magnolia extract included in a chewing gum formulation was standardized to 0.10% magnolol and 0.07% honokiol. The amount of magnolol and honokiol applied daily was 11.9 mg (92459).\n\nIn other clinical research, capsules containing a proprietary blend of magnolia and phellodendron bark extracts (Relora, Next Pharmaceuticals, Inc.) were standardized to contain 1.5% honokiol and 0.1% berberine (14349, 34246, 94904).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, magnolia might have additive effects and increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.\nIn vitro research shows that the chemicals magnolol and honokiol, isolated from magnolia bark, inhibit platelet aggregation that is experimentally induced by collagen and arachidonic acid. However, they do not inhibit platelet aggregation that is induced by adenosine diphosphate, platelet-activating factor, or thrombin (18273). This interaction has not been reported in humans.\nless\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of large doses of magnolia bark and CNS depressants might have additive effects.\nIn vitro and animal research shows that constituents extracted from magnolia bark, especially honokiol and magnolol, have sedative effects. These effects may be due to the inhibition of catecholamine release and modulation of gamma-aminobutyric acid-A (GABA-A) receptors (11946, 11952).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, magnolia may have antiplatelet effects.\nIn vitro evidence suggests that magnolia might inhibit platelet aggregation (18273). Theoretically, concomitant use of magnolia and herbs that affect platelet aggregation could increase the risk of bleeding in some people. See other products with antiplatelet activity here. See other products with anticoagulant activity here.\nless\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, magnolia might have sedative effects.\nIn vitro and animal research suggests that magnolia may have sedative effects (11946, 11952). Theoretically, concomitant use with herbs and supplements that have sedative properties might have additive effects. See other products with sedative effects here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, magnolia might cause additive CNS depression and/or excessive bleeding when used perioperatively. Magnolia might have CNS depressant and antiplatelet effects (11946, 11952, 18273). Tell patients to discontinue magnolia at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with magnolia.",
            "Pharmacokinetics": "Absorption\nMagnolol a component of magnolia, is reported to have an oral bioavailability of approximately 10% (95034).\nDistribution\nMagnolol and honokiol, components of magnolia, appear to pass through the blood brain barrier (95034).\nMetabolism\nMagnolol and honokiol, components of magnolia, appear to have first order half-lives that are independent of dose (95034). Magnolol is largely metabolized in the liver. Its major metabolites are glucuronides. The metabolic pathways for honokiol are glucuronidation and sulphation (95034).",
            "Mechanism of Action": "General\nThe applicable parts of magnolia are the bark and flower bud. Magnolia bark contains the active constituents magnolol, dihydroxydihdromagnolol, honokiol, dihydrohonokiol, and obovatol (11945, 11946, 11947, 11948, 94904, 95032, 95035). Magnolol and honokiol are thought to be the most active constituents (95035). The ratio of magnolol to honokiol is reported to be approximately 4:1 (95034). Magnolia also contains magnoliaterpenoids, volatile oils, and various minerals (92462, 95035). Proportions of constituents in the bark differ depending on harvesting site and time (95035).\nAnti-inflammatory effects\nMagnolia lignans, including magnolol and honokiol, appear to downregulate the activation of nuclear factor- kappa beta and block its activation, leading to a decrease in transcription of genes involved in pro-inflammatory responses. Magnolol and honokiol also inhibit the formation of eicosanoids such as prostaglandin E2 and thromboxane B2 likely via inhibition of phospholipase A2 and cyclooxygenase (95035).\nAnticancer effects\nLaboratory research suggests that magnolol might have anti-leukemic properties (11949). Honokiol and magnolol appear to target numerous signaling pathways involved in cancer initiation and progression, leading to regulation of certain genes and induction of apoptosis. Obovotaol and alkaloids may also play a role in magnolia's anticancer effects (95035).\nAntidiabetes effects\nIn animals, honokiol and magnolol help to prevent insulin resistance, reduce fasting blood glucose and plasma insulin, and induce glucose uptake in adipocytes. Honokiol also enhances insulin signaling pathways. Laboratory research suggests that magnolia may also inhibit the formation of advanced glycation end products, which play a role in diabetic complications. Furthermore, honokiol and magnolol inhibit acyl-CoA cholesterol acyl-transferase which is responsible for the formation of cholesteryl esters from cholesterol. Magnolol activates proliferator-activated receptor gamma, causes adipocyte differentiation, and increases insulin-stimulated glucose uptake (95035).\nAntimicrobial effects\nThe anti-bacterial effects of the magnolia constituents magnolol and honokiol are thought to play a role in the prevention of gingivitis as seen in clinical trials. Both bacterial counts and pH levels of plaque are improved (92459). Furthermore, magnolia bark extract, in combination with zinc acetate in tablets or chewing gum, reduces the production of bacterial volatile sulfur-containing compounds (92466, 92467).\n\nBoth magnolol and honokiol also appear to be active against many gram positive and gram negative bacteria, as well as a few fungal strains. They may alter cell permeability. Alkaloids found in magnolia may also interfere with the viral reproduction cycle (95035).\nAntiplatelet effects\nMagnolol and honokiol have reversible antiplatelet effects in vitro. They inhibit collagen- and arachidonic acid-induced platelet aggregation, probably by inhibiting thromboxane A2 formation (18273, 95035). They also activate pathways that inhibit platelet aggregation and alter the cytosolic calcium concentration which affects platelet responses to agonists (95035). The antiplatelet effects of honokiol are 5 to 10 times more potent than those of magnolol (18273).\nCardiovascular effects\nThe positive effects of magnolia on atherosclerosis are attributed to the antioxidant activities of magnolol and honokiol. Laboratory research suggests that honokiol decreases the expression of inducible nitric oxide synthase, reactive oxygen species generation, intracellular calcium accumulation, and alleviates effects of oxidized low density lipoprotein. Magnolol also interferes with reactive oxygen species generation (95035).\nCNS effects\nMagnolia constituents seem to have central nervous system effects. Magnolol, honokiol, and dihydroxydihydromagnolol seem to have antidepressant effects (11950). These effects may be related to altered serotonin turnover in the brain (95034). Magnolia also interacts with dopamine and serotonin receptors. Honokiol and magnolol increase acetylcholine release in the brain, and magnolol appears to modulate serotonergic activity (95035).\n\nHonokiol and dihydrohonokiol seem to have anxiolytic effects in animals, possibly by interacting with gamma-aminobutyric acid-A (GABA-A) receptors and muscarinic receptors (11946, 11947, 95034, 95035). In animals, honokiol increased glutamic acid decarboxylase (GAD), an enzyme involved in the synthesis of GABA (95035). Honokiol is reported to have similar effects as diazepam (95031). Magnolia been used in drug sponsored clinical trials showing some efficacy for reduction of anxiety and stress (34246, 94904). These effects may be attributed to its ability to modulate neurotransmitters and enzymes including acetylcholine, brain-derived neurotrophic factor, choline acetyltransferase and acetylcholinesterase (94904). In one clinical trial, magnolia reduced the levels of the stress hormone cortisol, compared to placebo (94904).\n\nDihydrohonokiol doesn't seem to cause motor dysfunction, CNS depression, amnesia, or physical dependence at doses that produce an anxiolytic effect (11948). At high doses, magnolia bark seems to have CNS depressant effects. Honokiol seems to inhibit catecholamine secretion (11952).\n\nMagnolol and honokiol might enhance cholinergic function, which could be useful in diseases such as Alzheimer's. At high doses, these compounds increase acetylcholine release in the hippocampus of the brain and have a neurotrophic effect, theoretically improving neuronal function (11951). In animals, magnolia dose-dependently inhibited a scopolamine-induced increase in acetylcholinesterase, leading to increased levels of acetylcholine. Also, magnolol, honokiol and its derivatives are neuroprotective and act as antioxidants and reduce reactive oxygen species. Furthermore, magnolia may also possibly decrease beta-amyloid peptide release and beta-amyloid peptide-induced cell death (95035).\n\nIt also appears that magnolol is a partial agonist of both endocannabinoid receptors CB1 and CB2, exhibiting higher potency at CB2. The fecal metabolite, tetrahydromagnolol (THM) is a full CB1 agonist and partial CB2 agonist. Another component of magnolia, honokiol, is a full agonist at the CB1 receptor, and is an antagonist or inverse agonist at the CB2 receptor. Honokiol, magnolol and its metabolite THM all have higher activity at CB1 than tetrahydrocannabinol (THC) (95034).\nGastrointestinal effects\nIt is thought that magnolia is an antispasmodic and acts to relax gastrointestinal tract smooth muscle. Both magnolol and honokiol are non-competitive muscarinic antagonists, and inhibit contractions induced by acetylcholine, serotonin, or calcium dependent contractions induced by acetylcholine. Alkaloids present in magnolia may also play a role (95035).\nRespiratory effects\nThe constituent magnone may have platelet-activating factor antagonist activity, which might explain the use of magnolia in nasal congestion and rhinitis (11953). There is interest in using magnolia for asthma. Magnolol appears to suppress the conversion of cortisol to cortisone by blocking hydroxysteroid dehydrogenase. It increases the production of corticosterone, a glucocorticoid similar to cortisol (11945, 95035). Additionally, magnolol inhibits T-lymphocyte proliferation and suppress type IV allergic reactions, which are lymphocyte mediated. Magnolol and honokiol also induce bronchodilation through calcium antagonism. Furthermore, alkaloids present in magnolia inhibit acetylcholine induced contraction (95035). This may explain magnolia's use for asthma.\nWeight loss effects\nFor weight loss, researchers suggest that a specific magnolia product containing a combination of extracts of magnolia plus phellodendron (Relora, Next Pharmaceuticals) helps reduce cortisol levels and therefore helps to reduce stress. It's theorized that reducing stress will reduce stress-induced eating habits. However, clinical research suggests that this magnolia product does not significantly reduce cortisol levels in overweight females (14349). However, it has reduced cortisol levels in other clinical research (94904). Some weight loss products include magnolia bark with claims that it reduces cortisol levels. Currently, clinical evidence that magnolia bark causes weight loss or reduces cortisol levels is conflicting. In fact, it appears to increase levels of corticosterone, a glucocorticoid similar to cortisol (11945)."
        }
    },
    "Maidenhair Fern": {
        "sections": {
            "Overview": "Maidenhair is a plant that grows to about 35 cm in height and is native to Europe (18). Traditionally, it is used for cough, wound healing, dysmenorrhea, and menorrhagia, and for general scalp, gastrointestinal, liver, and kidney health (106345).",
            "Safety": "LIKELY SAFE when used orally in amounts found in alcoholic drinks. Maidenhair fern is approved by the US Food and Drug Administration (FDA) for use as a flavoring agent in alcoholic drinks (97997).\nThere is insufficient reliable information available about the safety of maidenhair fern when used in larger amounts as medicine.\nPREGNANCY: UNSAFE when used orally. Maidenhair fern is contraindicated in pregnancy (12, 18).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, maidenhair fern is generally well tolerated when used in the small amounts found in alcoholic drinks. There is currently a limited amount of information available about the adverse effects of maidenhair fern when used medicinally.\nSerious Adverse Effects (Rare)\nOrally: Emesis.\nGastrointestinal\nOrally, large doses of maidenhair fern have been reported to cause emesis (12).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of maidenhair fern.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of maidenhair fern.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with maidenhair fern.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of maidenhair fern.",
            "Mechanism of Action": "General\nThe applicable parts of maidenhair fern are the dried fronds, herb, and root. Maidenhair fern contains flavonoids, phenylpropanoids, triterpenoids, and carotenoids (106345).\nAnti-inflammatory effects\nAn ethanolic extract of maidenhair fern fronds suppressed release of prostaglandin E2, interleukin 6, and tumor necrosis factor from monocytes and macrophages in vitro, by inhibiting activation of nuclear factor kappa-B. The extract also demonstrated anti-inflammatory activity in mice (99707). In an animal model of ulcerative colitis, maidenhair fern extract demonstrated both anti-inflammatory and antioxidant effects (106345)."
        }
    },
    "Maitake Mushroom": {
        "sections": {
            "Overview": "Maitake is a type of mushroom that was first used in East Asian traditional medicine (61239, 92842). It forms large clumps at the base of stumps and on the roots of trees such as oak, elm, and persimmon in temperate forests of Asia, Europe, and eastern North America (61216).",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using maitake mushroom for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately as extracts. A maitake mushroom extract 3 mg/kg twice daily has been used safely for up to 12 weeks (92843). Doses up to 5 mg/kg twice daily of another maitake mushroom extract have been used safely for up to 3 weeks (61239). Maitake mushroom polysaccharides (MMP) 1-1.5 grams daily have also been used safely for up to 2 years (8188).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, maitake mushroom is generally well tolerated.\nMost Common Adverse Effects\nOrally: Gastrointestinal effects, including diarrhea and epigastric pain.\nDermatologic\nIn a clinical trial, one patient experienced rash and pruritus after two doses of maitake mushroom polysaccharide extract. The allergic reaction cleared without intervention (61239).\nless\nGastrointestinal\nIn clinical research of a polysaccharide extract from maitake mushroom, one patient reported nausea (61239) and 2 out of 26 reported epigastric pain (17131). In a clinical trial of a liquid extract from maitake mushroom, 2 out of 21 patients experienced diarrhea, and one experienced nausea. One patient withdrew from the study due to diarrhea (92843).\nless\nImmunologic\nIn a clinical trial of a liquid extract from maitake mushroom, 4 out of 21 patients experienced eosinophilia (92843).\nless\nMusculoskeletal\nIn a clinical trial of a polysaccharide extract from maitake mushroom, one patient reported joint swelling (61239).\nless\nPulmonary/Respiratory\nThere is one case of occupational hypersensitivity pneumonitis (HP) caused by maitake mushroom spores (61228).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAllergic rhinitis (hay fever). Although there has been interest in using oral maitake mushroom for allergic rhinitis, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nCancer. Although there has been interest in using oral maitake mushroom for cancer, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nChemotherapy-induced anemia. Although there has been interest in using oral maitake mushroom for preventing chemotherapy-induced anemia, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nChemotherapy-induced diarrhea. Although there has been interest in using oral maitake mushroom for preventing chemotherapy-induced diarrhea, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nChemotherapy-induced leukopenia. Although there has been interest in using oral maitake mushroom for preventing chemotherapy-induced leukemia, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nChemotherapy-induced nausea and vomiting (CINV). Although there has been interest in using oral maitake mushroom for preventing CINV, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nChemotherapy-related fatigue. Although there has been interest in using oral maitake mushroom for preventing chemotherapy-related fatigue, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nChronic fatigue syndrome (CFS). Although there has been interest in using oral maitake mushroom for CFS, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nCoronavirus disease 2019 (COVID-19). Although there has been interest in using oral maitake mushroom for COVID-19, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nDiabetes. Although there has been interest in using oral maitake mushroom for diabetes, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nHIV/AIDS. Although there has been interest in using oral maitake mushroom for HIV/AIDS, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nHyperlipidemia. Although there has been interest in using oral maitake mushroom for hyperlipidemia, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nHypertension. Although there has been interest in using oral maitake mushroom for hypertension, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nLaryngeal cancer. It is unclear if maitake mushroom is beneficial for improving quality of life in patients with laryngeal cancer.\nClinical research in patients with laryngeal or pharyngeal cancer undergoing chemo-radiation treatment shows that taking maitake mushroom polysaccharides D-fraction 1 gram 3 times daily during treatment modestly improve survival over 5 years and prevents the decline in overall quality of life when compared with taking placebo (111935).\nless\nMyelodysplastic syndromes. Although there has been interest in using oral maitake mushroom for myelodysplastic syndromes, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nObesity. Although there has been interest in using oral maitake mushroom for obesity, there is insufficient reliable information about the clinical effects of maitake mushroom for this purpose.\nPharyngeal cancer. It is unclear if maitake mushroom is beneficial for improving quality of life in patients with pharyngeal cancer.\nClinical research in patients with laryngeal or pharyngeal cancer undergoing chemo-radiation treatment shows that taking maitake mushroom polysaccharides D-fraction 1 gram 3 times daily during treatment modestly improve survival over 5 years and prevents the decline in overall quality of life when compared with taking placebo (111935).\nless\nPolycystic ovary syndrome (PCOS). Maitake mushroom may have some benefit in PCOS, but it does not appear to be as effective as clomiphene.\nPreliminary clinical research in patients with PCOS shows that taking three tablets of a specific combination product (SX-Fraction, Maitake Products, Inc.), each containing maitake mushroom powder 250 mg plus maitake SX-fraction (a glycoprotein-rich extract) 18 mg, three times daily starting on the first day of menses for up to 28 weeks, can improve ovulation cycle rates, but does not appear to be as effective as clomiphene. After 12 weeks of treatment, patients taking the maitake mushroom product had an ovulatory cycle rate of about 42% compared with about 70% in those taking clomiphene 50 mg daily. However, 13 out of 15 patients who failed monotherapy with maitake mushroom or clomiphene alone ovulated when both maitake mushroom and clomiphene were used for 4 cycles (17131).\nless\nMore evidence is needed to rate the effectiveness of maitake mushroom for these uses.",
            "Dosing & Administration": "Adult\nOral:\nA polysaccharide extract of maitake mushroom has been used in a dose of 1-1.5 grams daily for up to 2 years. There is insufficient reliable information to determine a typical dose of other forms of maitake mushroom. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nSome clinical trials have used products standardized for certain constituents, including polysaccharides (17131, 61239). In one clinical trial, a commercially available maitake mushroom product (SX-Fraction, Maitake Products, Inc.) was standardized to contain more than 18% maitake mushroom extract (MSX) (17131).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, combining maitake mushroom with antidiabetes drugs might increase the risk of hypoglycemia.\nClinical research shows that taking maitake mushroom polysaccharide (MMP) can lower blood glucose levels in patients with types 2 diabetes (8188).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, combining maitake mushroom with antihypertensive drugs might increase the risk of hypotension.\nAnimal research shows that maitake mushroom can lower blood pressure (1213, 1214, 61226).\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nThere is limited evidence that maitake mushroom may increase the anticoagulant effects of warfarin.\nIn a case report, a patient previously stabilized on warfarin developed an elevated international normalized ratio (INR) of 5.1 after taking maitake mushroom (Grifron-Pro Maitake D-Fraction) 1 drop/kg daily in three divided doses for one week. The elevated INR resolved after holding warfarin for two days, then reducing the dose by 11%. It is thought that the beta-glucan constituent of maitake mushroom might cause warfarin dissociation from proteins, resulting in increased free warfarin levels and increased warfarin effects (17209).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, maitake mushroom might have hypoglycemic effects.\nMaitake mushroom might lower blood glucose levels and have additive effects when used with other herbs and supplements that also lower glucose levels (19, 1212, 8188). This might increase the risk of hypoglycemia in some patients. See other products with hypoglycemic potential here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nAnimal research suggests that maitake mushroom can lower blood pressure (1213, 1214, 61226). Theoretically, combining maitake mushroom with other herbs or supplements with hypotensive effects might increase the risk of hypotension in some patients.",
            "Interactions with Conditions": "PERIOPERATIVE\nMaitake mushroom has hypoglycemic effects, which might interfere with blood glucose control perioperatively. Tell patients to discontinue maitake mushroom at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with maitake mushroom.",
            "Pharmacokinetics": "Absorption\nIn animals, 500 mg/kg of argaricoglycerides, secondary metabolites of maitake mushroom, produced a Tmax of about 1 hour and a Cmax of about 0.63 mcg/mL. The bioavailability estimated as the area under the curve was 3.2%. Doses of 100 or 300 mg/kg could not be detected in the plasma (92842).\nDistribution\nAnimal research suggests that beta-glucan from maitake mushroom is distributed to the liver and spleen with a prolonged half-life (61246).",
            "Mechanism of Action": "General\nThe applicable parts of maitake mushroom are the fruiting body and mycelium. Active constituents include polysaccharides such as beta-glucans in the fruit body, specifically the \"D-fraction\" of beta-glucan, a water-soluble glycoprotein called \"SX-fraction\" or MSX, the secondary metabolites argaricoglycerides, and fiber (17131, 61218, 61232, 61239, 92842, 92843).\nAnti-inflammatory effects\nThere is interest in using maitake mushroom for its anti-inflammatory activity, which has been shown to confer analgesic effects. Animal research suggests that argaricoglycerides extracted from maitake mycelia attenuate endotoxin-induced increases in proinflammatory mediators such as interleukin-1beta, tumor necrosis factor-alpha, and nuclear factor-kappa B. These extracts also decrease levels of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and intracellular adhesion molecule-1 (ICAM-1). Animal models also show that these extracts confer both peripheral and central analgesic effects (92842).\nAntineoplastic effects\nThere is interest in using maitake mushroom for its antineoplastic effects. Multiple antitumor mechanisms have been proposed, based on results of laboratory and animal research (61243), including induction of nitric oxide synthase by maitake D-fraction (61223, 61247), enhanced production of tumor necrosis factor by macrophages (61220, 61244, 61245), apoptosis (61233, 61234), antiangiogenesis with increased vascular endothelial growth factor (VEGF) levels induced by D-fraction (61219), oxidative damage and induced apoptosis by beta-glucan (61215), increased Kupffer cell activity against neoplastic cells (61250), enhanced lymphocyte activity (61249), and alternative complement pathway activation (61241). There is also interest in using maitake mushroom for myelodysplastic syndromes (MDS). It is thought that neutrophil dysfunction in patients with MDS, and not actual neutrophil count, contributes to an increase in infections, even in patients with neutropenia. Preliminary clinical research shows that taking maitake fruiting body extract (beta-glucan) 3 mg/kg twice daily for 12 weeks, increases endogenous neutrophil and monocyte reactive oxygen species (ROS) production, and increases ROS responses to bacterial stimuli, compared to age-matched healthy controls, in patients with MDS. These effects are necessary for bactericidal activity. Furthermore, in laboratory research, maitake mushroom beta-glucan induces granulocyte colony-stimulating factor (G-CSF), stimulates interleukin (IL)-12 production, and activates natural killer cells. It may also enhance differentiation and migration of hematopoietic cells (92843).\nAntiviral effects\nA novel anti-herpes simplex virus protein has been purified from an extract of maitake mushroom (61237). In addition, laboratory research suggests that the D-fraction from maitake mushroom inhibits the hepatitis B virus and exhibits a synergistic effect when combined with interferon-alpha (61232).\nCardiovascular effects\nMaitake mushroom powder and extracts produce a decrease in blood pressure in animal models of hypertension (1214, 61226, 61242).\nHormonal effects\nThere is interest in using maitake mushroom for polycystic ovary syndrome (PCOS). In patients with PCOS, insulin resistance with resultant hyperinsulinemia leads to hyperandrogenism. In animals, maitake mushroom has been shown to decrease blood glucose. A specific fraction called SX-fraction (MSX) may decrease glucose and improve insulin resistance (17131).\nHypoglycemic effects\nThere is interest in using maitake mushroom for its hypoglycemic effects. Enhanced insulin-hypoglycemic activity has been observed in rats consuming a specific glycoprotein extracted from maitake mushroom (61238). An alpha-glucan from the fruit body of maitake mushroom has also exhibited an antidiabetic effect in mice (61236). Antidiabetic effects of maitake mushroom extracts have been shown in other animal studies, resulting in reduced levels of blood glucose in diabetic models (1212, 61217, 61222, 61226). In these studies, depending on the model, insulin levels were increased or decreased, and fructosamine was decreased. Decreased glycated hemoglobin has also been observed in an animal model after treatment with maitake mushroom powder (61226). In human research, maitake mushroom reduced blood glucose in patients with type 2 diabetes (8188). The extract responsible for improving insulin resistance is believed to be the water-soluble glycoprotein called \"SX-fraction\" or MSX (17131). Polysaccharides also appear to have a hypoglycemic effect, possibly by activating insulin receptors (1212, 8188). Another theory is that maitake mushroom can improve glucose tolerance by activating peroxisome proliferator-activated receptor delta (PPARd), which seems to increase insulin sensitivity. Research in obese mice models fed a high-fat diet shows that consuming a lipid soluble maitake mushroom extract activates PPARd-target genes and improves glucose tolerance (99569).\nImmunomodulating effects\nLaboratory research suggests that maitake mushroom possesses immunomodulating activities (61231, 61235). The relatively low-molecular-mass polysaccharides isolated from mycelia of maitake mushroom may enhance innate immunity by enhancing phagocytosis and increasing natural killer cell cytotoxicity, and therefore may serve as biological response modifiers (61231). Activation of helper T cells, decreased activation of B cells, and increased production of Interferon-gamma, interleukin (IL)-12 p70, and IL-18, but suppression of IL-4, have also been observed (61224). In an animal immunosuppression model, a maitake polysaccharide extract increased lymph node levels of T-cells and natural killer cells, but not B cells (111936). In human research, increasing doses of maitake mushroom resulted in increases in some immunologic parameters and decreases in others for many of the endpoints measured (61239). The optimal dose with the largest immunological effect varied for different parameters tested, but positive effects were most often seen with doses between 5-7 mg/kg daily (61239). The \"D-fraction\" of beta-glucan in maitake mushroom may be the component responsible for the immune-stimulating effects (17131, 61232).\nLipid effects\nIn animal research, maitake mushroom reduced plasma levels of triglycerides (1212, 61226) and total cholesterol (1214). Fiber from maitake mushroom also resulted in a reduction in cholesterol (61218). Maitake mushroom extract also seems to improve lipid levels in animals fed a high-fat diet. Research in obese mice models fed a high-fat diet shows that consuming a lipid soluble maitake mushroom extract lowers total blood cholesterol levels. This effect might occur because maitake mushroom activates peroxisome proliferator-activated receptor delta (PPARd), a key regulator of lipid metabolism (99569). Additional research in high-fat fed rats shows that consuming a 95% maitake mushroom ethanol extract reduces total cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol, and weight (99570).\nPhotoprotective effects\nExopolysaccharide from maitake mushroom demonstrated photoprotective potential in human dermal fibroblasts exposed to ultraviolet-A (UVA) light (61230). It has been proposed that exopolysaccharide may contribute to inhibitory action in photoaging skin by reducing the MMP 1-related matrix degradation system."
        }
    },
    "Malabar Nut": {
        "sections": {
            "Overview": "Malabar nut is a type of shrub. It grows commonly in Southeastern Asia, including India. The leaves have been used in Ayurvedic and Unani medicine (48569, 99091, 99095).",
            "Safety": "There is insufficient reliable information available about the safety of Malabar nut.\nPREGNANCY: UNSAFE when used orally (18); contraindicated.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDental plaque. Preliminary clinical research in adults with or without chronic gingivitis shows that using an Ayurvedic toothpaste (Sudantha, Link Natural Products) containing nine herbs, including Malabar nut leaf, twice daily for 12-24 weeks can reduce dental plaque compared with baseline or an unknown control toothpaste (99090, 43570). Due to poor study methodology, and the use of nine different herbs in the toothpaste formulation, further study is needed to determine the effect of Malabar nut leaf dental health.\nUpper respiratory tract infection (URTI). Preliminary clinical research in patients with acute URTIs shows that taking a specific combination product (Kan Jang, Swedish Herbal Institute) containing extracts from Echinacea purpurea root, Malabar nut leaf, and Siberian ginseng root 30 mL orally once daily for 3-4 days does not reduce the severity or frequency of cough compared to bromhexine hydrochloride or placebo (95648). Other preliminary clinical research in patients with acute URTIs shows that taking this product 30 mL orally three times daily for 6 days does not improve the frequency or severity of symptoms compared to taking bromhexine hydrochloride or a combination of only Echinacea purpurea root and Siberian ginseng root (48569).\nMore evidence is needed to rate Malabar nut for these uses.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Malabar nut.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Malabar nut.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Malabar nut.",
            "Mechanism of Action": "General\nThe applicable part of Malabar nut is the leaf. Constituents include pyrroquanazoline alkaloids, including vasicine, vasicinone, vasicol, pregnane, adhatodinine, vasicinol, and vasicinolone (99091, 99092, 99095).\nAntibacterial effects\nMalabar nut leaves are traditionally thought to have antibacterial effects and they are used to treat tuberculosis. The constituent vasicine has antibacterial effects against some, but not most bacteria. The derivative vasicine acetate, found in very low amounts in the leaf, is more active. Vasicine acetate and another constituent, 2-acetyl benzylamine, have antibacterial effects against Mycobacterium tuberculosis (99091, 99096).\nAntioxidant effects\nIn vitro, Malabar nut leaf extract acts as an antioxidant and scavenges free radicals (105512).\nLipid effects\nThere is interest in using Malabar nut for hyperlipidemia. Animal research in rats with hyperlipidemia shows that consuming Malabar nut leaf extract 200 mg/kg daily for 14 days reduces triglyceride and low-density lipoprotein cholesterol levels and increases high-density lipoprotein cholesterol levels when compared with control. Taking Malabar nut leaf extract also reduced lactate dehydrogenase levels and adipose tissue weight (105512).\nRespiratory effects\nMalabar nut leaf is used for respiratory symptoms, such as cough, phlegm, and other symptoms. The constituent vasicine has been shown to have expectorant and bronchial dilating effects (48569). Isolated polysaccharides from Malabar nut leaves have antitussive effects in an animal model (99095).\nUterine effects\nMalabar nut is contraindicated during pregnancy (18). The constituent vasicine is thought to have uterine stimulating effects (99091)."
        }
    },
    "Male Fern": {
        "sections": {
            "Overview": "Male fern is an evergreen plant that grows in parts of Nigeria. Traditional Nigerian healers commonly use the leaves for various purposes, including as an anticancer agent. However, male fern can be highly toxic when taken orally (2, 6).",
            "Safety": "LIKELY UNSAFE when used orally. Male fern can be a violent poison (2, 11). For this reason, it should not be used internally (2). Canada requires that it be labeled \"For external use only\" (12).\nThere is insufficient reliable information available about the safety of male fern when used topically.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally (12); contraindicated. There is insufficient reliable information available about the safety of male fern used topically; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nWhen used orally, male fern may be unsafe.\nMost Common Adverse Effects\nOrally: Diarrhea, dyspnea, headaches, nausea, optic neuritis, tremors, and vertigo.\nSerious Adverse Effects (Rare)\nOrally: Symptoms of toxicity include cardiac and respiratory failure, coma, muscular weakness, seizures, and temporary or permanent blindness. Death has occurred with severe poisoning.\nCardiovascular\nOrally, male fern can cause cardiac failure (6).\nless\nGastrointestinal\nOrally, male fern can cause nausea and diarrhea (6).\nless\nNeurologic/CNS\nOrally, male fern can cause coma, headaches, muscle weakness, seizures, tremors, and vertigo (6, 11).\nless\nOcular/Otic\nOrally, male fern can cause optic neuritis and temporary or permanent blindness (6, 11).\nless\nPulmonary/Respiratory\nOrally, male fern can cause dyspnea and respiratory failure (6).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nHemorrhoids. Although there has been interest in using topical male fern for hemorrhoids, there is insufficient reliable information about the clinical effects of male fern for this purpose.\nIntestinal parasite infection. Although there has been interest in using oral male fern for intestinal parasite infection, there is insufficient reliable information about the clinical effects of male fern for this purpose.\nRheumatoid arthritis (RA). Although there has been interest in using topical male fern for RA, there is insufficient reliable information about the clinical effects of male fern for this purpose.\nWound healing. Although there has been interest in using topical male fern for wound healing, there is insufficient reliable information about the clinical effects of male fern for this purpose.\nMore evidence is needed to rate male fern for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nTaking male fern with fats, oils, or alcohol can increase the absorption and toxic potential of male fern (2).\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of male fern.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "CASTOR OIL\nTaking male fern with castor oil enhances the absorption and toxic potential of male fern (6).",
            "Interactions with Conditions": "GASTROINTESTINAL (GI) CONDITIONS\nTheoretically, damaged GI mucosa or conditions which prolong GI transit may increase absorption and the risk of side effects.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nMale fern can be toxic when taken orally. Symptoms of toxicity include cardiac or respiratory failure, coma, muscular weakness, seizures, and temporary or permanent blindness. Death has occurred with severe poisoning (11).\nTreatment\nTreatment of toxicity consists of giving a saline cathartic followed by demulcent fluids. Toxicity-related seizures have been treated with benzodiazepines (6002).",
            "Pharmacokinetics": "Absorption\nTaking male fern orally with fats and oil may increase exposure to male fern (6002).",
            "Mechanism of Action": "General\nThe applicable parts of male fern are the above ground parts, leaf, and rhizome. Male fern contains volatile oils, tannins, filmarone, and a group of chemicals known as filicins, including filicin, albaspidin, and desaspidin. The filicins are derivatives of phloroglucinol and may be inactivated by alkaline environments (6). Male fern leaf extract also contains total phenols and flavonoids, including quercetin-3-O--L-rhamnopyranoside. Total phenol and flavonoid content is higher in ethyl acetate extracts than water extracts (104843).\nAnthelmintic effects\nMany constituents of male fern, including filmarone and the group of filicins, have anthelmintic effects and have been used to treat tapeworms (6).\nAnti-inflammatory effects\nAnimal research in rats shows that use of male fern leaf extract 200-400 mg/kg orally reduces chemically-induced edema and arthritis when compared with placebo. Other research in mice shows that topical administration of male fern leaf extract also reduces chemically-induced edema when compared with placebo (104843)."
        }
    },
    "Malic Acid": {
        "sections": {
            "Overview": "Malic acid is an organic alpha hydroxy acid found in wines and fruits (90831, 90832). Malic acid is used to acidify or flavor certain foods, as well as prevent food discoloration (90832). In addition to its food uses, malic acid is sometimes used to adjust the acidity of cosmetics (26968) and may also be used for medicinal purposes.",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Malic acid has Generally Recognized as Safe (GRAS) status in the United States. Allowed maximum levels of malic acid in foods are as follows: 3.4% for nonalcoholic beverages; 3% for chewing gum; 0.8% for gelatins, puddings, and fillings; 6.9% for hard candy; 2.6% for jams and jellies; 3.5% for processed fruits and fruit juices; 3% for soft candy; and 0.7% for all other food categories (26969, 95594).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts, short-term. Malic acid 1200 mg twice daily has been used with apparent safety for up to 6 months (3262). ...when used topically on oral mucosal surfaces. Specific malic acid combination products (Xeros Dentaid, Dentaid) have been used with apparent safety in spray and lozenge formulations for up to 6 months (92211, 92213, 95565, 104757, 104778).\nThere is insufficient reliable information available about the safety of malic acid when used topically on the skin. Historically, malic acid has been used with apparent safety in cosmetics as a pH adjuster or fragrance ingredient, and at concentrations below 2% when used in shampoo, hair styling products, or sun protection products (26868, 95595, 111742).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in amounts commonly found in foods (26969, 95594). There is insufficient reliable information available about the safety of using malic acid in medicinal amounts during pregnancy or lactation.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, malic acid seems to be well tolerated. Topically, malic acid seems to be well tolerated when applied to oral mucosal surfaces. A thorough evaluation of safety outcomes with topical malic acid use on the skin has not been conducted.\nMost Common Adverse Effects\nTopical: Eye irritation, skin irritation, and skin peeling.\nDermatologic\nTopically, malic acid may cause moderate to strong skin irritation and peeling (26968, 95564, 95595). In patients first patch tested with malic acid, next instructed to avoid foods containing malic or citric acid, and then challenged with foods containing high amounts of malic and citric acid, skin reactions including immediate hives and delayed contact dermatitis occurred (26968).\nless\nGastrointestinal\nOrally, diarrhea and nausea have been reported for patients taking a specific combination product (Super Malic) containing malic acid1200 mg and magnesium 300 mg twice daily. However, it is unclear if the adverse effect is due to malic acid, since it is known that magnesium can have a laxative effect at this dose (3262).\nless\nOcular/Otic\nTopically, malic acid might irritate the eyes, especially in formulations containing 2.27% or more malic acid (26968, 95564, 95595).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDry mouth. Most clinical research shows that topical malic acid, used as either a mouth spray or a lozenge for up to 2 weeks, improves symptoms in patients with dry mouth from various causes.\nA meta-analysis of five small clinical studies in patients with dry mouth from various causes shows that using a mouth spray containing malic acid 1%, with or without xylitol and fluoride, up to 8 times daily for 2 weeks improves dry mouth symptoms and increases salivary flow when compared with placebo or xylitol and fluoride alone (107916). Dry mouth in the evaluated patients was associated with antihypertensive therapy (92211), antidepressant therapy (92213), aging (95565), graft-versus-host disease (101174), and Sjogren syndrome (104778). Malic acid-containing products evaluated for dry mouth include Xeros Dentaid spray (92211, 92213, 95565), Xeros Dentaid tablets (104778), and SalivAktive (101174). Additionally, a small clinical study in patients with dry mouth due to type 2 diabetes shows that using malic acid 1% mouth spray on-demand for 2 weeks modestly increases salivary flow and improves patient-reported xerostomia scores at the 2-week follow-up, but not at the 1-month follow up, when compared with placebo (111743). Despite most studies showing consistent and positive results, one small clinical study in patients with idiopathic or drug-induced dry mouth failed to show significant improvement with Xeros Dentaid spray when compared with placebo. However, the malic acid spray performed similarly to betaine-based mouthwash and the study was likely underpowered to detect differences between groups (107917).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. Topical malic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nAn open-label, non-randomized clinical study in patients with mild-to-moderate acne shows that applying a specific cream (Hyseac AHA cream, Uriage) containing malic acid and arginine glycolate twice daily for 60 days, alone or in combination with prescribed pharmacological treatment, improves acne severity in about 64% of patients when compared to baseline. Pharmacological treatment consisted primarily of antibiotics, but also included retinoids and benzyl peroxide (92207). These findings are limited by the lack of a comparator group. Also, it is unclear if these findings are due to malic acid, arginine glycolate, or the combination.\nless\nActinic keratoses. Although there has been interest in using topical malic acid for actinic keratoses, there is insufficient reliable information about the clinical effects of malic acid for this purpose.\nFatigue. Although there has been interest in using oral malic acid for fatigue, there is insufficient reliable information about the clinical effects of malic acid for this purpose.\nFibromyalgia. Oral malic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with fibromyalgia shows that taking a specific product (Super Malic) containing malic acid 1200 mg and magnesium hydroxide 300 mg twice daily for 6 months reduces pain and tenderness when compared to baseline. However, taking malic acid 600 mg with magnesium hydroxide 150 mg twice daily for 1 month does not reduce pain and tenderness when compared with placebo (3262). The validity of the findings in the follow-on, open-label, 6-month phase of the study is limited by a lack of blinding and placebo control. Also, it is unclear if these findings are due to malic acid, magnesium, or the combination.\nless\nGastroesophageal reflux disease (GERD). Oral malic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA very small clinical study in patients with GERD shows that using a specific lozenge containing malic acid 25.58 mg, xylitol 422 mg, and fluoride 0.58 mg (Xeros Dentaid tablets, Dentaid) three times daily in combination with omeprazole 40 mg daily for 6 months may improve saliva buffering capacity and some symptoms of GERD when compared with omeprazole alone (104757). It is unclear if these findings are due to malic acid, other ingredients, or the combination.\nless\nPsoriasis. Although there has been interest in using topical malic acid for psoriasis, there is insufficient reliable information about the clinical effects of malic acid for this purpose.\nWarts. Although there has been interest in using topical malic acid for warts, there is insufficient reliable information about the clinical effects of malic acid for this purpose.\nWrinkled skin. Although there has been interest in using topical malic acid for wrinkled skin, there is insufficient reliable information about the clinical effects of malic acid for this purpose.\nMore evidence is needed to rate malic acid for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nMalic acid is most often used topically as a mouth spray containing malic acid 1% and administered 4-8 times daily for up to 2 weeks. Lozenges containing malic acid 25.58 mg have been taken four times daily for up to 6 months. Research on the application of malic acid to the skin is limited; typical dosing is unavailable.\nChildren\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nFormulations of malic acid used in clinical research have included topical creams (92207), oral tablets (3262), and oral mouth sprays (92211, 92213, 95565, 101174).",
            "Interactions with Drugs": "ANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, malic acid might increase the risk of hypotension when taken with antihypertensive drugs.\nAnimal research shows that malic acid isolated from tagetes roots can reduce mean arterial blood pressure (26970).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, malic acid might have hypotensive effects.\nTaking malic acid with other products with hypotensive effects might increase the risk of hypotension. Animal research shows that malic acid isolated from tagetes roots can reduce mean arterial blood pressure (26970).\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with malic acid.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of malic acid.",
            "Mechanism of Action": "General\nMalic acid is an alpha hydroxy acid found in fruits such as bananas, strawberries, nectarines, cherries, mangoes, peaches, tomatoes, and grapes (95564).\nDermatologic effects\nMalic acid is known for its exfoliant effects. Malic acid disrupts cellular skin adhesions by chelating calcium ions, which speeds up skin desquamation. In a case report, a 42 year old man with cutaneous warts received a topical application of malic and citric acid in equal parts 10 grams/10 mL on each wart twice daily for 10 days. An occlusive dressing was also applied. The patient experienced a strong irritant reaction which caused the skin to peel and eliminate the warts. The patient did not experience recurrence of warts for at least 6 months after the application of malic and citric acid (95564).\nGastrointestinal effects\nMalic acid is used for dry mouth because its acidity stimulates saliva production. It is thought that the sour taste stimulates the production of saliva. However, if used too frequently, the acidity can corrode teeth (95565).\nHypotensive effects\nEvidence from animal research suggests that malic acid isolated from tagetes roots can reduce mean arterial blood pressure in rats (26970).\nWeight gain effects\nMalic acid is involved in the Krebs cycle, a process used by the body to generate energy. Evidence from animal research suggests that chronic consumption of malic acid increases weight gain and changes eating habits in rats (26968)."
        }
    },
    "Mallow": {
        "sections": {
            "Overview": "Mallow is an annual plant native to Europe, North Africa, and Asia. It grows wild in fields and hedgerows. The ancient Greeks and Romans used mallow for its emollient and laxative properties, and it is used for cooking in Turkey in the Central Anatolia region (95894, 95896). It has traditionally been used for its purported emollient, demulcent, expectorant, diuretic, spasmolytic, and laxative properties.",
            "Safety": "POSSIBLY SAFE when mallow flower extract is used orally and appropriately, short-term. Mallow flower extract has been used with apparent safety in doses of 1 gram daily for 4 weeks (95897). ...when used topically and appropriately. Mallow extract cream 10% has been used with apparent safety when applied topically twice daily for up to 14 days in adults (115973).\nCHILDREN: POSSIBLY SAFE when used topically and appropriately, short-term. A cream containing mallow flower extract 5% has been applied with apparent safety twice daily in children for 4 weeks (106747).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, mallow seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Diarrhea, indigestion, nausea, vomiting.\nGastrointestinal\nOrally, mallow might cause nausea, vomiting, diarrhea, and acid regurgitation (95895, 95897).\nless\nHepatic\nIn a case report, a 36-year-old female developed hepatic failure after consuming mallow for dinner the day before. The patient received supportive care but died from liver failure (95894). There is insufficient information and analysis in the report to make a definitive conclusion about causality of the hepatotoxicity.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtopic dermatitis (eczema). It is unclear if topical mallow flower extract improves symptoms of atopic dermatitis in children.\nPreliminary research in children (mean age 13 months) with eczema shows that applying a cream containing mallow flower extract 5% in a Eucerin base to a palm size area of affected skin twice daily for 4 weeks is associated with improvements in subjective scores for skin thickening, redness, and overall eczema symptoms when compared with a placebo cream (106747).\nless\nConstipation. It is unclear if oral mallow flower is beneficial for functional constipation.\nPreliminary clinical research shows that taking a syrup containing mallow flower aqueous extract 0.5 gram twice daily after breakfast and lunch for 4 weeks increases defecation frequency and decreases the frequency of hard stools when compared with placebo in patients with functional constipation (95897).\nless\nCough. Oral mallow has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small study in children 3-6 years of age with acute cough shows that taking a specific syrup (KalobaTUSS, Schwabe Pharma Italia Srl) containing acacia honey with extracts of mallow, elecampane, great plantain, and sandy everlasting, 5 mL four times daily for 8 days, produces rapid and sustained reductions in both nighttime and daytime cough scores when compared with placebo (105734). It is unclear if this effect is due to mallow, other ingredients, or the combination.\nless\nDry eye. Topical mallow has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical crossover study in patients with moderate dry eye disease shows that applying specific eye drops containing mallow extract 0.5% and hyaluronic acid 0.15% (Visiodoron Malva, Weleda AG, Penta Arzneimittel GmbH) 1 drop 2 times daily for 1 month improves signs and symptoms of dry eye when compared to baseline and similarly to hyaluronic acid eye drops alone (113836). It is unclear if this effect is due to mallow, hyaluronic acid, or the combination.\nless\nDry mouth. Oral mallow has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking a mixture of mallow and Alcea digitata powder, 4 grams three times daily for 4 weeks, improves dry mouth symptoms when compared with using artificial saliva (Hypozalix) in patients with dry mouth from radiation therapy for head and neck cancers (95895).\nless\nPostpartum complications. It is unclear if topical mallow cream is beneficial for episiotomy pain and healing.\nA small clinical study conducted in Iran in adults who underwent episiotomy shows that applying a topical mallow extract cream 10% twice daily for 14 days does not improve wound healing or reduce pain scores when compared with placebo (115973).\nless\nWound healing. Although there has been interest in using topical mallow for wound healing, there is insufficient reliable information about the clinical effects of mallow for this purpose.\nMore evidence is needed to rate mallow for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Traditionally, one cup of tea prepared by steeping 1.5-2 grams of the dried flowers or 3-5 grams of the dried leaves in 150 mL boiling water has been used.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mallow.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mallow.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mallow.",
            "Mechanism of Action": "General\nThe applicable parts of mallow are the leaves and flowers. Mallow contains naphthoquinones (including malvone A), anthocyanidins, monoterpenes, diterpenes, polysaccharides, phenolics, flavonoids, mucilage, carotenoids, and vitamin C (95896, 106747). The various phenolic acids and flavonoids contained in mallow include kaempferol, cinnamic acid, gallic acid, chlorogenic acid, syringic acid, and quercetin (115971).\nAntioxidant effects\nMallow is sometimes used for reducing pain and inflammation, which may be explained by its antioxidant effects. Preliminary animal and in vitro research shows that mallow flowers, fruits, stems, and leaves have antioxidant activity (95896, 102048, 115971).\nGastrointestinal effects\nMallow contains mucilage which protects and soothes mucous membranes (1526).\nHepatic effects\nAnimal research shows that mallow flower extract improves hepatic function and reduces liver tissue damage in rats experiencing hepatic injury after exposure to gentamycin. These effects are thought to be due to the antioxidant and anti-inflammatory effects of mallow (102048).\nImmunologic effects\nThe mucilage of mallow has been shown in vitro to inactivate serum complement, which is a component in the host defense system (1526).\nMetabolic effects\nAnimal research suggests that mallow reduces fasting blood glucose, glycated hemoglobin, alpha-amylase activity, insulin levels, body weight, and leptin in diabetic rats with overweight and obesity. Phenolic acids in mallow may ameliorate hyperglycemia by inhibiting alpha-amylase (115971).\nRenal effects\nTraditionally mallow is used for urinary complaints. Some preliminary research suggests that mallow has kidney protectant effects. Animal models show that giving a mallow decoction in addition to the kidney-toxic compound ammonium metavanadate, reduces oxidation activity and histological kidney damage in rats when compared with giving ammonium metavanadate alone (95898). Additional animal research shows that mallow flower extract improves kidney function and reduces renal injury in rats exposed to gentamycin, a known nephrotoxin. These effects are thought to be due to the antioxidant and anti-inflammatory effects of mallow (102048)."
        }
    },
    "Manaca": {
        "sections": {
            "Overview": "Manaca is a plant native to Brazil and other South American countries. It has been used in traditional medicine based on purported anesthetic, anti-inflammatory, diuretic, emetic, hypothermic, and laxative effects (106522, 106523).",
            "Safety": "There is insufficient reliable information available about the safety of manaca.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nOsteoarthritis. Although there has been interest in using oral manaca for osteoarthritis, there is insufficient reliable information about the clinical effects of manaca for this purpose.\nMore evidence is needed to rate manaca for this use.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of manaca.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with manaca.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of manaca.",
            "Mechanism of Action": "General\nThe applicable parts of manaca are the root, leaves, and flowers. Constituents found in manaca roots include alkaloids, coumarins, flavonoids, phenolic compounds, and steranes (106522). The primary constituents found in the oleoresin of manaca leaves include alpha-tocopherol, phytol, nonacosane, and heptacosane. The primary constituents found in the oleoresin of manaca flowers include geranyl linalool, tetracosane, and alpha-amyrin (106523).\nAnti-inflammatory effects\nAnimal research shows that manaca root extracts have anti-inflammatory effects. In a rat model of inflammation, manaca root extract significantly reduced inflammation when compared with placebo and indomethacin (106522).\nAntioxidant effects\nIn vitro studies show that manaca root extracts and oleoresin extracts from manaca leaves and flowers have antioxidant effects (106522, 106523). Leaf extracts show greater antioxidant capacity when compared with flower extracts (106523)."
        }
    },
    "Manchurian Thorn": {
        "sections": {
            "Overview": "Manchurian thorn is a small shrub that grows in eastern regions of Russia, northern China, and Korea (90834). The bark and roots of Manchurian thorn are used for medicinal purposes (90834). Manchurian thorn is considered by many herbalists to be an adaptogen, or a substance that acts to increase the body's ability to adapt and develop general resistance (26971, 90834).",
            "Safety": "There is insufficient reliable information available about the safety of Manchurian thorn.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nObesity. Preliminary clinical research shows that taking a specific combination product (Aralox) containing Manchurian thorn 150 mg and Engelhardia roxburghiana 150 mg three times daily for 15 weeks reduces total body weight and fat when compared with placebo in obese but otherwise healthy women (26972). It is unclear if these effects are due to Manchurian thorn, Engelhardia roxburghiana, or the combination.\nMore evidence is needed to rate Manchurian thorn for this use.",
            "Dosing & Administration": "Adult\nObesity: A specific combination product (Aralox) containing Manchurian thorn 150 mg and Engelhardia roxburghiana 150 mg three times daily for 15 weeks has been used (26972).\nStandardization & Formulation\nA specific commercial product (Aralox) that contains Manchurian thorn is reportedly comprised of Manchurian thorn 150 mg standardized to contain at least 20% triterpene saponins and Engelhardia roxburghiana 150 mg standardized to contain at least 20% flavonoid (dehydroquercetin-3-rhamnoside) (26972).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research suggests that saponins isolated from Manchurian thorn can lower plasma glucose levels (74988). Theoretically, concomitant use with antidiabetes drugs might affect glucose control and increase the risk of hypoglycemia; use with caution.\nSome antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.\nless\nHEPATOTOXIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research suggests that high doses of Manchurian thorn can induce liver damage (26974, 26975). Theoretically, concomitant use with other potentially hepatotoxic drugs might increase the risk of developing liver damage.\nSome of these drugs include acarbose (Precose, Prandase), amiodarone (Cordarone), atorvastatin (Lipitor), azathioprine (Imuran), carbamazepine (Tegretol), cerivastatin (Baycol), diclofenac (Voltaren), felbamate (Felbatol), fenofibrate (Tricor), fluvastatin (Lescol), gemfibrozil (Lopid), isoniazid, itraconazole, (Sporanox), ketoconazole (Nizoral), leflunomide (Arava), lovastatin (Mevacor), methotrexate (Rheumatrex), nevirapine (Viramune), niacin, nitrofurantoin (Macrodantin), pioglitazone (Actos), pravastatin (Pravachol), pyrazinamide, rifampin (Rifadin), ritonavir (Norvir), rosiglitazone (Avandia), simvastatin (Zocor), tacrine (Cognex), tamoxifen, terbinafine (Lamisil), valproic acid, and zileuton (Zyflo).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHEPATOTOXIC HERBS AND SUPPLEMENTS\nEvidence from animal research suggests that high doses of Manchurian thorn can induce liver damage (26974, 26975). Theoretically, concomitant use with other potentially hepatotoxic products might increase the risk of developing liver damage. Some of these herbs and supplements include androstenedione, chaparral, comfrey, DHEA, germander, niacin, pennyroyal oil, red yeast, and others.\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nEvidence from animal research suggests that saponins isolated from Manchurian thorn can lower plasma glucose levels (74988). Theoretically, Manchurian thorn might have additive effects with herbs and supplements that decrease blood glucose levels. Herbs and supplements with hypoglycemic potential include alpha-lipoic acid, devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, and Siberian ginseng.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nSaponins isolated from Manchurian thorn might lower plasma glucose levels (74988). Until more is known, use cautiously in diabetic patients. Theoretically, Manchurian thorn might affect glucose control and increase the risk of hypoglycemia in patients with diabetes.\nless\nLIVER DISEASE\nHigh doses of Manchurian thorn might adversely affect the liver (26974, 26975). Theoretically, Manchurian thorn might exacerbate liver dysfunction in patients with liver disease.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "In an animal model, the median lethal acute dose of Manchurian thorn root extract was approximately 16.5 grams/kg. In a sub-chronic toxicity analysis, a dose of 3.4 grams/kg resulted in weight loss over 70-90 days (26975).",
            "Pharmacokinetics": "Metabolism\nAnimal research shows that araloside A, a constituent of Manchurian thorn, is hydrolyzed to oleanolic acid. The process takes 20 hours and the metabolite is cleared within 4 hours of formation (26977).",
            "Mechanism of Action": "General\nThe applicable parts of Manchurian thorn are the bark and root (90834). Constituents in Manchurian thorn include aralosides (triterpenoid saponins), such as aralosides A, B, and C (26976, 26977, 26978), oleanosides (A, B, C, D, E, F, G, H, and I), saponins, saponosides (26979), and triterpenoids (spikenard) (26980, 74988). There is insufficient reliable information available about the mechanism of action of Manchurian thorn."
        }
    },
    "Manganese": {
        "sections": {
            "Overview": "Manganese is the twelfth most abundant element in the earth's crust. It is also an essential nutrient involved in normal cell growth, generation of the immune response, glucose regulation, and metabolism of carbohydrates, lipids, and proteins (99415). Manganese acts as a cofactor in several metabolic and enzymatic reactions (2003, 7135, 61506, 61556). It is found in foods including nuts, legumes, seeds, tea, whole grains, and leafy green vegetables (2005, 2008, 7135).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Oral manganese is safe when used in doses below the tolerable upper intake level (UL) of 11 mg daily for adults 19 years and older (1994, 7135). ...when used parenterally and appropriately. Parenteral manganese chloride and manganese sulfate are FDA-approved prescription products.\nPOSSIBLY UNSAFE when used orally in high doses. Doses exceeding 11 mg daily can cause significant adverse effects (7135). ...when used parenterally in moderate or high doses, long-term. Reports of neurotoxicity and Parkinson-like symptoms have been reported with parenteral nutrition manganese doses above 60 mcg daily. It is recommended that adults on long-term parenteral nutrition receive manganese in doses of no more than 55 mcg daily (99302).\nLIKELY UNSAFE when inhaled in moderate doses, long-term. According to the US Occupational Safety and Health Administration (OSHA), the permissible exposure limit (PEL) for manganese is 5 mg/m3. Exposure to higher amounts of manganese dust or fumes has been associated with central nervous system toxicity, Parkinson-like symptoms, and poor bone health (61296, 102516).\nCHILDREN: LIKELY SAFE when used orally and appropriately. Manganese is safe in children when used in daily doses less than the tolerable upper intake level (UL) of 2 mg in children 1-3 years, 3 mg in children 4-8 years, 6 mg in children 9-13 years, and 9 mg in children 14-18 years (7135).\nCHILDREN: POSSIBLY UNSAFE when used orally in excessive doses. Daily doses greater than the UL are associated with a greater risk of toxicity (7135).\nCHILDREN: LIKELY UNSAFE when inhaled at moderate doses, long-term. Exposure to high amounts of manganese dust has been associated with central nervous system toxicity and Parkinson-like symptoms (61296).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally and appropriately. Manganese is safe when used in doses below the tolerable upper intake level (UL) of 11 mg daily during pregnancy or lactation in those aged 19 or older. However, those under 19 years of age should limit doses to less than 9 mg daily (7135).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally in excessive doses. Doses over the UL are associated with a greater risk of toxicity (7135). Additionally, observational research shows that adults with higher blood manganese levels have greater odds of delivering low birth weight or small for gestational age (SGA) male, but not female, infants (102515).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when inhaled at moderate doses, long-term. Manganese salts can cross the placenta, and animal research suggests that large amounts of manganese may be teratogenic (61296).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and parenterally, manganese is generally well tolerated when used in appropriate doses. High doses might be unsafe.\nSerious Adverse Effects (Rare)\nAll routes of administration: Neurotoxicity, including Parkinson-like extrapyramidal symptoms, when used in high doses.\nCardiovascular\nChronic occupational exposure to manganese dust or fumes can cause orthostatic hypotension, and heart rate and rhythm disturbances (61363).\nless\nEndocrine\nChronic occupational exposure to manganese dust or fumes can cause elevations in thyrotropin-releasing hormone (TRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels (61378).\nless\nHepatic\nManganese intoxication may cause cirrhosis and hepatic steatosis. In one case, a 13-year-old female with manganese intoxication developed severe, life-threatening neurological symptoms, with liver biopsy indicating incomplete cirrhosis and microvesicular steatosis. Chelation therapy and multiple rounds of therapeutic plasma exchange were required before symptoms resolved. The source of manganese exposure was not identified, and it is not clear if the impaired liver function contributed to the manganese accumulation or if elevated manganese exposure led to the liver damage.\nless\nMusculoskeletal\nChronic occupational exposure to manganese dust or fumes has been associated with lower bone quality in females, but not males, suggesting that prolonged manganese exposure might increase the risk of osteoporosis in females (102516). A meta-analysis of 11 observational studies in adults also suggests that increased environmental exposure to airborne manganese sources is associated with lower motor function scores (108537).\nless\nNeurologic/CNS\nOrally, there is concern that higher doses of manganese might increase the risk of neurotoxicity, including Parkinson-like extrapyramidal symptoms (7135, 10665, 10666). One severe case of irreversible Parkinson disease possibly related to taking manganese 100 mg daily for 2-4 years has been reported (96418). In another case, a 13-year-old female with manganese intoxication (diagnosed from blood manganese levels and cranial MRI evidence) developed severe neurological symptoms including loss of consciousness, decorticate posture, clonus, increased reflexes in the extremities, isochoric pupils, and no painful stimulus response. Liver biopsy also showed incomplete cirrhosis and microvesicular steatosis. The patient was intubated, and chelation therapy and multiple rounds of therapeutic plasma exchange were required before symptoms resolved. The source of the child's manganese exposure was not identified (112137). Individuals with impaired manganese excretion can also experience these effects even with very low manganese intake. Manganese accumulation due to chronic liver disease seems to cause Parkinson-like extrapyramidal symptoms, encephalopathy, and psychosis (1992, 7135). One review recommends stopping supplementation if aminotransferase or alkaline phosphatase levels rise beyond twice normal (99302).\n\nChronic occupational exposure to manganese dust or fumes can also cause extrapyramidal reactions (1990, 7135). In 1837, Couper observed that exposure to manganese dust particles produces a neurological syndrome characterized by muscle weakness, tremor, bent posture, whispered speech, and excess salivation (61264). Additionally, observational research in children has found that elevated manganese levels detected in the hair and fingernails due to environmental exposure may be associated with impaired neurocognitive function or development (108535). A meta-analysis of 11 observational studies in adults also suggests that increased environmental exposure to airborne manganese sources is associated with lower cognitive function scores (108537).\n\nIntravenously, manganese might increase the risk of neurotoxicity when administered at high doses or for an extended duration. Cases of Parkinson-like symptoms have been reported in patients receiving parenteral nutrition containing more than 60 mcg of manganese daily. Moderate MRI intensity uptake for manganese in the globus pallidus and basal ganglion areas of the brain has been shown in patients receiving parenteral manganese (96416, 99302).\nless\nPsychiatric\nChronic occupational exposure to manganese dust or fumes can cause mood disturbance and dementia (1990, 7135). A case report describes a man who presented with confusion, psychosis, dystonic limb movements, and cognitive impairment after chronic industrial manganese exposure (99415). Symptoms of manganese toxicity from inhalational exposure develop slowly with initial fatigue and personality changes, progressing to hallucinations, delusions, hyperexcitability, Parkinson-like symptoms, dystonia, and dementia (99415). Additionally, observational research has found that chronic environmental exposure to manganese sources such as mining operations and various industrial processes may be associated with a greater risk for developing symptoms of depression (108536).\nless\nPulmonary/Respiratory\nChronic occupational exposure to manganese dust or fumes can cause acute chemical pneumonitis, pulmonary edema, or acute tracheobronchitis (61495).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nEFFECTIVE\nManganese deficiency. Oral and intravenous manganese can prevent and treat manganese deficiency.\nTaking manganese orally or intravenously is effective for preventing or treating manganese deficiency (15). However, the incidence of manganese deficiency is not well documented. Long-term home parenteral nutrition should provide no more than 55 mcg daily of manganese for adults or 1 mcg/kg daily (up to 50 mcg) of manganese for children unless clinically indicated (96416, 99302). A clinical trial in children aged 8-14 months who are manganese deficient shows that taking manganese in addition to other vitamins and minerals in a 30 mL beverage six days per week for up to 14 months promotes growth when compared with placebo (19348).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAllergic rhinitis (hay fever). It is unclear if intranasal manganese is beneficial in patients with allergic rhinitis.\nA small clinical study in patients with chronic allergic rhinitis shows that using an isotonic seawater nasal spray enriched with manganese (Sterimar Mn, Laboratori Baldacci) four puffs daily for 5 months, in addition to standard treatment with oral antihistamines, nasal corticosteroids, and nasal decongestants, reduces the number of acute exacerbations by about three when compared with the standard treatment alone (99416). However, the effect of the manganese in this product is unclear since nasal lavage with a plain saline nasal spray also helps in allergic rhinitis.\nless\nChronic obstructive pulmonary disease (COPD). Intravenous manganese has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients being treated for exacerbation of COPD shows that intravenous supplementation with manganese 0.4 mg, selenium 100 mcg, and zinc 2 mg daily may shorten the number of days spent on mechanical ventilation when compared with placebo (61432). It is unclear if these findings are due to manganese, other ingredients, or the combination.\nless\nMetabolic syndrome. It is unclear if oral intake of or environmental exposure to manganese decreases the risk of metabolic syndrome.\nA meta-analysis of 12 observational studies suggests that increased dietary intake of manganese or higher levels of manganese in the serum, whole blood, or urine are not associated with a lower risk of metabolic syndrome when compared with lower manganese intake or laboratory values (112138).\nless\nObesity. Oral manganese has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in overweight adults shows that taking a specific combination product (7-Keto Naturalean, Enzymatic Therapy, Inc.) containing manganese 500 mcg, 7-oxo-DHEA 100 mg, L-tyrosine 100 mg, asparagus root extract 100 mg, choline bitartrate 50 mg, inositol 50 mg, copper gluconate 500 mcg, and potassium iodide 100 mcg daily for 8 weeks reduces body weight by around 1.5 kg and body mass index (BMI) by around 0.7 kg/m2 when compared with placebo (61581).\nless\nOsteoarthritis. Oral manganese has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nSmall clinical studies in patients with osteoarthritis of the knee and lower back show that taking a specific combination product (Cosamin DS, Nutramax Laboratories) containing manganese ascorbate 228-304 mg (about 31-41 mg of elemental manganese), glucosamine hydrochloride 1500-2000 mg, and chondroitin sulfate 1200-1600 mg daily for 4 months improves pain and ability to do activities of daily living when compared with baseline or placebo (4237, 7169). The amount of manganese in the Cosamin DS formulation used in this study is considerably higher than the 1 mg of elemental manganese per 1500 mg of glucosamine hydrochloride in the current formulation. Since numerous studies show glucosamine with chondroitin without manganese might be effective for osteoarthritis, it is not possible to draw conclusions about the effects of manganese alone.\nless\nOsteoporosis. Oral manganese has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in postmenopausal patients shows that taking manganese 5 mg in combination with elemental calcium 1000 mg, zinc 15 mg, and copper 2.5 mg daily for 2 years reduces spinal bone loss when compared with placebo (1994). Another small clinical study in females with osteopenia shows that taking a specific combination product (Vitrum Osteomag, Unipharm Inc.) containing manganese 1.8 mg, calcium 600 mg, vitamin D (cholecalciferol) 200 IU, magnesium 40 mg, zinc 7.5 mg, copper 1 mg, and boron 250 mcg twice daily for one year improves bone mineral density when compared with no treatment (36840). However, since numerous studies have demonstrated the efficacy of calcium plus vitamin D for osteoporosis, it is not possible to draw conclusions about the effects of manganese alone.\nless\nPremenstrual syndrome (PMS). Oral manganese has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA very small clinical study in patients with PMS shows that taking manganese 1.0 mg or 5.6 mg in combination with calcium 587 mg or 1336 mg daily for about 24 weeks improves symptoms of PMS including pain, crying, loneliness, anxiety, restlessness, irritability, mood swings, depression, and tension (2004).\nless\nWound healing. Topical manganese has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nObservational research has found that applying an alginate dressing containing manganese, calcium, and zinc to chronic wounds for 12 weeks is associated with improved wound healing when compared with previous treatments (61327). It is unclear if these findings are due to manganese, other ingredients, or the combination.\nless\nMore evidence is needed to rate manganese for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch on the use of manganese alone is limited; typical dosing is unavailable. When used in combination with other ingredients, manganese is most often used in doses of 0.5-5.6 mg daily for up to 24 weeks. See Effectiveness section for condition-specific information.\n\nNo recommended dietary allowances (RDA) for manganese have been established; however, daily adequate intake (AI) levels are available (7135). In adults 19 years and older, these are 2.3 mg daily in males and 1.8 mg daily in females. During pregnancy and lactation the daily AI is 2 mg and 2.6 mg, respectively, for those 14-50 years of age.\n\nTaking manganese with milk and/or fat-containing foods might improve the absorption of manganese (24918, 61510). The clinical significance of this effect is unclear.\nIntravenous/Intramuscular:For prophylaxis of manganese deficiency in adults, total parenteral nutrition containing up to 200 mcg of elemental manganese daily has been used. The recommended daily dose is no more than 55 mcg daily. Research on the parenteral use of manganese for other indications is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\n\nIn infants and children, the daily Adequate Intake (AI) levels for manganese are based on age as follows: 3 mcg for 0-6 months old; 0.6 mg for 7-12 months old; 1.2 mg for 1-3 years old; 1.5 mg for 4-8 years old; 1.9 mg for males 9-13 years old; 2.2 mg for males 14-18 years old, and 1.6 mg for females 9-18 years old (7135).\nIntravenous/Intramuscular:For prophylaxis of manganese deficiency in children, total parenteral nutrition containing 1 mcg/kg (maximum 50 mcg) or 2-10 mcg of elemental manganese daily has been used. Research on the parenteral use of manganese for other indications is limited; typical dosing is unavailable.\nStandardization & Formulation\nSalt forms of manganese found in supplements and intravenous formulations include manganese chloride, manganese sulfate, and manganese ascorbate (7135). Intravenous trace element formulations contain 25-500 mcg of elemental manganese per mL (96416).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIPSYCHOTIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, the risk for manganese toxicity might increase when taken with antipsychotic drugs.\nHallucinations and behavioral changes have been reported in a patient with liver disease who was taking haloperidol and manganese. Researchers speculate that taking manganese along with haloperidol, phenothiazine-derivatives, or other antipsychotic medications might increase the risk of manganese toxicity in some patients (61493).\nless\nQUINOLONE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, manganese might reduce the absorption of quinolone antibiotics.\nManganese is a multivalent cation. Interactions resulting in reduced quinolone absorption have been reported between quinolones and other multivalent cations, such as calcium and iron (488).\nless\nTETRACYCLINE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, manganese might reduce the absorption of tetracycline antibiotics.\nManganese is a multivalent cation. Interactions resulting in reduced tetracycline absorption have been reported between tetracyclines and other multivalent cations, such as calcium and iron (488).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCALCIUM\nTaking manganese with calcium might reduce the absorption of manganese, potentially decreasing its effects.\nClinical research shows that concomitant administration of manganese and calcium can decrease manganese absorption (2000, 61427).\nless\nIP-6 (Phytic acid)\nTaking manganese with IP-6 might reduce the absorption of manganese, potentially decreasing its effects.\nIP-6 found in supplements and in foods, such as cereals, nuts, and beans, can decrease manganese absorption (7135). IP-6 chelates multivalent metal ions in the gastrointestinal tract and prevents absorption (1858).\nless\nIRON\nTaking manganese with iron might reduce the absorption of manganese, potentially decreasing its effects.\nClinical research shows that concomitant administration of manganese and iron can decrease manganese absorption (2004, 61265).\nless\nZINC\nTaking manganese with zinc might increase the absorption of manganese, potentially increasing its effects and adverse effects.\nClinical research shows that concomitant administration of manganese and zinc can increase manganese absorption and plasma levels (2000).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCHRONIC LIVER DISEASE\nTheoretically, manganese levels might accumulate and cause toxic effects in patients with chronic liver disease. Until more is known, use cautiously in these patients. Several cases of elevated manganese levels and associated toxicity have been reported in patients with liver disease (1992, 2001).\nless\nIRON-DEFICIENCY ANEMIA\nTheoretically, individuals with iron-deficiency anemia might have enhanced manganese absorption (2002). This might increase the risk for manganese-related adverse effects. Until more is known, use cautiously in patients with iron-deficiency anemia.\nless\nPARENTERAL NUTRITION\nPatients receiving parenteral nutrition are at increased risk of manganese toxicity. Toxicity has been reported at doses of 0.1 mg of manganese daily. Monitor for signs and symptoms of manganese toxicity in these patients. Manganese toxicity has been reported in patients receiving parenteral nutrition, either as a result of added manganese or as an unintended contaminant (12468).\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nALKALINE PHOSPHATASE\nTheoretically, manganese salts may cause a false increase in serum alkaline phosphatase test results due to enzyme activation in the laboratory procedure (275).\nless\nSTOOL COLOR\nTheoretically, manganese dioxide might cause stools to turn dark brown to black (275).\nless",
            "Overdose": "Presentation\nPatients presenting with manganese overdose may experience symptoms of neurotoxicity, including Parkinson-like extrapyramidal symptoms (7135, 10665, 10666). One severe case of irreversible Parkinson disease possibly related to taking manganese 100 mg daily for 2-4 years has been reported (96418).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with manganese.",
            "Pharmacokinetics": "Absorption\nTypically less than 5% of dietary manganese is absorbed (12468). It is unknown how the absorption of manganese from supplements compares with dietary sources. Males seem to absorb less manganese than females. This might be due to higher serum ferritin concentrations in males, resulting in decreased manganese absorption (7135).\n\nWhen manganese is inhaled, it bypasses the blood-brain barrier and accumulates in the brain (99415).\nDistribution\nAbsorbed manganese stays in the blood for a relatively short time, but accumulates in tissues, including bone, where it can remain for many years (99415).\nExcretion\nManganese is cleared hepatically. Chronic liver disease and biliary disorders can cause manganese accumulation and toxicity (1992, 99415).",
            "Mechanism of Action": "General\nManganese is an essential nutrient that acts as a cofactor in several metabolic and enzymatic reactions (2003, 7135). Manganese is found in several foods including nuts, legumes, seeds, tea, whole grains, and leafy green vegetables (2005, 2008, 7135). Manganese is involved in amino acid, cholesterol, and carbohydrate metabolism, normal cell growth, generation of the immune response, and glucose regulation (7135, 99415). Manganese metalloenzymes include arginase, glutamine synthetase, phosphoenolpyruvate decarboxylase, and manganese superoxide (7135).\nAnalgesic effects\nIn patients with premenstrual syndrome (PMS), low dietary manganese has been associated with altered mood and increased pain (7135).\nInflammatory effects\nThere seems to be a positive correlation between the level of dietary manganese intake and circulating levels of inflammatory biomarkers. Preliminary data show that interleukin 1-beta (IL-1-beta) levels are 46% higher in people in the highest quartile of manganese intake compared to the lowest. Similarly, IL-6 levels are 52% higher, and IL-8 levels are 32% higher (99417).\nNeurologic/CNS effects\nManganese accumulation seems to play a role in Parkinson symptoms and encephalopathy associated with chronic liver disease (1992, 10666). High levels of manganese in the brain interfere with mitochondrial function, leading to oxidation and depletion of dopamine and interference with dopaminergic neurotransmission (10665, 99415). Manganese competes for transport by transferrin in the brain, displacing iron and increasing unbound iron in the cerebrospinal fluid. This iron accumulates in neurons, causing oxidative stress and neuronal damage (12468, 99415). The globus pallidus and substantia nigra, areas of the brain associated with the extrapyramidal system, are high in transferrin receptor density, which may result in concentration of manganese (7135). Manganese also binds to acetylcholinesterase, leading to accumulation of acetylcholine and overstimulation of its receptors (99415).\nSkeletal effects\nResearchers think manganese might have a role in osteoporosis. Decreased plasma manganese concentrations have been linked to osteoporosis, and bone mineral density seems to improve when trace minerals including manganese are added to calcium supplementation (7135)."
        }
    },
    "Mangosteen": {
        "sections": {
            "Overview": "Mangosteen is a plant cultivated in Southeast Asia. The fruit is round and dark purple or red, and the fruit pulp is slightly acidic and sweet (92804). Mangosteen pericarp has reportedly been used in traditional medicine in Southeast Asia for infections, wounds, and diarrhea (92804, 92805).",
            "Safety": "POSSIBLY SAFE when used orally. Mangosteen has been used with apparent safety at a dose of up to 560 mg daily for 12 weeks (110127). It has also been used with apparent safety in combination with Sphaeranthus indicus (Meratrim, Laila Nutraceuticals) or Indian cassia (Cindura, Laila Nutraceuticals), for a total dose of 800 mg daily for up to 16 weeks (97876, 97878, 97879, 101079). ...when used topically as a single dose. Mangosteen pericarp 4% gel has been applied once along the gum line with apparent safety (97875).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, mangosteen is generally well tolerated. Topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\nSerious Adverse Effects (Rare)\nOrally: Lactic acidosis.\nDermatologic\nOrally, mangosteen extract up to 560 mg daily has been reported to cause skin rash. It is not known if this side effect was related to mangosteen (97877).\nless\nGastrointestinal\nOrally, mangosteen extract up to 560 mg daily has been reported to cause constipation, abnormal stool, abdominal discomfort, abdominal bloating, salivation, nausea and vomiting, and diarrhea. It is not known if these side effects were related to mangosteen (97877).\nless\nNeurologic/CNS\nOrally, mangosteen extract up to 560 mg daily has been reported to cause mild tiredness, headache, dizziness, and malaise. It is not known if these side effects were related to mangosteen (97877).\nless\nPulmonary/Respiratory\nOrally, mangosteen extract up to 560 mg daily has been reported to cause dry throat, flu-like symptoms, cough, and nasal congestion. It is not known if these side effects were related to mangosteen (97877).\nless\nRenal\nOrally, mangosteen extract up to 560 mg daily has been reported to cause abnormal urination. It is not known if this side effect was related to mangosteen (97877). In one case report, a patient with chronic kidney disease and metabolic syndrome consumed mangosteen juice daily for 12 months and later presented with severe lactic acidosis. The juice was reported to contain 250 mg of mangosteen with 25 mg alpha-mangostin per ounce. Alpha-mangostin appears to inhibit mitochondrial function, disrupting the electron transport chain and adenosine triphosphate (ATP) production, causing accumulation of reactive oxygen species and inducing apoptosis. Researchers speculate that these effects might have led to lactic acidosis in this patient (16399).\nless\nOther\nOrally, mangosteen extract up to 560 mg daily has been reported to cause weight loss. It is not known if this side effect was related to mangosteen (97877).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nPeriodontitis. Oral and topical mangosteen may modestly improve gum health.\nA small clinical study in adults with chronic periodontitis shows that applying a gel containing mangosteen pericarp 4% to the periodontal pocket following scaling and root planing procedures improves pocket depth, clinical attachment, and bleeding by 56% to 63%, compared with a 33% to 42% improvement with placebo (97875). Another small clinical study in similar patients shows that applying mangosteen 4% gel to the periodontal pocket following scaling and root planning improves pocket depth and clinical attachment when compared with placebo. However, plaque and bleeding indices were not compared between groups (110126). A clinical study in patients with generalized or localized gingivitis or stage I periodontitis shows that taking 194 mg of a product containing mangosteen and propolis orally improves the modified gingival index by 31% or 40% at weeks 4 or 8, respectively, compared with 16% or 25% in those receiving placebo. No changes in probing depth, clinical attachment, plaque index, bleeding, or gingival recession were observed (106789). It is unclear if these effects are due to mangosteen, propolis, or the combination.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlzheimer disease. It is unclear if oral mangosteen is beneficial for patients with Alzheimer disease.\nA small clinical study in adults with Alzheimer disease in Thailand shows that treatment with oral mangosteen pericarp extract, provided either as 220-280 mg daily for 24 weeks, or as 220-280 mg daily for 12 weeks followed by 440-560 mg daily for 12 weeks, does not consistently improve cognitive function scores to a clinically significant extent when compared with placebo. This study assessed cognitive function on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and Thai Mental State Examination (110127). However, the validity of this study is limited by poor methodology, including inadequate power and blinding.\nless\nAndrogenic alopecia. Mangosteen has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large clinical trial in males and females with androgenic and diffuse alopecia shows that applying a hair lotion containing fermented mangosteen 2%, fermented papaya 2%, and caffeine 0.5% to the scalp daily plus use of a shampoo containing fermented mangosteen 0.5% and fermented papaya 0.5% 3 times weekly for 14 weeks improves hair shaft and root quality, hair diameter, and the density and percentage of thick hairs compared to baseline (111719). It is unclear if these effects are due to fermented mangosteen, other ingredients, or the combination.\nless\nAtopic dermatitis (eczema). Although there has been interest in using topical mangosteen for eczema, there is insufficient reliable information about the clinical effects of mangosteen for this purpose.\nMuscle fatigue. It is unclear if oral mangosteen is beneficial in preventing muscle fatigue during physical activity.\nA very small clinical study in healthy, physically active adults shows that drinking 250 mL of a specific mangosteen juice product (Lord Duke Biotechnology Corporation) containing mangosteen, pomegranate, acerola, white grape, strawberry, passion fruit, and tamarind, 1 hour prior to physical activity, does not improve time to exhaustion when compared to the juice product without mangosteen (92805).\nless\nMuscle strength. Oral mangosteen has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne small clinical study in young, resistance-trained males shows that taking a combination product (CinDura, Laila Nutraceuticals) containing mangosteen fruit rind extract and Indian cassia leaf extract 400 mg twice daily for 42 days increases muscle strength and endurance when compared with placebo. Single bench and leg presses improved by approximately 23.5 kg and 29.3 kg, respectively, compared with 3.4 kg and 5.2 kg, respectively, in those taking placebo. Also, the number of leg extension repetitions increased by 6.5, compared to an increase of 2 with placebo (101079). It is not clear if these benefits are due to mangosteen, Indian cassia, or the combination.\nless\nObesity. Oral mangosteen has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in healthy adults who were overweight shows that taking a specific combination product containing a mixture of mangosteen and Sphaeranthus indicus (Meratrim, Laila Nutraceuticals) 400 mg twice daily for 16 weeks results in weight loss of 6.7%, compared with weight loss of 1.4% with placebo (97876). In adults with obesity, taking the same dose of this product for 8 weeks results in an additional reduction in body weight of 4.6% when compared with placebo (97878, 97879). This product also seems to improve body mass index (BMI), waist and hip measurements, and blood lipids in some patients (97876, 97878, 97879). It is not clear if these benefits are due to mangosteen, Sphaeranthus indicus, or the combination.\nless\nOsteoarthritis. Topical mangosteen has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large, single-blind clinical study in adults with knee osteoarthritis causing moderate pain shows that applying a specific cream (TMP-4) containing extracts of mangosteen peel, sesame seed, soybean, and gotu kola leaf four times daily for 4 weeks provides similar improvement in pain scores when compared with diclofenac 1% gel. Topical TMP-4 cream also seems to improve knee stiffness, stair climbing, and mobility similarly to diclofenac gel. However, patient impression of overall improvement was higher with diclofenac (110128). The validity of this study is limited by inadequate blinding.\nless\nSchizophrenia. It is unclear if oral mangosteen is beneficial in schizophrenia.\nA clinical study in adults with schizophrenia or schizoaffective disorder shows that taking mangosteen pericarp 1000 mg daily for 24 weeks does not improve total symptom severity when compared with placebo (106787). A secondary analysis of cognitive outcomes also did not demonstrate any differences (106790).\nless\nMore evidence is needed to rate mangosteen for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMangosteen has been used in doses of up to 560 mg daily for up to 12 weeks. See Effectiveness section for condition-specific information.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nIn one clinical study, a specific mangosteen-based juice product (Lord Duke Biotechnology Corporation) containing whole-fruit mangosteen 50%, pomegranate juice 7%, acerola juice 7%, white grape juice 12%, strawberry juice 6%, passion fruit juice 10%, and tamarind 8% was used. Upon analysis, the juice contained alpha-mangostin 1.22 mg/mL and hydroxycitric acid 1.11 mg/mL. Each 250 mL dose contained 305 mg of alpha-mangostin and 278 mg of hydroxycitric acid (92805).\n\nIn another clinical trial, a combination of pulverized and extracted mangosteen fruit rinds and Indian cassia leaves were used. The resultant powdered extracts were blended together in a ratio of 1:2 (CinDura, Laila Nutraceuticals). Alpha-mangostin was used as the standard for the mangosteen extract at 3.5%. Each capsule contained 400 mg of the combination of these plant products (101079).\n\nIn other clinical trials, a combination of pulverized and extracted Sphaeranthus indicus flowers and mangosteen fruit rinds were used. The resultant paste and powdered extract were blended together in a ratio of 3:1 (Meratrim, Laila Nutraceuticals). Alpha-mangostin was used as the standard for the mangosteen extract at 2%. Each capsule contained 400 mg of the combination of these plant products (97876, 97878, 97879).\n\nA topical gel containing mangosteen 4% was used in one clinical trial. The crude extract of the mangosteen pericarp was used and powdered. Mangosteen powder 4 grams was added to gelatin 12 grams, glycerin 0.2 mL, peppermint oil 0.1 mL, sodium saccharin 0.1 mL, and purified water 100 mL to make a gel (97875).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of mangosteen with anticoagulant or antiplatelet drugs may increase the risk of bleeding.\nIn vitro and animal research shows that gamma-mangostin, a constituent of mangosteen, is a potent and competitive antagonist of the serotonin 2A (5-HT2A) receptor. Antagonism of the 5-HT2A receptor is believed to reduce platelet aggregation (12017, 61685, 61686).\nless\nDONEPEZIL (Aricept)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of mangosteen with donepezil might increase the effects of donepezil.\nAnimal research shows that concomitant use of an aqueous extract of mangosteen pericarp with donepezil increases brain concentrations of donepezil at 4 hours by 64% without associated effects on systemic exposure (106791).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, mangosteen may have antiplatelet activity.\nIn vitro and animal research shows that gamma-mangostin, a constituent of mangosteen, is a potent and competitive antagonist of the serotonin 2A (5-HT2A) receptor. Antagonism of the 5-HT2A receptor is believed to reduce platelet aggregation (12017, 61685, 61686). Theoretically, combining mangosteen with herbs and supplements with anticoagulant/antiplatelet effects might increase the risk of bleeding in some people. See products with anticoagulant activity here. See products with antiplatelet activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nMangosteen might have antiplatelet effects (12017, 61685, 61686). Theoretically, use of mangosteen in patients with bleeding disorders might increase the risk of bleeding. Tell patients with bleeding disorders to avoid the use of mangosteen.\nless\nPERIOPERATIVE\nMangosteen might have antiplatelet effects (12017, 61685, 61686). Theoretically, mangosteen might cause excessive bleeding if used perioperatively. Tell patients to discontinue mangosteen at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation and treatment of overdose with mangosteen.",
            "Pharmacokinetics": "Absorption\nIn humans consuming 59 mL of mangosteen juice containing 94.2 mg of xanthones, the maximum plasma concentration (Cmax) of alpha-mangostin, a constituent of mangosteen, was approximately 3 ng/mL. The time to maximum plasma concentration (Tmax) was 1 hour. In another pharmacokinetic study, the Cmax of alpha-mangostin was 113 nmol/L and the Tmax was 3.7 hours following consumption of 60 mL of mangosteen juice containing 130 mg of xanthones. It has been suggested that the bioavailability of mangosteen is dependent on its incorporation into bile salt micelles (92804).\nMetabolism\nXanthones from mangosteen juice appear to undergo glucuronidation and sulfation (92804).\nExcretion\nBoth free xanthones and glucuronidated and sulfated xanthones have been detected in the urine after consumption of 60 mL of mangosteen juice containing 130 mL of xanthones. However, urinary excretion of xanthones accounted for only 2% of the total ingested dose, suggesting that mangosteen and its xanthones are primarily excreted in the feces. This is supported by findings of high concentrations of xanthones in animal feces (92804).",
            "Mechanism of Action": "General\nAll parts of the plant are used, including the fruit rinds, seeds, leaves, and bark (97876, 97877). Mangosteen contains anthocyanic glycosides, several prenylated xanthones (61665), isomangiferin, and mangiferin (61676). The fruit hulls and leaves contain terpenoids and sugars (61671). The medicinal properties of mangosteen have been attributed to the secondary metabolites known as xanthones, found in the pericarp of mangosteen. At least 68 different xanthones have been identified in mangosteen, with the pericarp containing higher amounts of approximately 50 of these xanthones. The most abundant, and often reported xanthones include alpha- and gamma-mangostin (12016, 61664, 92804, 92805, 97877). Mangosteen also contains sesquiterpenes, beta-mangostin, mangostenone C, gartanins, and garcinones (12015, 12016, 61674, 97875, 97877).\nAnti-allergy effects\nLaboratory research suggests that alpha-mangostin from the fruit hull of mangosteen is a competitive antagonist of histamine H1 receptors in smooth muscle (12017). Ethanol extracts of mangosteen fruit hull also appear to inhibit immunoglobulin E (IgE)-mediated histamine release and prostaglandin E2 synthesis. This is most likely due to alpha- and gamma-mangostin (12017, 61664).\nAnti-diabetic effects\nIn an obese rat model of type 2 diabetes, an ethanolic extract of mangosteen pericarp attenuates diabetes-induced increases in fasting blood glucose (106788).\nAnti-inflammatory effects\nThere is interest in using mangosteen and/or its xanthones for anti-inflammatory effects. Laboratory and animal research suggest that xanthones inhibit inflammatory responses and induced edema via multiple mechanisms including attenuation of the expression of inflammatory mediators and proinflammatory cytokines such as interleukin 8, tumor necrosis factor-alpha (TNF-alpha), nitric oxide, and prostaglandin E2, decreasing expression of inflammatory signaling pathways, and suppression of histamine release and reduced cyclooxygenase-2 mRNA (16399, 61662, 61669, 61677, 92804). In animals, pretreatment with mangosteen extract protected from systemic anaphylaxis and inhibited adjuvant-induced arthritis (61679). In an obese rat model of type 2 diabetes, an ethanolic extract of mangosteen pericarp attenuated diabetes-induced increases in levels of interleukin 6 and TNF-alpha, as well as increases in the expression of nuclear factor-kappa B (NF-kappa B) in glial cells in the hippocampal region (106788). In clinical research, results have been mixed, with some reports of reduction in periodontal inflammation and C-reactive protein levels with use of mangosteen, while other markers of inflammation have actually increased (92804). Alpha- and gamma-mangostin constituents have anti-inflammatory effects in laboratory research (97875).\nAnti-oxidant effects\nHuman, animal, and laboratory research suggests that mangosteen extract has antioxidant effects (97877, 106788). In an obese rat model of type 2 diabetes, an ethanolic extract of mangosteen pericarp attenuates diabetes-induced increases in superoxide dismutase activity (106788). Laboratory research suggests the antioxidant effects of mangosteen are primarily due to the xanthones alpha- and gamma-mangostin (61675).\nAnti-proliferative effects\nThere is interest in using mangosteen and/or its xanthones for anti-proliferative effects. Laboratory and animal research suggest that xanthones have anti-proliferative effects on models of mammary, mouth, liver, lung, stomach, adrenal, glioblastoma, prostate, leukemia, colon, and colorectal cancers. Induction of apoptosis and cell cycle arrest, as well as activation of various caspases, loss of mitochondrial potential, inhibition of deoxyribonucleic acid (DNA) topoisomerase II, induction of p53 and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways, and inhibition of matrix metalloproteinase activities which can lead to decreased adhesion and migration of cancer cells, are all possible mechanisms of action (12013, 12015, 61666, 61667, 61668, 61670, 61674, 92804). And in some cases, mangosteen has been more effective than traditional chemotherapeutic agents (12015, 61668). Additionally, alpha-mangostin is an inhibitor of mitochondrial function, disrupting the electron transport chain and ATP production, causing accumulation of reactive oxygen species, and inducing apoptosis. These effects might also lead to lactic acidosis, however (16399).\nAnti-viral effects\nLaboratory research suggests that an alcohol extract of fresh mangosteen fruit peel containing gamma-mangostin is a noncompetitive inhibitor of HIV-1 protease (61680). Isomangiferin and mangiferin also appear to inhibit HSV-1 replication (61676).\nAntibacterial effects\nLaboratory research suggests that alpha-mangostin, isolated from the stem bark of mangosteen, is active against five strains of vancomycin-resistant enterococci (VRE) and nine strains of methicillin-resistant Staphylococcus aureus (MRSA), with synergistic antibacterial effects against VRE and MRSA when combined with gentamycin and vancomycin, respectively (61671). Ethanolic and benzene extracts of whole mangosteen and mangosteen pericarps also have been reported to inhibit MRSA, the effect being due to alpha-mangostin and possibly tannin content (13702, 61682). Additional laboratory research suggests extracts of mangosteen fruit pericarps have activity against Salmonella enteritidis, possibly due to direct antimicrobial activity or the production of reactive oxygen species because the extract seemed to stimulate white blood cells to produce oxidative bursts (61684). Mangosteen and its xanthones have also demonstrated activity against Propionibacterium acnes, Staphylcoccus epidermidis, and Mycobacterium tuberculosis (12014, 61672).\nCognitive effects\nA small clinical study in adults with Alzheimer disease shows that treatment with oral mangosteen pericarp extract leads to a small reduction in serum levels of 4-hydroxynonenal when compared with placebo (110127).\nExercise effects\nThere is interest in using mangosteen for muscle fatigue. It is thought that fatigue is generated by overproduction of reactive oxygen species and depletion of adenosine triphosphate (ATP). Mangosteen has been shown to exhibit free radical scavenging properties in laboratory studies; however, in clinical research these effects have not translated into beneficial effects on physical fatigue or biochemical markers of physical fatigue (92805).\nHematologic effects\nLaboratory research suggests that mangosteen is a competitive 5-hydroxytrptamine 2A receptor antagonist, blocking platelet aggregation (61685).\nMusculoskeletal effects\nLaboratory research suggests that mangosteen is a competitive 5-hydroxytrptamine 2A receptor antagonist, blocking muscle contraction (61685). A methanolic extract of mangosteen (yielding alpha- and gamma-mangostin) also inhibited muscle contraction by blocking histamine and serotonin receptors (12017).\nNeurological effects\nMangosteen is used to improve mental health. In animal models, mangosteen extract prevented cognitive impairment and suppressed the activity of acetylcholinesterase (97877)."
        }
    },
    "Manna": {
        "sections": {
            "Overview": "Manna is the juice or sap extracted from the bark of the trunk and branches of the Fraxinus ornus tree. It contains approximately 40% to 90% mannitol, an osmotic laxative (18).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term (2, 18). Manna has been used traditionally with apparent safety at a dose of 20-30 grams daily for no more than a few days (2, 18).\nThere is insufficient reliable information available about the safety of manna when used orally for an extended duration.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, manna seems to be generally well tolerated.\nMost Common Adverse Effects\nOrally: Flatulence, nausea.\nGastrointestinal\nOrally, manna has been reported to cause flatulence and nausea (2, 18).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nConstipation. Although there has been interest in using oral manna for constipation, there is insufficient reliable information about the clinical effects of manna for this purpose.\nMore evidence is needed to rate manna for this use.",
            "Dosing & Administration": "Adult\nOral:\nTraditionally, the typical dose of manna is 20-30 grams daily for no more than a few days (2, 18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of manna.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIGOXIN (Lanoxin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, manna might increase the risk of adverse effects when taken with cardiac glycosides.\nManna contains mannitol, which acts as an osmotic laxative (19). Overuse or abuse of manna might increase the risk of adverse effects from cardiac glycoside drugs.\nless\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, manna might increase the risk of hypokalemia when taken with diuretic drugs.\nManna contains mannitol, which acts as an osmotic laxative (19). Overuse of manna might compound diuretic-induced potassium loss, increasing the risk of hypokalemia.\nless\nSTIMULANT LAXATIVES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, manna might increase the risk for fluid and electrolyte loss when taken with stimulant laxatives.\nDue to the osmotic laxative effects of manna, concomitant use with stimulant laxatives might compound fluid and electrolyte loss (18).\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, manna might increase the risk of bleeding when taken with warfarin.\nManna has osmotic laxative effects. In some people manna can cause diarrhea. Diarrhea can increase the effects of warfarin, increase international normalized ratio (INR), and increase the risk of bleeding.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCARDIAC GLYCOSIDE-CONTAINING HERBS\nTheoretically, the laxative effects of manna may increase the risk of potassium depletion.\nTaking manna with cardiac glycoside-containing herbs might increase the risk of cardiac glycoside toxicity due to potassium depletion (19). See cardiac glycoside-containing natural ingredients here.\nless\nHORSETAIL\nTheoretically, the laxative effects of manna may increase the risk of potassium depletion.\nTheoretically, due to manna's laxative effect, concomitant use with horsetail increases the risk of potassium depletion (19).\nless\nLICORICE\nTheoretically, the laxative effects of manna may increase the risk of potassium depletion.\nTheoretically, due to manna's laxative effect, concomitant use with licorice increases the risk of potassium depletion (19).\nless\nSTIMULANT LAXATIVE HERBS\nTheoretically, the laxative effects of manna may increase the risk of potassium depletion.\nTheoretically, taking manna with other laxative herbs may increase the risk of potassium depletion and hypokalemia (19). See other herbs with laxative effects here.\nless",
            "Interactions with Conditions": "GI OBSTRUCTION\nManna is contraindicated in cases of intestinal obstruction, appendicitis, abdominal pain of unknown origin, and inflammatory conditions of the intestines (18).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with manna.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of manna.",
            "Mechanism of Action": "General\nManna consists of the dried sap collected from the splits in the branches and trunk of Fraxinus ornus (18).\nImmunologic effects\nThe manna bark contains coumarins which can inactivate the serum complement, a component in the host defense system (1527).\nLaxative effects\nManna contains 40-90% mannitol (9, 18), which acts as an osmotic laxative (2, 18)."
        }
    },
    "Maqui": {
        "sections": {
            "Overview": "Maqui is a plant with edible purple-black berries. It is indigenous to Chile and Argentina (98665, 98668, 98671). Several varietals of maqui trees are now cultivated in Chile to improve fruit yields and preserve wild trees (109544). Maqui berry and juice are used as food and medicine (98670). Traditionally, they have been used for diarrhea, fever, and to improve general health and wellness.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Maqui berry extract has been used safely in doses of up to 180 mg daily for up to 3 months (98669, 98673, 112981). Additionally, maqui berry extract has been used with apparent safety in doses of up to 1000 mg daily for 1 month (112980).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nDry eye. It is unclear if oral maqui berry extract is beneficial for dry eye.\nPreliminary clinical research in patients with moderate dry eye shows that taking maqui extract (MaquiBright) 30 mg or 60 mg by mouth daily for 60 days improves overall symptoms of dry eye by up to 72% when compared with baseline. In patients taking 60 mg daily, tear production was increased by 50% over baseline (98673). The validity of these findings is limited by the lack of a control group. A small clinical trial in adults in India with dry eye disease shows that taking maqui berry extract (Maqvue) 30 mg twice daily for 4 weeks followed by 30 mg daily for 4 weeks improves some dry eye symptoms, such as tear fluid production and ocular discomfort, when compared with placebo (112981).\nless\nImpaired glucose tolerance (prediabetes). It is unclear if oral maqui berry is beneficial for improving glycemic control in adults with prediabetes.\nOne small clinical study shows that taking maqui extract (Delphinol) 180 mg once daily for 3 months does not reduce levels of fasting blood glucose, insulin, or total cholesterol when compared with baseline. Although taking this maqui extract decreased glycated hemoglobin (HbA1c) from 5.65% to 5.35%, this change is not likely to be clinically significant (98669). Furthermore, the validity of these findings is limited by the lack of a control group.\nless\nPsychological well-being. It is unclear if oral maqui berry is beneficial for improving psychological well-being.\nA small clinical trial in healthy adults shows that taking maqui berry extract (Maqui 500, Proeon) 500 mg sublingually twice daily for 30 days improves Short-Form 12 mental scores but does not improve measures of perceived stress or resilience when compared with no supplementation in the control group.(112980). The validity of this study is limited by the lack of a placebo in the control group.\nless\nMore evidence is needed to rate maqui for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nStandardized maqui berry extract (Delphinol; MaquiBright) has been used orally in clinical trials. This extract is standardized to contain at least 25% delphinidin glycosides and 35% total anthocyanins (98668, 98669, 98673).",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, maqui fruit extract may increase the risk of hypoglycemia when used with antidiabetes drugs.\nAnimal research shows that maqui berry reduces fasting blood glucose. However, maqui berry extract taken orally, either as a single dose or daily for 3 months, does not decrease fasting blood glucose in prediabetic patients (98668, 98669, 98672). It is unknown whether it might reduce blood glucose levels in patients with diabetes.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, maqui berry might lower blood glucose levels.\nAnimal research shows that maqui berry reduces fasting blood glucose. However, maqui berry extract, taken orally as a single dose or daily for 3 months, does not decrease fasting blood glucose in prediabetic patients (98668, 98669, 98672). Theoretically, maqui might increase the risk of hypoglycemia when used with other supplements with hypoglycemic potential. See other products with hypoglycemic effects here.\nless",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with maqui.",
            "Pharmacokinetics": "Absorption\nAfter oral consumption of maqui extract 1000 mg while fasting, plasma levels of the constituents delphinidin-3-O-glucoside and cyanidin-3-O-sambubioside peak after approximately 0.5-1 hour and 1-4 hours, respectively. Plasma levels return to baseline after about 8 hours (98665).\nMetabolism\nAfter oral consumption of maqui extract, the constituents delphinidin-3-O-glucoside and cyanidin-3-O-sambubioside are metabolized to gallic acid and protocatechuic acid (98665).",
            "Mechanism of Action": "General\nThe applicable parts of maqui are the berries and leaves. The berry contains a high concentration of phenolic antioxidants, with the majority of its antioxidant capacity coming from the aqueous, anthocyanin-rich fraction of the juice (17538, 98668, 98669). The average total anthocyanin content of fresh maqui berry is about 138 mg/100 grams. From dried berries, the average total anthocyanin content is about 212 mg/100 grams (17539, 17541). Primary anthocyanins from maqui berry include the delphinidin 3-sambubiosides and delphinidin 3-glucosides. Delphinidin 3-sambubioside-5-glucoside represents 34% of total anthocyanin content (17539, 98666). Maqui berries and leaves also contain caffeic and gallic acids, quercetin, rutin, myricetin, catechin, epicatechin, delphinidin, malvidin, petunidin, cyanidin, peonidin, coumarins, triterpenes, flavonoids, indole alkaloids, and anthocyanins (17540, 109544). The berries also contain dietary fiber, carbohydrates, proteins, fats, minerals, and vitamins (109545).\nAnalgesic effects\nIn animal research using a formalin pain model, a maqui berry extract containing 1.6% anthocyanins, given orally or parenterally, inhibits the central and inflammatory phases of nociception. Effects are dose-dependent, and the central effects of higher maqui doses are similar to those of tramadol. Delphinidin and cyanidin inhibit mediators of pain and inflammation such as tumor necrosis factor (TNF)-alpha induced by cyclooxygenase 2 (COX-2) expression (109545).\nAntidiabetic effects\nPolyphenol anthocyanin compounds from maqui berry might affect carbohydrate metabolism. In vitro, maqui polyphenols exhibit non-competitive inhibition of the enzyme alpha-glucosidase, which is involved in the breakdown of polysaccharide carbohydrates to monosaccharides (17542). The constituent delphinidin also seems to inhibit sodium-dependent glucose transport (98672). In an animal diabetic model, maqui extract reduces levels of fasting blood glucose (98672). However, in humans with impaired glucose tolerance, although a single dose of maqui extract reduces blood glucose peaks, daily consumption of maqui extract does not seem to affect fasting blood glucose (98668, 98669, 98672).\nAntioxidant effects\nThere is interest in using maqui to prevent cardiovascular disease, due to its antioxidant effects. In vitro, maqui berry juice significantly reduces low-density lipoprotein (LDL) cholesterol oxidation. It also reduces intracellular oxidative stress in a dose-dependent manner (17538). In humans, maqui extract reduces oxidized LDL levels in blood, as well as urinary measures of oxidation (98670). Maqui also normalizes measures of oxidative stress in the exhaled breath of smokers (98671).\nAntiplatelet effects\nMaqui extracts inhibit platelet aggregation induced by adenosine diphosphate (ADP), thombin-6 receptor activating peptide (TRAP-6), collagen, and phorbol 12-myristate 13-acetate (PMA). The degree of activity depends on the maqui variety and extract concentration. There is a positive correlation between concentration and antiplatelet activity for the phenolic compounds isorhamnetin, quercetin, rutin, and isorhamnetin-3-O-rutinoside (109544).\nOcular effects\nIn an animal model, maqui supplementation increased levels of delphinidin in the lachrymal glands, preventing a reduction in tear secretion (98673). Additionally, in clinical research in adults with dry eye disease, taking maqui berry extract for 2 months improves dry eye symptoms and reduces tear fluid levels of pro-inflammatory cytokines interleukin-6 (IL-6), IL-1beta, IL-17A, tumor necrosis factor-alpha (TNF-alpha), and matrix metalloproteinase 9 (MMP9) which are associated with compromised tear fluid production and increases levels of the anti-inflammatory cytokine IL-10 which may have antinociceptive effects (112981)."
        }
    },
    "Maral Root": {
        "sections": {
            "Overview": "Maral root comes from a perennial plant that is native to alpine and subalpine meadows in the Altai and Saian Mountains of Southern Siberia. It has also been introduced into parts of Central and Eastern Europe (26984).",
            "Safety": "There is insufficient reliable information available about the safety of maral root.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "Athletic performance. A small crossover study in healthy, recreationally active adult males shows that taking a 70:30 blend of maral root and rhodiola extracts at a dose of 350 mg or 175 mg, ninety minutes prior to isokinetic leg strength exercises, does not influence fatigability, performance variables, or affective responses when compared with placebo (105855). It is unclear if these effects are due to maral root, rhodiola, or the combination.\nMore evidence is needed to rate maral root for this use.\nless",
            "Dosing & Administration": "Adult\nOral:\nAthletic performance: A specific 70:30 blend of maral root and rhodiola extracts has been used as a single dose of 175 mg or 350 mg, 90 minutes prior to exercise (105855).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of maral root.",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro research shows that maral root tincture can reduce platelet aggregation (27412). Theoretically, maral root might increase the risk of bleeding when used concomitantly with anticoagulant/antiplatelet drugs. Some of these drugs include aspirin, clopidogrel (Plavix), nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nIn vitro research shows that maral root tincture can reduce platelet aggregation (27412). Theoretically, concomitant use of herbs and supplements that affect platelet aggregation could increase the risk of bleeding in some people. Some of these herbs and supplements include angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nMaral root might reduce platelet aggregation (27412). Theoretically, maral root may increase the risk of bleeding when used by patients with bleeding disorders.\nless\nCROSS-ALLERGENICITY\nMaral root may cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nSURGERY\nMaral root might reduce platelet aggregation (27412). Theoretically, maral root might interfere with the control of bleeding during and after surgery. Stop taking maral root at least 2 weeks before a scheduled surgery.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of maral root.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of maral root.",
            "Mechanism of Action": "General\nThe applicable part of the plant is the root. The major constituents of maral root include ecdysteroids (5-beta-cholest-6-on-7-ene derivatives) and flavonoids. The roots also contain various other constituents (26989, 26990, 26991, 26992, 26993, 26994, 26996, 2700). The essential oil from maral root contains at least 30 volatile components, including norsesquiterpene-13-norcypera-1(5),11(12)-diene, aplotaxene, and cyperene (27401).\nAnabolic effects\nAnimal research shows that feeding Japanese quails with 6 grams of 20-hydroecdysone, a constituent of maral root, increases their weight in a dose-dependent manner (27404). In rats fed a low-protein diet, administering maral root extract with or without rhodiola extract, in conjunction with resistance training, increases protein synthesis, mechanical power output, and type I to type II muscle fiber ratio in trained muscles, but does not improve muscle mass, when compared with placebo (105850).\nAntibacterial effects\nIn vitro research shows that essential oil from maral root moderately inhibits the growth of some bacteria, including Staphylococcus aureus, Listeria monocytogenes, Streptococcus pyogenes, and Enterococcus faecalis (27401). Additional evidence from in vitro research shows that a crude ethanolic extract of maral root inhibits the growth of Bacillus cereus and Staphylococcus aureus, but not Escherichia coli or Pseudomonas aeruginosa (12862).\nAnticancer effects\nIn vitro research suggests that maral root extracts inhibit the proliferation of human breast cancer cells. However, the maral root constituent 20-hydroxyecdysone does not affect breast cancer cell proliferation, indicating that this constituent is not the active principle (27411).\nAnticoagulant effects\nIn vitro research shows that an ethanol extract of maral root reduces collagen-induced and ADP-induced platelet aggregation (27412).\nAntifungal effects\nIn vitro, a thiophene polyine isolated from maral root inhibits the growth of various fungal species, particularly Trichophyton mentagrophytes, Aspergillus fumigatus, and Candida tropicalis (27000). Additional in vitro research shows that essential oil from maral root inhibits the growth of Candida albicans (27401).\nAntioxidant activity\nIn vitro research shows that 20-hydroecdysone, a maral root constituent, is effective at protecting mitochondrial lipids against free radical oxidation (27413).\nEstrogenic effects\nIn vitro, lipophilic maral root extract acts as an agonist at estrogen receptors (27411).\nNeuroprotective effects\nIn rats with cerebral ischemia, oral maral root extract 150 mg/kg for 5 days reduces damage, improves neuron structure, restores brain activity, protects the morphology of erythrocytes, and prevents the loss of membrane lipids of sphingomyelin and phosphatidylserine (27422). Other research in rats shows that administration of maral root extract 150 mg/kg protects against a decline in cerebral synapse density (27423).\nPhotosensitizer effects\nIn vitro, a specific thiophene polyacetylene constituent of maral root has greater phototoxicity than xanthotoxin due to its potential for generating singlet oxygen upon irradiation (26994)."
        }
    },
    "Maritime Pine": {
        "sections": {
            "Overview": "Maritime pine is a species of pine tree native to Mediterranean countries, including Spain, France, Portugal, Italy, Croatia, and Morocco (94729). Extracts from the bark of maritime pine are used in supplements for a variety of conditions. Pycnogenol is the US registered trademark for a specific extract derived from French maritime pine (2641). French maritime pine trees are grown exclusively in Landes de Gascogne in southwest France (50933).",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using maritime pine for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. A standardized extract of maritime pine bark (Pycnogenol, Horphag Research) has been safely used in doses of 50-450 mg daily for up to one year (2435, 2451, 2462, 2554, 2556, 7693, 10214, 10416, 12012, 14899) (15424, 15521, 15522, 15523, 15524, 100359, 105782). The same extract has also been used with apparent safety in a dose of 800 mg daily for 16 days (103617). A different standardized extract of maritime pine bark (Oligopin, DRT Group) has been used with apparent safety in doses of up to 150 mg daily for up to 12 weeks (105781, 105783). ...when applied topically as a cream or powder. A standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 0.5% cream has been used for up to 7 days (50912). Powder from a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 100 mg has been applied to the skin daily for up to 6 weeks (50887, 50896).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately, short-term. A standardized extract of maritime pine bark (Pycnogenol, Horphag Research), administered in a dose of 1 mg/lb body weight daily, has been safely used in a clinical study of children aged 6-18 years for up to 3 months (13120).\nPREGNANCY: POSSIBLY SAFE when used orally during the third trimester of pregnancy. In one small clinical study, a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) has been used at a dose of 30 mg daily with apparent safety during the third trimester of pregnancy (15423). However, more evidence is needed; use cautiously or avoid using.\nLACTATION: There is insufficient reliable information available regarding the safety of maritime pine when used during lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, maritime pine bark extract seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Gastrointestinal complaints, dizziness, and vertigo.\nCardiovascular\nA single case of chest pain has been reported for a patient treated with a standardized extract of maritime pine bark (Pycnogenol, Horphag Research). However, the patient had a history of myocardial infarction (50905). Another patient taking the same maritime pine bark extract experienced acute decompensation of heart failure. The patient previously has stable coronary artery disease (50929). It is not clear if either of these adverse effects were directly related to maritime pine bark extract.\nless\nGastrointestinal\nOrally, a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) may cause gastrointestinal problems (15521, 15522, 17300, 50891, 50942). Also, mouth ulcer and bad breath have been reported in a single trial (15521).\nless\nNeurologic/CNS\nOrally, a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) may cause dizziness and severe vertigo (15521, 15522, 17300, 50904, 50933). Also, headache has been reported in a single trial (15521).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAsthma. Oral maritime pine bark extract, taken as an adjunct to conventional asthma medications, may improve symptoms and reduce rescue inhaler use in patients with asthma.\nThree small clinical studies in children and adults with asthma of varying severity show that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 1 mg/lb body weight or 100 mg daily in addition to conventional asthma medications increases peak expiratory flow, decreases asthma symptoms, and decreases the need for rescue medications when compared with conventional therapy alone (13120, 50863, 50926). Maritime pine bark extract has not been studied as monotherapy for asthma and should not be used in place of conventional medicine for this purpose.\nless\nChronic venous insufficiency (CVI). Oral maritime pine bark extract may improve leg pain and heaviness and reduce edema in patients with CVI.\nSeveral clinical studies in patients with CVI show that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) reduces edema, the rate of ankle swelling, and symptoms of leg pain and heaviness when used for 3-12 weeks. The most commonly used dose is 100-120 mg three times daily (2451, 2462, 2493, 7693, 50892). However, lower doses of 50 mg three times daily (16906, 50892, 50900, 50915) or 45-100 mg once daily also seem to be effective (2435, 97401). When compared with the use of below-knee compression stockings worn throughout the day, maritime pine bark reduces induration and the rate of ankle swelling when compared to baseline in patients with CVI. While both treatments reduce venous edema and pain when compared with baseline, a more pronounced reduction is seen in patients taking the maritime pine bark extract (97401). Other clinical research in adults who have had CVI for more than 3 years shows that taking the same extract, 50 mg three times daily for 8 weeks, in addition to wearing compression stockings, improves microcirculation and subjective symptom scores when compared with compression stockings alone (103616). However, compliance with the use of compression stockings in this study was poor.\nless\nOsteoarthritis. Small clinical studies suggest that oral maritime pine bark extract may modestly improve symptoms and reduce the need for analgesics in patients with knee osteoarthritis.\nTwo small clinical studies in patients with knee osteoarthritis shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 100-150 mg daily for 3 months reduces overall osteoarthritis symptoms, pain, and the use of anti-inflammatory medication when compared with placebo (50903, 50905).\n\nTopical maritime pine bark has also been evaluated. Observational research in patients with knee osteoarthritis found that applying standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 220 mg, as two patches daily, for three weeks is associated with reduced pain and reduced need for rescue analgesics when compared with control (100356).\nless\nPOSSIBLY INEFFECTIVE\nHyperlipidemia. Oral maritime pine bark extract may not improve lipid levels in patients with hyperlipidemia.\nAlthough individual clinical trials have shown mixed results (7693, 91965, 97408), a meta-analysis of 4 small clinical trials in patients with hyperlipidemia shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 100-150 mg daily for 4-24 weeks does not reduce total cholesterol, low-density lipoprotein (LDL) cholesterol, or triglyceride levels when compared with a control (100357).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. It is unclear if oral maritime pine bark extract is beneficial in elderly patients with age-related cognitive decline.\nOne observational registry study in healthy elderly patients ages 55-70 years has found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 100 mg daily for 12 months is associated with improved cognitive function, mental performance, and attention when compared with matched controls (97405). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study. Also, a small clinical study in healthy elderly patients 60-85 years of age shows that taking the same extract, 150 mg daily for 3 months, improves spatial working memory, but not numeric working memory, episodic memory, attention, or psychomotor performance, when compared with placebo (50906).\nless\nAging skin. Although there has been interest in using oral and topical maritime pine for aging skin, there is insufficient reliable information about the clinical effects of maritime pine for this purpose.\nAllergic rhinitis (hay fever). It is unclear if oral maritime pine bark extract is beneficial in people with allergic rhinitis.\nA small clinical study in patients with birch allergies shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg twice daily, starting at least 5 weeks before allergy season, decreases nasal symptoms associated with birch allergies when compared with placebo (17300).\nless\nAndrogenic alopecia. It is unclear if oral maritime pine bark is beneficial for androgenic alopecia.\nA small clinical study in postmenopausal patients conducted in China shows that taking maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 6 months improves hair density when compared to baseline (112713). However, the interpretation of these findings is limited by the lack of a statistical comparison to the placebo group.\nless\nAntidepressant-induced sexual dysfunction. It is unclear if oral maritime pine bark is beneficial for improving sexual function in adults taking escitalopram.\nA small, open-label clinical study shows that taking standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg daily for 4 months with escitalopram 10-20 mg daily seems to improve sexual dysfunction when compared with escitalopram alone (100361).\nless\nAtherosclerosis. Oral maritime pine bark extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA non-randomized clinical trial in adults with atherosclerosis shows that taking a specific maritime pine bark product (Pycnogenol, Horphag Research) 150 mg and gotu kola 225 mg, in two divided doses daily for 3 months, reduces plaque height and length and increases plaque echogenicity and stability when compared to control (97030). However, these benefits may be at least partially due to gotu kola. Another non-randomized clinical study in adults with atherosclerotic plaques and no other cardiovascular risk factors shows that taking Pycnogenol 100 mg and gotu kola extract 100 mg daily for up to 4 years reduces plaque progression and increases plaque echogenicity to a greater extent than Pycnogenol alone or no treatment at all. Taking Pycnogenol with gotu kola is also associated with a reduced rate of clinical vascular events, including angina, myocardial infarction, minor transient ischemic attacks (TIAs), and minor strokes, when compared with taking Pycnogenol alone or receiving no treatment at all (97029).\nless\nAthletic performance. It is unclear if oral maritime pine bark extract is beneficial for improving exercise capacity in recreationally trained adults; the available evidence is conflicting.\nOne small clinical study shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 200 mg orally daily for 30 days improves exercise capacity during a treadmill test in recreational athletes aged 20-35 years (2554). Additionally, an observational registry study found that taking this same maritime pine bark extract 100 mg orally daily for 8 weeks along with training improves performance in the Army Physical Fitness Test, including reducing two-mile treadmill time by about 45-60 seconds and increasing the number of push-ups and sit-ups by about 5-7 when compared to control training alone. Taking this maritime pine bark extract during training also appears to improve total triathlon time by about 6 minutes when compared with training alone (91966). However, the validity of this finding is limited by the unblinded, non-randomized nature of the study. Additionally, a small study in college-age males who exercise regularly shows that taking the same maritime pine bark extract 800 mg daily, starting 14 days prior to a cycle ergometer test and continuing for 2 days after, does not improve maximum oxygen consumption or power generated in the test when compared with placebo (103617).\n\nMaritime pine extract has also been studied in combination with other ingredients. A small clinical study in non-professional athletes shows that taking a combination product (PycnoRacer, Kobayashi Pharmaceutical Company) containing maritime pine extract 15 mg, L-leucine 0.6 grams, L-arginine 0.3 grams, L-isoleucine 0.3 grams, and L-valine 0.3 grams four times daily for 3 weeks during training improves running distance by about 19%, compared with 9% in athletes drinking water plus Gatorade. Maritime pine park also improved maximal oxygen consumption and reduced subjective scores of muscle pain and cramps when compared with water and Gatorade (103613). It is unclear if these benefits are due to maritime pine, other ingredients, or the combination.\nless\nAttention deficit-hyperactivity disorder (ADHD). It is unclear if oral maritime pine bark extract is beneficial in children or adults with ADHD.\nA small clinical study in adults with ADHD shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) does not seem to improve ADHD symptoms when compared with placebo (9984). However, a small clinical study in children with ADHD shows that taking this standardized maritime pine bark extract 1 mg/kg daily for one month appears to improve attention and hyperactivity scores when compared with placebo (50891).\nless\nBenign prostatic hyperplasia (BPH). It is unclear if oral maritime pine bark extract is beneficial in patients with BPH.\nA small observational registry study in patients with BPH found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 8 weeks is associated with modest improvement of symptoms such as bladder emptying, urgency, flow, straining, and nocturia (100359). This study was limited by small size, reporting inaccuracies, and its unblinded, non-randomized design.\nless\nCognitive function. Small clinical studies suggest that oral maritime pine bark extract might improve cognitive function in healthy adults.\nA small observational registry study in healthy adults aged 30-55 years found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 12 weeks is associated with slightly improved memory and cognition when compared with matched controls (97410). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study. A small clinical study in healthy college students also shows that taking the same extract 100 mg daily for 2 months seems to reduce failed tests by 4.5% and improve average test scores by about 8% when compared with control (50928).\nless\nCognitive impairment. It is unclear if oral maritime pine bark extract improves cognitive function in patients with mild cognitive impairment.\nAn observational registry study in adults with mild cognitive impairment found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 8 weeks improves global cognitive function when compared to no supplementation. All patients in this study also received standard management of mild cognitive impairment, which included lifestyle modifications such as improved sleep, physical exercise, reduced sugar and salt intake, lowering cardiovascular risk factors, and avoiding use of stimulants or depressants (97406). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nCommon cold. It is unclear if oral maritime pine bark extract is beneficial in the treatment of the common cold.\nAn observational registry study in otherwise healthy adults with a cold found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg twice daily, along with best management for colds, is associated with about one less day of a perceived cold when compared to \"best management\" alone. This standardized maritime pine bark extract is also linked to reduced use of over-the-counter products to manage symptoms in cases of colds lasting longer than 4 days (91962). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nDental plaque. It is unclear if chewing gum containing maritime pine bark extract can reduce dental plaque.\nA small clinical study shows that chewing a minimum of six pieces of gum containing a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 5 mg daily for 14 days reduces gingival bleeding by 55% and prevents an increase in gingival plaque when compared with a control sugar-free gum (50857).\nless\nDiabetes. Small clinical studies suggest that oral maritime pine bark extract may modestly improve glycemic control in patients with type 2 diabetes.\nThree small clinical studies in patients with type 2 diabetes show that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50-200 mg daily for 3-12 weeks modestly decreases blood glucose and glycated hemoglobin (HbA1C) levels when compared with placebo (15521, 15522, 50908). Another small clinical trial in patients with type 2 diabetes and microalbuminuria shows that taking a different standardized maritime pine bark extract (Oligopin, DRT Group) 100 mg daily for 8 weeks reduces HbA1c by around 1%, but does not reduce fasting blood glucose, when compared with placebo (105781).\nless\nDiabetic foot ulcers. It is unclear if oral or topical maritime pine bark extract is beneficial for diabetic foot ulcers.\nA small clinical study in patients with diabetic foot ulcers shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily orally as well as applying the extract topically 100 mg daily heals ulcers in 89% of subjects compared with 61% of control subjects. Using oral or topical maritime pine bark extract alone seems to result in complete ulcer healing in about 85% of subjects (50896).\nless\nDiabetic microangiopathy. It is unclear if oral maritime pine bark extract is beneficial in patients with diabetic microangiopathy.\nA small, unblinded clinical study in patients with diabetic microangiopathy, symptoms of neuropathy, and edema in the absence of severe cardiovascular disease shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg three times daily for 4 weeks improves microcirculation (measured by laser Doppler flowmetry) and symptoms when compared with no treatment (15523).\nless\nDiabetic retinopathy. It is unclear if oral maritime pine bark extract is beneficial in patients with diabetic retinopathy.\nA small, unblinded clinical study in patients with retinopathy due to various causes, including diabetes, atherosclerosis, or central venous thrombosis, shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg three times daily for 2 months may slow or prevent further deterioration of retinal function when compared with no treatment (2536).\nless\nDry mouth. It is unclear if oral maritime pine bark extract is beneficial in patients with dry mouth.\nTwo small observational studies in otherwise healthy adults or patients with diabetes suggest that adding a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) for 2 weeks along with standard saliva supplements is associated with improvement in patient-reported mouth dryness, salivary flow, and the number of small mucosal breaks when compared with saliva supplements alone. One study dosed maritime pine bark extract 150 mg orally daily and the other used a spray formulation dosed 10 mg six times daily (103612, 112714). However, the validity of these findings is limited by the unblinded, non-randomized nature of the studies.\nless\nDysmenorrhea. It is unclear if oral maritime pine bark extract is beneficial in patients with dysmenorrhea.\nTwo small clinical studies in patients with dysmenorrhea show that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 30-60 daily for up to 3 menstrual cycles reduces pain when compared to baseline (15424, 50904). The validity of this finding is limited by the lack of a comparator group.\nless\nErectile dysfunction (ED). Small clinical studies suggest that oral maritime pine bark extract, taken alone or in combination with L-arginine, may modestly improve sexual function in patients with ED.\nSeveral small clinical studies in adults with ED show that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) at a dose of 120 mg daily for 3 months, either alone (12012) or in combination with L-arginine (10416, 32149, 50924), might improve sexual function when compared with placebo or baseline measurements. It seems to take up to 3 months of treatment for significant improvement. Similarly, a meta-analysis of 2 small clinical studies in males with mild to moderate ED shows that taking maritime pine 80 mg with L- arginine daily for 1-6 months improves International Index of Erectile Dysfunction scores by 9 points when compared with control (112715). It is unclear if this effect is from maritime pine, L-arginine, or the combination.\nless\nExercise-induced muscle soreness. Oral maritime pine bark extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in non-professional athletes shows that taking a combination product (PycnoRacer, Kobayashi Pharmaceutical Company) containing maritime pine extract 15 mg, L-leucine 0.6 grams, L-arginine 0.3 grams, L-isoleucine 0.3 grams, and L-valine 0.3 grams four times daily for 3 weeks during training improves subjective scores for muscle pain and cramps when compared with water plus Gatorade (103613). It is unclear if these benefits are due to maritime pine, other ingredients, or the combination.\nless\nGlaucoma. Oral maritime pine has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nOne small, unblinded clinical trial in Japanese patients with open-angle glaucoma shows that taking a specific product (Sante Glagenox, Saten Pharmaceutical Co. Ltd.) containing maritime pine extract 40 mg and bilberry fruit extract 90 mg daily for 4 weeks reduces intraocular pressure by 8.7% when compared to baseline (104192). The validity of this finding is limited by the lack of a comparator group.\nless\nHeart failure. Oral maritime pine bark extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small observational study in patients with mild to moderate heart failure has found that taking a specific combination product (PycnoQ10, Natural Health Science Inc.) containing a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) and coenzyme Q10 for 12 weeks is associated with improved exercise capacity and heart function (44178). It is unclear if these findings are due to maritime pine, coenzyme Q10, or the combination.\nless\nHemorrhoids. It is unclear if oral or topical maritime pine bark extract is beneficial in patients with hemorrhoids.\nA small clinical study in patients with acute hemorrhoidal episodes shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150-300 mg daily orally, alone or in combination with a cream containing 0.5% standardized maritime pine bark extract (Pycnogenol, Horphag Research) for 7 days, improves both quality of life and hemorrhoidal symptoms when compared with placebo tablets/cream (50912). Additionally, an observational registry study in postpartum adults with internal or external hemorrhoids found that taking this same extract of maritime pine bark 150 mg daily for 6 months, in conjunction with standard hemorrhoid care, is associated with improved symptoms, including thrombosis, pain, swelling, and bleeding, when compared to standard care alone (97416). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nHypertension. It is unclear if oral maritime pine bark reduces blood pressure; the available research is conflicting.\nA very small clinical study in patients with mild hypertension (systolic 140-159 mm Hg; diastolic 90-99 mm Hg) shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 200 mg daily for 8 weeks may modestly reduce systolic, but not diastolic, blood pressure when compared with placebo (10214). Another very small study in hypertensive patients treated with ramipril, taking this same standardized maritime pine bark extract 50 mg three times daily for 6 months, appears to further reduce diastolic, but not systolic, blood pressure (50913). Conflicting results have been reported with other maritime pine products. A small clinical study in adults with untreated, mild hypertension shows that taking a different standardized extract of maritime pine (Oligopin, DRT Group), 75 mg twice daily for 5 weeks, does not lower systolic or diastolic blood pressure when compared with placebo (97407). Also, a small clinical study in obese patients with prehypertension or hypertension shows that taking a different maritime pine bark extract (Toyo-FVG, Toyo Bio-Pharma) 200 mg daily for 12 weeks does not lower systolic or diastolic blood pressure when compared with placebo (50919).\n\nResults of meta-analyses are also contradictory. An analysis of 7 clinical trials using maritime pine bark extract 90-200 mg daily for 2-24 weeks shows no significant effect overall on systolic or diastolic blood pressure, mean arterial pressure, or pulse pressure (103609). However, an analysis of 12 trials using doses of 60-200 mg daily for 4-24 weeks shows a mean reduction of about 3 mmHg in systolic blood pressure, and about 2 mmHg in diastolic blood pressure. There was high heterogeneity between the studies, and the effect on diastolic blood pressure was only seen with a treatment duration of at least 12 weeks (103610).\nless\nIdiopathic interstitial pneumonia. Oral maritime pine bark extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small observational registry study in males less than 65 years old with idiopathic interstitial pneumonia has found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg three times daily in combination with gotu kola (Centellicum; Horphag Research) 225 mg three times daily for 8 months is associated with a modest improvement in Karnofsky Performance Scale scores and a reduction in fatigue when compared with pirfenidone (108862). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nIrritable bowel syndrome (IBS). It is unclear if oral maritime pine bark extract is beneficial in patients with IBS.\nAn observational registry study in adults with idiopathic IBS found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 4 weeks, in conjunction with standard treatment, is associated with reduced abdominal pain, cramps, and the use of medical care and rescue medications when compared to standard treatment alone. In both groups, standard treatment included specific nutritional recommendations and Buscopan Compositum, hyoscine-N-butylbromide, or acetaminophen for pain relief (97402). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nJet lag. It is unclear if oral maritime pine bark extract can prevent or treat jet leg.\nAn observational registry study found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for up to 10 days, starting 3 days before a plane flight, is associated with reduced signs and symptoms of jet lag when compared to control (97437). Additionally, a small clinical study shows that taking this extract 50 mg three times daily for 7 days, starting 2 days before a plane flight, reduces jet lag symptoms and the average duration of symptoms by a little over 1 day when compared with placebo (97412).\nless\nLeg cramps. It is unclear if oral maritime pine bark extract is beneficial for leg cramps.\nA small clinical study in patients experiencing at least 4 episodes of leg cramps per week associated with athletic activity, venous insufficiency, or an unknown cause shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 200 mg daily for 4 weeks may decrease the incidence of leg cramps when compared to baseline (15524). The validity of this finding is limited by the lack of a comparator group.\nless\nMale infertility. Although there has been interest in using oral maritime pine for male infertility, there is insufficient reliable information about the clinical effects of maritime pine for this purpose.\nMelasma. It is unclear if oral maritime pine bark extract is beneficial for melasma.\nA small clinical study in females with melasma shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 75 mg twice daily for 60 days, along with topical application of sunscreen during the day and a triple cream containing hydroquinone, tretinoin, and fluocinolone at night, improves scores related to melasma severity and aesthetics, but not quality of life, when compared with placebo plus sunscreen and triple cream (105782).\nless\nMeniere disease. It is unclear if oral maritime pine bark extract is beneficial in patients with Meniere disease.\nObservational registry research in patients with Meniere disease found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily along with standard treatment is associated with a greater reduction in the severity of tinnitus and the number of work-days lost when compared with standard treatment alone. After 6 months of treatment, about 87% of patients taking maritime pine bark were asymptomatic, compared to about 35% of patients receiving standard treatment alone (97413). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nMenopausal symptoms. Small clinical studies suggest that oral maritime pine bark extract might improve some menopausal symptoms.\nSeveral small clinical studies in patients with menopausal symptoms shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 60-200 mg daily for 2-6 months modestly reduces perimenopausal symptoms, including tiredness, headache, depression and anxiety, sleep disturbances, vaginal dryness, hot flashes, and loss of memory, when compared with placebo or control (14899, 50927, 50945).\nless\nMetabolic syndrome. It is unclear if oral maritime pine bark extract is beneficial in patients with metabolic syndrome.\nA small clinical study in patients with metabolic syndrome shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg three times daily for 6 months lowers triglyceride levels by 46 mg/dL, increases high-density lipoprotein (HDL) cholesterol levels by about 10 mg/dL, reduces fasting plasma glucose by 18 mg/dL, and lowers systolic and diastolic blood pressure by 7 mmHg and 5 mmHg, respectively, when compared to baseline. The validity of these findings is limited by the lack of statistical comparison to a control group. Taking the maritime pine bark extract was also associated with a reduction in the percentage of patients presenting with five risk factors of metabolic syndrome (91960).\nless\nOral mucositis. It is unclear if topical maritime pine bark extract is beneficial in children with chemotherapy-related oral mucositis.\nA small clinical study in children 6-15 years of age with chemotherapy-related oral mucositis shows that application of a solution containing a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 1 mg/kg in three divided doses daily for one week promotes complete healing in 58% of patients and improved healing in 38% of patients. This improvement was significantly greater than treatment with glycerine solution and similar to treatment with vitamin E solution (91964).\nless\nOsteopenia. It is unclear if maritime pine bark extract is beneficial in patients with osteopenia.\nA small clinical study in postmenopausal adults with osteopenia shows that taking a standardized extract of maritime pine bark (Oligopin, DRT Group) 150 mg daily for 12 weeks improves markers of bone turnover when compared with placebo (105783). It is unknown if maritime pine bark extract improves bone mineral density or reduces the risk of fractures in patients with osteopenia.\nless\nParkinson disease. It is unclear if oral maritime pine bark extract is beneficial in patients with Parkinson disease.\nTwo small observational studies in adults with mild to moderate Parkinson disease suggest that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 4 or 8 weeks in conjunction with carbidopa/levodopa therapy is associated with a reduction in scores for tremor, bradykinesia, and rigidity when compared with carbidopa/levodopa therapy alone. Maritime pine is also associated with an increase in the Karnofsky Performance Status Scale score from approximately 75 (cares for self, unable to carry on normal activity or do active work) to approximately 85 (normal activity with effort, some signs or symptoms of disease), compared with little to no change from a score of around 75 in the control group (103614, 112716).\nless\nPregnancy-related pain. It is unclear if oral maritime pine bark extract is beneficial for reducing pain during the third trimester of pregnancy.\nA small clinical study in patients in the third trimester of pregnancy shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 30 mg daily modestly reduces lower back pain, hip joint pain, pelvic pain, and pain due to varicose veins or calf cramps when compared with a control group (15423).\nless\nPsoriasis. It is unclear if oral maritime pine bark extract is beneficial in patients with psoriasis.\nAn observational registry study in adults with moderate to severe plaque psoriasis found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 12 weeks along with standard treatment is associated with improved quality of life, increased water and moisture content of the skin, reduced plaque severity and total affected body area, and reduced use of corticosteroids when compared with standard treatment alone (97417). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nRaynaud syndrome. It is unclear if oral maritime pine bark extract is beneficial in patients with Raynaud syndrome.\nA small clinical study in females with mild, primary Raynaud syndrome shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg twice daily for 4 weeks decreases coldness, burning pain, paresthesias, skin color changes, and low temperature areas of the hands when compared with lifestyle changes alone. The lowest finger temperature increased by 30% in those taking this product, compared with 13% in those implementing lifestyle changes alone (103615).\nless\nRestless legs syndrome (RLS). It is unclear if oral maritime pine is beneficial for RLS.\nA small observational study in adults with RLS suggests that taking maritime pine bark extract (Pycnogenol, Horphag Research) 150 mg daily along with standard management (i.e., regular sleep, exercise, vitamin C, B vitamins, proper footwear, and instruction on diet and posture) improves self-reported symptoms associated with RLS when compared to baseline. Maritime pine bark may also be associated with less analgesic use compared with standard management alone (112717). However, the interpretation of these findings, other than analgesic use, is limited by lack of a statistical comparison to the other study group.\nless\nSarcopenia. It is unclear if oral maritime pine bark extract is beneficial in patients with sarcopenia.\nObservational registry research in adults over 70 years of age with signs of muscle loss has found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily along with strength training for 2 months improves hand grip strength, walking distance, total weight lifted, number of steps climbed, and general fitness scores when compared with strength training alone (97404). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nSexual dysfunction. Oral maritime pine bark extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in females with sexual dysfunction shows that taking a specific combination tablet (Lady Prelox, Horphag Research) containing a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 20 mg, L-arginine 200 mg, L-citrulline 200 mg, and a standardized rose hip extract (Rosvita) orally 50 mg daily for 8 weeks, in combination with a management program consisting of lifestyle, diet, exercise, and stress control changes, improves overall sexual function when compared with the management program alone (91963). Taking the same product in a dose of 2 tablets twice daily for 8 weeks, in addition to the lifestyle management program, improves vaginal dryness in pre- and post-menopausal patients when compared with lifestyle management alone (103611). The effect of maritime pine alone on sexual dysfunction is unclear.\nless\nSjogren syndrome. It is unclear if oral maritime pine bark extract is beneficial in patients with Sjogren syndrome.\nA very small observational study in patients with Sjogren syndrome found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily in addition to standard therapy is associated with a reduction in dry eye, dry mouth, and the need for corticosteroids when compared with standard therapy alone (100360).\nless\nSystemic lupus erythematosus (SLE). It is unclear if oral maritime pine bark extract is beneficial in patients with SLE.\nA very small clinical study in adults with SLE shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 120 mg daily for 30 days, followed by 60 mg daily for 30 days, modestly reduces symptoms of SLE in some patients when compared with control (50851).\nless\nTraumatic brain injury (TBI). It is unclear if oral maritime pine bark extract is beneficial in patients with TBI.\nA clinical study in patients admitted to the intensive care unit with TBI shows that administering a standardized maritime pine bark extract (Oligopin, DRT Group) 50 mg three times daily with enteral nutrition for 10 days improves scores on the sequential organ failure assessment (SOFA) and APACHE II [Acute Physiology and Chronic Health Evaluation II], as well as nutritional status, when compared with placebo. At day 28, survival rate was 86% in the treatment group, compared to 71% in the placebo group; however, this difference was not statistically significant (108861).\nless\nUrinary tract infections (UTIs). It is unclear if oral maritime pine bark extract is beneficial in patients with recurrent UTIs or interstitial cystitis.\nAn observational registry study in adults aged 30-40 years with a recent history of recurrent UTIs has found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 2 months is associated with a normal urinalysis in 92% of patients, compared with 68% of those who received no supplementation (108860). Another observational registry study in patients with recurrent UTIs or interstitial cystitis has found that taking this same dose for 2 months is associated with a normal urinalysis in 100% of patients, compared with 35% of patients who took oral cranberry extract 400 mg daily and 36% of those who received no treatment (108859). However, the validity of these findings is limited by the unblinded, non-randomized nature of these studies.\nless\nVaricose veins. It is unclear if oral maritime pine bark extract is beneficial in patients with varicose veins.\nObservational registry research in postpartum adults has found that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg daily for 6 months, in addition to using below-knee compression stockings, is associated with reduced edema, leg cramps, total number of varicose veins, and number of visible spider vein clusters when compared with compression stockings alone (97403). However, the validity of these findings is limited by the unblinded, non-randomized nature of the study.\nless\nVenous thromboembolism (VTE). While some conflicting evidence exists, low-quality clinical research suggests that oral maritime pine bark extract might prevent superficial thrombosis during flights and reduce the incidence of post-thrombotic syndrome (PTS) in patients with a history of deep vein thrombosis (DVT).\nObservational registry research has found that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 10 days is not associated with reduced occurrence of DVT, a type of VTE, when compared with compression stockings or control (97437). However, an older clinical study in patients at moderate or high risk for thrombotic events shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 200 mg 2-3 hours before a flight seems to reduce superficial thrombosis, but not DVT risk, when compared with placebo (50874). Some observational research also has also found that taking standardized maritime pine bark extract (Pycnogenol, Horphag Research) is associated with reduced post-thrombotic syndrome (PTS) and recurrent DVT (100355). Also, some clinical research shows that taking standardized extract of maritime pine bark (Pycnogenol, Horphag Research) daily for one year, while wearing or not wearing compression stockings, reduces the incidence of PTS in patients with a single prior episode of DVT (50925).\n\nMaritime bark has also been studied in combination with other natural products. There is some evidence that taking a specific combination product (Flite Tabs, Aidan Products) before a flight and then again 6 hours later might decrease the risk of DVT during long-haul plane flights in high-risk patients. The product combines a blend of 150 mg of standardized extract of maritime pine bark (Pycnogenol, Horphag Research) plus nattokinase (12075).\nless\nWrinkled skin. It is unclear if oral maritime pine bark extract can reduce wrinkles or improve skin health in people with significant sun exposure.\nA small crossover study in Chinese adults working outdoors shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 50 mg twice daily for 12 weeks improves skin hydration and reduces transepidermal water loss and skin darkening when compared with placebo (105784).\nless\nBehcet syndrome. It is unclear if oral maritime pine bark extract is beneficial in patients with Behcet syndrome.\nA small clinical study in patients with Behcet syndrome shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 3 weeks reduces skin ulcer size and improves self-reported symptoms of burning and pain when compared to baseline (100358). The validity of these findings is limited by the lack of a comparator group.\nless\nMore evidence is needed to rate maritime pine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMaritime pine bark extract has most often been used at a dose of 50 mg, taken 2-3 times daily, for up to 1 year. Doses of up to 450 mg daily for up to 1 year have also been used. See Effectiveness section for condition-specific information.\nTopical:\nMaritime pine bark extract has been used in various topical formulations, including as a topical powder and cream. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nPycnogenol is a patented product manufactured by Horphag Research. It is prepared by powdering fresh maritime pine bark and then extracting with water and ethanol. Pycnogenol is standardized to contain about 70% procyanidin (50933). Oligopin is a patented product manufactured by DRT Group. It is standardized to contain >96% total polyphenols and 67% to 75% oligomeric proanthocyanidins, a subtype of procyanidin (97407).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, maritime pine bark extract might increase the risk of bleeding when used with antiplatelet or anticoagulant drugs.\nClinical research suggests that maritime pine bark extract inhibits platelet aggregation (3283, 50844, 50942). However, the clinical significance of this effect is unclear.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, maritime pine bark extract might increase the risk of hypoglycemia when used with antidiabetes drugs.\nOne clinical study shows that maritime pine bark extract decreases blood sugar in patients with diabetes being treated with antidiabetes agents (15522). Monitor blood glucose levels closely. Dose adjustments might be necessary.\nless\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, maritime pine bark extract might decrease the effectiveness of immunosuppressant therapy.\nIn vitro and animal research suggests that maritime pine bark extract has immunostimulant activity (2435, 2636). This effect has not been reported in humans.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, maritime pine might have antiplatelet effects.\nTaking maritime pine with other products that increase the risk of bleeding might have additive effects. Clinical research suggests that maritime pine bark extract may inhibit platelet aggregation (3283, 50844, 50942). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nMaritime pine might have hypoglycemic effects.\nTaking maritime pine with other products with hypoglycemic potential might increase the risk of hypoglycemia. One clinical study shows that maritime pine bark extract can decrease blood sugar (15522). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nAUTOIMMUNE DISEASES\nTheoretically, maritime pine might have immune stimulating effects; until more is known, avoid using in patients with multiple sclerosis, systemic lupus erythematosus (SLE), rheumatoid arthritis, or other autoimmune disorders. In vitro and animal research suggests that maritime pine bark extract has immune stimulating effects (2435, 2636).\nless\nBLEEDING CONDITIONS\nMaritime pine might have antiplatelet activity; use with caution in patients with bleeding conditions. Clinical research suggests that maritime pine bark extract inhibits platelet aggregation (3283, 50844, 50942).\nless\nPERIOPERATIVE\nMaritime pine bark extract has antiplatelet and hypoglycemic effects (3283, 15522, 50844, 50942), which might cause excessive bleeding or interfere with blood glucose control if used perioperatively. Tell patients to discontinue maritime pine at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with maritime pine.",
            "Pharmacokinetics": "Absorption\nFollowing a single oral intake of a standardized extract of maritime pine bark (Pycnogenol, Horphag Research), at least five known constituents can be detected in plasma starting within 30 minutes of ingestion. These constituents include catechin, caffeic acid, ferulic acid, taxifolin, and M1 (delta-(3,4-dihydroxy-phenyl)-gamma-valerolactone) (50894). Topical application of this same extract of maritime pine bark to ex-vivo human skin results in the absorption of detectable quantities of gallic acid, protocatechuic acid, catechin, p-hydroxybenzoic acid, and vanillin (97409).\nMetabolism\nConstituents of maritime pine bark extract are metabolized through glucuronide and sulfate conjugation (2431, 2543, 10212, 50894).\nExcretion\nFerulic acid and taxifolin conjugates of a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) are excreted in the urine within 18-24 hours. Conjugated metabolites of the procyanidin fraction are excreted within 28-34 hours (2431, 2543, 10212).",
            "Mechanism of Action": "General\nThe applicable part of maritime pine is the bark. Pycnogenol is the US registered trademark for a specific extract derived from maritime pine bark (2431, 2641). Pycnogenol contains several active constituents including flavonoid monomers such as catechin, epicatechin, and taxifolin. It also contains condensed procyanidins (also called flavonoids or proanthocyanidins) such as procyanidin B1, B3, B6, and B7 which are dimers, oligomers, and polymers of catechin and epicatechin (2431, 2433). Pycnogenol also contains phenolic acids including gallic, ferulic, caffeic, vanillic, p-coumaric, protocatechuic, and p-hydroxybenzoic acids, and their glucosides and glucose esters (2431, 2433, 2435, 2543).\nAnti-inflammatory effects\nVarious studies have investigated the anti-inflammatory effects of maritime pine bark extract. In humans, a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) has been shown to inhibit NF-kappa activation (50889), inhibit cyclooxygenase (COX)-1 and COX-2 activity (50888), and reduce C-reactive protein (CRP) levels (50907, 108863). Other clinical research shows that taking this specific extract decreases erythrocyte sedimentation rate (ESR) and reduces interleukin (IL)-6 (108863). Animal research suggests that this extract can reduce myeloperoxidase activity in rats with inflammatory bowel disease (50879). In vitro research shows that the standardized maritime pine bark extract may also reduce the production of IL-1 and IL-2 (50848, 50853). However, other research suggests that this extract does not affect levels of various inflammatory markers including CRP, IL-1, or IL-6 (7694). Human research in patients admitted to the intensive care unit with a traumatic brain injury shows that receiving a different standardized extract of maritime pine bark (Oligopin, DRT Group) reduces levels of IL-6, IL-1 beta and CRP after 10 days when compared with placebo (108861).\nAntiallergic effects\nSome clinical research shows that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) can improve symptoms of allergic rhinitis (17300). Preliminary research from animal models suggests that this effect may result from the ability of this extract to inhibit histamine release from mast cells; the effect is comparable to sodium cromoglycate (50862). Other evidence suggests that the antiallergic effects of this extract stem from its anti-inflammatory potential. Ex vivo research shows that this standardized maritime pine bark extract can inhibit lipooxygenase, leukotriene, and cyclooxygenase release from neutrophils (17300).\nAntiarthritic effects\nFor arthritis, a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) is thought to be beneficial due to its anti-inflammatory effects. In patients with osteoarthritis, this maritime pine bark extract was shown to reduce C-reactive protein levels (50907).\nAntiasthmatic effects\nFor asthma, a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) is thought to be beneficial due to its anti-inflammatory and antioxidant effects. In children with asthma taking this maritime pine bark extract decreases urinary levels of leukotrienes compared to placebo (13120).\nAnticancer effects\nIn vitro research shows that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) can cause differentiation and apoptosis in leukemia and breast cancer cells (50847, 50882). Also, evidence from animal research shows that this extract can protect against the toxicity and mutagenicity of chronic cigarette smoke exposure by up to 48%. The effect has been attributed to the antioxidant effects of the maritime pine bark extract (50866). In particular, in vitro research shows that the standardized extract of maritime pine bark can inhibit the metabolic activation of NNK, a tobacco-specific nitrosamine that plays a role in the carcinogenicity of tobacco (50835, 50836).\nAntidiabetic effects\nFor lowering blood glucose in patients with type 2 diabetes, the mechanism is unclear, but a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) does not seem to have an effect on insulin secretion (15522). Evidence from animal research suggests that the antidiabetic effects of this standardized maritime pine bark extract relate to its ability to reduce oxidative stress (50864, 50877). Oxidative stress is believed to play a role in the pathogenesis of diabetes and contribute to diabetes-related complications such as retinopathy, neuropathy, and nephropathy (91958, 91959).\nAntimicrobial effects\nIn vitro research shows that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) can inhibit the growth of various strains of Gram positive and Gram negative bacteria, yeast, and fungi (50885). Also, this extract appears to inhibit the growth of Escherichia coli O157:H7, Salmonella typhimurium, Listeria monocytogenes, and Aeromonas hydrophila bacteria in raw and cooked ground beef, suggesting it has potential use as a food preservative (50868, 50895).\nAntioxidant effects\nA standardized extract of maritime pine bark (Pycnogenol, Horphag Research) contains constituents with antioxidant effects, including the ability to recycle ascorbyl and tocopheryl radicals, helping to maintain vitamin C and E levels. These effects are thought to help prevent capillary permeability in patients with chronic venous insufficiency, to help improve athletic performance, and to help prevent retinopathy (2433, 2435, 2636, 2542, 2451, 2554, 7698). Also, evidence from animal research suggests that the antidiabetic effects of this extract relate to its ability to reduce oxidative stress in diabetic rats (50864, 50877, 50878). In vitro research has also shown that the standardized extract of maritime pine bark can inhibit the production of nitric oxide (NO) by macrophage cells (50940). The ability of this extract to protect DNA from radical-induced damage is controversial. Some in vitro research suggests that it protects DNA from damage by radicals (50875, 50876). However, other research suggests that it does not protect DNA from radical damage nor does it improve the ability of DNA to repair itself (50922).\nAntispasmodic effects\nFor pelvic pain, preliminary research suggests the ferulic acid and caffeic acid constituents of a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) have antispasmodic effects and can inhibit uterine contractions (15424).\nAntiviral effects\nA standardized extract of maritime pine bark (Pycnogenol, Horphag Research) has demonstrated antiviral activity in myocardial and liver cells. In mice infected with encephalomyocarditis (EMC) virus, maritime pine bark suppresses viral replication and reduces the extent of myocardial infiltration and necrosis (97411). In vitro research shows that maritime pine bark extract also suppresses the replication of hepatitis C virus (HCV) in mouse liver cells. Combining maritime pine bark extract with ribavirin and interferon-alpha (IFN-alpha), or with telaprevir, enhances the suppression of HCV replication. Two constituents of maritime pine, procyanidin and taxifolin, did not suppress replication of HCV, indicating that the antiviral activity of maritime pine derives from other constituents (97418).\nCardiovascular effects\nIn chronic venous insufficiency, procyanidins in a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) reduce capillary permeability, which contributes to edema and microbleeding, by cross-linking capillary wall proteins such as collagen and elastin (2435, 2544). There is also some evidence that procyanidins make elastin more resistant to degradation by elastase (2451, 2635), and that this extract might inhibit elastase and collagenase released by activated macrophages (2462). The standardized extract of maritime pine bark might also help prevent capillary permeability due to the antioxidant effects of several of its constituents (2433, 2435, 2636, 2542, 2451). The extract also seems to recycle ascorbyl and tocopheryl radicals, helping to maintain vitamin C and E levels, which is thought to help protect endothelial cells, improve vasorelaxation, and strengthen capillary and vascular integrity (2542, 7698). In humans with chronic venous insufficiency, taking the standardized maritime pine bark extract seems to improve the recovery of venous segments after ex vivo stretching and reduce passive dilation. This suggests that the extract helps improve the elasticity and tone of vein walls in patients with chronic venous insufficiency (91961). A small observational study in adults with restless legs syndrome suggests that taking maritime pine bark extract may improve positional limb blood flow (i.e., venoarteriolar reflex) measured by laser Doppler flowmetry (112717).\n\nSome research suggests that standardized extract of maritime pine bark (Pycnogenol, Horphag Research) might be useful in the prevention of cardiovascular disease. In vitro, this extract prevents oxidation of low-density lipoprotein (LDL) cholesterol and protects DNA from damage by free radicals (2433). It also seems to prevent free-radical induced endothelial damage in vitro (2433). In addition, in vitro research shows that the extract can reduce the expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) (50846). This suggests that standardized maritime pine bark extract may help prevent atherogenic processes. The standardized maritime pine bark extract inhibits epinephrine-induced platelet aggregation, such as that seen in smokers (2435, 3285), but it does not appear to increase bleeding risk or affect smoking-related increases in blood pressure or heart rate (3283). In non-smokers, it decreases serum thromboxane B2 and reduces systolic blood pressure (10214). The extract inhibits angiotensin converting enzyme (ACE) in vitro, but is unlikely to have clinically significant hypotensive effects when used orally in humans (2435). The standardized maritime pine bark extract might also increase production of nitric oxide from vascular endothelial cells by stimulating nitric oxide synthetase. This can lead to vasodilatation and possibly reduce the potential for atherogenesis and thrombus formation (2433, 2451, 2545, 2637, 50923). In human studies, taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) for 30 months attenuated atherosclerotic plaque progression in healthy asymptomatic adults with non-stenosing plaques (97415). Increased nitric oxide production might also be the mechanism for the possible benefit of the extract in erectile dysfunction (10416, 12012), hypertension (16906), and sexual enjoyment in peri-menopausal women (14899). Increased nitric oxide might also play a role in reducing vasomotor symptoms in peri-menopausal women.\nCoagulation effects\nA standardized extract of maritime pine bark (Pycnogenol, Horphag Research) inhibits epinephrine-induced platelet aggregation, such as that seen in smokers (2435, 3285). This effect is attributed to the ability of the extract to lower thromboxane B2 levels in smokers (50844). However, the extract does not appear to lower TxB2 levels in nonsmokers, nor does it appear to increase bleeding risk (3283, 50844).\nDermatologic effects\nThere is interest in using a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) to protect against sunburn. Skin exposure to ultraviolet radiation has been shown to increase levels of free radicals that can damage the skin. It is theorized that the extract may counteract the damaging effects of ultraviolet radiation through its antioxidant effects. Oral supplementation with the standardized maritime pine bark extract at doses of 1.10 mg/kg/day for four weeks followed by 1.66 mg/kg/day for an additional 4 weeks increases the amount of ultraviolet radiation, both UVA and UVB, required to cause erythema and pinkness of the skin in human volunteers. The higher dose appears more protective than the lower dose, since a greater amount of ultraviolet radiation is required to cause erythema when the higher dose is taken (7696).\n\nSome research suggests that topical maritime pine bark extract might be useful for skin diseases related to increased cell adhesion and inflammation such as psoriasis, atopic dermatitis, and lupus erythematosus. Preclinical research suggests that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) reduces inflammation in keratinocytes (10213). Research in animal models of wound healing suggests that gel formulations containing 1%, 2%, and 5% extract reduce wound healing time in a concentration-dependent manner. Researchers theorize that the standardized maritime pine bark extract might bind to collagen and elastin in wounds and inhibit the activity of metalloproteinases, which can slow wound healing (15422).\n\nThere is also interest in the effects of maritime pine bark on scalp circulation. A small clinical study in menopausal females shows that taking maritime pine bark (Pycnogenol, Horphag Research) 150 mg daily for 6 months increases peripheral microcirculation of blood at the scalp when compared to baseline (112713). However, interpretation of this finding is limited by lack of statistical comparison to the placebo group.\nErgogenic effects\nTaking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) while training for exercise tests or a triathlon appears to improve performance during the tests/competitions compared to training alone. This effect has been attributed to the ability of the extract to reduce oxidative stress (91966). In adults over 70 years of age, taking this standardized extract of maritime pine bark improves muscle function and measurably reduces oxidative stress (97404).\nHematologic effects\nIn vitro research shows that a standardized maritime pine bark extract (Pycnogenol, Horphag Research) can inhibit the formation of dense cells. Dense cells adhere to neutrophils, platelets, and vascular endothelial cells and have the potential to cause vaso-occlusion in patients with sickle cell anemia (5056). Also, a small clinical study in patients with tinnitus shows that taking a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) 100-150 mg daily for approximately 34 days improves cochlear arterial blood flow (50917).\nHepatic effects\nThere is developing interest in using maritime pine as a hepatoprotective agent. In vitro research shows that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) facilitates degradation of PLIN2 mRNA in mouse liver cells. PLIN2 is present in high quantities in fatty liver disease and atherosclerosis and is associated with hepatic lipid accumulation (97414).\nImmunostimulant effects\nLaboratory research shows that a standardized extract of maritime pine bark (Pycnogenol, Horphag Research) might stimulate the immune system. It seems to boost natural killer cell activity (2435) and improve T- and B-cell function in animal models (2636). This standardized extract also increases tumor necrosis factor-alpha (TNF-alpha) secretion and nuclear factor-KB (NF-KB) activity (7697). The standardized maritime pine bark extract appears to slow the development of immune dysfunction in animal models infected with a retrovirus similar to human immunodeficiency virus (HIV) by restoring imbalanced T-helper 1 and T-helper 2 cytokine secretion (7695).\n\nIn immunosuppressed animals infected with Cryptosporidium parvum, a protozoan that causes intestinal tract infection, a standardized maritime pine bark extract (Pycnogenol, Horphag Research) appears to increase oocyst shedding, although it does not appear to reduce tissue colonization (50852).\nNeurologic/CNS effects\nA standardized extract of maritime pine bark (Pycnogenol, Horphag Research) might have some activity in Alzheimer disease. In vitro, the extract protects animal brain cells from the toxic effects of high levels of glutamate, and also from the toxic effects of amyloid-beta-protein, which is found in the plaques characteristic of Alzheimer disease (2435, 7699, 50840, 50855). This protective potential has been attributed to the antioxidant effects of maritime pine bark extract (50855). In clinical research of healthy adults with high oxidative stress, this standardized maritime pine bark extract measurably reduces oxidative stress and improves cognitive function (97405, 97410).\n\nFor attention deficit hyperactivity disorder (ADHD), maritime pine bark is thought to be beneficial due to its antioxidant effects. In children with ADHD, the standardized maritime pine bark extract has been shown to increase reduced glutathione levels, reduce oxidized glutathione levels, reduce oxidative damage to DNA, and improve total antioxidant status, as well as normalize urinary catecholamine concentrations and decrease dopamine concentrations (50898, 50899, 50902).\nRenal effects\nMaritime pine bark extract is reported to improve renal cortical blood flow and reduce urinary albumin excretion (103609). It is also reported to inhibit angiotensin converting enzyme (ACE) (103609).\nSexual function enhancement\nPreliminary research shows that taking a combination product containing standardized extract of maritime pine bark (Pycnogenol, Horphag Research), L-arginine, L-citrulline, and rose hip extract (Lady Prelox, Horphag Research, Geneva, Switzerland) improves sexual function in women with sexual dysfunction. This effect has been attributed to the ability of the combination product to decrease oxidative stress.\nWeight loss effects\nThere is a developing interest in using a standardized extract of maritime pine bark to prevent obesity. In vitro, the extract appears to inhibit insulin-induced lipogenesis and may stimulate lipolysis (8307, 50839, 50880)."
        }
    },
    "Marjoram": {
        "sections": {
            "Overview": "Marjoram is a bushy perennial herb that grows to about 60 centimeters in height. It is native to areas around the Mediterranean (11, 18, 95324). Marjoram essential oil is steam-distilled from the leaves and flowers (11).",
            "Safety": "LIKELY SAFE when used in amounts commonly found in foods. Marjoram and its essential oil have Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when the leaf is used orally and appropriately in tea, short-term (12, 18). ...when marjoram oil is used orally and appropriately, short-term (11).\nPOSSIBLY UNSAFE when the flower, leaf, and oil are used orally, long-term. Marjoram contains arbutin, a hydroquinone glycoside (2, 18). Studies in animals suggest that long-term use of hydroquinone can damage the liver and kidneys and might cause cancer (2, 76395, 95524).\n\nThere is insufficient reliable information available about the safety of marjoram when used topically.\nPREGNANCY: POSSIBLY UNSAFE when used in medicinal amounts; marjoram has the potential for stimulating menstruation (19, 95324). Avoid amounts greater than those found in foods.\nLACTATION: Insufficient reliable information available; avoid amounts greater than those found in foods.",
            "Adverse Effects": "General\nOrally, marjoram and its essential oil are well tolerated in amounts commonly found in foods (4912). Marjoram leaf and marjoram oil seem to be well tolerated when used appropriately for medicinal purposes (2, 11, 12, 18). However, marjoram flower, leaf, and oil should not be used long-term due to the arbutin content (2, 76395, 95524).\n\nTopically, there are rare reports of allergic skin reactions with marjoram use (33865, 58049).\nImmunologic\nPossible allergic contact dermatitis in children with pre-existing childhood atopic eczema was observed in a randomized clinical trial employing extended use of essential oils, including sweet marjoram essential oil (58049). A case report describes a 38-year old woman who had an exacerbation of perioral dermatitis after eating food seasoned with marjoram. The dermatitis resolved within 3 weeks on a marjoram-free diet, but reappeared when she was rechallenged with marjoram (33865).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. Preliminary clinical research in adults shows that taking marjoram oil 2 drops daily for 3 months along with conventional treatment for asthma improves some measures of lung function. Forced vital capacity (FVC) increased by 0.3 mL with marjoram compared to 0.1 mL in the control group. The forced expiratory volume in 1 second (FEV1) increased by 4.1% with marjoram compared to 2.7% with control. While these improvements were statistically significant compared to baseline, statistical analysis between groups was lacking (76944).\nDysmenorrhea. Preliminary clinical research in women aged 19-45 years with primary dysmenorrhea shows that massaging the lower abdomen with a cream containing lavender, clary sage, and marjoram essential oils (2:1:1 ratio) diluted in unscented jojoba cream to a 3% concentration, in a dose of two grams daily, starting at the end of menstruation and continuing until the beginning of the next, might decrease the level and duration of pain when compared with a placebo cream containing synthetic fragrances. The decrease in pain duration, from 2.4 days to 1.8 days in the essential oils group, was statistically significant when compared to baseline (58095). It is unclear if these effects are due to marjoram, other ingredients, or the combination.\nParkinson disease. Preliminary clinical research in patients with Parkinson disease who are stabilized on levodopa shows that drinking a tea containing 5 grams of dried marjoram leaf daily for 30 days does not lower Unified Parkinson Disease Rating Scale part III motor scores (USPDRSIII), but does decrease scores on the Non-Motor Symptoms Scale (NMSS) and the Beck Depression Inventory (BDI), when compared with placebo tea (108498).\nPolycystic ovary syndrome (PCOS). Preliminary clinical research shows that drinking marjoram leaf tea 250 mL twice daily for 1 month modestly reduces levels of dehydroepiandrosterone sulfate (DHEA-S) and insulin in women with PCOS. Body weight, fasting glucose, and serum levels of follicle-stimulating hormone, luteinizing hormone, progesterone, and testosterone did not improve (95325).\nMore information is needed to rate marjoram for these uses.",
            "Dosing & Administration": "Adult\nOral:\nAsthma: Two drops of marjoram essential oil daily for three months has been used in addition to conventional treatment (76944).\n\nPolycystic ovary syndrome (PCOS): A tea prepared from 1.3-1.5 grams of dried marjoram leaf steeped in 250 mL of boiled water for 20 minutes has been used twice daily for one month (95325).\nTopical:\nDysmenorrhea: Applying a cream containing lavender, clary sage, and marjoram essential oils (2:1:1 ratio) diluted in unscented jojoba cream to a 3% concentration to the lower abdomen daily has been used from the end of one menstruation until the beginning of the next (58095).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of marjoram.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro research suggests that marjoram extract can inhibit acetylcholinesterase activity (31438, 76912). Theoretically, using marjoram in medicinal amounts along with anticholinergic drugs might decrease the effectiveness of marjoram or the anticholinergic agent.\nSome anticholinergic drugs include atropine, benztropine (Cogentin), biperiden (Akineton), procyclidine (Kemadrin), and trihexyphenidyl (Artane).\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro research suggests that marjoram extract inhibits platelet aggregation and adhesion (76932). Theoretically, marjoram might increase the risk of bleeding when used in medicinal amounts along with antiplatelet or anticoagulant drugs.\nSome anticoagulant or antiplatelet drugs include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), and others.\nless\nCHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro research suggests that marjoram extract can inhibit acetylcholinesterase activity (31438, 76912). Theoretically, using marjoram in medicinal amounts along with cholinergic drugs might have additive effects and increase the risk of cholinergic side effects.\nCholinergic drugs include bethanechol (Urecholine), donepezil (Aricept), echothiophate (Phospholine Iodide), edrophonium (Enlon, Reversol, Tensilon), neostigmine (Prostigmin), physostigmine (Antilirium), pyridostigmine (Mestinon, Regonol), succinylcholine (Anectine, Quelicin), and tacrine (Cognex).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nIn vitro research suggests that marjoram extract inhibits platelet aggregation and adhesion (76932). Theoretically, concomitant use with herbs with antiplatelet effects could increase the risk of bleeding in some people. These herbs include angelica, danshen, garlic, ginger, ginkgo, red clover, turmeric, willow, Panax ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nEvidence from in vitro research suggests that marjoram may inhibit platelet aggregation (76932). Theoretically, marjoram may increase the risk of bleeding in patients with bleeding disorders when used in medicinal amounts. Use with caution.\nless\nBRADYCARDIA\nMarjoram seems to inhibit acetylcholinesterase (AChE) and might increase acetylcholine levels and have cholinergic effects (31438, 76912). AchE inhibitors are used with caution or are contraindicated in people with bradycardia. Avoid using medicinal amounts of marjoram in people with these conditions until more is known about its effects in humans.\nless\nCROSS-ALLERGENICITY\nMarjoram can cause allergic reactions in people allergic to other plants in the Lamiaceae family, including basil, hyssop, lavender, mint, oregano, and sage (3705).\nless\nGASTROINTESTINAL TRACT OBSTRUCTION\nMarjoram seems to inhibit acetylcholinesterase (AChE) and might increase acetylcholine levels and have cholinergic effects (31438, 76912). AchE inhibitors are used with caution or are contraindicated in people with gastrointestinal tract obstruction. Avoid using medicinal amounts of marjoram in people with this condition until more is known about its effects in humans.\nless\nPEPTIC ULCER DISEASE\nMarjoram seems to inhibit acetylcholinesterase (AChE) and might increase acetylcholine levels and have cholinergic effects (31438, 76912). AchE inhibitors are used with caution or are contraindicated in people with peptic ulcer disease. Avoid using medicinal amounts of marjoram in people with this condition until more is known about its effects in humans.\nless\nPULMONARY CONDITIONS\nMarjoram seems to inhibit acetylcholinesterase (AChE) and might increase acetylcholine levels and have cholinergic effects (31438, 76912). AchE inhibitors are used with caution or are contraindicated in people with pulmonary conditions, including asthma and chronic obstructive pulmonary disease. Avoid using medicinal amounts of marjoram in people with these conditions until more is known about its effects in humans.\nless\nSEIZURES\nMarjoram seems to inhibit acetylcholinesterase (AChE) and might increase acetylcholine levels and have cholinergic effects (31438, 76912). AchE inhibitors are used with caution or are contraindicated in people with seizures. Avoid using medicinal amounts of marjoram in people with this condition until more is known about its effects in humans.\nless\nSURGERY\nEvidence from in vitro research suggests that marjoram may inhibit platelet aggregation (76932). Theoretically, using marjoram in medicinal amounts might cause excessive bleeding if used perioperatively. Tell patients to discontinue using medicinal amounts of marjoram at least 2 weeks before elective surgical procedures.\nless\nUROGENITAL TRACT OBSTRUCTION\nMarjoram seems to inhibit acetylcholinesterase (AChE) and might increase acetylcholine levels and have cholinergic effects (31438, 76912). AchE inhibitors are used with caution or are contraindicated in people with urogenital tract obstruction. Avoid using medicinal amounts of marjoram in people with this condition until more is known about its effects in humans.\nless",
            "Interactions with Lab Tests": "None Known",
            "Overdose": "Arbutin, also known as hydroquinone-beta-D-glucopyranoside or 4-hydroxyphenyl-beta-D-glucopyranoside, is present in marjoram extracts in variable amounts depending on the source. A preparation of the dried, ground herb contained a mean of 35.2-62.4 mg arbutin per gram. Samples of marjoram available commercially for culinary use contained 1.9-40.4 mg arbutin per gram (95524). There is concern that hydroquinone and other metabolites released from arbutin in the colon may have toxic effects, although the amount of marjoram that would need to be ingested to produce toxicity is unknown. These metabolites have hepatotoxic, nephrotoxic, mutagenic, and carcinogenic effects in animal studies (76935, 95524).",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of marjoram.",
            "Mechanism of Action": "General\nThe applicable parts of marjoram are the leaves and flowers and the essential oil distilled from these parts (11). Constituents of marjoram include terpinenes, p-cymene, 4-terpineol, terpinolene, sabinene, linalool, beta-caryophylline, borneol, carvachrol, sabinene, linalyl acetate, ocimene, cadinene, alpha-pinene, geranyl acetate, citral, estragole, eugenol, 3-carene, flavonoid glycosides, arbutin, tannins, carnosol, caffeic acid, labiatic acid, carnosic acid, sinapic acid, ferulic acid, coumarinic acid, syringic acid, vanillic acid, ursolic acid, rosmarinic acid, rutin, catechin, hydroquinone, steroids including beta-sitosterol, flavonoids, triterpenoids, quercetin, luteolin, and kaempferol glycosides, and vitamins A and C (11, 76916, 76922, 76926, 76933, 95324, 108497, 108498).\nAcetylcholinesterase inhibitor activity\nMarjoram herb extracts and essential oil are reported to have acetylcholinesterase inhibitory activity in vitro (31438, 76912). Constituents thought to be responsible for this activity include ursolic acid and alpha-pinene (31438, 76912, 95324).\nAnti-inflammatory effects\nSabinene hydrate and terpineol present in marjoram essential oil suppress production of several inflammatory mediators, including tumor necrosis factor alpha (TNF-alpha), interleukin-1-beta (IL-1-beta), IL-6, and IL-10. The essential oil also inhibits COX-2 and NF-kappa-B gene expression (95324).\nAntidiabetic effects\nIn vitro research suggests that a marjoram extract has agonist activity at the peroxisome proliferator-activated receptor gamma (PPAR-gamma), improving insulin sensitivity (38442, 95325). Constituents thought to be responsible for this activity include rosemarinic acid, luteolin, and hydroquinone glycosides (95323).\nAntimicrobial effects\nA methanol extract of marjoram has activity in vitro against Bacillus subtilis, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, and Staphylococcus aureus. It also has activity against several fungi including Aspergillus niger, and Candida albicans (76928, 95324). A marjoram extract has also been reported to have activity against Sporothrix brasiliensis, the fungus causing sporotrichosis (95521).\nAntioxidant effects\nAqueous extracts of marjoram herb and essential oil have antioxidant activity that is thought to be due to flavonoids, hydroxycinnamic acid, ursolic acid, carnosic acid, carnosol, rosmarinic acid, and caffeic acid (30627, 59327, 76913, 76936, 95324),\nAntiplatelet effects\nA methanol extract of marjoram leaves inhibited platelet aggregation induced by adenosine diphosphate (ADP), arachidonic acid, collagen, and thrombin. This activity is associated with the arbutin constituent (76932, 95324, 95522).\nAntiviral effects\nAn aqueous extract of marjoram herb had in vitro activity against the herpes simplex virus (11, 18).\nCardiac effects\nIn isolated rat hearts, perfusion with an extract of dried marjoram leaves reduces myocardial damage after ischemia-reperfusion, possibly by dilating coronary arteries and increasing antioxidant activity in the myocardium, leading to reduced apoptosis of cardiomyocytes. The extract also reduces the contractile response to the vasoconstrictor norepinephrine in an isolated aorta preparation (108499).\nDermatological effects\nArbutin isolated from marjoram extracts, and its metabolite hydroquinone, have skin-lightening effects as a result of reduced melanin formation in melanocytes, due to inhibition of tyrosinase (76935).\nGastroprotective effects\nAn ethanol extract of marjoram decreased gastric acid secretion and the incidence of experimentally induced ulcers in animals (76934, 95324).\nPsychiatric effects\nIn an animal model of depression, research shows that giving a polyphenol extract of marjoram leaves in a dose of 50-100 mg/kg orally daily for 21 days decreases depression scores when compared with untreated controls. Score reductions were similar to those seen with paroxetine 11.5 mg/kg daily (108497)."
        }
    },
    "Marsh Blazing Star": {
        "sections": {
            "Overview": "",
            "Safety": "There is insufficient reliable information available about the safety of marsh blazing star.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, marsh blazing star, which contains coumarin, can be associated with nausea and vomiting (286), diarrhea, dizziness, insomnia (287), asymptomatic SGOT elevations (286), and liver toxicity (6, 18).\n\nTopically, handling the plant can cause contact dermatitis (3837).\n\nMarsh blazing star can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of marsh blazing star.",
            "Dosing & Administration": "Adult\nORAL: The ground root is used as tea (6).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nCan cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The applicable part of marsh blazing star is the root. Marsh blazing star contains coumarin as its active principle (18). However, coumarin itself is not an anticoagulant. It has only 0.1%-0.02% of the anticoagulant effect of bishydroxy-coumarin (295). Some studies suggest coumarin might be effective in reducing edemas and inflammations by increasing venous and lymphatic return (295)."
        }
    },
    "Marsh Labrador Tea": {
        "sections": {
            "Overview": "Marsh Labrador tea is prepared from the leaves of a small, evergreen shrub, Rhododendron tomentosum, that grows in nutrient-poor, acidic soils of humid areas in North America, Europe, and Asia. Traditionally, it has been used by the indigenous peoples of North America as an abortifacient, diaphoretic, diuretic, expectorant, galactagogue, and narcotic (97164).",
            "Safety": "LIKELY UNSAFE when large amounts are used orally to induce abortion (2). The essential oil of marsh Labrador tea can cause severe gastrointestinal tract irritation, kidney and urinary tract damage, and paralysis (2).\nThere is insufficient reliable information available about the safety of marsh Labrador tea for its other uses.\nPREGNANCY: LIKELY UNSAFE when used orally; avoid using (2, 19). Marsh Labrador tea is considered to be a potential uterine stimulant and abortifacient (19, 97164).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, large amounts of marsh labrador tea can cause serious adverse effects due to the presence of ledol.\nMost Common Adverse Effects\nOrally: Diarrhea and vomiting.\nSerious Adverse Effects (Rare)\nOrally: Death, kidney damage, narcotic-like effects, paralysis, seizures.\nGastrointestinal\nOrally, ledol, a constituent of the essential oil of marsh Labrador tea, can cause gastrointestinal irritation resulting in diarrhea and vomiting (97164).\nless\nGenitourinary\nOrally, the essential oil of marsh Labrador tea can cause irritation and damage to the kidneys and urinary tract (2).\nless\nMusculoskeletal\nOrally, the essential oil of marsh Labrador tea can cause myalgias and arthralgias (2).\nless\nNeurologic/CNS\nOrally, large amounts of marsh Labrador tea can cause CNS depression, dizziness, and drowsiness. Conversely, marsh Labrador tea containing large quantities of ledol, a constituent of marsh Labrador tea essential oil, can cause central nervous system excitation in a dose-dependent manner. Small amounts of ledol can lead to mild stimulating effects similar to caffeine, while larger doses can lead to narcotic-like effects, spasms, seizures, paralysis, and even death (97164).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. Although there has been interest in using oral marsh Labrador tea for asthma, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nBack pain. Topical marsh Labrador tea has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with acute low back pain shows that using a topical homeopathic gel (Spiroflor SRL) containing marsh Labrador tea, comfrey, and poison ivy, for 1 week, might have similar efficacy to capsaicin cream for reducing pain scores on a visual analog scale (40358).\nless\nBurns. Although there has been interest in using topical marsh Labrador tea for burns, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nCommon cold. Although there has been interest in using oral marsh Labrador tea for the common cold, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nCough. Although there has been interest in using oral marsh Labrador tea for cough, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nDiabetes. Although there has been interest in using oral marsh Labrador tea for diabetes, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nDiarrhea. Although there has been interest in using oral marsh Labrador tea for diarrhea, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nHepatitis. Although there has been interest in using oral marsh Labrador tea for hepatitis, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nInsect bite. Topical marsh Labrador tea has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that using a homeopathic after-bite gel, containing marsh Labrador tea, echinacea, and stinging nettle, topically on mosquito bites does not reduce erythema or itching when compared with placebo (89235).\nless\nKidney failure. Although there has been interest in using oral marsh Labrador tea for kidney failure, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nOsteoarthritis. Topical marsh Labrador tea has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with knee osteoarthritis shows that topical use of a homeopathic gel containing marsh Labrador tea, comfrey, and poison ivy, 1 gram 3 times daily for 4 weeks, is as effective as topical piroxicam gel 5% for reducing pain scores on a visual analog scale (89245).\nless\nPostoperative swelling. Topical marsh Labrador tea has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small observational study in adults undergoing oculofacial surgery shows that applying hydrogel pads (OcuMend, Cearna Inc) containing homeopathic doses of marsh Labrador tea and arnica for 6 days postoperatively might improve swelling and healing when compared to historical data (96770). The validity of these results is reduced by the absence of a control group, and the lack of information on how efficacy was measured.\nless\nRheumatoid arthritis (RA). Although there has been interest in using oral marsh Labrador tea for RA, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nVenous leg ulcers. Although there has been interest in using topical marsh Labrador tea for venous leg ulcers, there is insufficient reliable information about the clinical effects of marsh Labrador tea for this condition.\nMore evidence is needed to rate marsh Labrador tea for these uses.",
            "Dosing & Administration": "Adult\nTopical:\nAll routes: Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of marsh Labrador tea.",
            "Interactions with Drugs": "CNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, marsh Labrador tea can potentiate the depressant effects of barbiturates and alcohol (2).\nLarge amounts of marsh Labrador tea can cause CNS depression (2, 97164).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, marsh Labrador tea might cause additive CNS depression when combined with anesthesia and other medications during and after surgical procedures. Tell patients to discontinue marsh Labrador tea at least 2 weeks before elective surgical procedures. Marsh Labrador tea has CNS depressant effects (97164).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with marsh Labrador tea.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of marsh Labrador tea.",
            "Mechanism of Action": "General\nThe applicable parts of marsh Labrador tea are the leaf and flowering shoots. They contain a high concentration of essential oils, up to 2.5%, which contributes to the specific taste of marsh Labrador tea. The essential oil contains ledol, cyclocolorenone, palustrol, sabinene, p-cymene, limonene, alpha- and beta-pinene, gamma-terpineol and germacrone. Ledol is a toxic sesquiterpene present in concentrations ranging from 4% to 31%, depending on the geographic source (97164). Marsh Labrador tea also contains phenolic acids, tannins, and flavonoids such as quercetin, hyperoside, and arbutin (97164).\nGenitourinary effects\nMarsh Labrador tea might stimulate uterine activity and have abortifacient properties (19, 97164).\nNeurologic\nLedol, a constituent of marsh Labrador tea essential oil, can cause central nervous system excitation and psychomotor stimulation in a dose-dependent manner. Small amounts of ledol can lead to mild stimulating effects similar to caffeine, while larger doses can lead to spasms, seizures, paralysis, and even death (97164)."
        }
    },
    "Marsh Marigold": {
        "sections": {
            "Overview": "Marsh marigold is a plant that grows in Europe, Asia and North America (100309).",
            "Safety": "LIKELY UNSAFE when the fresh above ground parts are used orally or topically because they cause severe local irritation (18).\nThere is insufficient reliable information available about the safety of the medicinal use of the dried above ground parts.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when the fresh above ground parts are used orally or topically (18). There is insufficient reliable information available about the safety of the dried above ground parts during pregnancy and lactation.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, ingestion of marsh marigold can cause severe irritation of the gastrointestinal tract with colic and diarrhea. Irritation of the urinary tract can also occur (18).\n\nTopically, skin contact with the fresh plant can cause blisters and burns that are difficult to heal (18).\nDermatologic\nTopically, skin contact with the fresh marsh marigold plant can cause blisters and burns that are difficult to heal (18).\nless\nGastrointestinal\nOrally, ingestion of marsh marigold can cause severe irritation of the gastrointestinal tract with colic and diarrhea. Irritation of the urinary tract can also occur (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of marsh marigold.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of marsh marigold.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of marsh marigold.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of marsh marigold.",
            "Mechanism of Action": "General\nThe applicable parts of marsh marigold are the above ground parts of the flowering plant. When the fresh plant is crushed or cut into small pieces, the glycoside ranunculin is enzymatically changed into a severely irritating protoanemonin, which in turn rapidly degrades into the less toxic anemonin (18). Both protoanemonin and ranunculin are destroyed to an unknown extent during the drying process (2).\nImmunologic effects\nThere is interest in using marsh marigold for arthritis and joint pain. Evidence from animal research suggests that polysaccharide fractions of marsh marigold attenuate inflammation and immune system response in a mouse model of collagen-induced arthritis. The interleukin-1b response was reduced similarly to using methotrexate in this model (100309)."
        }
    },
    "Marshmallow": {
        "sections": {
            "Overview": "Marshmallow is a perennial herb that is native to Europe and parts of Asia and cultivated throughout the world (92844). It has been used in traditional European medicine for more than 2000 years. The Emperor Charlemagne ordered marshmallow cultivation in monasteries (92846). Both the marshmallow leaf (unpeeled or peeled) and the dried root are used in commercial preparations (92845).",
            "Safety": "LIKELY SAFE when marshmallow root and leaf are used in amounts commonly found in foods. Marshmallow root has Generally Recognized As Safe (GRAS) status for use in foods in the US (4912).\nPOSSIBLY SAFE when marshmallow root and leaf are used orally in medicinal amounts (4, 12). ...when used topically (4, 62020).\nThere is insufficient reliable information available about the safety of marshmallow flower.\nPREGNANCY AND LACTATION: Insufficient reliable information available.",
            "Adverse Effects": "General\nOrally and topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nACE inhibitor-induced cough. It is unclear if oral marshmallow root is beneficial in patients with cough due to ACE inhibitors.\nA small clinical study in patients with ACE inhibitor-induced cough shows that taking marshmallow root 40 mg (20 drops) three times daily for 4 weeks improves cough when compared to baseline (62027). The validity of this finding is limited by the lack of a control group.\nless\nAtopic dermatitis (eczema). It is unclear if topical marshmallow is beneficial in children with eczema.\nA very small clinical study in children ages 3 months to 12 years with a recent diagnosis of mild to moderate eczema shows that applying a marshmallow 1% ointment twice daily for 1 week and then three times weekly for 3 weeks seems to reduce symptoms, as measured on the SCORing Atopic Dermatitis (SCORAD) scale, when compared with applying hydrocortisone 1% ointment (105437). This finding is limited by the large number of drop-outs due to non-compliance, most of which were in the marshmallow group.\nless\nBreast engorgement. It is unclear if topical marshmallow is beneficial in women with this condition.\nA small clinical study in breastfeeding women with breast engorgement shows that applying a compress containing 40-50 mL of a solution made from marshmallow leaves and stems 3 times daily for 2 days in conjunction with standard treatment improves patient-reported breast engorgement scores when compared with standard treatment alone. Standard treatment consisted of massage and alternating warm and cold compresses before and after breastfeeding (92845).\nless\nConstipation. Although there is interest in using oral marshmallow for constipation, there is insufficient reliable information about the clinical effects of marshmallow for this condition.\nCough. Although there is interest in using oral marshmallow for cough, there is insufficient reliable information about the clinical effects of marshmallow for this condition.\nDiarrhea. Although there is interest in using oral marshmallow for diarrhea, there is insufficient reliable information about the clinical effects of marshmallow for this condition.\nFever. It is unclear if topical marshmallow is beneficial for pediatric fever.\nA moderate-sized clinical study in children aged 6 months-10 years with fever receiving rectal acetaminophen shows that applying marshmallow extract body wash and lukewarm water reduces the time to defervescence by 8 minutes when compared with lukewarm water alone, but does not improve the change in body temperature, number of acetaminophen doses given, or incidence of fever recurrence (112375). However, the interpretation of these findings is limited to patients without fevers greater than 40 degrees Celsius or history of febrile seizures since these patients were not studied.\nless\nLeishmania lesions. Topical marshmallow has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research suggests that the topical application of an herbal extract containing a combination of marshmallow and Althaea rosa to affected areas for 5 days can help promote curing of Leishmania lesions (62020).\nless\nRespiratory tract infections. Although there is interest in using oral marshmallow for respiratory tract infections, there is insufficient reliable information about the clinical effects of marshmallow for this condition.\nVaginal candidiasis. It is unclear if vaginal marshmallow is beneficial for vulvovaginal candidiasis.\nA small clinical study in adults with vulvovaginal candidiasis shows that applying a vaginal cream comprised of marshmallow extract 4% and clotrimazole 1% daily for 7 days improves itching, dyspareunia, and dysuria at 7 days when compared with clotrimazole 1% alone. At 30 days, the marshmallow intervention also results in fewer positive yeast cultures and sustained reduction in itching (112371). However, the validity of these results is limited by significant differences between groups at baseline for dyspareunia and dysuria, and lack of adjustment for multiple comparisons which can increase false positive findings. Additionally, all primary outcomes were patient-reported.\nless\nVenous leg ulcers. Although there is interest in using topical marshmallow for venous leg ulcers, there is insufficient reliable information about the clinical effects of marshmallow for this condition.\nWounds. Although there is interest in using topical marshmallow for wounds, there is insufficient reliable information about the clinical effects of marshmallow for this condition.\nMore evidence is needed to rate marshmallow for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information about the standardization of marshmallow.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, marshmallow flower might have antiplatelet effects.\nAnimal research suggests that marshmallow flower extract has antiplatelet effects (92846). However, the root and leaf of marshmallow, not the flower, are the plant parts most commonly found in dietary supplements. Theoretically, use of marshmallow flower with anticoagulant/antiplatelet drugs can have additive effects, and might increase the risk for bleeding in some patients.\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, due to potential diuretic effects, marshmallow might reduce excretion and increase levels of lithium.\nMarshmallow is thought to have diuretic properties. To avoid lithium toxicity, the dose of lithium might need to be decreased when used with marshmallow.\nless\nORAL DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, mucilage in marshmallow might impair absorption of oral drugs.\nMarshmallow contains mucilage which can affect oral drug absorption (1, 11, 12, 19). To avoid changes in absorption, take marshmallow 30-60 minutes after oral medications.\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, marshmallow flower might increase bleeding risk.\nAnimal research suggests that marshmallow flower extract has antiplatelet effects (92846). Using marshmallow flower along with other products with anticoagulant/antiplatelet effects might increase the risk of bleeding. See other products with antiplatelet effects here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING CONDITIONS\nTheoretically, marshmallow flower might increase bleeding risk in patients with conditions associated with a high risk for bleeding. Animal research suggests that marshmallow flower extract has antiplatelet effects (92846).\nless\nPERIOPERATIVE\nTheoretically, marshmallow flower might increase bleeding risk during and after surgical procedures. Marshmallow flower might inhibit platelet aggregation (92846). Tell patients to discontinue marshmallow flower at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with marshmallow.",
            "Pharmacokinetics": "Absorption\nMarshmallow mucilage is not altered in the digestive tract until it reaches the colon, where it may be partially or completely digested via bacterial action (62029).",
            "Mechanism of Action": "General\nThe applicable parts of marshmallow are the leaves and the root. Marshmallow root preparations consist of peeled or unpeeled dried root of Althaea officinalis L. and contain mucilage polysaccharides (6.2-11.6%) composed of galacturonorhamnans, arabinans, glucaris, and arabinogalactans; carbohydrates (25-35%); flavonoids; glycosides; sugars (10% sucrose); amines (up to 12% asparagines); fat (1.7%); calcium oxalate; coumarins; phenolic acid (62031); and sterols. The mucilage rich roots are thought to be responsible for many of the pharmacological effects of marshmallow (92846). Purified homogenous mucilage of marshmallow is composed of L-rhamnose, D-galactose, galacturonic acid, and D-glucuronic acid in molar ratio of 3:2:3:3 (62022). Extracts from hybrid plants have been found to be more mucilaginous, with a different sugar composition compared to native plants (62023). The roots are also high in pectin which has reported pharmacological effects. Different colored flower petals have been tested for their flavonoid content. The highest flavonoid content was found in the white petals, followed by reddish pink, and then pink (92844). Additionally, the leaf includes mucilage, polysaccharide, flavonoid, phenolic acid, tannin, and fat (92845).\nAnti-cancer effects\nThere is interest in the effects of marshmallow on cell proliferation and apoptosis pathways. A study in carcinogen-induced rats suggests that marshmallow flower extract reduces mammalian target of rapamycin (mTOR), phosphatidylinositol 3-kinase (PI3K), and AKT protein expression when compared with control, but does not affect several other markers of cell proliferation and apoptosis except when in combination with silymarin (112374).\nAnti-inflammatory effects\nIn vitro and animal research suggests that marshmallow has anti-inflammatory effects. Marshmallow root extract may stimulate phagocytosis and the release of oxygen radicals and leukotrienes from human neutrophils. Additionally, marshmallow aqueous extract may induce the release of cytokines, interleukin (IL)-6, and tumor necrosis factor (TNF) from human monocytes (62033, 92845). An experimental study found that the anti-inflammatory properties of marshmallow alone were superior to dexamethasone monotherapy in rabbits (62026). In animal models of inflammation, intraperitoneal injections of marshmallow extract inhibited acute inflammation by 41-78% and inhibited chronic inflammation by 52-68%, with the optimum dose of 250 mg/kg showing similar inhibitory activity to diclofenac 10 mg/kg body weight. The anti-inflammatory effects are thought to be due to the presence of flavonoids which decrease the release of inflammatory mediators, stabilize cell membranes, and inhibit cyclooxygenase enzyme activity. Mucilage may also possess anti-inflammatory properties (92846). However, a study in carcinogen-induced rats suggests that marshmallow flower extract does not significantly reduce cytokine levels (i.e., IL-6, IL-1 beta, IL-10, TNF-alpha), but may decrease C-reactive protein levels when compared with control (112374).\nAntimicrobial effects\nSome in vitro and animal research suggests that marshmallow has antimicrobial activity against L. monocytogenes, P. aeruginosa, P. vulgaris, and S. aureus. But not all laboratory research has shown marshmallow to have Gram negative activity (92847). Some animal research suggests that marshmallow's antimicrobial effects may be explained by suppression of mucociliary action and stimulation of phagocytosis (31530, 62028). In an animal wound model, a hydroethanolic leaf extract of marshmallow showed increased epithelization of wound tissue compared to placebo, but no significant difference was seen when compared to zinc oxide. Scar area was smaller and the epidermis formation was intact in both the zinc and extract treated groups. The researchers suggest that antimicrobial effects of the extract may have contributed to the healing process. The active constituents in the extract may also increase the viability and strength of collagen fibrils. This is thought to be accomplished by increasing circulation or by preventing cell damage or promoting DNA synthesis. Flavonoids may possess anti-hemorrhage properties which may promote and accelerate the healing processes of epithelial wounds (92847).\nAntioxidant effects\nThe antioxidant effects of marshmallow flowers vary depending on flower color. Marshmallow extracts made from reddish pink flowers possess higher antioxidant activity compared to extracts made from white or pink flowers (92844). A study in carcinogen-induced rats suggests that marshmallow flower extract improves antioxidant enzyme levels by reducing nitric oxide and increasing glutathione peroxidase and superoxide dismutase but does not significantly affect catalase enzyme levels when compared with control. Liver tissue-specific antioxidants (i.e., ferric reducing ability, thiobarbituric acid reactive substances, thiol) also improved when compared with control (112374).\nAntiplatelet effects\nSome animal research suggests that marshmallow extract inhibits platelet aggregation. The inhibitory effect ranged from 17.9-72% and was time-dependent. Researchers suggest that flavonoids from marshmallow might inhibit platelet function through binding to the thromboxane A2 receptors (92846).\nAntitussive/mucociliary effects\nAnimal research shows that mucilaginous herbs like marshmallow root can inhibit coughing by forming a protective coating on the mucosal lining of the respiratory tract, shielding it from irritants (31530, 62030). Marshmallow reduced the transport velocity of isolated ciliary epithelia and may protect mucous layers in the hypopharynx and exert spasmolytic, antisecretory, and bactericidal properties (31530). Marshmallow root extract and a marshmallow polysaccharide have demonstrated greater antitussive activity than a non-narcotic cough suppressant in cats (62021). The extract seems to be less effective than marshmallow polysaccharide (62029). The demulcent properties of marshmallow may be due to the reduction of the local irritation that causes gastritis.\nDermatologic effects\nCombinations of marshmallow preparations with steroids have been used in the management of dermatological conditions, and the plant appears to possess anti-inflammatory activity that potentiates the effect of topical steroids (62024, 62025). In vitro, the anti-inflammatory effects of an ointment containing marshmallow extract and dexamethasone (0.05%) were superior to those of the individual ingredients in the alleviation of chemically induced rabbit ear irritation (62026).\nGastrointestinal effects\nIn a gastric ulcer induced animal model, an extract of marshmallow showed dose-dependent protection against ulceration. High dose extract was superior to cimetidine. Researchers suggest that mucilage and flavonoids from marshmallow may form a protective layer over the gastric mucosa (1, 4, 6, 7, 18, 92846).\nHepatic effects\nSome animal research suggests that a marshmallow flower extract might have hepatoprotective effects (92846). A study in carcinogen-induced rats suggests that marshmallow flower extract improves liver laboratory markers by decreasing aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and bilirubin when compared with control (112374).\nHypoglycemic effects\nAnimal research suggests that marshmallow might reduce plasma glucose levels, theoretically due to its fiber-containing mucilage (62022).\nHypolipidemic effects\nSome animal research shows that a marshmallow flower extract can significantly increase high density lipoprotein (HDL)-cholesterol in rats. The researchers suggest that this effect is due to pectin. The increase in HDL was only observed at a dose of 50 mg/kg daily. Doses of 250 mg/kg and 500 mg/kg daily did not appear to increase HDL levels. It is unclear why higher doses didn't increase HDL, but the researchers speculate it may be secondary to higher concentrations of certain components antagonizing the effects of pectin (92846)."
        }
    },
    "Mastic": {
        "sections": {
            "Overview": "Mastic is a type of evergreen shrub. It is found in the Mediterranean regions of France, Spain, Portugal, Greece, Turkey, and Africa. The resin is used in medicine (62051, 99986, 99987).",
            "Safety": "POSSIBLY SAFE when used orally in doses of up to 2.8 grams daily for up to 3 months (18, 62089, 62090, 99986, 99987). ...when a specific mastic extract (RPh201, Regenera Pharma) is administered by subcutaneous injection at doses up to 20 mg twice weekly for up to 4 weeks (103266).\nThere is insufficient reliable information available about the safety of mastic when used topically.Cases of allergic contact dermatitis have been reported with mastic gum-containing products (106467).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and subcutaneously, mastic seems to be well tolerated. A thorough assessment of safety outcomes with topical mastic has not been conducted.\nMost Common Adverse Effects\nTopically: Allergic contact dermatitis in sensitive individuals.\n\nSubcutaneously: Dizziness, headache, injection site erythema, and injection site pain.\nDermatologic\nSubcutaneously, administration of a specific mastic extract (RPh201, Regenera Pharma) has been most commonly reported to cause injection site pain and erythema. Pruritus, rash, and ecchymosis have also been reported with this extract (103266).\n\nTopically, use of a specific mastic gum- and storax gum-containing product (Mastisol Liquid Adhesive, Ferndale Laboratories) has been associated with cases of allergic contact dermatitis, with most of the reactions being attributed to mastic gum. Cross-allergenicity between mastic gum and both synthetic and natural fragrance-related substances was frequent (106467).\nless\nGastrointestinal\nOrally, nausea, diarrhea, and constipation have been rarely reported following use of mastic gum (62051, 62069, 62071). In one case, constipation ceased two days after discontinuing mastic gum (62051).\nless\nImmunologic\nThe pollen of mastic tree is allergenic to some individuals (4140).\nless\nNeurologic/CNS\nSubcutaneously, administration of a specific mastic extract (RPh201, Regenera Pharma) has been reported to cause headache and dizziness (103266).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDyspepsia. Oral mastic seems to improve symptoms in adults with functional dyspepsia.\nA clinical trial in adults with functional dyspepsia shows that taking mastic gum 350 mg three times daily for 3 weeks improves symptoms, including stomach pain, heartburn, and upper abdominal pain, in a greater percentage of patients when compared with placebo (62071).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBrittle nails. Topical mastic oil has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nTwo small clinical studies in patients with brittle nails shows that applying a water-based solution containing mastic oil and hyaluronic acid to the nails once daily for up to 6 months increases nail hardness, improves nail appearance, and decreases nail breakage when compared with untreated nails (103267, 103268). It is unclear if these findings are due to mastic, hyaluronic acid, or the combination.\nless\nCancer. Although there has been interest in using oral mastic for cancer, there is insufficient reliable information about the clinical effects of mastic for this purpose.\nCrohn disease. It is unclear if oral mastic is beneficial in patients with Crohn disease.\nA very small clinical study in patients with active Crohn disease shows that taking mastic 2.22 grams daily for 4 weeks improves symptoms, such as diarrhea, abdominal pain, weight loss, and non-gastrointestinal symptoms, by 39% when compared to baseline (62051). The validity of these findings is limited by the lack of a comparator group.\nless\nDyslipidemia. It is unclear if oral mastic is beneficial in patients with elevated total cholesterol.\nA large clinical study in adults with elevated total cholesterol shows that taking mastic essential oil 200 mg daily for 8 weeks modestly improves total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides when compared to baseline (112905). However, the interpretation of these findings is limited because the change from baseline to 8 weeks is not statistically compared between groups.\nless\nHalitosis. It is unclear if oral mastic is beneficial for halitosis in teenaged patients with fixed orthodontic appliances.\nA small clinical study in teenaged patients with fixed orthodontic appliances shows that using a specific formulation of mastic mouthwash (Mastiha Mouthwash Gingivaction, Mastihashop) 10 mL for 30 seconds twice daily for 14 days improves measures of hydrogen sulfide but does not improve other measures of malodorous volatile sulfur compounds or subjective halitosis scores when compared with placebo (112906). However, it is unclear whether any improvements are clinically significant.\nless\nHelicobacter pylori. It is unclear if oral mastic is beneficial in patients with H. pylori infection.\nA small clinical study in patients with H. pylori infection shows that taking mastic gum 0.35 or 1.05 grams three times daily for 2 weeks eradicates H. pylori in approximately one-third of patients by 5 weeks post-treatment. However, taking mastic gum alone or in combination with pantoprazole is less effective than a combination of pantoprazole, amoxicillin, and clarithromycin (62069).\nless\nInflammatory bowel disease (IBD). It is unclear if oral mastic is beneficial in patients with IBD.\nA small clinical study in adults with IBD that is in remission shows that taking mastic 2.8 grams daily for 3 months does not improve quality of life when compared with placebo (99987).\nless\nMetabolic syndrome. It is unclear if oral mastic is beneficial in patients with metabolic syndrome.\nA moderate-sized clinical study in patients with abdominal obesity and at least 1 other metabolic syndrome risk factor shows that taking mastic essential oil 200 mg once daily for 3 months improves triglyceride and low-density lipoprotein levels, but does not improve total cholesterol, high-density lipoprotein, glucose, or insulin levels when compared with control (112904). However, the interpretation of these findings is limited by differences in body mass index and percent of patients with hypertension among groups at baseline.\nless\nNonalcoholic fatty liver disease (NAFLD). It is unclear if oral mastic is beneficial in patients with NAFLD.\nA small clinical study in obese adults with NAFLD or nonalcoholic steatohepatitis (NASH) shows that taking mastic 2.1 grams daily for 6 months does not improve liver inflammation fibrosis scores. However, when stratified by BMI, a subgroup analysis suggests improvement in liver fibrosis among patients with severe obesity (106473).\nless\nPeptic ulcers. Small clinical studies suggest that oral mastic powder may modestly improve symptoms and healing rates in patients with peptic ulcers.\nOne small clinical study in adults with duodenal ulcers shows that taking mastic powder 1 gram daily orally for 2 weeks improves symptoms and ulcer healing in a greater percentage of patients when compared with placebo (62090). Another small clinical study in patients with gastric ulcers shows that taking mastic powder 1 gram twice daily for 4 weeks may help improve symptoms and ulcer healing in patients with gastric ulcer (62089).\nless\nPeriodontitis. It is unclear if brushing with a dentifrice containing mastic essential oil is beneficial in patients with periodontitis.\nA small clinical study in patients with periodontitis shows that brushing with a dentifrice containing mastic essential oil using a sonic toothbrush for 12 weeks reduces plaque accumulation, as well as gingival swelling, bleeding, and redness, when compared with using a sonic toothbrush alone (62096).\nless\nWound healing. Although there has been interest in using topical mastic for wound healing, there is insufficient reliable information about the clinical effects of mastic for this purpose.\nMore information is needed to rate mastic for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMastic gum or powder has most often been used in doses of 1-2.8 grams daily for up to 3 months. Doses up to 2.1 grams daily have been used for up to 6 months. See Effectiveness section for condition-specific information.\nOral:\nMastic has been used in various topical formulations, including as mastic oil in a water-based solution and as mastic essential oil in toothpaste. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mastic.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nIndividuals allergic to mastic tree might also have an allergic reaction to Schinus terebinthifolious and other Pistacia species (4140). Avoid or use with caution in patients sensitive to these plants.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mastic.",
            "Pharmacokinetics": "Absorption\nIn humans, consuming mastic increases terpene levels in the blood within 0.5 hours, peaking 2-4 hours after intake (99988).",
            "Mechanism of Action": "General\nThe applicable part of mastic is the resin. Mastic resin contains the triterpenes mastihadienonic acid and isomastihadienonic acid, oleanolic acid, and tirucallol (18, 99987). The volatile oil of mastic contains alpha-pinene and beta-myrcene (62038).\nAnti-inflammatory effects\nThe anti-inflammatory effects of mastic possibly play a role in its various clinical effects. In animal models, mastic gum had anti-inflammatory effects related to edema, asthma, and allergic contact dermatitis (62078, 62080, 108885). The reduction in inflammation is related to reduced inflammatory cytokines and enzymes and reduced activity of neutrophils and eosinophils (62059, 62065, 62078, 62080, 62087, 108885). In a rat model of colitis, rectally administered mastic oil was associated with reductions in tumor necrosis factor (TNF)-alpha levels and increases in interleukin 6 (IL-6) levels (106472). In a mouse model of colitis, orally administered aqueous extract of mastic leaf was associated with dose-dependent reductions in systemic, local, and peritoneal macrophage levels of TNF-alpha, IL-6, and nitrites (106475). However, a moderate-sized clinical study in patients with abdominal obesity and at least 1 other metabolic syndrome risk factor shows that taking mastic essential oil 200 mg once daily for 3 months does not improve TNF-alpha, IL-6, or C-reactive protein levels when compared with control (112904).\nAnti-obesity effects\nThere is interest in the effects of mastic on hormones related to obesity. A moderate-sized clinical study in patients with abdominal obesity and at least 1 other metabolic syndrome risk factor shows that taking mastic essential oil 200 mg once daily for 3 months improves adiponectin levels but does not improve leptin levels when compared with control (112904). However, the interpretation of these findings is limited clinically, since leptin resistance was not assessed.\nAnticancer effects\nMastic gum has been traditionally used for cancer. Tumor growth is reduced in animal models (62061, 62068). This effect might be due to increased apoptosis and reduced neovascularization. Cellular signaling is also affected (62042, 62044, 62053, 62068, 62072, 62073).\nAntimicrobial effects\nThere is some in vitro evidence that mastic extract has antibacterial and antifungal activity (4141, 62035, 62039, 62043, 62055). Also, in humans, chewing mastic gum has antibacterial effects in the mouth (62036, 62039, 62046). Mastic gum also has antibacterial effects against Helicobacter pylori (62048, 62069).\nBone effects\nAnimal research suggests that mastic might protect against bone loss. In a rat model of postmenopausal osteoporosis, mastic powder minimized reductions in bone mineral density caused by ovary removal. Anti-inflammatory and antioxidant effects are purported to explain any effect on bone metabolism (108884).\nGastrointestinal effects\nFor prevention of gastric and duodenal ulcers, some researchers think mastic might have antisecretory and possibly cytoprotective effects. Animal models show that it seems to help protect the gastric mucosa during aspirin, phenylbutazone, or reserpine therapy (4142). This effect has not yet been found in humans. Mastic gum has antibacterial effects against Helicobacter pylori (62048, 62069). In a rat model of colitis, orally administered mastic oil was associated with improvements in the severity and extent of inflammation, as well as reductions in crypt damage and total colitis index scores (106472). Research in colitis-induced mice suggests that orally administering high and low doses of mastic as an aqueous extract or as masticadieonic acid, a specific constituent of mastic, may improve disease activity index scores, inflammation, histology, and mucus production (106475, 112907).\n\nSome research in humans suggests that mastic helps to reduce symptoms of Crohn disease and ulcerative colitis (62051). Animal and human research suggests that this benefit may have been due to decreased production of inflammatory cytokines (62051, 62086, 112907). In humans, taking mastic resulted in a decrease in fecal lysozyme (99987).\nLipid effects\nIn people with inflammatory bowel disease, taking mastic improved the oxidation of low-density lipoprotein (LDL) cholesterol (99986). In human research, mastic powder decreased levels of LDL cholesterol (62050)."
        }
    },
    "Meadowsweet": {
        "sections": {
            "Overview": "Meadowsweet is a plant found mainly in damp meadows in Europe and Asia. All parts of the meadowsweet plant (flowers, leaves, and roots) have been used as medicine (4, 101059, 112302). Meadowsweet has been traditionally used for its antacid, antibacterial, antirheumatic, anti-gout, anti-inflammatory, antiseptic, antiulcerogenic, and diuretic properties.",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Some experts have warned that meadowsweet might interfere with the body's immune and inflammatory response against COVID-19. There is no strong evidence to support these warnings, but there's also no evidence that meadowsweet has benefit against COVID-19 infection.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term (12). Meadowsweet flower has been used with apparent safety at doses of 2.5-3.5 grams daily. Meadowsweet herb has been used with apparent safety at doses of 4-5 grams daily (12).\nPOSSIBLY UNSAFE when used in large amounts or for prolonged periods of time. Meadowsweet contains salicylates and high amounts of tannins (4).\nPREGNANCY: LIKELY UNSAFE when used orally. Some evidence suggests meadowsweet might stimulate uterine activity (4).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, meadowsweet seems to be well tolerated.\nDermatologic\nMeadowsweet contains salicylate constituents. There is insufficient reliable information available to know if the side effects and toxicity normally associated with salicylates could occur with meadowsweet use. Orally, adverse reactions associated with salicin include skin rashes (4).\nless\nGastrointestinal\nOrally, large doses of meadowsweet can cause nausea and other stomach complaints (18).\n\nMeadowsweet contains salicylate constituents. There is insufficient reliable information available to know if the side effects and toxicity normally associated with salicylates could occur with meadowsweet use. Adverse reactions associated with salicylates include gastric irritation, hematochezia, nausea, and vomiting (4).\nless\nImmunologic\nMeadowsweet contains salicylate constituents. There is insufficient reliable information available to know if the side effects and toxicity normally associated with salicylates could occur with meadowsweet use. Orally, salicylates can cause hypersensitivity in sensitive individuals (4).\nless\nOcular/Otic\nMeadowsweet contains salicylate constituents. There is insufficient reliable information available to know if the side effects and toxicity normally associated with salicylates could occur with meadowsweet use. Orally, adverse reactions with salicylates include tinnitus (4).\nless\nPulmonary/Respiratory\nOrally, large doses of meadowsweet can cause bronchospastic activity (4).\nless\nRenal\nMeadowsweet contains salicylate constituents. There is insufficient reliable information available to know if the side effects and toxicity normally associated with salicylates could occur with the use of meadowsweet. Orally, adverse reactions with salicylates include renal irritation (4).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nHeadache. Although there has been interest in using oral meadowsweet for headache, there is insufficient reliable information about the clinical effects of meadowsweet for these conditions.\nRespiratory tract infections. Although there has been interest in using oral meadowsweet for respiratory tract infections, including cold, flu, bronchitis, and pneumonia, there is insufficient reliable information about the clinical effects of meadowsweet for these conditions.\nMore evidence is needed to rate meadowsweet for these uses.",
            "Dosing & Administration": "Adult\nOral:\nTraditionally, 2.5-3.5 grams of meadowsweet flower or 4-5 grams of meadowsweet herb has been used daily. As a liquid extract prepared 1:1 in 25% alcohol, meadowsweet is used in doses of 1.5-6 mL three times daily. As a tincture prepared 1:5 in 45% alcohol, meadowsweet is used in doses of 2-4 mL three times daily.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of meadowsweet.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nASPIRIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, meadowsweet might have an additive effect with other salicylate-containing drugs, such as aspirin.\nMeadowsweet contains salicin, a plant salicylate; however, salicin doesn't seem to have the antiplatelet effects of aspirin (12).\nless\nCHOLINE MAGNESIUM TRISALICYLATE (Trilisate)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, meadowsweet might have an additive effect with other salicylate-containing drugs, such as choline magnesium trisalicylate (12).\nMeadowsweet contains salicin, a plant salicylate (12).\nless\nSALSALATE (Disalcid)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, meadowsweet might have an additive effect with other salicylate-containing drugs such as salsalate (12).\nMeadowsweet contains salicin, a plant salicylate (12).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nASPIRIN ALLERGY\nMeadowsweet contains salicylate constituents (4). Use meadowsweet cautiously in individuals with a history of aspirin allergy.\nless\nASTHMA\nTheoretically, meadowsweet might exacerbate asthma due to bronchospastic effects. Use cautiously in individuals with a history of asthma (4).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with meadowsweet.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of meadowsweet.",
            "Mechanism of Action": "General\nThe applicable parts of meadowsweet are the leaves, flowers, fruit, and roots (112302). Meadowsweet contains high levels of phenolic compounds, including tannins, flavonoids, hydroxycinnamic acids, proanthocyanidins, chlorogenic acid, ellagic acid, and salicylic acid. Flavonoids include catechins and quercetin derivates, including spiraeoside, isoquercitrin, and rutoside (7, 12, 62100, 62102, 101059, 112302). The distribution of the different phenolic compounds is highly variable across the various parts of the plant. The highest levels are found in the leaves, flowers, and fruit, with slightly lower levels found in the roots and much lower levels found in the stems. The one exception is catechins, which are found in the highest concentration in the roots.\nAnti-gout effects\nIn vitro, a methanolic extract of meadowsweet aerial parts has demonstrated xanthine oxidase activity. Fractionation and purification of the methanolic extract revealed that spiraeoside, a glycosylated flavonoid constituenttion of meadowsweet, possesses xanthine oxidase activity approximately 25 times that of allopurinol (106707).\nAnti-inflammatory effects\nMeadowsweet is traditionally used as an anti-inflammatory and antirheumatic agent. In animal research, meadowsweet inhibited inflammation. The inhibition of cyclooxygenase enzyme activities seems to play a role in this inhibition (101059). In vitro research found extracts of the meadowsweet flowering tops to exhibit anti-inflammatory activity in a dose-dependent manner (112303).\nAntimicrobial effects\nMeadowsweet is traditionally used for bladder infections. Laboratory research suggests that meadowsweet has mild urinary antiseptic and antibacterial effects (4, 62098). In vitro research found extracts from the flowers and fruit of meadowsweet to exhibit antibacterial activity against gram-negative Pseudomonas aeruginosa and gram-positive Bacillus subtilis (112302).\nAntioxidant effects\nThe leaves, flowers, fruit, and roots of meadowsweet have been found to demonstrate antioxidant activity in vitro (112302).\nAntiulcerogenic effects\nMeadowsweet is traditionally used for dyspepsia, heartburn, and peptic ulcer disease. In laboratory research, meadowsweet has demonstrated antacid activity (4)."
        }
    },
    "Medium Chain Triglycerides (MCTs)": {
        "sections": {
            "Overview": "Medium chain triglycerides (MCTs) are fat molecules containing three medium chain saturated fatty acids attached to a glycerol backbone (93730, 93731, 93734, 93736). MCTs are sometimes consumed to induce ketosis. MCTs are more efficiently metabolized into ketones than other forms of fat, thereby allowing for the consumption of less fat and more carbohydrates than classical diets intended to induce ketosis (96973, 96979, 98417). See the Ketogenic Diet for more information about the safety and efficacy of various dietary patterns that induce ketosis.",
            "Safety": "LIKELY SAFE when used orally and appropriately (11726, 11727, 11728, 11729, 11730, 93729). ...when used parenterally and appropriately (2275, 2276, 2278, 11726, 11727, 11728, 11729).\nThere is insufficient reliable information available about the safety of MCTs when used topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, MCTs can cause significant gastrointestinal upset, especially with higher doses.\nMost Common Adverse Effects\nAbdominal discomfort, diarrhea, essential fatty acid deficiency, intestinal gas noises, irritability, nausea, reflux, vomiting. Gastrointestinal disturbances are thought to be associated with higher doses of MCT. Since MCTs are fats, excessive consumption can result in weight gain.\nCardiovascular\nThere is some concern that MCTs may further increase the risk for hypertriglyceridemia in some preterm infants due to immature lipoprotein lipase activity in these infants. A case of extremely elevated triglyceride levels of 4,736 mg/dL and associated lipemia retinalis has been reported at 43 weeks post-menstrual age (PMA) for a preterm infant born at 30 weeks' gestational age. It was discovered that the baby had been receiving MCT supplements in addition to breast milk starting at 42 weeks' PMA. MCT supplements were discontinued. One month later triglycerides were reduced to 287 mg/dL, and the retinal vasculature had a normal hue. However, at 2-month follow-up, triglyceride levels were elevated to levels higher than normal for age despite MCT discontinuation. Investigators speculated that a genetic disorder of lipid metabolism may also have contributed to the elevated triglyceride levels in addition to use of MCTs (96330).\nless\nGastrointestinal\nOrally, MCTs can cause significant gastrointestinal upset. Diarrhea is the most commonly reported side effect (11723, 93737, 93738, 101967). Other reported side effects include vomiting, irritability, nausea, reflux, abdominal discomfort, intestinal gas noises, and essential fatty acid deficiency (11723, 93738, 101967). Taking MCTs with food can reduce these adverse effects (93737). Gastrointestinal disturbances are thought to be associated with higher doses of MCT, such as 85 grams (93731).\nless\nOther\nExcessive consumption of MCTs can result in weight gain. MCT oil contains 6-8.5 calories per gram. One tablespoon provides about 14 grams and about 115 calories (11724).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCachexia. Intravenous MCTs can provide calories in critically ill patients and patients with refractory cachexia, but do not seem to offer any advantages over long chain triglycerides.\nSeveral small clinical studies in critically ill patients and patients with refractory cachexia secondary to cancer show that receiving parenteral nutrition with a 1:1 mixture of MCTs and long chain triglycerides is similarly effective to long chain triglycerides alone for improving metabolic parameters or nutritional status (2275, 2276, 93739).\nless\nPOSSIBLY INEFFECTIVE\nHIV/AIDS-related wasting. Oral MCTs do not seem to promote weight gain or prevent weight loss in patients with HIV infection.\nA large clinical study in patients with HIV infection shows that taking a peptide-based supplement containing MCTs (Peptamen Oral Complete Elemental Diet, Nestl Clinical Nutrition) with multivitamins and minerals is no more effective than taking multivitamins and minerals alone for promoting weight gain or preventing weight loss (11730).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. It is unclear if oral MCTs are beneficial in patients with age-related cognitive decline.\nA small, single-blind clinical study in older adults residing in a nursing home shows that taking MCTs 6 grams (a 3:1 mixture of caprylic acid:capric acid), with or without L-leucine 1.2 grams and vitamin D (cholecalciferol) 20 mcg, daily for up to 3 months increases mini-mental state exam (MMSE) scores by an average of 3.5 points, compared with a 0.7-point decline in those receiving a long chain triglyceride control. MMSE scores returned to baseline 1.5 months after discontinuation of MCT supplementation (105710).\nless\nAlzheimer disease. Small clinical studies suggest that oral MCTs do not improve cognition in patients with Alzheimer disease or mild cognitive impairment.\nA meta-analysis of small clinical studies in patients with Alzheimer disease or mild cognitive impairment shows that taking MCTs (as combinations of caprylic acid and capric acid) in doses of 20-56 grams or 22.5-165 mL daily for up to 6 months does not improve cognition when compared with placebo or baseline (103012).\nless\nAthletic performance. It is unclear if oral MCTs are beneficial for endurance athletic performance.\nA very small clinical study in 10 male recreational endurance runners shows that taking a ketone supplement containing MCTs and a salt form of beta-hydroxybutyrate 60 minutes prior to a run does not improve 5-kilometer run time when compared with placebo (107738). This study may have been inadequately powered to detect a difference between groups.\nless\nCeliac disease. Although there has been interest in using oral MCTs for celiac disease, there is insufficient reliable information about the clinical effects of MCTs for this purpose.\nChylothorax. It is unclear if oral MCTs improve time to resolution of spontaneous congenital chylothorax in neonates.\nA small retrospective study in neonates with spontaneous congenital chylothorax shows that administering MCTs does not improve the time to resolution of chylothorax when compared with total parenteral nutrition (11729).\nless\nChyluria. Although there has been interest in using oral MCTs for chyluria, there is insufficient reliable information about the clinical effects of MCTs for this purpose.\nCystic fibrosis. Although there has been interest in using oral MCTs for cystic fibrosis, there is insufficient reliable information about the clinical effects of MCTs for this purpose.\nDiabetes. Although there has been interest in using oral MCTs for diabetes, there is insufficient reliable information about the clinical effects of MCTs for this purpose.\nEpilepsy. It is unclear if oral MCTs are beneficial in adults and adolescents aged 12 years or older with drug-resistant epilepsy.\nA small clinical study in adults and adolescents aged 12 years or older with drug-resistant epilepsy shows that adjunctive treatment with MCTs (Stepan Lipid Nutrition) as part of a non-ketogenic diet, 47-65 mL daily (about 35% of energy intake), or a maximally tolerated dose not exceeding 100 mL, for 12 weeks reduces median seizure frequency by 46% when compared with baseline (101967). The validity of this study is limited by its small sample size and the lack of a comparator group.\nless\nGallbladder disease. Although there has been interest in using oral MCTs for gallbladder disease, there is insufficient reliable information about the clinical effects of MCTs for this purpose.\nHypertriglyceridemia. Oral MCTs might improve triglyceride levels and body weight in some patients with overweight and hypertriglyceridemia, but its effect in other populations is unclear.\nClinical research in patients with overweight and hypertriglyceridemia shows that taking 25-30 grams of an oil containing MCTs 13% daily for 8 weeks decreases triglyceride levels by 78 mg/dL when compared with consuming oil containing only long chain fats. Body weight, body fat, and waist circumference also decreased (93740). However, this benefit may be restricted to this specific population only. Some research in patients with obesity or patients with a normal body weight shows that taking 25-30 grams of an oil containing MCTs daily for 8 weeks does not lower triglyceride levels (93741).\nless\nObesity. Small clinical studies suggest that oral MCTs modestly improves weight loss; however, any effects may not be clinically relevant.\nA meta-analysis of clinical research shows that taking MCTs decreases body weight by 0.5 kg, waist circumference by 1.5 cm, and hip circumference by 0.8 cm when compared with a control group not taking MCTs. Doses used in available research have ranged from 1-54 grams daily, or 1% to 24% of energy for 4-16 weeks (93735). Most research shows that at least 4 weeks is needed before effects are seen. The greatest benefit seems to occur in patients of Asian descent, males, and patients with higher body mass indices at baseline (93730, 93731, 93735, 93736). While MCTs may improve weight loss in some patients, the effects are generally modest and may not be clinically relevant.\nless\nPrematurity. It is unclear if oral or topical MCTs are beneficial in preterm infants.\nA meta-analysis of small studies involving 136 otherwise healthy preterm infants receiving full enteral diets with formula as the predominant source of nutrition shows that administration of formulas containing at least 30% of fat by weight as MCTs (ranging in concentration from 6% to 80%) for at least 7 days does not affect short-term growth, including weight, length, and head circumference, when compared with formulas containing less than 30% of fat by weight as MCTs. Due to small study sizes, it is unclear whether either type of formula was better tolerated. The validity of this analysis is limited by the presence of unclear risk of potential bias in the included studies (105711).\n\nMCT oil has also been evaluated for the prevention of gastrointestinal Candida infections. A very small clinical study in preterm infants shows that adding MCT oil (Nestl Health Science) 0.5 mL per ounce of formula or breast milk for 1 week reduces Candida colonization when compared with no MCT oil (101968).\n\nTopical use of MCT oil has also been evaluated for growth in preterm infants. A small clinical study in preterm infants weighing 1500-2000 grams shows that massage with MCT oil, consisting of tactile and kinesthetic stimulation, three times daily for 7 days increases weight gain when compared with no massage (107739). The validity of this finding is limited by unclear reporting. Also, it is unclear if this effect is due to MCT oil, massage, or the combination.\nless\nPrimary intestinal lymphangiectasia. It is unclear if oral MCTs are beneficial for the management of primary intestinal lymphangiectasia.\nA review of 55 case reports suggests that taking MCTs as part of a low-fat, high-protein diet resolves symptoms in 63% of patients with primary intestinal lymphangiectasia, compared with 36% of patients receiving no treatment or other treatments such as diuretic therapy, albumin transfusions, resection of isolated segments of affected bowels, etc. Mortality is also reduced by 79% in patients treated with diet restrictions and MCTs when compared with those receiving no treatment or other treatments (93733).\nless\nSarcopenia. It is unclear if oral MCTs are beneficial in frail older adults.\nA small clinical study in older adults residing in a nursing home shows that taking MCTs 6 grams, leucine 1.2 grams, and vitamin D (cholecalciferol) 20 mcg daily for 3 months increases body weight by 1.1 kg, right-hand grip strength by 13%, and peak expiratory flow by 28% when compared with baseline. These improvements are also significant when compared with patients receiving no supplementation (93729). In a second study in this same population conducted by the same research group, taking MCTs 6 grams, with or without leucine 1.2 grams and vitamin D (cholecalciferol) 20 mcg, daily for 3 months does not increase body weight or hand grip strength. There were small to moderate improvements in opening and closing the legs, repetitive swallowing, and measures of functional independence (101970). The validity of these findings is limited by the single-blind nature of the studies and the large number of endpoints. It is also unclear if any benefits are due to MCTs, other ingredients, or the combination.\nless\nShort bowel syndrome. Although there has been interest in using oral MCTs for short bowel syndrome, there is insufficient reliable information about the clinical effects of MCTs for this purpose.\nMore evidence is needed to rate MCTs for these uses.\nless",
            "Dosing & Administration": "Adult\nOral:\nMCTs have most often been used in doses of 6-56 grams daily for 4-24 weeks. See Effectiveness section for condition-specific information.\nIntravenous:\nA fat mixture containing 50% MCTs and 50% long chain triglycerides has been used as a fat source in total parenteral nutrition formulations.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nMCTs used in clinical research have included 50% to 75% caprylic acid and 25% to 45% capric acid (101967, 101970, 105709). MCT oil contains 6-8.5 calories per gram. One tablespoon provides about 14 grams of MCTs and about 115 calories (11724).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nMCTs can cause ketosis; use with caution in patient with diabetes (11724).\nless\nHEPATIC CIRRHOSIS\nMCTs are primarily metabolized in the liver and can cause narcosis and coma in patients with hepatic cirrhosis. Use with caution in patients with hepatic cirrhosis (11724).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with MCTs.",
            "Pharmacokinetics": "Absorption\nMCTs are efficiently absorbed. At physiological pH, MCTs are weak electrolytes and highly ionized, which increases their solubility (11724). Unlike long chain triglycerides (dietary fat), MCTs don't require the intestinal lymphatic system or bile salts for absorption. They are absorbed directly into the portal circulation (11723, 93731, 93736).\nMetabolism\nMCTs are metabolized primarily in the liver by beta-oxidation (11724, 93731, 93736).",
            "Mechanism of Action": "General\nMedium chain triglycerides (MCTs) are semi-synthetic lipids composed of three medium-chain (6-12 carbon atoms in length) saturated fatty acids attached to a glycerol backbone (93730, 93731, 93734, 93736). MCTs are made from hydrolyzed coconut oil or palm kernel oil. The resulting fatty acids are fractionated and esterified to produce MCTs. These fatty acids include mostly lauric acid, but also caproic acid, caprylic acid, and capric acid (11724, 11725).\nAnti-chylothorax effects\nMCTs are absorbed by the portal system rather than by the intestinal lymph system. Therefore, MCTs have been tried for chylothorax, an effusion of a milky fluid (chyle) into the pleural space, due to trauma or a defect of the thoracic duct. Administering MCTs may decrease lymph flow in the thoracic duct and allow the thoracic duct defect to heal (11726, 11727, 11728, 11729).\nAnti-stress effects\nThere has been some interest in using MCTs for injured and stressed patients since it causes mild ketosis and may decrease skeletal muscle catabolism (11725). However, clinical trials have not shown any clear advantage of MCTs over long chain triglycerides (2275, 2276, 2278).\nAntidiabetic effects\nLaboratory and human research suggests that MCTs are less likely to induce insulin resistance than other longer chain fats (93731, 93734).\nCholesterol lowering effects\nAnimal research shows that MCTs increase cholesterol excretion, thereby reducing blood levels (93730). However, evidence from research in humans is not as consistent. In fact, some human research shows that MCTs may have negative effects on some blood lipids (93731, 107733). A small meta-analysis shows that MCT oil does not significantly affect total, low-density lipoprotein (LDL), or high-density lipoprotein (HDL) cholesterol levels, although it does increase triglyceride levels by 12 mg/dL when compared with control. However, a subgroup analysis demonstrates that the effect of MCT oil on total and LDL cholesterol differs by the fatty acid composition of the control. Total and LDL cholesterol are increased when compared with a control containing primarily unsaturated fatty acids, but little or no improvement in levels is observed when compared with a control containing longer chain saturated fatty acids (107733). Only the MCT lauric acid seems to offer benefit on cholesterol levels. Although lauric acid does not seem to reduce LDL cholesterol, it does appear to improve the ratio of total cholesterol to HDL cholesterol by increasing HDL cholesterol levels (93734).\nCognitive effects\nThere is interest in using MCTs for cognitive impairment, including mild cognitive impairment and Alzheimer disease. In patients with Alzheimer disease, some research suggests that there is decreased glucose metabolism in some parts of the brain. The brain primarily utilizes glucose as an energy source, but at times of fasting it can use ketone bodies such as beta-hydroxybutyrate, acetoacetate, and acetone. Taking MCTs increases levels of ketone bodies and can lead to ketosis. Therefore, it is theorized that taking MCTs might improve energy metabolism in the brain and improve cognitive symptoms of Alzheimer disease. However, this has not been confirmed by clinical research (17028, 93734, 103012, 103013). Secondary analysis of a small clinical study in patients with mild cognitive impairment shows that taking a ketogenic MCT supplement 30 grams daily for 6 months increases white matter energy supply through a nearly threefold uptake of ketones in white matter fascicles, without effects on glucose uptake, when compared with placebo. Several improved measures of processing speed are associated with such increases in ketone uptake, suggesting that ketones may play a role in myelin integrity (107735). Ketone bodies produced by consuming MCTs might also inhibit beta-amyloid damage in the brain (17029).\nGastrointestinal effects\nA small crossover study in adults of various weights shows that a single 25-gram dose of MCT oil delays all phases of gastric emptying (105709).\nInflammatory effects\nMCTs have been suggested to have anti-inflammatory effects in animal models. However, effects in humans are unclear. There is evidence from in vitro research that MCTs can induce inflammatory mediators in macrophages (93734). Secondary analysis of a small clinical study in older adults with mild cognitive impairment shows that taking a ketogenic MCT supplement 15 grams twice daily for 6 months increases levels of the pro-inflammatory cytokine interleukin (IL)-8 when compared with placebo (107734). However, it is unclear if these were acute or chronic increases. Also, some patients were taking anti-inflammatory drugs during the study, and baseline levels of IL-8 were at the low end of the usual range established in other studies.\nMetabolic effects\nA very small clinical study in healthy adults shows that MCT supplementation in combination with a ketogenic diet increases the formation of beta-hydroxybutyrate, but does not result in faster time to nutritional ketosis, when compared with a long chain triglyceride control in combination with a ketogenic diet (107737). A clinical study in 7 healthy adult females with no special nutrition habits shows that MCT supplementation in combination with caffeine influences ketogenesis, with increases in the formation of beta-hydroxybutyrate, when compared with MCT supplementation alone (107736).\nTriglyceride lowering effects\nIn healthy people, single doses of MCT oil can reduce blood triglyceride levels (834). Triglyceride levels are also reduced in individuals with hypertriglyceridemia, especially in overweight individuals, using an oil containing medium- and long-chain fatty acids (93740, 93741). Although the mechanism of action is not clear, it is possible that the weight loss that accompanies the use of this oil results in benefits on blood fat levels (93731).\nWeight loss effects\nMedium chain fatty acids found in dietary MCTs are preferentially oxidized in the mitochondria, meaning that they are used first for energy production and are not stored as easily as long chain fatty acids (93729, 93731). Animal and human research suggests that MCTs might increase lipolysis and upregulate thermogenesis by brown adipose tissue (93730, 93731). Some preliminary evidence suggests that MCTs may increase metabolic rate and energy expenditures by the body when substituted in the diet for other types of fat (93731). MCTs may also induce satiety (93731, 93732, 93738). It has been suggested that increased satiety might decrease caloric intake, and in combination with increased metabolic rate, may lead to a slight decrease in body fat (10421, 11724, 93731, 93736, 101965, 105709).\n\nA small crossover study in adults with a body mass index (BMI) classified as normal to obese shows that a single 25-gram dose of liquid MCT oil modestly reduces caloric intake at the subsequent ad libitum lunch meal when compared with conjugated linoleic acid, but has no effect when compared with an equicaloric control. MCT oil also reduces caloric intake over the next 48 hours and delays all phases of gastric emptying. However, it does not affect levels of peptide YY or total ghrelin, which are involved in the regulation of appetite and satiety. These findings may have been confounded by high subjective nausea scores reported with MCT oil and the potential impact of nausea on caloric intake (105709). Also, the MCT formulation might be important, with one study showing a greater reduction in subsequent caloric intake with liquid MCTs when compared with solid MCTs (101965)."
        }
    },
    "Melanotan": {
        "sections": {
            "Overview": "The term \"melanotan\" describes two synthetic products known as melanotan-I and melanotan-II. These products were originally developed as analogues to alpha-melanocyte-stimulating hormone (alpha-MSH), an endogenous peptide hormone responsible for pigmentation of the skin. Melanotan-I, also known as afamelanotide, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of erythropoietic porphyrias (95749). Melanotan-II is an unapproved new drug that can increase skin pigmentation and induce penile erections. Commercial products containing melanotan-I or melanotan-II are unlicensed and unregulated in the U.S. Despite advice by the FDA to avoid use, these products remain available on the internet, in some tanning salons and spas, and from cosmetic physicians (99175, 99176, 99177, 99178, 99180, 99183, 99185).",
            "Safety": "POSSIBLY UNSAFE when used subcutaneously. Although subcutaneous melanotan has been used with apparent safety in some preliminary clinical research, moderate to severe nausea is common (5685, 5687, 5688, 99190). Furthermore, there are at least three cases of rapidly-developing melanoma thought to be related to the use of melanotan in individuals also using tanning beds (99176, 99184, 99187). In addition, subcutaneous injection of melanotan has been associated with at least one case of systemic toxicity and rhabdomyolysis, and two cases of priapism requiring reversal surgery (99183, 106742, 106744).\nThere is insufficient reliable information available about the safety of intranasal melanotan.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nSubcutaneously, melanotan can cause gastrointestinal cramping (5685), nausea (5685, 5687, 5688, 99176, 99190), decreased appetite (5687), facial flushing (5685, 5688), fatigue, somnolence (5685), dizziness, yawning, stretching, and spontaneous penile erections (5685, 5687, 5688, 99190, 106742). It can also cause increased pigmentation of the face, upper body, and buttocks (5685). In case reports of light-skinned individuals with sun-seeking behavior, melanotan has been associated with changes to existing nevi and the development of melanoma (99176, 99177, 99178, 99184, 99186, 99187, 99188, 99189).\n\nThere is a case of systemic toxicity after use of subcutaneous melanotan. Symptoms included overall body aches, sweating, anxiety, pupil dilation, tachycardia, muscle tremors, and rhabdomyolysis (99183). There is also a case of posterior reversible encephalopathy syndrome (PRES) resulting in a single seizure for a patient who used melanotan subcutaneously daily for one week (99179).\nDermatologic\nSubcutaneously, melanotan can cause facial flushing (5685, 5688, 99190). It can also cause increased pigmentation of the face, upper body, and buttocks (5685). In case reports of individuals with light skin and a history of use of tanning beds, the eruption of new nevi, and darkening of existing nevi or change to dysplastic nevi, were thought to be related to the use of subcutaneous melanotan. In all cases, the changes occurred suddenly after 1-4 injections of melanotan. Whether the melanotan use, the tanning bed, or the combination played a role in these changes is not completely clear (99177, 99178, 99188, 99189). Pigmentary changes, resulting in an eruptive pigmented lesion, also occurred in a 63-year-old male with light skin and a history of multiple actinic keratoses and basal cell carcinomas who had used subcutaneous melanotan for 15 days. A history of tanning beds was not mentioned (99186). There is also a case report of a female who developed transverse pigmented streaks on the ngernails after use of subcutaneous melanotan suggested by a physician for tanning (99185).\nless\nGastrointestinal\nSubcutaneously, melanotan can cause gastrointestinal cramping (5685), nausea (5685, 5687, 5688, 99176, 99190), and decreased appetite (5687). Severe nausea has occurred after up to 20% of injections, with vomiting rarely (99190).\nless\nGenitourinary\nSubcutaneously, melanotan-II can cause spontaneous penile erections and priapism (5685, 5687, 5688, 106742). In two case reports, males aged 41 and 55 using subcutaneous melanotan-II for tanning developed ischemic priapism lasting 22 hours and 30 hours, respectively. In one case the dose was unknown, and in the other it was 2 mg. Both patients had used melanotan-II previously without adverse effects, both required surgical management, and both subsequently developed erectile dysfunction (106742, 106744).\nless\nNeurologic/CNS\nMelanotan can cause fatigue and somnolence (5685), as well as yawning and stretching (5685, 5687, 5688, 99190).\n\nThere is a case report of posterior reversible encephalopathy syndrome (PRES) occurring in a 20-year-old female who had a single seizure following use of subcutaneous melanotan daily for 1 week. The seizure resulted in reduced sensation on one side and reduced concentration and word-finding ability. Magnetic resonance imaging of the brain showed almost complete resolution within 2 weeks. An effect of melanotan on blood pressure was thought to be responsible (99179). Melanotan may cause systemic toxicity and rhabdomyolysis due to overstimulation of certain sympathomimetic pathways. A case of sympathomimetic overdrive characterized by tachycardia, hypertension, diaphoresis, tremulousness, and mydriasis has been reported for a 39-year-old patient who used subcutaneous melanotan 6 mg. The patient developed renal injury and rhabdomyolysis, which necessitated hospitalization in the intensive care unit for 3 days (99183).\nless\nOncologic\nSubcutaneously, melanotan has been associated with cases of melanoma, particularly in patients with fair skin and existing moles who also use tanning beds. In one case report, melanoma occurred in a 20-year-old female who had self-injected with melanotan at doses of 0.1 mL (1 mg) on alternate days for 3-4 weeks, while also using a tanning bed (99176). In another case, a 23-year-old female self-injected with two injections a week apart before noticing changes in an existing mole. The patient, who also used a tanning bed, had a total of 7 weekly injections before being diagnosed with melanoma (99184). A third female was diagnosed with melanoma after progressive darkening of a pigmentary nevus on the abdomen. In addition to the occasional use of tanning beds, the patient used melanotan 100 mg daily for 2 days, followed by 50 mg daily for 5 days (99187). Whether the melanotan use, the tanning bed, or the combination played a role in the development of melanoma in these patients is not completely clear (99176, 99184, 99187).\nless",
            "Effectiveness": "Erectile dysfunction (ED). Preliminary clinical research shows that using melanotan-II subcutaneously is superior to placebo in males with psychogenic or organic erectile dysfunction for initiating spontaneous sustained penile erections. Melanotan-II resulted in erections in at least 63% of participants, maintaining peak rigidity without pain for up to 45 minutes. The typical dose used was 0.025 mg/kg. However, because of side effects, including severe nausea, melanotan-II is not recommended for this use (5685, 5687, 5688, 99190).\nThere is insufficient reliable information available about the effectiveness of melanotan for its other uses.\nless",
            "Dosing & Administration": "Adult\nSubcutaneous:Erectile dysfunction (ED): The typical dosage is 0.025 mg/kg (5685, 5687, 5688, 99190).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of melanotan.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with melanotan.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of melanotan.",
            "Mechanism of Action": "General\nThe melanotans, melanotan-I and melanotan-II, were originally developed as synthetic analogues to alpha-melanocyte-stimulating hormone (alpha-MSH) (99175, 99176, 99177, 99178, 99183, 99185). Melanotan-I, a linear tridecapeptide, has two amino acid substitutions (norleucine for methionine at position 4 and racemization of D-phenylalanine at position 7) in the alpha-melanocyte-stimulating-hormone peptide sequence (5685, 5686, 99175). Melanotan-II is a cyclic heptapeptide containing a lactam bridge between the amino acids lysine and aspartic acid (5685, 5686, 99175, 99181). Melanotans available on the internet do not appear to be pure compounds, with reports that they contain 4% to 6% unknown impurities (99175).\nSexual effects\nMelanotan-II has non-specific effects at various melanocortin receptors (99175). This results in spontaneous penile erections and increased sexual motivation, including in males with erectile dysfunction (5685, 5687, 5688). There are distinct melanocortin receptors found primarily in the brain and nervous system, including melanocortin-3 and -4 receptors. Melanocortin-5 receptors might also play a role in effects on sexual motivation (5686, 99181, 99183, 99190). Animal data suggest melanotropic peptides act in the hypothalamic regions surrounding the third ventricle. Increased sexual motivation has been shown in both male and female animals (5687, 99190). The central mechanism is thought to involve a dopamine-oxytocin pathway (5687).\nSkin pigmentation effects\nMelanotan-I has melanotropic potency that is 26- to 1000-fold greater than alpha-melanocyte-stimulating hormone, as well as increased resistance to degradation by plasma enzymes (5685, 5686, 99178). Melanotan-II has an even greater melanotropic potency than melanotan-I (5685, 5686, 99181). Melanotropic effects involve the melanocortin-1 receptor in melanocytes, resulting in the intracellular synthesis of eumelanin, leading to hyperpigmentation (99176, 106742)."
        }
    },
    "Melatonin": {
        "sections": {
            "Overview": "Melatonin is an endogenous hormone produced in the brain by the pineal gland (1773, 96314, 96318, 96320). Melatonin regulates the body's circadian rhythm, endocrine secretions, and sleep patterns (1773, 7043).",
            "Warnings": "Most commercial melatonin that is found in supplements is synthesized in the laboratory. However, in rare cases it can be derived from animal pineal gland. Melatonin from animal sources should be avoided due to the possibility of contamination (1772, 8266). Melatonin supplements have been shown to have high lot-to-lot variability in content, with some products containing almost five times above the amount indicated on the label. In addition, some melatonin supplements may be contaminated with serotonin (108144).\n\nBecause of its potential for causing daytime sleepiness, people should not drive or use machinery for 4-5 hours after taking melatonin (1772).\n\nCoronavirus disease 2019 (COVID-19): Despite some laboratory data suggesting benefit, there is no good evidence from clinical trials to support the use of melatonin for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "LIKELY SAFE when used orally and appropriately, short-term or as a single dose. Melatonin seems to be safe when used up to 8 mg daily for up to 6 months. Melatonin 10 mg daily has been used safely for up to 2 months (1049, 1068, 1077, 1085, 1738, 1754, 5854, 5855, 5857, 12226), (14283, 15005, 62850, 89502, 89503, 88285, 88289, 88293, 88294, 88295)(88296, 88299, 89508, 89510, 89511, 96313, 96314, 96316, 96317, 96319)(96321, 97438, 99345, 103484, 106301, 106303, 107811, 110286, 110299). ...when used topically and appropriately (1066, 1768, 1769, 4713, 4714, 96314).\nPOSSIBLY SAFE when doses of up to 8 mg daily are used orally and appropriately for longer than 6 months, doses of 10 mg daily are used for longer than 2 months, or doses of 50 mg daily are used for up to 5 days (7040, 7043, 62435, 106296, 107811). There is some evidence melatonin can be used safely in doses of up to 10 mg daily for up to 2 years in some patients (7040, 7043, 62435). ...when used intravenously under the supervision of a healthcare professional. A one-time dose of intravenous melatonin combined with a single bolus of intracoronary melatonin has been used with apparent safety in one clinical trial (96324).\nCHILDREN: POSSIBLY SAFE when used orally in low doses, short-term (9980, 15034, 62792, 88282, 88283, 88286, 88288, 95748, 96318, 97434)(97439, 97446, 106293, 110292, 113216, 113223, 113224). Although melatonin has been safely used in clinical research in doses up to 12 mg daily (88283), it is often advised that daily doses of melatonin be limited to 3 mg daily for children and infants 6 months or older and 5 mg daily for adolescents (95746). There is some concern that taking melatonin might adversely affect gonadal development in children (1739, 1740, 1742, 1743). While some evidence suggests that long-term use of melatonin in children may delay puberty, the available research includes only 3 small, observational studies with incomplete follow-up and poor measures of pubertal timing (95747). Although rare, pediatric overdose with melatonin has resulted in hospitalization, mechanical ventilation, and death (108145). Due to potential risks, the International Pediatric Sleep Association (IPSA) expert consensus recommendations for typically developing children state that only verified melatonin products should be used. Also, melatonin should be used in combination with behavioral approaches under medical supervision after a thorough sleep evaluation. IPSA states that melatonin should generally be avoided in children under 2 years, in children without sleep complaints, and in adolescents trying to accommodate early school schedules (116912).\nCHILDREN: There is insufficient reliable information available about the safety of melatonin when used long-term.\nPREGNANCY: POSSIBLY UNSAFE when used orally or parenterally in high doses or with frequent use. High doses of melatonin 75-300 mg daily seem to inhibit ovulation, causing a contraceptive effect (769, 1740, 6002, 8271, 95728). Advise pregnant patients and patients wishing to become pregnant to avoid using melatonin frequently or in high doses.\nPREGNANCY: There is insufficient reliable information available about the safety of melatonin in lower doses during pregnancy. Some research shows that taking melatonin 2 mg daily does not affect anterior pituitary hormone levels in females who are not pregnant; this suggests that low doses may not have a contraceptive effect (62898). Other research shows that taking melatonin 3 mg daily during the follicle stimulating stage of in vitro fertilization does not negatively impact pregnancy rates (62818, 62819, 88297, 89512, 88297). However, it is not known if melatonin is safe for use throughout pregnancy (95729). Until more is known about the safety of melatonin, avoid using during pregnancy.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, melatonin is generally well tolerated.\nMost Common Adverse Effects\nOrally: Dizziness, drowsiness, headache, and nausea.\nSerious Adverse Effects (Rare)\nOrally: There is concern that melatonin may increase the risk for seizure.\nCardiovascular\nMelatonin might increase levels of very low-density lipoprotein (VLDL) cholesterol and triglycerides (62176). Several rare or poorly described cases of abnormal heart rhythms, palpitations, fast heart rate, or chest pain have been reported. However, in these cases, the patients were taking other drugs that could account for the symptoms, and melatonin was not thought to be the cause (1079, 9181, 62776, 62789, 63067). Additionally, four cases of elevated left ventricular end-diastolic pressure associated with melatonin intake have been reported (114510).\nless\nDermatologic\nPapular skin rash and pruritus has been reported with melatonin use. However, the effect was generally mild and did not require cessation of melatonin treatment (62450, 62754, 109696), and had similar rates as placebo (96316). Cutaneous flushing, angiokeratoma, and nasal mucosal ulcers have also been reported (62770, 62914, 114510). Two cases of fixed drug eruption on the genitalia have been reported for patients who used oral melatonin (Nature's Bounty Natural melatonin) for preventing jet lag (88284).\nless\nEndocrine\nOrally, melatonin use might be associated with higher rates of precocious puberty, growth hormone deficiency, elevated cortisol, and increased progesterone (114510). A case of gynecomastia (increased breast size) has been reported for a 56 year-old patient with amyotrophic lateral sclerosis (ALS) who used oral melatonin, long-term (89430). Also, reduced sperm concentration and sperm motility has been reported for two men who used oral melatonin 3 mg daily for 6 months. Improvement in sperm quality was observed for only one of the two men following melatonin cessation (62231).\nless\nGastrointestinal\nOrally, melatonin may cause nausea (62384, 62770, 114510), abdominal cramps, or mild abdominal pain (62450, 62754, 62914, 96316), diarrhea (62804, 62811, 62914), constipation (96316), or decreased appetite (62345, 62792). Often these symptoms occur during the first few days of treatment and subside after a few days (62804). In some cases, rates of symptoms are similar between melatonin and placebo (96316). Less often, melatonin has been reported to cause abnormal feces (62450), odd taste in the mouth (1070), pouchitis (114510), or reflux esophagitis (1745) when used orally. A case of exacerbated symptoms of Crohn disease, including increased diarrhea and abdominal cramps, has been reported for a patient who took oral melatonin 3 mg at bedtime for 4 days. Symptoms resolved within 24 hours of melatonin treatment cessation (62218).\nless\nGenitourinary\nOrally, melatonin may increase enuresis in adults and children (58685, 62450, 62710, 62770, 62804, 62804, 62811). In perimenopausal adults, melatonin has caused a resumption of spotting or menstrual flow (11806). Decreased libido has been noted for one patient treated with melatonin 3 mg daily for 8 weeks (15216).\nless\nHematologic\nA case of nose bleed has been reported with oral melatonin (62450). Some melatonin preparations contain contaminants that are associated with eosinophilia-myalgia syndrome (9715, 9716).\nless\nHepatic\nA case of autoimmune hepatitis has been reported for a patient who took melatonin orally to treat insomnia (63037). Melatonin use has also been linked to a few cases of Gilbert's syndrome (114510).\nless\nMusculoskeletal\nOrally, melatonin might increase fall risk. Analysis of a large adverse event database suggests that the rate of accidents and falls is higher with melatonin use when compared with the average rate of all other medications combined. However, the rate of accidents and falls with melatonin use seems to be lower when compared with other sleep medications (114510). Other clinical evidence shows that a single dose of melatonin 3 mg may increase fall risk due to increased postural swaying while standing on one or both feet in healthy adults ages 60-71 years (97442).\n\nA single case of ataxia has been reported for an 81-year-old female who used melatonin for 4 days (9181). Weakened muscle power has been reported for two patients treated with melatonin 5 mg in the evening (62456). Some melatonin preparations contain contaminants that are associated with eosinophilia-myalgia syndrome (9715, 9716). There are also reports of back pain, dropped head syndrome, fractures, growth retardation, and myalgia associated with melatonin intake (114510).\nless\nNeurologic/CNS\nOrally, melatonin may cause migraine-like headache (1070, 1077, 15034, 62384, 62450, 62710, 62754, 62804, 62792, 62914, 88288, 88293, 88294, 96318)(106297, 114510) or dizziness (62345, 62384, 62450, 62456, 62770, 62784, 62792, 62804, 62811, 89510)(110297). Often these symptoms occur during the first few days of treatment and subside after a few days (62804). Melatonin may also cause drowsiness or fatigue when taken orally (1077, 8273, 15216, 62384, 62456, 62784, 62804, 62811, 88288, 89510, 96314, 96316, 96318, 97446)(106293, 106297, 114510). These symptoms appear to be more common if melatonin is taken in the morning or at very high doses (greater than 50 mg) (8269, 62874). A case of excessive drowsiness has been reported when melatonin was combined with citalopram, nortriptyline, and oxycodone. Sedation improved with discontinuation of melatonin (96315). Indiscriminate use of melatonin may cause irregular sleep-wake cycles to occur (62998). Less commonly, melatonin may also cause behavior worsening (62811), confusion or disorientation (63014, 63067), nighttime awakening (62710, 62811), mood swings or agitation (96318), stereotypy (96318), tic (114510), excitement before bedtime (62811), insomnia (114510), nightmares or more intense dreams (62401, 62462, 62780, 62784, 88283, 114510), feelings of a \"rocking\" sensation (62155), or reduced alertness when taken orally.\n\nA case of generalized epilepsy has reportedly occurred after treatment with melatonin for 4 months (9708). Also, some case reports raise concerns about increased risk of seizure with melatonin treatment, but conflicting evidence suggests that melatonin may decrease the risk of seizures (1699, 8248, 9695, 9697, 9744, 9746, 62123, 62256, 62384, 62754)(63070, 63071, 89431). One patient experienced hyponatremia with confusion and seizures after taking prolonged-release melatonin 2 mg. However, malnutrition and cannabis abuse were also thought to contribute to this reaction (96321).\n\nAlthough there is concern that melatonin might affect cognitive function in healthy adults, research in humans suggests that oral or topical melatonin do not impact most measures of cognitive function (97442, 97448).\nless\nOcular/Otic\nThere are six case reports of pupillary disorder associated with melatonin intake (114510).\nless\nPsychiatric\nOrally, melatonin may cause mood changes, including dysphoria (sadness) (1764), dips in mood (62345, 62450, 62792), nervousness (62784), suicide or self-injury (114510), or transient depression (1077). Delusions and hallucinations have also been reported in clinical research (62347). An analysis of adverse event case reports indicates that drug abuse, dependence, and withdrawal have been associated with melatonin use; however, the rate appears to be lower when compared with all other medications combined or sleep medications (114510).\n\nThis analysis also suggests that melatonin use might be associated with educational problems, social behavior disturbances, defiant behavior, oppositional defiant disorder, and school refusal at disproportionately higher rates when compared with all other drugs combined or other sleep medications (114510). An isolated incident of aggressiveness was also noted in a child diagnosed with attention deficit-hyperactivity disorder (ADHD) who took melatonin in combination with methylphenidate (9980). Severe irritability has been reported in two children with autism spectrum disorder who had abruptly discontinued melatonin due to the completion of a clinical trial (106293).\nless\nOther\nThere are case reports of body temperature fluctuation and post viral fatigue syndrome associated with melatonin intake (114510).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIKELY EFFECTIVE\nDelayed sleep phase syndrome (DSPS). Oral melatonin shortens the time needed to fall asleep in children and adults with DSPS.\nMost clinical research shows that taking melatonin orally reduces the length of time needed to fall asleep and advances sleep onset time in young adults and children with DSPS (8244, 12226, 15005, 62714, 62792, 63055, 88288, 88290, 89509). In adults, 0.3-5 mg daily for up to 9 months has been used (8244, 62714, 62792, 63055, 88290, 89509). In children, 1-6 mg before bedtime for up to one month has been used (62714, 62792, 89509). In addition to improving sleep, melatonin also improves measures of quality of life such as mental health, vitality, and bodily pain in young adults with DSPS (8244, 12226, 15005). However, relapse to pre-treatment sleeping patterns seems to occur within one year after stopping supplementation (63048).\nless\nNon-24-hour sleep wake disorder. Oral melatonin improves non-24-hour sleep wake disorder in blind children and adults.\nTaking oral melatonin 0.5-4 mg daily in children and 0.5-10 mg daily in adults for up to 6 years helps improve circadian rhythm sleep disorders in blind children and adults (1082, 1744, 1749, 6585, 62346, 62350).\nless\nPOSSIBLY EFFECTIVE\nBeta blocker-induced insomnia. Oral melatonin seems to improve sleep in patients with insomnia related to the use of beta-blockers.\nBeta-blockers such as atenolol and propranolol seem to decrease endogenous melatonin levels (1780). This might result in insomnia as a side effect. Clinical and preclinical research shows that taking a melatonin supplement might decrease the insomnia caused by beta-blockers (1062, 89502). Taking melatonin 5 mg at night after taking atenolol 100 mg appears to attenuate the changes in sleep onset latency, total wake time, and wakefulness after sleep onset when compared with taking atenolol 100 mg alone (1062). Also, in patients taking atenolol or metoprolol, taking melatonin 2.5 mg one hour before bedtime for 20-28 days increases total sleep time by 13-37 minutes and decreases sleep latency by 8-14 minutes when compared with placebo (89502).\nless\nCancer. In patients with various types of cancer, most research shows that oral or combined intramuscular/oral melatonin in combination with chemotherapy or other treatments seems to improve tumor regression and survival rates.\nThere is some evidence that taking combined high-dose melatonin with conventional chemotherapy or with interleukin-2 (IL-2) might improve tumor regression rate in patients with breast, lung, kidney, liver, pancreatic, stomach, or colon cancer (1692, 5854, 5855, 5857, 7040, 7043, 8268, 62407, 62844). Melatonin plus chemotherapy in patients with metastatic solid tumors seems to increase the regression rate and one-year survival rate by about 40% to 50% when compared with chemotherapy alone (7040, 62407, 62844, 89504). The addition of melatonin also seems to help reduce chemotherapy toxicities, including hematologic complications, cachexia, asthenia, and neuropathy (8268, 62844, 89504). There is also some preliminary evidence that melatonin alone, orally or intramuscularly, might improve stabilization rate and possibly one-year survival rate in patients with resistant or untreatable neoplasms of the lung, liver, pancreas, colon, breast, or brain (1080, 1688, 1693, 2566). Also, when used in combination with radiotherapy, high-dose melatonin seems to increase the survival time and percent survival in patients with brain glioblastomas when compared with radiotherapy alone (62991). However, high-dose melatonin treatment does not seem to improve the survival of patients with brain metastases who receive radiation therapy (62455). Melatonin 10-40 mg daily has been used in most clinical trials (1080, 1692, 1693, 2566, 5854, 5855, 5857, 7040, 7043, 8268)(62455, 62844, 62991, 89504). In one study, melatonin 20 mg intramuscularly daily for 2 months, followed by oral melatonin 10 mg daily as maintenance, was used (1688).\n\nThe effect of melatonin on quality of life and sleep quality in patients with cancer has also been investigated. A meta-analysis of six clinical trials shows that taking melatonin 20 mg daily does not improve sleep quality or quality of life when compared with a control, usually placebo. The duration of studies varied widely; from a period of 7 days or until death. However, there was a modest effect of melatonin on symptoms of depression in patients taking it for at least 14 days or those who underwent surgery (109697).\nless\nEmergence delirium. Oral melatonin seems to be beneficial for reducing sevoflurane-induced agitation in children. It is unclear if oral melatonin is beneficial for adults undergoing surgery.\nTwo meta-analyses of clinical research in adults undergoing various types of surgery with anesthesia show that taking perioperative melatonin 3-6 mg or the melatonin receptor agonist ramelteon 8 mg orally daily for 1 day to 12 weeks reduces the risk of emergence delirium by 43% to 59% when compared with placebo or no treatment (112053, 114514). Subgroup analysis of one meta-analysis suggests that higher melatonin of 5 mg or greater decreases the incidence of emergence delirium, while lower melatonin doses of 3 mg and ramelteon do not impact emergence delirium incidence when compared with control. Additionally, melatonin intake is most beneficial for reducing emergence delirium in the early postoperative period within 3 days of surgery and for cardiopulmonary surgeries. No benefit was observed for hospital or intensive care unit (ICU) length of stay, mortality, late postoperative periods of 7 days up to 12 weeks, or other surgery types when compared with control (114514). However, the validity of the results of both meta-analyses is limited by high heterogeneity. Another small clinical study conducted in Egypt in older patients undergoing surgery for colorectal cancer shows that taking melatonin 5 mg the night before surgery, 5 mg twelve hours before surgery, and 5 mg two hours before surgery reduces the incidence of delirium and decreases nurse-reported delirium scores six hours postoperatively, but at no other timepoints up to three days postoperatively, when compared with placebo (114508).\n\nIn children, clinical research shows that taking melatonin reduces the incidence of sevoflurane-associated emergence delirium (97440, 106292, 113216). Meta-analyses of 3-4 small clinical studies in children aged 2-9 years show that taking melatonin 0.05-0.5 mg/kg 40-45 minutes prior to sevoflurane reduces the incidence of agitation by 60% when compared with placebo (97440, 113216). The most recent analysis also shows that taking melatonin reduces the incidence of agitation by 52% when compared with midazolam (113216). Most research shows that doses of melatonin 0.2 mg/kg or greater may be most effective (97440, 106292). However, clinical research shows that taking melatonin is less effective than dexmedetomidine (109701, 113216). One study shows that taking melatonin 0.5 mg/kg before surgery is 55% less effective than intranasal dexmedetomidine 2 mg/kg for reducing the incidence of sevoflurane-associated emergence delirium (109701).\nless\nHypertension. Oral controlled-release melatonin seems to reduce blood pressure by a small amount in patients with hypertension. Immediate-release melatonin may not have the same effect.\nControlled-release melatonin 2-24 mg, taken before bedtime for up to 4 weeks, seems to lower systolic blood pressure (SBP) by 4-6 mmHg and diastolic blood pressure (DBP) by about 4 mmHg in individuals with essential hypertension or high blood pressure at nighttime (62359, 62416, 62441, 62826, 108947). Some evidence shows that immediate-release melatonin does not have this effect (62826).\n\nSome evidence also suggests that melatonin seems to slightly reduce blood pressure in patients without hypertension, but to a lesser degree (103689). However, a very small clinical study in healthy young adults consuming a high sodium diet (6900 mg daily) shows that taking melatonin 10 mg before bedtime for 10 days decreases nighttime SBP but does not improve nighttime DBP, daytime SBP or DBP, 24-hour SBP or DBP, or nocturnal dipping of SBP or DBP when compared with placebo (112442).\nless\nInsomnia. In patients with insomnia, oral melatonin seems to shorten the time it takes to fall asleep by about 7-12 minutes, although the effect on the amount of time asleep is inconclusive. Melatonin is more likely to be beneficial in older adults or people with certain comorbidities.\nShort-term melatonin treatment appears to modestly reduce the time it takes to fall asleep (sleep latency) in otherwise healthy adults with insomnia. This reduction in sleep latency appears to amount to only about 7-12 minutes and might not be considered clinically relevant. Melatonin does not appear to improve sleep efficiency and may only increase total sleep time by about 8 minutes (15005, 88290). Despite lack of substantial improvements in objective measures, some patients report minor improvement in subjective feelings of sleep quality (1070, 1083, 12226, 88290). A meta-analysis of clinical studies in healthy adults and those with sleep disorders shows that melatonin reduces sleep latency by 9 minutes and increases total sleep time by about 20 minutes when compared with placebo. Dose-response analysis indicates that melatonin doses of 3 to 5 mg daily optimally reduce sleep latency and increase total sleep time, and that higher doses provide no additional benefit. Furthermore, melatonin is most effective at reducing sleep onset latency when administered 2 to 3 hours prior to desired bedtime and in patients who are healthy rather than those with insomnia (114507).\n\nWhile clinical research remains limited, available studies in children aged 6-12 years with insomnia due to delayed onset of sleep shows that melatonin 5 mg or 0.05-0.15 mg/kg at bedtime for up to 4 weeks seems to shorten the time that it takes to fall asleep and increases the duration of sleep (9708, 62345, 62770). More evidence is needed on the long-term effects of melatonin for insomnia. The International Pediatric Sleep Association (IPSA) recently published expert consensus recommendations for typically developing children stating melatonin should only be used under medical supervision after a thorough sleep evaluation. Behavioral approaches should precede and accompany melatonin use. Additionally, except in rare cases, melatonin should be avoided in children under 2 years, in children without sleep complaints, and in adolescents trying to accommodate early school schedules. If starting melatonin, treatment should begin with the lowest dose 30-60 minutes before bedtime, and be limited to short-term use (116912).\n\nSome evidence shows that taking oral melatonin might be most beneficial for insomnia in elderly patients who could be melatonin deficient (1072, 1729, 1738, 1754, 7081, 15005, 62357, 62465, 62472, 62613)(62776, 62789). Taking sustained-release melatonin preparations 2 mg daily seems to improve sleep maintenance and sleep quality in elderly individuals (1738, 1754, 62465, 62472, 62613, 62776), while immediate-release preparations seem to decrease sleep latency (1738, 63041). In these clinical trials, controlled-release, fast-release, or slow-release melatonin 2-3 mg before bedtime for up to 29 weeks has been used (1072, 1738, 1754, 7081, 62357, 62465, 62472, 62613, 62776, 62789). However, using a melatonin patch placed on the gums does not improve sleep parameters in elderly patients with insomnia (63062).\n\nSome research shows that taking melatonin when taken either alone or in combination with other sleep aids such as bright-light treatment seems to be beneficial for insomnia in patients with certain comorbid conditions. Taking melatonin 2-12 mg for up to 4 weeks has been used to improve insomnia in patients with depression (1053, 1729), schizophrenia (8245, 62452), bipolar disorder (62140), asthma (62375), cystic fibrosis (62708), hospitalization (9709, 106295), and insomnia termed \"ICU syndrome\", which refers to sleep disturbances while in the intensive care unit (8240). Insomnia is also improved in children with epilepsy aged 3-12 years taking 6-9 mg of melatonin before bedtime for 4 weeks and children aged 3 months to 2 years taking 3 mg of melatonin before bedtime for 2 weeks (62394, 99342, 113223), and quality of sleep is modestly improved in adults with epilepsy taking 3 mg before bedtime for 8 weeks (110299). There is also evidence that melatonin can improve total sleep time and sleep-onset latency in children with tuberous sclerosis (1747), autism spectrum disorders (1056, 62811, 88286, 96318, 106293, 110290), developmental disabilities (9707), and neurodevelopmental disorders (21819, 62143, 88283). It also appears to decrease sleep latency and increase sleep time in adults and children with intellectual disabilities, with or without epilepsy (62373, 62561). While some evidence shows that fast-release melatonin is more effective for improving the time to fall asleep in children with sleep-wake cycle disturbances and neurodevelopmental disabilities, it is unclear if controlled-release melatonin provides any additional benefits in this population (62143, 95746).\n\nHowever, there is conflicting evidence regarding the effects of melatonin in patients with insomnia and comorbid conditions such as Alzheimer disease or dementia. Some clinical research shows that taking melatonin 3-5 mg before bedtime for up to 10 weeks, either alone or in combination with bright-light treatment, improves impaired sleep related to Alzheimer disease or dementia (1729, 62474, 63059). But not all research agrees. Meta-analyses of several clinical studies show that taking melatonin 3-10 mg daily improves subjective sleep quality, but not objective outcomes such as number of awakenings at night and sleep efficiency in these patients. Also, immediate-release melatonin 2.5-10 mg or prolonged-release melatonin 1.5-2.5 mg for 10 days to 24 weeks shows inconsistent effects on total sleep time at night in patients with Alzheimer disease (96319, 96320).\n\nThere is also mixed evidence regarding the effects of melatonin in patients with Parkinson disease. In some individual studies, subjective outcomes such as sleep quality seem to improve. However, improvement may not be clinically significant and might be dependent on dose and formulation. Also, objective outcomes such as sleep efficiency and total sleep time at night do not seem to improve (62403, 62454, 62829, 96320, 116924).\n\nMelatonin has also been evaluated in postoperative patients and patients with traumatic brain injury (TBI). Taking melatonin before bed does not improve sleep quality soon after tracheostomy, laparoscopic cholecystectomy, or total knee arthroplasty (62439, 62552, 99343, 100255) or 2-6 weeks after total joint arthroplasty (106305). In adults with TBI, one clinical study shows that taking prolonged-release melatonin (Circadin, Sigma Pharmaceuticals) 2 mg two hours prior to bedtime for 4 weeks improves sleep quality, efficiency, and fatigue when compared with placebo. However, melatonin did not improve sleep onset latency or daytime sleepiness. There appears to be no association between TBI severity and the effect of treatment (96317).\n\nThere is mixed evidence regarding the effect of melatonin in patients undergoing hemodialysis. Some evidence shows that taking melatonin (Pharma Nord) 3 mg before bed for 6 weeks reduces time needed to fall asleep, improves sleep efficiency, and increases actual sleep time when compared with placebo (62521). Other clinical research in patients undergoing hemodialysis shows that taking immediate-release melatonin 3 mg (Puritans Pride, USA) for 3 months modestly improves various sleep measures when compared with placebo. After treatment, 63.0% of those taking melatonin had no insomnia compared with 7.7% of those taking placebo (110291). However, other evidence shows that taking immediate-release melatonin (Pharma Nord) 3 mg nightly for 12 months does not improve quality of life or sleep efficiency in these patients, indicating that melatonin may not improve sleep long-term (89501).\n\nFinally, limited evidence shows that melatonin does not improve insomnia in patients with substance use disorders (97441).\n\nMelatonin has also been evaluated in combination with other ingredients. A very small clinical study in middle-aged adults with poor sleep quality shows that taking melatonin 1.9 mg and magnesium citrate 200 mg at bedtime for 4 weeks improves subjective sleep quality and objective sleep measures including latency by 17 minutes, efficiency, number of awakenings, and awakening length when compared with placebo. However, the combination of melatonin and magnesium does not improve other subjective measures of mood or daytime sleepiness and reduces total sleep time by 42 minutes when compared with placebo (116160). It is unclear whether these effects are due to melatonin, magnesium, or the combination.\nless\nJet lag. Taking oral melatonin 2-3 mg daily while travelling seems to improve alertness and reduce daytime sleepiness in people with jet lag. It is unclear if it improves sleep efficiency in this population. Higher doses might have a hypnotic effect.\nMost research shows that melatonin can modestly improve certain symptoms of jet lag such as alertness and psychomotor performance. Melatonin also seems to improve, to a lesser extent, other jet lag symptoms such as daytime sleepiness and fatigue (12226). Melatonin might not be effective for decreasing the time to fall asleep (sleep latency) or sleep efficiency in patients with jet lag (6496, 14283), although some research shows a beneficial effect of melatonin on these outcomes (62364).\n\nDoses between 0.5-5 mg appear to be equally effective. Although doses of up to 8 mg have been used, doses greater than 5 mg do not seem to be more effective and seem to produce a greater hypnotic effect. Travelers traveling eastward through five or more time zones may find 2-3 mg of melatonin, either slow-release or fast-release, to be useful when taken at local bedtime on the day of arrival and for 2-5 nights thereafter. Taking melatonin in advance of travel does not help prevent jet lag. The usefulness of melatonin for westward travel or over fewer time zones is less clear, although some evidence suggests that slow-release formulations are less effective than fast-release preparations (1049, 1077, 1079, 1085, 1722, 8273, 9181, 9750, 62706).\nless\nMigraine headache. Oral melatonin 3-4 mg seems to prevent migraines when used prophylactically. It is unclear if oral melatonin is beneficial for treating migraine.\nMelatonin production might be altered in people with migraine headache (6712, 96316). Meta-analyses and individual clinical studies in adults have shown that taking melatonin modestly reduces migraine severity, migraine duration, migraine frequency, migraine-related disability, and the need for analgesics and increases the likelihood of a 50% reduction in the baseline frequency of migraine, when compared with placebo or baseline. Immediate- or prolonged-release melatonin (occasionally as Circadin, Sigma Pharmaceuticals) in doses of 3-4 mg each evening for up to 6 months have been used in these studies (12149, 96316, 97438, 103486, 110286, 114512). Meta-analyses have included two or three individual clinical trials (103486, 110286). One meta-analysis shows that taking melatonin reduces the frequency of migraine days by about 1.7 (103486). An additional meta-analysis in adults with migraines shows that taking melatonin modestly reduces the use of analgesic medications from baseline, when compared with placebo (110286). In contrast, other clinical research shows that taking extended-release melatonin (Circadin, Neurim Pharmaceuticals Ltd.) 2 mg nightly for 8 weeks does not reduce migraine attack frequency when compared with placebo (62784).\n\nSome clinical research also shows that melatonin is as effective as standard treatment for migraine prevention. Some research shows that taking melatonin 3 mg daily for 12 weeks is as effective as amitriptyline 25 mg in reducing migraine frequency, intensity, and duration, as well as reducing analgesic use (96316). A meta-analysis of two clinical trials shows that taking melatonin 3 mg each evening for 8-12 weeks is as effective as standard treatment; however, only one study each compared melatonin with amitriptyline (96316) and valproate (110286). More research comparing melatonin with standard treatments is needed.\n\nMelatonin has also been investigated in children. Preliminary clinical research in children 5-15 years of age with migraine headache shows that taking melatonin 0.3 mg/kg daily for 90 days reduces migraine frequency, severity, and duration, and decreases analgesic use when compared to baseline (97446).\n\nSome research also suggests that melatonin might help to TREAT migraine headache in children and adolescents aged 9-17 years. Preliminary clinical research shows that taking melatonin 1-8 mg reduces pain by a small amount 2-4 hours later. The higher doses of 2 mg for children weighing less than 40 kg and 8 mg for children weighing at least 40 kg seemed to have the greatest benefit (103487). This study is limited by the lack of a comparator group and a very high drop-out rate.\nless\nPre-procedural anxiety. Most research shows that oral or sublingual melatonin reduces preoperative anxiety in adults. The benefit in children is unclear.\nA meta-analysis of 18 clinical studies in adults shows that taking oral or sublingual melatonin 3-10 mg or 0.05-0.4 mg/kg 20-120 minutes prior to surgery reduces preoperative anxiety by an average of 12 points on a 100-point visual analogue scale when compared with placebo. It also reduces postoperative anxiety by about 5 points when compared with placebo. Furthermore, a meta-analysis of 7 small clinical trials suggests that melatonin is comparable to benzodiazepines such as midazolam, oxazepam, or alprazolam for reducing preoperative anxiety (105005). In some cases, melatonin might also be preferable to benzodiazepines because it does not cause anterograde amnesia, respiratory depression, or impairment of cognitive and psychomotor skills (88299, 99337).\n\nHowever, research in children is conflicting. Two small clinical studies in children aged 2-10 years preparing to undergo outpatient elective surgery show that taking melatonin 0.05-0.5 mg/kg 30-45 minutes before anesthesia is less effective than midazolam 0.5 mg/kg for reducing preoperative anxiety, including during separation from parents and when putting on the anesthesia mask (62601). In contrast, another small clinical study in children aged 2-5 years undergoing minor elective surgery shows that taking oral melatonin 0.25-0.5 mg/kg 1 hour before anesthesia is similar to midazolam 0.25-0.5 mg/kg for reducing anxiety when separating from parents and when putting on the anesthesia mask (62399). A third study in children aged 3-8 years found no differences between melatonin 0.3 mg/kg, midazolam 0.3 mg/kg, and placebo for reducing preoperative anxiety (106292).\nless\nPre-procedural sedation. Oral melatonin might reduce the sedative dose required to achieve adequate sedation in children. It is unclear if oral melatonin is beneficial for this purpose in adults.\nA clinical study in children aged 5-14 years undergoing surgery shows that oral melatonin 0.5 mg/kg reduces the propofol dose required for adequate sedation by 0.77 mg/kg when compared with midazolam 0.5 mg/kg (97444). However, taking melatonin 0.5 mg/kg 45 minutes before surgery is less effective than intranasal dexmedetomidine 2 mg/kg for successful mask acceptance and parental separation (109701). A meta-analysis of clinical and observational studies in children undergoing non-operative procedures, such as electroencephalogram (EEG) and magnetic resonance imaging (MRI), suggests that enteral or parenteral melatonin is no better for adequate sedation than sleep deprivation or chloral hydrate (105884). This finding is limited by imprecision, inconsistency, and a high risk of bias.\n\nA small clinical study in adults undergoing total abdominal hysterectomy shows that taking extended-release melatonin 5 mg, 90 minutes before surgery, decreases the use of midazolam for sedation during surgery when compared with placebo (108945). However, the validity of this finding is unclear, as 0% of patients in the melatonin group required midazolam, compared with 100% of patients in the placebo group. In adults undergoing lower extremity orthopedic surgery with spinal anesthesia, a small study shows that giving melatonin 10 mg orally the night before surgery, followed by 10 mg 2 hours prior to surgery, increases the sedation score when compared with placebo (108951).\nless\nSunburn. Most research shows that topical melatonin seems to protect against erythema from ultraviolet (UV) light exposure.\nWhen applied prior to UV light exposure, a gel containing melatonin 0.05% to 2.5% seems to significantly decrease erythema (1066, 1768, 1769). In one study, topically applied melatonin in combination with vitamin E 2% and/or vitamin C 5%, was modestly photoprotective when used prior to UV exposure, but had no effect when used during or after UV exposure (4713, 4714). Other preliminary clinical research shows that applying a cream containing melatonin 12.5% prior to sun exposure reduces erythema in adults with high sun reactivity, but not in those with mild to moderate sun reactivity. Creams containing melatonin 0.5% or 2.5% did not reduce erythema in any skin types when compared with placebo (97443). The differences in these findings may be related to the different topical formulations used.\nless\nThrombocytopenia. Oral melatonin seems to improve and prevent thrombocytopenia associated with cancer, cancer treatment, and other disorders.\nClinical research shows that taking melatonin can improve thrombocytopenia associated with cancer, cancer treatment, and other disorders. Melatonin 20-40 mg daily beginning up to 7 days before chemotherapy and continuing for up to four chemotherapy cycles or until disease progression has been used (1694, 1695, 1696, 1697, 2564, 8268).\nless\nTemporomandibular disorders (TMD). Oral melatonin seems to moderately reduce pain in females with TMD.\nClinical research shows that taking melatonin 5 mg at bedtime for 4 weeks reduces pain by 44% and increases the ability to withstand pain by 39% when compared with placebo in females with TMD. This results in reduced analgesic use and improved sleep quality (89508).\nless\nPOSSIBLY INEFFECTIVE\nAthletic performance. Most research suggests that oral melatonin does not improve athletic performance or physical strength.\nTaking melatonin 6 mg one hour prior to heavy resistance exercise does not seem to improve maximal strength or maximal jumping ability (62424). Also, taking melatonin 5 mg at night does not appear to improve exercise performance the following morning in healthy athletes (62179). Furthermore, taking melatonin 5 mg 15 minutes prior to exercise does not appear to impact endurance during a cycling trial when compared with placebo (99338). However, some research disagrees. One small clinical trial in professional soccer players shows that taking melatonin 5 mg daily during a six-day training schedule modestly attenuates deterioration in physical performance, such as jumping, agility, and sprints, when compared with placebo (109700).\nless\nCachexia. Oral melatonin does not seem to improve appetite or body composition in patients with cachexia and cancer.\nClinical research in cachectic patients with advanced lung or gastrointestinal cancers shows that taking melatonin 20 mg each evening for 28 days does not improve appetite, body weight, or body composition when compared with placebo (88287).\nless\nCancer-related fatigue. Oral melatonin does not seem to improve fatigue in patients with cancer.\nA meta-analysis of five clinical trials shows that taking melatonin does not reduce fatigue in patients with cancer (109697). Most studies used melatonin 20 mg daily, with a duration of 7 days to one year (99344, 109697). Although most studies included in the analysis were small, one contained over 700 patients and lasted one year. However, some research disagrees. Preliminary clinical research in adults with breast cancer shows that taking melatonin 18 mg orally daily for 2 years moderately improves fatigue scores when compared with placebo (112054).\nless\nCancer-related pain. Oral melatonin does not seem to improve pain in patients with cancer.\nA meta-analysis of five clinical trials shows that taking melatonin does not reduce pain in patients with cancer (109697). Most studies used melatonin 20 mg daily, with a duration of 10 days to one year (109697). Although most studies included in the analysis were small, one contained over 700 patients and lasted one year.\nless\nCritical illness (trauma). Oral melatonin does not seem to be beneficial for reducing hospital stay in critically ill patients.\nA meta-analysis of clinical research in critically ill patients shows that taking melatonin does not reduce the length of stay in the ICU or the hospital, or affect mortality or sleep quality, when compared with placebo (109696). One additional small clinical study shows that receiving melatonin 3 mg through a nasogastric tube once at 9 pm, followed by a 0.5 mg hourly maintenance dose for 6 hours during the overnight period, does not improve sleep when compared with placebo in patients in the ICU that are being weaned off sedatives and mechanical ventilation (104997). Another moderate-sized clinical study in critically ill adults admitted to the ICU shows that administering enteral melatonin 3 mg once daily at night for 7 days does not improve consciousness levels or reduce delirium risk, mortality risk, length of ICU stay, or length of mechanical ventilation when compared with standard care (113496).\nless\nDementia. It is unclear if oral melatonin improves behavior or cognition in patients with dementia. However, it might reduce evening confusion (sundowning).\nMost clinical research shows that taking melatonin does not improve cognition or behavioral or affective symptoms in patients with probable Alzheimer disease or other forms of dementia (62421, 62530, 96319). However, a network meta-analysis in patients with mild Alzheimer disease and mild cognitive impairment suggests that melatonin improves cognitive function more effectively than aducanumab, donanemab, lecanemab, and placebo (114515). This analysis included only two clinical trials comparing melatonin to placebo and is limited by significant heterogeneity, including differences in study durations. Other clinical research shows that taking melatonin 2.5-3 mg before bedtime for up to 10 weeks reduces sundowning, which is the confusion and restlessness experienced by some dementia patients in the evening (62788).\nless\nInfertility. Oral melatonin does not seem to increase fertility in females undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).\nSome clinical research shows that taking melatonin does not improve fertility rate or clinical pregnancy rate in adults undergoing IVF, although oocyte and embryo quality might be improved (62775, 62818, 62819, 88297, 89512). Also, results from meta-analyses of clinical research show that melatonin does not improve clinical pregnancy rate, total number of oocytes retrieved, or the rate of miscarriage, although it seems to increase the number of mature oocytes (89505, 106304). Most studies have used single doses of 3 mg daily which may not be adequate (106304).\n\nMelatonin has also been evaluated in adults undergoing ICSI. Although one study shows that taking melatonin improves the fertilization rate, the clinical pregnancy rate was not evaluated (88297). Other research in females taking melatonin and undergoing ICSI does not show an increase in clinical pregnancy rate (97445).\nless\nShift work disorder. Oral melatonin does not seem to improve sleep in individuals doing shift work.\nTaking melatonin orally doesn't seem to significantly improve the time it takes to fall asleep (sleep latency), sleep efficiency, or adjustment to rotating shift work. However, slight increases in total sleep time during the day or overall sleep quality may occur (1052, 1054, 1721, 14283, 62200, 62401, 62462, 62942).\nless\nLIKELY INEFFECTIVE\nBenzodiazepine withdrawal. Oral melatonin does not facilitate benzodiazepine discontinuation in patients with insomnia.\nAlthough some small studies show benefit (349, 1751), results from larger clinical studies and a meta-analysis of clinical research show that taking melatonin 2-5 mg before bedtime for up to 6 weeks does not help facilitate benzodiazepine discontinuation in patients with insomnia (62464, 62467, 63075, 88295, 96321, 96323).\nless\nDepression. Most research shows that oral melatonin does not reduce symptoms of depression or prevent depression. In some patients, taking melatonin might make symptoms worse.\nMost research shows that taking melatonin 5-10 mg daily before bedtime for 4-12 weeks, alone or with fluoxetine, does not improve depression symptoms in patients with rapid cycling bipolar disorder (1766) or major depressive disorder (MDD) (1053, 62746, 96326). However, some research shows that taking slow-release melatonin 3 mg in combination with immediate-release buspirone 15 mg daily for 6 weeks is more effective at improving depression severity and depression symptoms than placebo or buspirone alone in patients with MDD (88289). However, buspirone is not commonly used for the management of depression. Also, there is some concern that oral melatonin may worsen symptoms in some patients with unipolar or bipolar depression (1764).\n\nEvidence regarding the effects of melatonin for preventing depression is unclear. One clinical study shows that taking melatonin 6 mg daily for 12 weeks reduces the percentage of breast cancer patients who develop depression following a lumpectomy or mastectomy by about 75% when compared with placebo when an intention to treat analysis is used. However, when only patients who took all of the doses are considered, melatonin does not appear to have an effect (89511). Also, a meta-analysis of clinical research including two studies in patients with irritable bowel syndrome (IBS) who were at risk for depression shows that melatonin does not prevent depression when compared with placebo (96326).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcute kidney injury (AKI). It is unclear if oral melatonin is beneficial for acute kidney injury.\nA meta-analysis of randomized clinical trials in adults with drug-induced acute kidney injury shows that taking melatonin 3-30 mg daily for up to 6 days modestly improves glomerular filtration rate, but not serum creatinine or incidence of acute kidney injury, when compared with placebo (111463). Another meta-analysis of 5 clinical trials shows that taking melatonin inhibits the occurrence of acute kidney injury in at risk patients by 44% when compared with placebo. However, changes in serum creatinine and urea nitrogen were not statistically significant. Doses of melatonin varied from single doses of up to 5 mg and 6 mg to 30 mg daily for 5 to 14 days (113225).\nless\nAge-related macular degeneration (AMD). It is unclear if oral melatonin prevents vision loss in patients with AMD.\nPreliminary clinical research shows that taking melatonin 3 mg daily for 3-6 months may delay the loss of clear vision in individuals with AMD when compared with baseline (62419). The validity of this finding is limited by the lack of a comparator group.\nless\nAtopic dermatitis (eczema). Oral melatonin might improve some symptoms of atopic dermatitis. However, it is unclear if it improves sleep in this population.\nPreliminary clinical research in children ages 1-18 years with atopic dermatitis and sleep disturbance shows that taking melatonin 3 mg daily for 4 weeks modestly reduces the overall atopic dermatitis symptom score by 19% when compared with placebo (97439). In another clinical study in children with atopic dermatitis, taking melatonin 6 mg daily 1 hour before bedtime for 6 weeks seems to improve disease severity and sleep quality when compared with placebo (99347). It is unclear whether melatonin improves sleep latency in this population, as conflicting results exist (97439, 99347).\nless\nAttention deficit-hyperactivity disorder (ADHD). It is unclear if oral melatonin is beneficial for ADHD.\nSome small clinical studies in children with ADHD who are taking stimulants show that melatonin 3-5 mg daily for up to 3 months might reduce insomnia when compared with placebo (9980, 15034). However, improved sleep related to melatonin treatment does not seem to result in fewer symptoms of ADHD (15034).\nless\nAutism spectrum disorder. It is unclear if oral melatonin is beneficial for this condition.\nOne clinical trial in children aged 6-15 years with autism spectrum disorder shows that taking melatonin (Nobelpharma Co., Ltd) 1 mg or 4 mg before bedtime does not affect behavior when compared with placebo. However, this study was designed to evaluate sleep outcomes, not behavior, as a primary endpoint (106293). Also, a secondary analysis of results from a clinical trial in children with autism spectrum disorder shows that taking prolonged-release melatonin mini-tablets (PedPRM) 2-5 mg nightly for 13 weeks improves externalizing behavior in 26% more patients when compared with those taking placebo. There was no difference between groups in behaviors such as hyperactivity, inattention, emotional behavior, and relationships with peers (101256). The validity of these findings is limited by the secondary nature of the analysis, which was not designed to evaluate these outcomes.\nless\nBenign prostatic hyperplasia (BPH). It is unclear if oral melatonin is beneficial for BPH.\nOne very small clinical study shows that taking controlled-release melatonin 2 mg nightly for 4 weeks reduces excessive urination at night in some men with BPH when compared with placebo. However, it is unclear if this improvement is clinically significant (62360).\nless\nBeta-thalassemia. It is unclear if oral melatonin is beneficial in patients with beta-thalassemia.\nA small clinical study in adults with thalassemia and iron overload shows that taking melatonin (Natrol Melatonin Advance, Natrol LLC) 20 mg daily for 12 months modestly improves lumbar spine bone mineral density and reduces self-reported bone and back pain when compared to baseline but not when compared with placebo. Additionally, there was no effect on iron levels or control (116925). Although the majority of patients in this study had beta-thalassemia, about 7% had other types of thalassemia. Furthermore, this study may have been underpowered to detect a difference between groups.\nless\nBipolar disorder. It is unclear if oral melatonin is beneficial for this condition.\nPreliminary clinical research shows that taking melatonin 3 mg at bedtime for 30 days increases sleep duration and reduces mania severity when compared to baseline in patients with bipolar disorder and treatment-resistant insomnia (62140). However, other research shows that melatonin is not beneficial in patients with bipolar disorder when compared with placebo. Taking melatonin 3-10 mg daily before bedtime for 3-12 weeks does not seem to improve mania or other symptoms when compared with placebo (1766, 103694). Also, taking a specific brand of slow-release melatonin (Cronocaps, Productos Medix) 5 mg each evening for 8 weeks may attenuate the increase in blood pressure and fat mass that is associated with use of second-generation antipsychotics, but it does not appear to improve mania or depression in patients with bipolar disorder (88300). There is also some concern that oral melatonin may worsen symptoms in some patients with bipolar depression (1764).\nless\nBronchopulmonary dysplasia. It is unclear if oral melatonin reduces the risk of bronchopulmonary dysplasia (BPD) in premature infants.\nA small clinical study in premature infants with respiratory distress syndrome who received surfactant shows that giving melatonin 3 mg daily for 7 days reduces the incidence of BPD to 45%, compared with 60% in those not receiving melatonin. Melatonin also reduced the duration of hospital stay, need for mechanical ventilation, and mortality (108948).\nless\nChronic fatigue syndrome (CFS). It is unclear if oral melatonin is beneficial for patients with CFS.\nMany patients with CFS have circadian rhythm disturbances. Some very small clinical studies have evaluated the use of melatonin for addressing these disturbances. One study shows that taking melatonin 5 mg in the evening for 12 weeks might improve some measures of fatigue, concentration, motivation, and activity when compared with baseline (14437). However, other preliminary clinical research shows that taking the same dose of melatonin does not improve CFS symptoms when compared with placebo (9705).\n\nMelatonin has also been studied in combination with zinc. In patients with CFS, taking melatonin 1 mg plus zinc 10 mg before bedtime for 16 weeks modestly reduces self-reported levels of physical fatigue, but not self-reported cognitive or psychological symptoms, mood, sleep quality, or quality of life (QOL) measures, when compared with placebo. However, some measures of sleep quality and QOL worsened within 4 weeks of melatonin discontinuation, suggesting that there may have been a modest benefit (106241). It is unclear whether any benefit is related to melatonin, zinc, or the combination. Also, all patients in this study were White females, limiting the generalizability of the results.\nless\nChronic obstructive pulmonary disease (COPD). It is unclear if oral melatonin is beneficial for COPD.\nSome clinical research shows that taking melatonin 3 mg daily for 3 months improves shortness of breath in patients with COPD when compared with placebo, although melatonin does not seem to improve lung function or exercise capacity (62854). Another small clinical trial shows that taking melatonin 3 mg daily in combination with rehabilitative exercise training improves exercise capacity, health status, and quality of life when compared with placebo. The distance walked in 6 minutes was increased by 46 meters (113221).\nless\nCluster headache. It is unclear if oral melatonin prevents cluster headaches.\nA very small clinical study in adults with cluster headaches shows that taking melatonin orally 10 mg every evening for 14 days might reduce the frequency of episodic cluster headaches when compared with placebo (1127). However, 2 mg at bedtime does not seem to be effective (9702).\nless\nCognitive impairment. Oral melatonin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research in adults 70 years and older with mild cognitive impairment shows that taking two capsules containing melatonin 5 mg, docosahexaenoic acid (DHA) 720 mg, eicosapentaenoic acid (EPA) 286 mg, vitamin E 16 mg, soy phospholipids 160 mg, and L-tryptophan 95 mg (IBSA Farmaceutici) before bedtime for 12 weeks modestly improves cognitive function and sensitivity to smells when compared with placebo. The observed improvement on the mini-mental state examination (MMSE) scale falls below the score generally considered to be indicative of true changes in cognitive function, and may not be clinically significant. Also, it is not known if any potential benefit is due to melatonin, other ingredients, or the combination (62847).\nless\nColorectal cancer. It is unclear if oral melatonin is beneficial for colorectal cancer prevention.\nPopulation research suggests that any history of melatonin use is associated with an approximate 20% reduction in the incidence of colorectal cancer, especially rectal cancer, in individuals aged 60 years and older (106291).\nless\nContraception. Although there has been interest in using oral melatonin for contraception, there is insufficient reliable information about the clinical effects of melatonin for this use.\nCoronary artery bypass graft (CABG) surgery. It is unclear if oral melatonin is beneficial for recovery from CABG surgery.\nClinical research shows that taking melatonin perioperatively during CABG surgery reduces the length of stay in the ICU by about 0.5 days and modestly reduces levels of creatine kinase-MB when compared with placebo. However, there was no effect on the length of hospital stay or levels of cardiac troponin-I, C-reactive protein, or erythrocyte sedimentation rate. Oral melatonin 3 mg was provided the night before and morning of surgery, as well as at bedtime for 3 days after surgery (109699).\nless\nCoronavirus disease 2019 (COVID-19). Preliminary clinical studies suggest that oral melatonin may reduce disease severity in patients with COVID-19, although some conflicting findings exist.\nA meta-analysis of mainly small and preliminary randomized clinical trials in patients with COVID-19 shows that taking melatonin improves clinical outcomes when compared with placebo. However, the clinical outcomes differed between individual trials, and included specific symptoms, hospital discharge, removal from quarantine, and survival. Dosing also varied, with doses of 2-24 mg daily in 1-4 divided doses for 6-14 days. There was no effect of melatonin on C-reactive protein levels or oxygen saturation (109695).\n\nIndividual clinical trials have been conducted in hospitalized and/or non-hospitalized patients with mild to severe COVID-19. One clinical trial in outpatients with mild to moderate COVID-19 shows that taking melatonin 10 mg daily modestly reduces time to symptom resolution and quality of life improvement when compared with placebo (109462). However, it is unclear if any beneficial effects are clinically meaningful. In patients hospitalized and receiving standard care for mild to moderate COVID-19, a small clinical trial shows that taking melatonin 3 mg three times daily for 14 days reduces the mean time to hospital discharge by approximately 3.5 days when compared with placebo. Also, persistent symptoms of cough, dyspnea, and fatigue after 14 days occurred in only 0% to 8% of patients taking melatonin, compared with 15% to 30% of those taking placebo. However, there was no difference in the number of patients with other symptoms, including fever, myalgia, chill, and headache (106300). The validity of this study is limited by its high attrition rate. Another small clinical trial in patients hospitalized with COVID-19 shows that taking melatonin (Norm Life Vanatonin Melatonin) 3 mg nightly for 7 days does not reduce symptoms or prevent ICU admission or death when compared with standard care alone (106295). The low dose and short duration of use in this study might have played a role in the lack of benefit.\n\nMelatonin has also been evaluated in patients hospitalized for severe COVID-19. A meta-analysis of 3 low- to moderate-quality clinical studies in hospitalized adults with severe- to- critical COVID-19 shows that taking melatonin 10-21 mg daily for 5 to 14 days reduces the odds of in-hospital mortality by approximately 81% when compared with placebo or standard of care alone (116926). The validity of these results is limited by the heterogeneity across clinical studies and the use of aggregate data rather than individual patient data. A large single-center clinical trial shows that taking melatonin 10 mg daily reduces the incidence of thrombosis at day 17 and the incidence of sepsis at day 11 when compared with standard care alone (106289). Another similar study shows that taking melatonin (Danna Pharmaceutical Company, Iran) 5 mg twice daily for 7 days results in invasive mechanical ventilation rates of about 51% compared with 71% in patients given standard care only. There were also modest improvements in the time to improvement of clinical status and lengths of stay in the hospital and ICU (110297). However, the validity of these studies is limited by a lack of blinding.\nless\nDelirium. It is unclear if oral melatonin is beneficial for preventing delirium in hospitalized patients; the available research is conflicting.\nResearch is conflicting on whether melatonin reduces the incidence of delirium. One meta-analysis of 10 clinical trials shows that melatonin reduces the incidence of delirium in critically ill patients in the intensive care unit (ICU) by 21% when compared with a control, usually placebo (109696). However, other meta-analyses of 14 small clinical and observational studies of hospitalized patients show that taking melatonin does not reduce the incidence of delirium when compared with control (105003, 112440). Melatonin might be less beneficial in non-acute medical patients when compared with postoperative patients or those in the ICU (105003).\n\nThere is also a lack of consensus within the available research on whether melatonin reduces the duration of delirium in hospitalized patients. One meta-analysis of 10 clinical trials shows that melatonin does not reduce the duration of delirium (109696). Additionally, a moderate-sized clinical study in older hospitalized patients with delirium shows that taking oral melatonin immediate release 5 mg nightly for 5 nights does not reduce the severity of delirium when compared with placebo. Furthermore, subgroup analysis suggests that those with pre-existing cognitive impairment experienced less improvement in delirium but did have improved sleep quality when compared with placebo (114511). However, a meta-analysis of 2 small, randomized controlled trials shows that taking melatonin 3-5 mg daily for 5 or more days reduces the duration of delirium by approximately 2 days when compared with placebo (112051). This analysis is limited by substantial heterogeneity and a lack of dose-response evaluation. Most studies in these analyses have used doses of 0.5-10 mg daily for up to 14 days, although one study used a very high single dose of 50 mg/kg (105003, 105891, 107809, 108949, 109696, 112051).\n\nSome research suggests that melatonin may be beneficial for patients undergoing cardiac procedures. A subgroup analysis of one meta-analysis including 3 small studies suggests that melatonin reduces the incidence of delirium in patients in cardiovascular care units, but not in the general ICU population (112440). Two large clinical studies in the meta-analysis suggest that, in older patients admitted to the ICU after acute heart failure or percutaneous coronary intervention (PCI), taking melatonin 3 mg once daily for up to 7 days is associated with a 27% incidence of delirium, compared with a 37% to 40% incidence with placebo (107809, 108949). Additionally, a small clinical study in patients undergoing coronary artery bypass graft (CABG) surgery suggests that taking prolonged-release melatonin (Webber Naturals) 3 mg twice before surgery and twice after surgery reduces the occurrence of delirium over the next 48 hours when compared with placebo (105891). The validity of this study is limited by a high risk of bias due to insufficient blinding and incomplete outcome data.\n\nMelatonin has also been investigated when administered enterally. A small clinical study shows that receiving melatonin 3 mg through a nasogastric tube once at 9 pm, followed by a 0.5 mg hourly maintenance dose for 6 hours during the overnight period, does not reduce delirium or improve sleep when compared with placebo in patients in the ICU that are being weaned off sedatives and mechanical ventilation (104997). Another moderate-sized clinical study in critically ill adults admitted to the ICU shows that administering enteral melatonin 3 mg daily at 9 pm for 7 days or until discharge does not reduce the incidence of continued or new-onset delirium at 24 hours, 3 days, or 7 days after ICU admission when compared with standard care alone (113496).\nless\nDiabetes. Most research shows that oral melatonin is beneficial for improving glycemic control. However, it is unclear if oral melatonin is beneficial in patients with type 2 diabetes.\nMost research on the use of melatonin for glycemic control has been conducted in mixed populations, such as those with schizophrenia, metabolic syndrome, nonalcoholic steatohepatitis (NASH), or perimenopause (103490, 106294, 106298). Two recent meta-analyses of clinical research in these populations show that taking melatonin modestly reduces fasting glucose and insulin, insulin resistance, and glycated hemoglobin (HbA1c), and improves insulin sensitivity (106294, 106298). The most common doses of melatonin used were 3 -10 mg for 8-24 weeks; however, 10 mg may be more effective (106294, 106298). This contrasts with an earlier meta-analysis showing only modest beneficial effects of melatonin on fasting glucose levels and insulin sensitivity (103490).\n\nResearch on the use of melatonin in patients with type 2 diabetes is limited. One small clinical trial in patients with type 2 diabetes show that taking melatonin (NatureMade) 6 mg daily for 8 weeks does not improve glycemic control (104368). However, this trial may have been underpowered to detect a difference. Another very small study in adults with type 2 diabetes shows that taking melatonin 3 mg daily before bed for 7 days increases absolute glucose level at breakfast on day 7 and the glycemic difference between post-dinner on day 6 and pre-breakfast on day 7 but does not change most measures of glycemic variability including mean glucose levels, pre-prandial glucose levels, and post-prandial glucose levels compared with placebo (112441).\nless\nDiabetic neuropathy. It is unclear if oral melatonin is beneficial for improving pain in patients with diabetic neuropathy.\nA clinical study in patients with painful diabetic neuropathy living in Iran shows that taking melatonin 3 mg nightly for 1 week and then 6 mg nightly for 7 weeks, in conjunction with pregabalin 150 mg daily seems to reduce pain and sleep interference to a greater degree than placebo and pregabalin (105895).\nless\nDry mouth. It is unclear if oral melatonin is beneficial for dry mouth caused by radiation treatment.\nA small clinical study in patients with head and neck cancer undergoing chemoradiation shows that taking melatonin 20 mg orally at bedtime and using 10 mL of melatonin 0.2% oral gargle 15 minutes before each radiation session does not delay the onset or reduce the incidence of grade 2 dry mouth when compared with placebo. However, the incidence of grade 3 dry mouth is delayed by approximately 16 days (96314).\nless\nDysmenorrhea. It is unclear if oral melatonin is beneficial for dysmenorrhea.\nA small clinical trial shows that taking melatonin 10 mg nightly before bed during the week of menstruation has a statistically significant effect on pain severity when compared with placebo. However, the pain reduction was not considered clinically significant (106301).\nless\nDyspepsia. It is unclear if oral melatonin is beneficial for dyspepsia in adults.\nPreliminary clinical research shows that taking melatonin 5 mg nightly for 12 weeks improves dyspeptic symptoms in individuals with functional dyspepsia. However, the benefit seems to be decreased in patients with prior Helicobacter pylori infection (62456).\nless\nEndometriosis. It is unclear if oral melatonin reduces endometriosis-related pain.\nPreliminary clinical research shows that taking melatonin 10 mg daily for 8 weeks reduces pain by about 39% and analgesic use by about 46%, as well as pain during menstruation, intercourse, and evacuation, when compared with placebo in adults with endometriosis (89503). Other clinical research in adults with endometriosis shows that taking melatonin 20 mg orally daily does not improve pain scores or reduce pain during intercourse, urination, or defecation when compared with placebo (111464). However, the study may have been inadequately powered to detect a difference between groups.\nless\nEndotracheal intubation-associated adverse effects. It is unclear if oral melatonin is beneficial for endotracheal intubation-related hemodynamic effects.\nClinical research shows that taking immediate-release melatonin (Healthy Hey Nutrition) 6 mg, 2 hours prior to the induction of anesthesia, is as effective as clonidine 0.2 mg for attenuating the hemodynamic response to laryngoscopy and tracheal intubation (103483). It is not known if melatonin prevents other adverse effects associated with endotracheal intubation.\nless\nEpilepsy. It is unclear if oral melatonin is beneficial for epilepsy in children or adults.\nThere is some low-quality evidence that taking melatonin 3 mg at bedtime for 3 months might reduce the frequency and duration of both nocturnal and daytime seizures in children aged 2-15 years with epilepsy (9699, 9745, 9746, 62785). Also, taking melatonin 1.5 mg before bed for 3 months might reduce the seizure severity in children with epilepsy that is not successfully controlled with other treatment (62754). Furthermore, taking fast-release melatonin 10 mg daily for 3 weeks seems to reduce diurnal seizure frequency in both adults and children aged 9 years and up with intractable epilepsy (88291). However, taking melatonin might not be beneficial for seizure reduction in younger children. In infants and children aged 3 months to 2 years with infantile epileptic spasms syndrome receiving adrenocorticotrophic hormone (ACTH) and magnesium sulfate, adding on melatonin 3 mg daily for 2 weeks before bedtime does not reduce spasm frequency or improve response rate when compared with placebo (113223).\n\nLimited research has also assessed melatonin as an adjunct therapy in adults with seizure disorders. A small clinical study in adults with epilepsy involving generalized onset motor seizures that recurred within the last three days shows that adding melatonin 3 mg before bed to therapy with valproate 20 mg/kg in two divided doses daily for 8 weeks results in 82% of patients having at least a 50% reduction in seizure frequency, compared with only 53% of patients in the group taking valproate and placebo. Adding melatonin may also improve seizure severity (105006). However, other clinical research in adults under valproic acid treatment for idiopathic generalized tonic-clonic seizures alone shows that taking melatonin 3 mg before bed for 8 weeks modestly reduces seizure severity, but not frequency (110299).\nless\nFibromyalgia. It is unclear if oral melatonin is beneficial for this condition.\nPreliminary clinical research shows that taking melatonin 3-5 mg daily for up to 60 days may decrease the severity of pain and stiffness, as well as the number of painful joints, in people with fibromyalgia when compared with placebo (9701, 62797).\nless\nGastroesophageal reflux disease (GERD). It is unclear if oral melatonin is beneficial for GERD.\nClinical research shows that taking melatonin 3 mg daily at bedtime for 8 weeks may improve symptoms of GERD, including heartburn and epigastric pain. However, taking omeprazole 20 mg twice daily seems to be more effective (62723).\nless\nHeart failure. It is unclear if oral melatonin is beneficial for heart failure.\nA meta-analysis of 2 moderate-quality clinical studies in adults with mild to moderate heart failure shows that taking melatonin 10-20 mg daily for 24 weeks improves patient-reported quality of life when compared with placebo. Ejection fraction and stage of heart failure were not improved (116913). However, the interpretation of these results is limited by the small number of available clinical trials. Clinical research in this population also shows that taking melatonin improves a composite score reflecting all-cause mortality, hospitalization for exacerbation, and quality of life when compared with placebo. Melatonin also attenuates an increase in serum B-type natriuretic peptide levels, but does not affect left ventricular ejection fraction or left ventricular end-diastolic or end-systolic diameter (108950).\nless\nHelicobacter pylori. It is unclear if oral melatonin is beneficial for Helicobacter pylori eradication.\nOne very small clinical study shows that taking melatonin 5 mg twice daily in combination with omeprazole 20 mg twice daily for 21 days improves ulcer healing rates when compared with omeprazole alone in individuals with H. pylori-associated gastroduodenal ulcers (62803).\nless\nIrritable bowel syndrome (IBS). It is unclear if oral melatonin is beneficial for IBS.\nIn patients with IBS who also have poor sleep, taking melatonin 3 mg at bedtime for 2 weeks seems to decrease symptoms of IBS-related abdominal pain and increase the rectal pain threshold when compared with placebo. However, taking melatonin does not seem to influence stool frequency or consistency, bloating, mood, sleep, or overall quality of life (13112). In other small clinical studies, taking melatonin 3 mg at bedtime for 8 weeks decreased severity and frequency of pain, reduced bloating, improved bowel habits, decreased extracolonic symptoms such as headache, heartburn and nausea, and improved overall quality of life when compared with placebo (15216, 62410). However, other clinical research shows that melatonin does not significantly affect the amount of time needed for food to travel through the colon in patients with IBS (62500). Also, one small clinical study shows that taking melatonin 3 mg in the morning and 5 mg in the evening for 6 months improves abdominal pain, bloating, and bowel habits in 50% to 70% of postmenopausal patients with constipation-predominant IBS when compared with placebo. However, beneficial effects were reduced in patients with diarrhea-predominant IBS (89510). Other clinical research in patients with IBS shows that taking melatonin 6 mg orally daily for 8 weeks improves IBS symptom severity scores, abdominal pain scores, and bloating scores, when compared with placebo. These results were not different between those with or without sleep disorders at baseline (112055). The large number of endpoints, many with inconsistent results, in these studies makes it difficult to draw conclusions.\nless\nIschemia-reperfusion injury. It is unclear if intravenous or intracoronary melatonin is beneficial for ischemia-reperfusion injury.\nA meta-analysis of 9 low-quality clinical trials in patients with myocardial ischemia-reperfusion injury shows that giving melatonin in doses of 2-50 mg by intravenous or intracoronary injection within 2.5-3.5 hours of ischemia onset improves left ventricular ejection fraction and reduces the infarct size, but does not improve left ventricular end-diastolic or end-systolic volumes, when compared with control. Also, giving melatonin orally for up to 12 weeks does not improve cardiac function. The patients in this study experienced injury as a result of an ST-elevation myocardial infarction, ischemic heart disease, acute coronary syndrome, or coronary heart disease (108946).\nless\nKidney failure. It is unclear if oral melatonin is beneficial for improving mood and quality of life in patients on hemodialysis.\nA small clinical trial in patients undergoing hemodialysis shows that taking immediate-release melatonin 3 mg (Puritans Pride, USA) for 3 months modestly improves depression, anxiety, and quality of life when compared with placebo. After treatment, 73.1% and 57.7% of those taking placebo had severe depression and anxiety, respectively, when compared with 22.2% and 14.8% of those taking melatonin (110291).\nless\nKidney transplant. It is unclear if oral melatonin is beneficial for improving post-transplant kidney function.\nA small clinical study in patients that have received kidney transplants shows that taking melatonin 3 mg daily for an average of 25 days does not affect urine volume or kidney function, as measured by the blood urea nitrogen over creatinine (BUN/Cr) ratio, when compared with placebo (103693).\nless\nLung cancer. It is unclear if melatonin is beneficial in patients with early stage non-small cell lung cancer (NSCLC).\nA clinical study in patients who have undergone complete surgical resection of early stage NSCLC shows that taking melatonin 20 mg daily for 1 year does not improve 2-5 year disease-free survival, pain, anxiety, fatigue, or quality of life when compared with placebo (105894). The validity of these findings is limited by a high study withdrawal rate.\nless\nMelasma. Although there has been interest in using oral melatonin for melasma and other causes of hyperpigmentation, there is insufficient reliable information about the clinical effects of melatonin for these conditions.\nMenopausal symptoms. It is unclear if oral melatonin is beneficial for improving symptoms of menopause; evidence is conflicting.\nA meta-analysis of 3-5 clinical studies in patients with menopausal symptoms shows that taking melatonin does not seem to improve vasomotor or psychological symptoms, but may modestly improve physical symptoms, when compared with placebo (105897). This analysis is limited due to inconsistent evidence and some risk of bias within the included studies. Studies included in the meta-analysis used melatonin 3 mg daily for 3-12 months alone or in combination with soy isoflavones 80 mg or fluoxetine 20 mg (11806, 62840, 105897). In contrast, a small study in adults with menopausal symptoms shows that taking melatonin 3 mg daily for 12 weeks improves climacteric symptoms, anxiety, depressive symptoms, sleep quality, and menopausal quality of life and decreases luteinizing hormone and follicle stimulating hormone levels but does not change uterine volume, endometrial thickness, or estradiol levels when compared with placebo (112443).\nless\nMetabolic syndrome. It is unclear if oral melatonin is beneficial for this condition.\nPreliminary clinical research in adults with metabolic syndrome shows that taking melatonin 5 mg nightly for 2 months reduces systolic and diastolic blood pressure, as well as low-density lipoprotein (LDL) cholesterol levels, when compared to baseline (62795). The validity of these findings is limited by the lack of a comparator group.\nless\nMultiple sclerosis (MS). It is unclear if oral melatonin is beneficial for MS.\nA small clinical study in patients with relapsing-remitting MS (RRMS) receiving interferon-beta once weekly shows that taking melatonin 3 mg daily for 12 months does not affect relapse rate, disability, brain lesions, fatigue, or depression when compared with placebo (99345). This small study may not have been adequately powered to detect a difference between groups. A second clinical study in patients with RRMS and receiving treatment shows that taking a specific 3 mg melatonin supplement (Melatonin, Jamieson Laboratories) nightly for 12 weeks modestly improves walking stride length and speed, and patient-reported fatigue, pain and sleep quality scores but not quality of life or fall risk when compared with placebo (116910). A second publication with the same 27 patients found modest improvements in non-dominant limb strength and dexterity, objective cognitive tests, and self-reported mood (116911). The validity of these results is limited by small sample size and the inclusion of only patients with mild disability cases.\nless\nMyocardial infarction (MI). The benefits of administering oral or intravenous melatonin immediately after an MI are unclear.\nA meta-analysis of 5 small clinical studies in patients after MI shows that oral or intravenous melatonin, used in conjunction with medical reperfusion, is associated with modestly lower troponin levels and modestly higher left ventricular ejection fraction when compared with control (105889). One clinical study included in this analysis that evaluated patients with ST-segment elevation myocardial infarction (STEMI) shows that intravenous administration of melatonin 51.7 mcmol over 60 minutes immediately prior to percutaneous coronary intervention, combined with a bolus intracoronary dose of melatonin 8.6 mcmol administered within 60 seconds after restoration of blood flow to the infarcted artery, does not reduce myocardial infarct size when compared with placebo. However, subgroup analyses suggest that the timing of melatonin administration after symptom onset may alter its effects (96324).\nless\nNeonatal encephalopathy. It is unclear if oral or intravenous melatonin is beneficial for neonates with encephalopathy.\nA meta-analysis of two small clinical studies in term or late preterm infants with neonatal encephalopathy who are receiving therapeutic hypothermia shows that receiving melatonin 5 mg/kg intravenously daily for 3 days, or 10 mg/kg orally daily for 5 days, does not reduce mortality when compared with hypothermia alone, although a nonsignificant trend towards a reduction was noted (104994). One of those small studies in term infants with neonatal encephalopathy also shows that receiving adjunct oral melatonin treatment results in fewer seizures and less white matter abnormalities when compared with hypothermia alone (99333).\nless\nNocturnal enuresis. It is unclear if oral melatonin is beneficial for reducing nighttime wettings.\nPreliminary clinical research shows that taking melatonin 5 mg nightly before bedtime for 3 months does not reduce the number of wet beds when compared with placebo in children with nighttime wettings (nocturnal enuresis) (62824).\nless\nNonalcoholic fatty liver disease (NAFLD). It is unclear if oral melatonin is beneficial for NAFLD.\nA meta-analysis of clinical research, as well as individual clinical trials, show that taking melatonin 6-18 mg daily for 4-56 weeks improves some liver indices, but not others (62853, 88285, 103484, 103485). Overall, taking melatonin seems to modestly reduce levels of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT). However, there is no effect on alanine aminotransferase (ALT) and levels of aspartate aminotransferase (AST) slightly increased (103485). One small clinical study shows that taking melatonin (Nature Made, USA) 6 mg daily for 12 weeks has a small benefit on systolic and diastolic blood pressure, body mass index (BMI), abdominal circumference, and liver enzymes, but not plasma lipid levels, when compared with placebo (103484). Larger studies are needed to determine the effect of melatonin in this population.\nless\nObesity. It is unclear if melatonin is beneficial for improving weight loss.\nA meta-analysis of clinical research shows that taking melatonin up to 10 mg daily, usually for 4-24 weeks, modestly reduces body weight when compared with placebo. However, there was no effect on body mass index (BMI) or waist circumference. Also, the studies included in the analysis were not limited to overweight or obese individuals. Populations included those with metabolic syndrome, nonalcoholic steatohepatitis (NASH), schizophrenia, polycystic ovary syndrome (PCOS), and others, as well as postmenopausal adults (106288). A small clinical trial in overweight or obese individuals shows that although taking melatonin 3 mg daily for 12 weeks modestly reduces waist circumference and body fat mass when compared with placebo, there is no effect on body weight or BMI (106290).\nless\nOral mucositis. Most research shows that melatonin does not prevent or reduce the severity of oral mucositis in patients with head and neck cancer receiving radiation and chemotherapy. It is unclear if oral or topical melatonin is beneficial in patients with other types of cancer.\nA meta-analysis of seven clinical trials including patients undergoing chemotherapy or radiotherapy shows that melatonin does not reduce the rate of oral mucositis when compared with a control, usually placebo (109697). Although a small clinical study in patients with head and neck cancer undergoing radiation and chemotherapy with cisplatin shows that melatonin delays the onset of severe mucositis by 16 days when compared with placebo (96314), a meta-analysis shows that melatonin does not reduce the rate of oral mucositis in patients with head and neck cancer (109697). A sub-analysis in one meta-analysis suggests that taking melatonin, usually 20 mg daily, reduces the rate of oral mucositis by 53% in patients with cancer types other than head and neck (109697). Most studies investigating the effect of melatonin have used oral melatonin 20 mg at bedtime. However, in one study, 10 mL of melatonin 0.2% oral gargle was also used 15 minutes before radiation (96314). In another, swishing with 10 mL of a melatonin 3% gel mouthwash for 2 minutes and then swallowing, starting 2-3 days before radiotherapy and continuing until 1-4 weeks after the end of radiotherapy, was used (105893).\n\nMelatonin has also been investigated for oral mucositis severity. Although some individual research disagrees (96314), a meta-analysis of three clinical trials shows that melatonin does not reduce the severity of oral mucositis when compared with placebo. However, the form of melatonin provided in these studies was heterogeneous, including oral, gargle, and gel formulations (96314, 105893, 109697).\nless\nOsteopenia. It is unclear if oral melatonin is beneficial for improving bone mineral density.\nA small clinical study in postmenopausal adults with osteopenia shows that taking melatonin 3 mg nightly for 1 year increases tibia thickness by 2.2% and volumetric bone mineral density (BMD) in the spine by 3.6% when compared with placebo. However, the BMD of other skeletal sites was not impacted. Additionally, a 1 mg melatonin dose was not beneficial (99334).\nless\nOsteoporosis. Although there has been interest in using oral melatonin for osteoporosis, there is insufficient reliable information about the clinical effects of melatonin for this condition.\nPain (acute). It is unclear if oral melatonin is beneficial for acute pain.\nClinical research in patients undergoing laparoscopic cholecystectomy shows that taking melatonin 6 mg two hours before induction with propofol reduces the number of patients requiring intraoperative fentanyl to 10%, compared with 35% of those taking placebo (106299). Also, preliminary clinical research in preterm infants also given standard treatments shows that oral melatonin (Syrup Trunap, Brio Bliss Life Science Pvt. Ltd) 20 minutes prior to retinopathy of prematurity screening, is not inferior to 24% sucrose for reducing pain (110295). However, the effect of sucrose itself is inconclusive and this study is limited by a lack of blinding. Also, it is unclear if melatonin is beneficial for other causes of acute pain.\nless\nPain (chronic). It is unclear if melatonin is beneficial for most causes of chronic pain.\nA meta-analysis of 5 clinical studies shows that taking melatonin 3-12 mg daily for up to 12 weeks modestly reduces chronic pain when compared with placebo (103692). However, it is difficult to draw clinical conclusions from this analysis, as it pools the effects observed in various types of chronic pain, including migraine, burning mouth syndrome, endometriosis, and irritable bowel syndrome (IBS).\nless\nPeriodontitis. Small clinical studies suggest that oral melatonin may improve some measures of periodontitis severity.\nA meta-analysis of 7 small clinical trials in patients with periodontitis treated with subgingival instrumentation to remove calculus and bacterial biofilms shows that adding oral melatonin in doses of 3-10 mg daily improves probing depth, clinical attachment loss, and gingival index when compared with instrumentation alone (108953).\nless\nPolycystic ovary syndrome (PCOS). It is unclear if melatonin is beneficial for PCOS.\nA meta-analysis of clinical studies in adults with PCOS shows that taking melatonin 3-10 mg daily for 3-12 weeks does not improve glycemic parameters, hormone levels, lipid levels, weight, or pregnancy rates when compared with placebo (116907). The majority of clinical trials were conducted in Iran. However, a small clinical study shows that taking melatonin 6 mg daily for 8 weeks might modestly reduce testosterone levels (105887). Also, a prospective cohort study in patients with PCOS has found that taking melatonin (Armonia Fast, Nathura) 2 mg before bedtime for 6 months increases follicle-stimulating hormone and the total number of menstrual cycles from approximately 2.5 to 4 when compared to baseline (96313). The validity of this study is limited by its observational nature and the lack of a comparator group.\n\nMelatonin has also been evaluated in patients with PCOS taking metformin. A clinical study shows that taking melatonin (Razak Pharmaceutical Company) 3 mg daily for 12 weeks, with or without sildenafil, does not have an effect on acne, insulin, testosterone, weight, or most measures of sexual function, when compared with metformin alone (116927).\nless\nPostoperative nausea and vomiting (PONV). It is unclear if melatonin is beneficial for reducing PONV.\nA small clinical trial shows that taking melatonin (Nature Made, USA) 3 mg, 5 mg, or 10 mg, one hour prior to lumbar discectomy surgery does not reduce postoperative nausea when compared with placebo (110294).\nless\nPostoperative pain. It is unclear if melatonin is beneficial for reducing pain postoperatively.\nThree meta-analyses, as well as most individual clinical studies, show that taking melatonin in addition to standard therapy modestly alleviates pain and reduces analgesic use after surgery when compared with placebo (62471, 62512, 62551, 62743, 88293, 88294, 103488, 103691, 103692, 105892)(110294, 111462). However, any benefit is likely to be small and may not be clinically relevant (103488, 109701, 111462). Melatonin has been used in doses of 1-10 mg daily for a duration of 1-21 days, usually starting the night before surgery (62471, 62512, 62743, 103488, 103691, 105892, 110294, 111462). This research is limited by poor methodology, as well as the heterogeneity of the included studies. The studies evaluated melatonin across a wide variety of surgeries, including abdominal hysterectomy, cataract surgery, cesarean section, prostatectomy, lumbar laminectomy, lumbar discectomy, laparoscopic cholecystectomy, wisdom teeth extraction, and corrective jaw surgery.\nless\nPostoperative recovery. It is unclear if oral melatonin improves the rate of recovery after surgery.\nIn females undergoing total abdominal hysterectomy, taking extended-release melatonin 5 mg, 90 minutes before surgery, shortens hospital stay to a mean of 2.7 days, compared with 3.4 days for placebo (108945).\nless\nPostoperative sleep disturbance. It is unclear if melatonin is beneficial for improving postoperative sleep disturbance.\nA meta-analysis of randomized trials in adults undergoing anesthesia for surgery shows that taking melatonin 5-12 mg orally or sublingually or ramelteon 8 mg orally daily for 1-6 days does not improve sleep scores or sleep time when compared with placebo or no intervention (112052). In addition, a small clinical trial shows that taking melatonin (Nature Made) 5 mg each night before bed for 4 weeks, starting 2 weeks after surgery for orthopedic trauma, does not reduce postoperative sleep disturbance when compared with placebo. All patients were also given education related to sleep hygiene (110293).\nless\nPostural tachycardia syndrome (POTS). It is unclear if melatonin is beneficial for POTS.\nPreliminary clinical research in patients with POTS shows that taking a single dose of melatonin 3 mg reduces sitting and standing heart rate, after 2 and 4 hours, when compared with placebo. However, melatonin does not appear to affect blood pressure or orthostatic symptoms (88292). It is unclear if melatonin is beneficial when taken as more than a single dose.\nless\nPre-eclampsia. It is unclear if oral melatonin reduces the severity of pre-eclampsia.\nA small clinical trial in patients with pre-eclampsia shows that taking sustained-release melatonin 10 mg with vitamin B6 10 mg three times daily, starting during recruitment and continuing until delivery, attenuates the need to increase the dose of antihypertensive medication on certain days, but does not affect overall pre-eclampsia severity, when compared with control (99341).\nless\nPremenstrual syndrome (PMS). Oral melatonin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study conducted in Spain in adults with normal menstrual cycles shows that taking a combination product containing melatonin 1 mg, gamma-aminobutyric acid (GABA), rhodiola, vitex agnus-castus, and vitamin B6 (Premen-Calm, Naturlider S.A., Spain) before bed starting on the day of menstruation onset for 3 months does not improve somatic or affective PMS symptoms, pain, need for analgesics, mood, quality of life, or subjective sleep quality when compared with placebo (114509).\nless\nProstate cancer. Oral melatonin has only been evaluated in combination with medication; its effect when used alone is unclear.\nOne small clinical study in patients with metastatic prostate cancer that is refractory or resistant to treatment with the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin shows that taking melatonin 20 mg daily in combination with intramuscular triptorelin injected every 28 days can decrease levels of prostate-specific antigen (PSA) and growth factors for prostate cancer when compared to baseline (7255). The validity of these findings is limited by the small study size and lack of a comparator group.\nless\nPruritus. Small clinical trials suggest that oral melatonin might be beneficial for some types of pruritus.\nOne small clinical trial in patients with pruritus due to various types of chronic liver disease shows that taking melatonin 10 mg nightly for 2 weeks modestly reduces the severity, frequency, and extent of pruritus when compared with placebo (106297). Another small clinical study in patients undergoing hemodialysis shows that taking melatonin 10 mg daily for 2 weeks reduces the severity of pruritus and reduces the affected body area when compared with placebo (104996).\nless\nPsoriasis. It is unclear if topical melatonin is beneficial for psoriasis.\nA very small clinical study in adults with mild to moderate plaque psoriasis shows that applying melatonin 5% cream twice daily for 8 weeks does not reduce psoriasis severity when compared with placebo (114513). The validity of this result is limited by the small sample size.\nless\nRadiation dermatitis. It is unclear if topical melatonin is beneficial for radiation-related dermatitis.\nIn females with breast cancer, a small clinical study shows that applying a specific melatonin emulsion cream (Praevoskin, PraevoMed GmbH) twice daily during radiation treatment and continuing for another 2 weeks results in fewer cases of grade 1 or 2 acute radiation dermatitis when compared with placebo (99336). In contrast, another clinical trial in patients with breast cancer shows that applying a cream providing melatonin 25 mg and dimethylsulfoxide 150 mg twice daily during and for 3 weeks after radiation treatment does not improve quality of life or breast symptoms at the end of treatment when compared with placebo. However, there was a modest reduction in breast symptoms over time (110298). Other preliminary clinical research in adults receiving radiation for breast cancer shows that applying melatonin cream 25 mg/gram twice daily throughout radiation therapy does not improve radiation dermatitis scores or reduce the need for adjunctive treatment when compared with placebo (112056).\nless\nRapid eye movement sleep behavior disorder (RBD). It is unclear if oral melatonin is beneficial for RBD.\nOne very small clinical study shows that taking melatonin 3 mg before bed for 4 weeks increases the likelihood of muscle atonia during rapid eye movement (REM) sleep in patients with RBD when compared with placebo (62762). The validity of this finding is limited by the small study size.\nless\nRestless legs syndrome (RLS). It is unclear if oral melatonin is beneficial for RLS.\nOne very small clinical study shows that taking melatonin 3 mg before bedtime does not improve symptoms of RLS and may actually worsen motor symptoms in individuals with RLS when compared with baseline (62753). The validity of this finding is limited by the small study size and lack of a comparator group.\nless\nRheumatoid arthritis (RA). It is unclear if oral melatonin is beneficial for RA.\nA small clinical study in patients with RA shows that taking melatonin 6 mg daily for 12 weeks does not affect disease activity or erythrocyte sedimentation rate (ESR) when compared with placebo (105890).\nless\nSarcoidosis. It is unclear if oral melatonin is beneficial for this condition.\nOne very small clinical study shows that taking melatonin 20 mg daily for one year, followed by 10 mg daily for another year, improves lung function and skin lesions in patients with chronic sarcoidosis when compared with baseline (62435). The validity of this finding is limited by the small study size and lack of a comparator group.\nless\nSchizophrenia. It is unclear if oral melatonin is beneficial for schizophrenia or for attenuating the adverse effects associated with antipsychotic medications.\nSome clinical research shows that taking melatonin orally 3 mg each evening for 8 weeks reduces the weight gain and increased waist circumference associated with olanzapine when compared with placebo. It also seems to improve some symptoms of schizophrenia (88296). Other clinical research shows that taking a specific brand of slow-release melatonin (Cronocaps, Productos Medix) 5 mg each evening for 8 weeks reduces adverse effects from second generation antipsychotics, such as increased diastolic blood pressure and waist circumference, when compared with placebo. However, it does not seem to improve symptoms of schizophrenia (88300).\nless\nSeasonal affective disorder (SAD). It is unclear if oral melatonin is beneficial for SAD.\nSome preliminary clinical research shows that oral melatonin, 0.25-2 mg taken daily for 3 weeks, may decrease winter depression symptoms in patients with SAD (10670, 62308). However, sublingual melatonin 0.5 mg daily for 6 days does not appear to improve this condition (62388). Reasons for these discrepancies may include the duration of treatment, route of administration, or the severity of SAD at baseline.\nless\nSepsis. It is unclear if oral melatonin is beneficial for sepsis in neonates or adults.\nThere is conflicting research about the effect of melatonin on neonatal sepsis. While some preliminary research in Egypt shows that giving a single dose of melatonin 20 mg in addition to antibiotics reduces sepsis severity, another more recent study did not find a difference in outcomes between groups receiving antibiotics only or antibiotics with melatonin (99339, 99340).\n\nIn adults with early septic shock given standard care, a small clinical trial shows that taking melatonin 50 mg daily for 5 days increases the number of ventilator-free days by 6.9 and the number of vasopressor-free days by 2.6. ICU and hospital lengths of stay were reduced by 5.25 and 6.9 days, respectively. However, after 28 days there was no significant difference in the mortality rate, the number of patients requiring ventilation or renal replacement therapy, or the number of patients recovered from organ dysfunction (106296).\n\nIntravenous melatonin has also been investigated. A small clinical trial in patients with severe sepsis shows that a continuous infusion of melatonin, 60 mg over 24 hours, for 5 days following post-surgical sepsis diagnosis modestly reduces sepsis severity when compared with placebo. Hospital stay was reduced by approximately 5.2 days in patients given melatonin; however, it is unclear if this difference is statistically significant (110300).\nless\nSmoking cessation. It is unclear if oral melatonin is beneficial in patients trying to quit smoking.\nOne very small clinical study shows that taking melatonin 0.35 mg as a single oral dose 3.5 hours after initiation of nicotine withdrawal in smokers seems to reduce subjective symptoms of anxiety, restlessness, irritability, depression, and cigarette craving over the next 10 hours when compared with baseline (2424). The validity of these findings is limited by the small study size and lack of a comparator group.\nless\nStabbing headache. Although there has been interest in using oral melatonin for stabbing headaches, there is insufficient reliable information about the clinical effects of melatonin for this condition.\nStress. It is unclear if oral melatonin is beneficial for stress reduction.\nPreliminary clinical research shows that taking melatonin 3 mg one hour prior to stress modestly improves memory accuracy during a laboratory-induced stressful situation when compared with placebo (62509).\nless\nTardive dyskinesia. It is unclear if oral melatonin is beneficial for this condition.\nOne small clinical study shows that taking melatonin orally 10 mg daily for 6 weeks decreases symptoms by 24% to 30% in patients with tardive dyskinesia when compared with placebo (7082). However, other small clinical studies show that taking melatonin 2-20 mg daily for 4-12 weeks does not reduce abnormal, involuntary movement in patients with tardive dyskinesia when compared with placebo (62146, 62825).\nless\nTension headache. It is unclear if oral melatonin is beneficial for reducing the frequency of tension headaches.\nA small clinical study in patients with chronic tension headache shows that taking a specific melatonin supplement (Melaxen) 3 mg nightly for 30 days seems to reduce headache severity and reduce the median number of days with a headache by 6 when compared with baseline (104998). The validity of this finding is limited by the lack of a control group.\nless\nTinnitus. It is unclear if oral melatonin is beneficial for improving tinnitus intensity or severity.\nSome clinical research shows that taking melatonin 3 mg nightly for one month reduces tinnitus intensity and improves the quality of sleep in individuals with chronic tinnitus when compared with placebo. The effect seems to be greatest in men, those who have not received prior treatment for tinnitus, and those with a history of noise exposure (62820). Other clinical research shows that taking melatonin 3 mg daily for 3 months is more effective for reducing tinnitus severity than sertraline 50 mg daily (97447). However, other clinical research shows that taking melatonin 3 mg nightly for 30-40 days does not significantly reduce tinnitus intensity when compared with placebo, although the effects might be significant when melatonin is combined with sulpiride or sulodexide (62469, 62614).\nless\nTraumatic brain injury (TBI). It is unclear if oral melatonin is beneficial for children who have experienced a concussion.\nA small clinical study in children ages 8-18 years who have experienced a concussion shows that taking melatonin 3 mg or 10 mg one hour before bedtime for 28 days does not improve persistent post-concussive symptoms when compared with placebo (103690). One small observational study in children in the same age group who have experienced a concussion within 14 days has found that receiving a prescription for melatonin is not associated with improved symptoms and recovery at 15-35 days after concussion (105001). The validity of these findings is limited by small study size and short duration of follow-up.\nless\nUlcerative colitis. Oral melatonin may be modestly beneficial for reducing symptoms or sustaining remission in patients using the medication mesalazine.\nA small clinical study shows that taking melatonin 5 mg daily in combination with mesalazine 1 gram twice daily for 12 months may help to sustain remission in patients with ulcerative colitis when compared with mesalazine alone (62821). Another small clinical trial in patients with mild to moderate ulcerative colitis shows that taking melatonin 3 mg daily for 3 months modestly improves overall symptoms, some measures of quality of life, and levels of fecal calprotectin when compared with placebo. However, there was no effect on other markers of inflammation, such as C-reactive protein and erythrocyte sedimentation rate (106303).\nless\nMore evidence is needed to rate melatonin for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMelatonin has most often been used in doses of up to 8 mg daily for up to 6 months. See Effectiveness section for condition-specific information.\n\nClinical studies that have evaluated melatonin have used both slow-release and fast-release formulations (89502, 89503, 89508, 96318).\nIntramuscular:\nResearch is limited; typical dosing is unavailable.\nIntravenous:\nResearch is limited; typical dosing is unavailable.\nSublingual:\nResearch is limited; typical dosing is unavailable.\nBuccal:\nResearch is limited; typical dosing is unavailable.\nTopical:\nMelatonin has been used in various topical formulations, including as a gargle, cream, and gel. See Effectiveness section for condition-specific information.\nChildren\nOral:\nMelatonin has most often been used in doses of up to 3 mg daily for up to 3 months. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nIn supplements, melatonin is available in tablet, capsule, gummy, chewable, sublingual, and liquid formulations (108144, 108145). Clinical studies that have evaluated melatonin have used both slow-release and fast-release formulations. Some of these formulations have been authenticated with certificates of analyses (89503, 89508) or have met the United States Pharmacopeia (USP) standards for identity, purity, dose, and stability (89502).\n\nIn the European Union and some other countries, a prescription prolonged-release melatonin product (2 mg, Circadin, Neurim Pharmaceuticals Ltd) is available for treating insomnia in patients 55 years and older. The tablets should not be crushed. There is also a small diameter prolonged-release tablet for pediatric patients (PedPRM, Neurim Pharmaceuticals Ltd), helping to facilitate swallowing in children (96318).\n\nAn analysis of melatonin products available in Canada, including single-ingredient and combination products containing L-theanine, 5-hydroxytryptophan, and/or herbal ingredients, such as lavender, chamomile, valerian, lemon balm, and others, demonstrated high lot-to-lot variability. Melatonin content ranged from -83% to +478% of the labeled quantity. Serotonin, a possible by-product of melatonin biosynthesis or degradation, was found in about 27% of tested products at levels of up to 74.3 mcg/mL (108144). Analyses of gummy products declaring melatonin on the label available in the United States found that one product claiming a melatonin dose of 5 mg per serving did not contain detectable levels of melatonin. The actual quantity of melatonin in the remaining products ranged from 74% to 347% of the labeled quantity, with only 12% of products containing melatonin amounts within 10% of the declared quantity. Only one sample of each brand was analyzed (110328).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonquantitative systematic review)\nTheoretically, melatonin may have anticoagulant effects and may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.\nThere are isolated case reports of minor bleeding and decreased prothrombin activity in people taking melatonin with warfarin (Coumadin) (63067). The mechanism, if any, of this interaction is unknown (9181). Taking melatonin orally seems to decrease coagulation activity within one hour of dosing in healthy men (62481).\nless\nANTICONVULSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Clinical cohort study)\nTheoretically, melatonin may reduce the effects of anticonvulsants.\nSome clinical research suggests that melatonin may increase the frequency of seizures in certain patients, particularly children with neurological impairment (8248, 9744).\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, taking melatonin with antidiabetes drugs might increase the risk of hypoglycemia.\nSome clinical research shows that melatonin reduces levels of fasting blood glucose and improves glycemic control (19034, 19035, 103490). However, other research suggests that melatonin might impair glucose utilization and increase insulin resistance (9713), while other research has found no effect on glucose levels (19036, 104368). Until more is known, use melatonin cautiously in combination with antidiabetes drugs.\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nA (High-quality meta-analysis (quantitative systematic review))\nTheoretically, taking melatonin with antihypertensive drugs might increase the risk of hypotension or hypertension.\nSome clinical research suggests that taking melatonin decreases blood pressure in healthy adults (1724, 62165, 62187, 63042). Also, melatonin seems to lower systolic and diastolic blood pressure in individuals with high blood pressure at nighttime or untreated essential hypertension (62359, 62416, 62441, 62826). However, melatonin seems to worsen blood pressure in patients who are taking antihypertensive medications. Immediate-release melatonin 5 mg at night in combination with nifedipine GITS (Procardia XL) increases systolic blood pressure an average of 6.5 mmHg, diastolic blood pressure by an average of 4.9 mmHg, and heart rate by 3.9 bpm (6436). Also, results from animal research suggest that melatonin reduces the effectiveness of certain antihypertensive drugs, including methoxamine and clonidine (62432).\nless\nCAFFEINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, taking caffeine with melatonin might increase levels of melatonin.\nSome evidence suggests that caffeine consumption can decrease endogenous melatonin levels (8265, 22303, 37585), while other evidence suggests that caffeine increases endogenous melatonin levels (62328). When administered in combination with melatonin supplements, caffeine seems to increase melatonin effects and levels (62352, 96315). The reason for this discrepancy is not completely clear. Part of the discrepancy may result from the fact that caffeine can inhibit melatonin synthesis as well as inhibit melatonin metabolism. By functioning as an adenosine receptor antagonist, caffeine may indirectly inhibit the synthesis of melatonin. Conversely, because melatonin and caffeine are both metabolized by cytochrome P450 1A2 (CYP1A2) enzyme, concomitant use of melatonin and caffeine may reduce the metabolism of melatonin, resulting in higher serum levels (22306, 96315).\nless\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking melatonin might increase the sedative effects of CNS depressants.\nMelatonin has sedative effects. Theoretically, concomitant use of melatonin with alcohol, benzodiazepines, or other sedative drugs might cause additive sedation (96315).\nless\nCONTRACEPTIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, taking contraceptive drugs with melatonin might increase the effects and adverse effects of melatonin.\nContraceptive drugs can increase the levels of endogenous melatonin (8265). Theoretically, these drugs may increase the effects and adverse effects of oral melatonin.\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, melatonin might increase levels of drugs metabolized by CYP1A2. Also, other CYP1A2 substrates might decrease the metabolism of melatonin, increasing melatonin levels.\nMelatonin is metabolized in the liver primarily by the CYP2C19 and CYP1A2 enzymes (62118, 62405, 96315). Theoretically, combined administration of melatonin with drugs metabolized by the CYP1A2 enzyme might reduce the metabolism of these drugs, resulting in increased serum levels. Conversely, some drugs metabolized by CYP1A2 may inhibit the metabolism of melatonin, resulting in increased serum levels of melatonin. Until more is known, use melatonin cautiously in patients taking drugs metabolized by these enzymes.\nless\nCYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, melatonin might increase levels of drugs metabolized by CYP2C19. Also, other CYP2C19 substrates might decrease the metabolism of melatonin, increasing melatonin levels.\nMelatonin is metabolized in the liver primarily by the CYP2C19 and CYP1A2 enzymes (62118, 62405). Theoretically, combined administration of melatonin with certain drugs metabolized by the CYP2C19 enzyme may reduce the metabolism of these drugs, resulting in increased serum levels. Conversely, some drugs metabolized by CYP2C19 may inhibit the metabolism of melatonin, resulting in increased serum levels of melatonin. Until more is known, use melatonin cautiously in patients taking drugs metabolized by these enzymes.\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, melatonin might increase levels of drugs metabolized by CYP2D6.\nLaboratory research suggests that certain lots of melatonin inhibit CYP2D6 (96315). Theoretically, combined administration of melatonin with certain drugs metabolized by the CYP2D6 enzyme may reduce the metabolism of these drugs, resulting in increased serum levels. Until more is known, use melatonin cautiously in patients taking drugs metabolized by these enzymes.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, melatonin might increase levels of drugs metabolized by CYP3A4.\nLaboratory research shows that certain lots of melatonin inhibit CYP3A4 (96315). Theoretically, combined administration of melatonin with certain drugs metabolized by CYP3A4 may reduce the metabolism of these drugs, resulting in increased serum levels. Until more is known, use melatonin cautiously in patients taking drugs metabolized by these enzymes.\nless\nFLUMAZENIL (Romazicon)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking flumazenil with melatonin might reduce the effects of melatonin.\nAnimal research shows that flumazenil may inhibit the effect of melatonin (9703).\nless\nFLUVOXAMINE (Luvox)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, taking fluvoxamine with melatonin might increase levels of melatonin.\nFluvoxamine can significantly increase melatonin levels. In some cases, fluvoxamine might increase bioavailability of exogenously administered melatonin by up to 20 times (5038, 6499, 8251). Some researchers think this might be a beneficial interaction and be potentially useful for cases of refractory insomnia (6499). However, this interaction might also cause unwanted excessive drowsiness and possibly other adverse effects. Fluvoxamine is known to increase endogenous melatonin secretion (6498, 22313). It seems to increase serum levels of exogenously administered melatonin possibly by decreasing melatonin metabolism by inhibiting cytochrome P450 (CYP450) 1A2 and 2C19 or by inhibiting melatonin elimination. This effect has been found in healthy people taking fluvoxamine 50-75 mg and melatonin 5 mg (5038, 6498, 6499, 8251).\nless\nIMMUNOSUPPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, melatonin might interfere with immunosuppressive therapy.\nMelatonin can stimulate immune function. Theoretically, melatonin might interfere with immunosuppressive therapy (7040).\nless\nMETHAMPHETAMINE (Desoxyn)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, taking melatonin with methamphetamine may increase the adverse effects of methamphetamine.\nAnimal research suggests that melatonin exacerbates the adverse effects of methamphetamine, resulting in greater depression of tryptophan hydroxylase (TPH) and tyrosine hydroxylase (TH) activity, as well as a significant reduction in dopamine levels (22307). This has not been shown in humans.\nless\nNIFEDIPINE GITS (Procardia XL)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, taking melatonin with extended release nifedipine reduces the effects of nifedipine.\nMelatonin can decrease the effectiveness of extended release nifedipine (GITS). Immediate-release melatonin 5 mg at night in combination with nifedipine GITS 30-60 mg daily increases systolic and blood pressure by an average of 6.5 mmHg and 4.9 mmHg, respectively. Concomitant use with melatonin also increases heart rate by 3.9 bpm (6436). The mechanism of this interaction is not known.\nless\nSEIZURE THRESHOLD LOWERING DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking melatonin with drugs that lower the seizure threshold might increase the risk of seizure activity.\nSome clinical evidence suggests that melatonin may increase the frequency of seizures in certain patients, particularly children with neurological disabilities (8248, 9744).\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, melatonin may have antiplatelet effects and may increase the risk of bleeding with warfarin.\nThree cases of increased prothrombin time have been reported for patients aged 48-72 years who took melatonin orally in combination with warfarin (9181). However, three cases of decreased prothrombin time have also been reported for patients aged 51-84 years who took melatonin orally in combination with warfarin (9181). Until more is known, use melatonin cautiously in patients taking warfarin.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, melatonin may have antiplatelet effects in some people.\nTheoretically, melatonin might increase the effect of herbs with antiplatelet/anticoagulant activity and might theoretically increase the risk of bleeding in some people (9181, 62481, 63067). See other products with anticoagulant activity here.\nless\nCAFFEINE\nTheoretically, taking caffeine with melatonin might increase levels and adverse effects of melatonin.\nSome evidence suggests that caffeine consumption can increase or decrease endogenous melatonin levels (8265, 22303, 37585, 62328). When administered in combination with melatonin supplements, caffeine seems to increase melatonin levels (62352). The reason for this discrepancy is not completely clear. By functioning as an adenosine receptor antagonist, caffeine might indirectly inhibit the synthesis of melatonin. Conversely, because melatonin and caffeine are both metabolized by cytochrome P450 1A2 (CYP1A2), concomitant use of melatonin and caffeine might reduce the metabolism of melatonin, resulting in higher serum levels (22306).\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, taking melatonin with herbs and supplements with hypoglycemic potential might increase the risk of hypoglycemia.\nSome clinical research shows that melatonin reduces levels of fasting blood glucose and improves glycemic control (19034, 19035, 103490). However, other research suggests that melatonin might impair glucose utilization and increase insulin resistance (9713), while other research has found no effect on glucose levels (19036, 104368). See other herbs with hypoglycemic effects here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, taking melatonin with herbs and supplements with hypotensive effects might increase the risk of hypotension.\nSome clinical evidence suggests that taking melatonin decreases blood pressure in healthy adults (1724, 62165, 62187, 63042). Also, melatonin seems to lower systolic and diastolic blood pressure in individuals with high blood pressure at nighttime or untreated essential hypertension (62359, 62416, 62441, 62826). Theoretically, combining melatonin with other herbs and supplements with hypotensive effects might increase the risk of hypotension in some individuals.\nless\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, melatonin might have sedative effects.\nTheoretically, concomitant use with herbs that have sedative properties might enhance therapeutic and adverse effects (1772). See other products with sedative-hypnotic activity here.\nless\nSEIZURE THRESHOLD LOWERING HERBS AND SUPPLEMENTS\nTheoretically, melatonin might increase the risk of seizures.\nSome clinical evidence suggests that melatonin may increase the frequency of seizures in certain patients, particularly children with neurological disabilities (8248, 9744). Theoretically, patients taking supplements that also lower the seizure threshold might be at greater risk. See other products with seizure threshold-lowering activity here.\nless\nVITEX AGNUS-CASTUS\nTheoretically, taking vitex agnus-castus with melatonin might increase the effects and side effects of melatonin.\nClinical research in healthy males suggests that taking vitex agnus-castus 120-480 mg daily for 2 weeks significantly increases melatonin levels (62281).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nTheoretically, melatonin might increase bleeding; until more is known avoid in patients with bleeding disorders. Melatonin has demonstrated anticoagulant activity in some people (9181, 62481, 63067).\nless\nDEPRESSION\nTheoretically, melatonin might worsen symptoms in people with depression; until more is known, avoid use in patients with depression. Melatonin has been shown to worsen dysphoria in some people with depression (1764, 62384).\nless\nHYPERTENSION\nTheoretically, melatonin might worsen blood pressure; until more is known, avoid use in people with hypertension. Melatonin has been shown to increase blood pressure in patients who are taking antihypertensive medications. Immediate-release melatonin 5 mg at night in combination with extended-release nifedipine (Procardia XL) increases systolic blood pressure by 6.5 mmHg, diastolic blood pressure by 4.9 mmHg, and heart rate by 3.9 bpm (6436). The mechanism of this interaction is not known.\nless\nSEIZURE DISORDERS\nTheoretically, melatonin might increase the risk of seizures; until more is known use with caution. Exogenous melatonin may increase the incidence of seizures (9695, 9697, 9744, 62384). Children with multiple neurological disorders, including seizure activity, might have an increase in seizure activity after treatment with oral melatonin for sleep disorders (8248, 62754, 89431). However, multiple case reports and some clinical research suggests that melatonin actually reduces the incidence of seizure (1699, 9746, 62123, 62256, 63070, 63071).\nless\nTRANSPLANT RECIPIENTS\nTheoretically, melatonin might have immunostimulant effects; until more is known, avoid in transplant recipients. Melatonin can stimulate immune function and might interfere with immunosuppressive therapy used by transplant recipients (7040).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nIn the US, cases of pediatric overdose have been reported to poison control centers. From 2012 to 2021, over 260,000 pediatric melatonin ingestions were reported to the American Association of Poison Control Centers' National Poison Data System (NPDS). In 2021, melatonin accounted for 4.9% of all ingestions, compared with only 0.6% in 2012. Most cases were related to unintentional ingestions in children 5 years and under and were asymptomatic. In symptomatic cases, the most common symptoms were related to the central nervous system, followed by the gastrointestinal and cardiovascular systems. Over 4,000 children required hospitalization and almost 300 required intensive care. Also, five children required mechanical ventilation and two children under age five died following unintentional exposure (108145). The dose of melatonin consumed in these cases is unknown. Also, in one case report, a 3-month-old infant who received 8-10 dissolvable melatonin 5 mg tablets daily for an unknown duration was found unresponsive. The child's twin also received similar doses of melatonin without incident. The deceased infant had a melatonin level of 1400 ng/mL, whereas average nocturnal melatonin levels in infants and toddlers are around 0.325 ng/mL. The researchers could not definitively state that melatonin caused this infant's death, citing a lack of evidence on the physiologic effects and reference lab values for melatonin in infants (102514).\n\nPossible melatonin toxicity has also been reported in adults, although in most cases melatonin was taken in addition to other psychotropic medications during a suicide attempt (62822, 112439). In one case, a psychotic episode was reported in a 73-year-old female who took a large amount (possibly an overdose) of melatonin (63030).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with melatonin.",
            "Pharmacokinetics": "Absorption\nIn human research, melatonin supplementation increases plasma levels of melatonin, occasionally into the daylight hours (7081, 62424, 62439, 62807, 62787, 62908, 62917, 63013). The bioavailability of synthetic melatonin varies widely, with significant interpatient variability (97436). The calculated oral bioavailability of melatonin from supplements has ranged between 3% to 76% (1126, 62908, 62917, 63013). Within about 1 hour, doses between 1-5 mg lead to serum concentrations 10-100 times those of the usual night-time peak (105005, 109698). Lower oral doses such as 0.1-0.3 mg, taken at daytime, lead to peak serum concentrations that are in the normal night-time range (105005). When administered in gelatin capsules, melatonin reaches peak levels after 40 to 150 minutes. The peak levels are 350-10,000 times higher than nighttime concentrations (62916, 62917, 97436). In human research, the average peak serum concentration is 2630 pg/mL following a 2.5 mg dose, 3550.5 pg/mL following a 10 mg dose, and 64,730 pg/mL following a 75 mg dose (62524, 97436). The mean elimination half-life is 40.8 minutes in healthy volunteers (97436) and 1.8 to 2.1 hours in older adults (92848). Most studies show that levels return to baseline in about 4-8 hours (105005, 109698). In healthy patients, a 2 mg dose of a prolonged-release melatonin formulation led to near physiological plasma levels which were sustained for 5-7 hours (96321). Taking a specific prolonged-release tablet (Oniria) results in levels of melatonin that are above normal endogenous levels for at least 8.5 hours (109698). In older adults with insomnia complaints, the time to maximum level, which was 1.3 to 1.5 hours, did not change when doses of 0.4 mg and 2 mg were compared (62848). The maximum concentrations were 405  93 pg/mL and 3999  700 pg/mL (0.4 mg and 2 mg doses, respectively). Use of melatonin 2 mg resulted in a maintenance of melatonin levels >50 pg/mL for an average of 10 hours.\n\nThe physiologic half-life of melatonin is approximately 30-60 minutes (1072, 1742, 62905, 62917, 63013, 96318). Nutritional supplements do not appear to mimic the physiologic release of melatonin, as dissolution testing has ranged from 4 to 12 hours (63066, 96317), with controlled-release formulations available (62122). The time delay between administration and maximal effect varies linearly from 220 minutes at noon, to 60 minutes at 9 p.m. (63093).\n\nMelatonin may also be delivered transdermally (1058, 62946, 97448, 103489), intravesically, rectally, vaginally (103489), or transmucosally (1058) to mimic physiological activity. Time to maximal concentrations range from 24 minutes with rectal administration to 21 hours with transdermal administration (103489). When a cream containing 12.5% melatonin was applied to 80% of the body surface area of healthy adults, an average peak serum level of 4,977.2  10,369.6 pg/mL was reached at 12 hours (97448).\nDistribution\nMelatonin levels in saliva are one-quarter to one-third of those in serum and may be used to estimate levels in plasma (62737, 62845, 62852, 62890, 108953) and gingival crevicular fluid (62737). Melatonin has also been found in platelets (62790). Melatonin is very lipid-soluble and readily passes through the blood-brain barrier (62243, 62477, 96322, 108949). The volume of distribution for intravenously administered melatonin is 1.2 L/kg (97436).\nMetabolism\nMelatonin is metabolized in the liver via the hepatic microsome cytochrome P450 system, primarily (but not exclusively) by the CYP2C19 and CYP1A family (particularly CYP1A2) and possibly CYP2C9 and CYP2C19 (6498, 48439, 62118, 62174, 62405, 96315). First-pass hepatic metabolism, which is extensive (up to 60% of the oral dose) (but can be avoided with the sublingual formulation), includes 6-hydroxylation, followed by conjugation and excretion as the sulfate or glucuronide, and is extensive (62908, 62917, 63013, 96315). Melatonin is deacetylated in the pineal gland and retina to 5-methoxytryptamine (96315). The 6-sulphatoxymelatonin metabolite of melatonin is inactive (62896, 62920) and can be determined in serum (62896, 62920) and saliva (1743, 62845, 62890). In patients with liver cirrhosis, melatonin levels are elevated compared to controls due to reduced metabolism (62405, 63026).\n\nIn case studies in patients with insomnia, a loss of response to melatonin treatment was found to be associated with a slow melatonin metabolism (62765). The authors suggested that in some patients, there may be decreased activity of CYP1A2, resulting in decreased melatonin metabolism and therefore persistent melatonin in plasma at levels of >50 pg/mL up to four hours after supplementation.\nExcretion\nUrine melatonin levels were found to correlate well with plasma levels (8239). Up to 85% of 6-hydroxymelatonin sulfate was excreted in urine (1751) with a physiologic excretion of 11.1 to 40.2 mcg (19.0  7.4 mcg) in children (62392). In human research, consumption of diets enriched with Jerte Valley cherries (a food source of melatonin) increased urinary levels of 6-sulfatoxymelatonin (62761). In older adults, oral doses of 0.4 mg and 2 mg resulted in an apparent total clearance of 379-478 L/hr (62848). When delivered orally, intravenously, transdermally, intravesically, rectally, or vaginally, the elimination half-life ranged from 45-47 minutes with oral or intravenous administration up to 14.6 hours with transdermal administration (103489, 105005).",
            "Mechanism of Action": "General\nMelatonin is a hormone synthesized endogenously in the pineal gland (1123, 1773, 62288). It is produced from tryptophan, which is converted to 5-hydroxytryptophan, then to serotonin, then to N-acetylserotonin, and finally to melatonin (1773). The synthesis of melatonin in the pineal gland depends on the norepinephrine-induced stimulation of post-synaptic pineal beta-1 adrenoreceptors and alpha-1 adrenoreceptors (1773, 1780, 62173, 62868, 62877, 62885, 62924, 62926), while alpha-2 adrenoreceptors appear to function as downregulators of melatonin synthesis (62869, 62878). The norepinephrine-induced increase in activity and number of alpha-1 and beta-1 adrenoreceptors increases the activity of the enzyme serotonin N-acetyltransferase, which catalyzes the rate-limiting step of melatonin production from serotonin (1773). Following synthesis, melatonin is collected by the venous capillary system, then secreted into the cerebrospinal fluid and the venous systemic circulation (1123, 8239). In the brain, melatonin appears to increase the binding of gamma-aminobenzoic acid (GABA) to its receptors by affecting membrane characteristics, not by increasing the number of receptors. Melatonin may decrease neurotransmission by a direct effect on nerve cells (9695).\n\nMelatonin's primary role seems to be regulation of the body's circadian rhythm, endocrine secretions, and sleep patterns (1773, 7043). Circadian rhythm of melatonin begins at the end of the neonatal period (62278, 62339). Endogenous melatonin is also involved in several other functions including growth hormone secretion and sexual maturation (1776, 1777, 1778, 6497, 8246), pain control, balance, and sexual activity (1776, 1777, 1778, 6497). However, it does not appear to directly affect heart function or blood pressure (9714).\n\nExcretion of melatonin is similar in males and females (9747). Melatonin release peaks between one to three years of age. Nocturnal serum melatonin levels naturally decline with increasing pubertal stages (1781, 8246, 8263). Melatonin suppression by light is not affected by age (1775, 62157). However, there is good evidence that melatonin levels can be abnormally low in certain conditions or disease states. Since light inhibits melatonin secretion and darkness stimulates its secretion (1773, 62205, 62887, 62928, 63015), people who suffer from an insufficient amount of environmental light often have decreased endogenous melatonin secretion (8247). Infants with low melatonin production are more likely to experience a life-threatening event (ALTE) (8262). Insomniacs of all ages can also have decreased melatonin levels. Patients with sleep disorders related to other conditions, such as fibromyalgia and depression, can also have low levels (6498). Recent information also shows that music therapy can improve endogenous serum melatonin levels in patients with Alzheimer's disease, possibly a contributing factor to patients' relaxed and calm mood (8241). Also, some research suggests that meditation techniques might increase endogenous melatonin concentrations (9748). In other conditions, melatonin's response to light can be altered. For example, in patients with bipolar I disorder, melatonin response to light appears to be abnormal, but is not affected in less severe bipolar II disorder or unipolar depression (1123).\nAnalgesic effects\nSome clinical evidence shows that melatonin may reduce pain associated with conditions such as endometriosis (89503), temporomandibular disorder (89508), fibromyalgia (9701, 62797), gastroesophageal reflux disease (62723), irritable bowel syndrome (13112, 15216, 62410, 89510), migraine headaches (6712, 12149), and post-operative recovery (62471, 62512, 62743). Antinociceptive activity of melatonin may be related to the activation of MT1 and MT2 receptors, which reduces cyclic AMP formation and lessens pain; the opening of potassium channels; the inhibition of 5-lipoxygenase and cyclooxygenase-2 expression; and the indirect activation of opioid receptors (62543). However, there does not appear to be a clear relationship between pain perception and urinary concentrations of melatonin metabolites (9700).\nAnti-inflammatory effects\nIn human research, melatonin had anti-inflammatory effects in infants with respiratory distress (62366), or in adults with COVID-19 (106300), sepsis (110300), or diabetes (116909). In animal research, melatonin has been reported to reduce cardiac inflammatory injury induced by acute exercise (62624). Also in both human and laboratory research, melatonin has been reported to decrease the upregulation of or suppress levels of proinflammatory cytokines (62171, 62520, 62557, 62606, 62669, 62693, 62741, 62787, 116909). Potential mechanisms of action may include the inhibition of nitric oxide and malondialdehyde (MDA) production or an increase of glutathione levels (62220, 62252); the inhibition of phospholipase A2 (62575), mitogen-activated protein kinases (62522), or NF-kappaB (62610, 62624, 62626, 62741); or the regulation of mast cells (62701).\n\nHowever, some conflicting evidence from clinical research shows that melatonin may not have anti-inflammatory effects. In patients with rheumatoid arthritis, melatonin induced a proinflammatory response, increasing levels of certain inflammatory cytokines, as well as plasma kynurenine concentrations (62460). Also, in patients with ulcerative colitis, melatonin does not reduce levels of C-reactive protein (CRP) or erythrocyte sedimentation rate (106303).\nAnti-obesity effects\nIn patients with type 2 diabetes, nocturnal endogenous plasma melatonin levels have been shown to be higher in obese subjects vs. nonobese subjects and lean nondiabetic controls (62856). However, some evidence from animal and human research suggests that melatonin may play a role in body weight control (62635, 106288). Some evidence from animal models suggests that melatonin inhibits adipocyte differentiation (62635) or reduces gut motility, causing a decrease in appetite (62599). Other animal research has indicated that exogenous melatonin lacks an effect on leptin secretion (62707).\nAntiaging effects\nMelatonin has been identified as countering some of the deleterious effects of aging (62572, 62593, 62611, 62615, 62616, 62631, 62660, 62724). Evidence from animal research suggests that melatonin may reduce age-related neurodegeneration by reducing oxidative stress-related impairments and apoptosis that occur in the brain during the aging process (62523). Other animal research has indicated that melatonin may improve longevity (cellular and otherwise) by preventing age-related mitochondrial impairment (62611), maintaining youthful rhythmic activity (62593), improving monoaminergic neurotransmission (62722), and reversing immunosenescence (62567, 62565). An experimental model of age-induced neuronal apoptosis indicated that melatonin may exert a protective effect via prosurvival Akt and prevention of DNA damage (62538).\nAntiarthritic effects\nIn vitro, melatonin has beneficial effects on articular chondrocytes, enhancing the synthesis of the cartilage matrix (62519). Melatonin also inhibits the proliferation of fibroblast-like synoviocytes, involved in other types of arthritis (62596).\nAntibacterial effects\nPreliminary evidence shows that melatonin alone or in combination with isoniazid (INH) is active against some Mycobacterium species (330).\nAnticancer effects\nAccording to the \"melatonin hypothesis\" of cancer, the exposure to light at night and anthropogenic electric and magnetic fields may be related to the increased incidence of cancer and childhood leukemia via melatonin disruption (7042, 62447). Patients with endometrial cancer have been found to have melatonin plasma levels that are six times lower than tumor-free controls (62190, 63040). Postmenopausal adults with breast cancer have also been found to have lower levels of melatonin when compared with cancer-free controls (101257). Furthermore, some earlier observational research has found that females with estrogen receptor (ER)- or progesterone receptor (PR)-positive breast cancer have lower plasma melatonin levels than those with ER- or PR-negative breast cancer (62906). There is some clinical evidence that taking combined high-dose melatonin with conventional chemotherapy or with interleukin-2 (IL-2) might improve tumor regression rate in patients with breast cancer, lung cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer, or colon cancer (1692, 5854, 5855, 5857, 7040, 7043, 8268, 62407, 62844).\n\nThe anticancer effects of melatonin are not entirely clear. In animal models, melatonin appears to protect against the formation of mammary tumors (62321). In vitro, at pharmacological concentrations, melatonin exhibits cytotoxic activity in cancer cells (62211, 62248). Melatonin inhibits proliferation and induces apoptosis of various types of cancer cells (1064, 5856, 7040, 9751, 62154, 62158, 62197, 62330, 62893, 62934). At both physiological and pharmacological concentrations, melatonin acts as a differentiating agent in some cancer cells and lowers their invasive and metastatic capabilities through alterations in adhesion molecules and maintenance of gap junctional intercellular communication (62211). In other cancer cell types, melatonin, either alone or in combination with other agents, induces apoptotic cell death.\n\nBiochemical and molecular mechanisms of melatonin's oncostatic action may include regulation of estrogen receptor expression and transactivation, calcium/calmodulin activity, protein kinase C activity, cytoskeletal architecture and function, intracellular pH, melatonin receptor-mediated signal transduction cascades, and fatty acid transport and metabolism (62211). These and other possible anticancer mechanisms may include or operate by modulation of apoptosis (62496, 62533, 62592, 62605, 62629, 62650), downregulation of HIF-1 alpha expression (antiangiogenic) (62607), antiestrogenic effects (62590, 62658, 62747), increase in estrogen receptor activity in breast tumors (62921) and decreased expression of estrogen receptors (9711, 62828), antiproliferative effects (62587, 62674), suppression of linoleic acid uptake and metabolism (62583), SIRT1 inhibition (62572), cytoskeletal dynamics (inhibition of cancer cell migration) (62487, 62556), epigenetic regulation (62505), reduction of oxidative stress (62711, 62828), enhanced IL-2-induced lymphocytosis (2568), modulation of melatonin receptor expression (62667), stimulation of expression of the growth-inhibitory factor, TGF-beta (62312, 62934), nuclear signaling via nuclear RZR/ROR receptors (62296), aromatase activity (62828), G-protein coupled membrane receptors, or via retinoid orphan receptors with involvement of the calcium signaling pathway (62180), and stimulation of melatonin receptors and associated biomolecular cascades (62715).\n\nMelatonin also appears to affect hormones that influence cancer cell growth. For example, it seems to reduce levels of insulin-like growth factor 1 (IGF-1) and prolactin (PRL), which have a role in breast cancer and prostate cell proliferation (1064, 5854, 5855, 5857, 7043, 7255). Melatonin might also improve survival in patients with cancer by preventing the immunosuppression caused by chemotherapy (7040) or preventing thrombocytopenia associated with cancer chemotherapy by preventing chemotherapy-induced apoptosis of bone marrow cells, and acting synergistically with cytokines to stimulate platelet generation (2564).\n\nHowever, some conflicting research has not shown that melatonin has oncostatic effects against MCF-7 cells or ZR-75-1 and T-47D cell lines (62340).\nAnticonvulsant effects\nThe relationship between melatonin and seizure risk is controversial. Both anticonvulsant (62318, 62525, 63071, 63081) and proconvulsant (9695) properties have been associated with melatonin in preclinical studies. The production of melatonin is increased in patients with uncontrolled epilepsy. This observation may be explained in two contradictory ways. The brain may be attempting to reduce epileptic nerve transmissions by increasing the concentration of melatonin (9696). In contrast, it may be that melatonin has proconvulsant activity. Concentrations of melatonin are increased at night and there is also an increased incidence of seizures during the night (9697). It is thought that melatonin might increase seizure activity by affecting the activity of dopamine in the brain (9744). However, many people with seizures have low endogenous melatonin levels, which increase after a seizure occurs. This suggests that melatonin levels increase to compensate for the increased nerve activity that occurs during a seizure (8249). In addition, some anticonvulsant medications increase concentrations of endogenous melatonin (9698), and exogenous melatonin may be used to treat some types of epilepsy (9699). Until more is known about the potential for melatonin to increase seizure activity, it should be avoided in people with seizure disorders (9744).\n\nIn animals, intraventricular injection of antimelatonin antibody has elicited transitory epileptiform abnormalities in the electroencephalogram (62915). Proposed mechanisms of action include altered brain GABAergic neurotransmission, interactions with benzodiazepine brain receptors, tryptophan metabolite activity, free radical scavenger activity, or modulation of brain amino acids and nitric oxide (NO) production (9695, 62318, 62415).\nAntidiabetic effects\nMelatonin supplementation may impact blood sugar levels both positively and negatively. Although some research has found that melatonin supplementation does not affect glucose levels (19036, 63079), melatonin has been reported to elevate blood sugar levels in patients with type 1 diabetes (63036). Also, in postmenopausal patients, low doses of melatonin have reduced glucose tolerance and insulin sensitivity (9713). Furthermore, a large melatonin bolus might also reduce insulin sensitivity. A small clinical study in healthy adult males shows that taking four doses of melatonin 10 mg hourly seems to temporarily reduce insulin sensitivity, but does not affect other glycemic parameters, when compared with placebo (103690).\n\nHowever, some conflicting evidence has shown beneficial effects. In patients with type 2 diabetes mellitus who had a suboptimal response to the oral hypoglycemic agent metformin, melatonin and zinc acetate administration improved impaired fasting and postprandial glycemic control and decreased the level of glycated hemoglobin (19034, 19035). Beneficial effects on glucose levels and insulin sensitivity have also been reported in animal models (62709). Although the mechanism of action is not entirely clear, melatonin may stimulate glycogen synthesis via the PKCzeta-Akt-GSK3beta pathway (62670) as well as inhibit insulin secretion via stimulation of melatonin receptors in pancreatic islet cells (19038). In animal research, melatonin has been suggested as influencing gene expression in insulinoma beta-cells (62618).\n\nInterestingly, endogenous melatonin levels have also shown some correlation with blood glucose levels. However, although endogenous melatonin levels are negatively correlated with plasma levels of insulin, glucose, and leptin in patients with metabolic syndrome (62851), in patients with type 2 diabetes, nocturnal plasma melatonin levels were higher in obese subjects vs. nonobese subjects and lean nondiabetic controls (62856).\nAntioxidant effects\nMany of melatonin's proposed therapeutic or preventive uses are based on its antioxidant activity (10671, 62120, 62191, 62216, 62227, 62239, 62240, 62245, 62251, 62258)(62265, 62273, 62274, 62277, 62279, 62282, 62284, 62285, 62286, 62292)(62293, 62295, 62297, 62299, 62300, 62305, 62306, 62311, 62319, 62322)(62326, 62460, 62471, 63087, 63091, 63092). Preliminary data suggest that melatonin may decrease oxidative renal damage caused by cisplatin (9749). Antioxidant, or free radical-scavenging properties of melatonin have been shown in laboratory and human research against both reactive oxygen and reactive nitrogen species (62202, 62212, 62216, 62238, 62240, 62251, 62279, 62286, 62292, 62295)(62349, 62477, 62621, 62672, 62673, 62718, 62750, 62763, 62774, 62795)(62809, 62813, 62839, 62858, 63091, 63092, 109700, 110300). Melatonin may reduce oxidative damage under a variety of conditions in which excessive free radical generation is believed to be involved (30066, 62191, 62516, 62531, 62546, 62557, 62559, 62563, 62564, 62582)(62626, 62632, 62634, 62639, 62644, 62648, 62653, 62678, 62683, 62688)(62692, 62726, 62733, 62735, 62736, 62738, 62744, 63087), including animal models of ischemia and reperfusion injury (10671, 62120, 62227, 62239, 62245, 62258, 62265, 62273, 62274, 62277)(62282, 62284, 62285, 62293, 62297, 62299, 62300, 62305, 62306, 62311)(62319, 62322, 62326, 62485, 62492, 62527, 62534, 62536, 62550, 62555)(62562, 62566, 62568, 62603, 62625, 62641, 62666, 62698, 62739, 62740), as well as in nerve tissues, including brain, spinal cord, optic nerve, and spinal cord white matter (62263), and for protection against UV-induced erythema or other damage (1769, 62254, 63086), protection against stroke-induced neurologic damage (10671, 32513, 62203, 62219, 62236, 62253, 62273, 62322), reduced oxidation during blood storage (62842), or protection against other toxins, including heavy metals and radiation (62159, 62176, 62185, 62198, 62209, 62210, 62228, 62247, 62283, 62293)(62300, 62306, 62323, 62326, 62931, 62976, 63051, 63056). Melatonin has been reported as being a more efficient antioxidant than glutathione (62294), vitamin C (62235, 62255), or vitamin E (7082, 62279, 62314, 62944, 62953, 62974, 63088) and synergy has been observed with other antioxidants (62264, 62292). In human research, other potential antioxidant effects of melatonin include an increase in the activity of antioxidant enzymes, glutathione peroxidase, glutathione reductase, and superoxide dismutase (62378, 62382, 116909). As a result, melatonin has been proposed as a supplement to prevent or treat many conditions that are associated with oxidative damage.\n\nHowever, a clinical study in preterm neonates shows that oral administration of a single dose of melatonin 0.5 mg/kg at birth does not improve biomarkers of oxidative stress injury at 24 and 48 hours when compared with placebo (107808). Also, animal and other laboratory research has demonstrated a lack of antioxidant effects (62249, 62266, 62768, 62781, 62805). Negative effects have even been shown in some research. In animals, melatonin injection increased photoreceptor susceptibility to light-induced damage (62398).\nAntiparasitic effects\nIn animal research, melatonin therapy controlled Trypanosoma cruzi proliferation by stimulating the host's immune response (62649, 62652).\nAntiviral effects\nIn animals infected with Venezuelan equine encephalomyelitis virus, administering melatonin 3 days before and 5 days after the infection reduces mortality rates compared to mice administered melatonin along with luzindole, a melatonin receptor antagonist (62497). This suggests that the protective effect of melatonin is mediated by interactions with melatonin receptors.\nBlood pressure effects\nThere is conflicting evidence regarding the effects of melatonin on blood pressure. In animals and humans, research has shown both increases and decreases in blood pressure (1724, 8272, 9714, 62137, 62141, 62165, 62168, 62187, 62196, 62411)(62432, 62513, 62551, 62766, 62795, 62826, 62849, 63010)(63042, 63082, 106299). Some research shows that melatonin has mixed effects depending on the time of day, with decreases at night (62359, 62416, 62441, 62681). However, other research shows that melatonin does not alter blood pressure in animals or humans (62630, 62796). Potential mechanisms for antihypertensive effects have been suggested. Melatonin possibly acts via direct effects on the hypothalamus, through antioxidant activity, by inhibiting the sympathetic nervous system and decreasing norepinephrine levels while activating the parasympathetic nervous system, by a direct calcium channel blocking effect, by relaxing smooth muscle in the aorta wall, and by increasing cardiac vagal tone (8272, 62226). Other evidence suggests that melatonin lowers blood pressure via GABA(A) receptors (62513), reduces oxidative load, restores the nitric oxide pathway, and enhances cyclic guanosine monophosphate production in the endothelium (8272, 62226, 62713, 108947). Melatonin also appears to attenuate reflex sympathetic increases in response to orthostatic stress (62324).\nBone effects\nIn laboratory research, melatonin impaired osteoclast activity and bone resorption through free radical-scavenging and antioxidant methods and promoted osteoblast differentiation (3265, 62242, 62271). However, in human research, melatonin lacked effects on N-terminal telopeptide (NTX) or osteocalcin (OC), although the NTX:OC ratio in the melatonin group was reduced (62840). Also, the effects on bone density are mixed (62840, 116925).\nCardiovascular effects\nPreliminary clinical research shows that serum melatonin levels at nighttime are more than five times lower in patients with coronary heart disease than healthy controls (62941). In addition, following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction, low levels of platelet melatonin were found to be associated with angiographic no-reflow (62790).\n\nPotential cardioprotective effects of melatonin have been shown in both human and animal research. In humans, the inclusion of melatonin in the combined treatment of cardiovascular disease resulted in anti-ischemic and antianginal effects (62766). Also, melatonin resulted in decreased renal blood flow velocity and conductance, as well as increased forearm blood flow and vascular conductance (62796). Melatonin also increased peripheral blood flow, as measured by distal to proximal skin temperature gradient and finger pulse volume (62355). In animals, fatty streaks were inhibited by melatonin (62237). In models of experimental ischemia-reperfusion, melatonin reduced damage to tissues and limited cardiac pathophysiology (62446).\n\nThe potential mechanisms of action have been investigated. Melatonin may act directly on the cardiovascular system rather than modulating cardiac autonomic activity (62344). Relaxation of precontracted rat aorta and reduction of contractile response to alpha-adrenergic but not beta-adrenergic agonists have been observed (62432). However, in contrast to these potential benefits, in animals, melatonin increased the size of atherosclerotic lesions when provided in addition to an atherogenic diet (62230).\nChemoprotective effects\nIn animal research, melatonin reduced the toxic effects of doxorubicin; malondialdehyde levels were reduced compared to animals given doxorubicin alone (88298).\nCoagulation effects\nThere are isolated case reports of minor bleeding and decreased prothrombin activity in people taking melatonin with warfarin (Coumadin) (63067). Also, in human research, melatonin lowered plasma levels of procoagulant factors (62481). However, in animals, melatonin enhanced platelet responsiveness (62537). Also, it is thought that melatonin plays a role in mediating the influence of the psychoendocrine system and of lighting conditions on hematopoiesis. This is because melatonin regulates hematopoietic cell growth by influencing apoptosis-related mechanisms (1695). Increased platelet counts after melatonin use have been observed in patients with decreased platelets due to cancer therapies (1694, 1696, 2565, 7255, 62867, 63016, 63068). Stimulation of platelet production (thrombopoiesis) has been suggested but not clearly demonstrated. Cases of idiopathic thrombocytopenic purpura (ITP) treated with melatonin have been reported (62260, 62289).\nCognitive effects\nAlthough vigilance, reaction time, and tasks in humans undergo circadian variations, they do not seem to correlate with endogenous melatonin levels (1078, 62981, 63057). Exogenous melatonin may cause decrements in performance, including a slowing of choice-reaction time (62175, 62919) or learning (62891). Some studies have failed to confirm a decrement in performance (62332, 62356, 63080), including a study of high-dose melatonin (50 mg) in elderly persons (mean age: 84.5 years) (63085). Animal research suggests a possible role of the GABAergic system (62215).\n\nChronic benzodiazepine use leads to decreased levels of melatonin. Supplementation with melatonin is therefore thought to improve the melatonin imbalance and improve sleep quality, especially withdrawal insomnia when benzodiazepines are discontinued (96323). Due to its antioxidant, inflammatory effects, and its modulatory effects on stress and cortisol secretion, there is interest in using melatonin for reversal of cognitive dysfunction that occurs during benzodiazepine withdrawal. However, current clinical research does not support melatonin for this use (96322).\nDental effects\nIn human research, salivary and gingival crevicular fluid melatonin levels were lower in individuals with periodontal disease (62737). The effect of supplementary melatonin on symptoms of periodontal disease is not clear.\nDermatologic effects\nDermatologic use of melatonin has been proposed because of its immunomodulatory and antioxidant abilities. Study findings indicate that melatonin may accumulate in the stratum corneum (1768). In human research, free radical scavenging was suggested as a possible mechanism of action in the protection against UV-induced erythema (1769).\nEndocrine effects\nIn clinical and laboratory studies, melatonin has been reported as producing varying hormonal effects. Such reports include changes in levels of cortisol in some, but not all, studies (62346, 62350, 62720, 62755, 62975, 62987, 63044), progesterone (769, 62369, 62685, 62812, 62987), estradiol (769), thyroid hormone (T4 and T3) (2425, 62225, 62507), testosterone (62244, 62507), growth hormone (1076, 1741, 1777, 1779, 62884, 62913, 62922), prolactin (62182, 62411, 62883, 62922, 62978, 63044, 63072), oxytocin and vasopressin (1779, 62680, 62719, 63017, 63050), adrenocorticotrophic hormone (62350), thyroid-stimulating hormone (TSH) (62383), and gonadotropin-inhibitory hormone (62697).\n\nMelatonin also appears to affect levels of luteinizing hormone (LH) (1741, 62133, 62136, 62515, 62863, 62936, 62938, 62989). However, the LH response to melatonin was found to be distorted in patients with menstrual abnormalities (62608, 62871), was absent in postmenopausal adults (62918, 62943), and was not observed in males (62773, 62876, 62925), in whom only a decrease in basal luteinizing hormone level was noted (1741, 62133, 62136).\n\nIn humans, although melatonin did not change basal oxytocin secretion, the oxytocin response to insulin-induced hypoglycemia was reduced (63052). Enhanced growth hormone levels may be mediated via the serotonin pathway (62442, 62911, 62912) or through naloxone-sensitive opioid-mediation (62888, 63053); however, this effect has not been confirmed in other studies (62898, 62927).\n\nUnder stimulus situations and in combination with estradiol treatment, melatonin reduced peak values of norepinephrine and increased epinephrine levels in humans in some, but not all, studies (9704, 62152, 62509, 63010). In human research, during a heavy-resistance exercise session, melatonin increased the area under the curve of growth hormone (62424). It has been proposed that administering melatonin to aging females may lead to a recovery of pituitary and thyroid function (2425, 11806). Although it has been suggested that melatonin may modulate hypothalamic-pituitary-thyroid axis function and affect body temperature (62383), in healthy young men, melatonin lacked an effect on suppressing hypothalamic-pituitary-adrenal system activity (62411). Research has suggested that melatonin may mimic the effect of drugs that act through the estrogen receptor interfering with the effects of endogenous estrogens, as well as those that interfere with the synthesis of estrogens by inhibiting the enzymes controlling the interconversion from their androgenic precursors (62395).\n\nSome evidence suggests that melatonin peak time (acrophase) is advanced in postmenopausal adults when compared with premenopausal adults (89432). Some clinical evidence suggests that hormone replacement therapy does not affect serum levels or the duration of endogenous melatonin secretion, but it does appear to delay melatonin acrophase by 2.4 hours in postmenopausal adults after about 6 months of treatment (89507). Theoretically, some of the positive effects of hormone therapy in postmenopausal adults may be related to its ability to delay advanced melatonin peak time.\nExercise performance effects\nMelatonin may have beneficial effects during exercise. In human research, in combination with exercise melatonin increased the area under the curve of growth hormone (62424) and protected against the overexpression, or inhibited the expression, of inflammatory mediators (62813). Melatonin also decreased exercise-induced increases in triglyceride levels and improved antioxidant status (62839).\nGastrointestinal effects\nResearch has been conducted concerning the effects of melatonin in patients with duodenal ulcers, dyspepsia, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), and ulcerative colitis. In patients with GERD, a melatonin-containing supplement inhibited gastric acid secretion and synthesis of nitric oxide (16011); nitric oxide affects lower esophageal sphincter relaxation, a major mechanism. Melatonin may also regulate pancreatic secretion and maintained the integrity of the pancreas (62448), affect bowel functions, reduce gut contractions induced by serotonin, and inhibit proliferation of epithelium, (62970). In animals, high doses of melatonin have been shown to inhibit motility by interacting with serotonin and CCK2 (62417). Protective effects of melatonin in the gastrointestinal tract may be due to its effects on prostaglandins and cytoprotection from its free radical-scavenging activity (62193, 62267, 62325, 62349, 62477, 62478). In animal models of gastric ulcer, beneficial effects of melatonin may be due to the downregulation of matrix metalloproteinases-9 and -3 (62591). Melatonin showed similar benefit in a model of NSAID-induced gastropathy by preventing activation of the mitochondrially mediated apoptosis (by mitigating oxidative stress) (62542).\nGraft effects\nIn animals, melatonin improved the survival of human-derived ovarian grafts (62832). The mechanism of action is unclear.\nHepatoprotective effects\nVarious hepatoprotective effects of melatonin have been shown in humans. In patients with nonalcoholic steatohepatitis (NASH), use of melatonin resulted in improvements in liver function (62853). In patients with steatohepatitis, melatonin decreased levels of proinflammatory cytokines, triglycerides, and GGTP (62787). Also, decreased transaminases have been shown following liver resection (62807).\nHypolipidemic effects\nIn human and animal research, melatonin reduced cholesterol levels (62787, 62795, 62839, 63025, 110291). However, there is some evidence of increases in very low-density lipoprotein (VLDL)-cholesterol and triglyceride levels in human research (62176).\nImmune effects\nResearchers have conducted studies concerning the effects of melatonin as they relate to cachexia, chemotherapy side effects, HIV/AIDS, ischemia-reperfusion injury, and sepsis. Researchers noted increased platelet counts after melatonin use in patients with decreased platelets due to cancer chemotherapy (1694, 1696, 2565, 7255, 62464, 62867, 63016). Although not clearly demonstrated, studies have indicated possible stimulation of platelet production (thrombopoiesis). Melatonin has been reported to promote neutrophil apoptosis in patients receiving hepatectomy involving ischemia and reperfusion of the liver (62293, 62300, 62306, 62326). Preliminary clinical studies suggest that combined therapy with low-dose subcutaneous IL-2 and melatonin improved the immune status in AIDS patients with CD4 cell counts below 200/mm3, who generally do not respond to IL-2 alone. The mean number of lymphocytes, eosinophils, T lymphocytes, natural killer (NK) cells, and CD25- and DR-positive lymphocytes increased with the treatment. An increase in the subjects' CD4:CD8 mean ratio was noted (63002). In cancer patients who achieved disease control, melatonin induced a decrease in the number of regulatory T lymphocytes; this change was lacking in individuals with progressed disease (62783). A combination hormone therapy including melatonin was found to improve leukocyte function in ovariectomized aged rats (62567).\n\nActivation of melatonin receptors has been associated with the release of cytokines by type 1 T-helper cells (Th1), including gamma-interferon (gamma-IFN) and IL-2, as well as novel opioid cytokines (62167). There is indirect evidence that melatonin may amplify the immunostimulatory effect of IL-2, as measured by an increase in the number of T-lymphocytes, natural killer cells, and eosinophils in cancer patients (7043, 62301, 62334, 62977, 62983). In animal research, inhibition of the circadian synthesis of melatonin has been associated with reversible immunosuppression (62881) and elicited T cell autoimmunity in mice (62954, 63032).\n\nAdministration of melatonin agonists has reportedly reduced neophobia, and treatment with a melatonin antagonist during the dark period has reportedly reversed the anxiolytic-like effect of endogenous melatonin (62288). A study in rats showed that melatonin attenuated kainic acid (KA)-induced neuronal death, lipid peroxidation, and microglial activation, and the number of DNA breaks (62272). Other mechanisms through which melatonin may modulate the immune system, according to laboratory research, include the following: suppression of TNF-alpha, IL-1 beta, and IL-6 (62520); inhibition of Th1 cells (62647); stimulation of humoral activity/antibody production (62532, 62628, 62695); inhibition of NF-kappaB (62541), IKK, and JNK pathways (62485); prevention of T cell apoptosis (62742); and stimulation of mononuclear cell production (62687).\nNeurologic effects\nIt has also been proposed that melatonin may reduce the amount of neurologic damage patients experience after stroke, due to its antioxidant properties (10671, 32513, 62203, 62219, 62236, 62253, 62273, 62322). Melatonin has also been suggested as a possible therapeutic strategy for Alzheimer's disease, having been shown in laboratory study to attenuate amyloid-beta-induced phosphorylation of tau-protein and prevent GSK-3beta activation and neuroinflammation (62732), and mitigate amyloid-beta-mediated mitochondrial dysfunction (62712) and amyloid-beta load (62659). Also, in vitro evidence suggests that melatonin may inhibit the biochemical processes involved with the development of myeloid plaques found in the brains of patients with Alzheimer's disease; however, the clinical significance is unclear (9710). Possible neuroprotective mechanisms include the prevention of FGF9 downregulation (62581), the prevention of the induction of mitochondrial NO synthase (62571), or the inhibition of 6-hydroxydopamine production (62663). Other animal research has indicated that melatonin preserved hippocampal cytochrome oxidase and sirtuin-1 expression following sleep deprivation (62623). According to a review, melatonin mechanisms related to a reduction in headache pathophysiology include its anti-inflammatory effect, toxic free radical scavenging, reduction of proinflammatory cytokine upregulation, nitric oxide synthase activity and dopamine release inhibition, membrane stabilization, GABA and opioid analgesia potentiation, glutamate neurotoxicity protection, neurovascular regulation, 5-HT modulation, and its similarity in chemical structure to indomethacin (62425).\n\nHowever, in a rodent model of Parkinson's disease, melatonin was found to potentiate neurodegeneration (62637). Also, although a number of preliminary animal studies have also suggested that melatonin may aid in recovery from or mitigate spinal cord injury (62327, 62522, 62751), not all findings have been positive (62498).\nOpioid tolerance effects\nIn animals, researchers have concluded that melatonin acutely reversed and prevented tolerance to and dependence on morphine (62126, 62276), and reduced the incidence of naloxone-induced withdrawal (62126); however, the exact mechanism is not well understood.\nOptic/ocular effects\nIn human research, melatonin stabilized vision in patients suffering from age-related macular degeneration (62419) and decreased intraocular pressure in the eye (62551, 62889, 62961). However, information in available reviews suggests that high doses of melatonin may increase intraocular pressure and the risk of glaucoma, age-related maculopathy, and myopia (63036), as well as retinal damage (63003).\nPsychiatric effects\nIn patients with schizophrenia, melatonin lacked effects on P50 suppression, suggesting a lack of effect on sensory gating in these patients (62846). However, increases in the P50 ratio occurred in some individuals with high baseline P50 suppression.\nRadioprotective effects\nAnimal and in vitro research has shown that melatonin possesses a protective effect against damage caused by ionizing radiation (62504, 62577, 62609, 62661, 62662, 62696, 62734). The specific mechanisms may involve downregulation of apoptotic pathways via control of oxidative load (62511). Furthermore, there is interest in whether melatonin might be protective against medical imaging radiation. One in vitro study suggests that X-ray radiation of 100 mGy seems to result in fewer double-stranded DNA breaks in blood samples taken from volunteers after melatonin ingestion when compared with blood samples taken before melatonin ingestion (104999). However, a clinical study in females with hyperthyroidism receiving 10-20 mCi iodine-131 shows that taking melatonin 300 mg prior to radioiodine therapy has no effect on chromosomal damage when compared with placebo (107810).\nReproductive effects\nDue to its antioxidant potential and role in determining sexual status in certain mammals, melatonin has been suggested as a means of improving reproductive success in a variety of conditions (62573). In animals, exposure to exogenous melatonin increased sperm motility, ejaculate volume, sperm concentration, total sperm output, total function sperm fraction, and blood testosterone concentration, and decreased means of reaction time, dead sperm, abnormal sperm, and blood triiodothyronine concentration (62507, 62689) and regulate follicular development and oocyte competence (62604, 62612).\n\nAlso, melatonin implants have been shown to improve semen characteristics (62686). Additional veterinary research has indicated that melatonin may increase reproductive success (62486, 62502, 62589) or activity, depending on the dose (6497, 62627) and improve the viability of embryos produced with in vitro fertilization (62488, 62490, 62549, 62668, 62731). There is preliminary evidence that very high melatonin doses plus norethisterone can have additive or synergistic effects on inhibiting ovarian function and possibly act as a contraceptive (769). In vitro, melatonin has been shown to decrease kisspeptin gene expression, while increasing that of RFRP-3 in cell lines from rat hypothalamus (62576). In other research, melatonin lacked an effect on luteal blood flow or function in humans (62528). In a rat model of endometriosis, melatonin was shown to induce regression of endometriotic foci (62682). Other reproductive applications of melatonin include the suppression of estrus (in cats) (62594), induction of estrus (in goats) (62588), and inhibition of gonad function (in fish) (62585).\nSleep effects\nMelatonin, administered in the day or night in doses beyond the physiological range, appears to elicit a hypnotic effect. Various studies have been conducted in humans. For example, exogenous melatonin exerted hypnotic effects primarily when circulating levels of endogenous melatonin were low (1758) and even very low doses may cause sleep when ingested before endogenous melatonin onset (1078, 1753, 1756, 62947, 62997), although some studies have failed to confirm this finding (62895). Functional magnetic resonance imaging suggests melatonin may play a role in priming sleep-associated brain activation patterns in anticipation of sleep (62420). Also, melatonin has been shown to decrease the amount of anesthesia required during surgery (62233, 62430, 62443, 62444) and potentiate the effects of gamma-aminobutyric acid (GABA) and benzodiazepines, and improve quality of sleep in combination with benzodiazepines (62964). Melatonin may interact directly with the GABA-benzodiazepine-chloride ion channel as suggested in both human and animal research (62183, 62269), but not with the benzodiazepine receptor as suggested in human research (63005).\n\nRandomized clinical trials have demonstrated some effect of melatonin on circadian rhythm entraining (62207, 62377, 62409). Endogenous circadian rhythmicity influences autonomic control of heart rate, and the timing of these endogenous rhythms may be altered by extended sleep/rest episodes and associated changes in the photoperiod, as well as by melatonin treatment (62461), with no evidence of changes in the duration of endogenous melatonin secretion or pituitary or gonadal hormones (62335). In visually impaired individuals, disturbances of sleep and sleep-related neuroendocrine patterns may be caused by the absence of light cues as the lack of light signal in blind persons leads to various unusual free-running melatonin secretory patterns (62367, 62923, 62929). Also, people who suffer from an insufficient amount of environmental light often have decreased endogenous melatonin secretion (8247). In individuals who are completely blind, a single administration of a pharmacological dose of melatonin improved sleep function by synchronizing the inhibition of pituitary-adrenal activity with central nervous sleep processes (62350). Disturbances in the circadian rhythm of melatonin (and declines in nighttime melatonin) have been associated with aging (1773, 1775, 1781, 62134, 62116, 62170, 62900, 63046). In human research, exogenous melatonin is able to shift circadian rhythms, as well as endogenous melatonin secretion and core body temperature (62418, 62945, 63001, 63023). However, light appears to be a stronger regulator of circadian rhythm than melatonin itself (8274, 62960, 62986, 62999, 63008, 63015, 63018, 63033). The time of administration of melatonin is of critical importance, since it may cause both phase delay and phase advance. In human research it was determined that for phase delay, melatonin should be administered in the early morning; however, for phase advance, melatonin should be administered 1-2 hours before 9 p.m. (8274).\n\nClinically, melatonin is used in many disease states thought to have low levels of melatonin such as traumatic brain injury and Alzheimer's disease (62847, 96317, 96319, 96320). Decreased membrane fluidity is thought to play a role in the pathogenies of Alzheimer's disease. Stress and rapid eye movement contribute to neuronal rigidity. Melatonin has been added to other ingredients to help promote sleep and improve cognition in patients with Alzheimer's disease (62847). Additionally, in patients with depression, the circadian rhythm is altered. Patients with depression often have insomnia and early-morning awakening. It has been hypothesized that low melatonin secretion is a marker of depression, and melatonin may improve these symptoms, although the majority of clinical research does not support melatonin for this use (96326).\n\nLow-dose melatonin has been noted to be more effective entraining blind people with a free-running melatonin secretory pattern due to the potential of excess hormone discharging into the wrong zone of the phase-response curve (62232). Free-running patterns are also observed after pineal gland damage (62952) or under special working regimens (62901, 62955). The nocturnal onset of melatonin secretion strongly correlates with a steep rise in sleep propensity and precedes it by approximately two hours (63047). The specific events taking place during this interval currently remain obscure. It is possible that melatonin does not actively induce sleep but switches off a wakefulness-generated mechanism that opposes a sleep-inducing mechanism (63047), the alerting process being dependent on the suprachiasmatic nucleus (63039).While measuring endogenous melatonin, some authors have not found a link between melatonin secretion and the sleep-waking cycle in humans (62899). It has been suggested by some that natural sleep is largely determined by a functioning circadian system without melatonin involvement (62886, 62949, 63045, 63046).\nThermoregulating effects\nThe central thermoregulatory centers, including the preoptic area of the anterior hypothalamus, are likely to be involved with the regulation of core temperature following melatonin administration (1132). In human research, hypothermic effects of melatonin have been reported with doses from 15mg (1757, 62418, 63007) and ingestion of melatonin 1.6 mg was reported to result in approximately 0.4 C decrease of body temperature in humans (62418, 62945, 63001, 63023). The hypothermic effects may be mediated by GABA receptor activity (63063). Melatonin may also influence chloride flux or other intracellular actions via a different mechanism that is not well understood (63005). Melatonin did not appear to exert hypothermic effects by central benzodiazepine receptors (63005). Melatonin appeared to increase heat loss and decrease heat production when taken during the day (63063). A parallel relationship was found between rectal core body temperature and the decline in sleep onset latency following melatonin administration (63063).\nToxicity protective effects\nA number of laboratory studies have established melatonin's ability to prevent or mitigate damage from a number of chemical sources, including (but not limited to) methamphetamines (62563, 62717), organophosphorus compounds (62493, 62494, 62664), alcohol (62636, 62675), nicotine (62716), beta-cyfluthrin (62700), and benzo(a)pyrene (62694).\nVestibular effects\nIn human research, melatonin attenuated the muscle sympathetic nerve activity (vestibulosympathetic reflex) response to baroreceptor unloading, while lacking effects on the vestibulocollic reflexes (62779). In human research, melatonin positively benefitted balance (1776).\nWeight loss effects\nMelatonin may inhibit preadipocyte differentiation into adipocytes. It may also increase the metabolic rate and energy expenditure by converting white adipose tissue to brown (96316)."
        }
    },
    "Mentabolan [FAST FACTS]": {
        "sections": {
            "Overview": "Mentabolan is marketed as a prohormone, or a hormone precursor. Usually, a segment of the prohormone is cleaved or altered to produce a biologically active hormone such as testosterone, estrogen, or a derivative (91094, 91095).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Warnings": "Prohormones which are intended to provide anabolic activity in the body meet the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469). Certain prohormones have also been prohibited by the National Collegiate Athletic Association (NCAA) (13163).",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Prohormones can be converted to active hormones in the body and cause adverse effects such as menstrual irregularities, infertility, hair loss, and acne. Prohormones have also been associated with hepatotoxicity and increased risk of cardiovascular disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing prohormones are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Prohormones can be converted to active hormones in the body and cause adverse effects such as menstrual irregularities, infertility, hair loss, and acne. Prohormones have also been associated with hepatotoxicity and increased risk of cardiovascular disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing prohormones are dangerous (91094). Avoid using.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using mentabolan for athletic performance, there is insufficient reliable information about the clinical effects of mentabolan for this purpose.\nExercise-induced muscle damage. Although there is interest in using mentabolan for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of mentabolan for this purpose.\nMuscle strength. Although there is interest in using mentabolan to increase muscle strength, there is insufficient reliable information about the clinical effects of mentabolan for this purpose.\nObesity. Although there is interest in using mentabolan for weight loss, there is insufficient reliable information about the clinical effects of mentabolan for this purpose.\nMore evidence is needed to rate mentabolan for these uses.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Mercury Herb": {
        "sections": {
            "Overview": "Mercury herb is an annual plant found in North America, Europe, and northern parts of Africa. It typically grows to around 16-24 inches tall (4144).\n\nKEY HIGHLIGHTS\nSometimes used for constipation, infections, swelling, and other conditions, but there is insufficient reliable evidence to rate its effectiveness for these uses.\nLikely unsafe when used orally. High doses might cause nerve paralysis, liver failure, kidney failure, and even death.\nNo known major interactions.",
            "Safety": "LIKELY UNSAFE when the fresh plant, particularly the root and rhizome, are used orally (18).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally (18); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, mercury herb might cause diarrhea and overactive bladder (18). Symptoms of poisoning might include nerve paralysis, liver and kidney failure, and death (18). The pollen has shown to be allergenic (4143, 4144), and may be responsible for rhinitis and asthmatic symptoms (4143). Mercury herb might also cause allergic reactions in individuals allergic to ash, castor bean plant, mugwort, olive, pellitory-of-the-wall, and Salsola kali (4143).\nGastrointestinal\nOrally, mercury herb might cause diarrhea (18).\nless\nGenitourinary\nOrally, mercury herb might cause overactive bladder (18).\nless\nHepatic\nOrally, mercury herb poisoning might cause liver failure (18).\nless\nImmunologic\nThe pollen from mercury herb can be allergenic (4143, 4144) and may be responsible for rhinitis and asthmatic symptoms (4143). Mercury herb might also cause allergic reactions in individuals allergic to ash, castor bean plant, mugwort, olive, pellitory-of-the-wall, and Salsola kali (4143).\nless\nNeurologic/CNS\nOrally, mercury herb poisoning might cause nerve paralysis (18).\nless\nPulmonary/Respiratory\nThe pollen from mercury herb can be allergenic (4143, 4144) and may be responsible for rhinitis and asthmatic symptoms (4143).\nless\nRenal\nOrally, mercury herb poisoning might cause kidney failure (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of mercury herb.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mercury herb. It is typically administered as an extract or in juice (18).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nIndividuals allergic to mercury herb might also be allergic to ash, castor bean plant, mugwort, olive, pellitory-of-the-wall, and Salsola kali (4143).\nless",
            "Interactions with Lab Tests": "None known.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mercury herb.",
            "Mechanism of Action": "General\nThe applicable parts of mercury herb include the flowering plant, root, and rhizome. Mercury herb contains saponins, a small amount of cyanogenic glycosides, pyridone derivatives including hermidin, amines including methylamine, and flavonoids including rutin, narcissin, and isorhamnetin. The insignificant amount of cyanogenic glycosides are not believed to account for the plant's toxicity (18).\nLaxative effects\nThe root and stock of mercury herb are thought to have laxative effects (18)."
        }
    },
    "Mesoglycan": {
        "sections": {
            "Overview": "Mesoglycan is a naturally-occurring glycosaminoglycan that is typically extracted from bovine lung and aortic tissue and porcine intestinal mucosa. It contains heparan sulfate, dermatan sulfate, chondroitin sulfate, and hyaluronic acid (6635).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Mesoglycan has been used safely at doses of up to 200 mg daily for up to 18 months (6635, 6637, 6638, 6639, 6644, 6645, 11479, 31647, 31649, 97777)(97778, 97779, 103263, 103264, 103265). ...when used intramuscularly under the supervision of a healthcare provider. Mesoglycan has been used with apparent safety at doses of 60 mg daily for up to 5 days and doses up to 30 mg daily for up to 3 weeks (6630, 11479, 103263). Since mesoglycan products are derived from animals, there are concerns about contamination with diseased animal parts (1825).\nHowever, there are no reports of disease transmission to humans due to use of contaminated mesoglycan.\nThere is insufficient reliable information available about the safety of mesoglycan when used topically or intravenously.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, mesoglycan seems to be well tolerated. Some adverse effects reported in clinical studies include nausea, vomiting, epigastric pain, dyspepsia, heartburn, headache, diarrhea, and local cutaneous reactions (6629, 97778, 97779, 103265).\n\nHowever, there is some concern about potential contamination. Mesoglycan is derived from raw animal tissues gathered from slaughterhouses, possibly from sick or diseased animals (6620). Products made from contaminated or diseased organs might present a human health hazard. There is also concern that mesoglycan produced from cows in countries where bovine spongiform encephalitis (BSE) has been reported might be unsafe (1825). However, there are no reports of disease transfer to humans from contaminated mesoglycan.\nDermatologic\nOrally, mesoglycan has been reported to cause local cutaneous reactions (6629, 97778).\n\nSubcutaneously, injections of mesoglycan into the scalp were thought to result in edema, redness, and local hair loss in a 32-year-old female (97780).\nless\nGastrointestinal\nOrally, mesoglycan has been reported to cause nausea, vomiting, epigastric pain, dyspepsia, heartburn, and diarrhea (6629, 97779, 103265).\nless\nNeurologic/CNS\nOrally, mesoglycan has been reported to cause headache (6629).\nless\nOther\nMesoglycan is derived from raw animal tissues gathered from slaughterhouses, possibly from sick or diseased animals (6620). Products made from contaminated or diseased organs might present a human health hazard. However, there are no reports of disease transfer to humans from contaminated mesoglycan.\n\nThere is also some concern that mesoglycan that is obtained from cows in countries where bovine spongiform encephalopathy (BSE) has been reported might be unsafe. However, there are no reports of BSE transfer to humans from contaminated mesoglycan (1825).\nless",
            "Effectiveness": "POSSIBLY EFFECTIVE\nCerebrovascular disease. Preliminary clinical research in small groups of patients with cerebrovascular disease shows that taking mesoglycan 96-100 mg daily orally for 6 months seems to reduce ischemic events, improve quality of life, and provide subjective improvement when compared with baseline (6635, 6637, 6639). The validity of this finding is limited by the lack of a comparator group. There is also some preliminary evidence that mesoglycan might be comparable to standard antiplatelet drug therapy (6639).\nPeripheral arterial disease (PAD). The majority of preliminary clinical research shows that mesoglycan improves walking distance in patients with PAD, although it may not be as effective as other therapies. Alternating intravenous and oral mesoglycan seems to improve walking distance when compared with baseline in patients with intermittent claudication due to PAD (6629). Also, injecting mesoglycan 30 mg intramuscularly for 3 weeks then taking oral mesoglycan 100 mg daily for 20 weeks appears to improve clinical response and walking distance in patients with PAD when compared with placebo (31635). Taking mesoglycan 100 mg daily orally for a total of 120 days increases walking distance by approximately 39% when compared with baseline (97779). However, taking oral mesoglycan 48 mg daily for 6 months is less effective at improving pain-free walking distance and total walking distance than oral defibrotide 800 mg daily in patients with intermittent claudication due to PAD (31647).\nVenous insufficiency. There is some evidence from uncontrolled trials that administering mesoglycan orally or parenterally may improve the subjective and objective symptoms associated with various venous conditions, including varicose syndromes, post-phlebitic syndromes, and thrombophlebitis, when used over a 1-3 month period (6630, 6638, 6644, 6645). Some research also shows that applying mesoglycan topically might be beneficial for treating leg ulcers in patients with chronic venous insufficiency (6627).\nVenous leg ulcers. Clinical research shows that administering a combination of intramuscular and oral mesoglycan as an adjunct to traditional chronic venous stasis ulcer therapy improves the rate of healing when compared with traditional therapy alone. At least 75% of patients taking mesoglycan were fully healed approximately 46 days earlier than patients taking traditional therapy alone (11479).\nPOSSIBLY INEFFECTIVE\nStroke. Clinical research in patients with acute ischemic stroke shows that adding intramuscular mesoglycan for 5 days, followed by 25 days of oral mesoglycan, to intravenous dexamethasone therapy is no more effective than dexamethasone alone (6641).\nVenous thromboembolism (VTE). Clinical research shows that taking oral mesoglycan plus compression stockings following standard deep venous thrombosis (DVT) therapy is no better than placebo for preventing recurrent DVT and/or pulmonary embolism during a follow-up period ranging from 5 to 48 months (6640).\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtherosclerosis. Preliminary clinical research shows that taking oral mesoglycan 200 mg daily for 18 months might slow the progression of atherosclerosis by decreasing the rate of carotid and femoral artery intima-media thickening (6628, 31649).\nChronic venous insufficiency (CVI). Preliminary clinical research in adults with unilateral lower limb edema due to CVI shows that taking mesoglycan 100 mg daily for one month reduces pain and swelling by approximately 43% and 63%, respectively, when compared with placebo (97778).\nCutaneous necrotizing venulitis. Preliminary clinical research shows that intramuscular mesoglycan 10 mg/kg daily for 20 days might be useful for treating cutaneous necrotizing venulitis in patients with reduced fibrinolytic activity (6634).\nDiabetic retinopathy. Preliminary clinical research in adults with diabetic retinopathy shows that taking mesoglycan 100 mg daily for 6 months reduces the occurrence of microhemorrhages, microaneurysms, and exudates, compared with no change in those taking placebo (97777).\nHypertension. Preliminary clinical research shows that taking mesoglycan 100 mg daily orally for a total of 120 days reduces systolic blood pressure by 5 mmHg when compared to baseline in patients with hypertension (97779). The validity of this finding is limited by the lack of a comparator group.\nHypertriglyceridemia. Preliminary clinical research in a small group of patients shows that taking mesoglycan 96 mg daily reduces total triglyceride and very low density lipoprotein (VLDL) levels when compared to baseline in patients with hypertriglyceridemia (6646).The validity of this finding is limited by the lack of a comparator group.\nMetabolic syndrome. Preliminary clinical research in a small group of patients with metabolic syndrome shows that taking mesoglycan 50 mg twice daily for 90 days improves vascular function, as measured by brachial flow-mediated dilation and arterial stiffness, when compared with placebo (103265).\nPostoperative pain. Preliminary, prospective clinical research in a small group of patients undergoing open excisional diathermy hemorrhoidectomy shows that intramuscular mesoglycan (Prisma, Mediolanum Farmaceutici) 60 mg daily for 5 days postoperatively, then 50 mg orally twice daily for 30 days, reduces pain after rectal examination, but not spontaneous pain or pain after defecation, and shortens the time to full resumption of normal daily activities, when compared with ketorolac 10 mg orally every 4-6 hours for 5 days (103263). A retrospective, observational study in a larger group of patients undergoing the same surgery shows that giving the same mesoglycan regimen in conjunction with the ketorolac regimen reduces pain on postoperative day 1 and after 1, 3, and 6 weeks of follow-up when compared with the ketorolac regimen alone. The addition of mesoglycan also reduces the incidence of postoperative rectal thromboses and the time to recovery of normal activities, but does not reduce postoperative bleeding or time to wound healing, when compared with ketorolac alone (109651).\nTinnitus. Observational research in patients with tinnitus has found that taking mesoglycan 50 mg daily for 90 days is associated with an improvement in tinnitus when compared to baseline (103264). The validity of this finding is limited by the lack of a comparator group .\nVertigo. Observational research in patients with vertigo has found that taking mesoglycan 50 mg daily for 90 days is associated with an improvement in vertigo symptoms when compared to baseline (103264). The validity of this finding is limited by the lack of a comparator group.\nMore evidence is needed to rate mesoglycan for these uses.",
            "Dosing & Administration": "Adult\nOral:\nAtherosclerosis: Mesoglycan 200 mg daily for 18 months has been used (6628, 31649).\n\nCerebrovascular disease: Mesoglycan 96-100 mg daily for up to 6 months has been used (6635, 6637, 6639).\n\nChronic venous insufficiency (CVI): Mesoglycan 50 mg twice daily for one month has been used (97778).\n\nDiabetic retinopathy: Mesoglycan 100 mg daily for 6 months has been used (97777).\n\nHypertension: Mesoglycan 50 mg twice daily for 60 days, then 60 days off, followed by an additional 60 days of twice daily mesoglycan has been used (97779).\n\nHypertriglyceridemia: Mesoglycan 96 mg daily for 2 months has been used (6646).\n\nMetabolic syndrome: Mesoglycan 50 mg twice daily for 90 days has been used (103265).\n\nPeripheral arterial disease (PAD): Mesoglycan 50 mg twice daily for 60 days, then 60 days off, followed by an additional 60 days of twice daily mesoglycan has been used (97779). Mesoglycan 90 mg daily intravenously for ten days, then orally 100 mg daily for 20 days, repeated, and then orally only for a mean of 12 months has been used (6629). Mesoglycan 30 mg intramuscularly for 3 weeks then orally 100 mg daily for 20 weeks has been used (31635).\n\nPostoperative pain: Intramuscular mesoglycan 60 mg for five days after surgery, followed by mesoglycan 50 mg by mouth twice daily for 30 days, has been used (103263).\n\nTinnitus: Mesoglycan 50 mg daily for 90 days has been used (103264).\n\nVenous insufficiency: Mesoglycan 48-50 mg three times daily for 30 days has been used (6638, 6645).\n\nVenous leg ulcers: As an adjunct to traditional chronic venous ulcer therapy, 30 mg intramuscular mesoglycan daily has been used for three weeks followed by 100 mg oral mesoglycan daily for up to 21 weeks (11479).\n\nVertigo: Mesoglycan 50 mg daily for 90 days has been used (103264).\nTopical:\nVenous insufficiency: Topical application with mesoglycan twice daily for 2 months has been used (6627).\nIntravenous/Intramuscular:Cutaneous necrotizing venulitis: Intramuscular mesoglycan 10 mg/kg daily for 20 days has been used (6634).\n\nPeripheral arterial disease (PAD): Mesoglycan 90 mg daily intravenously for ten days, then orally 100 mg daily for 20 days, repeated, and then orally only for a mean of 12 months has been used (6629). Mesoglycan 30 mg intramuscularly for 3 weeks, then orally 100 mg daily for 20 weeks has been used (31635).\n\nPostoperative pain: Intramuscular mesoglycan 60 mg for five days after surgery, followed by mesoglycan 50 mg by mouth twice daily for 30 days, has been used (103263).\n\nVenous insufficiency: Mesoglycan 30 mg daily for up to 3 months has been used (6630).\n\nVenous leg ulcers: As an adjunct to traditional chronic venous ulcer therapy, 30 mg intramuscular mesoglycan daily has been used for three weeks followed by 100 mg oral mesoglycan daily for up to 21 weeks (11479).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mesoglycan.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, combined use might increase bleeding risk. However, human evidence suggests that mesoglycan has profibrinolytic activity without affecting coagulation (6631, 6642, 31646). These agents include aspirin, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, ticlopidine (Ticlid), warfarin (Coumadin), and others.\nTHROMBOLYTIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, combined use might increase bleeding risk (6629). These drugs include alteplase (Activase), anistreplase (Eminase), reteplase (Retevase), streptokinase (Streptase), and urokinase (Abbokinase).",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nConcomitant use of herbs and supplements that affect platelet aggregation could theoretically increase the risk of bleeding in some people. Some of these herbs include angelica, clove, danshen, garlic, ginger, ginkgo, Panax ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nMesoglycan might cause bleeding in people with coagulation disorders (6633).\nless\nHEPARINOID HYPERSENSITIVITY\nMesoglycan might cause allergic reactions in people hypersensitive to heparin or heparinoid derivatives (15).\nless\nPERIOPERATIVE\nMesoglycan has antiplatelet effects. Mesoglycan might cause excessive bleeding if used perioperatively. Tell patients to discontinue mesoglycan at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mesoglycan.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mesoglycan.",
            "Mechanism of Action": "General\nMesoglycan belongs to a broad class of compounds called glycosaminoglycans (GAG). GAGs, also called mucopolysaccharides, are amino hexose polysaccharides contained in mucoproteins, glycoproteins, and blood group substances. GAGs are a heparinoid (non-heparin) byproduct of heparin extraction from bovine lung and aortic tissue and porcine intestinal mucosa (15). Mesoglycan specifically is composed of dermatan sulfate and heparan sulfate, with smaller concentrations of chondroitin sulfate, hyaluronic acid, and related hexosaminoglycans (6614). The concentrations of these substances can vary depending on the origin of the product.\nCirculatory effects\nMesoglycan seems to have numerous pharmacological effects on the vascular system. Mesoglycan exhibits profibrinolytic activity without influencing hemagglutination in humans after oral administration (6631, 6642). It seems to also decrease plasma fibrinogen concentrations without affecting prothrombin time, partial thromboplastin time, or antithrombin III (6633). Mesoglycan might restore normal fibrinolysis in patients with reduced cutaneous fibrinolytic activity (6634). However, it has been shown to prolong activated partial thromboplastin time (aPTT) (6629). Mesoglycan seems to reduce pericapillary connective tissue edema, and capillary and venule dilation, in patients with primary venous insufficiency (6630). It also improves arterial wall elasticity, transcutaneous oxygen perfusion, and blood flow (6643, 6644). Mesoglycan reduces total triglyceride and very low density lipoprotein concentrations and increases lipoprotein lipase activity in patients with hypertriglyceridemia (6646). In patients recovering from a cerebral ischemic episode, mesoglycan reduces total cholesterol and triglyceride concentrations and increases HDL cholesterol concentrations (6633)."
        }
    },
    "Methasterone [FAST FACTS]": {
        "sections": {
            "Overview": "Methasterone meets the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, gynecomastia (in males), hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094). Avoid using.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using methasterone for athletic performance, there is insufficient reliable information about the clinical effects of methasterone for this purpose.\nErectile dysfunction (ED). Although there is interest in using methasterone for ED, there is insufficient reliable information about the clinical effects of methasterone for this condition.\nExercise-induced muscle damage. Although there is interest in using methasterone for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of methasterone for this purpose.\nMuscle strength. Although there is interest in using methasterone to improve muscle strength, there is insufficient reliable information about the clinical effects of methasterone for this purpose.\nObesity. Although there is interest in using methasterone for weight loss, there is insufficient reliable information about the clinical effects of methasterone for this purpose.\nMore evidence is needed to rate methasterone for these uses.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Methionine": {
        "sections": {
            "Overview": "Methionine is a sulfur-containing amino acid. It is considered an essential amino acid because it cannot be synthesized by the human body and therefore must be obtained through dietary intake. Sources of methionine include protein-rich foods such as seeds, meat, and fish (9, 9343, 63121).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in food (94500).\nPOSSIBLY SAFE when used orally or intravenously and appropriately in medicinal amounts under the supervision of a healthcare professional (2410, 2411, 2413).\nPOSSIBLY UNSAFE when used orally or intravenously in excessive doses. Doses larger than 100 mg/kg should be avoided to prevent severe and potentially lethal cerebral effects (9339).\nCHILDREN: LIKELY SAFE when used orally in amounts commonly found in foods (94500).\nCHILDREN: POSSIBLY SAFE when used intravenously and appropriately (9338).\nCHILDREN: POSSIBLY UNSAFE when used intravenously in infants receiving parenteral nutrition. In infants, blood methionine concentration can increase due to lower enzyme activity and inability to metabolize methionine. High levels of methionine can cause liver toxicity (9338).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in amounts commonly found in food (94500). There is insufficient reliable information available about the safety of methionine in medical doses during pregnancy and lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, methionine is well tolerated when used in amounts commonly found in foods. Intravenously, methionine is generally well tolerated.\nMost Common Adverse Effects\nAll ROAs: Dizziness, drowsiness, hypotension, irritability, and vomiting. Methionine may also cause headache, increased homocysteine levels, increased urinary calcium excretion, and leukocytosis.\nSerious Adverse Effects (Rare)\nAll ROAs: Cerebral edema, hepatic encephalopathy. In infants, intravenous methionine has been linked to liver toxicity.\nCardiovascular\nOrally or intravenously, methionine can cause hypotension (9339, 9340). High-dose methionine (75-100 mg/kg daily) may increase plasma concentrations of homocysteine, which is a risk factor for vascular disease (63112, 63114, 63115). However, a study of patients with type 2 diabetes and a history of cardiovascular disease (CVD) showed that methionine loading did not increase homocysteine concentrations, and that a cause-effect relationship between increased intake of methionine and endothelial dysfunction has not been clearly established (63110).\nless\nGastrointestinal\nOrally or intravenously, methionine can cause vomiting (9339, 9340).\nless\nGenitourinary\nOrally or intravenously, methionine may increase urinary calcium excretion (9340, 63112, 94095).\nless\nHematologic\nOrally or intravenously, methionine may cause leukocytosis when used at a dose of 8-13.9 grams daily for 4-5 days (9340).\nless\nHepatic\nA single dose of 8 grams of methionine has reportedly caused hepatic encephalopathy in patients with cirrhosis (9340). Long-term use of methionine-containing parenteral nutrition solution has been linked to liver toxicity in infants (9338).\nless\nNeurologic/CNS\nOrally or intravenously, methionine can cause dizziness, drowsiness, headache, and irritability (9339, 9340, 94095).\n\nA case of cerebral edema ultimately leading to death has been reported in a patient receiving methionine 100 mg/kg orally. The post-load plasma concentrations of methionine were substantially higher in this patient than those previously reported in humans receiving this usual oral loading dose, leading the authors to postulate that an overdose of methionine may have been administered erroneously. This can occur when plasma methionine levels rise above 3000 mcmol/L (9339). Another case of progressive cerebral edema associated with high methionine levels and betaine (N,N,N-trimethylglycine) therapy in a patient with cystathionine beta-synthase (CBS) deficiency has been reported (63119). The authors stated that the cerebral edema was most likely precipitated by the betaine therapy, but that the exact mechanism is uncertain.\nless\nOncologic\nAlthough one case-control study of incident, histologically-confirmed gastric cancer has indicated that a diet rich in methionine, salt, and nitrite is associated with an increased risk of gastric cancer (2409), a large observational study that adjusted for multiple factors, including sodium intake, has found no association between high dietary intake of methionine and gastric cancer (108041).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nNeural tube birth defects. High dietary intake of methionine during pregnancy seems to reduce the risk of neural tube birth defects.\nPopulation research has found that higher dietary intake of methionine during pregnancy is associated with a reduced risk of neural tube defects when compared with lower dietary intake (63117, 63135).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcetaminophen poisoning. It is unclear if oral methionine is beneficial in patients with acute acetaminophen poisoning.\nObservational research has found that taking methionine 2.5 grams every 4 hours for a total of four doses, starting within 10 hours of acetaminophen overdose, may have similar efficacy to acetylcysteine for preventing liver damage and death (2413).\nless\nAllergic rhinitis (hay fever). Although there has been interest in using oral methionine for seasonal allergies, there is insufficient reliable information about the clinical effects of methionine for this purpose.\nAndrogenic alopecia. Oral methionine has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized clinical study in adults with androgenic alopecia or telogen effluvium shows that taking a combination product containing methionine, hydrolyzed collagen, taurine, cysteine, iron, and selenium (GFM Oral, Cantabria Labs) daily along with conventional therapy, consisting primarily of finasteride or minoxidil, for 12 weeks improves hair loss when compared with conventional therapy alone (111636). It is unclear if this effect is due to methionine, other ingredients, or the combination.\nless\nAsthma. Although there has been interest in using oral methionine for asthma, there is insufficient reliable information about the clinical effects of methionine for this purpose.\nBreast cancer. It is unclear if high dietary intake of methionine reduces the risk of breast cancer.\nA meta-analysis of observational studies suggests that higher dietary intake of methionine is associated with a 6% lower risk of breast cancer, especially for postmenopausal adults, when compared with lower intake. Increasing dietary intake of methionine by 1 gram daily may be associated with a 4% reduction in the risk of breast cancer. These results appear to be more prominent in postmenopausal adults when compared with premenopausal adults; however, this could have been by chance due to the small number of studies that assessed premenopausal adults (94093). A more recent meta-analysis, including 4 additional observational studies, suggests that there is no significant association between methionine intake and breast cancer risk. This finding is largely influenced by inclusion of the European Prospective Investigation into Cancer and nutrition (EPIC) cohort study, which analyzed data from over 300,000 subjects and found no relationship between methionine intake and breast cancer risk (111416).\nless\nCisplatin-associated ototoxicity. It is unclear if oral D-methionine prevents cisplatin-associated ototoxicity.\nA small clinical study in adults with cancer receiving cisplatin shows that taking D-methionine 100 mg/kg one hour prior to chemotherapy for up to 5 cycles prevents shifts in the hearing threshold at all four tested frequencies, compared with shifts occurring at three of the four tested frequencies in those receiving placebo (108039). The validity of these findings is limited by the lack of statistical comparison between groups.\nless\nColorectal cancer. It is unclear if high dietary intake of methionine reduces the risk of colorectal cancer.\nA meta-analysis of observational research has found that higher dietary intake of methionine is associated with an 11% lower risk of colorectal cancer, a 23% lower risk of colon cancer, and a 12% lower risk of rectal cancer, when compared with lower intake of methionine. Increasing dietary intake of methionine by 1 gram daily is associated with a 11% reduction in the risk of colorectal cancer. Subgroup analyses have shown a significant inverse relationship between risk of colorectal cancer and dietary methionine intake in patients followed for at least 13.3 years, in Western populations, and in males (94094).\n\nThere is some evidence that high dietary intake of methionine and folate might have a synergistic effect in decreasing the risk of colon cancer, especially in those with a family history of colon cancer and in those who consume large amounts of alcohol (9325, 9326).\nless\nGenital herpes. Oral L-methionine has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with genital warts caused by herpes simplex virus (HSV) shows that taking acyclovir 200 mg five times daily for 5 days followed by 4 capsules of a combination product providing a total daily dose of L-methionine 200 mg, coenzyme Q10 50 mg, vitamin E 50 mg, and selenium 50 mcg for 90 days increases the rate of skin reepithelization by approximately 2 days and decreases the incidence of relapse when compared with acyclovir alone. Patients receiving combination therapy had a relapse rate of 13%, compared with a rate of 43% with acyclovir alone (94091).\nless\nHerpes zoster (shingles). Oral L-methionine has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with herpes zoster shows that taking acyclovir 800 mg five times daily for 10 days followed by 4 capsules of a combination product providing a total daily dose of L-methionine 200 mg, coenzyme Q10 50 mg, vitamin E 50 mg, and selenium 50 mcg for 90 days increases the rate of skin reepithelization by approximately 2 days, decreases the incidence of relapse, and decreases postherpetic neuralgia pain when compared with acyclovir alone. Patients receiving combination therapy had a relapse rate of 7%, compared with a rate of 44% with acyclovir alone (94091).\nless\nHuman papillomavirus (HPV). It is unclear if oral methionine is beneficial for the treatment of HPV lesions or for reducing the incidence of relapse.\nA clinical study in patients aged 14 years or older with cutaneous warts caused by HPV shows that receiving conventional therapy in combination with one capsule of a product containing methionine, echinacea, inulin, taurine, vitamin A, vitamin C, coenzyme Q10, vitamin B3, zinc gluconate, and probiotics (Immuno Skin Plus tablets, Morgan Pharma S.r.l) daily for 20 days each month for 4 months reduces the number of warts at 6 months by about 5, with complete remission achieved in 86% of patients. The group receiving conventional therapy alone had a reduction in the number of warts by about 3, with complete remission achieved in 55% of patients. Conventional therapy consisted of either liquid nitrogen cryotherapy or topical therapy with salicylic acid 15% and lactic acid 15%. These findings are limited by the fact that patients in the combination therapy group had more warts at baseline when compared with those receiving conventional therapy alone (94092).\n\nAnother small clinical study in patients with skin warts caused by HPV shows that cryotherapy followed by taking 4 capsules of a product containing a total dose of L-methionine 200 mg, coenzyme Q10 50 mg, vitamin E 50 mg, and selenium 50 mcg daily for 180 days increases the rate of complete recovery and decreases the incidence of relapse when compared with cryotherapy followed by placebo. At 180 days, 56% of patients in the active group experienced complete recovery, compared with 44% in the placebo group, and 30% of patients in the active group experienced a relapse, compared with 41% in the placebo group (94091). It is unclear if these effects are due to methionine, other ingredients, or the combination.\nless\nMenopausal symptoms. It is unclear if oral L-methionine is beneficial for reducing hot flashes.\nPreliminary clinical research in postmenopausal adults experiencing at least 5 hot flashes daily for the prior two months shows that taking L-methionine 1 gram twice daily for 12 weeks, then 2 grams twice daily for 8 weeks, does not improve hot flashes when compared with placebo (94090).\nless\nPancreatitis. Oral methionine has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA meta-analysis of eight randomized and nonrandomized clinical studies in patients with chronic or recurrent acute pancreatitis shows that taking a combination of methionine, selenium, vitamin E, vitamin C, and beta-carotene reduces pain when compared with placebo. However, when the two nonrandomized studies were excluded, the significant reduction in pain was lost. Daily doses of individual components studied included methionine 1.6-2.88 grams, selenium 300-600 mcg, vitamin E 188-280 mg, vitamin C 540-720 mg, and beta-carotene 12-54 mg. The study durations ranged from 10 weeks to 12 months (94095). The validity of these findings is limited by the heterogeneity of the included studies.\nless\nParkinson disease. Although there has been interest in using oral methionine for Parkinson disease, there is insufficient reliable information about the clinical effects of methionine for this purpose.\nWound healing. Although there has been interest in using oral methionine for wound healing, there is insufficient reliable information about the clinical effects of methionine for this purpose.\nUrinary tract infections (UTI). Oral methionine has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA low-quality observational study in patients with symptomatic UTI and culture-confirmed bacteriuria during pregnancy has found that taking a specific combination of methionine 800 mg, Hibiscus sabdariffa extract 200 mg, and Boswellia serrata 200 mg (Acidif Plus, Biohealth S.r.l) daily for one week increases the rate of negative urine cultures to 70% and symptom resolution to 63%, compared with 43% and 46%, respectively, in patients who increased fluid intake but did not take the combination product (97263). The validity of these findings is limited by the fact that the study groups were not comparable at baseline.\nless\nMore evidence is needed to rate methionine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Research is limited; typical dosing is unavailable.\n\nThe recommended dietary allowance (RDA) of methionine plus cysteine is 19 mg/kg daily. The RDA of methionine plus cysteine in pregnancy or lactation is 25 mg/kg daily or 26 mg/kg daily, respectively (94500).\nChildren\nGeneral: Research is limited; typical dosing is unavailable.\n\nThe recommended dietary allowance (RDA) and adequate intake (AI) of methionine plus cysteine in children vary by age and sex as follows: 59 mg/kg daily (0-6 months); 43 mg/kg daily (7-12 months); 28 mg/kg daily (1-3 years); 22 mg/kg daily (4-8 years); 22 mg/kg daily (9-13 years, male); 21 mg/kg daily (9-13 years, female); 21 mg/kg daily (14-18 years, male); 19 mg/kg daily (14-18 years, female) (94500).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization and formulation of methionine.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nACIDOSIS\nMethionine can cause changes in the serum pH and should not be used in patients with acidosis (9340). Metabolism of methionine can result in the formation of sulfuric acid (9344).\nless\nATHEROSCLEROSIS\nTheoretically, methionine might promote or exacerbate atherosclerosis (2410). Dietary or supplemental methionine can increase homocysteine levels (2410, 2411, 63112, 63114, 63115), especially in patients who are deficient in folate, vitamin B12, or B6, or patients who have disorders of homocysteine metabolism (9343). Hyperhomocysteinemia is associated with an increased risk for vascular disease (2410, 2411).\nless\nCIRRHOSIS\nMethionine may aggravate existing liver damage in patients with cirrhosis (9, 9336, 9338, 63109).\nless\nLIVER DISEASE\nMethionine may aggravate existing liver damage in patients with liver disease (9, 9336, 9338, 63109).\nless\nMETHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) DEFICIENCY\nTheoretically, use of methionine in patients with a specific genetic mutation conferring MTHFR deficiency could increase the risk of adverse vascular effects from hyperhomocysteinemia (11014, 11709). Patients with the MTHFR C677T mutation have homocysteine metabolic deficiency and should avoid the use of methionine supplements.\nless\nSCHIZOPHRENIA\nThe use of large doses of methionine (e.g., 20 grams daily for 5 days) in patients with schizophrenia might cause agitation, confusion, delirium, disorientation, listlessness, and other similar symptoms (9339, 9340).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with methionine.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of methionine.",
            "Mechanism of Action": "General\nMethionine is an essential amino acid. It plays a role in many cellular functions. It is used for protein synthesis and methylation of DNA, RNA, and other molecules (9336, 9342).\nAnticancer effects\nA higher intake of methionine was significantly associated with a lower risk of pancreatic, colorectal, and breast cancer (63127, 94093, 94094). In cancer, inflammation promotes tumor growth via gene mutations and cell proliferation (94094). Methionine is required for the synthesis of S-adenosylmethionine (SAM), which decreases inflammation in animals and induces apoptosis in colon cancer cells in laboratory research (94094). Methionine may help to protect DNA from cancer via methylation. Methionine is a one-carbon nutrient, exhibiting one-carbon metabolism, which is vital for DNA synthesis and repair, as well as synthesis of protein and other amino acids. Methionine deficiency could lead to issues with DNA repair, and ultimately, cancer (94093, 94094). Methionine might also act synergistically with folate to decrease the risk of colon cancer (9325, 9326). While there is some evidence that a high dietary intake of methionine with salt and nitrates might increase the risk of gastric cancer (2409), a large observational study that adjusted for sodium intake has found no association between dietary intake of methionine and gastric cancer (108041).\n\nRates of methylation are much higher in tumor than in normal tissue (9342). Most tumors are dependent on exogenous, preformed methionine for growth (9341). Preliminary clinical evidence suggests restriction of dietary methionine in cancer patients might inhibit tumor growth and improve cancer treatment outcomes (9341, 9342). Furthermore, many human cancer cell lines and primary tumors have absolute requirements for methionine, whereas normal cells are relatively resistant to exogenous methionine restriction (63125). The effect of methionine restriction on tumors has been evaluated in clinical trials, animal models, and in vitro studies. In a pilot Phase I clinical trial involving patients with metastatic breast cancer, the intravenous infusion of methioninase was found to safely and effectively deplete methionine without signs of side effects (63134). Dietary restriction of methionine was also found to be safe and feasible in a Phase I clinical trial involving patients with advanced cancer (9342). Preliminary data from the study showed that the level of serum prostate-specific antigen (PSA) was reduced 25% in a patient with prostate cancer after the diet had been followed for 12 weeks. In another patient (with renal cell cancer), an objective radiographic response occurred (9342). It is not clear whether either patient had received anticancer treatment. Because of potential toxicity and quality-of-life problems, prolonged methionine restriction with diet or with methioninase may not be suitable (63125).\n\nIn cultures of AH109A cells (hepatoma), a D-methionine-supplemented medium inhibited cell growth to an extent similar to that manifested in a methionine-free medium (63111). In another in vitro study, the activity of c-Jun N-terminal kinase 1 (JNK1) increased dramatically in response to methionine restriction, suggesting that JNK1 may play a critical role in signaling cancer cells to undergo apoptosis in response to methionine restriction (63120).\nAntioxidant effects\nThere is interest in using methionine for pain secondary to pancreatitis. In patients with chronic pancreatitis, levels of antioxidants are depleted, and oxidative stress is present. This is present both in circulation and within the pancreas itself. Oxidative stress results in malfunctioning of the transsulfuration pathway within the pancreas. Methionine is required for maintenance of this pathway and is depleted secondary to oxidative stress. The combination of low levels of methionine in addition to oxidative stress ultimately leads to inflammation within the pancreas, pain, and fibrosis. Supplementation with methionine is thought to improve the pathway and ameliorate inflammation and pain (94095).\n\nPatients with alcohol-induced liver disease often exhibit hypermethioninemia, which is thought to be caused by decreased metabolism of methionine to SAMe. With low levels of glutathione, the liver is at an increased risk of damage from free radicals (9336, 9338). Toxic levels of methionine can be corrected with glycine. Glycine seems to enhance the degradation of methionine through transsulfuration by acting as a receptor for methyl groups. Excessive methionine competes for glycine and limits the availability of glycine for other metabolic interactions, such as the synthesis of glutathione (2415).\n\nMethionine has also been studied for its effects on hearing. In an animal model, a rescue dose of D-methionine, administered after impulse or steady-state noise exposure, has no protective effect on temporary hearing threshold shifts, but alters some serum and cochlear antioxidant levels (108040).\nAntiviral effects\nOxidative stress is thought to play a role in viral skin infections. Deficiencies in antioxidants also play a role in pathogenesis. Reactive oxygen and nitrogen species (ROS/RNS) are produced in infected cells, as well as secreted from phagocytes. This damages viral cells, allowing the immune system to clear the cells via the lymphatic system. However, inflammation caused by overproduction of ROS/RNS can damage the surrounding healthy tissue. There is interest in using supplements with antioxidant properties, including methionine, to help control the ROS/RNS system and limit damage to the surrounding healthy tissue (94091).\n\nLaboratory research shows that in granulocytes from healthy patients, L-methionine alone exhibits prooxidant effects via stimulation of ROS/RNS production. When combined with coenzyme Q10, vitamin E, and selenium, the combination inhibited the formation of reactive oxygen species overall. This suggests a small effect on stimulation of granulocytes with overall antioxidant properties (94091).\nEndocrine effects\nMany amino acids are known to stimulate growth hormone. There is preliminary evidence that methionine also potentiates the secretion of basal growth hormone and growth hormone induced by growth hormone releasing hormone (GHRH) (2412).\nHepatic effects\nIn acetaminophen poisoning, methionine seems to prevent liver damage and necrosis by promoting glutathione synthesis. The toxic metabolite of acetaminophen (N-acetyl-p-benzquinoneimine) will then bind to glutathione instead of liver cells (9340).\nHormonal effects\nThere is interest in using methionine for post-menopausal symptoms, particularly hot flashes. Similar to gabapentin, L-methionine appears to have high affinity for the alpha-2-delta subunit of calcium channels. Its interaction with this site leads to decreases in calcium currents, which is thought to help ameliorate hot flashes (94090).\nNutrient effects\nDietary methionine usually has no effect on homocysteine levels. Levels can increase and possibly lead to hyperhomocysteinemia if enzymes that metabolize homocysteine are defective and/or there is a deficiency in folate, vitamin B12, or vitamin B6 (9343). Hyperhomocysteinemia might cause endothelial damage and increase the risk for vascular disease (2410, 2411). Hyperhomocysteinemia that is unresponsive to vitamin supplementation sometimes responds to dietary restriction of methionine (9345)."
        }
    },
    "Methoxydienone [FAST FACTS]": {
        "sections": {
            "Overview": "Methoxydienone meets the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, gynecomastia (in men), hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094). Avoid using.",
            "Effectiveness": "The effectiveness of methoxydienone is unknown.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Methoxylated Flavones": {
        "sections": {
            "Overview": "Methoxylated flavones are flavonoids with methoxy groups attached (94024). Flavonoids are plant pigments found in all vascular plants. Over 4000 unique flavonoids have been identified (12078). They are responsible for many of the yellow, red, and orange colors in plants. They are also polyphenolic antioxidants (94025). Common food sources of flavonoids include red wine, stems, flowers, fruits, vegetables, nuts, seeds, herbs, spices, coffee, and teas. Methoxylated flavones are prominent components of citrus fruits. Flavonoids are grouped based on slight differences in structure. These subdivisions include flavanols, anthocyanidins, flavones, flavanones, and chalcones (12078).",
            "Safety": "LIKELY SAFE when consumed orally in amounts typically found in foods (12078).\nThere is insufficient reliable information available about the safety of methoxylated flavones when used in amounts greater than those in foods or when taken as a dietary supplement.\nPREGNANCY AND LACTATION: LIKELY SAFE when consumed orally in amounts typically found in foods (12078). There is insufficient reliable information available about the safety of methoxylated flavones when used in amounts greater than those found in foods during pregnancy or breast-feeding; avoid using in amounts greater than those typically found in foods.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of methoxylated flavones.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of methoxylated flavones. 5-methoxyflavone and 2'-methoxyflavone are the commercially available products most often used for research (94024).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence suggests that some methoxylated flavones have antiplatelet effects (12079, 12083). Theoretically, methoxylated flavones might additive effects when used with anticoagulant or antiplatelet drugs.\nSome anticoagulant or antiplatelet drugs include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nSome in vitro evidence suggests that methoxylated flavones might induce CYP1A2, possibly by increasing gene transcription (12078). However, other in vitro research has not shown this effect (100676). So far this interaction has not been reported in humans. Theoretically, concurrent use of methoxylated flavones and drugs metabolized by CYP1A2 might increase drug metabolism, decrease serum levels, and reduce effectiveness.\nSome drugs metabolized by CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), Pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline (Slo-bid, Theo-Dur, others), zileuton (Zyflo), Zolmitriptan (Zomig), and others.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro evidence suggests that methoxylated flavones might inhibit cytochrome P450 3A4 (CYP3A4). This effect seems to be structure-dependent, and does not occur with all methoxylated flavones (100676). So far this interaction has not been reported in humans. Theoretically, concurrent use of certain methoxylated flavones with drugs metabolized by CYP3A4 might result in increased drug levels and an increased risk for adverse effects.\nSome drugs metabolized by CYP1A2 include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), Pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline (Slo-bid, Theo-Dur, others), zileuton (Zyflo), Zolmitriptan (Zomig), and others.\nless\nORGANIC ANION-TRANSPORTING POLYPEPTIDE SUBSTRATES (OATP)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nIn vitro, methoxylated flavones inhibit organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1 (106331). This may reduce the bioavailability of oral drugs that are substrates of OATP. However, this interaction has not been reported in humans.\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro evidence shows that some methoxylated flavones including tangeretin, nobiletin, and heptamethoxyflavone, inhibit P-glycoprotein (15327, 94025). Theoretically, these methoxylated flavones might increase absorption and blood levels of drugs that are transported by P-glycoprotein.\nSome of these drugs include some chemotherapeutic agents (daunorubicin, docetaxel, etoposide, paclitaxel, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir, saquinavir), H2 antagonists (cimetidine, ranitidine), some calcium channel blockers (diltiazem, verapamil), corticosteroids, erythromycin, cisapride (Propulsid), fexofenadine (Allegra), cyclosporine, loperamide (Imodium), quinidine, and others.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nSome methoxylated flavones have antiplatelet effects (12079, 12083). Theoretically, methoxylated flavones might additive effects when used with other herbs and supplements with anticoagulant or antiplatelet effects. These herbs include angelica, clove, danshen, garlic, ginger, ginkgo, red clover, turmeric, vitamin E, willow, and many others.\nLICORICE\nIn animal research, glycyrrhizin, a constituent of licorice, reduced plasma levels of the methoxylated flavone, nobiletin, possibly by increasing its clearance and efflux (104561). Theoretically, licorice might reduce levels of supplemental methoxylated flavones.",
            "Interactions with Conditions": "SURGERY\nMethoxylated flavones have antiplatelet effects. Methoxylated flavones might cause excessive bleeding if used perioperatively. Tell patients to discontinue methoxylated flavones at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is limited information on the toxicity of methoxylated flavones. One in vitro study showed that 5,7-dimethoxyflavone, 5,7,4'-trimethoxyflavone, and 3,5,7,3',4'-pentamethoxyflavone were not toxic to human peripheral blood mononuclear cells (PBMCs). However, 5-methoxyflavone and 2'-methoxyflavone, two commercially available products, were toxic to PBMCs (94024).",
            "Pharmacokinetics": "Absorption\nAnimal research shows that the methoxylated flavone nobiletin has better bioavailability than the methoxylated flavone tangeretin (94022).",
            "Mechanism of Action": "General\nCitrus foods are a predominant source of methoxylated flavones. Orange juice contains 2-7 ppm of the methoxylated flavones sinensetin, tangeretin, nobiletin, and heptamethoxylated flavone (12079). Methoxylated flavones might be more stable than some other flavonoids due to the methylation of the phenolic groups, which may help to resist oxidative breakdown (12078).\nAnti-inflammatory effects\nIn vitro research shows that the methoxylated flavone nobiletin has anti-inflammatory effects, with an estimated potency of about 68% relative to hydrocortisone (12081). Additional in vitro research shows that methoxylated flavones reduce the production of nitric oxide in inflamed cells. Although nitric oxide typically exerts an anti-inflammatory effect, it can become pro-inflammatory when overproduced. Nobiletin and 3,4,5,7,8,3',4'-heptamethoxyflavone demonstrated the most potent inhibition of nitric oxide overproduction (100674).\nAnticancer effects\nThe chemical structure and/or degree of methoxylation are thought to play a role in the activity of the various methoxylated flavones (94023, 94025). In vitro research shows that methoxylated flavones can induce apoptosis in tumor cells (12078, 94023, 94025, 100674). The methyoxylated flavones 5,7-dimethoxyflavone (DMF), 5,7,4'-trimethoxyflavone (TMF), and 3,5,7,3',4'-pentamethoxyflavone (PMF) in addition to commercially available 5-methoxyflavone (5-MF) and 2'-methoxyflavone (2'-MF) showed cytotoxicity toward two different leukemia cell lines. Additionally, each of the flavones induced apoptosis in one of the two cell lines (94024). In another in vitro study, adding the methoxylated flavone tangeretin to conventional therapy with paclitaxel increased apoptosis and caused an accumulation of cells arrested in the G2/M-phase (94025). In another in vitro study, tangeretin induced apoptosis of HL-60 leukemia cells (12078). Nobiletin and tangeretin have demonstrated the ability to induce their own metabolism in breast cancer cells via induction of CYP1 enzyme expression. This produces metabolites with greater antiproliferative and apoptotic activity than the parent compounds (100677).\n\nMethoxylated flavones also affect drug efflux transporters. In vitro, treatment with tangeretin increased the sensitivity of a paclitaxel resistant cell line, decreased the IC50 of paclitaxel, and decreased cell colony formation. Tangeretin also decreased the IC50 of docetaxel and daunorubicin, leading to an enhancement of the cytotoxicity of the chemotherapeutic agents. Overexpression of ATP-binding cassette transporters (ABC) leads to multidrug resistance (MDR) in cancer cells. It is thought that tangeretin can sensitize cells that overexpress the P-glycoprotein ABCB1. Tangeretin increases the intracellular accumulation of chemotherapeutic drugs, likely by inhibiting ABCB1 efflux activity. In order for the ABC transporters to function, ATP hydrolysis must occur. Tangeretin was shown to increase the ABCB1 ATPase activity, as well as inhibit verapamil-stimulated ATPase activity. Thus, it is possible tangeretin may act as a substrate of ABCB1 and also as an inhibitor (94025).\n\nPolymethoxylated flavones have also been shown to inhibit proliferation of human peripheral blood lymphocytes, with inhibition similar to prednisolone. The flavones also showed suppressive effects against reactive oxygen species (94023).\n\nMethoxylated flavones have also been shown to have in vitro activity against other human cancer cell lines including melanoma, prostate, colon, and lung cancer cells (12084). Additionally, nobiletin and tangeretin seem to induce liver metabolism and detoxification of some hydrocarbon carcinogens and inhibit growth of squamous cell carcinoma and gliosarcoma cells in culture (12078).\nAntioxidant effects\nIn vitro research shows that methoxylated flavones have antioxidant capabilities and seem to decrease lipid peroxidation (12078).\nAntiviral effects\nIn vitro research suggests that tetramethoxyflavones may have antiviral activity against rhinovirus (12081).\nCardiovascular effects\nThere is interest in using methoxylated flavones for cardiovascular disease. In vitro and animal studies show that methoxylated flavones decrease platelet aggregation and erythrocyte sedimentation rate (12079, 12080, 12082, 12083). The antiplatelet effects of the methoxylated flavones seem to be greater than the flavonoids quercetin, rutin or hesperidin. The methoxylated flavone sinensetin has the greatest antiplatelet effect and tangeretin the least. Nobiletin and heptamethoxyflavone fall in between the two (12079, 12082). These effects on platelet adhesion could theoretically play a role in prevention cardiovascular disease. There is also in vitro evidence that nobiletin can prevent experimentally induced thrombosis to a greater extent than heparin (12081).\nImmunologic effects\nIn vitro research shows that methoxylated flavones may alter immune function. Tangeretin seems to reduce expression of class II histocompatibility antigens in human blood monocytes. However, neither tangeretin nor nobiletin seem to decrease antigen-induced histamine release (12078). Other in vitro research shows that heptamethoxyflavones can inhibit T cell growth in spleen cells through inhibition of phosphodiesterase activity and an increase in cyclic AMP concentrations (100678).\nLipid effects\nDietary consumption of methoxylated flavones might reduce lipid levels. In animal models of hyperlipidemia, a diet consisting of 1% tangeretin or 1% tangeretin plus nobiletin, significantly reduces total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. However, a diet consisting of a smaller concentration of these methoxylated flavones, 0.25%, does not seem to significantly reduce cholesterol levels (12112). In vitro research shows that methoxylated flavones strongly inhibit sterol regulatory element-binding proteins, which play a role in the regulation of lipogenesis and lipid homeostasis (100674).\nNeurologic effects\nThere is interest in the use of methoxylated flavones for the prevention and treatment of Alzheimer disease. In vitro research shows that some, but not all, methoxylated flavones inhibit acetylcholinesterase activity and neurite outgrowth in a dose-dependent manner (100675).\nPigment effects\nThere is interest in using methoxylated flavones to alter skin pigment. It is hypothesized that melanin production is altered by changes in melanosomal pH. In vitro research shows that polymethoxylated flavones suppress melanin production in melanocytes by decreasing pH and causing the degradation of tyrosinase (100679)."
        }
    },
    "Methyldiazinol [FAST FACTS]": {
        "sections": {
            "Overview": "Methyldiazinol meets the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, gynecomastia (in men), hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094). Avoid using.",
            "Effectiveness": "The effectiveness of methyldiazinol is unknown.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Methylene Blue": {
        "sections": {
            "Overview": "Methylene blue is a synthetic blue dye. This dye is of interest as a supplement. Methylene blue specifically relates to methylthioninium chloride stabilized in its oxidized form. Methylthioninium is in equilibrium between oxidized and reduced (leuco) forms (116418). The reduced leuco form is also of clinical interest. Some methylene blue products are available as prescription medications (116418, 116426, 116431); these are not within the scope of this topic.",
            "Warnings": "In medicine, methylene blue is used intraamniotically, intradermally, intradiscally, intraosseously, intraparenchymally, intrauterinely, intravenously, subcutaneously, and topically. Examples of use, generally in acute care settings, include analgesia, carbon monoxide and cyanide poisoning, ifosfamide-induced encephalopathy, methemoglobinemia, refractory vasoplegia, shock, as a surgical dye, and for pathogen reduction in the blood supply (116362, 116377, 116388, 116391, 116392, 116395, 116397, 116400, 116406, 116407)(116411, 116412, 116413, 116416, 116420, 116422, 116425, 116427, 116430, 116431)(116448). Topical methylene blue is also of interest when used as part of photodynamic therapy for conditions such as acne or eczema (116421). Oral methylene blue is sometimes used as a dye during swallowing assessment (116430). These uses are not the focus of this topic.\n\nCoronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using methylene blue for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "LIKELY SAFE when prescription methylene blue products are used intravenously and appropriately, short-term. Methylene blue is available as an FDA-approved prescription product (116431).\nThere is insufficient reliable information available about the safety of any form of supplemental or non-prescription methylene blue product.\nCHILDREN: LIKELY SAFE when prescription methylene blue products are used intravenously and appropriately, short-term. Methylene blue is available as an FDA-approved prescription product (116431). Cases of hemolytic anemia, hyperbilirubinemia, and acute renal failure have occurred rarely in neonates (116386, 116390).\nCHILDREN: There is insufficient reliable information available about the safety of any form of supplemental or non-prescription methylene blue product.\nPREGNANCY: LIKELY UNSAFE when prescription methylene blue is used intra-amniotically. When provided during the second trimester, methylene blue has caused fetal intestinal atresia and death. When used close to term, adverse effects have been reported in the newborn including hemolytic anemia, hyperbilirubinemia, methemoglobinemia, photosensitivity, and respiratory distress. Phototherapy and blood exchange transfusion have been required (116381, 116393, 116431).\nPREGNANCY: There is insufficient reliable information available about the safety of methylene blue given by intrauterine injection during the first trimester. Inadvertent exposure in 4 case reports has not resulted in adverse effects (116385).\nPREGNANCY: There is insufficient reliable information available about the safety of oral supplemental or non-prescription methylene blue products. However, fetal toxicity, including fetal loss, malformations, and reduced fetal weight, has been observed in animal studies at high doses (116431).\nLACTATION: POSSIBLY UNSAFE when prescription methylene blue products are administered to patients who are lactating. Breast-feeding should be discontinued during and for 8 days after treatment (116431).\nLACTATION: There is insufficient reliable information available about the safety of oral supplemental or non-prescription methylene blue products.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOverall, prescription forms of methylene blue are generally well tolerated when used as prescribed. It is unclear how methylene blue found in supplemental or non-prescription products may alter the occurrence and likelihood of adverse effects.\nMost Common Adverse Effects\nOrally: Abdominal pain, blue/green urine, diarrhea, dysuria, fecal discoloration, headache, nausea, and vomiting.\n\nIntravenous: Blue skin, diarrhea, dysuria, headache, hypokalemia, hypomagnesemia, myoclonus, and nausea.\nSerious Adverse Effects (Rare)\nOrally: Hemolytic anemia, methemoglobinemia.\n\nIntravenous: Altered mental status, anaphylaxis, death, extravasation, hemolytic anemia, hypertension, methemoglobinemia, palpitations, phototoxicity, seizure-like symptoms, and tachycardia.\nCardiovascular\nWhen used intravenously, hypertension, palpitations, and tachycardia have been reported (116431).\nless\nDermatologic\nWhen used intravenously, blue skin, necrotic ulcers, papules, and phototoxicity have been reported (116431). Extravasation has occurred following intravenous infusion of methylene blue. In one case, blistering and skin irritation occurred (116362, 116458). Intraparenchymally, redness, broken blood vessels, and skin necrosis have been reported rarely (116392). Blue skin color has occurred rarely when methylene blue is given for chromopertubation during laparoscopy (116375).\nless\nGastrointestinal\nOrally, gastrointestinal adverse effects are common, including abdominal pain, diarrhea, fecal discoloration, nausea, and vomiting (116388, 116408, 116409, 116414, 116417, 116419, 116430, 116432, 116444). Blue feces, saliva, and vomitus have also occurred rarely when methylene blue is given for chromopertubation during laparoscopy (116375). When used intravenously, the most common adverse events include diarrhea and nausea. Other adverse effects include lower abdominal pain, dry mouth, flatulence, burning mouth, and tongue eruptions (116431).\nless\nGenitourinary\nOrally, common adverse effects include blue or green urine and urethritis (116394, 116409, 116423, 116424, 116430, 116444). Increased frequency of urination and urinary tract burning have also been reported (116388, 116414, 116417, 116419, 116424, 116430). Blue urine has also occurred when methylene blue is given for chromopertubation during laparoscopy (116375). When used intravenously, dysuria has been reported (116431).\nless\nHematologic\nOrally, methylene blue has resulted in dose-dependent reductions in red cell count and hemoglobin, occasionally with anemia, and increases in methemoglobin. The rate of having methemoglobin levels greater than 3.5% during treatment was 1.3% (116414, 116417, 116432). In another clinical trial, there was a case of megaloblastic anemia requiring vitamin B12 injections following use of methylene blue. The relationship with methylene blue is unclear (116423).\n\nMethemoglobinemia has been reported following use of high doses of methylene blue for chromopertubation during laparoscopy (116375, 116379, 116431).\n\nWhen used intravenously, hemolysis has been reported. Anemia requiring red blood cell transfusions has also occurred (116431). The most common adverse events include hypokalemia and hypomagnesemia (116431). Other adverse effects associated with intravenous methylene blue have included induration, infusion site extravasation, itching, redness, and swelling (116431).\nless\nHepatic\nOrally, methylene blue has rarely resulted in mild-to-moderate acute increases in alanine transaminase, aspartate transaminase, or gamma-glutamyl transferase (116388). Intravenously, methylene blue has resulted in elevated bilirubin and liver enzymes (116431).\nless\nImmunologic\nAn anaphylactic-like reaction to methylene blue, requiring epinephrine, has been reported in an infant during surgery . However, skin-prick testing was negative (116391). In a case report, a 44-year-old female developed a systemic allergic reaction with acute pulmonary edema following subcutaneous injection with methylene blue (116395). In a case report involving a 41-year-old female, chromopertubation with methylene blue resulted in anaphylactic shock-induced sudden cardiopulmonary arrest. There are at least 4 other cases of allergic reactions, including one death, usually within 10 minutes after use of methylene blue for chromopertubation during laparoscopy. Symptoms include hives and occasionally hemodynamic changes and shock (116375).\nless\nMusculoskeletal\nWhen used intravenously, myalgia has been reported (116431). In a case report, methylene blue instilled into the joint was thought to be the cause of knee effusion in a 13-year old male (116389).\nless\nNeurologic/CNS\nOrally, headache, dizziness, weakness, and falls have been reported in clinical research (116388, 116409, 116414, 116417, 116419, 116424, 116430). When used intravenously, headache is common. Other adverse effects include myoclonus and seizure-like symptoms (116431).\nless\nOcular/Otic\nWhen used intravenously, itchy and red eyes and blurred vision have been reported (116431).\nless\nPulmonary/Respiratory\nWhen used intravenously, nasal congestion, runny nose, sneezing, and oropharyngeal pain have been reported (116431).\nless\nOther\nIntraparenchymally, fat necrosis has been reported rarely (116392).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. Although there is interest in using oral methylene blue for preventing age-related cognitive decline, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nAge-related fatigue. Although there is interest in using oral methylene blue for age-related fatigue, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nAging skin. Although there is interest in using oral methylene blue for aging skin, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nAlzheimer disease. It is unclear if oral methylene blue is beneficial in patients with Alzheimer disease.\nClinical research in patients with moderate Alzheimer disease shows that taking methylene blue 138 mg daily for 24 or 50 weeks modestly improves cognition when compared with placebo. However, there was no improvement with doses of 69 mg or 228 mg daily. The effect of methylene blue on cognition in patients with mild Alzheimer disease is unclear due to a lack of worsening symptoms in the placebo group over the 24-week period in this study (116417).\n\nA stabilized version of the reduced form of methylene blue, the dihydromethanesulfonate salt of leucomethylthioninium, has also been investigated. Clinical research in patients with mild or moderate Alzheimer disease, most taking acetylcholinesterase inhibitors and/or memantine, shows that taking leucomethylthioninium 75 mg or 125 mg twice daily for 15 months does not reduce the rate of progression when compared with taking 4 mg twice daily as control (116432). Another clinical trial specifically in patients with mild Alzheimer disease shows that taking leucomethylthioninium 4 mg or 100 mg twice daily as monotherapy for 18 months modestly reduces the rate of progression when compared with taking leucomethylthioninium 4 mg twice daily as add-on with acetylcholinesterase inhibitors and/or memantine, with the effect of the 4 mg and 100 mg monotherapy doses appearing comparable (116414). The interpretation of these results is limited by the lack of a placebo group.\nless\nAmyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). Although there is interest in using oral methylene blue for ALS, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nAnxiety. It is unclear if oral methylene blue is beneficial in patients with claustrophobia.\nA small clinical trial in patients with claustrophobia shows that taking methylene blue following a series of claustrophobic chamber exposures as part of fear extinction training has differential effects on fear renewal during a repeat exposure. In patients with low-end fear following training, having taken methylene blue results in less fear during a repeat exposure after 1 month when compared with having taken placebo. However, fear was increased during a repeat exposure in patients who had taken methylene blue and had moderate to high levels of post-training fear. Taking methylene blue modestly increased memory recall 1 month post-exposure therapy when compared with taking placebo. Methylene blue was taken in doses of approximately 87 mg 3 times: immediately following the completion of training, before bed that evening, and upon awakening the next morning (116424). It is unclear if taking methylene blue is beneficial for other types of anxiety.\nless\nBipolar disorder. It is unclear if oral methylene blue is beneficial in patients with bipolar disorder.\nA small crossover study in patients with bipolar disorder treated with lamotrigine shows that adding methylene blue 65 mg 3 times daily for 3 months has moderate to large beneficial effects on depression and anxiety, but not mania, when compared with adding methylene blue 5 mg 3 times daily as control. (116419). The effect of methylene blue in patients treated with other mood stabilizers is unclear.\nless\nCancer. Although there is interest in using oral methylene blue for cancer treatment, there is insufficient reliable information about the clinical effects of methylene blue for this purpose.\nChronic fatigue syndrome (CFS). Although there is interest in using oral methylene blue for CFS, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nCognitive function. Although there is interest in using oral methylene blue for improving cognitive function, there is insufficient reliable information about the clinical effects of methylene blue for this purpose.\nCognitive impairment. Although there is interest in using oral methylene blue for cognitive impairment, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nCoronavirus disease 2019 (COVID-19). It is unclear if oral methylene blue is beneficial in patients with COVID-19.\nA clinical trial in patients hospitalized with acute respiratory distress syndrome associated with COVID-19 shows that taking methylene blue modestly improves oxygen saturation over a 5-day period and at discharge, and overall disease severity at discharge, when compared with not taking methylene blue. There was no effect on the length of hospitalization or mortality rate 3 months post-discharge. Methylene blue was given as 1 mg/kg every 8 hours for 2 days and then every 12 hours for 5 days. All patients also received standard care including remdesivir, corticosteroids, antibiotics, and/or anticoagulants (116408). Another clinical trial in patients hospitalized with severe COVID-19 shows that taking a syrup containing methylene blue and other ingredients modestly improves oxygen saturation and rate of respiration 3 and 5 days after treatment initiation when compared with standard care only. The length of hospital stay was reduced, but the mortality rate was not reduced. In this study, the colorless reduced form of methylene blue (leucomethylene blue) was given as 1 mg/kg every 8 hours for 2 days and then every 12 hours for 12 days. Dextrose, N-acetylcysteine, and vitamin C were included in the syrup as part of the methylene blue reduction process (116409). It is unclear if any effect is due to leucomethylene blue, other ingredients, or the combination. Also, the validity of both studies is limited due to the lack of blinding and single-center design.\nless\nDepression. Although there is interest in using oral methylene blue for depression, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nHuntington disease. Although there is interest in using oral methylene blue for Huntington disease, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nKidney stones (nephrolithiasis). Although there is interest in using oral methylene blue for kidney stones, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nMalaria. It is unclear if oral methylene blue is beneficial in patients with malaria.\nThere has been interest in the use of oral methylene blue for malaria, largely based on anecdotal evidence from the early 1900s. A systematic review describes this historical evidence as well as more contemporary clinical data (116444). One small, open-label and uncontrolled study in adults shows that taking methylene blue 780 mg daily as monotherapy for 7 days results in 100% cure rate at 28-day follow-up and taking this dose of methylene blue for 3 or 5 days results in at least 85% cure rate. This systematic review also reported findings from clinical trials in children taking methylene blue in addition to conventional antimalarial agents. The overall findings were mixed as to whether adding methylene blue was beneficial for improving parasite clearance in this population. In these studies, methylene blue was used orally in single or divided doses of 4 mg/kg to 24 mg/kg daily for 3 days (116444). The validity of the available research is limited by a lack of blinding, appropriate comparator groups, and meta-analysis.\nless\nMemory. Although there is interest in using oral methylene blue for memory, there is insufficient reliable information about the clinical effects of methylene blue for this purpose.\nParkinson disease. Although there is interest in using oral methylene blue for Parkinson disease, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nPost-traumatic stress disorder (PTSD). Although there is interest in using oral methylene blue for PTSD, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nSchizophrenia. Although there is interest in using oral methylene blue for schizophrenia, there is insufficient reliable information about the clinical effects of methylene blue for this condition.\nStroke. Although there is interest in using oral methylene blue for stroke recovery, there is insufficient reliable information about the clinical effects of methylene blue for this purpose.\nTraumatic brain injury (TBI). Although there is interest in using oral methylene blue for TBI recovery, there is insufficient reliable information about the clinical effects of methylene blue for this purpose.\nMore evidence is needed to rate methylene blue for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch on the use of methylene blue supplements and non-prescription products is limited; typical dosing is unavailable.\n\nAbsorption of methylene blue may be reduced when taken with food. Taking methylene blue 100 mg with food resulted in a 52% reduced absorption when compared with the fasted state. However, food does not affect the absorption of methylene blue when taken in a lower dose of 60 mg or as its reduced leucomethylene blue form. Taking methylene blue or leucomethylene blue with food seems to delay the time to peak plasma levels by 0.5-0.75 or 1.5 hours, respectively (116418).\nChildren\nOral:\nResearch on the use of methylene blue supplements and non-prescription products is limited; typical dosing is unavailable.\nStandardization & Formulation\nOral methylene blue is available in gelatin capsules, solutions, or tablets. Some studies have used modified-release tablets (116430).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nConcomitant use may increase anticholinergic effects and adverse effects.\nIn a case report, a critically-ill male in his mid-60s developed a toxicological process attributed to anticholinergic syndrome following treatment with methylene blue for vasoplegia. Symptoms included anhidrosis, fever, lactic acidosis, mucosal dryness, and pupil dilation (116377). Potential exacerbating factors included renal failure and use of fentanyl intra-operatively.\nless\nSEROTONERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nC (Consensus)\nCombining serotonergic drugs with methylene blue can cause additive serotonergic effects, including serotonin syndrome.\nMethylene blue inhibits monoamine oxidase A. Intravenous or intrapulmonary use has resulted in serotonin syndrome, including reported fatalities, in patients taking some serotonergic drugs (116383, 116396, 116397, 116398, 116399, 116401, 116402, 116403, 116404, 116405)(116406, 116407, 116431). This effect has not been reported with oral methylene blue. However, tell patients to avoid taking methylene blue with serotonergic drugs.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH SEROTONERGIC PROPERTIES\nTheoretically, methylene blue might have serotonergic effects.\nTaking methylene blue with products that have serotonergic properties might increase the risk of serotonergic adverse effects, including serotonin syndrome. Intravenous or intrapulmonary use has resulted in serotonin syndrome, including reported fatalities, in patients taking some serotonergic drugs (116383, 116396, 116397, 116398, 116399, 116401, 116402, 116403, 116404, 116405)(116406, 116407, 116431). See other products with serotonergic properties here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nGLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY\nIntravenous methylene blue increases the risk of hemolytic anemia in patients with G6PD deficiency and should be avoided. In these patients, methylene blue may not be reduced to its active form and can accumulate leading to hemolysis (116378, 116431). Whether oral methylene blue also increases the risk of adverse effects in patients with G6PD deficiency is unclear. Until more information is available, tell patients to avoid use.\nless\nKIDNEY DISEASE\nOral methylene blue might increase the risk of adverse effects and drug interactions in patients with kidney disease. Methylene blue is excreted in urine; thus, excretion might be delayed (116431). Until more information is available, tell patients to avoid use.\nless\nLIVER DISEASE\nOral methylene blue might increase the risk of adverse effects and drug interactions in patients with liver disease. Methylene blue is metabolized by the liver; thus, metabolism might be delayed (116431). Until more information is available, tell patients to avoid use.\nless\nPERIOPERATIVE\nMethylene blue might affect serotonin levels when taken in conjunction with serotonergic drugs (116383, 116396, 116397, 116398, 116399, 116401, 116402, 116403, 116404, 116405)(116406, 116407, 116431). Using methylene blue with serotonergic drugs during surgery might increase the risk for serotonergic effects on the central nervous system or vascular system. Tell patients to discontinue methylene blue at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nBISPECTRAL INDEX MONITORING\nMethods other than bispectral index monitoring should be used to assess depth of anesthesia. Methylene blue in the blood may cause false bispectral index readings (116431).\nless\nPULSE OXIMETRY\nMethods other than pulse oximetry should be used to assess oxygen saturation. Due to interference with light absorption, methylene blue in the blood may cause false underestimation of oxygen saturation with pulse oximetry, and a false overestimation of methemoglobin with co-oximetry (116380, 116384, 116431).\nless\nURINE TEST\nTaking methylene blue might interfere with urine tests using a blue indicator, such as the dipstick test for leucocyte esterase, and cause false results (116431).\nless",
            "Overdose": "Presentation\nThere is insufficient reliable information available about the presentation of overdose with oral methylene blue. When given intravenously, a single intravenous dose of 3 mg/kg or more has resulted in symptoms of overdose, including hypotension, wheezing, and reduced oxygenation (116431). Cumulative intravenous doses of methylene blue 7 mg/kg or more have resulted in symptoms of overdose lasting up to 12 hours. Symptoms include cardiopulmonary (chest pain and tightness, ECG changes, rapid breathing, shortness of breath, and tachycardia,), gastrointestinal (abdominal pain, nausea, and vomiting), hematologic (methemoglobinemia), and neurologic (apprehension, confusion, dizziness, headache, numbness, pupil dilation, tingling, and tremor). A single intravenous dose of 20 mg/kg or more has resulted in severe intravascular hemolysis and death (116431).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with oral methylene blue. When given intravenously, some symptoms require observation and monitoring until resolved. Supportive measures for cardiopulmonary, hematologic, and neurologic toxicities, should be used as needed (116431).",
            "Pharmacokinetics": "Absorption\nWhen methylene blue is taken orally, maximal plasma concentrations occur after approximately 2 hours (116366). When taken orally in doses of 200 mg or 400 mg as modified release tablets, levels start to rise in blood after 3-12 hours with peak levels at a median time of 16 hours. Peak levels were not affected by dose (116388). In an animal study, when given orally, plasma levels of methylene blue are 3 times higher 2 hours after leucomethylene blue is used compared with conventional methylene blue (116418). When a 2 mg/kg dose is given as a 5-minute intravenous infusion, the average maximal concentration is 2917 ng/mL (116431).\nDistribution\nMethylene blue is widely distributed throughout the body (116444). In an animal study, when given orally at lower doses, total brain levels of methylene blue are 4 times higher after leucomethylene blue is used compared with conventional methylene blue. However, there is no difference with higher doses (116418).\nMetabolism\nAnimal research suggests that oral methylene blue is less extensively metabolized when provided in its reduced leucomethylene blue form (116418). Some methylene blue is metabolized to azure B (116431). In vitro, methylene blue is metabolized by cytochrome P450s 1A2, 2C19, and 2D6, as well as by uridine-5-diphospho-glucuronosyltransferase 1A4 and 1A9 (116431).\nExcretion\nWhen methylene blue is taken orally in modified release tablets, the elimination half-life ranged from 6-27 hours. Approximately 23% to 40% of methylene blue is excreted without undergoing metabolism over a period of up to 72 hours (116366, 116388). When given intravenously, the half-life of methylene blue is 24 hours. Approximately 40% of methylene blue is excreted without undergoing metabolism (116388, 116431).",
            "Mechanism of Action": "General\nMethylene blue, or methylthioninium chloride, is a synthetic blue dye used in medicine (116411, 116418, 116426, 116431).\nAnti-aging effects\nMethylene blue is of interest to slow aging. In skin fibroblasts in vitro, methylene blue prevents cell death and increases cell proliferation. Skin thickness and hydration are also improved in vitro. Mechanisms of action include its antioxidant effects as well as upregulation of the proteins elastin and collagen (116426).\nAntimalarial effects\nMethylene blue is of interest for the treatment of malaria. In laboratory and human research, methylene blue inhibits Plasmodium falciparum (116444).\nCoronavirus disease 2019 (COVID-19) protective effects\nMethylene blue is of interest for reducing COVID-19 symptoms (116408, 116409, 116410). In laboratory and/or clinical research, methylene blue has various effects that might play a role in mitigating symptoms, including the inhibition of nitric oxide synthases, inflammation, and methemoglobinemia (116410). In vitro, methylene blue has antiviral effects against SARS-COV-2 and inhibits interaction of the virus with ACE2 receptors (116408).\nImmune effects\nMethylene blue is of interest for immune health. However, the effect of methylene blue on immune health has not been investigated in human research.\nMetabolic effects\nIn vitro, methylene blue inhibits cytochrome P450s (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4, uridine-5-diphospho-glucuronosyltransferase 1A4 and 1A9, P-glycoprotein, organic cation transporter 2, multidrug and toxin extrusion (MATE) 1, and MATE2-K. Methylene blue also induces CYP1A2 (116431).\n\nAdditionally, methylene blue is a substrate of CYP 1A2, 2C19, 2D6 and P-glycoprotein (116431).\nMethemoglobin protective effects\nIn red blood cells, the enzyme NADPH-dependent diaphorase reduces methylene blue to leucomethylene blue, which then reduces methemoglobin to hemoglobin (116378, 116431).\nNeurological effects\nMethylene blue is of interest for its potential beneficial effects on cognitive function in both healthy individuals and in individuals with cognitive decline. In the brain, methylene blue is thought to donate electrons to the electron transport chain, promoting energy production. Cognitive-enhancing effects of methylene blue have been shown in animal models (116426, 116428, 116429). Human research has found that taking a single dose of methylene blue results in some neurological benefit while undergoing attention and short-term memory tasks based on functional magnetic resonance imaging. There was no effect on cerebrovascular reactivity, suggesting that any cognitive enhancing effects of methylene blue are not due to changes in cerebral blood flow or vascular tone (116415, 116416).\n\nLaboratory research has found that methylene blue inhibits amyloid-beta, tau and huntingtin protein misfolding and aggregation, possibly preventing or slowing Alzheimer or Huntington disease (116426, 116428, 116429). Methylene blue also seems to play a role in cellular signaling in the control of the expression of proteins involved in cell protection, such as antioxidant and anti-inflammatory enzymes, as well as protection against the degeneration of neurons, and inducing the formation of mitochondria (116428, 116429). Laboratory research has also found that methylene blue inhibits monoamine oxidase A and B, involved in the regulation of neurotransmitters, such as serotonin and dopamine (116428)."
        }
    },
    "Methylstenbolone": {
        "sections": {
            "Overview": "Methylstenbolone is a type of anabolic androgenic steroid. Methylstenbolone is purchased over the internet for body building (108298, 91137).",
            "Warnings": "Methylstenbolone meets the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469).\n\nMethylstenbolone has been confirmed as a contaminant in some over-the-counter supplements (113154, 113158).",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, gynecomastia (in men), hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094). Avoid using.",
            "Adverse Effects": "General\nOrally, methylstenbolone is possibly unsafe. As an anabolic androgenic steroid, there is concern that it might cause serious side effects including heart disease and liver injury.\nHepatic\nThere is a case of cholestatic jaundice with elevated liver enzymes, dark urine, clay stools, and pruritus in a 26-year-old male, likely related to the use of a product (Super DMZ Rx 2.0) containing methylstenbolone 10 mg and dymethazine 10 mg per capsule. The product was used at manufacturer-recommended doses of two capsules daily for up to 1 month. Liver enzyme levels gradually decreased after discontinuation (108298). The specific role of methylstenbolone cannot be determined from this report.\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related testosterone deficiency. Although there is interest in using oral methylstenbolone for testosterone deficiency, there is insufficient reliable information about the clinical effects of methylstenbolone for this condition.\nAthletic performance. Although there is interest in using oral methylstenbolone for improving athletic performance and recovery, there is insufficient reliable information about the clinical effects of methylstenbolone for this use.\nErectile dysfunction (ED). Although there is interest in using oral methylstenbolone for ED, there is insufficient reliable information about the clinical effects of methylstenbolone for this condition.\nExercise-induced muscle damage. Although there is interest in using oral methylstenbolone for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of methylstenbolone for this purpose.\nMuscle strength. Although there is interest in using oral methylstenbolone for improving muscle mass, there is insufficient reliable information about the clinical effects of methylstenbolone for this use.\nObesity. Although there is interest in using oral methylstenbolone for weight loss and reducing abdominal obesity, there is insufficient reliable information about the clinical effects of methylstenbolone for these uses.\nSexual arousal. Although there is interest in using oral methylstenbolone for increasing sexual arousal, there is insufficient reliable information about the clinical effects of methylstenbolone for this use.\nMore evidence is needed to rate methylstenbolone for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of methylstenbolone.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with methylstenbolone.",
            "Pharmacokinetics": "Excretion\nIn humans, metabolites of methylstenbolone are excreted in urine (113152, 91137). Hydroxylated, glucoroconjugated, and sulfoconjugated metabolites have been found in the urine following a single dose of oral methylstenbolone. Levels remain increased for up to 29 days (113152, 91137). Unmetabolized methylstenbolone was found in the urine for up to 45 hours after dosing (91137).",
            "Mechanism of Action": "General\nMethylstenbolone is a type of anabolic androgenic steroid (108298, 91137).\nAnabolic affects\nAs an anabolic androgenic steroid, methylstenbolone is used for its purported anabolic and muscle building effects (108298, 91137). Research specific to methylstenbolone is lacking in humans, as well as in animal models."
        }
    },
    "Methylsulfonylmethane (MSM)": {
        "sections": {
            "Overview": "Methylsulfonylmethane (MSM) is a naturally occurring compound found in some green plants, algae, fruits, vegetables, grains, and milk, as well as the urine of humans and animals (8574). It is a metabolite of dimethylsulfoxide (DMSO), produced by oxidation (10625, 47901). In the body, about 15% of ingested DMSO is converted to MSM, which acts as a source of sulfur for amino acid synthesis. Commercially, MSM is produced by combining DMSO and hydrogen peroxide (14335). Contrary to some MSM promotional literature, there is no Recommended Dietary Allowance (RDA) for sulfur or MSM.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short term. MSM in doses of 1.5-6 grams daily or 50 mg/kg daily has been used safely in studies lasting up to 6 months (8574, 12469, 14335, 17127, 19312, 96446, 96448, 102555). One specific product (OptiMSM, Bergstrom Nutrition) is Generally Recognized As Safe (GRAS) by the United States Food and Drug Administration (FDA) (102555). ...when used topically. Topical cream containing MSM and silymarin, as well as topical gel containing MSM, hyaluronic acid, and tea tree oil, have been used with apparent safety for up to 20 days (19318, 19319).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, MSM is generally well tolerated.\nMost Common Adverse Effects\nOrally: Bloating, diarrhea, gastrointestinal discomfort, nausea.\nDermatologic\nIn rare cases, MSM has caused pruritus when taken orally (8574).\nless\nGastrointestinal\nOrally, MSM may cause mild gastrointestinal discomfort, nausea, bloating, and diarrhea (8574, 12469).\nless\nImmunologic\nOrally, MSM may increase allergy symptoms (8574).\nless\nNeurologic/CNS\nOrally, MSM may cause headache, fatigue, insomnia, and difficulty concentrating (8574, 14335).\nless\nOcular/Otic\nIn a case report, a 35-year-old female presented with bilateral acute angle closure glaucoma, which resolved 4 days after discontinuing a multi-ingredient product. Although the product contained over 35 vitamins, minerals, and other ingredients, only MSM contained sulfur, which the authors suggest acted like a sulfa-drug to cause acute angle closure glaucoma (90613).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nOsteoarthritis. Most clinical research shows that MSM is modestly beneficial when used alone or in combination with other ingredients.\nClinical research shows that taking MSM 1.5-6 grams orally in two to three divided doses daily, either alone or in combination with glucosamine, can modestly improve joint function and some symptoms of osteoarthritis such as pain and swelling (12469, 14335, 17127, 19312). However, MSM does not seem to reduce stiffness or total symptom score (14335). Also, some patients may not consider the modest benefit to be clinically significant (17127).\n\nSome clinical research has evaluated MSM in combination with other ingredients. One clinical study in adults with knee osteoarthritis shows that taking MSM 500 mg, glucosamine sulfate 1500 mg, and chondroitin sulfate 1200 mg daily for 12 weeks is associated with greater reductions in pain and osteoarthritis scores when compared with glucosamine sulfate and chondroitin sulfate alone (96447). Clinical studies using combination products containing MSM 5 grams daily and boswellic acid 7.2 mg daily with or without vitamin C (Lignisul, Triterpenol; Artosulfur C, Laborest Italia S.p.A), orally for 60 days show reductions in anti-inflammatory drug use, but conflicting results for pain reduction (19313, 96446). Also, one small study suggests that taking a combination of MSM with collagen type II, cetyl myristoleate, lipase, vitamin C, turmeric, and bromelain (AR7 Joint Complex, Robinson Pharma) orally for 12 weeks improves scores for joint pain and tenderness, but does not improve X-rays of affected joints (19314). Other clinical research in middle-aged adults with knee osteoarthritis shows that taking a combination of MSM 750 mg, glucosamine sulfate 750 mg, chondroitin sulfate 400 mg, and hydrolyzed type 2 collagen 1250 mg (Dynavit Collagen Quatro, Turkey) once daily for 2 months reduces pain and osteoarthritis scores and improves quality of life when compared with baseline (115346). The validity of these findings is limited by the lack of a control group.\nless\nPOSSIBLY INEFFECTIVE\nChronic venous insufficiency (CVI). Clinical research suggests that topical MSM is not beneficial in CVI.\nClinical research shows that topical application of MSM plus EDTA can reduce the circumference of the calf, ankle, and foot in patients with CVI. However, application of MSM alone appears to increase swelling in these patients (19315).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. It is unclear if oral MSM improves the appearance of aging skin to a clinically meaningful extent.\nPreliminary clinical research shows that taking MSM (OptiMSM, Bergstrom Nutrition) 3 grams daily for 16 weeks improves facial wrinkles associated with aging by a moderate amount when compared with placebo. When compared with baseline, taking MSM 1 gram daily for 16 weeks is as effective as taking 3 grams for reducing fine lines and wrinkles and improving smoothness, radiance, firmness, and elasticity (102000).\nless\nAllergic rhinitis (hay fever). It is unclear if oral MSM is beneficial in patients with allergic rhinitis.\nPreliminary clinical research shows that taking MSM (OptiMSM 650 mg) 2600 mg orally for 30 days might relieve some symptoms of seasonal allergic rhinitis when compared with baseline (8574). However, this study lacked blinding and a control group, and also did not provide information on severity of symptoms (12000).\nless\nAlzheimer disease. Although there is interest in using oral MSM for Alzheimer disease, there is insufficient reliable information about the clinical effects of MSM for this condition.\nAndrogenic alopecia. Although there is interest in using oral and topical MSM for androgenic alopecia, there is insufficient reliable information about the clinical effects of MSM for this condition.\nAromatase inhibitor-induced arthralgia. Oral MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with estrogen receptor positive (ER+) breast cancer and aromatase inhibitor-induced arthralgia shows that taking a specific combination product (Opera, GAMFARMA s.r.l) containing MSM 200 mg, boswellia 40 mg, alpha-lipoic acid 240 mg, and bromelain 20 mg once daily for 6 months reduces arthralgia intensity when compared to baseline, with around 22% of patients having complete symptom resolution at the end of the study (109570). The validity of these findings is limited by a lack of control group.\nless\nAsthma. Although there is interest in using oral MSM for asthma, there is insufficient reliable information about the clinical effects of MSM for this condition.\nAthletic performance. It is unclear if topical MSM is beneficial for improving athletic performance.\nA small clinical study in healthy, physically active adults shows that applying a specific cream containing magnesium and MSM (MagPro, Custom Prescription Shoppe) prior to stretching and pedaling on a stationary bicycle does not appear to improve flexibility or endurance when compared with a placebo cream (19317).\nless\nChemotherapy-induced peripheral neuropathy. Oral MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with chemotherapy-induced peripheral neuropathy shows that taking a specific product (OPERA, GAMFARMA s.r.l.) containing MSM 200 mg, alpha-lipoic acid 240 mg, boswellia 40 mg, and bromelain 20 mg daily for 12 weeks reduces overall pain when compared with baseline (96449). The validity of these findings is limited by the lack of a placebo group. Additionally, it is not clear if benefit is associated with MSM, other ingredients, or the combination.\nless\nChronic fatigue syndrome (CFS). Although there is interest in using oral MSM for CFS, there is insufficient reliable information about the clinical effects of MSM for this condition.\nChronic obstructive pulmonary disease (COPD). Although there is interest in using oral MSM for COPD, there is insufficient reliable information about the clinical effects of MSM for this condition.\nConstipation. Although there is interest in using oral MSM for constipation, there is insufficient reliable information about the clinical effects of MSM for this condition.\nDiabetes. Although there is interest in using oral MSM for diabetes, there is insufficient reliable information about the clinical effects of MSM for this condition.\nDyslipidemia. It is unclear if oral MSM is beneficial for dyslipidemia.\nA very small clinical study in adults with overweight or obesity shows that taking a specific MSM product (OptiMSM, Bergstrom Nutrition) 3 grams daily for 16 weeks modestly increases high-density lipoprotein (HDL) cholesterol when compared with baseline, but not when compared with placebo. Taking MSM also did not improve total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, or triglycerides (110572). However, this study may have been underpowered to detect differences between groups.\nless\nDyspepsia. Although there is interest in using oral MSM for dyspepsia, there is insufficient reliable information about the clinical effects of MSM for this condition.\nExercise-induced muscle damage. It is unclear if oral MSM is beneficial for preventing exercise-induced muscle damage.\nClinical research shows that taking MSM 50 mg/kg in 200 mL water orally daily beginning 10 days prior to a 14-km run can attenuate the increase in creatine kinase (CK) and bilirubin levels caused by exercise-induced muscle damage (19320). However, other clinical research shows that taking MSM (OptiMSM, Bergstrom Nutrition) 3 grams daily beginning 3 weeks prior to a 13.1-mile run and continuing for 2 days after does not reduce muscle or joint pain or alter serum markers of oxidative stress or muscle damage when compared with placebo (96448).\nless\nGingivitis. Oral MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small crossover study in adults shows that chewing a gum containing MSM, xylitol, and ethylenediaminetetraacetic acid (EDTA) for 15 minutes twice daily for 14 days reduces gingival, plaque, and sulcus bleeding indices similarly to chlorhexidine mouthwash 0.12% used twice daily for 14 days (115345).\nless\nHangover. Although there is interest in using oral MSM for hangover, there is insufficient reliable information about the clinical effects of MSM for this condition.\nHemorrhoids. Topical MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study shows that applying a specific gel containing MSM in combination with hyaluronic acid and tea tree oil (Proctoial, BSD Pharma) for 14 days improves symptoms of hemorrhoids, including pain during defecation, visible bleeding, and inflammation/irritation, when compared with placebo (19318). It is not clear if these effects are due to MSM, the other ingredients, or the combination.\nless\nInsect bite. Although there is interest in using oral MSM for preventing insect bites, there is insufficient reliable information about the clinical effects of MSM for this condition.\nInterstitial cystitis. Although there is interest in using oral MSM for interstitial cystitis, there is insufficient reliable information about the clinical effects of MSM for this condition.\nKnee pain. It is unclear if oral MSM is beneficial for knee pain.\nA moderate-sized clinical study in healthy adults with mild knee pain shows that taking MSM (OptiMSM, Bergstrom Nutrition) 1000 mg twice daily for 12 weeks modestly improves morning pain and pain while standing but does not benefit nocturnal or movement-associated pain, stiffness, or activities of daily living when compared with placebo (114751). Oral MSM has also been evaluated in combination with other ingredients. A small clinical study in adults with mild to moderate meniscal tears shows that taking a combination product containing MSM 500 mg, chondroitin sulfate, collagen peptides, glucosamine sulfate, hyaluronic acid, hydrolyzed collagen type II, and other ingredients (Naturagen 4 Joint, Naturagen) daily for 8 weeks improves some assessments of pain and function but does not improve objective measures, including leg strength, balance, or stair climbing time, when compared with placebo (116134). It is unclear if these effects are due to MSM, other ingredients, or the combination.\nless\nMuscle cramps. Although there is interest in using oral MSM for muscle cramps, there is insufficient reliable information about the clinical effects of MSM for this condition.\nObesity. It is unclear if oral MSM is beneficial for obesity.\nA very small clinical study in adults with overweight or obesity shows that taking a specific MSM product (OptiMSM, Bergstrom Nutrition) 3 grams daily for 16 weeks does not improve body weight, body mass index, waist circumference, or body composition when compared with placebo. (110572). However, this study may have been underpowered to detect differences between groups.\nless\nOsteoporosis. Although there is interest in using oral MSM for osteoporosis, there is insufficient reliable information about the clinical effects of MSM for this condition.\nPeriodontitis. Although there is interest in using topical MSM for periodontitis, there is insufficient reliable information about the clinical effects of MSM for this condition.\nPneumonia. Although there is interest in using oral MSM for pneumonia, there is insufficient reliable information about the clinical effects of MSM for this condition.\nPostoperative pain. Oral MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients who have undergone arthroscopic rotator cuff repair shows that taking a specific combination product (Tenosan, Agave s.r.l.) containing MSM 550 mg, arginine alpha-ketoglutarate 500 mg, collagen peptides 300 mg, apple and grape polyphenols 125 mg, bromelain 40 mg, and vitamin C 60 mg for 3 months can reduce postoperative pain and slightly improve repair integrity (19322). However, improvement in overall functional outcomes was not observed.\nless\nRheumatoid arthritis (RA). Although there is interest in using oral and topical MSM for RA, there is insufficient reliable information about the clinical effects of MSM for this condition.\nRosacea. Oral MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research in patients with rosacea shows that topical application of a cream containing silymarin and MSM twice daily for one month improves skin redness, papules, itching, hydration, and skin color when compared to baseline (19319). The validity of these findings is limited by the lack of a comparator group.\nless\nScleroderma. Although there is interest in using oral and topical MSM for scleroderma, there is insufficient reliable information about the clinical effects of MSM for this condition.\nStretch marks (striae distensae). Although there is interest in using topical MSM for stretch marks, there is insufficient reliable information about the clinical effects of MSM for this condition.\nSystemic lupus erythematosus (SLE). Although there is interest in using oral MSM for SLE, there is insufficient reliable information about the clinical effects of MSM for this condition.\nTemporomandibular disorder (TMD). Although there is interest in using oral MSM for TMD, there is insufficient reliable information about the clinical effects of MSM for this condition.\nTendinopathy. Oral MSM has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with Achilles tendinopathy shows that taking two sachets orally daily of a specific combination product (Tenosan, Agave s.r.l.) each containing MSM 550 mg, arginine alpha-ketoglutarate 500 mg, collagen peptides 300 mg, apple and grape polyphenols (Vinitrox) 125 mg, bromelain 50 mg, and vitamin C 60 mg for 60 days might improve the outcomes of extracorporeal shock wave therapy (ESWT) (19321). However, it is unclear if any benefit is due to MSM, other ingredients, or the combination.\nless\nWound healing. Although there is interest in using topical MSM for wound healing, there is insufficient reliable information about the clinical effects of MSM for this condition.\nMore evidence is needed to rate MSM for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMSM has been used in doses of 1-6 grams daily for up to 16 weeks. In combination products, lower doses of 200-550 mg daily for up to 12 weeks have been used. See Effectiveness section for condition-specific information.\nTopical:\nMSM has been used in creams and gels. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nOral combination products containing MSM that have been used in clinical research include Instaflex Joint Support (Direct Digital), which contains glucosamine sulfate 1500 mg, methylsufonlylmethane 500 mg, white willow bark extract 250 mg, ginger root concentrate 50 mg, Indian frankincense extract 125 mg, turmeric root extract 50 mg, cayenne 40 m H.U. 50 mg, and hyaluronic acid 4 mg per three capsules (89560); AR7 Joint Complex (Robinson Pharma), which contains collagen type II, MSM, cetyl myristoleate, lipase, vitamin C, turmeric, and bromelain (19314); Artrosulfur C (Laborest Italia S.p.A), which contains MSM 5 grams, boswellic acid 7.2 mg, and vitamin C (96446); and Tenosan (Agave s.r.l.), which contains MSM 550 mg, arginine-L-alpha-ketoglutarate 500 mg, hydrolyzed collagen type I 300 mg, Vinitrox 125 mg, bromelain 50 mg, and vitamin C 60 mg per sachet (19321, 19322).\n\nTopical combination products containing MSM that have been used in clinical research include Proctoial (BSD Pharma), which contains MSM, hyaluronic acid, and tea tree oil (19318); and MagPro (Custom Prescription Shoppe), which contains magnesium and MSM (19317).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CHRONIC VENOUS INSUFFICIENCY\nTopical application of a lotion containing MSM to the lower extremities resulted in increased swelling in patients with chronic venous insufficiency (19315).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with MSM.",
            "Pharmacokinetics": "Distribution\nSupplemental MSM crosses the blood-brain barrier. Following ingestion of 1-3 grams, MSM is detectable at levels of 0.42-3.4 mmol/kg of brain tissue (12351). MSM is found in human cerebrospinal fluid in concentrations of 0-25 micromol/L (14335).\nExcretion\nIn animal research, giving DMSO resulted in MSM excretion in the urine, but not the feces (10625, 47901).",
            "Mechanism of Action": "General\nMSM is a naturally occurring compound that is a metabolite of dimethylsulfoxide (DMSO). Unlike DMSO, MSM is an odorless substance (10625, 47901). In the body, about 15% of ingested DMSO is converted to MSM. Commercially, MSM is produced by combining DMSO and hydrogen peroxide to produce MSM and water (14335).\n\nMSM is a source of sulfur for synthesis of the amino acids cysteine and methionine. Incorporation of MSM-derived sulfur into methionine is regulated by a limiting step involving micro-organisms in the intestinal lumen (3501).\nAnti-inflammatory effects\nMSM might have anti-inflammatory activity. In vitro, MSM displayed anti-inflammatory activity by inhibiting the oxidative function of stimulated neutrophils (63890) and reducing levels of nuclear factor-kappaB, interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor-alpha (96448). Also, in humans, MSM seems to reduce homocysteine levels, possibly by donating methyl groups (14335). However, clinical research shows that taking MSM daily for 12 weeks does not change plasma concentrations of IL-1-beta, IL-6, or high-sensitivity C-reactive protein (hs-CRP) when compared with placebo (114751). Also, MSM does not appear to decrease CRP or erythrocyte sedimentation rate (14335).\nAntiarthritic effects\nMSM is primarily used for osteoarthritis (OA). Preliminary research suggests MSM might inhibit degenerative changes in joints in animal models of osteoarthritis (8576). It might also stabilize cell membranes, slow or stop leakage from injured cells, and scavenge hydroxyl free radicals which trigger inflammation (17127). It also has anti-inflammatory effects via inhibition of nuclear factor-kappa-B transcription (115344). However, human research suggests that MSM does not change plasma levels of procollagen type II C-terminal propeptide or collagen type II cleavage, which are markers of collagen synthesis and degradation, respectively, when compared with placebo (114751). In animal research, MSM promotes cartilage formation by increasing expression of SOX-9, a transcription factor important for chondrocyte differentiation. In an animal model of posttraumatic ankle OA, oral MSM given for 8 weeks slows radiographic progression similarly to weekly intra-articular methylprednisolone and prevents histopathological worsening to a greater extent than methylprednisolone (115344).\nAnticancer effects\nMSM delays chemically-induced colon cancer onset in animals (3502). A 4% MSM solution delays the latency period between induction and onset of chemically-induced mammary tumors or cancers in rats (3503).\nAntioxidant effects\nIn humans, MSM seems to reduce urine and blood malondialdehyde (MDA) levels, and improve antioxidant status, suggesting that it might reduce lipid peroxidation (14335, 19320, 19323). In an animal model of periodontitis, MSM reduced levels of MDA in the mandibular tissue (116646). Also, glutathione levels were restored (116646).\nBone effects\nIn humans, MSM is of interest for periodontitis. In an animal model of periodontitis, MSM reduces alveolar bone loss (116646).\nHair growth effects\nMSM may affect hair growth. A study in mice with induced hair loss suggests that applying MSM 10% solution alone or in combination with minoxidil 5% solution once a day for 3 weeks increases hair growth, number of hair follicles, and diameter of hair follicles when compared with untreated controls (111755).\nMuscle endurance effects\nResearchers suspect that MSM might enhance the healing of exercise-induced muscle damage, but evidence is conflicting. In one clinical trial, consuming MSM for 10 days prior to an extended running exercise attenuated an increase in creatine kinase (CK) and bilirubin (19320). However, in another clinical trial, consuming MSM for 21 days prior to an extended running exercise did not lead to changes in serum levels of CK, 8-hydroxy-2-deoxyguanosine (8-OHdG), malondialdehyde (MDA), or lactate dehydrogenase (LDH) compared to placebo (96448). Additional clinical research has found an increased trolox equivalent antioxidant capacity (TEAC) and reduced homocysteine levels in athletes taking MSM (96448)."
        }
    },
    "Methylsynephrine": {
        "sections": {
            "Overview": "Methylsynephrine is a synthetic compound. Although it is sometimes found as an ingredient in dietary supplements, it is not approved for use in medications or dietary supplements in the U.S. (94386, 99910). Some products claim that methylsynephrine is a natural constituent of bitter orange or Acacia rigidula; however, it has not been found to occur in nature (94386). Due to stimulant effects, methylsynephrine is banned by the World Anti-Doping Agency (WADA) for use by athletes (94386) and by the U.S. Department of Defense (DOD) for use by military personnel (99917).",
            "Safety": "POSSIBLY UNSAFE when dietary supplements containing methylsynephrine are used orally. Methylsynephrine has stimulant effects. Single doses greater than 84 mg or chronic intake of methylsynephrine has been shown to increase blood pressure and cause palpitations and arrhythmias (99910, 94386). Dietary supplements with methylsynephrine on the label have been shown to contain as much as 250 mg of methylsynephrine in a single dose (99910).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information available about the adverse effects of methylsynephrine. Orally, it has been reported to cause increased blood pressure, palpitations, and arrhythmia (94386, 99910).\nCardiovascular\nOrally, methylsynephrine has been reported to cause increased blood pressure (94386), palpitations, and arrhythmias (99910).\n\nIn the Netherlands, the supplement dexaprine was removed from the market because of reported cases of tachycardia, palpitations, chest pain, and a single report of cardiac arrest. As little as half a tablet was associated with these adverse effects, which occurred within one hour of ingestion. Dexaprine was found to contain methylsynephrine, synephrine, deterenol, yohimbine, caffeine, theophylline, and possibly beta-methyl-beta-phenylethylamines. Therefore, it is unclear if these effects were due to methylsynephrine, the other ingredients, or the combination (99913).\nless\nGastrointestinal\nIn the Netherlands, the supplement dexaprine was removed from the market following reported cases of nausea and vomiting. As little as half a tablet was associated with these adverse effects, which occurred within one hour of ingestion. Dexaprine was found to contain methylsynephrine, synephrine, deterenol, yohimbine, caffeine, theophylline, and possibly beta-methyl-beta-phenylethylamines. Therefore, it is unclear if these effects were due to methylsynephrine, the other ingredients, or the combination (99913).\nless\nPsychiatric\nIn the Netherlands, the supplement dexaprine was removed from the market following reported cases of agitation. As little as half a tablet was associated with this adverse effect, which occurred within one hour of ingestion. Dexaprine was found to contain methylsynephrine, synephrine, deterenol, yohimbine, caffeine, theophylline, and possibly beta-methyl-beta-phenylethylamines. Therefore, it is unclear if these effects were due to methylsynephrine, the other ingredients, or the combination (99913).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of methylsynephrine.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of methylsynephrine.\n\nResearch shows that there is a lack of quality control with supplement products claiming to contain methylsynephrine. In one study, only 52% of supplements with methylsynephrine listed on the label were found to contain methylsynephrine (99910). Of these, 43% contained levels above what was stated on the label (99910).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nBETA-ADRENERGIC AGONISTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nMethylsynephrine has beta agonist activity (94386, 99910). Theoretically, concomitant use of large amounts of methylsynephrine might increase the cardiac inotropic effects of beta-agonists. Beta-adrenergic agonists include albuterol (Ventolin, Proventil), metaproterenol (Alupent), terbutaline (Brethine, Bricanyl), and isoproterenol (Isuprel).\nSTIMULANT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nMethylsynephrine has cardiac stimulant effects (94386, 99910). Theoretically, taking methylsynephrine with other stimulant drugs might increase the risk of hypertension and adverse cardiovascular effects.\nSome stimulant drugs include amphetamine, caffeine, diethylpropion (Tenuate), methylphenidate, phentermine (Ionamin), pseudoephedrine (Sudafed, others), and many others.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH STIMULANT PROPERTIES\nMethylsynephrine has cardiac stimulant effects (94386, 99910). Theoretically, taking methylsynephrine with herbs and supplements with stimulant properties might increase the risk of hypertension and adverse cardiovascular effects. Some herbs and supplements with stimulant properties include ephedra, bitter orange, caffeine, and caffeine-containing supplements such as coffee, cola nut, guarana, and mate.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCARDIOVASCULAR DISEASE (CVD)\nMethylsynephrine has long-lasting inotropic and cardiac stimulating effects (94386, 99910). Theoretically, methylsynephrine might increase the risk of hypertension and cardiac events in individuals with CVD.\nless\nHYPERTENSION\nMethylsynephrine has been shown to increase blood pressure (94386, 99910). Theoretically, taking methylsynephrine might exacerbate high blood pressure.\nless\nSURGERY\nMethylsynephrine has been shown to increase blood pressure (94386, 99910). Theoretically, taking methylsynephrine might interfere with surgical procedures by increasing blood pressure and heart rate. Tell patients to discontinue using methylsynephrine at least 2 weeks before elective surgical procedures.\nless\nTACHYARRHYTHMIAS\nSome, but not all, studies suggest that methylsynephrine can increase heart rate in healthy people (99910, 99911, 99912, 99915). Theoretically, methylsynephrine might worsen tachyarrhythmias.\nless",
            "Overdose": "There is insufficient reliable information available about the toxicology of methylsynephrine.",
            "Pharmacokinetics": "Absorption\nIn humans, the time to maximum plasma concentration of methylsynephrine after oral administration is 0.7-1.7 hours (99914, 99915).\nDistribution\nIn animal research, methylsynephrine does not cross the blood-brain barrier (94386).\nExcretion\nThe elimination half-life of methylsynephrine from plasma is approximately 2 hours (99915). Approximately 50% of methylsynephrine is excreted in the urine (99910, 99914).",
            "Mechanism of Action": "General\nMethylsynephrine is a chemical related to the natural alkaloid, synephrine. It contains a methyl group on the alpha carbon (94386). Methylsynephrine is a synthetic compound that has not been found to occur in nature. However, some products make unsubstantiated claims regarding its presence in bitter orange and Acacia rigidula (94386, 99910).\nCardiovascular effects\nMethylsynephrine appears to act as a beta-1 agonist, causing inotropic effects. Heart muscle contraction is increased in both speed and force, resulting in changes in left ventricular ejection fraction and stroke volume. Other possible effects include increased blood pressure and variable effects on heart rate; however, these changes have not occurred in all studies (94386, 99910, 99911, 99912, 99915)."
        }
    },
    "Mezereon": {
        "sections": {
            "Overview": "Mezereon is a flowering plant that is native to Europe but has been cultivated all over the world. The bark has traditionally been used as medicine for its purported antitumoral, anticoagulant, abortifacient, hallucinogenic, and immunostimulant effects (18).",
            "Safety": "POSSIBLY UNSAFE when used topically. Acute skin contact can cause redness, swelling, and blistering; prolonged skin contact can lead to necrosis (18).\nLIKELY UNSAFE when used orally. The plant is poisonous and can cause death (18).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally or topically (18); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, mezereon is generally regarded as unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity. Topically, mezereon can cause significant irritation.\nMost Common Adverse Effects\nOrally: Abdominal pain, diarrhea, reddening and swelling of the oral mucous membranes, salivation, thirst, vomiting.\n\nTopically: Blistering, redness, swelling.\nCardiovascular\nOrally, mezereon can cause headache, dizziness, stupor, tachycardia, spasms, and death through circulatory collapse (18).\nless\nDermatologic\nTopically, mezereon can cause red, painful swelling of the skin, blister formation, and shedding of the epidermis (18). Extended exposure can cause necrosis (18). Contact with the eyes can cause severe conjunctivitis (18).\nless\nGastrointestinal\nOrally, mezereon can cause reddening and swelling of the oral mucous membranes, salivation, thirst, stomach pains, vomiting, and severe diarrhea (18).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nHeadache. Although there has been interest in using oral mezereon for headache, there is insufficient reliable information about the clinical effects of mezereon for this purpose.\nJoint pain. Although there has been interest in using topical mezereon for joint pain, there is insufficient reliable information about the clinical effects of mezereon for this purpose.\nToothache. Although there has been interest in using oral mezereon for toothache, there is insufficient reliable information about the clinical effects of mezereon for this purpose.\nMore evidence is needed to rate mezereon for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mezereon.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mezereon.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mezereon.",
            "Mechanism of Action": "General\nThe applicable part of mezereon is the bark. Mezereon contains diterpenes including mezerein and daphnetoxin (18)."
        }
    },
    "Milk Thistle": {
        "sections": {
            "Overview": "Milk thistle is a plant native to Europe that was introduced into North America by early colonists. Milk thistle is found throughout the eastern United States, California, South America, Africa, Australia, and Asia (8957, 95028). The mature plant grows up to 2 meters high and has large, bright purple flowers and many stout spines (8957).",
            "Safety": "LIKELY SAFE when used orally and appropriately. A specific milk thistle extract standardized to contain 70% to 80% silymarin (Legalon, Madaus GmbH) has been safely used in doses up to 420 mg daily for up to 4 years (2613, 2614, 2616, 7355, 63210, 63212, 63278, 63280, 63299, 63340)(88154, 97626, 105792). Higher doses of up to 2100 mg daily have been safely used for up to 48 weeks (63251, 96107, 101150). Another specific milk thistle extract of silymarin (Livergol, Goldaru Pharmaceutical Company) has been safely used at doses up to 420 mg daily for up to 6 months (95021, 95029, 102851, 102852, 105793, 105794, 105795, 113979, 114909, 114913)(114914). Some isolated milk thistle constituents also appear to be safe. Silibinin (Siliphos, Thorne Research) has been used safely in doses up to 320 mg daily for 28 days (63218). Some combination products containing milk thistle and other ingredients also appear to be safe. A silybin-phosphatidylcholine complex (Silipide, Inverni della Beffa Research and Development Laboratories) has been safely used in doses of 480 mg daily for 7 days (7356) and 240 mg daily for 3 months (63320). Tree turmeric and milk thistle capsules (Berberol, PharmExtracta) standardized to contain 60% to 80% silybin have been safely used twice daily for up to 12 months (95019, 96140, 96141, 96142, 97624, 101158).\nPOSSIBLY SAFE when used topically and appropriately, short-term. A milk thistle extract cream standardized to silymarin 0.25% (Leviaderm, Madaus GmbH) has been used safely throughout a course of radiotherapy (63239). Another milk thistle extract cream containing silymarin 1.4% has been used with apparent safety twice daily for 3 months (105791, 110489). A cream containing milk thistle fruit extract 25% has been used with apparent safety twice daily for up to 12 weeks (111175). A milk thistle extract gel containing silymarin 1% has been used with apparent safety twice daily for 9 weeks (95022).\nThere is insufficient reliable information available about the safety of intravenous formulations of milk thistle or its constituents.\nCHILDREN: POSSIBLY SAFE when used orally and appropriately, short-term. A milk thistle extract 140 mg three times daily has been used with apparent safety for up to 9 months (88154, 98452). A specific product containing the milk thistle constituent silybin (Siliphos, Thorne Research Inc.) has been used with apparent safety in doses up to 320 mg daily for up to 4 weeks in children one year of age and older (63218).\nPREGNANCY AND LACTATION: While research in an animal model shows that taking milk thistle during pregnancy and lactation does not adversely impact infant development (102850), there is insufficient reliable information available about its safety during pregnancy or lactation in humans; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, milk thistle is well tolerated.\nMost Common Adverse Effects\nOrally: Abdominal bloating, diarrhea, dyspepsia, flatulence, and nausea. However, these adverse effects do not typically occur at a greater frequency than with placebo.\nSerious Adverse Effects (Rare)\nOrally: Allergic reactions, including anaphylaxis, have been reported.\nDermatologic\nOrally, milk thistle may cause allergic reactions including urticaria, eczema, skin rash, and anaphylaxis in some people (6879, 7355, 8956, 63210, 63212, 63238, 63251, 63315, 63325, 95029). Allergic reactions may be more likely to occur in patients sensitive to the Asteraceae/Compositae family (6879, 8956). A case report describes a 49-year-old female who developed clinical, serologic, and immunopathologic features of bullous pemphigoid after taking milk thistle orally for 6 weeks. Symptoms resolved after treatment with prednisone and methotrexate (107376). Topically, milk thistle can cause erythema (110489).\nless\nGastrointestinal\nMild gastrointestinal symptoms have been reported, including nausea, vomiting, bloating, diarrhea, epigastric pain, abdominal colic or discomfort, dyspepsia, dysgeusia, flatulence, constipation, and loss of appetite (2616, 6879, 8956, 13170, 63140, 63146, 63160, 63210, 63218, 63219)(63221, 63244, 63247, 63250, 63251, 63320, 63321, 63323, 63324, 63325)(63327, 63328, 95024, 95029, 107374, 114914). There is one report of a 57-year-old female with sweating, nausea, colicky abdominal pain, diarrhea, vomiting, weakness, and collapse after ingesting milk thistle; symptoms subsided after 24-48 hours without medical treatment and recurred with re-challenge (63329).\nless\nMusculoskeletal\nIn one clinical study three patients taking milk thistle 200 mg orally three times daily experienced tremor; the incidence of this adverse effect was similar for patients treated with fluoxetine 10 mg three times daily (63219).\nless\nNeurologic/CNS\nWith oral milk thistle use, CNS symptoms have been reported, including headache, dizziness, and sleep disturbances (114913, 114914).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDiabetes. Oral milk thistle extracts of silymarin seem to improve glycemic control in patients with diabetes.\nA meta-analysis of 22 clinical studies in healthy adults and adults with diabetes or other medical conditions shows that taking milk thistle reduces fasting blood glucose by around 22 mg/dL, reduces glycated hemoglobin by 0.85%, and reduces fasting insulin by 3.8 mU/mL when compared with placebo or control (113987). The validity of this analysis is limited by heterogeneity between clinical trials, including population, background treatments, and outcomes. Most of these studies were conducted in the Middle East, so it is unclear whether these results are generalizable to other geographic locations.\n\nA meta-analysis of 7 small heterogeneous clinical trials in patients with type 2 diabetes shows that taking milk thistle containing silymarin 210-600 mg alone or with other ingredients daily for up to 6 months reduces fasting blood glucose and glycated hemoglobin when compared with control. Sub-group analyses suggest that studies conducted for less than 3 months seem to have a greater glycemic benefit than those lasting 3 months or longer. Furthermore, there was a greater glycemic benefit when milk thistle was used in combination with other natural ingredients (105054). Most studies in the analysis used silymarin in divided doses of 420-600 mg daily, while only one study used 200 mg daily (15102, 63190, 97626, 105054). Additionally, a meta-analysis of 22 clinical studies in healthy adults and adults with diabetes or other medical conditions shows that taking milk thistle reduces fasting blood glucose by around 22 mg/dL, reduces glycated hemoglobin by 0.85%, and reduces fasting insulin by 3.8 mU/mL when compared with placebo or control (113987). The validity of this analysis is limited by heterogeneity between clinical trials, including population, background treatments, and outcomes. Most of these studies were conducted in the Middle East, so it is unclear whether these results are generalizable to other geographic locations.\n\nMost studies of combination products have been conducted in Italy and involve a specific product (Berberol, PharmExtracta) containing milk thistle standardized to silymarin 105-210 mg with tree turmeric standardized to berberine 500-1000 mg (96141, 105054). In addition to improving glycemic indices in patients with type 2 diabetes (105054), this product has shown glycemic benefit in patients with concomitant obesity and metabolic syndrome (97624) and in patients with type 1 diabetes (96142).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. It is unclear if oral or topical milk thistle is beneficial in patients with acne when used alone or in combination with other treatments.\nA small clinical trial in patients with acne vulgaris shows that taking a milk thistle extract standardized to silymarin 140 mg daily for 2 months does not improve acne severity based on the Global Acne Grading system scale when compared with doxycycline 100 mg daily, and silymarin is less effective than doxycycline when evaluated using the Acne Severity Index (ASI) scale. In addition, using silymarin in combination with doxycycline does not appear to be more effective than doxycycline alone (101160).\n\nThere is also interest in using milk thistle topically for acne. A small quasi-experimental study in adults with mild to moderate acne suggests that applying silymarin 1.4% cream twice daily for 3 months improves global acne scores and appearance of acne when compared to baseline, but not when compared with biweekly salicylic acid chemical peels (113143). However, the interpretation of these results is limited by the use of subjective outcomes. Similarly, observational research in patients aged 12-25 years with mild-to-moderate acne suggests that applying a specific cream (Cleanance Comedomed, Pierre Fabre Dermo-Cosmetique) containing milk thistle fruit extract 25% twice daily for 8-12 weeks as initial or add-on therapy is associated with moderate improvements in acne scores when compared to baseline (111175). The interpretation of these results is limited by the lack of a comparator group. Further, most patients were also prescribed other skincare products or treatments.\n\nTopical milk thistle has also been evaluated in combination with other ingredients. A small open-label study conducted in Korea in adults with acne vulgaris shows that applying a specific topical product (Silymarin CF, Skinceuticals) containing silymarin 0.5%, vitamin C 15%, salicylic acid 0.5% and ferulic acid 0.5%, twice daily for 3 months moderately improves acne scores when compared to baseline (110488). A similar open-label study conducted in Brazil in adults with acne shows that applying a serum with this same combination and concentration of ingredients once daily for 12 weeks improves investigator's global assessment of acne severity, global lesion count, inflammatory and non-inflammatory lesions, post-inflammatory hyperpigmentation, skin clarity, skin tone evenness, and overall skin appearance and reduces skin surface oil when compared to baseline. Additionally, an open-label study conducted in the US and Germany in adults with acne shows that applying this same serum daily for 4 weeks in addition to prescription topical acne medications reduces investigator-assessed erythema, dryness, and scaling when compared to baseline (113985). In the aforementioned studies, it is unclear if these effects are due to milk thistle, other ingredients, or the combination. The validity of the studies is also limited by the lack of a comparator group.\nless\nAcute kidney injury (AKI). It is unclear if oral milk thistle extract reduces the incidence of vancomycin-induced acute kidney injury.\nA moderate-sized clinical study in hospitalized patients in Iran shows that taking a specific milk thistle extract (Livergol, Goldaru Herbal Products Pharmaceutical Company) 140 mg three times daily for the duration of vancomycin treatment, ranging from 7 to 14 days, reduces the incidence of acute kidney injury, but not hospital length of stay or need for kidney replacement therapy, compared with placebo (114909). The validity of these results is limited by the use of a per-protocol analysis.\nless\nAlcohol-related liver disease. It is unclear if oral milk thistle is beneficial in patients with alcohol-related liver disease, as evidence is conflicting.\nSome preliminary research shows that taking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 420 mg orally daily for one month to 4 years improves some liver function tests (2613, 2618, 17228, 63260, 63339). Some studies also report improvements in liver histology and survival (2616, 17228, 63278). However, in other studies, taking a similar dose of the same product for 3 months to 2 years is not associated with any benefit over placebo (7321, 7322, 7355, 63158). A meta-analysis of clinical research also shows that milk thistle extract does not reduce mortality or complications related to liver disease in patients with alcohol-related liver disease (63192). Reasons for the conflicting findings are unclear but might relate to the low methodological quality of many of these studies.\nless\nAllergic rhinitis (hay fever). It is unclear if oral milk thistle is beneficial in patients with allergic rhinitis.\nOne preliminary clinical trial shows that taking a milk thistle extract of silymarin 140 mg orally three times a day plus cetirizine (Zyrtec) 10 mg daily for one month decreases the severity of allergic rhinitis symptoms when compared with placebo plus cetirizine (18105).\nless\nAlzheimer disease. It is unclear if oral milk thistle is beneficial in patients with Alzheimer disease.\nA small, single-blind clinical study in patients with Alzheimer disease shows that taking milk thistle 450 mg daily for 3 months improves scores on the Mini Mental State Exam (MMSE) when compared with placebo (113978). However, another small clinical study in patients with Alzheimer disease shows that taking milk thistle extract (Livergol, Goldaru Herbal Products Pharmaceutical Company) 140 mg three times daily for 6 months does not improve MMSE or Clinical Dementia Rating scores when compared with placebo (114913).\n\nOther preliminary clinical research shows that taking a supplement containing a milk thistle extract of silymarin 150 mg in combination with ferulic acid, gamma-oryzanol, and apigenin orally twice daily for 3 months to 2 years may stabilize mental functioning in patients with Alzheimer disease when compared to baseline (63223). It is unclear if this effect is due to milk thistle, other ingredients, or the combination.\nless\nAmanita mushroom poisoning. While an intravenous milk thistle constituent, silibinin, has been studied for treating Amanita mushroom poisoning, this product is not readily available in the U.S.\nPreliminary evidence from uncontrolled studies shows that administering silibinin, a constituent of milk thistle, intravenously (IV) within 48 hours of Amanita phalloides (death cap) mushroom poisoning, followed by oral therapy, may lessen liver damage (2615, 63293). However, silibinin is not readily available in the US.\nless\nAtrial fibrillation. It is unclear if oral milk thistle is beneficial for preventing atrial fibrillation after coronary artery bypass grafting.\nA clinical study in patients undergoing coronary artery bypass grafting shows that taking oral milk thistle constituent silymarin 400 mg daily 3 days before surgery reduces the incidence of postoperative atrial fibrillation when compared with placebo. However, the validity of these findings is limited by the single-center study design (116131).\nless\nBenign prostatic hyperplasia (BPH). It is unclear if oral milk thistle is beneficial for benign prostatic hyperplasia.\nA small clinical study in patients with benign prostatic hyperplasia shows that adding milk thistle extract (Liversil, Rose Pharmed Pharmaceutical Company) 240 mg twice daily for 3 months to tamsulosin improves prostate symptom scores, irritation, obstruction, prostate volume, and post-void residuals, but not serum prostate specific antigen levels, when compared with placebo plus tamsulosin (114910). However, it is unclear whether the noted improvements are clinically significant.\n\nMilk thistle has also been studied in combination with other ingredients. Preliminary clinical research shows that taking a milk thistle extract of silymarin 190 mg along with selenium 80 mcg orally three times daily for 6 months may improve lower urinary tract symptoms, urinary flow rates, and residual volumes in adults aged 45-70 years with BPH when compared with placebo (88155). It is unclear if these effects are due to milk thistle, selenium, or the combination.\nless\nBeta-thalassemia. Meta-analyses of clinical studies in patients with beta-thalassemia suggest that oral silymarin, a constituent of milk thistle, reduces serum ferritin levels.\nMost small clinical studies and meta-analyses of these studies show that taking silymarin in conjunction with conventional iron chelation medications such as deferiprone, deferasirox, or deferoxamine, is more effective for reducing serum ferritin levels than taking a conventional medication alone (88154, 98452, 107375). In one meta-analysis, the combination of silymarin and deferasirox appeared to be more effective than combinations with other iron chelation medications (107375). However, one preliminary clinical study in patients 12 years of age and older with beta-thalassemia shows that taking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 140 mg orally three times daily for 3 months, in conjunction with deferoxamine, does not improve serum ferritin when compared with deferoxamine alone (63212). This difference in outcome is likely due to the shorter duration of therapy. Silymarin also does not seem to affect total iron binding capacity or liver iron concentration in patients with beta-thalassemia (107375).\nless\nChemotherapy-induced acral erythema. It is unclear if topical milk thistle is beneficial in patients with acral erythema due to capecitabine.\nPreliminary clinical research shows that applying a gel containing a milk thistle extract of silymarin 1% twice daily to the hands and feet, starting from the first day of chemotherapy and continuing for 9 weeks thereafter, prolongs the time to onset of acral erythema and decreases its severity when compared with placebo in patients with gastrointestinal cancer who are receiving capecitabine for the first time (95022).\nless\nChemotherapy-induced hepatotoxicity. Results of clinical studies are mixed over whether oral milk thistle prevents or improves chemotherapy-induced hepatotoxicity.\nOne small clinical study in children and adults up to age 21 with acute lymphoblastic leukemia (ALL) and elevated liver function tests (LFTs) shows that taking a specific product containing the milk thistle constituent silibinin (Siliphos, Thorne Research, Inc.) 80-320 mg (depending on patient weight) daily for 28 days concurrently with chemotherapy does not improve LFTs or bilirubin levels when compared with placebo (63218).\n\nAnother small clinical study in patients with non-metastatic breast cancer receiving doxorubicin, cyclophosphamide, and paclitaxel shows that taking a specific milk thistle extract of silymarin (Livergol, Goldaru Pharmaceutical Company) 140 mg three times daily with meals for 4 weeks does not improve fatty liver grading or LFTs when compared with placebo (105795). A similar small clinical study in patients with non-metastatic breast cancer receiving doxorubicin and cyclophosphamide, with or without paclitaxel shows that taking this same milk thistle extract 140 mg three times daily for 9 weeks attenuates an increase in fatty liver grade liver grade but does not consistently improve LFTs after each course of chemotherapy (114914). Conversely, a large clinical study in children aged 5-14 with elevated liver enzymes and receiving chemotherapy for ALL shows that taking silymarin 70 mg capsules twice daily or 50 mg syrup three times daily for 9 months modestly improves aspartate aminotransferase, alanine aminotransferase, and bilirubin levels, but does not improve alkaline phosphatase or albumin levels (113144).\n\nObservational research in patients with a variety of solid tumors and elevated LFTs due to chemotherapy or targeted therapy suggests that taking silymarin 150-900 mg daily is associated with reduced or stabilized LFTs in over half of patients; however, doses above 300-450 mg daily don't seem to have much more benefit (111176). The interpretation of these results is limited by the lack of a comparator group.\nless\nChemotherapy-induced nephrotoxicity. It is unclear if oral milk thistle is beneficial for the prevention of cisplatin-induced nephrotoxicity.\nA small clinical study shows that taking a milk thistle extract standardized to 70% to 80% silymarin (Liverherb, Amin Pharmaceutical Company) 140 mg orally three times daily with meals, starting 24-48 hours before cisplatin and continuing until the end of three 21-day cycles, does not prevent cisplatin-induced nephrotoxicity when compared with placebo (95025).\nless\nChemotherapy-induced peripheral neuropathy. It is unclear if oral milk thistle is beneficial for chemotherapy-induced peripheral neuropathy.\nA small clinical study in adults with cancer receiving cisplatin chemotherapy shows that taking a specific product (Livergol, Goldaru) containing milk thistle 140 mg three times daily for 3 months improves overall symptoms of chemotherapy-induced peripheral neuropathy when compared to baseline, but not when compared with placebo, with the possible exception of hyposthesia to touch and pins and needles sensation which had worsened only in the placebo group (113979).\nless\nCirrhosis. It is unclear if oral milk thistle extracts of silymarin are beneficial for cirrhosis from various causes.\nPreliminary clinical research shows that taking a milk thistle extract of silymarin 420 mg orally daily for up to 4 years might improve liver function tests and decrease mortality in people with cirrhosis due to a variety of causes (2616, 63145, 63278, 63340). However, a meta-analysis of clinical research evaluating milk thistle studies for the treatment of various liver diseases shows that effect sizes are generally small or lack statistical significance (63161). An observational study in adults with hepatitis B virus-related liver cirrhosis suggests that taking milk thistle 150 mg 2-3 times daily for at least 30 days in combination with anti-viral therapy is associated with lower mortality and liver transplantation rates at 1- and 2-year follow up and greater improvement in international normalized ratio, model for end-stage liver disease score, and the Charlson comorbidity index at 1-year follow-up when compared with anti-viral therapy alone (113986).\nless\nContrast induced nephropathy. It is unclear if oral milk thistle is beneficial for reducing the risk of nephropathy from contrast agents.\nPopulation research in Taiwanese patients with liver cirrhosis has found that taking silymarin daily for at least 90 days during a one-year period does not reduce the risk of contrast-induced nephropathy during the following four or more years (98453).\nless\nCoronavirus disease 2019 (COVID-19). It is unclear if oral milk thistle is beneficial for COVID-19.\nPreliminary clinical research in adults hospitalized with COVID-19 requiring non-invasive oxygen support shows that taking a specific milk thistle product (SinaLive, Exir Nano Sina Company), 70 mg orally three times daily for 2 weeks, does not improve time to symptom resolution, lung scores, or length of stay when compared with placebo (109504).\nless\nCritical illness (trauma). It is unclear if oral milk thistle is beneficial in critically ill patients with trauma-induced liver injury.\nOne small clinical study in patients admitted to the intensive care unit (ICU) due to trauma-induced liver injury shows that taking a specific milk thistle extract (Livergol, Goldaru Pharmaceutical Company) containing silymarin 140 mg three times daily for 14 days reduces markers of liver injury, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), when compared with placebo (105793). Whether this milk thistle extract improves morbidity, mortality, or length of ICU stay in these patients is unclear.\nless\nDiabetic nephropathy. It is unclear if oral milk thistle is beneficial for improving kidney function in patients with this condition.\nPreliminary clinical research in type 2 diabetic patients with diabetic nephropathy shows that taking a milk thistle extract of silymarin 140 mg orally three times daily for 3 months, in combination with conventional treatment decreases the urine albumin to creatinine ratio when compared with placebo. However, serum creatinine and estimated glomerular filtration rate are not improved (63250).\nless\nDyslipidemia. Oral milk thistle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA meta-analysis of three clinical trials in adults with hypercholesterolemia shows that taking a specific combination product (Berberol, PharmExtracta) containing milk thistle extract 105 mg and tree turmeric extract 588 mg twice daily for 3 months, along with diet and exercise, reduces levels of LDL cholesterol by an average of 34 mg/dL when compared with diet and exercise alone. There was no effect on HDL cholesterol or triglyceride levels (101158). The studies included in this meta-analysis are generally of low quality, lasted for no more than 12 months, and sometimes include patients with statin intolerance (95019, 96140, 101158). Other clinical research shows that taking a similar product (Berberol K, PharmExtracta) containing milk thistle extract 105 mg, tree turmeric extract of berberine 500 mg, and monacolin K and KA 10 mg, taken once daily for 3 months along with diet and exercise, reduces levels of LDL cholesterol by about 28% when compared with diet and exercise alone in patients with hypercholesterolemia (97625). It is possible that any benefit of this product is due to the monacolin content. It is unclear if these effects are due to milk thistle, other ingredients, or the combination.\nless\nDyspepsia. Oral milk thistle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA specific combination product containing milk thistle (Iberogast, Medical Futures, Inc.) seems to improve symptoms of dyspepsia. The combination includes milk thistle plus peppermint leaf, German chamomile, caraway, licorice, clown's mustard plant, celandine, angelica, and lemon balm (19532). A meta-analysis of clinical research using this combination product shows that taking 1 mL orally three times daily over a period of 4 weeks reduces severity of acid reflux, epigastric pain, cramping, nausea, and vomiting when compared with placebo (13089).\nless\nEndometriosis. It is unclear if oral milk thistle is beneficial in patients with endometriosis.\nPreliminary clinical research in females with ovarian endometrioma shows that taking a specific silymarin product (Goldaru Pharma) 140 mg twice daily for 12 weeks moderately improves pain scores, but not other sexual function scores, when compared with placebo (110486). However, some researchers have also recommended to avoid using milk thistle in estrogen-sensitive conditions, such as endometriosis, due to its estrogenic effects (93025, 93026).\nless\nGambling disorder. It is unclear if oral milk thistle is beneficial for gambling disorder.\nA small clinical study in adults with gambling disorder shows that taking milk thistle 150 mg twice daily for 2 weeks and then 300 mg daily for the next 6 weeks does not improve symptoms associated with gambling disorder, including gambling urges, thoughts, and behaviors, or improve symptoms of anxiety and depression when compared with placebo (113974). The interpretation of these results is limited by the small sample size and a strong placebo effect.\nless\nHepatitis. Small clinical studies suggest that oral milk thistle extracts of silymarin may improve hepatitis symptoms. It is unclear whether these products can improve liver function in these patients.\nIn people with hepatitis due to a variety of causes, taking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 140 mg orally three times daily for 4 weeks reduces symptoms such as jaundice, dark urine, and scleral icterus, but does not improve liver function tests (LFTs) (63210, 63317). However, some improvements in LFTs are seen with a silybin-phosphatidylcholine complex (Silipide, Inverni della Beffa Research and Development Laboratories) taken as 160-360 mg orally daily for 2 weeks to 3 months (63320, 63321). However, there are methodological problems with these latter studies.\nless\nHepatitis B. Small clinical studies suggest that oral milk thistle extracts may improve liver function in people with hepatitis B, although it is unclear if these products can improve disease-related complications.\nPreliminary clinical studies suggest that taking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 140 mg orally three times daily for 28 days to one year, or a silybin-phosphatidylcholine complex (Silipide, Inverni della Beffa Research and Development Laboratories) 240 mg orally twice daily for 7 days, improves liver function tests (LFTs) and liver histology (7356, 63263, 63299). However, another study shows that taking a milk thistle extract of silymarin 140 mg orally three times daily for 5-25 days has no effect of LFTs (63288). A meta-analysis of clinical research and a review conclude that any clinical effect of milk thistle in people with viral hepatitis is very limited and results suggest that it lacks a significant effect on mortality, liver disease complications, or liver histology (17228, 63192).\nless\nHepatitis C. Small clinical studies suggest that oral milk thistle extracts may improve liver function but do not seem to reduce hepatitis C virus (HCV) RNA levels.\nPreliminary clinical studies show that taking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 140 mg orally three times daily for 3-12 months, or a silybin-phosphatidylcholine complex (Silipide, Inverni della Beffa Research and Development Laboratories) 240 mg orally twice daily for 7 days, improves liver function tests (LFTs) and liver histology (7356, 63299). However, other studies report that taking silymarin 125-140 mg three times daily for up to one year, 166 mg twice daily for 3 months, or 400 mg daily for 8 weeks does not improve serum HCV RNA levels, anti-HCV antibody levels, LFTs, or hepatomegaly (13170, 63208, 63247, 63288, 108658). Also, taking higher doses of silymarin, up to 700 mg three times daily for 6 months, does not have a significant effect on serum HCV RNA levels or LFTs when compared with placebo (63251). A meta-analysis of clinical research and a review conclude that any clinical effect of milk thistle in people with viral hepatitis is limited and most results show that milk thistle lacks a significant effect on mortality, liver disease complications, or liver histology (17228, 63192, 88156).\n\nPreliminary clinical research in adults with HCV-related advanced chronic liver disease shows that taking a specific milk thistle combination product containing silybinphospholipid complex 303 mg, vitamin D 10 mcg, and vitamin E 15 mg (Realsil 100 D, Ibi Lorenzini), twice daily for 12 months, improves liver stiffness scores, but not liver fibrosis scores, when compared with control (108659). It is unclear if this effect is due to milk thistle, other ingredients, or the combination.\nless\nHyperlipoproteinemia. It is unclear if oral milk thistle is beneficial in patients with hyperlipoproteinemia secondary to liver disease.\nOne very small crossover study shows that taking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 420 mg orally daily for 7 months does not significantly improve cholesterol levels in patients with hyperlipoproteinemia secondary to liver disease when compared with placebo (63255).\nless\nHypoxic liver injury. It is unclear if oral milk thistle is beneficial for reducing liver injury in patients with hypoxia.\nPreliminary clinical research in patients presenting to the emergency department with hypoxia shows that taking a milk thistle extract of silymarin 280 mg every 8 hours for 3 days reduces markers of liver injury, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), when compared with placebo (103871).\nless\nInfertility. It is unclear if oral milk thistle is beneficial for patients undergoing in vitro fertilization.\nPreliminary clinical research shows that taking a milk thistle extract of silymarin 70 mg orally three times daily in combination with human chorionic gonadotropin (HCG) lowers the proportion of early and total apoptosis of follicle cells during in vitro fertilization due to male infertility. However, it does not have an effect on the number of oocytes retrieved or the thickness of the endometrium when compared with HCG plus placebo (63227).\nless\nLactation. It is unclear if oral milk thistle is beneficial for increasing milk production.\nA small clinical study shows that taking a milk thistle extract standardized to 60% silymarin (BIO-C, Milte Italia S.r.l.) 240 mg twice daily for 4 weeks does not increase milk production when compared with placebo in mothers of preterm newborns (95027).\nless\nMelasma. It is unclear if topical milk thistle is beneficial in patients with melasma.\nPreliminary clinical research in adults with melasma shows that applying silymarin 1.4% cream twice daily for 3 months moderately improves melasma appearance scores when compared to baseline. These improvements were similar to hydroquinone cream 2% (110489). One small clinical trial in females with melasma shows that application of silymarin 1.4% cream twice daily to the affected area for 3 months is as effective for improving melasma area and severity as a specific type of laser therapy (low fluence Q switched ND:YAG 1064 nm) (105791).\nless\nMenopausal symptoms. It is unclear if oral milk thistle reduces menopausal symptoms such as hot flashes.\nOne small clinical study in postmenopausal patients shows that taking milk thistle fruit extract 200 mg, containing 80% silymarin, twice daily for 8 weeks seems to reduce the number and severity of daily hot flashes and overall climacteric symptoms when compared with taking placebo (105053). This finding is limited by incomplete reporting and potentially inadequate blinding. Other preliminary clinical research has evaluated milk thistle in combination with black cohosh, dong quai, red clover, American ginseng, and chasteberry (Phyto-Female, SupHerb), with some evidence of benefit for reducing hot flashes and night sweats. (19552).\nless\nMetabolic dysfunction-associated steatotic liver disease (MASLD). It is unclear if oral milk thistle is beneficial for MASLD.\nA meta-analysis of clinical studies in adults with MASLD shows that taking milk thistle monotherapy may decrease the liver enzymes alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) when compared with no intervention or placebo. (117139). The validity of these findings are limited by insufficient power, risk of bias, and heterogeneity across studies.\n\nFurthermore, a moderate-sized clinical study in patients with MASLD shows that taking milk thistle extract equivalent to 51.6 mg of silybin twice daily for 6 months reduces liver stiffness, but not levels of ALT, AST, or bilirubin when compared with placebo (114918). A moderate-sized, open-label, non-controlled study in patients with MASLD shows that taking milk thistle standardized to silymarin 150 mg twice daily for 6 months does not improve liver stiffness or liver enzymes when compared with essential phospholipids. It is unclear if any changes in these outcomes are statistically significant when compared to baseline (114462). The validity of these findings is limited by the lack of a placebo group.\n\nHowever, a clinical study in Romania in adults with MASLD shows that taking a specific combination product, Esentin Trio, containing milk thistle (standardized to silymarin 100 mg), vitamin E, and essential phospholipids twice daily for 6 months reduces liver function tests (ALT, AST, GGT, alkaline phosphatase) and improves liver fibrosis and steatosis when compared with baseline. Additionally, the milk thistle combination improved blood glucose, body mass, and lipid profiles compared to baseline (117138). The validity of these findings is limited by the lack of a comparator group. It is unclear if this effect is due to milk thistle, vitamin E, essential phospholipids, or the combination.\n\nAlso review milk thistle's effectiveness in nonalcoholic fatty liver disease (NAFLD), a similar condition.\nless\nMetabolic syndrome. Oral silymarin, a constituent of milk thistle, seems to improve some of the laboratory abnormalities associated with metabolic syndrome.\nA meta-analysis of 11 low-quality clinical trials in adults with metabolic syndrome, conducted in Asia and Africa, shows that silymarin, 140-2100 mg daily for 45 days to 12 months, modestly reduces fasting blood glucose, glycated hemoglobin, total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels, and increases high-density lipoprotein cholesterol levels, when compared with placebo (107374).\nless\nMultiple sclerosis (MS). Oral milk thistle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with MS shows that taking a supplement containing a milk thistle extract of silymarin 150 mg in combination with ferulic acid, gamma-oryzanol, and apigenin twice daily for 3-24 months may stabilize clinical symptoms of MS when compared to baseline (63223). It is unclear if this effect is due to milk thistle, other ingredients, or the combination.\nless\nNonalcoholic fatty liver disease (NAFLD). Small clinical studies suggest that oral milk thistle extracts of silymarin may slightly improve markers of liver function patients with NAFLD.\nFour meta-analyses of up to 23 mostly small clinical trials in patients with NAFLD show that taking milk thistle products containing a total of silymarin 140-2100 mg daily, either alone or in combination with other ingredients, for 8-48 weeks reduces aspartate aminotransferase (AST) by 7-13 IU/L and alanine aminotransferase (ALT) by 9-17 IU/L when compared with control (97622, 105051, 113976, 113982). However, these changes in liver enzymes may not be clinically impactful and some experts note that serum AST levels do not reliably reflect the spectrum of liver histology in patients with NAFLD (98130).\n\nMetabolic indices have also been evaluated. A meta-analysis of up to 20 mostly small clinical studies in patients with NAFLD shows that taking milk thistle for up to 48 weeks slightly improves serum lipids when compared with control (113976). A small clinical study in adults with NAFLD and a body-mass index (BMI) of at least 35 kg/m2 shows that taking milk thistle extract 140 mg 4 times daily for 8 weeks, in addition to lifestyle modifications, reduces BMI by approximately 1 kg/m2 when compared with placebo with lifestyle modifications (108657). However, another small clinical trial in adults with NAFLD and a BMI of at least 40 kg/m2 shows that taking a specific silymarin product (Livergol, Goldaru Pharmaceuticals) 140 mg three times daily for 4 weeks did not reduce BMI or improve liver enzymes, such as AST and ALT, when compared with placebo (110484). A meta-analysis of 7 small clinical trials also shows there is little to no change in BMI associated with silymarin use in these patients (113976).\n\nOne small clinical study in patients with NAFLD shows that taking a specific combination product (Eurosil 85, MEDAS SL) containing milk thistle extract standardized to silymarin 540 mg and vitamin E 36 mg daily for 3 months, in addition to following a low-calorie diet, does not appear to improve NAFLD-Fibrosis score or fatty liver index (FLI) when compared with following a low-calorie diet alone (96261), though a meta-analysis of 2 small clinical studies in patients with NAFLD shows that taking milk thistle for 12-24 weeks does reduce FLI when compared with control (113976).\n\nAlso review milk thistle's effectiveness in metabolic dysfunction-associated steatotic liver disease (MASLD), a similar condition.\nless\nNonalcoholic steatohepatitis (NASH). It is unclear if oral milk thistle is beneficial in patients with NASH.\nClinical research in patients with NASH shows that taking a milk thistle extract of silymarin 700 mg three times daily for 48 weeks improves fibrosis in more patients when compared with placebo (96107). However, there is no significant between-group difference in global histological improvement with this product (96107) or with a specific silymarin product (Legalon, Rottapharm Madaus, Mylan) 420 or 700 mg three times daily for 48-50 weeks (101150). Pooling 1 of these clinical studies (96107) into a meta-analysis with another clinical trial that evaluated milk thistle in combination with phosphatidylcholine and vitamin E suggests an improvement in fibrosis by at least one stage when compared with placebo (113984). However, it is unclear if this effect is due to milk thistle, other ingredients, or the combination.\n\nMetabolic indices have also been evaluated. A meta-analysis of small clinical studies in patients with NASH or nonalcoholic fatty liver disease (NAFLD) shows that taking milk thistle reduces aspartate aminotransferase (AST) by about 13 IU/L, alanine aminotransferase (ALT) by about 17 IU/L, serum triglycerides by about 23 mg/dL and increases high-density lipoprotein cholesterol by about 2 mg/dL, but does not alter gamma-glutamyl transferase, total cholesterol, low-density lipoprotein cholesterol, body mass index, or insulin resistance when compared with control (113982). However, trials on NAFLD and NASH were not analyzed separately which limits the generalizability of these findings to patients with NASH specifically. The dose and duration of milk thistle treatment was also not described.\nless\nObesity. It is unclear if oral milk thistle is beneficial in patients with obesity.\nA meta-analysis of 11 clinical studies in healthy adults and adults with various medical conditions shows that taking milk thistle does not reduce body weight or body mass index when compared with placebo or control (113987). A very small open-label study in adult females with obesity suggests that taking a specific milk thistle extract product (Neocholal-S, Italmex) 151.5 mg, containing silybin 45 mg, twice daily for 12 weeks does not reduce body weight but may reduce fasting blood glucose levels and insulin resistance when compared to baseline (113980). The validity of this study is limited by the lack of a comparator group and very small sample size.\nless\nObsessive-compulsive disorder (OCD). It is unclear if oral milk thistle is beneficial in patients with OCD.\nPreliminary clinical research shows that taking milk thistle leaf extract 200 mg orally three times daily for 8 weeks has a limited effect on OCD symptom scores when compared to baseline, but does not provide any benefit over fluoxetine 10 mg three times daily (63219).\nless\nParkinson disease. Oral milk thistle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking a supplement containing a milk thistle extract of silymarin 150 mg in combination with ferulic acid, gamma-oryzanol, and apigenin orally twice daily for 3 months to 24 months may stabilize clinical symptoms in patients with Parkinson disease when compared to baseline (63223). It is unclear if this effect is due to milk thistle, other ingredients, or the combination.\nless\nPostpartum complications. It is unclear if topical milk thistle is beneficial in postpartum patients with an episiotomy.\nPreliminary clinical research in postpartum patients shows that applying milk thistle 3% in Eucerin ointment twice daily to the suture site for 10 days reduces episiotomy pain and improves the healing rate when compared with placebo. The milk thistle product was prepared with an ethanolic extract of the seeds to provide 1.53% silybin (107373).\nless\nProstate cancer. Oral milk thistle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with a history of prostate cancer who have had radiotherapy or radical prostatectomy shows that taking a dietary supplement containing a milk thistle extract of silymarin 160 mg, soy isoflavones (Novasoy, ADM) 62.5 mg, lycopene (Lyc-O-Mato, LycoRed Natural Products Industries, Ltd.) 15 mg, vitamins, minerals, and antioxidants orally daily for 10 weeks increases the time it takes for prostate-specific antigen (PSA) levels to double by 2.6-fold when compared with placebo (60361).\nless\nRadiation dermatitis. It is unclear if topical milk thistle is beneficial in patients with dermatitis due to radiation.\nPreliminary clinical research in females with breast cancer undergoing radiotherapy shows that applying a specific topical product containing a milk thistle extract of silymarin (Leviaderm, Madaus GmbH) significantly reduces the incidence of radiation dermatitis and prolongs the time to the onset of radiation dermatitis when compared with applying a panthenol-containing cream (63239). Additionally, meta-analysis pooling this study (63239) with one other small clinical study also shows that applying a cream or gel containing milk thistle extract reduces the incidence radiation dermatitis when compared with control (113674).\nless\nRheumatoid arthritis (RA). It is unclear if oral milk thistle is beneficial for rheumatoid arthritis.\nA moderate-sized clinical study in patients with rheumatoid arthritis (RA) on conventional RA medications shows that taking milk thistle (Silymarin Forte, Zenyth Pharmaceuticals SRL) 300 mg, in addition to standard RA medications, daily for 8 weeks reduces the number of tender and swollen joints, the duration of morning stiffness, severity of disease activity, and fatigue, depression and anxiety scores when compared with standard RA medicationsl (114915). The validity of this study is limited by the lack of blinding and lack of a placebo control.\nless\nToxin-induced liver damage. Most small clinical studies suggest that oral milk thistle extracts or constituents may reduce liver injury in people exposed to some, but not all, toxins and medications known to cause liver damage.\nTaking a milk thistle extract containing 70% to 80% silymarin (Legalon, Madaus GmbH) 420 mg orally daily for up to one month improves liver function tests (LFTs) in people with abnormal LFTs due to chronic occupational exposure to paints or organic solvents such as toluene or xylene (2614, 63280).\n\nMilk thistle extract has also shown some benefit for reducing drug-induced liver injury (DILI). In patients on isotretinoin therapy for acne, taking a specific milk thistle extract containing silymarin (Livergol, Goldaru Pharmaceutical Company) 140 mg daily for 30 days improves LFTs when compared with placebo (102852). A small clinical study in patients with relapsing-remitting multiple sclerosis who were initiating therapy with fingolimod shows that taking a specific milk thistle extract (Livergol, Goldaru Pharmaceutical Company) containing silymarin 140 mg daily for 6 months prevents fingolimod-induced LFT elevations when compared with placebo (105794). In patients receiving treatment for tuberculosis with rifampin, isoniazid, pyrazinamide, ethambutol, and streptomycin, taking the milk thistle constituent silibinin 70 mg orally three times daily for 6-12 months reduces the rate of liver toxicity to 14% compared with 53% in patients taking glucuronolactone 200 mg orally three times daily (63224). Additionally, in patients receiving standard treatment for tuberculosis with isoniazid, rifampicin, pyrazinamide, and ethambutol, taking a milk thistle extract of silymarin 140 mg orally three times daily for 4 weeks decreases the risk of DILI by 28% when compared with placebo. About 1 in every 4 patients who take silymarin for 4 weeks would avoid DILI (95024). A small clinical study in Iran, also in adults receiving standard treatment for tuberculosis, shows that taking a milk thistle extract of silymarin 150 mg twice daily for 2 weeks modestly improves LFTs when compared with control. None of the 16 patients in the silymarin group developed DILI compared with 2 of 21 patients in the control group; however, this finding was not statistically significant (112230). The interpretation of these findings is limited by the short study duration.\n\nHowever, taking a milk thistle extract of silymarin 420 mg orally daily for 3 months does not seem to prevent liver toxicity associated with tacrine (Cognex) therapy in people with Alzheimer disease (63140). Other research in people with elevated LFTs due to long-term therapy with phenothiazine or butyrophenone antipsychotic medications shows that taking silymarin 800 mg orally daily for 3 months also does not improve LFTs when compared with placebo (63344).\n\nA retrospective study in patients with DILI of various offending agents has also found that taking a milk thistle extract, containing a median of 450 mg silybin daily for 24 days is associated with 1.7-2.8 times higher likelihood of LFT normalization when compared with control (110485).\nless\nTrichotillomania. It is unclear if oral milk thistle is beneficial in patients with this condition.\nPreliminary clinical research in patients 12-65 years of age shows that taking milk thistle 150 mg twice daily for 2 weeks, and then 300 mg twice daily for 4 weeks, does not improve symptoms of trichotillomania when compared with placebo (99426).\nless\nUlcerative colitis. It is unclear if oral milk thistle is beneficial in patients with this condition.\nPreliminary clinical research in patients 16-75 years of age shows that taking a specific milk thistle extract of silymarin (Livergol, Goldaru Pharmaceutical Company) 140 mg daily for 6 months, in conjunction with standard medications, decreases disease activity and helps maintain remission when compared with placebo in patients with ulcerative colitis (95029).\nless\nVitiligo. It is unclear if oral milk thistle reduces the severity of this condition.\nPreliminary clinical research in a small number of patients with vitiligo shows that taking a specific milk thistle extract containing silymarin (Livergol, Goldaru Pharmaceutical Company) 140 mg twice daily along with phototherapy for 3 months does not improve the severity of vitiligo when compared with phototherapy plus placebo (102851). However, a small clinical study in patients with vitiligo undergoing hair follicle transplantation and phototherapy shows that taking this same milk thistle extract 70 mg twice daily for 3 months increases perifollicular re-pigmentation when compared with hair follicle transplantation plus phototherapy (114912). The validity of this study is limited by the lack of a placebo.\nless\nRadiation mucositis. It is unclear if oral milk thistle is beneficial for preventing or treating mucositis due to radiation.\nOne small clinical study in patients with head and neck cancer receiving radiotherapy for the first time shows that taking a specific product containing a milk thistle extract of silymarin (Livergol, Goldaru Pharmaceutical Company), 140 mg three times daily starting from the first day of radiotherapy and continuing for 6 weeks thereafter, reduces the severity and prolongs the time to onset of radiation-induced mucositis when compared with placebo (95021).\nless\nMore evidence is needed to rate milk thistle for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMilk thistle extracts have most often been used in doses of 140 mg three times daily for up to 4 years. Milk thistle extracts are typically standardized to silymarin content, with concentrations ranging from 70% to 80% (2613, 2614, 2618, 17228, 63210, 63260, 63263, 63278, 63280, 63299)(63317, 63339, 63340, 88154). See Effectiveness section for condition-specific information.\nTopical:\nMilk thistle has been used in various topical formulations, including gels and creams. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nMilk thistle extract is often standardized to silymarin content. Silymarin is a complex mixture of flavonolignans, with the six present in the highest quantities being silybin A, silybin B, isosilybin A, isosilybin B, silidianin, and silychristin (63240, 63249, 88157, 95021, 95022). The precise percentage of silymarin measured in a milk thistle preparation depends on how many of these flavonolignans are identified by the method used (63240, 63249). Silymarin is not the same as silibinin. Silibinin is a semi purified extract that is roughly a 1:1 mixture of silybin A and silybin B (95026).\n\nOne specific milk thistle extract (Legalon, Madaus GmbH) is standardized to contain 70% to 80% silymarin (63212, 88157). Each capsule contains 175 mg of dried milk thistle seed extract, equivalent to 140 mg of silymarin (95026, 101150).\n\nAnother product containing milk thistle extract (BIO-C, Milte Italia S.r.l.) 420 mg is standardized to 60% silymarin. The silymarin in this product is micronized to improve oral bioavailability (95027).\n\nAnother product containing milk thistle extract (Livergol, Goldaru Herbal Products Pharmaceutical Company) is standardized to at least 80% silymarin and 30% silybins. Each tablet provides 140 mg silymarin (97626). One specific combination product containing tree turmeric and milk thistle extract (Berberol, PharmExtracta) is standardized to contain 60% to 80% silybin from milk thistle extract and 85% berberine from tree turmeric (95019, 96140, 96141, 96142, 97624, 101158). The same product with added monacolins (Berberol K, PharmExtracta) has also been used (97625).\n\nAn analysis of milk thistle preparations available in the US and Czech Republic shows that there is a large variability in the manufacturer-recommended dose. Also, there are issues with standardization of milk thistle products to silymarin. Analysis shows that the total concentration of silymarin in the products was 35% to 125% of declared silymarin content, possibly due to the lack of a strict definition for silymarin. Also, there was variability in the specific flavonoid and flavonolignan composition of individual products (101157). There was evidence of fungal mycotoxin contamination in 100% of the products tested, with most products having more than one mycotoxin. Some mycotoxins exceeded EU recommendations by 19 times the maximal limits in 92% of products. Furthermore, some products contained measurable levels of pesticides and evidence of bacterial contamination (101157).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTaking milk thistle with antidiabetes drugs may increase the risk of hypoglycemia.\nClinical research shows that milk thistle extract, alone or along with tree turmeric extract, can lower blood glucose levels and glycated hemoglobin (HbA1c) in patients with type 2 diabetes, including those already taking antidiabetes drugs (15102, 63190, 63314, 63318, 95019, 96140, 96141, 97624, 97626, 113987). Additionally, animal research shows that milk thistle extract increases the metformin maximum plasma concentration and area under the curve and decreases the renal clearance of metformin, due to inhibition of the multi-drug and toxin extrusion protein 1 (MATE1) renal tubular transport protein (114919).\nless\nCYTOCHROME P450 2B6 (CYP2B6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might inhibit CYP2B6.\nAn in vitro study shows that silybin, a constituent of milk thistle, binds to and noncompetitively inhibits CYP2B6. Additionally, silybin might downregulate the expression of CYP2B6 by decreasing mRNA and protein levels (112229).\nless\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Lower quality RCT)\nIt is unclear if milk thistle inhibits CYP2C9; research is conflicting.\nIn vitro research suggests that milk thistle might inhibit CYP2C9 (7089, 17973, 17976). Additionally, 3 case reports from the World Health Organization (WHO) adverse drug reaction database describe increased toxicity in patients taking milk thistle and cancer medications that are CYP2C9 substrates, including imatinib and capecitabine (111644). However, contradictory clinical research shows that milk thistle extract does not inhibit CYP2C9 or significantly affect levels of the CYP2C9 substrate tolbutamide (13712, 95026). Differences in results could be due to differences in dosages or formulations utilized (95026).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nIt is unclear if milk thistle inhibits CYP3A4; research is conflicting.\nWhile laboratory research shows conflicting results (7318, 17973, 17975, 17976), pharmacokinetic research shows that taking milk thistle extract 420-1350 mg daily does not significantly affect the metabolism of the CYP3A4 substrates irinotecan, midazolam, or indinavir (8234, 17974, 93578, 95026). However, 8 case reports from the World Health Organization (WHO) adverse drug reaction database describe increased toxicity in patients taking milk thistle and cancer medications that are CYP3A4 substrates, including gefitinib, sorafenib, doxorubicin, and vincristine (111644).\nless\nESTROGENS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might interfere with estrogen therapy through competition for estrogen receptors.\nAnimal research suggests that a milk thistle extract of silymarin binds to estrogen receptor beta (93025, 93026).\nless\nGLUCURONIDATED DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might affect the clearance of drugs that undergo glucuronidation.\nLaboratory research shows that milk thistle constituents inhibit uridine diphosphoglucuronosyl transferase (UGT), the major phase 2 enzyme that is responsible for glucuronidation (7318, 17973). Theoretically, this could decrease the clearance and increase levels of glucuronidated drugs. Other laboratory research suggests that a milk thistle extract of silymarin might inhibit beta-glucuronidase (7354), although the significance of this effect is unclear.\nless\nHMG-CoA REDUCTASE INHIBITORS (\"Statins\")\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might interfere with statin therapy by decreasing the activity of organic anion transporting polypeptide 1B1 (OATB1B1) and inhibiting breast cancer resistance protein (BCRP).\nPreliminary evidence suggests that a milk thistle extract of silymarin can decrease the activity of the OATP1B1, which transports HMG-CoA reductase inhibitors into the liver to their site of action, and animal research shows this increases the maximum plasma concentration of pitavastatin and pravastatin (113975). The silibinin component also inhibits BCRP, which transports statins from the liver into the bile for excretion. However, in a preliminary study in healthy males, silymarin 140 mg three times daily had no effect on the pharmacokinetics of a single 10 mg dose of rosuvastatin (16408).\nless\nINDINAVIR (Crixivan)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, milk thistle may induce cytochrome P450 3A4 (CYP3A4) enzymes and increase the metabolism of indinavir; however, results are conflicting.\nOne pharmacokinetic study shows that taking milk thistle (Standardized Milk Thistle, General Nutrition Corp.) 175 mg three times daily in combination with multiple doses of indinavir 800 mg every 8 hours decreases the mean trough levels of indinavir by 25% (8234). However, results from the same pharmacokinetic study show that milk thistle does not affect the overall exposure to indinavir (8234). Furthermore, two other pharmacokinetic studies show that taking specific milk thistle extract (Legalon, Rottapharm Madaus; Thisilyn, Nature's Way) 160-450 mg every 8 hours in combination with multiple doses of indinavir 800 mg every 8 hours does not reduce levels of indinavir (93578).\nless\nLEDIPASVIR\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might increase the levels and clinical effects of ledipasvir.\nAnimal research in rats shows that milk thistle increases the area under the curve (AUC) for ledipasvir and slows its elimination (109505).\nless\nMORPHINE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, concomitant use of milk thistle with morphine might affect serum levels of morphine and either increase or decrease its effects.\nAnimal research shows that milk thistle reduces serum levels of morphine by up to 66% (101161). In contrast, laboratory research shows that milk thistle constituents inhibit uridine diphosphoglucuronosyl transferase (UGT), the major phase 2 enzyme that is responsible for glucuronidation (7318, 17973). Theoretically, this could decrease the clearance and increase morphine levels. The effect of taking milk thistle on morphine metabolism in humans is not known.\nless\nORGANIC ANION-TRANSPORTING POLYPEPTIDE SUBSTRATES (OATP)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nMilk thistle may inhibit one form of OATP, OATP-B1, which could reduce the bioavailability and clinical effects of OATP-B1 substrates.\nIn vitro research shows that milk thistle inhibits OATP-B1. Two case reports from the World Health Organization (WHO) adverse drug reaction database describe increased toxicity in patients taking milk thistle and cancer medications that are OATP substrates, including sorafenib and methotrexate (111644). OATPs are expressed in the small intestine and liver and are responsible for the uptake of drugs and other compounds into the body. Inhibition of OATP may reduce the bioavailability of oral drugs that are substrates of OATP.\nless\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, milk thistle might increase the absorption of P-glycoprotein substrates. However, this effect does not seem to be clinically significant.\nIn vitro research shows that milk thistle can inhibit P-glycoprotein activity (95019, 111644) and 1 case report from the World Health Organization (WHO) adverse drug reaction database describes increased abdominal pain in a patient taking milk thistle and the cancer medication vincristine, a P-glycoprotein substrate, though this patient was also taking methotrexate (111644). However, a small pharmacokinetic study in healthy volunteers shows that taking milk thistle (Enzymatic Therapy Inc.) 900 mg, standardized to 80% silymarin, in 3 divided doses daily for 14 days does not affect absorption of digoxin, a P-glycoprotein substrate (35825).\nless\nRALOXIFENE (Evista)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might decrease the clearance and increase levels of raloxifene.\nLaboratory research suggests that the milk thistle constituents silibinin and silymarin inhibit the glucuronidation of raloxifene in the intestines (93024).\nless\nSIROLIMUS (Rapamune)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Clinical cohort study)\nMilk thistle might decrease the clearance of sirolimus.\nPharmacokinetic research shows that a milk thistle extract of silymarin decreases the apparent clearance of sirolimus in hepatically impaired renal transplant patients (19876). It is unclear if this interaction occurs in patients without hepatic impairment.\nless\nSOFOSBUVIR (Solvaldi)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, milk thistle might decrease the levels and clinical effects of sofosbuvir.\nAnimal research in rats shows that milk thistle reduces the metabolism of sofosbuvir, as well as the hepatic uptake of its active metabolite (109505).\nless\nTAMOXIFEN (Nolvadex)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, the milk thistle constituent silibinin might increase tamoxifen levels and interfere with its conversion to an active metabolite.\nAnimal research suggests that the milk thistle constituent silibinin might increase plasma levels of tamoxifen and alter its conversion to an active metabolite. The mechanism appears to involve inhibition of pre-systemic metabolism of tamoxifen by cytochrome P450 (CYP) 2C9 and CYP3A4, and inhibition of P-glycoprotein-mediated efflux of tamoxifen into the intestine for excretion (17101). Whether this interaction occurs in humans is not known.\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, milk thistle might increase the effects of warfarin.\nIn one case report, a man stabilized on warfarin experienced an increase in INR from 2.64 to 4.12 after taking a combination product containing milk thistle 200 mg daily, as well as dandelion, wild yam, niacinamide, and vitamin B12. Levels returned to normal after stopping the supplement (101159). Although a direct correlation between milk thistle and the change in INR cannot be confirmed, some in vitro research suggests that milk thistle might inhibit cytochrome P450 2C9 (CYP2C9), an enzyme involved in the metabolism of various drugs, including warfarin (7089, 17973, 17976).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, milk thistle might have additive effects when used with other herbs and supplements that also lower glucose levels.\nClinical research suggests that silymarin, a constituent of milk thistle, may lower blood glucose levels, glycated hemoglobin (HbA1c), and insulin resistance in people with type 2 diabetes (15102, 63190, 63314, 63318, 95019, 96140, 96141, 97624, 97626, 113987). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCROSS-ALLERGENICITY\nMilk thistle may cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nHORMONE SENSITIVE CANCERS/CONDITIONS\nTheoretically, people with hormone sensitive conditions should avoid using milk thistle due to its estrogenic effects. Some of these conditions include breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids. Silymarin, a milk thistle constituent, can bind to estrogen receptor beta (93025, 93026).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with milk thistle.",
            "Pharmacokinetics": "Absorption\nBioavailability data for milk thistle in humans are controversial because of the complexity of the composition and the diversity of the constituents (63201).\n\nAfter oral administration of a specific silymarin product (Legalon, Madaus GmbH) in doses of 140-560 mg, silybin A accounted for 84% of measurable flavonolignans in plasma. At a higher dose of 700 mg, silybin A accounted for 54% of measurable flavonolignans, silybin B for 21%, and isosilybin A, isosilybin B, silychristin and silydianin for 4%, 8%, 11%, and 2% respectively (63217). In another study, the bioavailability of orally administered silybin was 23% to 47% and appeared to be higher when administered in a softgel capsule (63311). A silybin-phosphatidylcholine complex (Silipide, Inverni della Beffa Research and Development Laboratories) has been developed to increase bioavailability by up to 10-fold (63228, 95026). Following oral administration of this product, peak plasma levels of free silybin occurred at 2.4 hours, and conjugated silybin at 3.8 hours (63285). Following oral administration of silymarin (Legalon, Madaus GmbH), peak plasma levels of all constituent flavonolignans were achieved by 2 hours (63217). Additionally, a nanocrystal formulation of milk thistle (HydroMilkthistle, Bio-Synectics, Inc) increases oral bioavailability by about 1.5-fold when compared with milk thistle raw material in humans. Plasma silybin levels from the nano-crystal formulation and raw material each reached peak plasma levels at 1 hour after ingestion. However, peak plasma concentration was 2-fold higher and area under the curve 1.5-fold higher with the nano-crystal formulation than the raw material (114917).\n\nThe pharmacokinetics of silymarin are altered in patients with liver disease. The area under the curve for total silymarin flavonolignans was approximately two- to five-fold higher for patients with liver disease compared with healthy volunteers (63203, 63240).\nMetabolism\nSilymarin flavonolignans undergo rapid first-pass conjugation (63217, 63251). Clinical pharmacokinetic research also shows that the main phenolic compounds in milk thistle extract undergo phase II metabolic reactions, including glucuronidation, sulfation, and methylation (114908).\nExcretion\nSilymarin flavonolignans undergo biliary excretion (63217, 63251). After oral intake, less than 10% of silymarin is excreted in the urine, and 20% to 40% is recovered in the bile as glucuronide and sulfate conjugates (63281). In another study, approximately 5% of a single dose of silymarin was excreted in the urine as silibinin (63184). The elimination half-lives for milk thistle constituents are generally less than 4 hours, with most ranging between 0.8-2.4 hours (63217, 63228, 63285).",
            "Mechanism of Action": "General\nThe applicable parts of milk thistle are the seed and above ground parts. The seed is most commonly used medicinally. A standard milk thistle seed extract contains 70% to 80% silymarin, which is a mixture of flavonolignans including silybin A, silybin B, isosilybin A, isosilybin B, silydianin, silychristin A and B, and silibinin (63240, 63249, 95024, 95025, 101157, 114908). Silybin or silibinin is thought to be the most active component of silymarin (95021, 95022, 95025). Other constituents, including dehydrosilybin, desoxy-silydianin, silybinomer, and taxifolin, have also been isolated (63249, 114908).\nAnti-addictive effects\nIn vitro, milk thistle extract was able to bind to the mu-opioid receptor, the receptor involved in most of the effects of morphine (101161).\nAnti-inflammatory effects\nSilibinin decreases the production of tumor necrosis factor (TNF)-alpha and interleukin-1beta (IL-1beta) by peripheral blood mononuclear cells (PBMCs) via down-modulation of nuclear transcription factor-kappa B (NF-kappa B) (63252). Silymarin also regulates inflammatory mediators, downregulates the synthesis of prostaglandin and leukotrienes as well as inhibits cyclooxygenase (COX) II (95028). In laboratory research, a similar inhibition of NF-kappa B and IFN-B-dependent transcription has been seen in Huh7 cells in the presence of silibinin (63233). Silymarin is an inhibitor of inflammation mediated by tumor necrosis factor (TNF), possibly by an effect on intracellular signaling (7859). A meta-analysis of 3 clinical studies in healthy adults and adults with various medical conditions shows that taking milk thistle reduces interleukin 6 (IL-6) when compared with placebo or control (113981). However, preliminary clinical research in adults with stable rheumatoid arthritis (RA) shows that taking a milk thistle extract of silymarin 140 mg orally three times daily for 3 months does not lower proinflammatory cytokine levels, including TNF-alpha and IL-1beta, when compared to baseline (110487). Similarly, clinical research in adults with RA shows that taking milk thistle extract 300 mg daily for 8 weeks does not lower C-reactive protein (CRP) or erythrocyte sedimentation rate (114915). Meta-analyses evaluating the impact of milk thistle on CRP levels in healthy adults and adults with various medical conditions show mixed results (113981, 113987).\nAnticancer effects\nIn human leukocytes, silymarin protects against DNA damage caused by hydrogen peroxide, and in a mouse skin model it reduces UVB and chemically induced carcinogenesis. These effects may be attributable to the antioxidant properties of silymarin (63204, 63298, 63312). Chemically induced tumor promotion in rats can be prevented by silymarin, possibly via inhibition of tumor necrosis factor (TNF)-alpha (63300). Silymarin inhibits mitogenic signaling pathways involved in proliferation of androgen-independent and androgen-dependent prostate cancer cells (7319, 63148).\n\nSilybin A and silybin B, constituents of milk thistle, inhibit cell growth and induce apoptosis of K562 leukemia cells (63243), MCF7 human breast cancer cells, and T47D human breast carcinoma cells, via a purported mitochondrial and caspase-8 mediated pathway (63232).\n\nIn vitro, silibinin has shown an affinity for binding to p-glycoprotein, a transporter thought to be involved in the drug resistance of cancer cells (11481).\nAntidiabetic effects\nSilymarin seems to decrease insulin resistance and have a protective effect on the pancreas in rats with experimentally induced diabetes mellitus (63309). This is thought to be due to silymarin's antioxidant effects. Some research suggests that oxidative stress can contribute to pancreatic beta-cell dysfunction, reduced insulin secretion, and insulin resistance (15102). Laboratory research suggests that silibinin reduces glycolysis from carbohydrates in a dose-dependent manner, via inhibition of pyruvate kinase activity, affecting oxidative phosphorylation, and reducing formation of reactive oxygen species (ROS) formation (63197).\n\nAdditionally, there is interest in using silymarin for complications of diabetes, such as diabetic nephropathy, which is thought to be caused by oxidative stress and inflammation (95028). Silymarin also possesses anti-fibrotic properties via downregulation of transforming growth factor-beta (TGF-beta). TGF-beta plays a role in diabetic nephropathy as it causes hardening of the glomerulus in the kidney as well as interstitial fibrosis.\nAntilipemic effects\nEarly animal experimentation with silybin demonstrated decreased cholesterol synthesis (63270) and reduced biliary excretion of cholesterol salts by 60% to 70%, while leaving biliary flow rates unchanged (63211). In perfused livers from rats fed a high-cholesterol diet, silymarin normalized the clearance of low-density lipoproteins (LDL), providing significant protection against dietary-induced hypercholesterolemia (63310). In laboratory research, silymarin and silibinin inhibited the generation of oxidized LDL, likely through antioxidant and free radical scavenging mechanisms of action (63200). Milk thistle may inhibit cholesterol acyltransferase, which leads to a reduction of cholesterol absorption and lipoprotein biosynthesis. Milk thistle has also been shown to decrease myeloperoxidase (MPO) in patients with hyperlipidemia; MPO is a marker of cardiovascular risk (95019). Milk thistle, or silymarin, inhibits HMG-CoA reductase (95028). It also decreases very low-density lipoprotein (VLDL) synthesis and the amount of free VLDL that can be secreted into the intestine. By downregulating certain factors such as peroxisome proliferator-activated receptor gamma (PPAR gamma), it decreases lipid accumulation. In human research, silymarin has been shown to lower levels of total cholesterol, triglycerides, and LDL cholesterol (15102, 49769, 51423, 63229, 113987), although some conflicting research exists (105792).\nAntioxidant effects\nSilybin reduces lipid peroxidation in various types of cell cultures and in a rat model (63150, 63185, 63294, 63296, 63305, 63308). It also prevents the depletion of glutathione and protects DNA from degradation (95028).\n\nClinical research on the potential anti-oxidant effects of milk thistle is conflicting. A meta-analysis of 6 clinical trials shows that taking milk thistle increases serum glutathione (GSH) levels (113977), while another meta-analysis of 3 clinical studies shows no increase in GSH (113981). A meta-analysis of 7 clinical trials and an additional small clinical study do not indicate that taking milk thistle reduces malondialdehyde (MDA) levels, though 2 other meta-analyses of up to 9 clinical trials show that taking milk thistle does reduce MDA levels. Additionally, meta-analyses of up to 5 clinical trials show no effect of milk thistle on serum total antioxidant capacity (113977, 113981, 114913). There was significant heterogeneity in all analyses, which may be explained by variations in the studies that were pooled, including differences in the health conditions, doses of milk thistle, and durations of treatment evaluated.\nAntiviral effects\nIn cellular and human research, silibinin has been shown to reduce levels of hepatitis C viral (HCV)-RNA, inhibit the production of progeny HCV particles, and dose-dependently inhibit the fusion of HCV pseudoparticles and fluorescent liposomes (63225, 63233, 63236).\nDermatologic effects\nThere is interest in using milk thistle or silymarin for radiation induced mucositis. Mucositis is caused secondary to DNA damage from production of free radicals. This increases levels of proinflammatory cytokines, leading to tissue damage. Bacterial colonization then occurs, which leads to further damage and production of more inflammatory cytokines. Silymarin acts as an antioxidant, anti-inflammatory via inhibition of leukotrienes and prostaglandin formation, and immunomodulatory via increases in lymphocytes and suppression of T-cell activation (95021).\n\nThere is interest in using milk thistle for chemotherapy-induced acral erythema (also known as hand-foot syndrome). This condition may be caused by a direct toxic effect of chemotherapeutic agents. It is possible that toxic metabolites of chemotherapeutic agents build up in the stratum corneum of the palms and soles. With increased pressure and temperature in these areas, inflammation occurs leading to oxidative damage and production of free radicals. Silymarin acts as an antioxidant, anti-inflammatory, and immunomodulator via suppression of T-cell activation and increasing lymphocyte proliferation. When applied topically, silymarin is thought to protect the cell membrane from damage and block the uptake of toxins (95022).\nDrug metabolizing enzyme effects\nIn laboratory and animal research, silymarin and its flavonolignan, silibinin, inhibit cytochrome P450 2C9 (CYP2C9) and cytochrome P450 3A4 (CYP3A4), the major phase 1 hepatic enzymes (17101). However, milk thistle or silymarin does not seem to affect the metabolism of indinavir (Crixivan) or midazolam, CYP3A4 substrates, in healthy volunteers (10427, 14420, 95026). Milk thistle also does not seem to affect the metabolism of tolbutamide, a CYP2C9 substrate, in healthy volunteers (95026). This suggests that milk thistle is not a significant inhibitor of CYP3A4 or CYP2C9. Other research in healthy volunteers also suggests that milk thistle does not affect CYP1A2, CYP2D6, CYP2E1, CYP3A4, or CYP3A5 (13712, 95026).\n\nLaboratory research suggests that silymarin and silibinin also inhibit uridine diphosphoglucuronosyl transferase (UGT), the major phase 2 enzyme that is responsible for glucuronidation (6450, 7089, 7318). They also inhibit the organic anion transporting polypeptide 1B1 (OATP1B1), which transports drugs such as the HMG-CoA reductase inhibitors (\"statins\") into the liver (16408). Silibinin and silymarin also inhibit breast cancer resistance protein (BCRP) which transports statins from the liver into the bile (16408). In laboratory and animal research, silibinin also inhibits P-glycoprotein which promotes efflux of drugs into the intestine for excretion (17101, 95019).\nGastrointestinal effects\nThere is interest in using milk thistle or silymarin for ulcerative colitis (UC). UC involves an inflammatory process that is provoked by certain immune elements, microbes, and oxidative stress (95029). Silymarin possesses antioxidant properties and reduces inflammatory cytokines. Animal research suggests that treatment with silibinin, the major component of silymarin, and ursodeoxycholic acid inhibits nuclear factor (NF) kappa beta and is associated with a reduction in colitis.\nHepatoprotective effects\nAntioxidant and free radical-scavenging actions of milk thistle constituents such as silymarin and silybin are thought to be important mechanisms for their hepatoprotective effects (63153, 63204, 63264, 63272, 63282, 63289, 63331, 95024). Silymarin prevents hepatotoxicity of microcystin-LR (a toxin from the alga Microcystis aeruginosa) in rats and mice, possibly by preventing oxidation of protein-thiol groups (63207). In humans, superoxide dismutase levels in erythrocytes and lymphocytes are raised in the presence of silymarin (63262). Silymarin seems to alter outer hepatocyte cell membranes, stabilizing them and inhibiting binding and penetration of toxins such as alpha-amanitin from Amanita mushrooms (6879, 63303). It is this stabilization that may also lead to a reduction of gamma-glutamyl transferase levels (96261). Silibinin can ameliorate alpha-amanitin-induced increases in lipid peroxidation (63222). In rats, silymarin protects the liver from D-galactosamine-induced toxicity by activating enzymes in the UDP-glucuronic acid biosynthesis pathways, which detoxify phenols and other substances (63279). Silymarin, silibinin and silybin stimulate DNA polymerase in hepatocytes, increasing ribosomal RNA and protein synthesis, which can stimulate liver cell regeneration (6879, 63253, 63258, 63336). Silymarin and silibinin inhibit beta-glucuronidase, which is thought to reduce the hydrolysis of glucuronides into toxic metabolites in the liver and intestine (7354).\n\nA meta-analysis of 34 clinical trials shows that taking milk thistle reduces aspartate aminotransferase levels by 6.5 IU/L, alanine transaminase by 9.7 IU/L, and alkaline phosphatase by 15.4 IU/L when compared with control. However, there was no effect overall on gamma-glutamyl transferase or total bilirubin (113977). There was significant heterogeneity in all analyses, which may be explained by variations in the studies that were pooled, including differences in the health conditions, doses of milk thistle, and durations of treatment evaluated.\nNeuronal/CNS effects\nMilk thistle enhances nerve growth factor (NGF)-induced neurite outgrowth in PC-12 neural cells and prolongs their survival in culture (63159). There is also evidence that milk thistle extract protects cultured rat hippocampal neurons against oxidative stress-induced cell death (63223).\nPsychiatric effects\nThere is interest in using milk thistle or silymarin to treat obsessive compulsive disorder (OCD). The purported mechanisms behind its efficacy are three-fold. First, oxidative stress implicated in neurodegenerative disorders, including OCD, is thought to be ameliorated by silymarin, which possesses antioxidant effects and inhibits the formation of free radicals. Second, the disturbance of dopamine transmission associated with OCD may be prevented by silymarin, which appears to attenuate the loss of dopamine in the brain and improves deficits associated with dopaminergic hypofunction. Manipulation of dopamine may help to control behavior seen in OCD. Last, silymarin may inhibit monoamine oxidase (MAO) activity which leads to increased levels of dopamine in the brain, and improve executive function (95023). In clinical research, supplementation with milk thistle 150 mg to 300 mg twice daily for 8 weeks up to 4 months has led to symptomatic improvements in patients with trichotillomania (recurrent hair pulling), OCD related to contamination and washing obsessions, and nail biting (95023).\nRenal protective effects\nSeveral animal studies suggest that silymarin, silibinin, and silychristin can protect kidney cells from nephrotoxic drugs such as cyclosporine, cisplatin and ifosfamide (7320, 63290, 63295, 63308, 114919). Mechanisms may include prevention of lipid peroxidation (63308) and a regenerative effect on kidney cells, which is similar to the effects on hepatic cells (7320).\n\nAlternatively, laboratory and animal research suggests that silymarin has the potential to increase the risk of cisplatin-induced nephrotoxicity via inhibition of multi-drug and toxin extrusion protein 1 (MATE1) which may decrease the renal excretion of cisplatin and increase its accumulation in the kidney (114919).\n\nIn clinical research, silymarin has not been more effective than placebo in preventing acute kidney injury secondary to cisplatin (95025). However, in other clinical research in patients taking vancomycin, silymarin reduced the risk of acute kidney injury (114909).\n\nA meta-analysis of 7 clinical trials shows that taking milk thistle reduces serum creatinine levels by 0.04 mg/dL but does not affect blood urea nitrogen levels when compared with placebo or control (113977). There was significant heterogeneity in all analyses, which may be explained by variations in the studies that were pooled, including differences in the health conditions, doses of milk thistle, and durations of treatment evaluated."
        }
    },
    "Miracle Fruit": {
        "sections": {
            "Overview": "Miracle fruit is an evergreen shrub that is native to West Africa. The berry is used as a culinary and medicinal ingredient. The seed oil and leaf have also been used medicinally (15654, 102330).\n\nKEY HIGHLIGHTS\nMost commonly used for diabetes, chemotherapy-related taste disturbances, and other conditions, but there is no strong evidence to support any use.\nInsufficient reliable information available about the safety or possible side effects.\nNo known major interactions.",
            "Safety": "There is insufficient reliable information available about the safety of miracle fruit. The European Food Safety Authority (EFSA) has determined that the acceptable intake of the pitted and dried pulp and skin of miracle fruit is 10 mg/kg daily, or 0.7 grams daily for adults (106574).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted. Potential for cross-allergenicity exists (106574).\nImmunologic\nCross-allergenicity with miracle fruit exists with peanut allergens and might also exist with latex, peach, and soy allergens (106574).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of miracle fruit.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThe lyophilized pulp and skin of pitted miracle fruit contains the glycoprotein miraculin in amounts up to 2.5% (w/w) (106574).",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, miracle fruit leaf might have an additive effect with antidiabetes drugs and increase the risk of hypoglycemia. Evidence from an animal model shows that miracle fruit leaf increases insulin production and lowers fasting blood glucose and HbA1c in rats with streptozotocin-induced diabetes (102330). Some antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nMiracle fruit leaf might increase insulin production and lower fasting blood glucose and HbA1c (102330). Theoretically, concomitant use might have additive effects when used with other herbs and supplements with hypoglycemic potential. These include devil's claw, fenugreek, guar gum, Panax ginseng, Siberian ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCROSS-ALLERGENCITY\nMiracle fruit contains the glycoprotein miraculin. Glycoproteins are often allergenic. Preliminary research suggests that cross-allergenicity exists with peanut allergens and might also exist with latex, peach, and soy allergens (106574).\nless\nDIABETES\nMiracle fruit leaf might increase insulin production and lower fasting blood glucose and HbA1c (102330). Theoretically, miracle fruit leaf might increase the risk of hypoglycemia in patients with diabetes. Advise patients to closely monitor glucose levels. Dose adjustments to diabetes medications may be necessary.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of miracle fruit.",
            "Pharmacokinetics": "Metabolism\nIn vitro, the constituent miraculin is degraded by pepsin and trypsin (106574).",
            "Mechanism of Action": "General\nThe applicable parts of miracle fruit are the berry, seed oil, and leaf (98005, 102330). The lipid fraction of the seed oil contains polyphenols, triterpenes, phytosterols, and linoleic acid (98005). The leaf is rich in flavonoids (102330). An ethanolic extract of miracle fruit contains greater flavonoid and tannin content, but similar phenolic content, when compared with an aqueous extract (106573).\nAntidiabetes effects\nThe leaves of the miracle fruit plant are traditionally used for diabetes. In one animal diabetic model, an extract of the miracle fruit leaves reduced levels of fasting blood glucose and glycated hemoglobin (102330). However, in a mouse model of diabetes, high doses of an ethanolic extract of miracle fruit produced only modest reductions in blood glucose (106573). Potential mechanisms of action include an increase in insulin synthesis, a reduction of inflammatory cytokines as shown in the animal model, and/or the inhibition of the carbohydrate metabolizing enzymes alpha-amylase or alpha-glucosidase as shown in vitro (102330).\nAntioxidant effects\nIn vitro, an ethanolic extract of miracle fruit has greater antioxidant activity when compared with an aqueous extract, with quercetin being the most abundant antioxidant (106573).\nCardiovascular effects\nIn a mouse model of diabetes, high doses of an ethanolic extract of miracle fruit reduce total cholesterol levels when compared with control (106573). In hamsters receiving a high cholesterol diet, aqueous and ethanolic extracts of miracle fruit leaf and seed, but not pulp, reduce levels of total cholesterol, triglycerides, and non-high-density lipoprotein (non-HDL) cholesterol. An ethanolic extract of miracle fruit seed had the most potent effect, which may be related in part to two major triterpenoids, lupeol acetate and beta-amyrin acetate (106572).\nMusculoskeletal effects\nThere is interest in using miracle fruit to improve motor function. One small clinical study in healthy volunteers shows that applying a wrist band containing miracle fruit seed oil for 3-8 hours per day for 4-6 weeks improves hand motor skills more than a placebo wrist band (98005). The mechanism of this effect is unclear.\nTaste effects\nMiracle fruit appears to act directly on the tongue to block sour taste receptor sites and convert sour tastes into sweet (15651, 15653). Miracle fruit contains a glycoprotein called miraculin that is responsible for its ability to alter taste perception (15652). Miraculin itself has no taste; it produces a sweet taste only when in contact with an acidic solution. The effect of miraculin on taste buds subsides after about 30 minutes (15652).\nWeight loss effects\nIn a mouse model of diabetes, high doses of an ethanolic extract of miracle fruit attenuate diabetes-induced increases in weight (106573)."
        }
    },
    "Molybdenum": {
        "sections": {
            "Overview": "Molybdenum is a transition metal that most organisms require for life (63399). In the human body, molybdenum is considered an essential trace element (2663, 16478, 61497, 63460). The estimated dietary intake of molybdenum in adults in the US is 120-210 mcg/day (16483, 16484).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Molybdenum is safe in amounts that do not exceed 2 mg/day, the Tolerable Upper Intake Level (UL) (7135).\nPOSSIBLY UNSAFE when used orally in high doses. Use of molybdenum in doses exceeding the Tolerable Upper Intake Level (UL) of 2 mg/day might not be safe (7135).\nCHILDREN: LIKELY SAFE when used orally and appropriately. Molybdenum is safe in amounts that do not exceed the Tolerable Upper Intake Level (UL) of 0.3 mg/day for children 1 to 3 years, 0.6 mg/day for children 4 to 8 years, 1.1 mg/day for children 9 to 13 years, and 1.7 mg/day for adolescents (7135).\nCHILDREN: POSSIBLY UNSAFE when used orally in high doses. Molybdenum might not be safe when used in doses exceeding the UL of 0.3 mg/day for children 1 to 3 years, 0.6 mg/day for children 4 to 8 years, 1.1 mg/day for children 9 to 13 years, and 1.7 mg/day for adolescents (7135).\nPREGNANCY: LIKELY SAFE when used orally and appropriately. Molybdenum crosses the placenta by passive diffusion and is exchanged freely between the mother and fetus (16482). However, molybdenum is safe when used in amounts that do not exceed the Tolerable Upper Intake Level (UL) of 1.7 mg/day for women 14 to 18 years, or 2 mg/day for women 19 years of age and older (7135).\nPREGNANCY: POSSIBLY UNSAFE when used orally in high doses. Molybdenum might not be safe during pregnancy when used in doses exceeding the UL of 1.7 mg/day for women 14 to 18 years, or 2 mg/day for women 19 and older (7135).\nLACTATION: LIKELY SAFE when used orally and appropriately. Molybdenum is safe when used in amounts that do not exceed the Tolerable Upper Intake Level (UL) of 2 mg/day for breast-feeding women 19 years of age or older, or 1.7 mg/day for breast-feeding women ages 14 to 18 years (7135).\nLACTATION: POSSIBLY UNSAFE when used orally in high doses. Molybdenum might not be safe when used in doses exceeding the UL of 2 mg/day for breast-feeding women 19 or older, or 1.7 mg/day for breast-feeding women ages 14 to 18 years (7135).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, molybdenum is generally well tolerated when used appropriately in amounts that do not exceed the Tolerable Upper Intake Level (UL) of 2 mg/day (7135).\nGenitourinary\nEnvironmental exposure to molybdenum has been reported to be a reproductive toxicant in men. Circulating levels of molybdenum are inversely associated with testosterone levels and sperm concentration (63482, 63484).\nless\nHematologic\nOrally, in an area of Armenia, a very high dietary molybdenum intake of 10 to 15 mg/day due to high local soil levels has resulted in an increased incidence of hyperuricemia (7135, 16478, 16487). The mechanism likely involves increased xanthine oxidase activity, leading to increased uric acid production (2663).\nless\nImmunologic\nMolybdenum is present in some stainless steel angioplasty stents. Multiple cases report on patients with these stents who have developed a contact allergy to molybdenum, as indicated by positive skin patch tests. It is suggested that this increases the risk for restenosis of the stented artery (16485).\nless\nMusculoskeletal\nOrally, in an area of Armenia, a very high dietary molybdenum intake of 10 to 15 mg/day due to high local soil levels has resulted in an increased incidence of hyperuricemia, gout, and arthralgias (7135, 16478, 16487). There is also a case report of gout in a man with industrial exposure to molybdenum metal dust (16480). The mechanism likely involves increased xanthine oxidase activity, leading to increased uric acid production (2663).\nless\nNeurologic/CNS\nIn one case report of a man in his late thirties, dietary supplementation with molybdenum 300-800 micrograms daily for a cumulative dose of 13.5 mg over 18 days resulted in acute psychosis with visual and auditory hallucinations, petit mal seizures, and a life-threatening grand mal attack, related to frontal cortical damage. Chelation therapy with calcium ethylene diamine tetraacetic acid (CaEDTA) was required. A year later, the man was diagnosed with toxic encephalopathy with executive deficiencies, learning disability, major depression, and post-traumatic stress disorder (63368).\nless\nPsychiatric\nIn one case report of a man in his late thirties, dietary supplementation with molybdenum 300-800 micrograms daily for a cumulative dose of 13.5 mg over 18 days resulted in acute psychosis with visual and auditory hallucinations, petit mal seizures, and a life-threatening grand mal attack, related to frontal cortical damage. Chelation therapy with calcium ethylene diamine tetraacetic acid (CaEDTA) was required. A year later, the man was diagnosed with toxic encephalopathy with executive deficiencies, learning disability, major depression, and post-traumatic stress disorder (63368).\nless\nPulmonary/Respiratory\nPneumoconiosis has been reported with excessive intake of molybdenum or exposure in the workplace (63365, 63547, 63510).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIKELY EFFECTIVE\nMolybdenum deficiency. Oral molybdenum is beneficial for the prevention and treatment of molybdenum deficiency.\nTaking or consuming molybdenum can treat or prevent molybdenum deficiency (7135, 16478). However, molybdenum deficiency is very rare.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. Although there has been interest in using oral molybdenum for acne, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nAsthma. Although there has been interest in using oral molybdenum for asthma, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nAtopic dermatitis (eczema). Although there has been interest in using oral molybdenum for atopic dermatitis, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nCancer. Although there has been interest in using oral molybdenum for cancer, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nDental caries. Although there has been interest in using oral molybdenum for dental caries, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nEsophageal cancer. It is unclear if oral molybdenum is effective for the prevention of esophageal cancer.\nObservational studies suggest that low intake of molybdenum might be associated with an increased risk of esophageal cancer (16478, 17205). However, it is not known if molybdenum supplements reduce the risk of developing esophageal cancer.\nless\nHIV/AIDS. Although there has been interest in using oral molybdenum for HIV/AIDS, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nIron deficiency anemia. Although there has been interest in using oral molybdenum for iron deficiency anemia, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nLiver disease. Although there has been interest in using oral molybdenum for liver disease, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nMultiple sclerosis (MS). Although there has been interest in using oral molybdenum for MS, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nOsteoporosis. Although there has been interest in using oral molybdenum for osteoporosis, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nSexual desire. Although there has been interest in using oral molybdenum for increasing sexual desire, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nVaginal candidiasis. Although there has been interest in using oral molybdenum for vaginal candidiasis, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nWilson disease. Although there has been interest in using oral molybdenum for Wilson disease, there is insufficient reliable information about the clinical effects of molybdenum for this purpose.\nMore information is needed to rate molybdenum for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nThe National Institute of Medicine has determined the Recommended Dietary Allowance (RDA) of molybdenum. For individuals aged 19 years and older, the RDA is 45 mcg/day. For pregnant or lactating patients of all ages, the RDA is 50 mcg/day (7135). The estimated dietary intake of molybdenum in adults in the US is 120-210 mcg/day (16483, 16484). Tolerable Upper Intake Levels (UL) for molybdenum are 2 mg/day (7135).\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\n\nThe National Institute of Medicine has determined Adequate Intakes (AI) of molybdenum for infants: 0 to 6 months, 2 mcg/day; 7 to 12 months, 3 mcg/day (7135). The Recommended Dietary Allowance (RDA) for children: 1 to 3 years, 17 mcg/day; 4 to 8 years, 22 mcg/day; 9 to 13 years, 34 mcg/day; 14 to 18 years, 43 mcg/day. For pregnant or lactating women 14-18 years of age, the RDA is 50 mcg/day (7135). Tolerable Upper Intake Levels (UL) for molybdenum are: children 1 to 3 years, 0.3 mg/day; 4 to 8 years, 0.6 mg/day; 9 to 13 years, 1.1 mg/day; 14 to 18 years 1.7 mg/day (7135).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of molybdenum.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "COPPER\nMolybdenum can form poorly absorbed compounds with copper in the gut.\nTaking molybdenum with copper might decrease the absorption of both minerals. The compounds formed include copper molybdate and copper thiomolybdate (16486, 16487). Copper deficiency due to excessive molybdenum intake is unlikely to occur in most people because copper intake usually exceeds that of molybdenum. However, people with low copper intakes or dysfunction of copper metabolism may be at increased risk (16487).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCOPPER DEFICIENCY\nTheoretically, molybdenum might exacerbate copper deficiency. Until more is known, use with caution. Molybdenum can form poorly absorbed compounds with copper in the gut, decreasing absorption of both minerals (16486, 16487). Copper deficiency due to excessive molybdenum intake is unlikely to occur in most people because copper intake usually exceeds that of molybdenum. However, people with low copper intakes or dysfunction of copper metabolism may be at increased risk (7135, 16487).\nless\nGOUT\nTheoretically, taking molybdenum above the recommended Tolerable Upper Intake Level (UL) might exacerbate hyperuricemia and gout. Until more is known, use with caution. High dietary intake of molybdenum at levels of 10 to 15 mg daily, and industrial exposure to molybdenum dust, have been associated with an increased incidence of gout (7135, 16478, 16487).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with molybdenum.",
            "Pharmacokinetics": "Absorption\nMolybdenum is readily absorbed from the gastrointestinal tract by a passive process (7135, 16488). Between 28% and 93% of molybdenum present in food is absorbed (16487, 16489). Peak plasma levels occur about an hour after meals (7135, 16487). Blood levels of molybdenum reflect dietary intake (16483). For people in the United States, blood levels are typically in the range of 0.3 ng/mL to 5 ng/mL, but in some areas of the world with high soil and plant food levels of molybdenum, blood levels of 170 ng/mL have been reported (16478, 16483).\nDistribution\nMolybdenum is stored in several organs, particularly the liver, kidneys, adrenal glands and bones. It is also found in the lungs, spleen, skin, and muscles (2663, 16478, 16487). The amount stored increases with dietary intake, although overall retention of dietary molybdenum is low (16478). Turnover from tissues such as the kidneys and spleen is rapid, with an estimated residence time of 3 days or less. Turnover is slower in the liver, bones, and adrenal glands, with a residence time of 63-237 days (16488). Molybdenum is also present in breast milk in variable amounts. In one study, levels ranged from undetectable to 8.4 mcg/L, while in another they decreased with time post-partum: 15 mcg/L on the first post-partum day, 4.8 mcg/L at days 7-10, 2.6 mcg/L by 1 month, and 1.4 mcg/L by 2 months. These levels are lower than those found in infant formula and cow's milk (7135, 16481, 16486).\nMetabolism\nMolybdenum forms compounds with copper in the gut, including copper molybdate and copper thiomolybdate, using sulfides generated from sulfates by bacteria in the gut (16486, 16487).\nExcretion\nHomeostatic regulation of molybdenum levels is primarily under renal control, with about 90% of ingested molybdenum being excreted in the urine within a few hours (2663, 7135, 16478). Urinary levels increase with increased dietary intake (63567).",
            "Mechanism of Action": "General\nMolybdenum is an essential trace mineral. Dietary sources include milk, cheese, cereal grains, legumes, nuts, leafy vegetables, and organ meats (2663, 16478, 16484). In plants, molybdenum is important in the process of fixing atmospheric nitrogen at the start of protein synthesis (16487). The molybdenum content of plant-derived foods varies considerably depending on the soil content in the growing area (7135). There is also considerable variation in the molybdenum content of water. One study of mineral waters reported a range of 0.22 mcg/L to 21.95 mcg/L (16486). For people in the United States, blood levels are typically in the range of 0.3 ng/mL to 5 ng/mL, but in some areas of the world with high soil and plant food levels of molybdenum, blood levels of 170 ng/mL have been reported (16478, 16483).\n\nMolybdenum can exist in several oxidation states, but is most stable in its hexavalent form (2663, 16478). A complex of molybdenum and an organic moiety called molybdopterin forms a cofactor for the enzymes sulfite oxidase, which converts sulfites to sulfates; xanthine oxidase, which converts purines to uric acid; and aldehyde oxidase, which oxidizes pyrimidines, purines, and pteridines (2663, 7135, 16478, 16480). In these oxidation reactions, molybdenum is converted between oxidation states, facilitating electron transfers (2663, 16478).\nAntitumor effects\nMolybdenum is thought to be useful for cancer prevention. In animal research, molybdenum supplementation reduced the incidence of chemically-induced mammary, esophageal, and forestomach tumors (63533, 63563).\nCopper antagonism effects\nMolybdenum can form poorly absorbed compounds with copper in the gut, inhibiting absorption of both minerals. The compounds formed include copper molybdate and copper thiomolybdate, using sulfides generated from sulfates by bacteria in the gut (16486, 16487). A molybdenum compound, tetrathiomolybdate, has been used for complexing excess copper in the treatment of Wilson disease (16492, 63365, 63579). Molybdenum may also inhibit absorption of iron, possibly by competition for intestinal brush-border receptors (16487).\nMolybdenum homeostasis\nMolybdenum deficiency is very rare, but has occurred in a patient maintained on long-term total parenteral nutrition (TPN) without molybdenum. He presented with amino acid intolerance, and high sulfite and low sulfate levels in the urine, indicating diminished sulfite oxidase activity; and high xanthine and low uric acid levels in the urine, indicating diminished xanthine oxidase activity. Symptoms included headache, tachycardia, and mental disturbances. The level of abnormal metabolites in the urine was significantly reduced by addition of molybdenum 300 mcg/day to the TPN (7135, 16478). Preliminary data from animals, and observations in human populations with a low molybdenum intake, suggest a link between molybdenum deficiency and esophageal cancer. Further data is needed, but a suggested mechanism is intracellular accumulation of mutagenic sulfites (16478). A rare autosomal recessive disorder resulting in deficiency of the molybdenum cofactor has been described, which results in severe neuronal damage, progressive cerebral degeneration, and seizures, and is usually fatal in infancy (7135, 16478, 16479). Lack of sulfite oxidase appears to be the primary defect, causing accumulation of toxic sulfites and possibly a lack of sulfates for cells in the central nervous system to form sulfolipids and sulfoproteins (7135, 16478).\n\nElevated umbilical cord levels of molybdenum have been observed in mothers with gestational diabetes, but the significance of this is unknown (16482). People on long-term dialysis have elevated serum molybdenum levels. Free molybdenum in the plasma is removed by hemodialysis, but molybdenum bound to proteins is not, leading to accumulation (16490, 16491). The clinical significance of this is unclear."
        }
    },
    "Moneywort": {
        "sections": {
            "Overview": "Moneywort is a perennial plant that is indigenous to Europe. It has been introduced into America and Japan. The whole flowering plant is used in medicine (18).\n\nKEY HIGHLIGHTS\nTraditionally used for diarrhea, atopic dermatitis (eczema), as an expectorant, and for other conditions, but there is no strong evidence to support any use.\nThere is insufficient reliable information available about the safety of oral or topical use.\nNo known major interactions.",
            "Safety": "There is insufficient reliable information available about the safety of moneywort.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of moneywort.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: One cup of tea is typically taken 2-3 times daily with honey. The tea is prepared by steeping 2 heaping teaspoons of dried herb in 250 mL of boiling water for 5 minutes and straining (18).\nTopical:\nNo typical dosage.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of moneywort.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of moneywort.",
            "Mechanism of Action": "There is insufficient reliable information available about the possible mechanism of action or active ingredients."
        }
    },
    "Monolaurin": {
        "sections": {
            "Overview": "Monolaurin, a fatty acid ester, is the monoglyceride derivative of lauric acid. It occurs naturally in the blood as a product of lipid metabolism, and is also found in coconut oil and in human milk (14115, 103601). It is used commercially as a surfactant (14110).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Monolaurin has Generally Recognized as Safe (GRAS) status in the US (7705).\n\nThere is insufficient reliable information available about the safety of monolaurin when used orally or topically in medicinal amounts.\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in amounts commonly found in foods (7705). There is insufficient reliable information available about the safety of monolaurin when used in medicinal amounts during pregnancy or lactation.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "Bacterial vaginosis. Preliminary clinical research shows that applying a monolaurin 5% gel to the vagina twice daily for 3 days in premenopausal women does not improve clinical cure rates when compared with a placebo gel (103602).",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of monolaurin.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of monolaurin.",
            "Pharmacokinetics": "Absorption\nTopical application of monolaurin results in systemic absorption in preterm infants (mean gestational age 28 weeks). Applying coconut oil containing 280 mcg/mL monolaurin twice daily for 2 weeks increases plasma levels from the natural level of around 50 ng/mL up to levels of 100 to 200 ng/mL (103601).",
            "Mechanism of Action": "General\nMonolaurin is a product of lipid metabolism found naturally in the plasma. It is a fatty acid ester and monoglyceride derivative of lauric acid. It is also found in coconut oil and human milk (14115, 103601).\nAntimicrobial activity\nPreliminary research shows that monolaurin inhibits the growth of gram-positive organisms, including Staphylococcus aureus and Staphylococcus epidermidis (14112, 14113, 103601). Monolaurin strongly inhibits the production of gram-positive exotoxins at concentrations lower than those required to inhibit bacterial growth. Specifically, it inhibits toxic shock syndrome toxin-1 and staphylococcus enterotoxins by blocking bacterial membrane-associated signal transduction (14112, 14113). Other preliminary research shows that monolaurin inhibits induction of vancomycin resistance by the same mechanism (14111). However, other preliminary research shows that bacterial lipase can inactivate monolaurin (14114).\n\nIn vitro, monolaurin has demonstrated antiviral activity against rhinoviruses and cytomegalovirus (14115). It has also demonstrated antifungal activity against Candida albicans in vitro (103601).\nImmunologic effects\nPreliminary research shows that monolaurin increases T-cell proliferation by affecting the cell signaling cascade, suggesting immune system stimulation (14110)."
        }
    },
    "Monterey Pine": {
        "sections": {
            "Overview": "Monterey pine is a tree native to coastal California and Mexico that is now grown throughout the world. It is commonly cultivated for timber (63616, 63617). Monterey pine has traditionally been used as a medicine for various conditions.",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. A specific product containing Monterey pine bark extract (Enzogenol, ENZO Nutraceuticals) has been used with apparent safety at a dose of 1000 mg daily for up to 12 weeks (63614, 63618, 63620, 105777) or 480 mg daily for up to 6 months (105778).\nThere is insufficient reliable information available about the safety of Monterey pine when used topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Monterey pine seems to be well tolerated. Topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\nDermatologic\nContact dermatitis from Monterey pine sawdust has been reported (63615).\nless\nImmunologic\nMonterey pine pollen may cause seasonal rhinoconjunctivitis (63612).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCardiovascular disease (CVD). Although there has been interest in using oral Monterey pine for preventing CVD, there is insufficient reliable information about the clinical effects of Monterey pine for this condition.\nCognitive function. It is unclear if oral Monterey pine bark extract improves cognition.\nPreliminary clinical research shows that taking vitamin C 120 mg daily along with a specific product containing Monterey pine bark extract (Enzogenol, ENZO Nutraceuticals) 960 mg daily for 5 weeks improves response speed related to working memory tasks and immediate recognition tasks in middle-aged and elderly males when compared with baseline. Improvements in memory do not appear to occur with vitamin C alone (63620).\nless\nMigraine headache. Although there has been interest in using oral Monterey pine for preventing migraine headache, there is insufficient reliable information about the clinical effects of Monterey pine for this condition.\nNeurological trauma. It is unclear if oral Monterey pine bark extract is beneficial in patients with neurological trauma.\nA small clinical study in patients 3-12 months post-traumatic brain injury shows that taking a specific Monterey pine bark extract (Enzogenol, ENZO Nutraceuticals) 1000 mg daily for 12 weeks improves cognitive function scores when compared with placebo. However, measures of working memory, episodic memory, anxiety, and depression were not improved (105777). Another small clinical study in college students suffering from chronic concussion symptoms shows that taking a specific Monterey pine bark extract (Enzogenol, ENZO Nutraceuticals) 1000 mg daily for 6 weeks improves mental fatigue when compared with placebo (105779).\nless\nMore evidence is needed to rate Monterey pine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMonterey pine bark extract (Enzogenol, ENZO Nutraceuticals) has most often been used at a dose of up to 1000 mg daily for up to 12 weeks. Research on other Monterey pine products is limited. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nA specific Monterey pine bark extract (Enzogenol, ENZO Nutraceuticals), consisting of more than 80% proanthocyanidins and 1% to 2% taxifolin, along with other flavonoids and phenolic acids, has been studied in clinical research (63620, 105776, 105777, 105778, 105779).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Monterey pine.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Monterey pine.",
            "Mechanism of Action": "General\nThe applicable part of Monterey pine is the bark (63618, 63620). Constituents of Monterey pine bark include monomeric and oligomeric proanthocyanidins, flavonoids, flavonoid glycosides, flavonols, catechin, epicatechin, epigallocatechin, flavanones, taxifolin, quercetin, myricetin, dihydroquercetin, astringenen, trans-caffeic acid, trans-ferulic acid, trans-4-hydroxycinnamic acid, ferulic acid, 4-hydroxybenzoic acid, vanillic acid, glucopyranosiduronic acid, glucopyranoside, esters, and natural organic acids (63622, 63619, 105778).\nCardiovascular effects\nThere is interest in using Monterey pine extract to prevent cardiovascular disease (CVD). A high dietary intake of flavonoids (such as those found in Monterey pine) has been shown to exhibit a protective effect against CVD in humans (7716, 42212). In human research, Monterey pine bark extract and vitamin C resulted in a reduction in plasma levels of the inflammatory marker fibrinogen in heavy smokers when compared with vitamin C alone. However, no change was observed in light smokers (63618). In addition, antioxidant effects of Monterey pine bark extract have been shown in human studies and in vitro (63618, 63621, 63622, 63623). However, in human research, any benefit of Monterey pine bark extract on CVD risk factors is unclear (63614, 63618, 63620).\nCognitive effects\nIn human research, Monterey pine bark extract and vitamin C possibly improve cognitive function (63620). The mechanism of action is unclear. However, flavonoids (such as those found in Monterey pine ) have been shown to exhibit very high antioxidant activities and exert neuroprotective effects in vitro and in animal models (1419, 4639, 63613).\nHypoglycemic effects\nA small clinical study in healthy adults shows that taking a single 50 mg or 400 mg dose of a specific Monterey pine bark extract (Enzogenol, ENZO Nutraceuticals) 20 minutes before an oral glucose tolerance test reduces postprandial glucose when compared with placebo (105776)."
        }
    },
    "Moringa": {
        "sections": {
            "Overview": "Moringa is native to India, Pakistan, Bangladesh, and Afghanistan, and is now widely cultivated in the tropics (16344, 63728). The leaves retain a high vitamin and mineral content when dried, so moringa is sometimes cooked and used to combat malnutrition. Edible parts of moringa include the mature seeds, immature seed pods, seed oil, and leaves. Moringa seed oil is also used in cosmetics. The seed cake after oil extraction is used to fertilize soil, purify well water, and desalinate sea water (16341). Moringa has traditionally been used as an antiseptic and astringent and has been applied to the skin for various skin conditions.",
            "Safety": "LIKELY SAFE when used orally in food amounts. The leaves, fruit, and seeds are commonly used in foods (16341, 16344, 90573).\nPOSSIBLY SAFE when moringa leaf or seed is used orally and appropriately in medicinal amounts, short-term. Tablets and capsules containing up to 30 grams of moringa leaf powder have been used daily with apparent safety in clinical studies lasting up to 6 months (20578, 90572, 90572, 97209, 97210). A dried moringa seed kernel powder has also been used with apparent safety in doses of 3 grams twice daily for 3 weeks (19278). ...when moringa leaf extract is used topically and appropriately. Moringa leaf extract 2% has been used 3 times daily with apparent safety in a clinical trial lasting 3 months (112640).\nPOSSIBLY UNSAFE when moringa root or root bark are used orally. Moringa root contains spirochin, a potentially toxic alkaloid, while moringa root bark contains stimulant alkaloids similar to ephedrine. Although spirochin has not been studied in humans, animal data shows that it can cause nerve paralysis (63764).\nCHILDREN: POSSIBLY SAFE when moringa leaf is used orally and appropriately, short-term. Powdered dried moringa leaf has been used with apparent safety in doses of 15 grams twice daily for up to 2 months (90576).\nPREGNANCY: POSSIBLY SAFE when the leaf is used orally during the second or third trimesters, short-term. Moringa leaf powder or extract 500 mg daily for up to 4 months has been used with apparent safety during the second and third trimesters (105469, 105471, 105472, 110645). There is insufficient reliable information available about the safety of using moringa leaf by mouth during the first trimester.\nPREGNANCY: POSSIBLY UNSAFE when the root, bark, or flower are used orally. Traditionally, moringa root bark and gum from moringa trunk bark have been used to induce abortion. When taken orally along with black peppercorns to induce abortion, moringa root bark may cause fatality (63764). Animal research shows that moringa flower can cause uterine contractions (94634); however, this has not been assessed in humans.\nPREGNANCY: There is insufficient reliable information about the safety of using moringa seed during pregnancy; avoid using.\nLACTATION: POSSIBLY SAFE when moringa leaf is used orally, short-term. Moringa leaf powder or extract 2 grams daily has been used during lactation with apparent safety for up to 4 months (20578, 90571, 90573, 105471, 105472). There is insufficient reliable information available about the safety of using other parts of moringa during lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, moringa leaf and seed seem to be well tolerated. Orally, moringa root and root bark might be unsafe. However, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally: Transient diarrhea.\nSerious Adverse Effects (Rare)\nOrally: Allergic reactions, including anaphylaxis, have been reported.\nCardiovascular\nOrally, a case of bilateral pulmonary embolism after a 5-month history of taking moringa leaf extract is reported in a 63-year-old female without other risks for venous thromboembolism. The patient recovered with standard anticoagulant treatment. Researchers speculate that possible procoagulant effects of moringa may have played a role in this event (110644).\nless\nDermatologic\nOrally, Stevens-Johnson syndrome has been linked to the consumption of moringa leaves. A 53-year-old male presented with fever and generalized maculopapular rash 14 hours after eating food containing moringa leaves. Painful oral ulcers developed by the next day. The patient also reported a similar episode of oral ulcers after eating food containing moringa leaves three months earlier. The patient was treated with oral prednisolone and omeprazole and recovered within two weeks. Researchers speculate that the immunomodulatory effects of moringa may have played a role in this reaction (99876). There are also cases of fixed food eruption to moringa. In one case, suspected fixed food eruption occurred on the trunk and face of a 60-year-old female, reoccurring 8 hours after self reintroduction (112641).\nless\nGastrointestinal\nOrally, moringa leaf powder can cause diarrhea. In a clinical trial, taking moringa leaf powder 8 grams daily resulted in transient diarrhea in 4 of 16 patients (25%) (105470).\nless\nImmunologic\nOrally, cases of anaphylaxis are reported after ingestion of young moringa leaves and seedpods. In these cases, positive skin-prick testing confirmed moringa as the causative allergen. The patients recovered after standard treatment (110597, 110643). There are also cases of fixed food eruption to moringa. In one case, suspected fixed food eruption occurred on the trunk and face of a 60-year-old female, reoccurring 8 hours after self reintroduction (112641).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. It is unclear if oral moringa seed is beneficial in patients with asthma.\nA small clinical study in patients with mild to moderate asthma shows that taking powdered dried moringa seed kernels 3 grams twice daily for 3 weeks reduces the severity of asthma symptoms, including dyspnea, wheezing, chest tightness, and cough, and improves lung function when compared to baseline (19278). The validity of this finding is limited by the lack of a control group.\nless\nAthletic performance. It is unclear if oral moringa leaf extract is beneficial for athletic performance.\nA small clinical study in young, generally healthy adults shows that taking moringa leaf extract 1044 mg daily for 30 days increases the number of push-ups, but does not improve other measures of physical performance such as the number of pull-ups, hand grip strength, or sprint time, when compared with placebo (115743). This study was small and likely underpowered to detect statistically significant differences.\nless\nChild growth. It is unclear if oral moringa, taken during the second or third trimester or while breastfeeding, can improve infant growth.\nAn observational follow-up of a large randomized clinical trial conducted in Indonesia during the second trimester or 1 month after giving birth shows that taking 500 mg moringa leaf powder or extract daily for 4 months does not reduce stunting in infants followed for up to 11 months when compared with an unspecified dose of iron and folate (105471, 105472). Other observational data, also from a large randomized clinical trial conducted in Indonesia, suggests the rate of stunted growth in children aged 36 to 42 months is 25% after taking 500 mg moringa leaf extract daily for 3 months during the third trimester, compared to 42% with 500 mg moringa leaf flour, or 33% with iron 60 mg and 0.2 mcg folic acid (110645). Researchers propose that differences in the nutritional content between moringa leaf extract and flour may account for the variation in results among forms.\nless\nDiabetes. It is unclear if oral moringa leaf is beneficial in patients with diabetes; research is conflicting.\nA small clinical study in therapy-nave patients with type 2 diabetes shows that taking 4 grams of moringa leaf powder twice daily for 4 weeks does not affect fasting blood glucose (FBG) or postprandial glucose (PPG) when compared with placebo (105470). These findings are limited by the small size and short duration of the study. A non-randomized clinical study in patients with type 2 diabetes who are taking a sulfonylurea shows that taking 2 tablets containing an unspecified amount of powdered moringa leaf in addition to following a calorie-restricted diet for 90 days does not reduce glycated hemoglobin (HbA1c) when compared with standard treatment, although it modestly reduces PPG when compared with baseline (90572). Another small non-randomized clinical study in patients with type 2 diabetes who are taking hypoglycemic agents shows that taking powdered moringa leaf 8 grams daily for 40 days in addition to following a calorie-restricted diet reduces FBG, PPG, and lipid levels when compared with baseline (97208). It is unclear if any benefit identified in these studies is due to moringa or calorie restriction. Additionally, the validity of these findings is limited by the lack of a statistical comparison to the control group.\nless\nHIV/AIDS. It is unclear if oral moringa leaf is beneficial in patients with HIV; research is conflicting.\nPreliminary clinical research in normal weight Congolese patients with HIV who are on antiretroviral therapy shows that taking dried moringa leaf powder 10 grams three times daily with meals for 6 months increases body mass index (BMI) by 2 kg/m2 when compared with a nutritional counseling only group. However, there was no difference in immune function as measured by CD4 counts (97210). Results of other research are in conflict. A large clinical study in Nigerian adults treated with standard antivirals for HIV shows that taking moringa leaf powder 5 grams three times daily with meals for 6 months modestly increases CD4 counts but does not impact viral load or anthropometric parameters (i.e., weight, BMI) when compared with placebo. However, most patients were normal or overweight, and over half had an undetectable viral load at baseline (110648). Secondary analysis of this data suggests taking moringa may also improve quality of life (110649). However, the validity of this finding is limited by the inability to mask the taste of moringa leaf powder; patients may have been biased by knowing their study group assignment. Similarly, a small open label clinical study also in Nigerian adults treated with antiviral therapy for HIV shows that taking a moringa 200 mg capsule daily (Formula 10 Herbal Products, Nigeria) for 3 months modestly increases CD4 counts, lymphocyte and platelet counts, and hemoglobin when compared with antiviral therapy alone (110650).\n\nMoringa leaf has also been evaluated in combination therapy. A single-center clinical study in Uganda in adults with HIV who are on antiretroviral therapy shows that taking moringa leaf power 10 grams in combination with Sweet Annie daily for 12 months modestly improves CD4 counts andviral load suppression when compared with placebo (116056). It is unclear if these benefits are due to moringa leaf, Sweet Annie, or the combination.\nless\nHyperlipidemia. It is unclear if oral moringa leaf is beneficial in patients with hyperlipidemia.\nOne small clinical study in patients with hyperlipidemia shows that taking atorvastatin 10 mg daily with powder of an unspecified part of the moringa plant 1 gram twice daily for 45 days modestly reduces levels of total cholesterol and triglycerides when compared with taking atorvastatin alone (112639). Another small clinical study in patients with type 2 diabetes shows that taking powdered moringa leaf 8 grams daily in addition to following a calorie restricted diet for 40 days modestly reduces low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglyceride levels when compared with baseline (97208). The validity of these findings is limited by the lack of a statistical comparison to the control group, as well as small study size and short duration. In contrast, one small clinical study in patients of Indian descent with hyperlipidemia shows that taking 8 tablets of standardized dehydrated moringa drumstick leaf (DDL) 4.6 grams daily for 50 days has no effect on lipid levels when compared with baseline (97212).\nless\nImpaired glucose tolerance (prediabetes). It is unclear if oral moringa leaf powder is beneficial for patients with prediabetes.\nA small clinical study in treatment-nave adults with prediabetes shows that taking moringa leaf powder 2400 mg daily for 12 weeks modestly improves fasting blood glucose and glycated hemoglobin (HbA1c) but does not improve markers of insulin resistance or anthropometric measures (i.e. weight, BMI, waist circumference) when compared with placebo (110646).\nless\nIron deficiency anemia. It is unclear if oral moringa leaf flour is beneficial for anemia during pregnancy.\nA small clinical study in pregnant patients with anemia in Indonesia shows that consuming biscuits enriched with 5.6 grams of moringa leaf flour, in addition to iron 500 mg, daily for 60 days increases hemoglobin by 1 g/dL, compared to 0.66 mg/dL with iron 500 mg daily alone. (110647). The validity of this study is limited by poor methodology, including lack of randomization and blinding.\nless\nLactation. Small clinical studies suggest that oral moringa leaf may modestly increase breastmilk volume during the first week of lactation.\nA meta-analysis of 3 small clinical trials in breastfeeding patients shows that when started on postpartum day 3, moringa leaf increases breastmilk volume by about 120 mL per expression by day 7 when compared to control (90573). Studies included in the analysis used specific capsules containing moringa leaf (Natalac, Gruppo Medica Inc.) 250 mg twice daily on postpartum days 3-5 (20578), and specific capsules containing moringa leaf (Pro-Lacta, Pascual Laboratories, Inc.) 350 mg twice daily starting on postpartum day 3 and continuing for one week (90571). However, due to methodological limitations and the short duration of the included trials, the clinical significance of this finding is uncertain.\nless\nMalnutrition. It is unclear if oral moringa leaf is beneficial for children with malnutrition.\nOne small clinical study in children with mild-to-moderate malnutrition shows that supplementing food with powdered dried moringa leaf 15 grams twice daily for 2 months results in 23 of 30 children having a 20% or greater improvement in weight, compared with only 2 of 30 children receiving no additional intervention (90576). It is unclear if maternal consumption of moringa leaves prevents malnutrition in infants. An observational follow-up of a large randomized clinical trial in Indonesian patients in their second trimester or one month postpartum shows that consuming four capsules, each containing 500 mg moringa leaf powder or extract, daily for 4 months might protect the infant against being underweight, but does not reduce stunting in infants followed for up to 11 months, when compared with an unspecified dose of iron and folate (105471, 105472).\nless\nMenopausal symptoms. It is unclear if oral moringa leaf improves menopausal symptoms.\nA small clinical study in healthy postmenopausal patients shows that taking powdered moringa leaves 7 grams with food daily for 3 months modestly improves menopausal symptoms such as hot flashes and sleeping problems when compared with no dietary additives (90575).\nless\nObesity. Oral moringa leaf has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne small clinical study shows that taking a combination product containing moringa leaf extract 200 mg, green coffee bean extract 300 mg, banaba leaf extract 100 mg, and vitamin D3 500 IU (CraveCheck, Advocare International) daily for 2 months does not reduce body weight when compared with placebo. In fact, patients in the placebo group showed slightly greater weight loss than patients in the treatment group. However, taking the combination product appears to reduce fat mass and increase fat-free or lean mass as measured by dual energy X-ray absorptiometry, suggesting that the combination product might improve body composition (97211). It is not clear if this effect is due to moringa, the other ingredients, or the combination.\nless\nOral leukoplakia. It is unclear if topical moringa leaf improves oral leukoplakia.\nPreliminary clinical research in patients with oral leukoplakia shows that topical application 3 times daily for 3 months with a gel providing moringa leaf extract 2% reduces lesion size by about 77% compared to baseline. Moringa gel is modestly more effective for reducing lesion size than a specific cream (Retino-A) (112640). The validity of these findings is limited by the lack of a placebo group.\nless\nVitamin A deficiency. It is unclear if oral moringa leaf is beneficial in infants deficient in vitamin A.\nPreliminary clinical research conducted in rural Ghana shows that vitamin A-deficient infants aged 8-12 months who receive cereal supplemented with moringa leaf powder for 6 weeks do not have a significant improvement in vitamin A status when compared with those given cereal without moringa (98455).\nless\nMore evidence is needed to rate moringa for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMoringa leaves and seeds are typically used as powders or extracts in doses of 6-10 grams daily. See Effectiveness section for condition-specific information.\nTopical:\nA gel containing moringa leaf extract has been used. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of moringa.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, moringa might have additive effects when used with antidiabetes drugs; however, research is conflicting.\nAnimal research shows that moringa can lower blood glucose levels (12249, 20571, 20573, 20574). However, research in humans has not shown consistent blood glucose lowering effects (97207, 105470).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, moringa might decrease the levels and clinical effects of CYP1A2 substrates.\nIn vitro research shows that moringa extract induces CYP1A2 enzymes (111404).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, moringa might increase or decrease levels of CYP3A4 substrates.\nSome in vitro research suggests that moringa inhibits cytochrome P450 3A4 (CYP3A4) (20576). However, other in vitro research suggests that moringa extract induces CYP3A4 enzymes (111404). A pharmacokinetic study in patients with HIV shows no change in the pharmacokinetics of nevirapine, which is partially metabolized by CYP3A4, when administered concomitantly with moringa leaf powder 1.85 grams daily for 14 days (97209).\nless\nLEVOTHYROXINE (Synthroid, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, moringa leaf can antagonize the effects of levothyroxine.\nAnimal research suggests that moringa aqueous leaf extract might reduce serum triiodothyronine (T3) concentrations by inhibiting the peripheral conversion of thyroxine (T4) to T3 (16348).\nless\nNEVIRAPINE (Viramune)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nINSIGNIFICANT\nOccurrence\nUNLIKELY\nLevel of Evidence\nB (Nonrandomized clinical trial)\nMoringa leaf is unlikely to have a clinically significant interaction with nevirapine.\nNevirapine is partially metabolized by cytochrome P450 3A4 (CYP3A4). In vitro evidence suggests that moringa inhibits CYP3A4 (20576). However, a pharmacokinetic study in patients with HIV shows no change in nevirapine pharmacokinetics when administered concomitantly with moringa leaf powder 1.85 grams daily for 14 days (97209).\nless\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, moringa leaf extract might increase the levels and clinical effects of P-glycoprotein substrates.\nIn vitro research shows that moringa leaf extract inhibits renal P-glycoprotein transport activity (107850). So far, this reaction has not been reported in humans.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, moringa leaf might lower blood glucose levels.\nAnimal research suggests that moringa might lower blood glucose levels (12249, 20571, 20573, 20574). However, research in humans has not shown consistent blood glucose lowering effects (97207, 105470). Theoretically, moringa might have additive effects when used with other herbs and supplements that also lower glucose levels. See other products with hypoglycemic potential here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, moringa can reduce thyroid activity.\nAnimal research suggests that moringa aqueous leaf extract might reduce serum triiodothyronine (T3) concentrations by inhibiting the peripheral conversion of thyroxine (T4) to T3 (16348). Theoretically, moringa might have additive or antagonistic effects when used with other herbs and supplements with thyroid activity.\nless",
            "Interactions with Conditions": "HYPOTHYROIDISM\nTheoretically, moringa might further reduce thyroid hormone levels in people with hypothyroidism. Animal research suggests that aqueous moringa leaf extract might decrease the conversion of thyroxine (T4) to the active thyroid hormone triiodothyronine (T3) (16348).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with moringa.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of moringa.",
            "Mechanism of Action": "General\nThe applicable parts of moringa are the leaves, bark, flowers, fruit, seeds, and roots. Moringa leaves are a rich source of vitamins A and C, beta-carotene, calcium, iron, potassium, protein, and essential amino acids such as methionine, cystine, tryptophan, and lysine (16343, 16344). The fresh leaves have a total carotene content of 40 mg/100 grams, and retain 50% of this content when dried and stored for three months (16341). The ascorbic acid content of dried leaves is between 700-1400 mg per 100 grams (16343). The leaves also contain niazirin and niazirinin which are nitrile glycosides, beta-sitosterol and its glucopyranoside derivatives, glycerol-1-(9-octadecanoate), and mustard oil glycosides including 4-[(4'-0-acetyl-alpha-L-rhamnosyloxy)benzyl] isothiocyanate, niaziminin A, and niaziminin B (16338, 16339, 16347). Other isothiocyanates and the related compound, niazimicin are also present (16338).\n\nThe essential oil contains zeatin, quercetin, beta-sitosterol, caffeoylquinic acid, pterygospermin, and kaempferol (16338). The leaves are also rich in antioxidant phenolic compounds such as quercetin and kaempferol.\n\nMoringa seeds contain 38% to 42% oil. The oil contains tocopherols, sterols, and fatty acids. The main sterols present are campesterol, stigmasterol, beta-sitosterol, delta-5-avenasterol, and clerosterol. About 76% of the total fatty acid content is the mono-unsaturated oleic acid, with linoleic, palmitic, stearic, arachidic and behenic acids also present (16340). The residue of the seeds remaining after oil extraction has a protein content of 26% to 32% (16340). This residue and the seed kernels are able to remove contaminants, including lead, iron and cadmium, from drinking water (16340, 16349).\n\nMoringa root contains the alkaloids moringine, which is identical to benzylamine, and moringinine (16338, 16339). The fruit, also called the pod or drumstick, contains proteins, fats, carbohydrates, minerals, fiber, vitamin A, carotene, nicotinic acid, ascorbic acid, tocopherol, estrogenic substances and beta-sitosterol (16342, 16345).\n\nMoringa flowers contain flavonoids such as quercetin, kaempferol, rhamnetin, isoquercitrin, and kaempferitrin (16343).\nAnalgesic effects\nEvidence from animal research shows that moringa root and leaf extract have antinociceptive and anti-inflammatory effects (63679, 63775, 63776). This may explain why moringa has been used traditionally for chronic pain conditions, such as arthritis.\nAnti-inflammatory effects\nMoringa has been used for its anti-inflammatory effects. Numerous animal studies show that moringa reduces inflammation and edema (63652, 63658, 63774, 63775, 63776, 63781, 63783, 63785, 63792).\nAntiarsenic effects\nEvidence from in vitro and animal research shows that the seeds of moringa can prevent and reverse the effects of arsenic exposure (16349, 63683, 63719, 63731). It is thought that arsenic may be removed by binding to sulfhydryl-containing amino acids such as cysteine and methionine present in the protein-rich seeds. Also, antioxidants such as vitamins A, C and E, beta-carotene, beta-sitosterol, quercetin and kaempferol present in the seeds may protect against oxidative damage (16349).\nAntiasthmatic effects\nMoringa has been studied for use in asthma. In animal asthma models, moringa seed extract may decrease airway inflammation, acetylcholine-induced bronchoconstriction, and immune-mediated inflammatory response (63684, 63686, 63705, 63727, 63793).\nAntibacterial effects\nMoringa has antibacterial effects and has been used to treat bacteria in the water in efforts to make it potable. A substance called pterygospermin isolated from the root is reported to have antibacterial properties (16339, 16344, 63643, 63710). However, not all research is positive. While moringa seed has been shown to have short-term antibacterial activity against heterotrophic bacteria and fecal coliforms in water (63660, 63707, 63737), regrowth of some bacteria strains appears to occur in the supernant water within 24 hours of treatment (63737). Also, adding one crushed moringa seed per 5 liters of water does not reduce bacteria counts to make the water drinkable, especially when compared to chlorine (63714).\n\nIn vitro, moringa extracts inhibit Staphylococcus aureus, Vibrio cholerae, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, coliform bacteria, and other strains (63637, 63690, 63716, 63721, 63726, 63740, 63778, 63779).\nAntidiabetic effects\nSeveral animal studies suggest that moringa leaf can reduce blood glucose, although research in humans is conflicting (12249, 20571, 20573, 20574). This potential effect has been attributed to reduced intestinal glucose uptake and slower gastric emptying time due to moringa leaf fiber content (105470). One very small study in patients with type 2 diabetes shows that eating a meal containing moringa leaves 50 grams modestly reduces postprandial glucose levels and reduces glycemic response by about 20% when compared with a standard meal without moringa (97207).\nAntifertility effects\nMoringa is reported to have estrogenic, antiestrogenic, progestational, anti-progestational, and contraceptive activities (16338, 63736, 63766). Studies in animals indicate that root extracts initially increase estrogenic effects and then inhibit them, possibly by binding to receptors and then blocking them (16338). Extracts of both the root and bark can cause intense uterine contractions and have been used as abortifacients (16338). Preliminary animal research shows that moringa root and bark can prevent implantation (63735, 63765), while leaf extract can result in abortion (63661).\nAntifungal effects\nIn vitro research shows that essential oil from moringa leaf and ethanol extract of moringa seed have antifungal activity against Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis (16350).\nAntineoplastic effects\nPreliminary research indicates that several of the leaf and seed constituents, such as niazimicin, have anticancer properties (16338, 16344, 16345, 33322, 63624, 63745). Applied topically, a fruit extract reduces the incidence and tumor burden of skin papillomas induced in animals (16345).\nAntioxidant effects\nMoringa contains anti-oxidant constituents such as quercetin, kaempferol, gallic acid, chlorogenic acid, ellagic acid, ferulic acid, rutin, quercetin glucoside, kaempferol rhamnoglucoside, procyanidin, and vanillin (16343, 63693, 63697, 63698, 63715). In clinical research, moringa leaf extract reduced malonaldehyde and increased glutathione peroxidase (115743). In vitro studies indicate that leaf extracts can scavenge superoxide radicals, prevent peroxidation of lipid membranes, inhibit oxidation of rat hepatic microsomes, and inhibit peroxidation of linoleic acid and lipids (16343, 63633, 63680, 63704, 63787, 63794).\nAntiplatelet effects\nIn vitro moringa leaf extract significantly inhibits platelet aggregation induced by adenosine diphosphate, collagen, and epinephrine (63763).\nAntispasmodic effects\nEvidence from animal research shows that moringa seeds inhibits chemically induced spasms of the duodenum by up to 67% (63652). This may explain the use of moringa as an antispasmodic agent.\nAntiviral effects\nPreliminary research in animals shows that moringa extract delays the development of skin lesions, prolongs mean survival times, and reduces mortality after infection with herpes simplex-1 virus (HSV-1) (63653).\nCardiovascular effects\nMoringa root contains the alkaloids moringine, which is identical to benzylamine, and moringinine (16338, 16339). Moringinine has cardiac stimulant, hypertensive, and other sympathomimetic effects (16338, 63752). The root can also cause hypotension, bradycardia, and both positive and negative inotropic effects in animals, while high doses can cause kidney and liver dysfunction (16338).\n\nCertain constituents of moringa leaf have shown hypotensive effects such as beta-sitosterol, nitrile glycosides, and mustard oil glycosides (16347, 20575, 63742). However, research in humans has not demonstrated significant hypotensive effects after consumption of moringa leaf 120 grams as a single dose or 8 grams daily for 4 weeks (103222, 105470).\nChelating effects\nMoringa has been used to clean water. Moringa seeds, husks, and pods have been shown to adsorb chromium, cadmium, and nickel (63667). Moringa seeds have been used as a biosorbent for removal of arsenic, cadmium, lead, zinc, copper, cobalt, chromium, and silver ions from aqueous solutions, including polluted water (63659, 63664, 63669, 63688, 63702, 63723, 63730, 63762).\nGalactagogue effects\nMoringa leaf has been used traditionally as a galactagogue (63756, 63757). Moringa leaf can increase maternal serum prolactin levels, which can increases milk production (63769, 63770).\nGastrointestinal effects\nIn animal ulcer models such as aspirin-induced gastric ulcers and acetic acid-induced chronic gastric ulcers, moringa flower bud and leaf extracts decrease the ulcer index and increased healing (63678, 63741, 63784, 63785). The mechanism may involve modulation of 5-HT3 receptors on gastric tissue (63718).\nGenitourinary effects\nPreliminary data suggests an extract of moringa root has diuretic activity, and may help dissolve and prevent formation of kidney stones composed of oxalate, calcium, and phosphate (16339, 63652, 63786).\nHepatoprotective effects\nPreliminary animal data suggests that extracts of the stem bark leaf, and/or seed of moringa protect against carbon tetrachloride, rifampin, and acetaminophen induced hepatotoxicity (63703, 63774, 63682).\nImmune effects\nAnimal models show that moringa seed extract reduces delayed hypersensitivity reactions, immediate hypersensitivity reactions (such as anaphylactic shock), and humoral antibody response (63687, 63713).\n\nIn an animal model of immunosuppression, moringa extract given alone or conjugated with chitosan nanoparticles enhances immune response as shown by increased total leukocyte count, increased complement C3 and C4 levels, and reduced tumor necrosis factor-alpha levels compared with controls. The immune-enhancing effects were greater when moringa was conjugated with chitosan nanoparticles (116043).\nInsecticidal effects\nMoringa seed extract delays development and induces mortality of larva of yellow fever mosquito (63696, 63700).\nLipid effects\nPreliminary animal research suggests that a cooked and dried extract of moringa fruit can lower serum lipids by a similar amount to lovastatin, possibly due to its beta-sitosterol content (16342). Other animal research shows that moringa leaf extract can lower cholesterol levels and atherosclerotic plaque formation comparably to simvastatin or pravastatin (63680, 63717). Additional preliminary research shows that moringa leaf extract can lower serum cholesterol levels in animal models fed a high-fat diet (16346, 63629).\nNeurologic/CNS effects\nMoringa may have neuroprotective effects. Preliminary animal research suggests that moringa root extract inhibits penicillin-induced seizure by altering levels of serotonin, dopamine, and norepinephrine in different regions of the brain (63656).\nOcular effects\nPreliminary data from animals suggest that moringa leaf extract prevents experimentally induced cataracts. This effect is attributed to the antioxidant activity of moringa (63725).\nSunscreen effects\nPreliminary data from an in vitro study suggest that extracts of moringa leaves can absorb ultraviolet light. Aqueous, methanolic, and alcoholic extracts in concentrations of 2% to 4% had a sun protection factor (SPF) around 2 (98454).\nThyroid effects\nMoringa leaf extract may have anti-thyroid effects. A study in animal models reported reduced serum triiodothyronine (T3) levels and increased thyroxine (T4) levels, suggesting reduced peripheral conversion of T4 to T3 (16348).\nWound healing effects\nPreliminary data from animal research suggest that extracts from moringa leaf, pulp, and seed increase the rate of wound healing, increase strength of new skin, and decrease scar area. While the exact mechanism of action is unclear, it is thought that moringa may improve wound healing due to its antibacterial activity or its zinc content (63671)."
        }
    },
    "Mormon Tea": {
        "sections": {
            "Overview": "Mormon tea is an evergreen shrub that contains large amounts of tannins. Despite being in the Ephedra genus, Mormon tea contains no ephedrine or other alkaloids (515). Traditional uses of Mormon tea include asthma, sexually transmitted infections, and as a diuretic.",
            "Safety": "LIKELY SAFE when used in food amounts (12).\nThere is insufficient reliable information available about the safety of Mormon tea when used as a medicine.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using in amounts greater than those commonly found in foods.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Mormon tea is generally well-tolerated when consumed as a beverage. However, a thorough evaluation of safety outcomes with medicinal use has not been conducted.\nGastrointestinal\nOrally, Mormon tea might cause gastrointestinal disturbances such as constipation due to its tannin content (12, 515).\nless\nHepatic\nOrally, Mormon tea might cause necrotic conditions of the liver due to its tannin content (12, 515).\nless\nRenal\nOrally, Mormon tea might cause kidney damage due to its tannin content (12, 515).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCommon cold. Although there is interest in using oral Mormon tea for the common cold, there is insufficient reliable information about the clinical effects of Mormon tea for this condition.\nMore evidence is needed to rate Mormon tea for this use.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Research is limited; typical dosing is unavailable.\n\nSeparate the oral use of Mormon tea from other products by at least 1 hour. Mormon tea contains tannins which can alter the absorption of nutrients by binding with digestive enzymes, alkaloid substances, minerals, and nitrogen-rich compounds. However, tannins are neutralized during processing and dietary consumption, making it difficult to determine the extent, if any, to which Mormon tea might alter absorption (12, 103714, 103715).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Mormon tea.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Mormon tea.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Mormon tea.",
            "Mechanism of Action": "General\nMormon tea contains large amounts of tannins (515). Despite being in the Ephedra genus, it does not contain any ephedrine or other alkaloids (515).\nAstringent effects\nMormon tea is of interest for the common cold. Tannin constituents in Mormon tea have an astringent effect on mucosal tissue. This dehydrates the tissue, reducing internal secretions and binding external cells into a protective layer (12)."
        }
    },
    "Motherwort": {
        "sections": {
            "Overview": "Motherwort is a perennial plant that grows to about 1 meter in height. It is native to Europe and Scandinavia. It is also found in temperate regions of Russia, Iran, China, and Japan (94205, 94206). A related species, Leonurus japonicus, is called Chinese motherwort. It is native to temperate regions of Asia, including China, Korea, India, Thailand, and Malaysia (94207). Today both species can be found growing around the world and are considered interchangeable for medicinal purposes (4800).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Motherwort extracts have been used with apparent safety at doses of 1200 mg daily for up to 28 days (94209) or 800 mg daily, in combination with Lactiplantibacillus plantarum, for up to 12 weeks (115049)....when administered intramuscularly, short-term. One or more intramuscular injections have been used with apparent safety in total combined doses of 40-200 mg over 48 hours or less to prevent and/or stop postpartum bleeding (94203, 101890, 101891, 101892). Post-marketing surveillance of over 8000 females found that a specific motherwort product (Chengdu No 1 Pharma Company Ltd) has been used without significant adverse effects for a duration of 48 hours or less (104855) ...when administered by intrauterine injection, short-term. Post-marketing surveillance of over 1800 patients found that a specific motherwort product (Chengdu No 1 Pharma Company Ltd) has been used without significant adverse effects for a duration of 48 hours or less (104855).\nPREGNANCY: LIKELY UNSAFE when used orally or by injection. Alkaloids present in motherwort have uterine stimulant effects (4, 12, 19).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally or via intramuscular or intrauterine injection, motherwort appears to be generally well tolerated.\nMost Common Adverse Effects\nOrally: Diarrhea, stomach irritation.\n\nTopically: Contact dermatitis, photosensitivity.\n\nIntramuscular / Intrauterine: Abdominal pain, erythema, eyelid edema, fever, nausea, pruritus, rash.\nDermatologic\nMotherwort leaves can cause contact dermatitis, and the oil may cause photosensitivity reactions (4). Intramuscularly and via intrauterine injection, mild erythema, rash, and pruritus have been reported (101892, 104855).\nless\nGastrointestinal\nOrally, use of motherwort in amounts greater than 3 grams can cause diarrhea and stomach irritation (12). Intramuscularly and via intrauterine injection, abdominal pain and nausea have been reported (104855).\nless\nGenitourinary\nOrally, use of motherwort in amounts greater than 3 grams can cause uterine bleeding (12).\nless\nImmunologic\nMotherwort can also cause allergic reactions in sensitive individuals (4). Intramuscularly and via intrauterine injection, transient fever and chills lasting less than 24 hours have been reported (104855).\nless\nOcular/Otic\nIntramuscularly and via intrauterine injection, transient eyelid edema lasting less than 24 hours has been reported (104855).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nBleeding. Intramuscular motherwort injections, alone or in combination with standard treatment such as oxytocin, might reduce volume of blood loss and duration of bleeding after vaginal delivery, caesarian section, or induced abortion.\nIn females with postpartum bleeding after vaginal birth, most research shows that adding motherwort injection to oxytocin or carboprost treatment is more effective than those treatments alone. A meta-analysis of 29 low quality trials shows that injection with motherwort 40-140 mg, in addition to varying doses of oxytocin, is more effective than oxytocin alone for reducing blood loss after vaginal delivery (101890). This combination reduces the mean blood loss within 2 and 24 hours of delivery by 55 mL and 85 mL, respectively. Also, the risk of postpartum hemorrhage, defined as an estimated blood loss of at least 400 mL within 2 hours or at least 500 mL within 24 hours, is reduced by 71%, based on meta-analysis of 18 trials. Meta-analysis of 8 trials also shows motherwort alone to be more effective than oxytocin for reducing blood loss within 24 hours of delivery, but not within 2 hours of delivery. Meta-analysis of 4 trials shows that motherwort 40-200 mg is as effective as oxytocin for reducing the risk of postpartum hemorrhage (101890). Studies were all very low to low quality, with moderate to high risk of bias, and conducted in China, the latter of which limits generalizability to other geographic regions.\n\nIn females with post-caesarian bleeding, adding motherwort injection to oxytocin reduces blood loss and the rate of post-partum hemorrhage when compared with using oxytocin alone. In a large clinical trial, motherwort 40 mg was injected into the uterus during the caesarian section, followed by 20 mg intramuscular injections every 12 hours over the next 36 hours. However, motherwort injection into the uterus does not seem to be more effective than oxytocin for reducing bleeding during the caesarian section (94203). However, a meta-analysis of 8 trials shows that prophylactic injection with motherwort 60-200 mg, in addition to carboprost 250 mcg, reduces the mean blood loss within 2 and 24 hours of delivery by 127 mL and 147 mL, respectively, with a 72% decrease in the incidence of postpartum hemorrhage over carboprost alone (101891). In 7 of the 8 trials the mode of delivery was caesarian section and 1 was a vaginal delivery.\n\nA large observational study suggests that intramuscular injection of motherwort into the uterus combined with intravenous oxytocin is associated with a lower risk of post-partum hemorrhage after caesarian section when compared with intravenous oxytocin plus intramuscular injection of oxytocin into the uterus (112291).\n\nA meta-analysis of 9 clinical trials among patients undergoing induced abortion shows that motherwort injection combined with oxytocin lowers the volume of blood loss both 2 hours and 24 hours after the procedure when compared with oxytocin alone (112292). However, motherwort alone is not more effective than oxytocin for blood loss post-abortion. Meta-analysis indicates that motherwort injected alone or with oxytocin reduces the duration of blood loss compared with oxytocin or no treatment. Studies were primarily of very low quality, and all studies were conducted in China, limiting generalizability to other populations and geographic locations.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlcohol use disorder. Oral motherwort has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in males experiencing alcohol withdrawal syndrome with disordered sleep, anxiety, and irritability shows that a single dose of a combination product containing motherwort 50 mg, valerian 170 mg, hops 50 mg, and lemon balm 50 mg, taken 1 hour before bedtime, improves sleep quality and decreases awakenings when compared with placebo (63884).\nless\nAmenorrhea. Although there has been interest in using oral motherwort for amenorrhea, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nAnxiety. It is unclear if oral motherwort is beneficial in patients with anxiety.\nPreliminary clinical research in adults with anxiety and hypertension shows that taking a specific preparation of motherwort extracted in soybean oil (Farmagen Ltd.) 600 mg orally twice daily for 28 days reduces anxiety and depression scores when compared with baseline. A significant improvement occurred in 32% of subjects, and a moderate improvement occurred in 48% of subjects (94209). The validity of this finding is limited by the lack of a comparator group.\nless\nArrhythmia. Although there has been interest in using oral motherwort for arrhythmia, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nAsthma. Although there has been interest in using oral motherwort for asthma, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nCancer. Although there has been interest in using oral motherwort for cancer, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nDysmenorrhea. Although there has been interest in using oral motherwort for dysmenorrhea, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nFlatulence. Although there has been interest in using oral motherwort for flatulence, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nHeart failure. Although there has been interest in using oral motherwort for heart failure, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nHerpes zoster (shingles). Although there has been interest in using topical motherwort for herpes zoster, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nHypertension. It is unclear if oral motherwort is beneficial in patients with hypertension.\nPreliminary clinical research in adults with hypertension and anxiety shows that taking a specific preparation of motherwort extracted in soybean oil (Farmagen Ltd.) 600 mg orally twice daily for 28 days reduces blood pressure when compared with baseline. In subjects with mild hypertension, systolic and diastolic blood pressure decreased by 10% and 11%, respectively. In subjects with more severe hypertension, systolic and diastolic blood pressure decreased by 7% and 11%, respectively (94209). The validity of this finding is limited by the lack of a comparator group.\nless\nHyperthyroidism. Although there has been interest in using oral motherwort for hyperthyroidism, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nInsomnia. Although there has been interest in using oral motherwort for insomnia, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nMenopausal symptoms. Oral motherwort has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in adults with menopause shows that taking a combination of motherwort, burdock, dong quai, licorice root, and wild yam three times daily for 12 weeks reduces the number and severity of menopausal symptoms, such as hot flashes, sleep problems, mood changes, and vaginal dryness, in 71% of patients, compared with 17% of patients taking a placebo (48522).\nless\nPruritus. Although there has been interest in using topical motherwort for pruritus, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nWound healing. Although there has been interest in using topical motherwort for wound healing, there is insufficient reliable information about the clinical effects of motherwort for this purpose.\nMore evidence is needed to rate motherwort for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nIntramuscular / Intrauterine:Motherwort has typically been given as 1-4 injections providing a total dose of 40-200 mg over 48 hours. Motherwort is usually administered as an adjunct to oxytocin or carboprost. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThe European Pharmacopoeia defines motherwort for medicinal use as the aerial parts of Leonurus cardiaca, gathered during the flowering season, dried at 35, and standardized to contain a minimum of 0.2% flavonoids, expressed as hyperoside (94205, 94207).\n\nThe Chinese Pharmacopoeia specifies that Chinese motherwort (Leonurus japonicus) should contain a minimum of 0.04% stachydrine and 0.004% leonurine (94207).\n\nMost studies use an intramuscular preparation of motherwort (94203, 101890, 101891, 101892).",
            "Interactions with Drugs": "CNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking motherwort concomitantly with other CNS depressants may increase the risk of sedation.\nMotherwort has been reported to cause CNS depression and sedation (19, 94205).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with motherwort.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of motherwort.",
            "Mechanism of Action": "General\nThe applicable parts of motherwort are the above ground parts. Motherwort contains alkaloids (principally leonurine and stachydrine, with smaller amounts of leonurinine and leonuridine), flavonoids (hyperoside, quercetin, kaempferol, rutin, epicatechin), sesquiterpenes, monoterpenes, diterpenes, triterpenes, phenylpropanoid glycosides, beta-caryophylline, polysaccharides, and essential oils (94205, 94206, 94207, 94208).\nAnti-inflammatory effects\nIn lipopolysaccharide (LPS)-stimulated cells, which are an in vitro model of inflammation, the essential oil from motherwort roots decreased levels of the inflammatory mediators interleukin (IL)-1-beta, IL-6, tumor necrosis factor-alpha, and interferon-gamma (94204). Additionally, in human research, motherwort extract in combination with Lactiplantibacillus plantarum decreased levels of high-sensitivity C-reactive protein (hs-CRP) (115049).\nAnticancer effects\nExtracts of the above-ground parts of motherwort are reported to inhibit growth and induce apoptosis in several human cancer cell lines in vitro (63800). An ethanol extract of the above-ground parts of motherwort causes non-apoptotic death of both estrogen receptor positive and negative human breast cancer cells in vitro (63813). The essential oil from motherwort roots has activity in vitro against grade IV glioma cells (94204).\nAntimicrobial effects\nExtracts from both the aerial parts and roots of motherwort have shown in vitro activity against bacteria (Pseudomonas aeruginosa, Enterococcus faecalis, Eschericia coli, Staphylococcus aureus, Salmonella typhi), protozoa (Plasmodium falciparum), fungi (Aspergillus flavus, Candida albicans, Saccharomyces cerevisiae), and yeasts (Debaryomyces hansenii) (94204, 94205, 94206).\nAntioxidant effects\nExtracts of motherwort above-ground parts are reported to have antioxidant activity in vitro (63816). The extracts also have protective effects in animal models of myocardial infarction, ischemic stroke, and renal ischemic injury (94207, 94208). The mechanism of these effects is thought to involve scavenging of oxygen free radicals, reduced lipid peroxidation, increased activity of superoxide dismutase and glutathione peroxidase, and reduced intracellular content of nitric oxide (94207, 94208). Furthermore, human research suggests that an extract from motherwort, in combination with Lactiplantibacillus plantarum, increases total antioxidant status (115049).\nAntiplatelet effects\nIn humans, giving an intravenous infusion of motherwort daily for 15 days decreases blood viscosity, fibrinogen volume, and platelet aggregation (1533). It is not known if these effects occur when motherwort is taken orally.\nAntiviral effects\nA motherwort extract inactivates tick-borne encephalitis (TBE) virus in cell cultures, and increases survival rate and longevity in mice infected with TBE virus (63810).\nDiuretic effects\nMotherwort is reported to have potassium-sparing diuretic activity, possibly mediated by the alkaloid stachydrine (63829, 94207).\nUterine effects\nIn animal studies, the alkaloid leonurine isolated from motherwort has uterotonic effects, increasing the frequency and intensity of uterine muscle contractions (94205, 94207, 94208). This may lead to induction of labor and reduction in post-partum hemorrhage. In other animal studies, an extract of motherwort reduced uterine spasms induced by prostaglandins, giving it a possible role in the treatment of dysmenorrhea (94207)."
        }
    },
    "Mountain Ash": {
        "sections": {
            "Overview": "Mountain ash is a deciduous tree most commonly found in Europe and Asia. The flowers, fruits, and leaves are used as medicine (99894, 110424).",
            "Safety": "POSSIBLY UNSAFE when large amounts of fresh berries are ingested. The constituent, parasorbic acid, is an irritant and large amounts can cause gastric irritation and kidney damage (18).\nThere is insufficient reliable information available about the safety of the oral use of dried or cooked berries.\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when large amounts of fresh berries are ingested (18). There is insufficient reliable information available about the safety of dried or cooked berries; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, consuming large amounts of fresh mountain ash berries can cause serious adverse effects due to its parasorbic acid constituent. These adverse effects include gastroenteritis, vomiting, queasiness, gastric pain, diarrhea, kidney damage, and polymorphic xanthomas (18).\nDermatologic\nOrally, large amounts of fresh mountain ash berries may cause polymorphic xanthomas due to its parasorbic acid constituent (18).\nless\nGastrointestinal\nOrally, large amounts of fresh mountain ash berries may cause gastroenteritis, vomiting, queasiness, gastric pain, and diarrhea due to its parasorbic acid constituent (18).\nless\nRenal\nOrally, large amounts of fresh mountain ash berries may cause kidney damage, including albuminuria and glycosuria, due to its parasorbic acid constituent (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of mountain ash.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mountain ash.",
            "Interactions with Drugs": "NEPHROTOXIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTaking large amounts of fresh mountain ash berries may cause kidney damage due to its parasorbic acid constituent (18). Theoretically, taking mountain ash berries with nephrotoxic drugs might increase the risk for kidney damage. Until more is known, advise patients to avoid taking mountain ash berries if they are taking other potentially nephrotoxic drugs.\nSome potentially nephrotoxic drugs include cyclosporine (Neoral, Sandimmune); aminoglycosides including amikacin (Amikin), gentamicin (Garamycin, Gentak, others), and tobramycin (Nebcin, others); nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen (Advil, Motrin, Nuprin, others), indomethacin (Indocin), naproxen (Aleve, Anaprox, Naprelan, Naprosyn), piroxicam (Feldene); and numerous others.\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "KIDNEY DISEASE\nTaking large amounts of fresh mountain ash berries may cause kidney damage due to its parasorbic acid constituent (18). Theoretically, consuming mountain ash berries might exacerbate kidney problems in patients with existing kidney disease.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mountain ash.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mountain ash.",
            "Mechanism of Action": "General\nThe applicable parts of mountain ash are the berries, leaves, and flowers. The berries can be used fresh, dried, or cooked and then dried. Mountain ash berry contains parasorbic acid, cyanogenic glycosides, fruit acids (malic acid, tartaric acid), tannins, and vitamin C (18). Parasorbic acid can cause local irritation, but it is partially degraded by drying and completely destroyed by cooking (2). The berries also contain many phenolic compounds including caffeic and ferulic acid pseudodepsides (predominantly isomers of chlorogenic acid and cynarin), flavonols (mostly quercetin glycosides), flavan-3-ol derivatives, including proanthocyanidin oligomers and polymers, caffeoylquinic acids, hydroxycinnamic acids, and simple phenolic acids (110423, 110424).\n\nThe flowers of mountain ash contain numerous constituents, including flavonoids such as quercetin and kaempferol and flavanols such as catechins and proanthocyanidins (99894).\nAnti-gout effects\nWhile mountain ash has been traditionally used for gout, some in vitro research shows that mountain ash flower extracts don't seem to inhibit xanthine oxidase, a key enzyme in the conversion of xanthine to uric acid (99894). It is unknown whether mountain ash exerts anti-gout effects through other mechanisms.\nAnti-inflammatory effects\nIn vitro research suggests that mountain ash flower extracts have anti-inflammatory properties, possibly through inhibition of lipoxygenase and hyaluronidase (99894).\nAntioxidant effects\nIn vitro research suggests that mountain ash flower extracts have antioxidant effects (99894). In vitro research shows that berry extracts neutralize multiple oxidants generated in vivo, increase the non-enzyme antioxidant capacity of human plasma, and protect plasma proteins and lipids from oxidative or nitrative damage (110424). These extracts also protect human fibrinogen from structural damage caused by reactive oxygen species (110423).\nDietary effects\nIn vitro research shows that berry extracts inhibit alpha-amylase and alpha-glucosidase enzymes, involved in digestion of complex carbohydrates (110424).\nHematologic effects\nIn vitro research shows that extracts of mountain ash berries, and polyphenols isolated from them, reduce structural changes to fibrinogen, and reduce formation of high molecular weight fibrinogen protein aggregates which have prothrombotic activity. This is the result of reduced nitration of tyrosine residues in fibrinogen, reducing polymerization rates. The enzymatic activity of thrombin is decreased by mountain ash berry extracts, leading to reduced conversion of fibrinogen to fibrin, which could help prevent thromboembolic complications (110423).\n\nBerry extracts also inhibit hyaluronidase activity, reducing disruption of blood vessel endothelium, and reducing activation of platelets and the plasma coagulation proteins that lead to fibrin clot formation. The extracts do not affect activated partial thromboplastin time (APTT) or prothrombin time (PT) (110423)."
        }
    },
    "Mountain Flax": {
        "sections": {
            "Overview": "Mountain flax is a plant native to Europe, Northern Africa, Western Asia, and the Caucasus (102536).\n\nKEY HIGHLIGHTS\nSometimes used for constipation and as an emetic, but there is insufficient reliable evidence to rate its effectiveness for these uses.\nPossibly unsafe when used orally. Side effects may include vomiting, diarrhea, and inflammation of the gastrointestinal tract.\nNo known major interactions.",
            "Safety": "POSSIBLY UNSAFE when used orally, particularly with long-term use (18).\nPREGNANCY AND LACTATION: UNSAFE when used orally due to possible emetic effects (18).",
            "Adverse Effects": "General\nOrally, mountain flax can cause vomiting, gastrointestinal tract inflammation, and diarrhea (18).\nGastrointestinal\nOrally, mountain flax can cause vomiting, gastrointestinal tract inflammation, and diarrhea (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of mountain flax.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mountain flax.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of mountain flax.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mountain flax.",
            "Mechanism of Action": "General\nThe applicable parts of mountain flax are the above ground flowering parts. Mountain flax contains the lignan achromatin, tannins, and a volatile oil (18).\nLaxative effects\nMountain flax is thought to have laxative effects at 0.5 grams (18). The mechanism of this effect is unclear."
        }
    },
    "Mountain Laurel": {
        "sections": {
            "Overview": "",
            "Safety": "UNSAFE when used orally. Mountain laurel leaf is not only an irritant, but can also lead to cardiac arrest, respiratory failure, and death (18).\nThere is insufficient reliable information available about safety of the topical use of mountain laurel.\nPREGNANCY AND LACTATION: UNSAFE when used orally (18). There is insufficient reliable information available about safety of mountain laurel for topical use; avoid using.",
            "Adverse Effects": "General\nOrally, mountain laurel can result in painful oral and gastric mucous membranes, increased salivation, cold sweat, nausea, vomiting, diarrhea, and paresthesias (18). Dizziness; headache; fever attacks; and intoxicated states with temporary loss of vision, muscle weakness, coordination disorders, and spasms can also develop. Bradycardia, cardiac arrhythmias, drop in blood pressure, eventual cardiac arrest, and respiratory failure can lead to death (18).",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of mountain laurel.",
            "Dosing & Administration": "Adult\nTOPICAL: Mountain laurel is only available in homeopathic preparations (18).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The applicable part of mountain laurel is the fresh or dried leaf. Mountain laurel contains andromedan derivatives, flavonoids, and acylphloroglucinols (18). Andromedan derivatives act on the sodium channels, inhibiting conduction by preventing closure of the excitable cells (18). The andromedan derivative Grayanotoxin I and the acylphloroglucinol constituents can be cytotoxic (4145)."
        }
    },
    "Mouse-Ear Hawkweed": {
        "sections": {
            "Overview": "Mouse-ear hawkweed is a flowering plant that is native to large areas of Europe and temperate regions of Asia. It has traditionally been used as a medicine for respiratory tract conditions and for its purported diaphoretic, diuretic, and spasmolytic effects (18).",
            "Safety": "There is insufficient reliable information available about the safety of mouse-ear hawkweed.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information available about the safety of mouse-ear hawkweed.\nImmunologic\nMouse-ear hawkweed can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nFlatulence. Although there has been interest in using oral mouse-ear hawkweed for flatulence, there is insufficient reliable information about the clinical effects of mouse-ear hawkweed for this purpose.\nWound healing. Although there has been interest in using topical mouse-ear hawkweed for wound healing, there is insufficient reliable information about the clinical effects of mouse-ear hawkweed for this purpose.\nMore evidence is needed to rate mouse-ear hawkweed for these uses.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mouse-ear hawkweed.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nMouse-ear hawkweed can cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family. Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mouse-ear hawkweed.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mouse-ear hawkweed.",
            "Mechanism of Action": "General\nThe applicable parts of mouse-ear hawkweed are the above ground flowering parts (18). There is insufficient reliable information available about the possible mechanism of action and active ingredients."
        }
    },
    "Mugwort": {
        "sections": {
            "Overview": "Mugwort is a perennial plant native to Europe and parts of Asia and Africa. It has been widely naturalized, including in North America (101053). It has been traditionally used for gastrointestinal concerns, to promote labor and circulation, and as a sedative.",
            "Safety": "There is insufficient reliable information available about the safety of mugwort when used orally or topically.\nPREGNANCY: LIKELY UNSAFE when used orally. Mugwort is said to be an abortifacient and a menstrual and uterine stimulant (2, 12).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, adverse effects to mugwort seem to be rare; however, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nAll ROAs: Allergic reactions.\nImmunologic\nAllergy to mugwort pollen has been reported when taken orally or inhaled. Symptoms have included asthma, rhinitis, conjunctivitis, rash, and anaphylaxis (567, 3717, 31341, 35623, 57474, 63909, 63915, 63917, 92852, 92853)(101049, 101050, 101051, 101052).\nless\nPsychiatric\nOrally, mania has been reported in a 49-year-old male following the intake of 1 liter of an infusion thought to contain mugwort. The presence of thujone in the patient's serum and urine was confirmed, and thujone poisoning was considered to be the cause of these symptoms. Although thujone levels are normally low in mugwort, concentrations can be variable. It was postulated that the mugwort infusion contained an unusually high amount of thujone. It was also considered to be possible that the metabolism of thujone was decreased in this particular patient or that the poisoning was related to the chronic intake of small amounts. However, a sample of the plant was not analyzed, and adulteration or contamination by a related species cannot be ruled out (101053).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAnxiety. Although there has been interest in using oral mugwort root for anxiety, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nColic. Although there has been interest in using oral mugwort for colic, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nDysmenorrhea. Although there has been interest in using oral mugwort for dysmenorrhea, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nEpilepsy. Although there has been interest in using oral mugwort for epilepsy, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nHypertension. Although there has been interest in using oral mugwort for hypertension, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nHypertrophic scars. Topical mugwort has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with hypertrophic scarring from severe burns shows that applying a topical lotion containing mugwort extract 6.25 grams and menthol 2.5 grams per 1000 mL twice daily for 2 months improves subjective itching scores when compared with untreated areas (16055). It is unclear if this effect is due to mugwort, menthol, or the combination.\nless\nInsomnia. Although there has been interest in using oral mugwort root for insomnia, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nIntestinal parasite infection. Although there has been interest in using oral mugwort for intestinal parasite infections, there is insufficient reliable information about the clinical effects of mugwort for this purpose.\nMore evidence is needed to rate mugwort for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of mugwort.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nMugwort can cause an allergic reaction in patients sensitive to various plants or drugs. Cross-allergenicity with mugwort, birch, celery, fennel, and wild carrot has been called the \"celery-carrot-mugwort-spice syndrome\" (12192, 19673, 25597, 92852, 101049). This syndrome might be a risk factor for the development of hypersensitivity to oseltamivir (92853). There is also risk for cross-sensitivity with members of the Asteraceae/Compositae family, including ragweed, chrysanthemums, marigolds, daisies, and many other herbs. A white mustard-mugwort allergy syndrome has also been proposed based on clinical research (19662). Theoretically, mugwort might also cause allergic reactions in individuals with allergies to honey, royal jelly, hazelnut, pine nut, olive, latex, peach, kiwi, mango, Canarium indicum, Platycodon grandiflorus, and other plants of the genus Artemisia, including sage (3717, 5993, 19663, 19666, 19668, 19671, 19674, 19675, 101050, 101051)(101052). Mugwort pollen might cause reactions in people allergic to tobacco (3716).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mugwort.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mugwort.",
            "Mechanism of Action": "General\nThe applicable parts of mugwort are the above ground parts and root. Mugwort contains sesquiterpene lactones, lipophilic flavonoids, polyenes, umbelliferone and aesculetin. It also contains a complex volatile oil with constituents of 1,8-cineole, camphor, linalool, or thujone (18).\nAnti-inflammatory effects\nThere is interest in using mugwort as an anti-inflammatory. Research in mice shows that taking mugwort leaf extract 200-400 mg/kg daily orally for 3 days reduces chemically-induced paw edema when compared with control. Preliminary subgroup analyses show that plants grown at higher altitudes, as well as ethanolic extracts, retain more anti-inflammatory properties when compared with low altitude plants or ethyl acetate extracts (108655).\nAntimicrobial effects\nLaboratory research suggests the aqueous extract and the volatile oil of mugwort have antimicrobial properties (18).\nUterine effects\nSome evidence suggests mugwort can stimulate uterine activity, possibly due to its thujone content (19)."
        }
    },
    "Muira Puama": {
        "sections": {
            "Overview": "Muira puama is a type of bush native to the Amazon region. It is used in traditional Brazilian medicine (63922).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Taking muira puama 500-1050 mg daily, as part of a combination product, has been used with apparent safety for 1 month (63920, 103224).\n\nThere is insufficient reliable information available about the safety of muira puama when used long-term.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nErectile dysfunction (ED). Preliminary clinical research in middle-aged men with ED shows that taking two capsules of a specific combination product (Revactin, MD Concepts LLC) containing muira puama, ginger root, guarana, and L-citrulline twice daily for 3 months improves scores related to erectile function and intercourse satisfaction, but does not improve sexual desire or orgasmic function scores, when compared to baseline (103224). This study is limited by the lack of a placebo control, the use of per-protocol analysis, and a high dropout rate. In fact, 44% of patients withdrew in order to resume use of phosphodiesterase type 5 (PDE5) inhibitors. Further, it is unclear if these effects are due to muira puama, other ingredients, or the combination.\nSexual dysfunction. Preliminary clinical research in women with a low sex drive shows that taking 2-6 tablets of a specific combination product (Herbal vX) containing muira puama extract (HV-430) 350-1050 mg and ginkgo extract 32-96 mg modestly improves sexual desire and the frequency of sexual intercourse when compared with baseline (63920). The lack of control group limits the validity of these findings. Further, it is unclear if these effects are due to muira puama, ginkgo, or the combination.\nMore evidence is needed to rate muira puama for these uses.",
            "Dosing & Administration": "Adult\nOral:\nErectile dysfunction (ED): Two capsules of a specific combination product (Revactin, MD Concepts LLC) containing muira puama 125 mg, ginger root 125 mg, guarana 125 mg, and L-citrulline 400 mg twice daily for 3 months have been used (103224).\n\nSexual dysfunction: 2-6 tablets of a specific combination product (Herbal vX) containing muira puama extract (HV-430) 350-1050 mg and ginkgo extract 32-96 mg daily for one month has been used (63920).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of muira puama.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of muira puama.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of muira puama.",
            "Mechanism of Action": "General\nThe applicable parts of muira puama are the wood and root (5). Although the active constituents of muira puama are not yet understood, the plant contains alkaloids, especially magnoflorine and menisperine, and the triterpenoid lupeol (102841, 63921).\nNeurological effects\nMuira puama is traditionally for central nervous system disorders, especially those associated with aging. In an animal aging model, muira puama improved memory (63923). Also, muira puama extract inhibited acetylcholinesterase activity in the rat frontal cortex, hippocampus and striatum in vitro and in an animal model when given intraperitoneally (63921).\nSexual effects\nMuira puama is traditionally used for preventing sexual disorders, and as an aphrodisiac. In an animal model, muira puama caused a relaxation of the corpus cavernosum (40289)."
        }
    },
    "Mullein": {
        "sections": {
            "Overview": "Mullein is a flowering plant found in temperate and subtropical mountain areas (92839, 92841). It is a biennial plant with leaves growing close to the ground and a flower stem reaching up to 2 meters in height (107875). Infusions made from mullein leaves and stems have been used in folk medicine for respiratory disorders and gastroenteritis (92839). The leaves and flowers have also been used for respiratory conditions by peoples of the Malakand region of Pakistan, and in traditional Turkish medicine (92841).",
            "Safety": "POSSIBLY UNSAFE when the seeds are ingested. They are reported to be toxic (107875).\nThere is insufficient reliable information available about the safety of mullein leaf, flower, or root when used medicinally.",
            "Adverse Effects": "General\nInformation regarding the adverse effects of mullein is limited. A thorough evaluation of safety outcomes has not been conducted.\nDermatologic\nTwo case reports have described dermatitis, with positive patch tests, after topical exposure to the whole plant, or by occupational inhalation of plant dust (92839, 97316). In the case of topical exposure, the patient also had positive patch tests to other plants.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. Although there is interest in using oral mullein for asthma, there is insufficient reliable information about the clinical effects of mullein for this condition.\nBronchitis. Although there is interest in using oral mullein for bronchitis, there is insufficient reliable information about the clinical effects of mullein for this condition.\nCough. Although there is interest in using oral mullein for cough, there is insufficient reliable information about the clinical effects of mullein for this purpose.\nDiarrhea. Although there is interest in using oral mullein for diarrhea, there is insufficient reliable information about the clinical effects of mullein for this purpose.\nHemorrhoids. Although there is interest in using topical mullein for hemorrhoids, there is insufficient reliable information about the clinical effects of mullein for this purpose.\nInfluenza. Although there is interest in using oral mullein for influenza, there is insufficient reliable information about the clinical effects of mullein for this condition.\nMigraine headache. Although there is interest in using oral mullein for migraine headache, there is insufficient reliable information about the clinical effects of mullein for this condition.\nOtitis media. Topical mullein has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that applying a specific combination product containing mullein, garlic, calendula, and St. John's wort in olive oil (Otikon Otic Solution, Healthy-On Ltd), five drops into the affected ear three times daily for 3 days, reduces ear pain in children and adolescents with otitis media (39500, 39552). Whether this effect is due to mullein, one of the other ingredients, or the combination is unclear.\nless\nPneumonia. Although there is interest in using oral mullein for pneumonia, there is insufficient reliable information about the clinical effects of mullein for this condition.\nWound healing. It is unclear if topical mullein is helpful for healing episiotomy wounds.\nIn preliminary clinical research in primiparous patients with episiotomy wounds, applying a cream containing mullein flower extract 7.5%, 2 cm twice daily for 10 days, improves redness, edema, ecchymoses, discharge, and wound edge adhesions (REEDA score for episiotomy wound healing) at 10 days, but not earlier, when compared with placebo (107873).\nless\nMore evidence is needed to rate mullein for these uses.",
            "Dosing & Administration": "Adult\nAll routes:Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nA mullein flower extract used to prepare a topical cream contained 60.13 mcg/mL gallic acid equivalents, and 20.64 mcg/mL rutin equivalents (107873).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with mullein.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of mullein.",
            "Mechanism of Action": "General\nThe applicable parts of mullein are the flower, leaf, and root (92841).\n\nThe flowers of mullein contain iridoid glycosides such as aucubin, harpagide, and harpagoside, flavonoids including kaempferol, hesperidin, verbascoside, apigenin, quercetin and rutin, phenylethanoid glycosides such as verbascoside, triterpene saponins including thapsuines, polysaccharides, phenolic acids, phytosterol glycosides and digiprolactone. Polyphenolcarboxylic acids, with large concentrations of caffeic acid, ferulic acid, and rosmarinic acid are also present (12703, 59405, 63943, 63944, 63945, 92840, 92841, 107875). Mullein also contains tannins, alkaloids, steroids, volatile oils, carbohydrates, proteins, and fats (92841, 107873, 107875).\nAnthelmintic effects\nLaboratory research suggests that an aqueous methanolic extract of the aerial parts of mullein can induce paralysis in adult roundworms (Ascaridia galli) and tapeworms (Raillietina spiralis), comparable to albendazole. Paralysis occurred faster with higher concentrations of the extract (92841).\nAnti-inflammatory effects\nLaboratory research suggests that a mullein flower extract exhibits dose-dependent free radical scavenging activity, likely related to the polyphenol content, and also related to the caffeic, ferulic, and rosmarinic acids, and quercetin and apigenin. It also inhibits tumor necrosis factor-alpha induced intracellular adhesion molecule 1 at higher concentrations. However, in animals with acute inflammation of the paw induced by egg-white, giving the flower extract orally is ineffective. It is suggested that extracts need to contain higher concentrations of verbascoside, aucubin, and phenylethanoids to show anti-inflammatory effects (92840).\nAntibacterial effects\nLaboratory research suggests that various mullein species exhibit activity against strains of Staphylococcus aureus, Trichophyton mentagrophytes, Klebsiella pneumoniae, Staphylococcus epidermidis, and Escherichia coli (12703, 63942).\nAntioxidant effects\nConstituents of mullein, including verbascoside, quercetin, apigenin, and caffeic, ferulic, and rosmarinic acids, are thought to have antioxidant activity (63941, 92841).\nAntispasmodic effects\nLaboratory research suggests that an aqueous methanolic extract of the aerial parts of mullein produces a concentration dependent relaxation of spontaneous contractions in dissected jejunum. This is possibly mediated through actions on voltage sensitive L-type calcium channels (92841).\nAntitumor effects\nLaboratory research suggests that a saponin glycoside isolated from mullein flowers directly inactivates ribosomes, which may be beneficial in inhibiting protein synthesis in tumor cells (59405).\nAntiviral effects\nLaboratory research suggests that mullein exhibits activity against Herpes simplex type 1 virus (1534, 12702, 63934, 63943). It may also have activity against influenza A and B (1534)."
        }
    },
    "Musk": {
        "sections": {
            "Overview": "Musk is a fragrant secretion used by male musk deer to attract females and mark territory. It is produced by the preputial follicles and stored in a small sac close to the preputial orifice. Once removed from the sac, musk dries into small, reddish-brown grains. Musk is prized as a base for perfumes, and is also used in traditional Chinese medicine. Unfortunately, the male musk deer are killed to obtain the musk sacs, causing the species to become endangered (95932).",
            "Safety": "There is insufficient reliable information available about the safety of musk.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nMusk components are known to cause a variety of dermal hypersensitivity reactions (6).",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of musk.",
            "Dosing & Administration": "Adult\nNo typical dosage.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "ANABOLIC STEROIDS\nMusk contains several anabolic steroids that will give positive results in urine tests, such as those used by sports organizations to detect doping (95932, 95933).\nless",
            "Pharmacokinetics": "Excretion\nIn healthy young adults, taking musk 100-200 mg once daily for 3 days is associated with significant increases in urinary levels of anabolic-androgenic steroids, including testosterone, epitestosterone, androsterone, dehydroepiandrosterone, and others (95393). Many of these are included on the list of substances banned by the World Anti-Doping Agency and International Olympic Committee. The ratio of 5-alpha-androstane-3-alpha,17-beta-diol to 5-beta-androstane-3-alpha,17-beta-diol in the urine is suggested as a marker for musk ingestion (95933).",
            "Mechanism of Action": "General\nMusk used for medicine is the dried form of a secretion obtained from male musk deer (95932). The primary constituent thought to be responsible for the odor of musk is muscone (6). Musk also contains cholesterol, peptides, lipids, estrogens, progesterone, and significant quantities of testosterone and other anabolic-androgenic steroids. These include androsterone, etiocholanolone, several androstanediols and androstanediones, 4-androstene-3,17-dione, dehydroepiandrosterone (DHEA), epiandrosterone, and epitestosterone (95932, 95933). Quantities of steroids present depend on the musk source and the animals diet. Dried musk is reported to contain between 1 mg and 8 mg of total androgens per gram (95933).\nAnabolic-androgenic effects\nThe quantities of androgens present in musk are likely sufficient to produce anabolic and androgenic effects in humans. There are anecdotal reports of increased exercise tolerance after taking musk 100-200 mg once daily for 3 days (95933). After using a traditional Chinese medicine product containing musk, athletes have tested positive for banned exogenous steroids under international anti-doping rules (95932)."
        }
    },
    "Myrcia": {
        "sections": {
            "Overview": "Myrcia is a genus of medium-sized shrubs (2.5 to 3.5 meters in height). Myrcia species are most common in central and southeastern Brazil. Some species grow in other parts of South America, such as Bolivia, Peru, and Paraguay (29969).",
            "Safety": "There is insufficient reliable information available about the safety of Myrcia.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiabetes. Preliminary clinical research shows that consumption of an herbal tea containing Myrcia uniflora leaves 3 grams daily for 56 days does not improve fasting plasma glucose, insulin, or glycated hemoglobin levels when compared with placebo in patients with or without type 2 diabetes (27471).\nMore evidence is needed to rate Myrcia for this use.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nChildren\nInsufficient available evidence.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Myrcia.",
            "Interactions with Drugs": "LEVOTHYROXINE (Synthroid, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nIn vitro research shows that the Myrcia extract can inhibit thyroid peroxidase (TPO) activity, an enzyme involved in thyroid hormone biosynthesis (27495). Theoretically, Myrcia might decrease the effectiveness of thyroid replacement therapy.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "HYPOTHYROIDISM\nMyrcia might inhibit thyroid peroxidase (27495). Theoretically, this might decrease the amount of thyroid hormone produced by the thyroid gland and worsen hypothyroidism.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Myrcia.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Myrcia.",
            "Mechanism of Action": "General\nMyrcia contains beta-amyrin, catechin, desmanthin-1, gallic acid, ginkgoic acid, guaijaverin, mearnsitrin, myricitrin, myrciacitrin I, myrciacitrin II, myrciatracin III, myrciatracin IV, myrciatracin V, myrciaphenone A, myrciaphenone B, and quercitrin (27493, 27494, 27495).\nHypoglycemic effects\nMyrcia is traditionally used for diabetes. Although preliminary clinical research does not show that taking a tea containing Myrcia uniflora leaves improves fasting levels of blood glucose or long-term glucose control (27471), Myrcia extracts improve metabolic parameters of glucose homeostasis and decrease intestinal glucose absorption in an animal model. In addition, aldose reductase and alpha-glucosidase activities are reduced (27496).\nHypothyroid effects\nThe inhibition of thyroid peroxidase (TPO), an enzyme involved in thyroid hormone biosynthesis, by Myrcia might be due to the flavonoids mearnsitrin and myricitrin, as shown in vitro (27495)."
        }
    },
    "Myrrh": {
        "sections": {
            "Overview": "Myrrh is the yellow, aromatic, oleo-gum resin exuded from fissures or cuts in the bark of certain Commiphora trees (93646, 93651, 93652). The species used medicinally is Commiphora myrrham, which is native to Ethiopia, Somalia, Northern Kenya, and some Asian countries (93646). While myrrh is used worldwide, it is particularly popular in China and Egypt (93651). Traditionally, myrrh has been used as an analgesic and for various gastrointestinal conditions (93652, 98224).\n\nCoronavirus disease 2019 (COVID-19): Some experts have warned that myrrh might interfere with the body's immune and inflammatory response against COVID-19. There is no strong evidence to support these warnings, but there's also no evidence that myrrh has benefit against COVID-19 infection.",
            "Safety": "LIKELY SAFE when consumed in amounts commonly found in food. Myrrh is approved for use in foods as a flavoring agent in the US (11).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts, short-term. Myrrh 400 mg three times daily has been safely used for up to 12 months (93653, 104593). Myrrh 500 mg three times daily has been used with apparent safety for 2 weeks (104840). ...when used topically and appropriately (2, 4, 5, 11, 18). As a diluted bath, myrrh has been used with apparent safety for up to 7 days (104838, 104839).\nPOSSIBLY UNSAFE when used orally in excessive doses. Myrrh may cause kidney irritation and diarrhea when used in doses of 2-4 grams (12).\nPREGNANCY: LIKELY UNSAFE when used orally. Myrrh stimulates uterine tone and blood flow and may have an abortifacient effect (4, 12, 19, 93645). There is insufficient reliable information available about the safety of the topical use of myrrh during pregnancy.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, myrrh seems to be well tolerated.\nSerious Adverse Effects (Rare)\nOrally: Kidney impairment and heart rate changes at high doses.\nCardiovascular\nOrally, myrrh taken at doses of 2-4 grams may cause heart rate changes in some patients (12, 19).\nless\nDermatologic\nTopically, myrrh has been reported to cause dermatitis (6).\nless\nGastrointestinal\nOrally, myrrh may cause diarrhea in some patients when taken at doses of 2-4 grams (12, 19).\nless\nGenitourinary\nSevere lower abdominal pain has been reported in a pregnant woman drinking myrrh resin dissolved in 500 mL of water twice daily as prescribed by a traditional practitioner. This adverse effect resolved one day after discontinuing myrrh. The investigators suggest that this acute abdominal pain was related to myrrh's activity as a uterine stimulant (93645).\nless\nImmunologic\nOrally, myrrh has been reported to cause severe allergic skin reactions, with redness, swelling, and itching, in two case reports of individuals using oral traditional Chinese medicines containing myrrh (101114).\nless\nRenal\nOrally, myrrh may cause kidney impairment in some patients when taken at doses of 2-4 grams (12, 19).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIKELY INEFFECTIVE\nSchistosomiasis. Most research suggests that oral myrrh extract is not effective for treating schistosomiasis.\nAlthough one manufacturer-sponsored study shows that taking a specific myrrh extract (Mirazid, Pharco Pharmaceuticals) 600 mg once daily for 6 days cures schistosomiasis in about 90% of patients, multiple clinical studies show that taking this myrrh extract does not treat schistosomiasis in children or adults. In one study, only about 9% of adults and children treated with this myrrh extract at a dose of 600 mg every 3 weeks for 2 doses were cured compared to about 76% of patients treated with praziquantel (95541). A similar lack of benefit was shown in another clinical trial in which children were given a higher dose of 300 mg daily for 3 days or 600 mg daily for 6 days (95542, 95545). A systematic review of the available literature concludes that praziquantel continues to be the treatment of choice for schistosomiasis, and that myrrh appears ineffective for parasitological cure (95544).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBack pain. It is unclear if oral myrrh is beneficial in patients with back pain, and topical myrrh has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in adults with chronic low back pain shows that two 15-minute sessions of lumbar massage weekly with 5 mL of myrrh 2% and frankincense 2% essential oils for 3 weeks reduces measures of pain and disability when compared with placebo (111504). An observational study in adults with chronic lower back pain and sciatica suggests that taking a combination of myrrh 200 mg, palmitoylethanolamide 600 mg, and alpha-lipoic acid 800 mg daily for 30 days, along with periradicular infiltrations of oxygen-ozone, is associated with resolution of pain in 17% more patients when compared with periradicular steroid infiltrations at 60 days (111308). However, it is unclear if the effects in these studies are due to myrrh, other ingredients, or the combinations. Additionally, observational research in adults with chronic low back pain of varying intensity has found that taking a specific myrrh extract (MyrliMax, Sundyota Numandis Pharmaceuticals) 100 mg twice daily for 20 days is associated with reductions in pain and the need for rescue analgesics when compared to baseline (111112). The validity of these findings is limited by the lack of a control group.\nless\nCancer. Although there has been interest in using oral myrrh for cancer, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nCanker sores. Although there has been interest in using topical myrrh for canker sores, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nCommon cold. Although there has been interest in using oral myrrh for the common cold, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nCough. Although there has been interest in using oral myrrh for cough, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nCrohn disease. Oral myrrh has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nObservational research over a period of 24-28 days in a small group of patients with active inflammatory bowel disease (50% ulcerative colitis and 50% Crohn disease) has found that taking a specific combination product containing myrrh 100 mg, coffee charcoal 50 mg, and chamomile extract 70 mg per tablet (MYRRHINIL-INTEST, Repha GmbH) results in symptom resolution in 16-26 days. The probability of being free of symptoms did not differ between patients using other treatments, the myrrh combination product alone, or a combination of the myrrh product with other treatments. Overall efficacy was rated as good to very good by patients and physicians (104593). The validity of these findings is limited by the observational nature of the study. Also, it is unclear if these findings are due to myrrh, other ingredients, or the combination.\nless\nDental peri-implantitis. It is unclear if rinsing with myrrh mouthwash solution is effective for the prevention of dental peri-implantitis.\nA small clinical study in adults undergoing dental implant placement shows that rinsing with myrrh 1% mouthwash solution twice daily for 2 weeks leads to similar rates of postoperative bleeding, pain, redness, and swelling when compared with chlorhexidine 0.12% mouthwash (111114).\nless\nDiarrhea. Oral myrrh has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nObservational research over a period of 7-14 days in a group of patients with active diarrhea related to an acute inflammatory disorder has found that taking a specific combination product containing myrrh 100 mg, coffee charcoal 50 mg, and chamomile extract 70 mg per tablet (MYRRHINIL-INTEST, Repha GmbH), alone or in combination with other therapies, improves overall symptoms of diarrhea. The median time to symptom resolution was 4 days. The probability of symptom resolution with use of the myrrh combination product was similar to that observed when other treatments were used. Overall efficacy was rated as good to very good by patients and physicians (104593). The validity of these findings is limited by the observational nature of the study. Also, it is unclear if these findings are due to myrrh, other ingredients, or the combination.\nless\nGingivitis. Although there has been interest in using topical myrrh for gingivitis, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nHerniated disc. Oral myrrh has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small observational study in adults with acute lumbosacral radiculopathy secondary to lumbar disc herniation suggests that taking a combination supplement containing myrrh 100 mg, alpha-lipoic acid 404 mg, and palmitoylethanolamide (PEA) 306 mg (Tiobec Dol, Uriach Italy Srl) twice daily for 4 weeks, along with steroids and as needed opioids, is associated with reduced pain and disability and improved physical but not mental health as it pertains to quality of life when compared with steroids and as needed opioids alone (111711). However, it is unclear if these effects are due to alpha-lipoic acid, other ingredients, or the combination.\nless\nIntestinal parasite infection. It is unclear if oral myrrh extract is beneficial in children with intestinal parasite infections.\nA small clinical study in immunocompetent children shows that taking a specific myrrh extract (Mirazid, Pharco Pharmaceuticals) 10 mg/kg daily in combination with paromomycin 500 mg four times daily for 2 weeks improves symptoms such as abdominal pain, diarrhea, nausea, and vomiting when compared with paromomycin or myrrh extract alone. However, no differences in oocyst elimination were observed across groups (95546).\nless\nIrritable bowel syndrome (IBS). Oral myrrh has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nObservational research over a period of 24-28 days in a group of patients with IBS has found that taking a specific combination product containing myrrh 100 mg, coffee charcoal 50 mg, and chamomile extract 70 mg per tablet (MYRRHINIL-INTEST, Repha GmbH), alone or in combination with other therapies, improves overall symptoms of diarrhea. The probability of being free of symptoms did not differ between patients using other treatments or when the myrrh combination product was used in combination with other treatments. Overall efficacy was rated as good to very good by patients and physicians (104593). The validity of these findings is limited by the observational nature of the study. Also, it is unclear if these findings are due to myrrh, other ingredients, or the combination.\nless\nMiscarriage. It is unclear if oral myrrh is beneficial in patients with incomplete miscarriage.\nA small clinical study in adults with incomplete miscarriage (incomplete abortion) shows that taking myrrh 500 mg three times a day for 2 weeks increases the proportion of patients with successful complete abortion, defined as no retained products of conception, to 83%, compared to only 54% of those taking placebo (104840).\nless\nMuscle cramps. Although there has been interest in using oral myrrh for muscle cramps, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nOral mucositis. Although there has been interest in using topical myrrh for oral mucositis, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nPain (acute). It is unclear if oral myrrh extract is beneficial in patients with acute pain.\nA small clinical study shows that taking a specific, standardized myrrh extract (MyrLiq, Biosfered S.r.l.) 200-400 mg daily for 20 days can improve various types of acute pain, including headache, fever-associated pain, joint or muscle pain, lower back pain, and menstrual cramps, when compared with placebo (98224).\nless\nPain (chronic). It is unclear if oral myrrh extract is beneficial in patients with chronic pain.\nA small clinical study shows that taking a specific, standardized myrrh extract (MyrLiq, Biosfered S.r.l.) 200-400 mg daily for 20 days can improve various types of chronic pain, including joint or muscle pain and lower back pain, when compared with placebo (98224).\nless\nPeptic ulcers. Although there has been interest in using oral myrrh for peptic ulcers, there is insufficient reliable information about the clinical effects of myrrh for this purpose.\nSciatica. Oral myrrh has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nObservational research in patients with sciatic pain due to herniated discs has found that taking a combination of myrrh extract 200 mg, alpha-lipoic acid 800 mg, and palmitoylethanolamide 600 mg daily for 20 days along with 3 sessions of oxygen-ozone therapy over 30 days is associated with slight improvements in pain when compared with oxygen-ozone therapy alone (111113). The validity of these findings is limited by the observational nature of the study. Additionally, it is unclear if these findings are due to myrrh, other ingredients, or the combination.\nless\nTooth extraction. It is unclear if rinsing with myrrh extract solution is beneficial in patients undergoing tooth extraction.\nA small clinical study in healthy, non-smoking adults shows that using a mouthwash containing myrrh extract 0.5% twice daily for 7 days following simple tooth extraction decreases the socket size in 90% of patients compared with 40% in the control group. Swelling and tenderness also decreased when compared with control (105846).\nless\nTrichomoniasis. It is unclear if oral myrrh extract is beneficial in patients with trichomoniasis.\nA small clinical study in patients with resistant Trichomonas vaginalis shows that taking a specific myrrh extract (Mirazid, Pharco Pharmaceuticals) 600 mg daily for 6-8 days cures infections in most patients. In this small study, 85% (11/13) of patients who did not respond to combination therapy with metronidazole and tinidazole were cured after receiving this myrrh extract (93652). A lack of control group limits the validity of these findings.\nless\nUlcerative colitis. Oral myrrh has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nA small clinical study in patients with ulcerative colitis shows that taking a specific combination product containing myrrh 100 mg, chamomile extract 70 mg, and coffee charcoal 50 mg per tablet (MYRRHINIL-INTEST, Repha GmbH), four tablets three times daily for 12 months, is non-inferior to mesalamine therapy for maintaining remission (93653). In addition, observational research over a period of 24-28 days in a small group of patients with active inflammatory bowel disease (50% ulcerative colitis and 50% Crohn disease) has found that taking this same product results in symptom resolution in 16-26 days. The probability of being free of symptoms did not differ between patients using other treatments, the myrrh combination product alone, or the myrrh combination product with other treatments. Overall efficacy was rated as good to very good by physicians (104593). It is unclear if these findings are due to myrrh, other ingredients, or the combination.\nless\nUrinary tract infections (UTIs). Oral myrrh has only been evaluated in combination with other ingredients, its effect when used alone is unclear.\nA small clinical study in patients with at least 2 recurrent UTIs in the past 6 months or more than 3 UTIs in the past year shows that taking a combination of myrrh, hibiscus, and vegetable proteases (Aviur Retard ) for 6 months might reduce the risk of UTI recurrence. A UTI episode was not reported by 49% of females over the 6-month period, with an additional 35% reporting fewer than 2 UTIs (101115). The validity of these findings is limited by the lack of comparator group. Additionally, it unclear if this benefit is due to myrrh, other ingredients, or the combination.\nless\nWound healing. It is unclear if topical myrrh extract is beneficial for wound healing.\nTwo small clinical studies in patients requiring episiotomy during childbirth shows that using myrrh 1:5 tincture 10 mL or myrrh extract 20 mL, diluted in 5 L of water as a sitz bath, twice daily for 7 days, modestly improves ecchymosis, discharge, and wound healing scores when compared with either placebo, frankincense extract 20 mL, or betadine 10% solution 20 mL (104838, 104839). It is unclear if these modest effects are clinically relevant.\nless\nFasciolosis. It is unclear if oral myrrh extract is beneficial in patients with fasciolosis.\nA small clinical study in adults and children with fasciolosis shows that taking a specific myrrh extract (Mirazid, Pharco Pharmaceuticals) 600 mg daily for 6 days leads to a cure rate of about 94% at 3 months. However, the lack of standardized stool sample evaluation and absence of a control group limit the validity of this finding (95543). Furthermore, another small study in adults and children with fasciolosis shows that taking this same product, 600 mg daily for 6 days, leads to a 0% cure rate at both 1 and 2 months (95545).\nless\nMore evidence is needed to rate myrrh for these uses.",
            "Dosing & Administration": "Adult\nOral:\nMyrrh extract has most often been used at a dose of 600-1200 mg daily for up to 12 months, with doses at the top end of this range split and taken 3 times daily. See Effectiveness section for condition-specific information.\nTopical:\nMyrrh has been used in various topical formulations, including as a mouthwash and bath solution. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nA specific myrrh extract (MyrLiq, Biosfered S.r.l.) is standardized to contain curzerene 12.31 grams/kg, furanoeudesma-1,3-diene 18.84 grams/kg, lindestrine 6.23 grams/kg, and total furanodienes 40.86 grams/kg. A 200 mg dose of this myrrh extract contains 8 mg total furanodienes (98224).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, myrrh might increase the risk of hypoglycemia when taken with antidiabetes drugs.\nIn vitro and animal research suggests that myrrh has hypoglycemic effects (4, 104841).\nless\nWARFARIN (Coumadin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, myrrh might decrease the effectiveness of warfarin.\nIn one case, a patient who was previously stable on warfarin had a significant decline in international normalized ratio (INR) following consumption of an aqueous extract of myrrh (14425).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, myrrh might have hypoglycemic effects.\nTaking myrrh with other products with hypoglycemic potential might increase the risk of hypoglycemia. In vitro and animal research suggests that myrrh has hypoglycemic effects (4, 104841). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nMyrrh might have hypoglycemic effects (4, 104841). Theoretically, myrrh might interfere with blood glucose control if used perioperatively. Tell patients to discontinue myrrh at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with myrrh.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of myrrh.",
            "Mechanism of Action": "General\nThe applicable part of myrrh is the resin that exudes from cuts in the bark. Myrrh consists of around 30% to 61% gum, 23% to 40% alcohol-soluble resin, 2% to 17% volatile essential oils, and 10% to 25% bitter principles (93646, 93651, 93654). The volatile oil contains steroids, sterols, and terpenes. Furanodiene sesquiterpenes are responsible for the characteristic aroma of myrrh and include curzerine, furanoeudesma-1,3-diene, and lindestrine (93654, 98224).\nAnalgesic effects\nAnimal and preliminary human research suggests that myrrh has analgesic effects (93657, 93659, 98224). This activity is attributed to the furanodiene sesquiterpenes constituents, including curzerine, furanoeudesma-1,3-diene, and lindestrine (98224). Myrrh also seems to have some local anesthetic properties (93658).\nAnthelmintic effects\nIn vitro and animal research suggests that myrrh has anthelmintic effects against Eimeria stiedae, Fasciola gigantica, Giardia lamblia, and Schistosoma mansoni. Myrrh volatile oil appears to have more anthelmintic activity than a specific oleoresin extract of myrrh (Mirazid, Pharco Pharmaceuticals) (93654, 93655).\nAnti-inflammatory effects\nSome animal and in vitro research suggests that myrrh has anti-inflammatory effects (4, 8, 93657, 93659). These effects may be explained by inhibition of leukotriene biosynthesis in activated neutrophils (93653).\nAnticancer effects\nIn vitro and animal research suggests that myrrh might have anticancer effects (1536). Compared to frankincense, essential oil from myrrh showed higher anticancer activity in vitro. Breast cancer (MCF-7) and skin cancer (HS-1) cell lines were the most sensitive to myrrh essential oil, with concentration-dependent apoptosis observed in MCF-7 cells (93651).\nAntidiabetic effects\nMyrrh might have hypoglycemic effects (4). Ex vivo research in mouse and human islet cells shows that myrrh resin increases basal insulin secretion and glucose-stimulated insulin secretion (104841).\nAntimicrobial effects\nSome in vitro research suggests that myrrh has antibacterial and antifungal activity (4, 6, 93658). Sesquiterpenes from myrrh have been shown to have activity against Escerichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans (93658).\nAstringent effects\nMyrrh might have astringent effects (4, 6).\nCognitive effects\nSome preliminary animal research suggests that myrrh might improve memory impairment. In mice with scopolamine-induced memory impairment, oral administration of myrrh resin extract for 7 days reversed the effects of scopolamine on certain memory-related tasks. Researchers suggest that the memory-enhancing effects of myrrh may be due to activation of Akt and ERK in the hippocampus (93646).\nGastrointestinal effects\nSome animal research suggests that myrrh protects against the development of gastric ulcers (1535).\nLipid effects\nSome animal research suggests that myrrh might have anti-hyperlipidemic activity (93657).\nStimulant effects\nMyrrh can stimulate smooth muscle (6, 12) and possibly peristalsis (6). It stimulates uterine tone (6, 12) and promotes uterine blood flow (12, 19)."
        }
    },
    "Myrtle": {
        "sections": {
            "Overview": "Myrtle is a shrub commonly found in Iran and surrounding areas (98643, 98644). The leaves resemble those of the lingonberry plant (18). Various parts of the myrtle plant have been used in traditional Persian medicine (98641, 98642).",
            "Safety": "POSSIBLY SAFE when myrtle berry is used orally, short term. Myrtle berry powder 2,250 mg daily has been used with apparent safety for up to 5 days (106778). ...when diluted myrtle leaf extract is used topically and appropriately, short term. A paste containing myrtle leaf extract 5% has been used with apparent safety for up to 6 days (98643). Other myrtle leaf extracts have been applied to the face for up to 16 weeks with apparent safety (106780). ...when myrtle leaf extract is used intravaginally and appropriately, short term. Vaginal suppositories containing myrtle leaf extract 10% and leaf essential oil 0.5% have been used with apparent safety for up to three menstrual cycles (98644).\nLIKELY UNSAFE when the undiluted oil of myrtle leaf is used orally. Myrtle leaf contains cineole. Ingesting more than 10 grams of cineole can result in respiratory failure and collapse (18).\nThere is insufficient reliable information available about the safety of myrtle leaf and branch when used orally. There is also insufficient reliable information available about the safety of myrtle berry when used topically or myrtle berry extract when used orally or topically.\nCHILDREN: LIKELY UNSAFE when myrtle oil is used orally. Avoid facial contact with myrtle oil preparations which may cause glottal spasm, bronchospasm, asthma-like attacks, or respiratory failure in infants or small children (18).\nCHILDREN: There is insufficient reliable information available about the safety of myrtle berry or myrtle berry extract when used orally in children.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally (18); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is currently a limited amount of information on the adverse effects of oral and intravaginal myrtle. A thorough evaluation of safety outcomes has not been conducted. Topically, myrtle leaf seems to be generally well tolerated in adults.\nMost Common Adverse Effects\nTopically: Dry skin.\n\nIntravaginally: Vaginal irritation and dryness.\nSerious Adverse Effects (Rare)\nOrally: Hypotension, respiratory failure.\n\nTopically: Bronchial spasm and respiratory failure, most commonly in infants or children.\nCardiovascular\nOrally, very large amounts of undiluted myrtle leaf oil might lead to low blood pressure and circulatory disorders due to the cineole constituent (18).\nless\nDermatologic\nTopically, myrtle leaf extract has been reported to cause dry skin (106777).\nless\nGastrointestinal\nOrally, myrtle berry extract has been reported to cause constipation in infants and young children (106781).\nless\nGenitourinary\nIntravaginally, myrtle leaf extract suppositories have been reported to cause vaginal irritation and dryness (98644).\nless\nPulmonary/Respiratory\nOrally, consumption of very large amounts of undiluted myrtle leaf oil might lead to respiratory failure and collapse (18).\n\nTopically, facial contact with myrtle oil preparations may cause glottal or bronchial spasm, asthma-like attacks, or respiratory failure in infants and children (18).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAcne. It is unclear if topical myrtle is beneficial in patients with acne.\nPreliminary clinical research in adults and adolescents with mild to moderate acne shows that applying myrtle leaf extract topically to the face twice daily for 16 weeks reduces facial lesion count and acne severity scores by 23% to 45% when compared to baseline. Improvements were similar to clindamycin 1% topical solution (106777). Also, a small, single-blind trial in females whose mild-to-moderate acne resolved after receiving conventional acne therapy shows that applying a lotion containing myrtle extract and azelaic acid twice daily for 16 weeks reduces the risk of acne relapse, decreases the number of acne lesions, and improves post-inflammatory hyperpigmentation when compared with a placebo cream (111733). It is unclear if these effects are to myrtle, azelaic acid, or the combination.\nless\nBacterial vaginosis. Although there has been interest in using topical myrtle for bacterial vaginosis, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nCanker sores. It is unclear if topical myrtle is beneficial in patients with canker sores.\nA small clinical study in patients with recurring canker sores shows that applying a paste containing myrtle leaf extract 5% to canker sores four times daily for 6 days decreases ulcer size, pain, and redness when compared with placebo (98643).\nless\nDiarrhea. Although there has been interest in using oral myrtle for diarrhea, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nGastroesophageal reflux disease (GERD). It is unclear if oral myrtle is beneficial in patients with GERD.\nPreliminary clinical research in adults with GERD shows that taking myrtle berry or myrtle berry extract 1000 mg orally daily for 4 weeks improves GERD symptom scores and frequency when compared with baseline. The improvements were similar to taking omeprazole 20 mg daily. However, the study may have been inadequately powered to detect a difference between groups (98641). Preliminary clinical research in children 1-7 years of age with GERD shows that taking myrtle berry extract syrup 0.21 mL/kg orally three times daily and with meals along with omeprazole 1 mg/kg daily orally for 8 weeks does not reduce GERD scores or symptoms, including vomiting and regurgitation, when compared with taking placebo along with omeprazole. However, the study may have been inadequately powered to detect a difference between groups. (106781).\nless\nGingivitis. It is unclear if topical myrtle is beneficial in patients with gingivitis.\nA small cross-over trial in young adults with plaque-induced gingivitis shows that rinsing with an herbal mouth rinse containing fresh plant extracts of myrtle, pomegranate, Quercus brantii, Portulaca oleracea, and Boswellia serrata twice daily after brushing for 2 weeks improves gingivitis indices when compared with placebo, with similar improvements when compared with chlorhexidine 0.2% mouth rinse (111734). Information on the specific plant parts used for each species was lacking. Further, it is unclear if these findings are due to myrtle, other ingredients, or the combination.\nless\nHuman papillomavirus (HPV). It is unclear if intravaginal myrtle is beneficial in patients with HPV.\nClinical research in adults with cervicovaginal HPV infection shows that insertion of vaginal suppositories containing myrtle leaf extract 10% and essential oil 0.5% daily on non-menstruating days for up to three menstrual cycles reduces positive HPV tests by an additional 30% when compared with placebo suppositories. The myrtle leaf suppository also reduces symptoms of vaginal itching and burning when compared with placebo (98644).\nless\nIntestinal parasite infection. Although there has been interest in using oral myrtle for intestinal parasite infection, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nMenorrhagia. It is unclear if oral myrtle is beneficial in patients with menorrhagia.\nPreliminary clinical research in adults with menorrhagia shows that taking myrtle fruit syrup 5 mL three times daily for 7 days, starting on the first day of bleeding and repeating for three consecutive menstrual cycles, reduces the duration of bleeding by 2.4 days when compared to baseline. The validity of this study is limited by the lack of a comparator group (98642). Other preliminary clinical research in adults with menorrhagia shows that taking myrtle berry powder 750 mg orally three times daily for 5 days during menses for 2 cycles improves blood loss assessment scores by 58% and hemoglobin levels by 17% when compared to baseline. Improvements were similar to tranexamic acid 500 mg twice daily. However, the study may have been inadequately powered to detect a difference between groups (106778).\nless\nOropharyngeal candidiasis. Although there has been interest in using topical myrtle for oropharyngeal candidiasis, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nRespiratory tract infections. Although there has been interest in using oral myrtle for respiratory tract infections, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nVaginal candidiasis. Although there has been interest in using oral myrtle for vaginal candidiasis, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nVaginitis. It is unclear if intravaginal myrtle is beneficial in patients with vaginitis.\nPreliminary clinical research in adults with vaginitis secondary to bacterial vaginosis or trichomoniasis shows that applying a vaginal suppository containing myrtle extract 10% and oak gall extract 10% for 7 days reduces malodor discharge after intercourse when compared with placebo, but not when compared with metronidazole vaginal suppository. It is unclear if this effect is due to myrtle extract, oak gall, or the combination. Using the combination product did not reduce itching, dysuria, irritation, or dyspareunia when compared with placebo or metronidazole (106779).\nless\nWarts. Although there has been interest in using topical myrtle for warts, there is insufficient reliable information about the clinical effects of myrtle for this purpose.\nMore evidence is needed to rate myrtle for these uses.",
            "Dosing & Administration": "Adult\nAll routes of administration:Research is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of myrtle.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with myrtle.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of myrtle.",
            "Mechanism of Action": "General\nThe applicable parts of myrtle are the fruit, leaf, and branch. Myrtle contains a volatile oil containing terpenes, terpenoids, and phenylpropanoids, tannins, phenolic acids, flavonoids, and acylphloroglucinols (18, 98641, 98644). The berries also contain phenols, such as anthocyanins, flavonoids, and flavonols (98642, 106780). The volatile oil contains between 15% to 45% of 1,8-cineole, a constituent responsible for toxicity when taken in high doses (18). Myrtle leaf essential oil primarily contains eucalyptol, alpha-pinene, myrtenyl acetate, and d-limonene (109013).\nAnti-diabetic effects\nAnimal research in rats with chemically-induced diabetes shows that taking myrtle berry extract 0.25-1 gram/kg orally daily for 14 days reduces body weight and fasting blood glucose levels when compared with control. Treatment with myrtle berry extract also improved liver function tests (109014).\nAnti-inflammatory effects\nTaking syrup made from myrtle berries might help to reduce bleeding in those with heavy menstrual bleeding. This might be due to the anti-inflammatory effects of the berry tannins, anthocyanins, and flavonoids, including the inhibition of prostaglandin activity (98642).\nAntimicrobial effects\nThe constituent myrtol might have fungicidal, disinfectant, and antibacterial properties (18).\nAntioxidant effects\nAnimal research in rats with chemically-induced diabetes shows that taking myrtle berry extract 0.25-1 gram/kg orally daily for 14 days improves levels of oxidative stress markers, including superoxide dismutase, glutathione, and malondialdehyde, when compared with control (109014). Animal research in healthy rats also shows that consuming myrtle leaf essential oil 1 mcL/gram orally daily for 14 days improves organ and tissue levels of these same markers (109013).\nDermatologic effects\nThere is interest in using myrtle leaf extract for acne. Preliminary clinical research in adults and adolescents with mild to moderate acne shows that applying myrtle leaf extract topically to the face twice daily for 16 weeks reduces levels of sebum in the stratum corneum (106777). In vitro research also suggests that myrtle may improve acne due to its antimicrobial properties and potential to inhibit Cutibacterium acnes biofilm formation in pilosebaceous follicles. Such biofilm formation may increase the virulence of C. acnes and the risk of antibiotic resistance (111733).\nGastrointestinal effects\nMyrtol, a constituent of myrtle, is purported to stimulate mucous membranes of the stomach; however, this has not been validated in laboratory or clinical research (18). Animal research in healthy rats shows that consuming myrtle leaf essential oil 1 mcL/gram orally daily for 14 days reduces fecal Lactobacillus and Bifidobacterium colonies and increases Enterobacteriaceae colonies when compared with control. Taking myrtle leaf essential oil also increased fecal levels of alpha-glucuronidase and beta-galactoside (109013).\nLipid-lowering effects\nAnimal research in healthy rats shows that consuming myrtle leaf essential oil 1 mcL/gram orally daily for 14 days reduces low-density lipoprotein cholesterol levels, but does not affect high-density lipoprotein cholesterol or triglyceride levels, when compared with control (109013).\nWound healing effects\nAnimal research in rats with chemically-induced diabetes shows that topically applying a myrtle berry extract gel 6% once daily for 21 days improves wound healing rates when compared with control. In contrast, rats without chemically-induced diabetes did not demonstrate improved wound healing rates with myrtle berry extract gel (106780)."
        }
    }
}